Clustering O 0 0.00011846987763419747
of O 0 3.901857326127356e-06
missense O 0 5.91686402913183e-05
mutations O 0 7.756623858767853e-07
in O 0 3.821276663984463e-07
the O 0 1.5146515579544939e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 8.479862117383163e-06
in O 0 2.035429105262665e-07
a O 0 1.0755117045846418e-06
sporadic B-Disease 0 5.785581379313953e-05
T I-Disease 1 0.9995701909065247
- I-Disease 1 0.9939741492271423
cell I-Disease 1 0.8309773206710815
leukaemia I-Disease 1 0.9994522929191589
. O 0 1.1176939551660325e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999966621398926
telangiectasia I-Disease 1 1.0
( O 1 0.945854663848877
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.548795012240589e-07
is O 0 1.5022488142335533e-08
a O 0 1.1772142727295432e-07
recessive B-Disease 0 1.8476885088603012e-05
multi I-Disease 1 0.9999350309371948
- I-Disease 1 1.0
system I-Disease 0 0.3787517249584198
disorder I-Disease 1 0.9996755123138428
caused O 0 3.848809228657046e-06
by O 0 3.402913506533878e-08
mutations O 0 3.114670832360389e-08
in O 0 1.7746856428857427e-08
the O 0 1.2518229652869195e-07
ATM O 0 7.05752318026498e-05
gene O 0 1.466536048155831e-07
at O 0 1.3216254046710674e-06
11q22 O 0 3.2286257919622585e-05
- O 0 2.358273559366353e-05
q23 O 0 0.00025534824817441404
( O 0 1.3614824183605378e-06
ref O 0 2.073219366138801e-05
. O 0 4.5623821165463596e-08
3 O 0 8.651687153360399e-07
) O 0 5.991535658722569e-07
. O 0 1.2966748954568175e-06

The O 0 8.666436769999564e-06
risk O 0 9.7252668638248e-06
of O 0 4.0789300328469835e-06
cancer B-Disease 1 0.8521709442138672
, O 0 1.5819109648873564e-06
especially O 0 1.1774363883887418e-05
lymphoid B-Disease 1 0.9999998807907104
neoplasias I-Disease 1 0.9999994039535522
, O 0 2.547651831719122e-07
is O 0 4.933619379698939e-08
substantially O 0 2.948377471057029e-07
elevated O 0 1.4184325891619665e-06
in O 0 1.690084445726825e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 9.843012804822138e-08
and O 0 3.6817557891311026e-09
has O 0 3.5952678612005684e-09
long O 0 2.5312386853215685e-08
been O 0 1.3853095559568374e-08
associated O 0 1.5228097538511065e-07
with O 0 2.458535277582996e-07
chromosomal O 1 1.0
instability O 1 1.0
. O 0 5.0954415200976655e-05

By O 0 3.572824425646104e-06
analysing O 0 0.000246124662226066
tumour B-Disease 1 1.0
DNA O 0 4.346944024291588e-06
from O 0 6.019254783495853e-08
patients O 0 9.080611818035322e-09
with O 0 7.11094250149813e-09
sporadic B-Disease 0 0.00014135298260953277
T I-Disease 1 0.9990072846412659
- I-Disease 0 0.23018738627433777
cell I-Disease 0 0.0006673156749457121
prolymphocytic I-Disease 0 0.0033936805557459593
leukaemia I-Disease 1 0.9426681995391846
( O 0 3.7745539884781465e-06
T B-Disease 0 0.0013405079953372478
- I-Disease 0 7.477767212549224e-05
PLL I-Disease 1 0.699157178401947
) O 0 2.0683376789065733e-08
, O 0 4.2196721672382864e-09
a O 0 3.4720226693707446e-08
rare O 0 1.1608150174424736e-07
clonal B-Disease 0 1.1966934835072607e-05
malignancy I-Disease 0 8.022505062399432e-05
with O 0 9.425823677133849e-09
similarities O 0 1.1029982260879478e-07
to O 0 2.8859778566925343e-08
a O 0 7.980651162142749e-07
mature B-Disease 0 1.2401959793351125e-05
T I-Disease 0 0.03608490526676178
- I-Disease 0 0.00021727265266235918
cell I-Disease 0 0.00029933280893601477
leukaemia I-Disease 0 0.0009917222196236253
seen O 0 5.119429715705337e-07
in O 0 8.404847307019736e-08
A B-Disease 1 0.9999784231185913
- I-Disease 1 0.5521945953369141
T I-Disease 1 0.9964039325714111
, O 0 9.928802668923709e-09
we O 0 7.887702935249763e-09
demonstrate O 0 3.3930689369299216e-08
a O 0 1.2444699493130429e-08
high O 0 1.4533712011655098e-08
frequency O 0 1.4230439049356391e-08
of O 0 2.361692708063856e-08
ATM O 0 2.8455356186896097e-06
mutations O 0 5.7027225608408116e-08
in O 0 3.4227355172333773e-07
T B-Disease 0 0.059931669384241104
- I-Disease 0 0.010585200041532516
PLL I-Disease 1 0.9982330799102783
. O 0 4.21762524638325e-06

In O 0 4.843512215302326e-06
marked O 0 2.111140020133462e-06
contrast O 0 2.3773668544890825e-07
to O 0 3.202050535833223e-08
the O 0 2.3956198447194765e-07
ATM O 0 2.8832526368205436e-05
mutation O 0 4.1115534088476124e-08
pattern O 0 1.94599863334588e-07
in O 0 7.511830091289085e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999725818634033
T I-Disease 1 0.9999995231628418
, O 0 1.9357955238774593e-08
the O 0 1.5353410987017924e-08
most O 0 1.9092245562291055e-09
frequent O 0 7.006762281491774e-09
nucleotide O 0 4.104775541691197e-08
changes O 0 2.3180317665350003e-09
in O 0 3.984025997993967e-09
this O 0 3.123522773762488e-08
leukaemia B-Disease 0 2.876370672311168e-05
were O 0 3.770312275719334e-07
missense O 0 2.300312917213887e-05
mutations O 0 1.4746241276952787e-06
. O 0 2.0330560346337734e-06

These O 0 2.080220610878314e-06
clustered O 0 1.0570672202447895e-05
in O 0 9.790883837013098e-08
the O 0 7.378082500508754e-08
region O 0 1.5578193313103839e-07
corresponding O 0 1.6504803568295756e-07
to O 0 2.5846262019513233e-08
the O 0 2.3172775343027752e-07
kinase O 0 1.8904895568994107e-06
domain O 0 8.474274437730855e-08
, O 0 1.3393112174853172e-09
which O 0 3.0125923977664115e-10
is O 0 8.243155602549734e-10
highly O 0 5.948921799614482e-09
conserved O 0 1.0028308139453657e-07
in O 0 2.497910500665057e-08
ATM O 0 4.0481922042090446e-05
- O 0 4.355781300091621e-07
related O 0 8.639667470333734e-08
proteins O 0 2.614055638616719e-08
in O 0 1.512408687176503e-08
mouse O 0 1.6645041966967256e-07
, O 0 7.112434641243226e-09
yeast O 0 2.1378484404976916e-07
and O 0 7.325289175241778e-08
Drosophila O 0 9.719871741253883e-06
. O 0 6.414641688934353e-07

The O 0 5.379089543566806e-06
resulting O 0 1.3796885696137906e-06
amino O 0 1.6431662288596272e-06
- O 0 1.3254816622065846e-06
acid O 0 1.2051265230184072e-07
substitutions O 0 5.7681944554133224e-08
are O 0 3.3536389221211493e-09
predicted O 0 2.0164831937563577e-07
to O 0 1.989947406855208e-08
interfere O 0 5.249186756373092e-07
with O 0 1.245410743422326e-07
ATP O 0 0.03909442946314812
binding O 0 4.855213546761661e-07
or O 0 3.237417445234314e-07
substrate O 0 2.4880782802938484e-06
recognition O 0 1.9015303678315831e-06
. O 0 2.4003795715543674e-06

Two O 0 2.9577347504528007e-06
of O 0 2.4093124011415057e-06
seventeen O 0 2.4139575543813407e-05
mutated O 0 2.0619645511033013e-05
T B-Disease 0 0.004857209976762533
- I-Disease 0 0.00012232322478666902
PLL I-Disease 0 0.008508929051458836
samples O 0 1.4059345687655878e-07
had O 0 3.878962218095694e-08
a O 0 3.426811190365697e-08
previously O 0 1.813930765592886e-07
reported O 0 9.093421908801247e-07
A B-Disease 1 0.9741666913032532
- I-Disease 0 0.15962187945842743
T I-Disease 1 0.9986458420753479
allele O 0 4.920978881273186e-06
. O 0 1.3541661019189632e-06

In O 0 1.8127233261111542e-06
contrast O 0 4.124128736293642e-07
, O 0 2.5073665810282364e-08
no O 0 2.7473243235931477e-08
mutations O 0 2.4189208858160782e-08
were O 0 5.1807539591663954e-08
detected O 0 3.296179897915863e-07
in O 0 2.512512864427663e-08
the O 0 1.7549311337461404e-07
p53 O 0 4.6127826180963893e-07
gene O 0 1.5599209035599415e-08
, O 0 2.9860840466966465e-09
suggesting O 0 4.655225183114453e-08
that O 0 3.6184446550180382e-09
this O 0 1.910031102170251e-07
tumour B-Disease 1 1.0
suppressor O 0 0.0004144514095969498
is O 0 2.1438301800458248e-08
not O 0 4.5289820782556944e-09
frequently O 0 3.85923648593689e-08
altered O 0 1.0754167334425802e-07
in O 0 4.647843709904009e-08
this O 0 8.525462362740654e-07
leukaemia B-Disease 0 0.03603482246398926
. O 0 7.63486332289176e-06

Occasional O 0 0.00010498883784748614
missense O 0 4.8523190343985334e-05
mutations O 0 9.028388490150974e-07
in O 0 1.538475515872051e-07
ATM O 0 1.0600047971820459e-05
were O 0 2.5238723111442596e-08
also O 0 6.198513702315722e-09
found O 0 1.4154426963841615e-08
in O 0 6.720767942169914e-08
tumour B-Disease 1 0.9999998807907104
DNA O 0 1.2206706969664083e-06
from O 0 2.7610825625856705e-08
patients O 0 2.630660134173013e-09
with O 0 4.992334545761423e-09
B B-Disease 0 0.018985362723469734
- I-Disease 0 0.008537692949175835
cell I-Disease 0 0.0016380862798541784
non I-Disease 0 7.94332881923765e-05
- I-Disease 0 0.004843749571591616
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 1.5104438716662116e-05
( O 0 9.551208535185651e-08
B B-Disease 0 1.5420523595821578e-06
- I-Disease 0 2.1912150316438783e-07
NHL I-Disease 0 2.566607406606636e-07
) O 0 5.530354840743712e-09
and O 0 1.7470176416622962e-09
a O 0 5.7458382940467345e-08
B B-Disease 0 5.674474778061267e-06
- I-Disease 0 5.108595814817818e-06
NHL I-Disease 0 1.5430145140271634e-05
cell O 0 4.2640553147066385e-05
line O 0 7.697210094192997e-06
. O 0 2.3618965769856004e-06

The O 0 1.5430674693561741e-06
evidence O 0 7.510210480177193e-07
of O 0 1.1056901882966486e-07
a O 0 6.84801904071719e-08
significant O 0 2.565662171605254e-08
proportion O 0 5.026974392308148e-08
of O 0 5.4042359920458694e-08
loss O 0 1.6779556517576566e-06
- O 0 3.8013617995602544e-06
of O 0 1.9668557342811255e-06
- O 0 6.251510058064014e-06
function O 0 2.3549662842015096e-07
mutations O 0 5.996460661350511e-09
and O 0 1.4582741680868594e-09
a O 0 3.194035258502481e-08
complete O 0 3.1341642170445994e-07
absence O 0 6.658534061898536e-07
of O 0 2.09608288059826e-07
the O 0 1.2059520315688133e-07
normal O 0 4.970000873072422e-07
copy O 0 4.476638650885434e-07
of O 0 9.970917602686313e-08
ATM O 0 9.162032256426755e-06
in O 0 7.443538230234026e-09
the O 0 1.40559608396984e-08
majority O 0 1.3170999402234429e-08
of O 0 2.486638095433591e-07
mutated O 0 2.4890488930395804e-05
tumours B-Disease 1 1.0
establishes O 0 4.055293629789958e-06
somatic O 0 1.1343264532115427e-06
inactivation O 0 1.2978155154996784e-06
of O 0 2.7066406005360477e-08
this O 0 5.02948482861143e-09
gene O 0 6.4879874805967575e-09
in O 0 2.58311660950028e-09
the O 0 4.3129574578415486e-08
pathogenesis O 0 0.00024219519400503486
of O 0 2.0298284653108567e-06
sporadic B-Disease 0 0.029879823327064514
T I-Disease 1 0.9999979734420776
- I-Disease 1 0.9722384214401245
PLL I-Disease 1 0.9999426603317261
and O 0 3.407316739867383e-08
suggests O 0 1.3085055172723514e-07
that O 0 2.5649233847957476e-08
ATM O 0 3.7290142245183233e-06
acts O 0 6.457249668301301e-08
as O 0 1.7256716944302752e-07
a O 0 1.010552114166785e-05
tumour B-Disease 1 1.0
suppressor O 0 0.0027135678101330996
. O 0 5.3515359468292445e-06

As O 0 1.1198503671039362e-06
constitutional O 0 7.890991469139408e-07
DNA O 0 1.1375460644558189e-06
was O 0 1.81148806177589e-07
not O 0 4.760893901334384e-09
available O 0 1.2624989054188518e-08
, O 0 2.3478770927454207e-08
a O 0 3.9231676396411785e-07
putative O 0 4.9255329940933734e-05
hereditary O 1 0.9142869114875793
predisposition O 0 0.16341471672058105
to O 0 2.3809388949302956e-05
T B-Disease 1 1.0
- I-Disease 1 0.9999672174453735
PLL I-Disease 1 0.9999884366989136
will O 0 2.927971820554376e-08
require O 0 1.6440512951021446e-08
further O 0 7.337119001249448e-08
investigation O 0 8.803600053397531e-07
. O 0 1.7046302502876642e-07
. O 0 8.785450518189464e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.034051135182380676
kinase O 0 5.049261380918324e-05
is O 0 3.870832188113127e-08
involved O 0 3.297688522252429e-08
in O 0 6.6214682625798105e-09
the O 0 2.83505290354924e-08
modulation O 0 1.1114306630588544e-07
of O 0 6.60309567024342e-08
the O 0 7.047846111163381e-07
Ca2 O 0 0.010932901874184608
+ O 0 7.696482498431578e-05
homeostasis O 0 6.57922646496445e-05
in O 0 2.6305215783395397e-07
skeletal O 1 0.9785091280937195
muscle O 0 8.533250365871936e-05
cells O 0 3.412591104279272e-05
. O 0 2.913160187745234e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999945163726807
DM B-Disease 1 1.0
) O 0 4.843780516239349e-06
, O 0 3.6968582861618415e-08
the O 0 6.65181261183534e-08
most O 0 3.2761597879016335e-08
prevalent O 0 0.00012749983579851687
muscular B-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999986886978149
in O 0 6.6718648668029346e-06
adults O 0 1.94608196579793e-06
, O 0 8.901262305016644e-08
is O 0 6.235941185650518e-08
caused O 0 2.479815179867728e-07
by O 0 9.030698322476383e-08
( O 0 1.807143235055264e-06
CTG O 0 0.011848886497318745
) O 0 1.7964843834761268e-07
n O 0 7.546589699813921e-07
- O 0 3.685917420170881e-07
repeat O 0 2.4515415475434565e-07
expansion O 0 1.3638745599564572e-07
in O 0 9.136484457883398e-09
a O 0 4.2669725530686264e-08
gene O 0 2.6587278156853245e-08
encoding O 0 2.974472401717776e-08
a O 0 1.0457009125275363e-07
protein O 0 1.2521004464360885e-06
kinase O 0 7.993517101567704e-06
( O 0 2.24146424443461e-06
DM B-Disease 1 0.9999996423721313
protein O 0 2.291526470798999e-06
kinase O 0 1.674245709182287e-06
; O 0 1.2802443549730924e-08
DMPK O 0 0.0001004100195132196
) O 0 1.8723049777236156e-08
and O 0 1.2297807217009904e-09
involves O 0 2.324545889109686e-08
changes O 0 6.8843575284915914e-09
in O 0 8.236154513951988e-08
cytoarchitecture O 0 4.1114417399512604e-05
and O 0 4.3201947619309067e-07
ion O 0 0.00036196253495290875
homeostasis O 1 0.5264610052108765
. O 0 1.2422035069903359e-05

To O 0 1.3163662515580654e-06
obtain O 0 1.565882143950148e-06
clues O 0 5.5660366342635825e-06
to O 0 4.37444747092286e-08
the O 0 1.354628125227464e-07
normal O 0 1.3910068901168415e-06
biological O 0 1.0910627679550089e-05
role O 0 2.37738095165696e-06
of O 0 4.4484245336207096e-06
DMPK O 1 0.9998893737792969
in O 0 9.8681607596518e-07
cellular O 0 3.360947812325321e-05
ion O 0 1.011720723909093e-05
homeostasis O 0 0.00011567179171834141
, O 0 1.0480067480500566e-08
we O 0 6.639286898035834e-09
have O 0 1.3556207267839682e-09
compared O 0 1.4209988741242796e-08
the O 0 1.7736164537041077e-08
resting O 0 2.039409764620359e-06
[ O 0 3.4947902349813376e-06
Ca2 O 0 5.3085068429936655e-06
+ O 0 3.000908179728867e-07
] O 0 5.717904727475798e-08
i O 0 1.5309723266909714e-08
, O 0 1.1809465627621307e-09
the O 0 3.45481265817682e-09
amplitude O 0 4.965414746038732e-08
and O 0 5.15918507915103e-09
shape O 0 1.3082672012387775e-07
of O 0 2.1657982074430038e-07
depolarization O 0 1.2573112144309562e-05
- O 0 1.4940162145649083e-05
induced O 0 4.2135925468755886e-05
Ca2 O 0 3.0928655178286135e-05
+ O 0 6.092543571867282e-07
transients O 0 1.567063776519717e-07
, O 0 1.1110948827663947e-09
and O 0 5.350915821544788e-10
the O 0 3.3508447128127727e-09
content O 0 1.363710033785992e-08
of O 0 1.4876474097036407e-07
ATP O 0 0.0001508102286607027
- O 0 2.6999200599675532e-06
driven O 0 9.75503553490853e-07
ion O 0 7.065505087666679e-07
pumps O 0 2.520550879125949e-07
in O 0 2.2867398641324144e-08
cultured O 0 6.246921202546218e-06
skeletal O 0 0.00021938324789516628
muscle O 0 2.843927688900294e-07
cells O 0 8.030982456830316e-08
of O 0 6.416048137225516e-08
wild O 0 5.699155636307296e-08
- O 0 2.2406767641314218e-07
type O 0 7.037368732198956e-08
and O 0 8.892180325403842e-09
DMPK O 0 0.00014970787742640823
[ O 0 2.8894535262224963e-06
- O 0 4.112207079742802e-06
/ O 0 9.870111171039753e-06
- O 0 5.110286565468414e-06
] O 0 2.3890040665719425e-06
knockout O 0 3.7539164623012766e-05
mice O 0 1.13506766865612e-05
. O 0 1.0223246817986364e-06

In O 0 5.326916379999602e-06
vitro O 0 1.0208641469944268e-05
- O 0 3.756769956453354e-06
differentiated O 0 2.4473745270370273e-06
DMPK O 0 0.0004262668080627918
[ O 0 7.588435437355656e-06
- O 0 1.453407730878098e-05
/ O 0 3.6655892472481355e-05
- O 0 1.312162567046471e-05
] O 0 1.9633289412013255e-06
myotubes O 0 3.145817572658416e-06
exhibit O 0 1.3707359869385982e-07
a O 0 6.355320891771044e-08
higher O 0 1.7352564896100375e-07
resting O 0 4.645929948310368e-06
[ O 0 2.9205373266449897e-06
Ca2 O 0 5.278631761029828e-06
+ O 0 2.319274017281714e-07
] O 0 5.5556679257051655e-08
i O 0 1.7242232530634283e-08
than O 0 2.929372522331164e-09
do O 0 4.144090848257065e-09
wild O 0 1.3519114361315587e-07
- O 0 1.3921772961111856e-06
type O 0 1.0968864216920338e-06
myotubes O 0 3.601501157390885e-05
because O 0 2.0358285723887093e-08
of O 0 2.8679462360514663e-08
an O 0 1.3563353107315379e-08
altered O 0 5.3288097490167274e-08
open O 0 3.1993092619586605e-08
probability O 0 4.067816661290635e-08
of O 0 1.8679816804478833e-08
voltage O 0 1.354076601955967e-07
- O 0 6.009572928178386e-08
dependent O 0 1.025645417485066e-07
l O 0 1.3775741081190063e-07
- O 0 4.655811025600087e-08
type O 0 7.200161888931689e-08
Ca2 O 0 8.098331250039337e-07
+ O 0 9.914442955505365e-08
and O 0 2.3285217309876316e-08
Na O 0 0.00019712881476152688
+ O 0 1.2765303836204112e-06
channels O 0 3.589124162317603e-07
. O 0 3.198443607743684e-07

The O 0 2.6418516426929273e-05
mutant O 0 5.5219450587173924e-05
myotubes O 0 0.0001728142669890076
exhibit O 0 1.6759231584728695e-06
smaller O 0 1.6851049622346181e-07
and O 0 4.775365880504978e-08
slower O 0 4.022618213639362e-06
Ca2 O 0 7.628226285305573e-06
+ O 0 2.612486014186288e-07
responses O 0 1.143672623271641e-08
upon O 0 2.7324356111080306e-08
triggering O 0 2.050747838211464e-07
by O 0 2.0273811074389414e-08
acetylcholine O 0 1.1133290627185488e-06
or O 0 1.7566515353450995e-08
high O 0 2.1438468422729784e-07
external O 0 2.473254653523327e-06
K O 0 5.294485890772194e-05
+ O 0 1.6547070117667317e-05
. O 0 1.7899584463521023e-06

In O 0 1.253701498171722e-06
addition O 0 1.5555168886294268e-07
, O 0 2.21523048793415e-08
we O 0 9.881381934917499e-09
observed O 0 2.3865435849756977e-08
that O 0 2.2711903469030403e-09
these O 0 1.823815765078507e-08
Ca2 O 0 5.649006925523281e-05
+ O 0 3.023336603291682e-06
transients O 0 4.387123340165999e-07
partially O 0 7.134829616006755e-08
result O 0 3.024281269858875e-09
from O 0 2.3887509748021785e-09
an O 0 7.822111847133328e-09
influx O 0 3.058175579440103e-08
of O 0 4.349629278976863e-08
extracellular O 0 1.2391523114274605e-06
Ca2 O 0 9.069500492842053e-07
+ O 0 2.653226438553702e-08
through O 0 2.971312529354009e-09
the O 0 2.0615713580696138e-08
l O 0 2.448700229251699e-07
- O 0 1.9094956371645821e-07
type O 0 5.837724188495486e-07
Ca2 O 0 9.994410902436357e-06
+ O 0 1.4789394526815158e-06
channel O 0 1.4424606433749432e-06
. O 0 3.084708168898942e-07

Neither O 0 1.841903940658085e-05
the O 0 4.87380759750522e-07
content O 0 1.9020875186015473e-07
nor O 0 1.3701072987259977e-07
the O 0 6.753716519369846e-08
activity O 0 3.074857204410364e-07
of O 0 4.342500403708982e-07
Na O 0 0.0143607622012496
+ O 0 5.729646545660216e-06
/ O 0 1.3715535942537826e-06
K O 0 4.306395567255095e-06
+ O 0 1.4894006881149835e-06
ATPase O 0 9.48943488765508e-06
and O 0 4.136385811648324e-08
sarcoplasmic O 0 1.465371224185219e-05
reticulum O 0 1.1207284842384979e-05
Ca2 O 0 8.856088243192062e-06
+ O 0 1.9127485302306013e-06
- O 0 1.087972577806795e-06
ATPase O 0 1.5409676052513532e-05
are O 0 8.698694209385849e-09
affected O 0 4.747910509195208e-08
by O 0 1.3116878960772738e-07
DMPK O 0 0.0020700839813798666
absence O 0 3.690246376208961e-05
. O 0 8.420687663601711e-06

In O 0 2.08749793273455e-06
conclusion O 0 3.283067599113565e-06
, O 0 9.703838799168807e-08
our O 0 7.066988416681852e-08
data O 0 1.3043468527484947e-07
suggest O 0 1.490348324750812e-07
that O 0 2.5975449347015456e-08
DMPK O 0 0.010661987587809563
is O 0 7.459801310005787e-08
involved O 0 1.6246347911419434e-07
in O 0 2.561696454961293e-08
modulating O 0 1.4600306030843058e-06
the O 0 4.892631011443882e-08
initial O 0 1.4231395084607357e-07
events O 0 5.0332488399362774e-08
of O 0 8.220177249995686e-08
excitation O 0 7.454035312548513e-06
- O 0 2.4085078621283174e-05
contraction O 0 1.088487624656409e-05
coupling O 0 2.0731781660288107e-06
in O 0 1.6437415695236268e-07
skeletal O 0 0.006430582143366337
muscle O 0 4.706472282123286e-06
. O 0 6.159448275866453e-07
. O 0 3.1890276659396477e-06

Constitutional O 0 0.0012493511894717813
RB1 O 1 0.999998927116394
- O 0 0.00019876175792887807
gene O 0 8.293769724332378e-07
mutations O 0 4.625998428764433e-08
in O 0 1.5727284363720173e-08
patients O 0 1.079353584287901e-08
with O 0 1.8805724977255522e-08
isolated O 0 6.038209448888665e-06
unilateral B-Disease 0 1.5946989151416346e-05
retinoblastoma I-Disease 1 0.9826090335845947
. O 0 2.293846227985341e-05

In O 0 2.021918817263213e-06
most O 0 7.726090700543864e-08
patients O 0 3.890409772111525e-08
with O 0 1.5187598734200947e-08
isolated O 0 9.321378797721991e-07
unilateral B-Disease 0 1.1986167010036297e-06
retinoblastoma I-Disease 1 0.9995294809341431
, O 0 1.4999430959505844e-06
tumor B-Disease 0 0.2838047742843628
development O 0 3.0421105634559353e-07
is O 0 4.916013818245801e-09
initiated O 0 3.5094071648700265e-08
by O 0 5.196080010705373e-09
somatic O 0 1.818810488884992e-07
inactivation O 0 5.421125024440698e-07
of O 0 6.040358613290664e-08
both O 0 1.1443423986179369e-08
alleles O 0 6.06500591970871e-08
of O 0 4.051181576869567e-07
the O 0 4.427888143254677e-06
RB1 O 1 0.9916442036628723
gene O 0 1.8553551853983663e-05
. O 0 5.60334001420415e-06

However O 0 2.1686846594093367e-06
, O 0 6.310315114887999e-08
some O 0 3.6105303191646954e-09
of O 0 1.0242999337606307e-08
these O 0 9.86556347726264e-09
patients O 0 7.887796016348148e-08
can O 0 7.559866332940146e-08
transmit O 0 0.00010889741679420695
retinoblastoma B-Disease 1 0.9999998807907104
predisposition O 1 0.9996529817581177
to O 0 6.857703738205601e-07
their O 0 9.291397304878046e-07
offspring O 0 2.669499554031063e-05
. O 0 2.100712663377635e-06

To O 0 6.521208320009464e-07
determine O 0 3.6799184499614057e-07
the O 0 1.1636546304316653e-07
frequency O 0 1.7157502441023098e-07
and O 0 1.4065722808709324e-08
nature O 0 2.1129275751263776e-07
of O 0 1.7230799187473167e-07
constitutional O 0 1.3070382919977419e-05
RB1 O 1 0.9999997615814209
- O 0 4.0689996239962056e-05
gene O 0 1.992042228948776e-07
mutations O 0 1.3357809969249956e-08
in O 0 4.3908126023950445e-09
patients O 0 2.655533570816715e-09
with O 0 2.203211835194452e-09
isolated O 0 2.3312509256356861e-07
unilateral B-Disease 0 4.857042767980602e-07
retinoblastoma I-Disease 0 2.8766447940142825e-05
, O 0 3.617547594814141e-09
we O 0 3.4742799748244124e-09
analyzed O 0 8.505219284415944e-08
DNA O 0 4.0966889969240583e-07
from O 0 1.1058862270374448e-07
peripheral O 0 7.396282398985932e-06
blood O 0 3.067043508053757e-07
and O 0 4.5476298282665084e-08
from O 0 1.4215826013241895e-05
tumor B-Disease 1 0.9999997615814209
tissue O 0 0.018186183646321297
. O 0 1.0409154128865339e-05

The O 0 2.5256983917643083e-06
analysis O 0 7.868695206525445e-07
of O 0 5.820990622851241e-07
tumors B-Disease 1 0.9999784231185913
from O 0 1.398096571847418e-07
54 O 0 6.841333402007876e-07
( O 0 8.194739109512739e-08
71 O 0 2.1571364072769939e-07
% O 0 1.8655320843663503e-08
) O 0 4.385054097610919e-09
of O 0 5.713268969032015e-09
76 O 0 2.1162247776373988e-07
informative O 0 5.599465566774597e-07
patients O 0 2.096766138492967e-08
showed O 0 9.212291729454591e-08
loss O 0 3.1618651519238483e-07
of O 0 4.701451814526081e-07
constitutional O 0 8.884740054782014e-06
heterozygosity O 1 0.9999990463256836
( O 1 0.7536749839782715
LOH O 1 1.0
) O 0 3.421923338464694e-06
at O 0 1.1892870134033728e-05
intragenic O 0 0.0002455908979754895
loci O 0 1.666450953052845e-05
. O 0 4.982623522664653e-06

Three O 0 9.475591468799394e-06
of O 0 3.831311460089637e-06
13 O 0 2.117834083037451e-05
uninformative O 0 0.16114887595176697
patients O 0 1.4132435808278387e-06
had O 0 8.270485523098614e-07
constitutional O 0 7.985669071786106e-06
deletions O 0 7.006405940046534e-05
. O 0 1.637064815440681e-05

For O 0 3.1935715014697053e-06
39 O 0 3.257012394897174e-06
randomly O 0 8.101977186925069e-07
selected O 0 2.9318446195247816e-06
tumors B-Disease 1 1.0
, O 0 2.1155922240723157e-06
SSCP O 1 0.9997102618217468
, O 0 1.1614100685619633e-06
hetero O 0 0.00016338957357220352
- O 0 2.7953485641774023e-06
duplex O 0 8.280190741061233e-06
analysis O 0 5.554046822453529e-08
, O 0 3.4154810091280297e-09
sequencing O 0 4.8149313869316757e-08
, O 0 3.169715601103462e-09
and O 0 3.5326688241354987e-09
Southern O 0 9.768127284814909e-08
blot O 0 2.653267472396692e-07
analysis O 0 2.6801631136663673e-08
were O 0 5.730184771124414e-09
used O 0 1.4203783926802771e-08
to O 0 1.3271288068494869e-08
identify O 0 2.937902365829359e-07
mutations O 0 7.644690640518093e-07
. O 0 2.8297206426941557e-06

Mutations O 0 5.693039383913856e-06
were O 0 2.9034478643552575e-07
detected O 0 2.834253507444373e-07
in O 0 1.2536779614436e-08
21 O 0 1.9698502740084223e-07
( O 0 7.363602350096699e-08
91 O 0 5.362978185985412e-07
% O 0 6.806180152807428e-08
) O 0 1.6620353093799167e-08
of O 0 1.4188869101872115e-07
23 O 0 7.132210157578811e-05
tumors B-Disease 1 1.0
with O 0 0.0002528261684346944
LOH O 1 1.0
. O 0 3.50772388628684e-05

In O 0 2.791128963508527e-06
6 O 0 1.9556819097488187e-06
( O 0 1.9475470480756485e-07
38 O 0 3.180182091000461e-07
% O 0 4.408554588053448e-08
) O 0 1.3534563692019219e-08
of O 0 9.283146340521853e-08
16 O 0 2.8597736672963947e-05
tumors B-Disease 1 1.0
without O 0 0.13976223766803741
LOH O 1 1.0
, O 0 2.938663712370726e-08
one O 0 6.354554216159158e-09
mutation O 0 2.9386231226169457e-09
was O 0 1.8267435564212064e-08
detected O 0 2.169212542924015e-08
, O 0 1.071922106632428e-09
and O 0 6.817685305193777e-10
in O 0 6.665374030490057e-09
9 O 0 2.4437753154415987e-07
( O 0 4.111702267550754e-08
56 O 0 9.740109163658417e-08
% O 0 7.725659223467574e-09
) O 0 2.9704965154309093e-09
of O 0 1.2336436761017922e-08
the O 0 4.0947747947939206e-07
tumors B-Disease 1 1.0
without O 0 0.0442107729613781
LOH O 1 1.0
, O 0 4.070036041525782e-08
both O 0 6.364598181818337e-09
mutations O 0 1.3582457825123129e-08
were O 0 5.006144121466605e-08
found O 0 4.041338002025441e-07
. O 0 8.971141483016254e-07

Thus O 0 7.203319455584278e-06
, O 0 1.2832714446631144e-07
a O 0 1.0384422211018318e-07
total O 0 4.688587651457965e-08
of O 0 6.645826999829296e-08
45 O 0 7.911285848649641e-08
mutations O 0 9.018078728217915e-09
were O 0 1.2343168265260829e-08
identified O 0 4.018179424747359e-07
in O 0 5.343440534488764e-07
tumors B-Disease 1 1.0
of O 0 6.627916445722803e-05
36 O 0 0.0002667379449121654
patients O 0 3.0159990274114534e-06
. O 0 3.6479507343756268e-06

Thirty O 0 8.711103146197274e-05
- O 0 3.7077800243423553e-06
nine O 0 1.3366455675623e-07
of O 0 3.073983023682558e-08
the O 0 1.881713451723499e-08
mutations O 0 3.577095242235373e-08
- O 0 9.926004196358917e-08
including O 0 4.9961070835990995e-09
34 O 0 7.085506581461232e-08
small O 0 1.8908231425029953e-08
mutations O 0 9.988426086238178e-09
, O 0 3.35842065268821e-09
2 O 0 3.0599903055872346e-08
large O 0 2.106824403824703e-08
structural O 0 9.527261681796517e-07
alterations O 0 4.554913175525144e-07
, O 0 3.082849175939373e-08
and O 0 2.1603188571361898e-08
hypermethylation O 0 0.00020215507538523525
in O 0 2.327354593489872e-07
3 O 0 1.085775420506252e-05
tumors O 1 1.0
- O 0 1.0020236231866875e-06
were O 0 3.3702036716931616e-08
not O 0 6.811748942681106e-09
detected O 0 1.0131086725095884e-07
in O 0 1.0654082949201893e-08
the O 0 9.392554289888722e-08
corresponding O 0 2.3426757707056822e-06
peripheral O 0 5.468389281304553e-05
blood O 0 9.102947842620779e-06
DNA O 0 0.00019852879631798714
. O 0 6.162113095342647e-06

In O 0 3.9296560316870455e-06
6 O 0 2.1858293166587828e-06
( O 0 2.2760968931834213e-07
17 O 0 1.9913564131002204e-07
% O 0 1.8969711135241596e-08
) O 0 3.867701270365842e-09
of O 0 1.2142537642034767e-08
the O 0 3.1065777506000813e-08
36 O 0 1.2765214307819406e-07
patients O 0 1.337711097448846e-08
, O 0 2.2240607133738877e-09
a O 0 2.7553220149911795e-08
mutation O 0 7.577792615620638e-09
was O 0 5.905242161929891e-08
detected O 0 5.193031427097594e-08
in O 0 3.0096418690561677e-09
constitutional O 0 2.2451937198297856e-08
DNA O 0 2.773193159555376e-07
, O 0 2.508226293329585e-09
and O 0 9.121036148584949e-10
1 O 0 9.279973234299632e-09
of O 0 5.186169271809149e-09
these O 0 1.0517127169151763e-09
mutations O 0 5.051722151705462e-09
is O 0 2.7193114426893317e-09
known O 0 7.269638668816469e-09
to O 0 3.31455529689606e-09
be O 0 1.461379550704578e-08
associated O 0 1.4735472575466702e-07
with O 0 3.8232631283108276e-08
reduced O 0 4.158990122959949e-06
expressivity O 0 0.00023089826572686434
. O 0 6.105611646489706e-06

The O 0 6.8948133957746904e-06
presence O 0 1.1122053820145084e-06
of O 0 4.1759585656109266e-07
a O 0 4.421325456860359e-07
constitutional O 0 5.07212575939775e-07
mutation O 0 1.0076028900130041e-07
was O 0 4.557094257506833e-07
not O 0 1.0972002861819874e-08
associated O 0 3.2683704631608634e-08
with O 0 3.925814784366821e-09
an O 0 1.8115047240030435e-08
early O 0 3.09259064579237e-07
age O 0 3.57559247277095e-06
at O 0 1.7497266526333988e-05
treatment O 0 3.5489713354763808e-06
. O 0 3.862900484818965e-06

In O 0 2.3217955913423793e-06
1 O 0 2.5975803055189317e-06
patient O 0 1.240536903424072e-06
, O 0 1.4037345863471273e-07
somatic O 0 2.7399923055781983e-05
mosaicism O 0 0.18218962848186493
was O 0 2.2719120806868887e-06
demonstrated O 0 1.6879164377314737e-07
by O 0 5.391322943637533e-09
molecular O 0 4.6183458835002966e-08
analysis O 0 9.074240914230813e-09
of O 0 6.132121033175508e-09
DNA O 0 6.518379080944214e-08
and O 0 9.371006193248377e-09
RNA O 0 1.8754681150312535e-05
from O 0 1.2949977872267482e-06
peripheral O 0 0.0004812816623598337
blood O 0 4.941001316183247e-05
. O 0 8.070066542131826e-06

In O 0 4.340887244325131e-06
2 O 0 1.4984489098424092e-06
patients O 0 4.45417924765934e-08
without O 0 3.2101468150358414e-08
a O 0 1.1301461455559547e-07
detectable O 0 3.3146250189020066e-06
mutation O 0 1.9362761349839275e-07
in O 0 1.0989452903231722e-07
peripheral O 0 0.0005540944403037429
blood O 0 3.91279645555187e-05
, O 0 6.755609547326458e-07
mosaicism O 1 0.999842643737793
was O 0 3.3979176805587485e-06
suggested O 0 1.3250907215933694e-07
because O 0 7.72934427573091e-09
1 O 0 1.547684114200365e-08
of O 0 1.553483741645323e-08
the O 0 9.807967416008978e-08
patients O 0 5.338433197721315e-07
showed O 0 0.05889564007520676
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 9.211185414415013e-08
the O 0 5.774226963239926e-08
other O 0 3.418681338018814e-09
later O 0 1.583139379590648e-07
developed O 0 2.8285720077292353e-07
bilateral B-Disease 0 1.1645905033219606e-05
retinoblastoma I-Disease 0 0.0013342128368094563
. O 0 3.2034179184847744e-06

In O 0 2.3551801859866828e-06
conclusion O 0 4.827851626032498e-06
, O 0 1.0767467273353759e-07
our O 0 1.0077970813426873e-07
results O 0 6.122294138322104e-08
emphasize O 0 1.1039578851068654e-07
that O 0 5.1959712088489596e-09
the O 0 5.074796405324378e-08
manifestation O 0 8.358680133824237e-06
and O 0 7.529272494366523e-08
transmissibility O 0 0.0011672098189592361
of O 0 1.446114879399829e-06
retinoblastoma B-Disease 0 0.00038169993786141276
depend O 0 1.457321872067041e-07
on O 0 2.6029407962369078e-08
the O 0 1.0504682457224135e-08
nature O 0 2.2665696874923924e-08
of O 0 5.305653250076148e-09
the O 0 6.134647456690345e-09
first O 0 8.154617425759625e-09
mutation O 0 1.5753093274284424e-09
, O 0 4.694543087602199e-10
its O 0 3.414196425577387e-10
time O 0 1.5413348375403757e-09
in O 0 2.1118200521641484e-09
development O 0 2.9245784460840696e-08
, O 0 9.400091816047507e-10
and O 0 2.9519187094706467e-10
the O 0 1.6470761421416569e-09
number O 0 4.1060085886890363e-10
and O 0 2.768673901254459e-10
types O 0 2.2099331253855325e-09
of O 0 1.781760872177074e-08
cells O 0 2.0024815583497002e-08
that O 0 1.5259484786867006e-09
are O 0 2.431719492435036e-09
affected O 0 1.967375240496949e-08
. O 0 4.1767549419091665e-08
. O 0 7.160622317314846e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 0 0.03642963245511055
the I-Disease 0 8.365662506548688e-05
fifth I-Disease 0 0.002110865665599704
component I-Disease 0 0.0001294614776270464
of I-Disease 0 1.7721137055559666e-06
complement I-Disease 0 5.701645477529382e-06
in O 0 2.1840476165380096e-06
man O 0 0.00075031683081761
. O 0 1.4940005712560378e-05

I O 0 0.003836508607491851
. O 0 0.0001465678942622617

Clinical O 0 0.4857323467731476
, O 0 5.014639555156464e-06
immunochemical O 0 0.4658074676990509
, O 0 6.30350598385121e-07
and O 0 3.022864518698043e-07
family O 0 4.632325726561248e-06
studies O 0 1.0325667062716093e-05
. O 0 5.589495231106412e-06

The O 0 3.551476993379765e-06
first O 0 7.298804121091962e-07
recognized O 0 1.0290073078067508e-06
human O 0 1.646614236960886e-06
kindred O 0 0.029836921021342278
with O 0 1.1292866474832408e-05
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.999900221824646
the I-Disease 0 0.0010796788847073913
fifth I-Disease 0 0.038346536457538605
component I-Disease 0 5.537326433113776e-05
of I-Disease 0 1.7408469830115791e-06
complement I-Disease 0 1.7833313904702663e-05
( O 0 4.009388794656843e-05
C5 O 0 0.4661535918712616
) O 0 3.973317461714032e-07
is O 0 2.10026882996317e-07
described O 0 1.6816738934721798e-06
. O 0 3.1212593967211433e-06

The O 0 2.03473427973222e-05
proband O 0 0.00015387254825327545
, O 0 2.7645720024338516e-07
a O 0 5.35450510597002e-07
20 O 0 6.914376058375638e-07
- O 0 9.747150215844158e-07
year O 0 2.785893116197258e-07
- O 0 4.048719802085543e-06
old O 0 3.3725748380675213e-06
black O 0 3.508109784888802e-07
female O 0 9.362949526803277e-07
with O 0 1.1808343742814031e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.00019212304323446006
age O 0 0.00036915630334988236
11 O 0 8.162405720213428e-06
, O 0 3.667033467991132e-07
lacked O 0 0.0001102420937968418
serum O 1 0.933743953704834
hemolytic O 1 1.0
complement O 0 0.0005664369091391563
activity O 0 0.00024723171372897923
, O 0 5.985162232491348e-08
even O 0 8.651936411752104e-08
during O 0 5.3861217566009145e-06
remission O 0 0.00010792702960316092
. O 0 6.591319561266573e-06

C5 O 1 0.9161608815193176
was O 0 5.284125654725358e-05
undetectable O 0 0.00016495278396178037
in O 0 7.911978059382818e-07
her O 0 9.236851497007592e-07
serum O 0 4.842653652303852e-06
by O 0 8.281504904061876e-08
both O 0 2.8345129976514727e-07
immunodiffusion O 0 0.0007217233069241047
and O 0 1.912799689307576e-06
hemolytic O 1 0.9999901056289673
assays O 0 0.0005179817671887577
. O 0 2.6423276722198352e-05

Other O 0 2.2253354359236255e-07
complement O 0 6.5970016294159e-07
components O 0 7.885823265496583e-07
were O 0 1.0451624632423773e-07
normal O 0 6.574517215085507e-07
during O 0 5.327783014763554e-07
remission O 0 7.088680831657257e-06
of O 0 4.506985987973167e-06
lupus O 0 0.00033027990139089525
, O 0 7.167714954903204e-08
but O 0 9.610745621557726e-08
C1 O 0 0.30185920000076294
, O 0 4.04119134600478e-07
C4 O 1 0.9444496035575867
, O 0 4.7080698095669504e-07
C2 O 0 7.354875560849905e-05
, O 0 5.7796036401214224e-08
and O 0 1.625987948727925e-07
C3 O 1 0.6559452414512634
levels O 0 9.91484739643056e-06
fell O 0 0.0008393455063924193
during O 0 8.618726133136079e-05
exacerbations O 0 0.01418120227754116
. O 0 1.1705610631906893e-05

A O 0 0.00010587002907413989
younger O 0 4.4027960939274635e-06
half O 0 1.7246298966711038e-06
- O 0 7.92502032709308e-06
sister O 0 2.817651648001629e-06
, O 0 2.684553024323577e-08
who O 0 2.2904895757847044e-08
had O 0 2.307398290213314e-07
no O 0 2.023612296397914e-06
underlying O 1 0.9997681975364685
disease O 0 0.25795358419418335
, O 0 9.251382948605169e-08
was O 0 3.890802872774657e-06
also O 0 2.9472463580759722e-08
found O 0 4.1780936044233385e-08
to O 0 4.87346305533265e-08
lack O 0 8.176086339517497e-06
immunochemically O 1 0.9830347299575806
detectable O 1 0.6956750750541687
C5 O 0 0.11495412886142731
. O 0 1.0340113476559054e-05

By O 0 1.7671993191470392e-05
hemolytic O 1 0.9998488426208496
assay O 0 2.1769150407635607e-05
, O 0 1.3490999606347032e-07
she O 0 9.936876210758783e-08
exhibited O 0 1.6931561219735158e-07
1 O 0 4.1428609165450325e-07
- O 0 1.0666118441804429e-06
2 O 0 1.48883401607236e-07
% O 0 2.2055001380749673e-08
of O 0 3.1846187908968204e-08
the O 0 7.612128882783509e-08
normal O 0 5.891449291084427e-06
serum O 0 8.540674753021449e-05
C5 O 0 0.0018027354963123798
level O 0 2.32036697411786e-07
and O 0 3.0792746130714477e-09
normal O 0 4.6219149396620196e-08
concentrations O 0 3.809737947335634e-08
of O 0 7.064465457062852e-09
other O 0 1.7165505683536253e-09
complement O 0 1.9284605912162078e-07
components O 0 8.632483741166652e-07
. O 0 9.793477602215717e-07

C5 O 1 0.9725213050842285
levels O 0 3.4942033835250186e-06
of O 0 3.864341238113411e-07
other O 0 1.6733082475184347e-08
family O 0 4.736694592111235e-08
members O 0 6.103601624118937e-09
were O 0 2.921562192170768e-08
either O 0 5.579114770171145e-08
normal O 0 5.149603339305031e-07
or O 0 1.871148391785482e-08
approximately O 0 1.0377235071246105e-07
half O 0 1.1295394841681627e-07
- O 0 1.0311804317097994e-06
normal O 0 1.3685729527423973e-07
, O 0 2.278470967453927e-09
consistent O 0 2.287093359143455e-08
with O 0 2.92606672225304e-09
autosomal O 0 9.638214351070928e-07
codominant O 0 1.5164524484134745e-05
inheritance O 0 5.493550361279631e-07
of O 0 1.3795383324577415e-07
the O 0 3.446463097134256e-07
gene O 0 5.5774717111489736e-06
determining O 0 0.0011939739342778921
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 6.915229459991679e-05

Normal O 1 0.9970371723175049
hemolytic O 1 0.9999992847442627
titers O 0 0.016945810988545418
were O 0 9.968596259568585e-07
restored O 0 1.1087010989285773e-06
to O 0 3.114872626497345e-08
both O 0 7.469910201507446e-08
homozygous O 0 2.5664960048743524e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999922513961792
deficient I-Disease 1 0.9999998807907104
( O 0 2.4801660401863046e-05
C5D B-Disease 1 1.0
) O 0 1.3435587788990233e-06
sera O 0 2.7050925837102113e-06
by O 0 6.619914838523755e-09
addition O 0 1.92954363598119e-08
of O 0 9.808267265043469e-08
highly O 0 1.1218855888728285e-06
purified O 0 2.7245954697718844e-05
human O 0 6.310185654001543e-06
C5 O 0 0.0013937524054199457
. O 0 4.268077645974699e-06

In O 0 8.6265445133904e-06
specific O 0 5.927126949245576e-06
C5 O 0 0.1389589011669159
titrations O 0 0.00018909525533672422
, O 0 3.811329563063737e-08
however O 0 7.990687223013992e-09
, O 0 2.4547401888952436e-09
it O 0 1.6588421747343318e-09
was O 0 6.423934451049718e-08
noted O 0 2.4411077603758713e-08
that O 0 1.1099848817863744e-09
when O 0 4.224971483779427e-09
limited O 0 7.549127545303236e-09
amounts O 0 3.866582076739178e-08
of O 0 4.4819444156019017e-07
C5 O 0 0.00015629710105713457
were O 0 7.01891025300938e-08
assayed O 0 5.863954811502481e-06
in O 0 1.3165147194627025e-08
the O 0 1.868562726770051e-08
presence O 0 3.3892717965500196e-08
of O 0 5.455803275822291e-08
low O 0 2.0384246113280824e-07
dilutions O 0 4.313634235586505e-06
of O 0 3.1021434665490233e-07
either O 0 2.5926206035364885e-06
C5D B-Disease 1 1.0
serum O 0 0.08749125152826309
, O 0 5.295717642184172e-08
curving O 0 2.8892500836263935e-07
rather O 0 3.4143152749521732e-09
than O 0 1.8891781472518687e-09
linear O 0 4.309602630314657e-08
dose O 0 8.516013849657611e-08
- O 0 5.688469073561464e-08
response O 0 6.331966062589345e-09
plots O 0 3.173631313302394e-08
were O 0 5.8157940685532594e-09
consistently O 0 1.2338272625811442e-08
obtained O 0 1.376407432474025e-08
, O 0 4.8022994469931746e-09
suggesting O 0 4.204570558385967e-08
some O 0 8.202742485252656e-09
inhibitory O 0 9.944097882907954e-07
effect O 0 3.3508598562548286e-07
. O 0 8.691969810570299e-07

Further O 0 3.260542825955781e-06
studies O 0 9.505679372523446e-07
suggested O 0 4.3199636934332375e-07
that O 0 3.334696430101758e-08
low O 0 1.4209495020622853e-06
dilutions O 0 5.811000301036984e-05
of O 0 1.6915380911086686e-05
C5D B-Disease 1 1.0
serum O 0 0.0004068167763762176
contain O 0 3.231963603411714e-07
a O 0 2.422518150524411e-07
factor O 0 1.8525336997754493e-07
( O 0 1.5117800344910393e-08
or O 0 1.4507871348712342e-08
factors O 0 7.289275316679777e-08
) O 0 2.9019409097941207e-08
interfering O 0 2.5636131795181427e-07
at O 0 1.1751481565625e-07
some O 0 4.0098853126835365e-09
step O 0 1.6183687989723694e-07
in O 0 9.716580251506457e-08
the O 0 9.8204134246771e-07
hemolytic O 1 0.9999669790267944
assay O 0 8.505010919179767e-05
of O 0 6.748700980097055e-05
C5 O 1 0.9953222870826721
, O 0 3.520556290936838e-08
rather O 0 2.107555729935484e-08
than O 0 9.961542701830695e-09
a O 0 1.2826744466565287e-07
true O 0 3.2898531117098173e-06
C5 O 0 0.0006769947940483689
inhibitor O 0 7.967761121108197e-06
or O 0 6.462448709498858e-07
inactivator O 0 0.00018328615988139063
. O 0 4.67749032395659e-06

Of O 0 7.423191618727287e-06
clinical O 0 6.884576123411534e-06
interest O 0 1.5567917444059276e-07
are O 0 5.335936581474243e-09
( O 0 2.2893583917493743e-08
a O 0 3.172802109929762e-08
) O 0 4.446418344628e-09
the O 0 8.527208272823827e-09
documentation O 0 1.6806077383080265e-06
of O 0 2.5694100258988328e-05
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 1 0.9948545694351196
vasculitis B-Disease 1 1.0
, O 0 1.3282629879540764e-05
and O 0 1.5856454410823062e-05
arthritis B-Disease 1 1.0
in O 0 1.7413716477676644e-06
an O 0 5.561866146308603e-06
individual O 0 5.836604941578116e-06
lacking O 0 0.010281001217663288
C5 O 1 0.8142058849334717
( O 0 2.414795687855076e-07
and O 0 2.2149261980075607e-08
its O 0 2.387617925592167e-08
biologic O 0 2.3541606424259953e-06
functions O 0 3.682923477299482e-08
) O 0 7.355443809586859e-09
, O 0 1.463724919048559e-09
and O 0 3.1844225034660667e-09
( O 0 1.400100586579356e-07
b O 0 1.3417098898571567e-06
) O 0 3.4042379581933346e-08
a O 0 5.6154021876864135e-08
remarkable O 0 2.198009951825952e-06
propensity O 0 7.914507477835286e-06
to O 0 2.598385435703676e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.5619098664719786e-07
the O 0 1.439449761164724e-06
proband O 1 0.6260222792625427
, O 0 2.2239937891299633e-08
even O 0 5.857597518144075e-09
during O 0 2.767784046397992e-08
periods O 0 1.7861918877315475e-07
of O 0 2.2521446396694955e-07
low O 0 1.5713183074694825e-06
- O 0 3.759648166123952e-07
dose O 0 1.8362774767410883e-07
or O 0 6.786292860994081e-09
alternate O 0 7.484942443625187e-08
- O 0 1.783111258646386e-07
day O 0 3.8327405604832165e-07
corticosteroid O 0 1.7590809875400737e-05
therapy O 0 1.3076291907054838e-05
. O 0 8.712443673175585e-07

Other O 0 4.6124921482260106e-07
observations O 0 2.5953813747037202e-06
indicate O 0 9.925698805091088e-07
that O 0 3.216607069589372e-08
the O 0 4.871902206105005e-07
C5D B-Disease 1 1.0
state O 0 2.7834286697725474e-07
is O 0 6.504519234340478e-08
compatible O 0 6.719793788079187e-08
with O 0 6.4169269897718095e-09
normal O 0 2.418078111077193e-06
coagulation O 0 7.746885239612311e-05
function O 0 1.7784257977382367e-07
and O 0 7.673818025466517e-09
the O 0 1.018640531924575e-07
capacity O 0 5.795587298962346e-07
to O 0 7.46438431065144e-08
mount O 0 0.0005722219357267022
a O 0 1.883124241430778e-05
neutrophilic O 1 0.9999513626098633
leukocytosis O 1 0.6416736245155334
during O 0 3.740266038221307e-05
pyogenic B-Disease 1 0.5639186501502991
infection I-Disease 0 1.3037430107942782e-05
. O 0 2.754219394773827e-07
. O 0 1.32034938360448e-06

Susceptibility O 1 0.8903403878211975
to O 0 8.853401959640905e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00019566966511774808
twins O 0 6.868869240861386e-05
: O 0 1.0964851071548765e-07
the O 0 7.280187475089406e-08
role O 0 2.0250358545581548e-07
of O 0 3.4758070910356764e-07
genes O 0 4.2336580463597784e-07
, O 0 5.390285764406144e-07
HLA O 1 0.997016429901123
, O 0 7.157550641068156e-08
and O 0 5.000571334790038e-08
the O 0 1.1422160923757474e-06
environment O 0 1.6388581570936367e-05
. O 0 5.375197360990569e-06

OBJECTIVE O 0 0.0002008528244914487
To O 0 2.2639346752839629e-07
determine O 0 2.400202561148035e-07
the O 0 6.275339359262944e-08
relative O 0 5.038911581323191e-07
effects O 0 3.642850288088084e-07
of O 0 9.6204296085034e-08
genetic O 0 5.332531145540997e-07
and O 0 6.285998832566975e-09
environmental O 0 2.1680507700239104e-07
factors O 0 8.076359137021427e-08
in O 0 4.1682156393108016e-08
susceptibility O 0 4.672911472880514e-06
to O 0 2.8350475531624397e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9991129040718079
AS B-Disease 1 0.999990701675415
) O 0 2.8364916033751797e-06
. O 0 1.6792907899798593e-06

METHODS O 0 6.607438263017684e-05
Twins O 0 4.5227141526993364e-05
with O 0 8.265062234613652e-08
AS B-Disease 0 0.00014873944746796042
were O 0 6.623352533097204e-08
identified O 0 1.1424041446161937e-07
from O 0 2.0608085904427753e-08
the O 0 7.636268151145487e-08
Royal O 0 0.0006725197308696806
National O 0 0.0013779221335425973
Hospital O 1 0.9999361038208008
for O 0 6.0264160310907755e-06
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.14941726624965668
. O 0 6.44586998532759e-06

Clinical O 0 0.0008135716780088842
and O 0 8.180807071767049e-07
radiographic O 0 9.3510199803859e-05
examinations O 0 1.5629546396667138e-05
were O 0 1.3135981191680912e-07
performed O 0 2.5620977339713136e-07
to O 0 3.159667016916501e-08
establish O 0 1.1792587883974193e-06
diagnoses O 0 1.2202761354274116e-05
, O 0 1.265694038465881e-07
and O 0 1.7320770950846054e-07
disease O 0 0.00011857102799694985
severity O 0 8.427805369137786e-06
was O 0 2.648342842803686e-06
assessed O 0 2.0852766624557262e-07
using O 0 2.3676010485473853e-08
a O 0 3.286373484456817e-08
combination O 0 3.355861011300476e-08
of O 0 5.379985168474377e-08
validated O 0 6.769817559870717e-07
scoring O 0 1.5286241250578314e-06
systems O 0 5.363936907087918e-06
. O 0 2.7208336632611463e-06

HLA O 0 0.007507298141717911
typing O 0 6.949320231797174e-05
for O 0 2.752323325694306e-06
HLA O 0 0.004011604003608227
- O 0 3.0527953640557826e-05
B27 O 0 0.0001159445455414243
, O 0 9.821611683946685e-07
HLA O 0 0.00017231766832992435
- O 0 2.719087888181093e-06
B60 O 0 1.1806850125140045e-05
, O 0 8.195364387120208e-08
and O 0 1.0618097689985007e-07
HLA O 1 0.5192371010780334
- O 0 0.0001242315338458866
DR1 O 0 0.054624903947114944
was O 0 1.7380655492615915e-07
performed O 0 2.5593912766908034e-08
by O 0 7.027883164312243e-09
polymerase O 0 5.766548838437302e-07
chain O 0 4.4289254930163224e-08
reaction O 0 3.197361708728863e-09
with O 0 1.0419272111761302e-09
sequence O 0 6.393936047288662e-08
- O 0 7.07231464502911e-08
specific O 0 6.529077722916554e-09
primers O 0 1.399957767489468e-07
, O 0 7.1171570859007716e-09
and O 0 6.290268306230473e-09
zygosity O 0 4.839827852265444e-06
was O 0 4.7010439629957546e-07
assessed O 0 8.657769967612694e-07
using O 0 9.809396033233497e-07
microsatellite O 0 6.432432564906776e-05
markers O 0 1.632361272640992e-05
. O 0 3.003564870596165e-06

Genetic O 0 0.00019664033607114106
and O 0 2.0039053083564795e-07
environmental O 0 3.103726555764297e-07
variance O 0 1.2430767526439013e-07
components O 0 1.4770054690416146e-07
were O 0 3.00432105859727e-08
assessed O 0 1.1558461920913032e-07
with O 0 7.881852503999198e-09
the O 0 7.897310183579975e-08
program O 0 4.2250383103237255e-07
Mx O 0 7.3431842793070246e-06
, O 0 2.5249686785855374e-09
using O 0 1.5049550494694586e-09
data O 0 6.483311665306246e-09
from O 0 9.79610614848525e-10
this O 0 6.644604866323789e-10
and O 0 6.978736477591951e-10
previous O 0 1.9292935249382026e-08
studies O 0 3.252202773751378e-08
of O 0 4.361791638984869e-08
twins O 0 7.715067340541282e-07
with O 0 1.1227488272425035e-07
AS B-Disease 1 0.9998613595962524
. O 0 1.1937664567085449e-05

RESULTS O 0 1.90337814274244e-05
Six O 0 2.252491412946256e-06
of O 0 1.146295176113199e-06
8 O 0 6.34783737041289e-06
monozygotic O 0 0.0006012866506353021
( O 0 0.00016823226178530604
MZ O 1 0.9999992847442627
) O 0 1.7963300251722103e-06
twin O 0 6.270838184718741e-06
pairs O 0 2.7798952828561596e-07
were O 0 7.199893730103213e-07
disease O 0 2.919737744377926e-05
concordant O 0 3.385240779607557e-05
, O 0 7.984109373637693e-08
compared O 0 5.1131259226622205e-08
with O 0 5.359559906992217e-09
4 O 0 1.7828783427376038e-07
of O 0 1.481675298009577e-07
15 O 0 3.3079132322200167e-07
B27 O 0 1.624089782126248e-05
- O 0 3.2170721624424914e-06
positive O 0 8.077528264038847e-07
dizygotic O 0 0.00010920283966697752
( O 0 4.644145064958138e-06
DZ O 0 0.0177814569324255
) O 0 3.143347555578657e-07
twin O 0 7.462176654371433e-07
pairs O 0 5.701547678427232e-08
( O 0 3.692608885330628e-08
27 O 0 3.7256404539220966e-07
% O 0 4.7619135301602e-08
) O 0 1.1533527910501107e-08
and O 0 5.28805399468979e-09
4 O 0 1.5751307103073486e-07
of O 0 4.501031298786984e-07
32 O 0 1.2260699804755859e-05
DZ O 1 0.9999861717224121
twin O 0 1.1383272976672743e-05
pairs O 0 1.7865650647763687e-07
overall O 0 2.958359459626081e-07
( O 0 1.8841916471501463e-08
12 O 0 1.1864807802908217e-08
. O 0 3.096283229808705e-09
5 O 0 8.315598876151853e-08
% O 0 6.604770419471606e-08
) O 0 1.0101044267685211e-07
. O 0 3.989370611634513e-07

Nonsignificant O 1 0.8744091391563416
increases O 0 3.2174862099054735e-06
in O 0 2.1257378080008493e-07
similarity O 0 3.039770319901436e-07
with O 0 1.3801088272202833e-08
regard O 0 1.6261941482298425e-07
to O 0 3.283215832539099e-08
age O 0 1.803188024496194e-05
at O 1 0.5604022741317749
disease O 1 0.996439516544342
onset O 1 0.9679020643234253
and O 0 5.047070317232283e-09
all O 0 4.707779943657897e-09
of O 0 4.632673622495531e-08
the O 0 1.2910466296034429e-07
disease O 0 7.976762503858481e-07
severity O 0 1.2386260550556472e-07
scores O 0 1.2807768179357026e-08
assessed O 0 3.151181005023318e-08
were O 0 1.4245157942127662e-08
noted O 0 5.532330860091861e-08
in O 0 1.468841333007731e-07
disease O 0 1.8103799447999336e-05
- O 0 7.334249676205218e-05
concordant O 0 0.013757516629993916
MZ O 1 0.9998421669006348
twins O 0 2.4753007892286405e-05
compared O 0 2.043884023805731e-06
with O 0 3.518764799537166e-07
concordant O 0 0.0007020332268439233
DZ O 1 0.9997243285179138
twins O 0 0.0001795295102056116
. O 0 7.577732503705192e-06

HLA O 1 0.9999845027923584
- O 0 0.003274639369919896
B27 O 0 0.0005214983248151839
and O 0 4.187627951068862e-07
B60 O 0 4.016322418465279e-05
were O 0 3.399557044758694e-07
associated O 0 2.002168884018829e-07
with O 0 1.3134573428885687e-08
the O 0 6.679898092443182e-07
disease O 0 0.000570440199226141
in O 0 1.8710559857026965e-07
probands O 1 0.9693938493728638
, O 0 4.4525314990551124e-08
and O 0 4.217017401941803e-09
the O 0 3.162030282055639e-08
rate O 0 2.8247038130757574e-07
of O 0 2.024093674890537e-07
disease O 0 6.544492862303741e-06
concordance O 0 6.975095402594889e-06
was O 0 6.124268452367687e-07
significantly O 0 6.338638769420868e-08
increased O 0 5.812415082573352e-08
among O 0 5.1637854880937084e-08
DZ O 1 0.8596085906028748
twin O 0 1.085176791093545e-06
pairs O 0 2.617248640035541e-08
in O 0 5.8731139951362366e-09
which O 0 4.153856369981668e-09
the O 0 4.267705122629195e-08
co O 0 2.1666007796738995e-06
- O 0 1.270348775506136e-06
twin O 0 1.0285226608175435e-06
was O 0 9.48923428722992e-08
positive O 0 6.378403583084946e-09
for O 0 4.903203620898466e-09
both O 0 4.603588621421295e-08
B27 O 0 3.848013511742465e-05
and O 0 1.7503191429568687e-06
DR1 O 1 0.7569374442100525
. O 0 9.40184236242203e-06

Additive O 0 2.4942481104517356e-05
genetic O 0 1.687608801148599e-06
effects O 0 4.867304710387543e-07
were O 0 6.207969960314585e-08
estimated O 0 5.7471094550010093e-08
to O 0 6.571455823944916e-09
contribute O 0 1.6956818171820487e-07
97 O 0 3.0628859803982778e-06
% O 0 3.521489588820259e-08
of O 0 1.9608942025683973e-08
the O 0 3.9990570854797625e-08
population O 0 1.1914563557979818e-08
variance O 0 2.0311321691224293e-07
. O 0 4.855139650317142e-07

CONCLUSION O 0 0.0004011820419691503
Susceptibility O 0 7.80723785283044e-05
to O 0 1.4028192651949212e-07
AS B-Disease 0 0.00012428850459400564
is O 0 5.0314540089857474e-08
largely O 0 1.3729888337365992e-07
genetically O 0 1.4210639776024436e-08
determined O 0 4.600656566822181e-08
, O 0 3.9005496610400314e-09
and O 0 1.6062815522133178e-09
the O 0 1.6374698930121667e-08
environmental O 0 4.444716594775855e-08
trigger O 0 8.094742298681012e-08
for O 0 4.863849767389183e-09
the O 0 2.002352204044655e-07
disease O 0 4.2256600863765925e-05
is O 0 1.2188462505946518e-07
probably O 0 4.019922016595956e-06
ubiquitous O 0 1.4739824109710753e-05
. O 0 2.2622282358497614e-06

HLA O 1 0.9999740123748779
- O 0 0.0005198675207793713
B27 O 0 8.323886140715331e-05
accounts O 0 1.8897202380685485e-07
for O 0 2.209925753504649e-08
a O 0 9.902725395249945e-08
minority O 0 1.9124110295365426e-08
of O 0 3.3673636323783285e-08
the O 0 1.1352469186931557e-07
overall O 0 3.3967583021876635e-06
genetic O 0 1.976271505554905e-06
susceptibility O 0 1.1798189234468737e-06
to O 0 1.678352816725237e-07
AS B-Disease 1 0.9978590607643127
. O 0 8.900785360310692e-06

Cell O 0 0.09051624685525894
cycle O 0 0.000374190101865679
- O 0 7.104602264007553e-05
dependent O 0 6.374894383043284e-06
colocalization O 0 9.719601075630635e-05
of O 0 2.1887849470658693e-06
BARD1 O 1 0.988548755645752
and O 0 4.637553843167552e-07
BRCA1 O 0 3.3519959288241807e-06
proteins O 0 5.755435594778646e-08
in O 0 5.681724601913629e-08
discrete O 0 7.131448001018725e-07
nuclear O 0 2.2168924260768108e-05
domains O 0 1.2717944628093392e-05
. O 0 2.4751279852353036e-06

Germ O 1 0.9999979734420776
- O 0 0.0004654869553633034
line O 0 4.187278591416543e-06
mutations O 0 1.3685729527423973e-07
of O 0 1.0530906280337149e-07
the O 0 8.744542014937906e-07
BRCA1 O 0 0.00013369839871302247
gene O 0 1.2017011385978549e-06
predispose O 0 5.374971806304529e-06
women O 0 2.95774338354704e-08
to O 0 1.1924157661269419e-08
early O 0 6.0509923059726134e-05
- O 1 0.9984013438224792
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.998262345790863
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 5.976777401883737e-07
compromising O 0 1.039137987390859e-05
the O 0 1.8135901314053626e-07
genes O 0 1.3382910424297734e-07
presumptive O 0 2.0966238025721395e-06
function O 0 1.4144852400477248e-07
as O 0 1.058895406913507e-07
a O 0 2.5636475129431346e-06
tumor B-Disease 0 0.003938138950616121
suppressor O 0 0.0003097679582424462
. O 0 3.4236143164889654e-06

Although O 0 1.5823817420823616e-06
the O 0 1.073204316526244e-06
biochemical O 0 7.459214248228818e-05
properties O 0 7.761554115859326e-06
of O 0 2.762365738817607e-06
BRCA1 O 0 2.0696241335826926e-05
polypeptides O 0 6.639238563366234e-07
are O 0 2.3589452613492767e-09
not O 0 6.028260113311035e-09
understood O 0 1.4580365359506686e-07
, O 0 5.71046898656391e-09
their O 0 4.946695497665132e-09
expression O 0 4.4878806448878095e-08
pattern O 0 2.5785456614357827e-07
and O 0 2.6731690638825967e-08
subcellular O 0 6.425358151318505e-05
localization O 0 8.212980901589617e-06
suggest O 0 1.1556345924645939e-07
a O 0 3.8273267222166396e-08
role O 0 1.3954736743926333e-07
in O 0 1.1170541114324806e-07
cell O 0 1.9991357476101257e-05
- O 0 7.068200375215383e-06
cycle O 0 3.4156091714976355e-05
regulation O 0 3.8746911741327494e-06
. O 0 1.349074523204763e-06

When O 0 9.335602953797206e-06
resting O 0 0.0004184110148344189
cells O 0 2.164467559850891e-06
are O 0 1.0222661828152013e-08
induced O 0 4.6565219236072153e-07
to O 0 2.5199664577257863e-08
proliferate O 0 1.2717040362986154e-06
, O 0 2.7301489069486706e-08
the O 0 1.349386877791403e-07
steady O 0 1.4440074664889835e-05
- O 0 2.2838200663954922e-07
state O 0 1.7238219740534078e-08
levels O 0 2.734182302788213e-08
of O 0 3.377835966489329e-08
BRCA1 O 0 9.4848367382383e-08
increase O 0 6.296294152718929e-09
in O 0 1.2297250329140752e-08
late O 0 9.992580771722714e-07
G1 O 0 4.2379400838399306e-05
and O 0 3.2758644685770832e-09
reach O 0 1.8302348081533637e-08
a O 0 2.3035719109998354e-08
maximum O 0 5.311772000027304e-08
during O 0 3.106889323589712e-07
S O 0 8.25624283606885e-06
phase O 0 1.275535578315612e-05
. O 0 1.5437326510436833e-06

Moreover O 0 2.2436744984588586e-05
, O 0 1.7108386884956417e-07
in O 0 1.6112755929498235e-07
S O 0 1.5450506907654926e-05
phase O 0 5.0606766308192164e-05
cells O 0 8.498636816511862e-06
, O 0 2.3908609136924497e-07
BRCA1 O 0 3.5677239793585613e-06
polypeptides O 0 8.034519396460382e-07
are O 0 1.3671817455929158e-08
hyperphosphorylated O 0 5.745898761233548e-06
and O 0 3.1184153925778446e-08
accumulate O 0 1.274119767913362e-06
into O 0 4.396555368657573e-07
discrete O 0 5.180455900699599e-06
subnuclear O 0 6.932434916961938e-05
foci O 0 3.56561504304409e-05
termed O 0 6.253859737626044e-06
" O 0 4.1850989873637445e-06
BRCA1 O 0 2.556139588705264e-05
nuclear O 0 0.00010592454782454297
dots O 0 2.6977169909514487e-05
. O 0 6.050504907761933e-06

" O 0 0.00011402490781620145
BRCA1 O 0 0.0006990573019720614
associates O 0 6.715619383612648e-05
in O 0 2.659479036992707e-07
vivo O 0 4.402741524245357e-06
with O 0 2.6461005830924478e-08
a O 0 6.321156433841679e-07
structurally O 0 3.837236363324337e-05
related O 0 4.669427653425373e-06
protein O 0 3.293317058705725e-05
termed O 0 0.00023698591394349933
BARD1 O 1 0.9997879862785339
. O 0 2.357320045121014e-05

Here O 0 1.032646559906425e-05
we O 0 4.1420233287681185e-07
show O 0 3.503796506265644e-07
that O 0 1.520838210922193e-08
the O 0 8.655403149759877e-08
steady O 0 1.3106543519825209e-05
- O 0 7.566573003714439e-07
state O 0 3.7629334315170127e-08
levels O 0 7.507318144917008e-08
of O 0 1.830193525620416e-07
BARD1 O 0 0.37532803416252136
, O 0 2.6144745035594497e-08
unlike O 0 1.6933395130536155e-08
those O 0 2.012078725854849e-09
of O 0 4.759661820230576e-08
BRCA1 O 0 4.46264493803028e-07
, O 0 8.866437362087254e-09
remain O 0 3.718292518328781e-08
relatively O 0 6.200076541063027e-08
constant O 0 2.939415821856528e-07
during O 0 5.643748295369733e-07
cell O 0 1.2382884960970841e-05
cycle O 0 1.601809162821155e-05
progression O 0 3.9747679693391547e-05
. O 0 1.6049341411417117e-06

However O 0 1.70738512679236e-05
, O 0 1.9782251001743134e-06
immunostaining O 0 0.0004383118648547679
revealed O 0 3.864669270114973e-05
that O 0 1.0813997732839198e-06
BARD1 O 1 0.9990261793136597
resides O 0 6.345541623886675e-05
within O 0 2.84474072032026e-06
BRCA1 O 0 1.1831454685307108e-05
nuclear O 0 3.655431282822974e-05
dots O 0 2.8207084596942877e-06
during O 0 2.29852162192401e-06
S O 0 2.307457907591015e-05
phase O 0 2.5342735625599744e-06
of O 0 1.4818645865943836e-07
the O 0 1.0908821224120402e-07
cell O 0 1.2933082871313673e-06
cycle O 0 2.954902527108061e-07
, O 0 1.937685789599186e-09
but O 0 1.3158387712763897e-09
not O 0 3.6948122339452993e-09
during O 0 3.6640059875026054e-07
the O 0 1.9017188606085256e-06
G1 O 0 0.0012912934180349112
phase O 0 2.02513638214441e-05
. O 0 3.4389024676784175e-06

Nevertheless O 0 0.00019855985010508448
, O 0 3.868345174851129e-06
BARD1 O 0 0.0048342254012823105
polypeptides O 0 4.798831923835678e-06
are O 0 2.356814832182863e-08
found O 0 2.174863311665831e-08
exclusively O 0 3.8353508813315784e-08
in O 0 7.334793217239621e-09
the O 0 1.4300066908390363e-08
nuclear O 0 6.460699069066322e-07
fractions O 0 4.311814336688258e-07
of O 0 8.132316509090742e-08
both O 0 2.0204595330142183e-08
G1 O 0 2.8090122214052826e-05
- O 0 1.2441097396731493e-07
and O 0 1.7526655682331693e-08
S O 0 4.452172106539365e-06
- O 0 1.2876778328063665e-06
phase O 0 5.135075298312586e-06
cells O 0 3.225609589208034e-06
. O 0 9.013401722768322e-07

Therefore O 0 1.3047182619629893e-05
, O 0 5.488701049216616e-07
progression O 0 3.937954261346022e-06
to O 0 9.30613950345105e-08
S O 0 1.2284013791941106e-05
phase O 0 2.440988055241178e-06
is O 0 2.9678982826908396e-08
accompanied O 0 1.8007709456924204e-07
by O 0 9.272135059745779e-09
the O 0 4.868910608024635e-08
aggregation O 0 3.0055281285967794e-07
of O 0 1.7485911030235002e-07
nuclear O 0 2.1016281607444398e-05
BARD1 O 0 0.19022773206233978
polypeptides O 0 5.875923307030462e-06
into O 0 7.21833316674747e-07
BRCA1 O 0 7.158640983107034e-06
nuclear O 0 3.356578963575885e-05
dots O 0 2.921888153650798e-05
. O 0 4.032985543744871e-06

This O 0 4.97625069328933e-06
cell O 0 1.825360050133895e-05
cycle O 0 1.8368435121374205e-05
- O 0 1.3776381820207462e-05
dependent O 0 2.4615571874164743e-06
colocalization O 0 7.340000593103468e-05
of O 0 2.6598443128023064e-06
BARD1 O 1 0.9987742304801941
and O 0 3.1639433473173995e-07
BRCA1 O 0 7.710257705184631e-06
indicates O 0 5.151174491402344e-07
a O 0 6.956018694381783e-08
role O 0 1.3165755774480203e-07
for O 0 6.167111621380172e-08
BARD1 O 0 0.39563170075416565
in O 0 1.501105089118937e-06
BRCA1 O 0 0.00012944616901222616
- O 0 0.00011583624291233718
mediated O 0 0.0006048174109309912
tumor B-Disease 1 0.9384257793426514
suppression O 0 0.00012467191845644265
. O 0 4.5626966311829165e-06

Ethnic O 0 1.8725369955063798e-05
differences O 0 3.5182247302145697e-06
in O 0 1.0950823252642294e-06
the O 0 5.524017979041673e-06
HFE O 0 0.021733781322836876
codon O 0 6.518512236652896e-05
282 O 0 4.122116297367029e-05
( O 0 1.3913152542954776e-05
Cys O 1 0.9747105836868286
/ O 0 0.0005937624373473227
Tyr O 0 0.0009266298147849739
) O 0 3.1304707590606995e-06
polymorphism O 0 2.052441777777858e-05
. O 0 2.4173980364139425e-06

Recent O 0 3.3292487842118135e-06
studies O 0 7.075214512042294e-07
have O 0 3.553478222784179e-08
shown O 0 4.2316594317526324e-07
that O 0 2.0267721083655488e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 1.0
HH B-Disease 1 1.0
) O 0 3.4213526305393316e-06
is O 0 3.028184281106405e-08
likely O 0 1.0546238549125064e-08
to O 0 5.063442554131825e-09
be O 0 2.1703463914946042e-08
caused O 0 1.2219956602166349e-07
by O 0 3.0359110780864285e-08
homozygosity O 0 3.023007775482256e-05
for O 0 3.570857742829503e-08
a O 0 7.736175575701054e-07
Cys282Tyr O 0 0.00026121994596906006
mutation O 0 7.898154308350058e-08
in O 0 2.117274000568159e-08
the O 0 3.22574351230287e-07
HFE O 1 0.8467783331871033
gene O 0 1.877921931736637e-06
located O 0 2.7751352718041744e-06
4 O 0 3.884518264385406e-06
. O 0 2.7478831725602504e-06

5 O 0 0.00024022723664529622
Mb O 0 0.0015718925278633833
telomeric O 0 0.00026283381157554686
to O 0 4.52645554105402e-06
HLA O 0 0.10685420036315918
- O 0 7.814478158252314e-05
A O 0 3.976322113885544e-05
. O 0 3.774906645048759e-06

Population O 0 1.239291805177345e-06
studies O 0 2.417961866285623e-07
of O 0 6.272670560747429e-08
this O 0 1.7606199165243197e-08
polymorphism O 0 2.2600430327202048e-07
are O 0 2.7147719627862443e-09
facilitated O 0 1.884373546090501e-07
by O 0 8.411916496697813e-09
the O 0 3.178065455244905e-08
fact O 0 3.649373070402362e-08
that O 0 6.102275129649115e-09
the O 0 1.116410857093797e-07
Cys282Tyr O 0 0.00024194730212911963
mutation O 0 2.137673078550506e-07
creates O 0 4.5036074425297556e-07
a O 0 1.2446773780538933e-06
Rsal O 0 0.0007461803616024554
restriction O 0 4.449048446986126e-06
site O 0 7.931916115921922e-06
. O 0 8.383671570300066e-07

We O 0 1.916351038744324e-06
have O 0 7.08601959331645e-08
studied O 0 1.0461811825734912e-06
the O 0 5.588731255556922e-07
codon O 0 4.6983645916043315e-06
282 O 0 6.228450274647912e-06
( O 0 2.8534816465253243e-06
Cys O 1 0.976836085319519
/ O 0 0.00010596738866297528
Tyr O 0 4.846658339374699e-05
) O 0 7.758949038816354e-08
polymorphism O 0 2.8342157065708307e-07
in O 0 1.289222772982157e-08
different O 0 7.783669708771868e-09
ethnic O 0 1.1289364465483231e-07
groups O 0 1.0249804915929417e-07
. O 0 1.165306571238034e-06

In O 0 3.4799668355844915e-06
agreement O 0 6.938440151316172e-07
with O 0 9.682078427886154e-08
previous O 0 1.0173314421990653e-06
observations O 0 1.528331040390185e-06
the O 0 2.7645720024338516e-07
Tyr O 0 2.6001927835750394e-05
allele O 0 1.0087432400496255e-07
appeared O 0 8.885334779051846e-08
to O 0 6.320648004987106e-09
be O 0 2.1839751340735347e-08
rare O 0 6.234359517520716e-08
or O 0 4.6358028527038186e-08
absent O 0 4.706947436261544e-07
in O 0 6.82603200630183e-08
Asiatic O 0 0.0001908965059556067
( O 0 3.123374483493535e-07
Indian O 0 1.2659128287850763e-06
, O 0 1.8986508365514965e-08
Chinese O 0 5.966139156043937e-07
) O 0 4.594772207155984e-08
populations O 0 2.9075867047367865e-08
. O 0 2.3449462105418206e-07

The O 0 1.1141682989546098e-05
highest O 0 7.367531907220837e-06
allele O 0 4.747114132896968e-07
frequency O 0 2.2549707523467077e-07
( O 0 5.28614059192023e-08
7 O 0 1.3783704844172462e-07
. O 0 4.386585317206482e-09
5 O 0 6.154491671850337e-08
% O 0 1.3425702327651834e-08
) O 0 1.1788901410625385e-08
was O 0 7.966281856397472e-08
found O 0 2.5290862737392672e-08
in O 0 6.062392543526585e-08
Swedes O 0 1.3147629942977801e-05
. O 0 3.431210870985524e-06

Saamis O 0 0.0022030111867934465
( O 0 2.9217821975180414e-06
2 O 0 1.3317218190422864e-06
% O 0 8.060355582983902e-08
) O 0 2.503567486655811e-08
and O 0 6.8615215731426815e-09
Mordvinians O 0 1.77604888449423e-05
( O 0 8.5343394573556e-08
1 O 0 5.5343249982797715e-08
. O 0 3.912889567914135e-09
8 O 0 5.60847652764096e-08
% O 0 1.7038624733345387e-08
) O 0 2.8195636936345636e-09
had O 0 4.257523666950647e-09
significantly O 0 8.745907997820268e-09
lower O 0 9.746313089920022e-09
frequencies O 0 1.3040365232086515e-08
of O 0 5.6731696673750776e-08
the O 0 6.797714036110847e-07
Tyr O 0 0.0001379584427922964
allele O 0 4.4536118366522714e-06
. O 0 1.1149738838867052e-06

Comparisons O 0 2.27383907258627e-06
with O 0 1.476585165249844e-08
allele O 0 7.711898319939792e-08
frequencies O 0 2.977270696646883e-08
based O 0 2.362170015146603e-08
on O 0 7.906851351435762e-08
prevalence O 0 2.3558316115668276e-06
estimates O 0 2.272498562660985e-07
of O 0 6.894031230331166e-07
HH B-Disease 1 0.999998927116394
showed O 0 3.875457537105831e-07
some O 0 5.559470661609112e-09
disagreements O 0 4.755977300874292e-08
with O 0 1.2731040666125182e-09
the O 0 2.2462046445070882e-08
RFLP O 0 1.9050462469749618e-06
data O 0 5.217464860152177e-08
, O 0 4.622512594920636e-09
particularly O 0 2.1020037266339386e-08
in O 0 6.307523392479197e-08
Finns O 0 1.985524249903392e-05
. O 0 3.746016091099591e-06

The O 0 9.478102583670989e-06
newly O 0 2.5756857212400064e-05
described O 0 5.236185825197026e-05
HFE O 1 0.9985364675521851
marker O 0 2.7120020604343154e-05
provides O 0 1.991440115034493e-07
a O 0 4.8409454223019566e-08
new O 0 5.004785919027199e-09
approach O 0 2.3542986227198526e-08
to O 0 3.879359944392036e-09
the O 0 3.679216220575654e-08
screening O 0 2.132611172100951e-07
of O 0 2.52158770308597e-06
HH B-Disease 1 1.0
as O 0 6.588313539168666e-08
well O 0 1.041101338472572e-08
as O 0 6.278880526622288e-09
studies O 0 3.4294199480200405e-08
of O 0 5.225990307167194e-08
the O 0 9.027736780353735e-08
relationship O 0 4.0637459619574656e-07
between O 0 4.161670688063168e-07
the O 0 3.4665351904550334e-06
HFE O 1 0.9999935626983643
Tyr O 0 0.0009722395334392786
allele O 0 1.922817318700254e-07
and O 0 8.713638699475723e-09
different O 0 4.770459227643187e-08
disorders O 0 0.08775445818901062
including O 0 8.108052134048194e-05
cancer B-Disease 1 1.0

Autosomal B-Disease 1 0.9999997615814209
dominant I-Disease 1 0.999996542930603
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
associated O 0 9.039054020831827e-06
with O 0 2.064940787249725e-07
a O 0 8.292409461319039e-07
missense O 0 5.228550435276702e-06
mutation O 0 8.894694758510013e-08
encoding O 0 2.574727204773808e-07
Gly23 O 0 0.00010226161975879222
- O 0 7.126777927624062e-05
- O 0 0.00021664542146027088
> O 0 7.987947901710868e-05
Val O 0 0.00035652201040647924
in O 0 2.1226617263891967e-06
neurophysin O 0 0.002849958138540387
II O 1 0.9996103644371033
. O 0 3.37158671754878e-05

Autosomal B-Disease 1 0.9999995231628418
dominant I-Disease 1 0.9999885559082031
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9763355851173401
ADNDI B-Disease 1 1.0
) O 0 4.3732607082347386e-06
is O 0 2.675444648048142e-07
an O 0 2.365167119933176e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9998596906661987
by O 0 0.00016772357048466802
progressive O 1 0.9999998807907104
degeneration O 1 1.0
of O 0 0.0001108385986299254
the O 0 7.884916703915223e-05
magnocellular O 1 0.9999520778656006
neurons O 0 3.7036930734757334e-05
of O 0 1.453882305213483e-06
the O 0 5.802495252282824e-06
hypothalamus O 0 9.926454367814586e-05
leading O 0 2.225981688752654e-06
to O 0 9.048284965729181e-08
decreased O 0 6.012295216351049e-06
ability O 0 5.2070756595412604e-08
to O 0 1.4183207497353578e-08
produce O 0 6.722921597202003e-08
the O 0 3.38690711032541e-07
hormone O 0 2.4460398435621755e-06
arginine O 0 7.81432208896149e-06
vasopressin O 0 1.3029451110924128e-05
( O 0 1.8369236158832791e-06
AVP O 0 0.00012421600695233792
) O 0 6.052399612599402e-07
. O 0 9.752737923918176e-07

Affected O 0 6.564019258803455e-06
individuals O 0 6.649631245636556e-08
are O 0 9.233398046148977e-09
not O 0 3.6294643734891e-08
symptomatic O 0 3.811836722888984e-05
at O 0 1.5692781744292006e-05
birth O 0 1.6209858586080372e-05
, O 0 2.785637498448068e-08
but O 0 1.553030415379908e-08
usually O 0 1.4232331579933089e-07
develop O 0 1.086693191609811e-05
diabetes B-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999837875366211
at O 0 0.00015749363228678703
1 O 0 1.4635389561590273e-05
- O 0 1.4388800991582684e-05
6 O 0 4.883857400272973e-06
yr O 0 0.00016757266712374985
of O 0 6.342750680232712e-07
age O 0 4.127774445805699e-06
. O 0 1.3796477560390485e-06

The O 0 1.972551217477303e-05
genetic O 0 4.5589888031827286e-05
locus O 0 1.8222657672595233e-05
of O 0 4.580492145578319e-07
the O 0 1.150193611465511e-06
disease O 0 0.00034575420431792736
is O 0 2.345295229133626e-07
the O 0 5.0340263442194555e-06
AVP O 1 0.9999549388885498
- O 0 0.00013537844642996788
neurophysin O 0 0.01628044620156288
II O 1 0.9999328851699829
( O 0 5.178282663109712e-06
NPII O 1 0.6882719993591309
) O 0 8.496220971210278e-08
gene O 0 1.3845963486858182e-08
, O 0 2.06138950353818e-09
and O 0 2.908272733748163e-09
mutations O 0 3.2731239940630985e-08
that O 0 1.2594395748521947e-08
cause O 0 5.024366600991925e-06
ADNDI B-Disease 1 0.9999997615814209
have O 0 1.4012436544419415e-08
been O 0 1.2819327821489424e-08
found O 0 6.260882479125485e-09
in O 0 2.9243536481260435e-09
both O 0 3.344651000602994e-09
the O 0 4.573307421651407e-08
signal O 0 3.4571877449707245e-07
peptide O 0 1.2634895085739117e-07
of O 0 6.085794979071579e-08
the O 0 2.852932539099129e-07
prepro O 0 0.021427033469080925
- O 0 0.26098692417144775
AVP O 1 0.9999730587005615
- O 0 8.22106740088202e-05
NPII O 0 0.004525657743215561
precursor O 0 3.578860741981771e-06
and O 0 7.360246456755704e-08
within O 0 9.73958663053054e-07
NPII O 0 0.0022164287511259317
itself O 0 5.250906724540982e-06
. O 0 2.672170694495435e-06

An O 0 1.3602684703073464e-05
affected O 0 2.103549377352465e-06
girl O 0 1.3009758731641341e-05
who O 0 8.845091059583865e-08
presented O 0 1.8149548850487918e-06
at O 0 9.717359716887586e-06
9 O 0 1.8733715023699915e-06
months O 0 1.1175272618402232e-07
of O 0 9.657198063450778e-08
age O 0 8.937113307183608e-07
and O 0 2.145085709059913e-08
her O 0 2.7545135594664316e-07
similarly O 0 3.397200885046914e-07
affected O 0 6.845942124300564e-08
younger O 0 1.0666245486845582e-07
brother O 0 1.134105787059525e-06
and O 0 1.3556576305973067e-08
father O 0 2.782250589916657e-07
were O 0 3.227398437388729e-08
all O 0 4.270520381766119e-09
found O 0 6.107188532666896e-09
to O 0 3.730615816266436e-09
have O 0 3.886855282075885e-09
a O 0 1.0394013116865608e-07
novel O 0 4.243343028065283e-07
missense O 0 6.981857723076246e-07
mutation O 0 2.6214951986958113e-08
( O 0 2.305501567434476e-08
G1758 O 0 1.6094708144009928e-06
- O 0 1.4923579101377982e-06
- O 0 3.2438133530376945e-06
> O 0 3.0259905088314554e-06
T O 0 6.644932568633521e-07
) O 0 4.815617682396578e-09
encoding O 0 6.613743330774469e-09
the O 0 6.06248296008971e-09
amino O 0 2.882303107298867e-08
acid O 0 3.821571326056983e-08
substitution O 0 1.2081183342615986e-07
Gly23 O 0 3.3212989364983514e-05
- O 0 1.524648268969031e-05
- O 0 2.0545920051517896e-05
> O 0 2.7482381483423524e-05
Val O 0 7.53538406570442e-05
within O 0 2.5818087578954874e-06
NPII O 0 0.003219097852706909
. O 0 9.523922926746309e-06

The O 0 8.169819921022281e-06
mutation O 0 8.175035759450111e-07
was O 0 1.1250419902353315e-06
confirmed O 0 1.3494627637555823e-07
by O 0 6.902715909973267e-08
restriction O 0 8.451165740552824e-07
endonuclease O 0 1.4635137631557882e-05
analysis O 0 2.6495101792534115e-06
. O 0 1.524275830888655e-06

A O 0 0.001139079686254263
T1 O 1 0.9752680063247681
- O 0 2.422430225124117e-05
weighted O 0 7.674986591155175e-06
magnetic O 0 3.3671053643047344e-06
resonance O 0 2.5145373001578264e-06
imaging O 0 4.9057639444072265e-06
of O 0 6.110675485615502e-07
the O 0 4.518451078183716e-06
fathers O 0 0.11393986642360687
pituitary O 1 0.9998291730880737
gland O 0 0.0004769211809616536
demonstrates O 0 9.01290331967175e-06
an O 0 1.2353164038358955e-06
attenuated O 0 0.0002441781107336283
posterior O 0 0.0006019850261509418
pituitary O 0 0.0026268698275089264
bright O 0 5.147636329638772e-05
spot O 0 4.2449053580639884e-05
. O 0 1.1489544704090804e-05

This O 0 8.715668968761747e-07
mutation O 0 1.4956235361296422e-07
may O 0 2.830352130445135e-08
be O 0 6.845573885527756e-09
valuable O 0 1.1537229482883049e-07
for O 0 1.6312352357772397e-08
developing O 0 1.552986645947385e-07
models O 0 1.8937144830033503e-07
of O 0 7.249757345562102e-07
dominantly B-Disease 1 0.9999790191650391
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 5.334774186849245e-07
as O 0 3.694250594321602e-08
the O 0 2.939768073417781e-08
early O 0 9.02734029750718e-08
age O 0 2.742474691785901e-07
of O 0 6.400757115443412e-07
onset O 1 0.9995959401130676
of O 0 4.3389321945142e-05
symptoms O 0 0.2596902549266815
suggests O 0 3.128966454823967e-06
that O 0 6.165250976408743e-09
this O 0 6.036544597520788e-09
mutation O 0 8.845188581574348e-09
may O 0 6.186607670599642e-09
be O 0 8.898253689437752e-09
particularly O 0 3.241525803332479e-08
deleterious O 0 4.2158697510785714e-07
to O 0 9.253994903701823e-08
the O 0 3.1155791475612205e-06
magnocellular O 0 0.007002882659435272
neuron O 0 0.00011203510803170502
. O 0 6.376617989189981e-07
. O 0 2.4867072170309257e-06

Frequent O 0 6.799747643526644e-05
inactivation O 0 0.0004069036222063005
of O 0 0.00042825148557312787
PTEN O 1 1.0
/ O 1 0.9999912977218628
MMAC1 O 1 0.9999998807907104
in O 0 7.216772064566612e-05
primary O 1 0.9999997615814209
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00022444140631705523

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 2.78545189758006e-06
the O 0 3.121998588540009e-07
most O 0 2.56176484469961e-08
common O 0 1.1462083904234532e-07
male B-Disease 0 9.908712854667101e-06
cancer I-Disease 0 2.318671249668114e-06
in O 0 2.9749203989126727e-08
the O 0 1.8516506372634467e-07
Western O 0 8.295019711113127e-07
world O 0 4.0535343970304893e-08
, O 0 2.2094737150979427e-09
yet O 0 2.3428476936260267e-09
many O 0 1.9108703508408098e-10
of O 0 1.912705549500515e-09
the O 0 1.1225213647492183e-08
major O 0 9.886514362733578e-08
genetic O 0 2.260129292608326e-07
events O 0 6.137271668649191e-08
involved O 0 7.981049066074775e-08
in O 0 1.0188053067849978e-08
the O 0 8.930018680075591e-08
progression O 0 7.55534938434721e-06
of O 0 3.351383526251084e-08
this O 0 1.330822030354284e-08
often O 0 5.6900645972746133e-08
fatal O 0 0.0030757691711187363
cancer B-Disease 0 2.7058098567067645e-05
remain O 0 6.200898496899754e-07
to O 0 1.2673923777128948e-07
be O 0 1.4823777974015684e-06
elucidated O 0 0.001893295207992196
. O 0 7.977600034791976e-06

Numerous O 0 2.923175816249568e-05
cytogenetic O 0 0.03778264671564102
and O 0 6.869118465147039e-07
allelotype O 0 0.0010802606120705605
studies O 0 1.2039907915095682e-06
have O 0 2.5251049251551194e-08
reported O 0 3.6360057720230543e-07
frequent O 0 3.251970497331058e-07
loss O 0 3.4898043850262184e-06
of O 0 1.1832007658085786e-05
heterozygosity O 1 0.9999946355819702
on O 0 4.868170071858913e-05
chromosomal O 1 0.9998527765274048
arm O 1 0.9971944093704224
10q O 1 0.999772846698761
in O 0 1.2000374226772692e-05
sporadic B-Disease 1 0.9999984502792358
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.793313852744177e-05

Deletion O 0 0.0007482289802283049
mapping O 0 3.68945075024385e-05
studies O 0 1.6443513004560373e-06
have O 0 4.8768665550369406e-08
unambiguously O 0 1.1884228570124833e-06
identified O 0 3.4619984035089146e-07
a O 0 3.1852420079303556e-07
region O 0 3.667565238174575e-07
of O 0 1.1840413662866922e-06
chromosome O 0 0.000288123672362417
10q23 O 0 0.00011497129162307829
to O 0 2.1569672270516094e-08
be O 0 2.4254440234017238e-08
the O 0 8.534648543445655e-08
minimal O 0 1.629384200896311e-06
area O 0 8.55932739796117e-07
of O 0 1.4386181419467903e-06
loss O 0 4.182334305369295e-05
. O 0 6.08241134614218e-06

A O 0 2.913138087023981e-05
new O 0 2.9121738407411613e-06
tumor B-Disease 0 0.0015019865240901709
suppressor O 0 0.00014348611875902861
gene O 0 1.6037008663261076e-06
, O 0 6.95425342200906e-07
PTEN O 1 0.9722157716751099
/ O 0 0.0011122244177386165
MMAC1 O 1 0.9999511241912842
, O 0 9.225585273497927e-08
was O 0 1.2181367310404312e-06
isolated O 0 3.2451484344164783e-07
recently O 0 5.097088617844747e-08
at O 0 5.8065975139243164e-08
this O 0 5.553334680996613e-09
region O 0 6.607328373320343e-08
of O 0 2.559970653237542e-07
chromosome O 0 3.479564475128427e-05
10q23 O 0 2.8767601179424673e-05
and O 0 6.489200288228858e-09
found O 0 1.523311610185374e-08
to O 0 3.6450442664204274e-09
be O 0 6.624386816866945e-09
inactivated O 0 1.0379768866641825e-07
by O 0 7.1941883561521536e-09
mutation O 0 1.538383820332001e-08
in O 0 1.0578836473484898e-08
three O 0 1.0105551382366684e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9994353652000427
lines O 0 1.1645094673440326e-05
. O 0 2.0784536900464445e-06

We O 0 2.977065832965309e-06
screened O 0 1.6554015019210055e-05
80 O 0 3.9178295992314816e-05
prostate B-Disease 1 0.9979836940765381
tumors I-Disease 1 1.0
by O 0 1.1504400276862725e-07
microsatellite O 0 5.2932387916371226e-05
analysis O 0 1.3225039197095612e-07
and O 0 7.972814408674367e-09
found O 0 8.264778728062083e-08
chromosome O 0 1.996497530853958e-06
10q23 O 0 5.006377250538208e-06
to O 0 4.6275605569690015e-08
be O 0 1.1361524343556084e-07
deleted O 0 2.287153620272875e-06
in O 0 9.700415404267915e-08
23 O 0 1.140394033427583e-06
cases O 0 2.738896114351519e-07
. O 0 9.03988166101044e-07

We O 0 3.1996014513424598e-06
then O 0 4.6651317120449676e-07
proceeded O 0 1.604759631845809e-06
with O 0 1.3416999067317192e-08
sequence O 0 3.379402642167406e-07
analysis O 0 1.6589513052167604e-07
of O 0 9.552793756029132e-08
the O 0 3.042189007373963e-07
entire O 0 7.198721868917346e-05
PTEN O 1 0.9999680519104004
/ O 0 0.0034804213792085648
MMAC1 O 1 0.9644666910171509
coding O 0 6.425162155210273e-06
region O 0 8.766621562017463e-08
and O 0 3.581428709154011e-09
tested O 0 2.5483096521838888e-08
for O 0 6.121743556519732e-09
homozygous O 0 2.003232708602809e-07
deletion O 0 2.1119222992638242e-07
with O 0 5.627214694214899e-09
new O 0 3.979486606908722e-08
intragenic O 0 0.0008013365441001952
markers O 0 1.373870645693387e-06
in O 0 1.1560926438392016e-08
these O 0 3.1477553896763766e-09
23 O 0 1.236395519299549e-07
cases O 0 7.88555176711725e-09
with O 0 3.478578136650867e-08
10q23 O 1 0.9470758438110352
loss O 0 0.0262615904211998
of O 0 0.0022245612926781178
heterozygosity O 1 0.9999988079071045
. O 0 2.1748526705778204e-05

The O 0 8.273931598523632e-06
identification O 0 3.1019828838907415e-06
of O 0 8.209489692490024e-07
the O 0 7.162350357248215e-07
second O 0 5.764966317656217e-06
mutational O 0 8.818149217404425e-05
event O 0 8.505622872689855e-07
in O 0 2.3799067605523305e-08
10 O 0 3.828728623034294e-08
( O 0 2.7861583262733802e-08
43 O 0 2.5708578732519527e-07
% O 0 3.3912027674887213e-07
) O 0 2.151364697056124e-06
tumors B-Disease 1 1.0
establishes O 0 0.0014359771739691496
PTEN O 1 0.9999985694885254
/ O 0 0.01136601623147726
MMAC1 O 0 0.24990613758563995
as O 0 6.622683201840118e-08
a O 0 6.801806762268825e-08
main O 0 1.4140805149054358e-07
inactivation O 0 7.351652016041044e-07
target O 0 1.577727033463816e-07
of O 0 1.0421626228662717e-07
10q O 0 4.174651621724479e-05
loss O 0 3.0983314900367986e-06
in O 0 9.420936066817376e-07
sporadic B-Disease 1 0.9997829794883728
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.752114364237059e-06
. O 0 8.094986696960405e-06

Risk O 0 0.00015718232316430658
reversals O 0 5.0503502279752865e-05
in O 0 4.4760838591173524e-07
predictive O 0 2.9929021820862545e-06
testing O 0 5.562569640460424e-07
for O 0 7.186110906332033e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.15340694214683e-05

The O 0 3.9744958257870167e-07
first O 0 1.1299974289613601e-07
predictive O 0 4.0013767943491985e-07
testing O 0 6.826579124208365e-08
for O 0 2.574265636212658e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.288539442612091e-05
HD B-Disease 0 0.0027412287890911102
) O 0 2.4826539046785e-08
was O 0 2.293164769184841e-08
based O 0 1.560702789227264e-09
on O 0 4.118230645389076e-09
analysis O 0 1.0109385328860299e-08
of O 0 9.986959703667253e-09
linked O 0 1.4069230758195772e-07
polymorphic O 0 1.942623981676661e-07
DNA O 0 1.438486378901871e-06
markers O 0 5.254846655589063e-07
to O 0 2.007908683765436e-08
estimate O 0 2.8817734687436314e-07
the O 0 4.334481928935929e-08
likelihood O 0 5.156841780262766e-07
of O 0 2.122348803368368e-07
inheriting O 0 3.3942421850952087e-06
the O 0 1.5161381838879606e-07
mutation O 0 6.056948365085191e-08
for O 0 1.0582756004851035e-07
HD B-Disease 0 0.00019415834685787559
. O 0 3.0735661766811972e-06

Limits O 0 3.600994205044117e-06
to O 0 8.735042911212076e-08
accuracy O 0 1.3096044995108969e-06
included O 0 8.469022816370853e-08
recombination O 0 3.187493575751432e-07
between O 0 2.8791054873522626e-08
the O 0 6.552971854034695e-08
DNA O 0 2.706186705836444e-06
markers O 0 4.1060212652155315e-07
and O 0 4.7854111784317865e-09
the O 0 6.115851647336967e-08
mutation O 0 7.255817280338306e-08
, O 0 2.053902292686871e-08
pedigree O 0 6.133316219347762e-07
structure O 0 1.6324872831319226e-07
, O 0 3.6875607012376577e-09
and O 0 1.251352799158667e-09
whether O 0 3.759947020398613e-09
DNA O 0 4.618539861667159e-08
samples O 0 6.194707857787307e-09
were O 0 8.299291032187739e-09
available O 0 2.2880968231220322e-08
from O 0 4.966949518347974e-08
family O 0 1.749683775642552e-07
members O 0 1.1973664015840768e-07
. O 0 1.0023065897257766e-06

With O 0 1.204743966809474e-07
direct O 0 7.06163945096705e-08
tests O 0 5.583316475821221e-09
for O 0 3.1966667091154477e-09
the O 0 3.037671802985642e-08
HD B-Disease 0 3.164143345202319e-05
mutation O 0 7.769786591893535e-09
, O 0 9.683307489183335e-10
we O 0 1.2153003048354094e-09
have O 0 6.026693588623289e-10
assessed O 0 2.8440650723382532e-08
the O 0 1.2213195788035591e-08
accuracy O 0 1.8455646966231143e-07
of O 0 1.4114957203048561e-08
results O 0 5.723336027330106e-09
obtained O 0 2.8759000514355648e-08
by O 0 4.972918521417569e-09
linkage O 0 1.4763844546905602e-07
approaches O 0 1.9448552990297685e-08
when O 0 3.6760579025241213e-09
requested O 0 1.3893793671115873e-08
to O 0 2.904996465602494e-09
do O 0 3.553700000935578e-09
so O 0 3.2219229506580405e-09
by O 0 3.8354515119465304e-09
the O 0 3.217895638840673e-08
test O 0 1.3850142011051503e-07
individuals O 0 1.397304743022687e-07
. O 0 1.1484573860798264e-06

For O 0 8.887976719051949e-07
six O 0 1.7230536286660936e-07
such O 0 8.186876954141553e-09
individuals O 0 7.943852686764785e-09
, O 0 8.024058750777385e-09
there O 0 3.287119554329365e-08
was O 0 1.5520672604907304e-06
significant O 0 4.943311751048896e-07
disparity O 0 5.056535314906796e-07
between O 0 1.0293867802602108e-07
the O 0 1.3758226202753576e-07
tests O 0 4.504526884829829e-07
. O 0 2.054911192317377e-06

Three O 0 3.28883356814913e-06
went O 0 2.1536595795623725e-06
from O 0 1.1630201157686315e-07
a O 0 5.645185296998534e-07
decreased O 0 5.7495603869028855e-06
risk O 0 8.028747089383614e-08
to O 0 3.896698075323002e-09
an O 0 1.5773638395444323e-08
increased O 0 4.3355235845865536e-08
risk O 0 1.2481906708217139e-07
, O 0 4.682472187766962e-09
while O 0 5.027758209763533e-09
in O 0 3.243095125782247e-09
another O 0 2.1670661709549677e-08
three O 0 6.524023543619251e-09
the O 0 4.9307782745700024e-08
risk O 0 4.6547816623387916e-07
was O 0 6.499634764622897e-06
decreased O 0 4.337020800448954e-05
. O 0 2.0982838577765506e-06

Knowledge O 0 0.00010754382674349472
of O 0 1.268390178665868e-06
the O 0 2.0746443851749063e-07
potential O 0 1.2241068247931253e-07
reasons O 0 2.2896117002346728e-08
for O 0 1.3370012874602821e-09
these O 0 1.1801267740807475e-09
changes O 0 2.962032397135772e-09
in O 0 6.035554278582822e-09
results O 0 1.1050762083186783e-08
and O 0 2.064387549793878e-09
impact O 0 2.4268462794907464e-08
of O 0 7.597881435117415e-09
these O 0 3.295611783471486e-09
risk O 0 6.275985953152485e-08
reversals O 0 2.272082468834924e-07
on O 0 9.984749915759039e-09
both O 0 2.471964632988488e-09
patients O 0 2.015893230122856e-09
and O 0 6.023027632195976e-10
the O 0 1.735321930596001e-08
counseling O 0 9.331485273378348e-08
team O 0 1.8691650893742917e-08
can O 0 5.425757620969307e-09
assist O 0 1.1879327388442107e-07
in O 0 1.0770092373491025e-08
the O 0 2.653732344981563e-08
development O 0 8.187146249838406e-08
of O 0 2.5016388960352742e-08
strategies O 0 2.0448648996307384e-08
for O 0 5.120891710674869e-09
the O 0 6.441921840405485e-08
prevention O 0 9.543884971208172e-07
and O 0 3.736811304833054e-09
, O 0 6.655884288164771e-09
where O 0 5.1806323675407384e-09
necessary O 0 4.483551663270191e-08
, O 0 1.572782437619935e-08
management O 0 9.215736440637556e-08
of O 0 4.3390809167931366e-08
a O 0 5.099742850234179e-08
risk O 0 6.262497720399551e-08
reversal O 0 1.143744938758573e-07
in O 0 4.017878030282418e-09
any O 0 1.1364445384742794e-08
predictive O 0 1.365761761462636e-07
testing O 0 2.9317384075966402e-08
program O 0 1.5048044588183984e-07
. O 0 4.4911860896945655e-08
. O 0 4.064133349857002e-07

A O 0 4.0301503759110346e-05
novel O 0 8.77528600540245e-06
common O 0 1.16967783014843e-06
missense O 0 9.859349120233674e-06
mutation O 0 3.532226742208877e-07
G301C O 0 3.71318674297072e-06
in O 0 6.540022923218203e-08
the O 0 2.631992117585469e-07
N O 0 1.310703100898536e-05
- O 0 7.297005595319206e-06
acetylgalactosamine O 0 0.000306023022858426
- O 0 2.358907659072429e-05
6 O 0 8.514244655088987e-06
- O 0 7.437817657773849e-06
sulfate O 0 1.2773701200785581e-05
sulfatase O 0 0.0003243854152970016
gene O 0 1.3998899248690577e-06
in O 0 7.496392981920508e-07
mucopolysaccharidosis B-Disease 0 0.01371938455849886
IVA I-Disease 1 0.9989721775054932
. O 0 3.307594306534156e-05

Mucopolysaccharidosis B-Disease 1 0.999593198299408
IVA I-Disease 1 0.9999905824661255
( O 0 0.0004903901717625558
MPS B-Disease 1 0.9999915361404419
IVA I-Disease 1 1.0
) O 0 1.694886123004835e-06
is O 0 9.955353874602224e-08
an O 0 6.393411808858218e-07
autosomal B-Disease 1 0.9992067217826843
recessive I-Disease 1 0.9999998807907104
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.12421352416276932
by O 0 9.211762517224997e-07
a O 0 0.00015018628619145602
genetic B-Disease 1 0.9999955892562866
defect I-Disease 1 0.998422384262085
in O 0 8.478217523588683e-07
N O 0 0.0005716026644222438
- O 0 4.343544424045831e-05
acetylgalactosamine O 0 0.002897006692364812
- O 0 5.576971307164058e-05
6 O 0 2.146651422663126e-05
- O 0 2.117329313477967e-05
sulfate O 0 5.324073936208151e-05
sulfatase O 0 0.07198579609394073
( O 0 1.7789439880289137e-05
GALNS O 1 0.9678955078125
) O 0 5.5582022469025105e-06
. O 0 3.3170535971294157e-06

In O 0 2.592679948065779e-06
previous O 0 7.23507298516779e-07
studies O 0 2.425865659461124e-07
, O 0 1.0047296328252742e-08
we O 0 7.377361832539009e-09
have O 0 2.819864786118842e-09
found O 0 8.11215805640586e-09
two O 0 3.4757778877292367e-09
common O 0 9.316507565415577e-09
mutations O 0 5.233022193351644e-08
in O 0 1.5733260738670651e-07
Caucasians O 0 2.905496694438625e-05
and O 0 9.389617616761825e-08
Japanese O 0 0.00012815168884117156
, O 0 2.224915220949697e-07
respectively O 0 5.155129201739328e-06
. O 0 1.505997488493449e-06

To O 0 2.811979584294022e-06
characterize O 0 1.8858452676795423e-05
the O 0 9.755780183695606e-07
mutational O 0 6.762731936760247e-05
spectrum O 0 1.639242555029341e-07
in O 0 6.010441477855011e-09
various O 0 4.864415537042532e-09
ethnic O 0 1.099961988160203e-08
groups O 0 1.7494118376149004e-09
, O 0 2.6560504906569804e-09
mutations O 0 5.288729454377972e-09
in O 0 6.285711062758992e-09
the O 0 1.0918313364527421e-07
GALNS O 0 0.041080787777900696
gene O 0 1.1569445490522412e-07
in O 0 4.5723133723640785e-08
Colombian O 0 6.638031209149631e-06
MPS B-Disease 1 0.9994310736656189
IVA I-Disease 1 1.0
patients O 0 6.019610765406469e-08
were O 0 1.2601844900927972e-08
investigated O 0 1.25743696344216e-07
, O 0 2.331725035276122e-09
and O 0 3.326290576310953e-09
genetic O 0 1.841221930476422e-08
backgrounds O 0 7.868004026079234e-09
were O 0 8.764042824793705e-09
extensively O 0 3.798121994691428e-08
analyzed O 0 2.3892487988064204e-08
to O 0 3.318610053426596e-09
identify O 0 1.526254855832576e-08
racial O 0 5.76015750652914e-08
origin O 0 3.463761188982062e-08
, O 0 7.1548731384041275e-09
based O 0 5.7623741334111855e-09
on O 0 3.6654036250638455e-08
mitochondrial O 0 4.022880375487148e-07
DNA O 0 3.6254624546927516e-07
( O 0 1.2777444169387309e-07
mtDNA O 0 6.690717668789148e-07
) O 0 1.712630961492323e-07
lineages O 0 9.952466371032642e-07
. O 0 3.4349227462371346e-07

Three O 0 7.350688520091353e-06
novel O 0 1.4187453416525386e-05
missense O 0 2.4009401386138052e-05
mutations O 0 2.9754036745544e-07
never O 0 1.5972703693023504e-07
identified O 0 1.396822426613653e-07
previously O 0 1.1429327173573256e-07
in O 0 4.717343848881228e-09
other O 0 1.1262867305461555e-09
populations O 0 2.0631358843559156e-09
and O 0 1.8079761021638774e-09
found O 0 1.431838025922616e-08
in O 0 1.184125153486093e-08
16 O 0 8.441784160595489e-08
out O 0 1.664030513381931e-08
of O 0 1.3175753110772348e-07
19 O 0 2.668307388375979e-06
Colombian O 0 2.279593172715977e-05
MPS B-Disease 1 0.9396985173225403
IVA I-Disease 1 0.9999995231628418
unrelated O 0 2.653257297424716e-06
alleles O 0 5.502758426700893e-08
account O 0 7.523185985292002e-08
for O 0 6.602994062632206e-08
84 O 0 4.289971457183128e-06
. O 0 2.0511481579887914e-06

2 O 0 2.7727786800824106e-05
% O 0 7.389039069494174e-07
of O 0 2.7099318344880885e-07
the O 0 1.1615857431479526e-07
alleles O 0 9.75760627852651e-08
in O 0 2.6811040498841976e-08
this O 0 6.428984278272765e-08
study O 0 6.714349183312152e-07
. O 0 6.348535634970176e-07

The O 0 6.928773655090481e-05
G301C O 0 0.0005262395134195685
and O 0 1.8504726995161036e-06
S162F O 0 0.0001141370739787817
mutations O 0 7.548605367446726e-07
account O 0 4.2647553755159606e-07
for O 0 4.4594582959689433e-07
68 O 0 2.8710210244753398e-05
. O 0 8.221843927458394e-06

4 O 0 6.220844807103276e-05
% O 0 2.203672693212866e-06
and O 0 3.3129330745396146e-07
10 O 0 3.0381870601559058e-06
. O 0 2.8825231765949866e-06

5 O 0 6.902741461090045e-06
% O 0 2.6465505698070046e-07
of O 0 5.028527993999887e-08
mutations O 0 4.8968974653007535e-08
, O 0 1.0906986425140985e-08
respectively O 0 3.216760831037391e-07
, O 0 3.108557677933277e-08
whereas O 0 5.1815149504363944e-08
the O 0 3.798513148467464e-08
remaining O 0 8.075795108197781e-07
F69V O 0 0.1311292201280594
is O 0 2.9651088695459293e-08
limited O 0 7.4907093861043e-09
to O 0 4.4953147870785415e-09
a O 0 5.3606971306408013e-08
single O 0 1.1060782156846471e-07
allele O 0 3.642374508672219e-07
. O 0 4.283411669803172e-07

The O 0 2.743161348917056e-05
skewed O 0 3.29718241118826e-05
prevalence O 0 1.6737456462578848e-05
of O 0 5.956053996669652e-07
G301C O 0 2.5066048692679033e-05
in O 0 6.602213886708341e-08
only O 0 4.488788363232743e-08
Colombian O 0 1.3675021364178974e-06
patients O 0 3.3218729100781275e-08
and O 0 8.04898281359101e-09
haplotype O 0 3.4674042126425775e-07
analysis O 0 2.3088196243747916e-08
by O 0 1.782779701642312e-09
restriction O 0 1.7176944311358966e-08
fragment O 0 5.674565883850846e-08
length O 0 2.206021854078699e-08
polymorphisms O 0 1.1362261176373067e-07
in O 0 4.487579197132163e-09
the O 0 6.687713494102354e-08
GALNS O 1 0.7665864825248718
gene O 0 2.54121658826989e-07
suggest O 0 7.941962110180611e-08
that O 0 1.1483480832907844e-08
G301C O 0 5.103838248032844e-06
originated O 0 3.680648603676673e-07
from O 0 6.531222851435814e-08
a O 0 2.129810354745132e-07
common O 0 1.8987961425409594e-07
ancestor O 0 1.0345893315388821e-05
. O 0 2.196672994614346e-06

Investigation O 0 8.172713569365442e-05
of O 0 2.14903116102505e-06
the O 0 3.261306460444757e-07
genetic O 0 8.47972955853038e-07
background O 0 2.3269373627954337e-07
by O 0 1.102903102179198e-08
means O 0 1.2808652627427364e-07
of O 0 2.3704618001829658e-07
mtDNA O 0 2.823577233357355e-06
lineages O 0 1.0036076503183722e-07
indicate O 0 2.39396555912208e-08
that O 0 1.1639355035342192e-09
all O 0 1.9472596868297387e-09
our O 0 2.4202730486422297e-08
patients O 0 7.361268039574043e-09
are O 0 1.8696062475953568e-09
probably O 0 2.266721566002161e-07
of O 0 1.3823159861203749e-06
native O 0 8.92159641807666e-06
American O 0 0.00016929465346038342
descent O 0 0.0013354026013985276

Low O 0 1.5089996850292664e-05
frequency O 0 2.2348449419951066e-06
of O 0 7.998526712071907e-07
BRCA1 O 0 8.771236934990156e-06
germline O 0 6.356585345201893e-06
mutations O 0 3.1198194250237066e-08
in O 0 1.6464394292370343e-08
45 O 0 3.307080476133706e-07
German O 1 0.9999960660934448
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.192934334743768e-05
. O 0 3.6985341012041317e-06

In O 0 1.9057348481510417e-06
this O 0 5.080287479586332e-08
study O 0 5.256319823843114e-08
we O 0 1.2126521120592315e-08
investigated O 0 3.9573401977577305e-07
45 O 0 9.927487099048449e-07
German O 1 0.9999895095825195
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.018391722293018e-08
for O 0 4.1673807515962835e-08
germline O 0 3.606938480515964e-05
mutations O 0 6.299660526565276e-08
in O 0 3.1697112490292056e-08
the O 0 3.056307207316422e-07
BRCA1 O 0 7.571866717626108e-06
gene O 0 1.5808687976459623e-06
. O 0 1.0603722557789297e-06

We O 0 9.574388286637259e-07
identified O 0 7.429782158396847e-07
four O 0 2.8059497481081053e-07
germline O 0 2.3239013899001293e-05
mutations O 0 4.7866549834907346e-08
in O 0 1.4843448248313962e-08
three O 0 2.6195965574515867e-07
breast B-Disease 1 0.9999679327011108
cancer I-Disease 1 0.6491038799285889
families O 0 2.1644638081852463e-08
and O 0 1.7700005017218245e-08
in O 0 5.077972105027584e-07
one O 0 0.47360554337501526
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.00021255857427604496
. O 0 2.216480332606352e-09
among O 0 2.7446922512552874e-10
these O 0 2.449042912910926e-10
were O 0 3.442275797738148e-09
one O 0 1.5880258885658805e-08
frameshift O 0 6.263357477109821e-07
mutation O 0 1.0115191351189878e-08
, O 0 3.345263621667982e-09
one O 0 1.7987449751899476e-08
nonsense O 0 2.3593952391820494e-06
mutation O 0 1.2387123149437684e-07
, O 0 2.1866304322770702e-08
one O 0 4.5048874852682275e-08
novel O 0 9.906350442179246e-07
splice O 0 5.358670023269951e-06
site O 0 3.3017610689967114e-07
mutation O 0 1.5739948011628258e-08
, O 0 3.6837435324343915e-09
and O 0 1.34143123275976e-08
one O 0 2.3367131518625683e-07
missense O 0 2.417740506643895e-05
mutation O 0 2.2933543277758872e-06
. O 0 3.1590036542183952e-06

The O 0 1.616135887161363e-05
missense O 0 5.553885057452135e-05
mutation O 0 5.376932108447363e-07
was O 0 1.1291307373539894e-06
also O 0 5.7431314814948564e-08
found O 0 7.529057199917588e-08
in O 0 2.481499734585668e-07
2 O 0 8.500793228449766e-06
. O 0 5.0219664444739465e-06

8 O 0 2.6307843654649332e-05
% O 0 5.544805503632233e-07
of O 0 8.062676926101631e-08
the O 0 2.7627525156503907e-08
general O 0 1.7726364376358106e-07
population O 0 2.143269917098678e-08
, O 0 4.613070370140804e-09
suggesting O 0 3.217159161295058e-08
that O 0 5.600720442977547e-10
it O 0 8.587758837386161e-10
is O 0 7.483226482918326e-09
not O 0 2.9457964956236538e-08
disease O 0 5.766737103840569e-06
associated O 0 6.347885573632084e-06
. O 0 9.44151179282926e-06

The O 0 7.150078999984544e-06
average O 0 3.996543455286883e-06
age O 0 1.6154989452843438e-06
of O 0 1.4514270333165769e-05
disease O 1 0.9999943971633911
onset O 1 1.0
in O 0 9.895472885546042e-07
those O 0 1.5666363140098838e-07
families O 0 3.7091766103003465e-07
harbouring O 1 0.9976744055747986
causative O 0 0.010629990138113499
mutations O 0 6.323386969597777e-07
was O 0 2.11181873055466e-06
between O 0 8.345978699253465e-07
32 O 0 3.3966675800911617e-06
. O 0 2.8015856514684856e-06

3 O 0 3.512114562909119e-05
and O 0 2.786854793157545e-06
37 O 0 3.97290350520052e-05
. O 0 1.107496427721344e-05

4 O 0 9.925083759299014e-06
years O 0 8.502362902618188e-07
, O 0 1.2116514369608922e-07
whereas O 0 3.0278326335064776e-07
the O 0 1.1871173200006524e-07
family O 0 6.877889404677262e-07
harbouring O 0 0.00021927909983787686
the O 0 5.40358030320931e-07
missense O 0 4.701784291682998e-06
mutation O 0 4.301103473380863e-08
had O 0 2.8040766153480945e-08
an O 0 2.7758412457501436e-08
average O 0 3.788716469443898e-07
age O 0 4.865253231400857e-07
of O 0 1.8602186173666269e-06
onset O 1 0.9880648255348206
of O 0 5.2490897360257804e-05
51 O 0 0.0002673744747880846
. O 0 1.5414438166772015e-05

2 O 0 0.00010553438914939761
years O 0 1.8212163922726177e-05
. O 0 8.612290912424214e-06

These O 0 4.609167660873936e-07
findings O 0 9.151240192295518e-07
show O 0 4.800791089110135e-07
that O 0 4.403680264886134e-08
BRCA1 O 0 2.3076852357917232e-06
is O 0 5.060915597709936e-08
implicated O 0 3.9517209415862453e-07
in O 0 1.8510567301177616e-08
a O 0 3.704347406596753e-08
small O 0 1.5505708717000743e-08
fraction O 0 2.861450525415421e-07
of O 0 5.098615292808972e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.0327794320328394e-06
suggesting O 0 1.154870346908865e-06
the O 0 4.7287869620049605e-08
involvement O 0 1.3123710118634335e-07
of O 0 4.680385501387718e-08
another O 0 1.22923310641454e-07
susceptibility O 0 4.724081463791663e-07
gene O 0 4.2249982357134286e-07
( O 0 6.99541431004036e-07
s O 0 2.029889219556935e-05
) O 0 8.663148946652655e-06

Paternal O 1 0.9990573525428772
transmission O 1 0.9999749660491943
of O 1 0.9999996423721313
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9990971088409424

We O 0 3.2238442599918926e-06
report O 0 8.45864065013302e-07
a O 0 1.449073181447602e-07
rare O 0 5.654437629232234e-08
case O 0 1.4532332670569303e-07
of O 0 2.205051714554429e-06
paternally O 1 0.9999995231628418
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 1.0
DM B-Disease 1 1.0
) O 0 0.00010715115058701485
. O 0 1.0016768101195339e-05

The O 0 3.725947317434475e-05
proband O 0 0.0011552701471373439
is O 0 3.9297168541452265e-07
a O 0 1.5139795550567214e-07
23 O 0 2.1321780252492317e-07
year O 0 3.81009392924625e-08
old O 0 1.6539308489882387e-05
, O 0 1.1320914381940383e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.46360090374946594
who O 0 4.597174665832426e-06
suffers O 1 0.9999874830245972
severe O 1 0.999996542930603
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.00015252424054779112

He O 0 8.208039616874885e-06
presented O 0 4.339786300988635e-06
with O 0 1.13693874936871e-06
respiratory O 1 0.9975239634513855
and O 0 1.86443833172234e-06
feeding O 1 0.6439875960350037
difficulties O 1 0.9999722242355347
at O 1 0.9985564351081848
birth O 1 0.6516329646110535
. O 0 1.0183071026403923e-05

His O 0 5.1748400437645614e-05
two O 0 1.2853949556301814e-05
sibs O 1 0.9999769926071167
suffer O 0 0.00031006993958726525
from O 0 2.9902297683293e-05
childhood O 1 0.9999998807907104
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.0011110811028629541

Their O 0 3.352149406055105e-06
late O 0 5.006439096177928e-06
father O 0 2.313586492164177e-06
had O 0 1.662882738173721e-07
the O 0 5.6448040908207986e-08
adult O 0 1.238737041830973e-07
type O 0 1.7491177004558267e-06
of O 0 0.004040728323161602
DM B-Disease 1 1.0
, O 0 1.8473589307177463e-06
with O 0 1.3719234459586005e-07
onset O 1 0.9956834316253662
around O 0 1.4493539310933556e-06
30 O 0 8.855926125761471e-07
years O 0 5.900468522668234e-07
. O 0 8.915814078136464e-07

Only O 0 1.008537083180272e-06
six O 0 1.567053402595775e-07
other O 0 5.2883359913380446e-09
cases O 0 1.0861604060607988e-08
of O 0 3.3529761367390165e-07
paternal O 1 0.9639390110969543
transmission O 1 0.9999994039535522
of O 1 1.0
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.4635709703725297e-05
been O 0 2.220735950686503e-06
reported O 0 3.052697138627991e-06
recently O 0 2.3788643375155516e-06
. O 0 1.9669028006319422e-06

We O 0 1.1775842949646176e-06
review O 0 5.768204687228717e-07
the O 0 1.3172059709631867e-07
sex O 0 1.3147662514256808e-07
related O 0 1.2081875411240617e-07
effects O 0 1.7335640905002947e-06
on O 0 4.197770067548845e-06
transmission O 1 0.832736611366272
of O 1 0.9996148347854614
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.12083432823419571

Decreased O 1 0.9997683167457581
fertility O 0 0.0013790937373414636
of O 0 9.535478397992847e-07
males O 0 1.900923365383278e-07
with O 0 3.074551813142534e-08
adult O 0 3.663713141577318e-05
onset O 1 1.0
DM B-Disease 1 1.0
and O 0 7.346794745899388e-07
contraction O 0 1.4945748262107372e-05
of O 0 7.594334761051869e-08
the O 0 5.399836311426043e-08
repeat O 0 3.577307268187724e-07
upon O 0 2.9498710318875965e-07
male O 0 1.4662679177490645e-06
transmission O 0 2.426786807063763e-07
contribute O 0 1.3579764868154598e-08
to O 0 3.759825339955114e-09
the O 0 3.971448947481804e-08
almost O 0 2.3860343389969785e-07
absent O 0 5.275086323308642e-07
occurrence O 0 7.324869670810585e-07
of O 0 2.0222529428792768e-07
paternal O 0 3.43007268384099e-05
transmission O 0 0.0008473404450342059
of O 1 0.8607844710350037
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.4686950147151947

Also O 0 1.1057529718527803e-06
the O 0 3.2740581445978023e-07
fathers O 0 9.213405292030075e-07
of O 0 2.797068816562387e-07
the O 0 5.143767225490592e-07
reported O 0 1.8723692846833728e-05
congenitally O 0 0.20072954893112183
affected O 0 2.0582558590831468e-07
children O 0 5.8628870647225995e-08
showed O 0 3.02984290101449e-07
, O 0 2.997509795932274e-08
on O 0 1.541825866979707e-07
average O 0 8.637259725219337e-07
, O 0 6.48743352371639e-08
shorter O 0 2.905901283156709e-06
CTG O 0 0.4501858353614807
repeat O 0 2.6508748760534218e-06
lengths O 0 3.1252384360414e-06
and O 0 1.829917017914795e-08
hence O 0 1.0905721836707016e-07
less O 0 1.9591819722108994e-08
severe O 0 6.39107099686953e-07
clinical O 0 1.898056325444486e-05
symptoms O 0 1.8754325310510467e-06
than O 0 1.9753466418137577e-08
the O 0 2.938221825843357e-07
mothers O 0 1.0139955293198e-06
of O 0 1.5596538105455693e-07
children O 0 1.0740224070104887e-06
with O 0 1.9219138266635127e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.001851061824709177

We O 0 7.089546670613345e-06
conclude O 0 1.950221303559374e-05
that O 0 4.931752073389362e-07
paternal O 0 0.00013487438263837248
transmission O 0 0.33546605706214905
of O 1 0.9999774694442749
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.060879550874233246
rare O 0 1.674207396717975e-06
and O 0 1.847966579759941e-08
preferentially O 0 2.2169639635194471e-07
occurs O 0 6.05289471877768e-08
with O 0 2.5342867360222954e-08
onset O 1 0.9998865127563477
of O 1 0.9150491952896118
DM B-Disease 1 1.0
past O 0 2.684466608116054e-06
30 O 0 2.5453422836108075e-07
years O 0 1.9858864774846552e-08
in O 0 7.106577104565304e-09
the O 0 6.125062412820625e-08
father O 0 2.6091151994478423e-06
. O 0 3.096943714808731e-07
. O 0 1.5725536286481656e-06

The O 0 0.00022198096849024296
RB1 O 1 0.9967333078384399
gene O 0 3.7665492982341675e-06
mutation O 0 3.629232878665789e-07
in O 0 7.230783438672006e-08
a O 0 7.631404059793567e-07
child O 0 8.769798114371952e-06
with O 0 1.4557797840097919e-05
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999998807907104
. O 0 0.0001377255393890664

The O 0 0.0001416877785231918
RB1 O 1 0.99616539478302
gene O 0 2.2509259451908292e-06
mutation O 0 1.7692198639451817e-07
was O 0 4.26808810516377e-07
investigated O 0 4.578518257858377e-07
in O 0 3.6773990075289475e-08
a O 0 1.947331611518166e-07
child O 0 2.1638752514263615e-06
with O 0 1.9370422705833334e-06
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.6467218399047852
using O 0 1.9504206250076095e-07
DNA O 0 1.909080538098351e-07
obtained O 0 2.6963970611859622e-08
from O 0 4.952227072863025e-09
both O 0 4.8329069635144606e-09
the O 0 8.896764569499283e-08
pineal B-Disease 0 0.08853617310523987
and I-Disease 0 9.018251603265526e-07
retinal I-Disease 1 0.9999974966049194
tumours I-Disease 1 1.0
of O 0 0.00012262171367183328
the O 0 5.0955390179296955e-05
patient O 0 0.00010454657603986561
. O 0 5.740520009567263e-06

A O 0 0.00011120744602521881
nonsense O 0 9.727630094857886e-05
mutation O 0 2.3489487830374856e-06
in O 0 6.195916171236604e-07
exon O 0 1.0238476534141228e-05
17 O 0 2.5974438813136658e-06
( O 0 8.100609534267278e-07
codon O 0 3.6265316794015234e-06
556 O 0 2.064630962195224e-06
) O 0 8.361786996147202e-08
of O 0 9.097778530531286e-08
the O 0 7.734316795904306e-07
RB1 O 1 0.9231809973716736
gene O 0 2.655021944519831e-07
was O 0 3.673761170830403e-07
found O 0 1.7814278052696864e-08
to O 0 3.01155989035351e-09
be O 0 1.4678690263281169e-08
present O 0 1.7976908850414475e-07
homozygously O 0 0.001170828938484192
in O 0 5.1942894430112574e-08
both O 0 1.6736530383809622e-08
the O 0 2.879885983020358e-07
retinal B-Disease 0 2.5575291147106327e-05
and I-Disease 0 1.1145215239594108e-07
the I-Disease 0 1.3182004295231309e-05
pineal I-Disease 1 0.9999998807907104
tumours I-Disease 1 1.0
. O 0 2.236466207250487e-05

The O 0 3.9849896893429104e-06
same O 0 2.3821509387289552e-07
mutation O 0 1.5430762800860975e-07
was O 0 4.451470090316434e-07
present O 0 2.2231208163248084e-07
heterozygously O 0 1.8696999177336693e-05
in O 0 2.869303372676768e-08
the O 0 2.183129765853664e-08
DNA O 0 1.7233790572390717e-07
from O 0 5.276155512490277e-09
the O 0 1.4395272529554859e-08
constitutional O 0 6.334131086305206e-08
cells O 0 2.952557842661463e-08
of O 0 1.3366679318949082e-08
the O 0 2.9930536271649544e-08
patient O 0 4.0512128407499404e-07
, O 0 1.6735221208818984e-08
proving O 0 6.992186172283255e-07
it O 0 1.7463446244647685e-09
to O 0 2.741533444705624e-09
be O 0 1.9624019742536802e-08
of O 0 4.393902202082245e-07
germline O 0 3.8692047382937744e-05
origin O 0 1.9934307147195796e-06
. O 0 1.478297804169415e-06

The O 0 3.892105269187596e-06
initial O 0 1.3200522062106756e-06
mutation O 0 1.3104099139127356e-07
was O 0 1.3781050256511662e-07
shown O 0 1.6559758009293546e-08
to O 0 6.823360543251056e-09
have O 0 1.029949903141869e-08
occurred O 0 1.2479590623115655e-06
in O 0 6.524150819586794e-08
the O 0 6.94744585416629e-07
paternally O 0 0.00010116426710737869
derived O 0 2.453446722938679e-05
RB1 O 0 0.0017934017814695835
allele O 0 7.804173037584405e-06
. O 0 2.4468843093927717e-06

The O 0 3.2337443371943664e-06
mutation O 0 3.90929642435367e-07
is O 0 1.8818390401520446e-08
in O 0 7.245414490597568e-09
an O 0 1.875428878861385e-08
area O 0 7.011270497514488e-08
of O 0 4.880271831098071e-08
the O 0 1.0755233859072177e-07
gene O 0 5.08372828278425e-08
that O 0 4.543752041286098e-09
encodes O 0 6.786812889458815e-08
the O 0 8.607950796601926e-09
protein O 0 6.058994017621444e-08
- O 0 3.748263210923142e-08
binding O 0 1.1252566878283687e-08
region O 0 2.942191379418091e-08
known O 0 3.005541771017306e-08
as O 0 7.879086716400252e-09
the O 0 7.464597473472168e-08
pocket O 0 1.563893965794705e-05
region O 0 5.527742175104322e-08
and O 0 3.478258348010854e-09
has O 0 1.9638350945427874e-09
been O 0 3.5431890754722417e-09
detected O 0 1.9535772111112237e-08
in O 0 1.2677658922655155e-09
other O 0 5.614239628748408e-10
cases O 0 7.938400159446246e-09
of O 0 3.738082909876539e-07
retinoblastoma B-Disease 0 0.11741523444652557
. O 0 8.149052632688836e-07
. O 0 3.0284791137091815e-06

Low O 0 4.633084245142527e-05
levels O 0 3.087091045017587e-06
of O 0 1.4196924666975974e-06
beta O 0 1.2081536624464206e-05
hexosaminidase O 0 7.431794074364007e-05
A O 0 2.3845834675739752e-06
in O 0 6.921608530774392e-08
healthy O 0 2.954282649625384e-07
individuals O 0 4.912386497579746e-09
with O 0 1.1851938097606762e-08
apparent O 0 0.12454915791749954
deficiency O 1 0.9999880790710449
of O 0 4.6073888370301574e-05
this O 0 1.626887410566269e-06
enzyme O 0 1.0059858141175937e-05
. O 0 2.004099542318727e-06

Appreciable O 0 0.001490479102358222
beta O 0 0.00016771125956438482
hexosaminidase O 0 0.0002251658879686147
A O 0 1.2300190974201541e-05
( O 0 9.724792562337825e-07
hex O 0 1.5886076653259806e-05
A O 0 2.0476497866184218e-06
) O 0 3.6284607318748385e-08
activity O 0 7.606061558362853e-08
has O 0 1.7456253109671138e-09
been O 0 5.705199868089039e-09
detected O 0 1.510452136699314e-07
in O 0 5.890966647825735e-08
cultured O 0 0.0004105549305677414
skin O 0 9.393542859470472e-05
fibroblasts O 0 0.018302753567695618
and O 0 2.0810421119676903e-06
melanoma B-Disease 1 1.0
tissue O 1 0.9573244452476501
from O 0 1.2490330618675216e-06
healthy O 0 2.8883680442959303e-06
individuals O 0 5.3572195568563075e-09
previously O 0 7.782678324019798e-08
reported O 0 1.3681031418855127e-07
as O 0 1.6346927367294484e-08
having O 0 1.2683756267506396e-06
deficiency B-Disease 1 0.6307392716407776
of I-Disease 0 8.776542017585598e-06
hex I-Disease 0 0.0007684339070692658
A I-Disease 0 2.6197615170531208e-06
activity O 0 1.4821246452356718e-07
indistinguishable O 0 4.013330823227079e-08
from O 0 1.0667863259428145e-09
that O 0 2.413770294751316e-10
of O 0 3.814585980421725e-09
patients O 0 6.698331667109869e-09
with O 0 3.38238834274307e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
( O 0 3.036987254745327e-05
TSD B-Disease 1 0.9931679964065552
) O 0 1.3868847190678935e-06
. O 0 9.71129793470027e-07

Identification O 0 7.201385596999899e-05
and O 0 1.098973143598414e-06
quantitation O 0 0.007765758782625198
of O 0 8.58936837175861e-05
hex O 0 0.002228169236332178
A O 0 6.525497155962512e-05
, O 0 2.038364499412637e-07
amounting O 0 5.518594662135001e-06
to O 0 3.838633801933611e-07
3 O 0 7.659616130695213e-06
. O 0 4.982167411071714e-06

5 O 0 7.467733666999266e-05
% O 0 1.2650350981857628e-05
- O 0 1.9607316062320024e-05
6 O 0 1.902147960208822e-05
. O 0 3.6494050164037617e-06

9 O 0 3.460305742919445e-05
% O 0 6.471638585026085e-07
of O 0 2.1049650911209028e-07
total O 0 4.977704293196439e-07
beta O 0 2.919612597906962e-06
hexosaminidase O 0 2.8099391784053296e-05
activity O 0 2.453403169511148e-07
, O 0 3.994191200007435e-09
has O 0 5.078800158209162e-10
been O 0 1.5670682529389524e-09
obtained O 0 2.5343014797840624e-08
by O 0 2.5694822269883844e-08
cellulose O 0 1.3237635357654653e-05
acetate O 0 3.1778156426298665e-06
gel O 0 8.371012881980278e-06
electrophoresis O 0 2.0743209461215883e-05
, O 0 3.121927250049339e-07
DEAE O 0 0.00159176392480731
- O 0 1.0029653822130058e-05
cellulose O 0 7.688092409807723e-06
ion O 0 4.517098204814829e-06
- O 0 3.4326835702813696e-06
exchange O 0 3.6030794490216067e-06
chromatography O 0 0.00010383836342953146
, O 0 4.464398557502136e-07
radial O 0 5.7556608226150274e-06
immunodiffusion O 0 7.346786878770217e-05
, O 0 2.9630575681949267e-07
and O 0 7.667470640626561e-07
radioimmunoassay O 0 0.004992904141545296
. O 0 1.7331016351818107e-05

Previous O 0 6.647100963164121e-05
family O 0 1.6815841945572174e-06
studies O 0 2.2899179441537854e-07
suggested O 0 4.147485199723633e-08
that O 0 1.0315320819742624e-09
these O 0 5.458035134964234e-10
individuals O 0 1.0446254972151792e-09
may O 0 1.4942415305085888e-08
be O 0 4.4589732794975134e-08
compound O 0 0.00015662335499655455
heterozygotes O 0 7.960256880323868e-07
for O 0 5.7729243607695935e-09
the O 0 2.985766656138367e-08
common O 0 4.452106949770496e-08
mutant O 0 6.719410521327518e-06
TSD B-Disease 0 0.453828364610672
gene O 0 2.592061143502633e-08
and O 0 1.65196845092197e-09
a O 0 2.080369476686883e-08
rare O 0 4.8537227570477626e-08
( O 0 7.412259606098814e-08
allelic O 0 9.043072282111098e-07
) O 0 2.5018758265105134e-07
mutant O 0 3.9094370549719315e-06
gene O 0 1.0225381856798776e-06
. O 0 6.820929456807789e-07

Thus O 0 9.4057259047986e-06
, O 0 1.9042020937831694e-07
the O 0 1.757386485223833e-07
postulated O 0 4.117528078495525e-06
rate O 0 6.575959332622006e-07
mutant O 0 7.527017942265957e-07
gene O 0 3.520563041092828e-08
appears O 0 1.5384955531771993e-08
to O 0 1.6014634063310496e-09
code O 0 4.729479030629591e-09
for O 0 2.296227430420572e-09
the O 0 1.496643164955458e-08
expression O 0 3.0720958221763794e-08
of O 0 4.946528164850861e-08
low O 0 1.3448055824483163e-07
amounts O 0 1.6591981477631634e-07
of O 0 1.027258122121566e-06
hex O 0 2.2516436729347333e-05
A O 0 7.732864105491899e-06
. O 0 1.197813276121451e-06

Heterozygotes O 0 0.0004001511842943728
for O 0 2.1213166689904028e-07
the O 0 2.846041127213539e-07
rare O 0 2.846377640253195e-07
mutant O 0 1.2217631137900753e-06
may O 0 5.60958923756516e-08
be O 0 3.633523348867129e-08
indistinguishable O 0 1.9473739030217985e-06
from O 0 1.7088622428218514e-07
heterozygotes O 0 1.331400540038885e-06
for O 0 4.1200710398925366e-08
the O 0 3.754481383566599e-07
common O 0 9.168300607598212e-07
TSD B-Disease 1 0.9869875907897949
mutant O 0 8.270068792626262e-05
. O 0 2.8975994155189255e-06

However O 0 3.174665607730276e-06
, O 0 2.568492902810249e-07
direct O 0 7.29403097921022e-07
visualization O 0 4.2249634134350345e-05
and O 0 2.8401927920640446e-07
quantitation O 0 0.034588638693094254
of O 0 2.0156030586804263e-05
hex O 0 0.00020967448654118925
A O 0 1.4917461612640182e-06
by O 0 6.608964042698062e-09
the O 0 7.062390672274432e-09
methods O 0 2.218494898897916e-08
described O 0 5.202509356649898e-08
may O 0 1.530283277872968e-08
prevent O 0 3.925240221747117e-08
false O 0 3.482389558939758e-07
- O 0 1.1371251957825734e-06
positive O 0 2.8435616172828304e-07
prenatal O 0 0.00011620598525041714
diagnosis O 0 5.182568565942347e-05
of O 0 9.855570169747807e-06
TSD B-Disease 1 1.0
in O 0 9.034349091052718e-07
fetuses O 0 3.740404508789652e-06
having O 0 1.4351934396472643e-07
the O 0 1.576850081619341e-07
incomplete O 0 7.545297194155864e-06
hex B-Disease 0 9.322555706603453e-05
A I-Disease 0 5.775102908955887e-05
deficiency I-Disease 0 0.02749941125512123
of O 0 5.822328716931224e-07
the O 0 4.816580485567101e-07
type O 0 3.838194061245304e-06
described O 0 4.707194420916494e-07
in O 0 3.695716443985475e-08
the O 0 2.1498559021893016e-07
four O 0 6.83606401707948e-07
healthy O 0 7.081896910676733e-06
individuals O 0 2.1109992758283624e-06

The O 0 6.758180097676814e-05
tumor B-Disease 1 0.8563534617424011
suppressor O 0 0.002068303059786558
gene O 0 1.4353607184602879e-05
Smad4 O 1 0.9992608428001404
/ O 0 0.008457091636955738
Dpc4 O 1 0.6062811613082886
is O 0 3.67597579042922e-08
required O 0 1.4384019308977258e-08
for O 0 1.8642303700744378e-08
gastrulation O 0 4.0965733205666766e-05
and O 0 1.2490762202332917e-08
later O 0 9.472416451217214e-08
for O 0 4.650699025887661e-08
anterior O 0 0.00019179853552486748
development O 0 3.4916317872557556e-06
of O 0 7.321880275412695e-07
the O 0 1.3652087318405393e-06
mouse O 0 5.6780577324389014e-06
embryo O 0 9.975470675271936e-06
. O 0 7.902461334197142e-07

Mutations O 0 1.6700370906619355e-05
in O 0 1.2671133617914165e-06
the O 0 8.727997737878468e-06
SMAD4 O 1 0.9999996423721313
/ O 1 0.9999955892562866
DPC4 O 1 1.0
tumor B-Disease 1 0.9999977350234985
suppressor O 0 0.00017759249021764845
gene O 0 1.4302500517260341e-07
, O 0 1.089160228673336e-08
a O 0 5.898668220538639e-08
key O 0 3.2728030419093557e-07
signal O 0 4.580771815199114e-07
transducer O 0 5.940941605331318e-07
in O 0 2.0854111326684688e-08
most O 0 2.615711558462408e-08
TGFbeta O 0 0.02965041808784008
- O 0 1.743748362059705e-05
related O 0 2.3729073745926144e-06
pathways O 0 4.608596384514385e-07
, O 0 2.5421769134226224e-09
are O 0 5.301007410807301e-10
involved O 0 1.1265881560973412e-08
in O 0 1.102352076287616e-08
50 O 0 1.5458290647529793e-07
% O 0 1.3620834238281532e-07
of O 0 3.3944461392820813e-06
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999102354049683
. O 0 1.623721072974149e-05

Homozygous O 0 0.01775076985359192
Smad4 O 1 0.9989529848098755
mutant O 0 0.00476894062012434
mice O 0 7.104175892891362e-05
die O 0 1.0149291483685374e-05
before O 0 3.055050228795153e-06
day O 0 1.0147608008992393e-05
7 O 0 2.081214370264206e-05
. O 0 1.624180640646955e-06

5 O 0 0.0001350120728602633
of O 0 5.191630407352932e-05
embryogenesis O 0 0.002227185759693384
. O 0 4.757137503474951e-05

Mutant O 0 0.00016605920973233879
embryos O 0 1.9999677078885725e-06
have O 0 1.6623745935362422e-08
reduced O 0 8.162277254086803e-08
size O 0 2.3655385916754312e-07
, O 0 3.417757099555274e-08
fail O 0 3.550802887275495e-07
to O 0 1.119077950306746e-07
gastrulate O 0 0.0008876610663719475
or O 0 4.078421795838949e-07
express O 0 4.326201974436117e-07
a O 0 3.42930945862463e-07
mesodermal O 0 5.992065416648984e-05
marker O 0 2.530269512135419e-06
, O 0 1.3570908841131768e-08
and O 0 1.068966337669508e-08
show O 0 1.1188234338987968e-06
abnormal O 0 0.0003046420752070844
visceral O 0 7.777693099342287e-05
endoderm O 0 0.004296714905649424
development O 0 4.405391518957913e-05
. O 0 5.367057838157052e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 0.9999994039535522
of O 0 1.5311969036702067e-05
the O 0 2.976309224322904e-05
Smad4 O 1 1.0
- O 1 0.9999744892120361
deficient O 0 0.00028537341859191656
embryos O 0 1.7565955090503849e-07
results O 0 1.4704919060193333e-08
from O 0 1.1661248855432405e-08
reduced O 0 7.633646958993268e-08
cell O 0 2.5382257717865286e-06
proliferation O 0 1.780981506271928e-06
rather O 0 2.8945665420110345e-08
than O 0 1.1356926954420032e-08
increased O 0 1.76312241251253e-07
apoptosis O 0 1.1717181223502848e-05
. O 0 4.888414650849882e-07

Aggregation O 0 0.00014964051661081612
of O 0 7.609015938214725e-06
mutant O 0 0.0001320845476584509
Smad4 O 1 0.9999408721923828
ES O 1 0.9929064512252808
cells O 0 1.3639747464821994e-07
with O 0 6.283817022278981e-09
wild O 0 3.0632082825832185e-07
- O 0 5.029956355429022e-06
type O 0 3.4048139241349418e-06
tetraploid O 0 4.503823583945632e-05
morulae O 0 0.0014796335017308593
rescues O 0 6.35341857559979e-05
the O 0 4.88311206936487e-06
gastrulation B-Disease 0 0.043108049780130386
defect I-Disease 0 0.000579451269004494
. O 0 1.0414445569040254e-05

These O 0 5.663903266395209e-07
results O 0 6.417603231057001e-07
indicate O 0 7.259096719280933e-07
that O 0 6.326439461190603e-08
Smad4 O 0 6.601480708923191e-05
is O 0 2.3052246334032134e-08
initially O 0 3.394162817471624e-08
required O 0 1.2798732740293417e-08
for O 0 6.740754177059216e-09
the O 0 5.287884974336521e-08
differentiation O 0 1.6447904727101559e-06
of O 0 9.860092831104339e-08
the O 0 2.3048954744808725e-07
visceral O 0 6.492492502729874e-06
endoderm O 0 1.2040451110806316e-05
and O 0 1.1944940148111982e-08
that O 0 1.1638850772044407e-08
the O 0 1.9999018263661128e-07
gastrulation B-Disease 0 0.0008775442838668823
defect I-Disease 0 1.8094202459906228e-05
in O 0 1.624166969804719e-07
the O 0 5.240214022705914e-07
epiblast O 0 0.0028261153493076563
is O 0 1.2717947583951172e-07
secondary O 0 1.0541511983319651e-06
and O 0 5.065222552502746e-08
non O 0 3.5394372389419004e-05
- O 0 0.00042772252345457673
cell O 0 5.729900294682011e-05
autonomous O 0 7.616174116265029e-06
. O 0 1.594514174030337e-06

Rescued O 0 0.0034421286545693874
embryos O 0 4.1951567254727706e-05
show O 0 1.99248952412745e-05
severe O 0 0.00012027999036945403
anterior O 1 0.916680634021759
truncations O 1 0.9997729659080505
, O 0 5.071606210549362e-06
indicating O 0 1.986047027457971e-05
a O 0 4.04225914962808e-07
second O 0 2.517670623092272e-07
important O 0 2.497915829735575e-07
role O 0 6.727142363160965e-07
for O 0 3.023285444214707e-07
Smad4 O 1 0.9999938011169434
in O 0 9.063569450518116e-06
anterior O 1 0.9838047623634338
patterning O 0 0.2206691950559616
during O 0 0.005499470047652721
embryogenesis O 1 0.9952912330627441
. O 0 4.772404645336792e-05

Prevalence O 0 0.03685246407985687
of O 0 1.419001000613207e-05
p16 O 0 0.00038762259646318853
and O 0 1.0003536772273947e-06
CDK4 O 1 0.9999709129333496
germline O 0 0.003297999035567045
mutations O 0 1.6703306471299584e-07
in O 0 1.1472440775150972e-07
48 O 0 2.885315552703105e-05
melanoma B-Disease 1 1.0
- O 1 0.9567743539810181
prone O 0 0.000456315407063812
families O 0 8.764916969994374e-08
in O 0 2.0947680923200096e-07
France O 0 7.858565368223935e-06
. O 0 6.5131862356793135e-06

The O 0 5.968279219814576e-05
French O 0 0.0014097782550379634
Familial B-Disease 1 0.9999997615814209
Melanoma I-Disease 1 1.0
Study O 0 0.005004613194614649
Group O 0 3.0462866561720148e-05
. O 0 4.302738034311915e-06

Germline O 0 0.431194543838501
mutations O 0 4.51446203442174e-06
in O 0 5.090647050565167e-07
the O 0 7.998831392797001e-07
p16 O 0 6.290389865171164e-05
and O 0 2.1829720253663254e-07
CDK4 O 1 0.9994691014289856
genes O 0 1.9758540759085008e-07
have O 0 2.574896962315165e-09
been O 0 1.1114769549180892e-08
reported O 0 2.3763051970604465e-08
in O 0 6.465318946879961e-09
a O 0 4.714485513090949e-08
subset O 0 3.1230646868607437e-07
of O 0 3.619989570324833e-07
melanoma B-Disease 1 0.9701953530311584
pedigrees O 0 4.901887223240919e-06
, O 0 1.3730197423456048e-08
but O 0 3.4813909532971365e-09
their O 0 6.3451439658024356e-09
prevalence O 0 2.4572295842517633e-07
is O 0 1.7475642044573192e-09
not O 0 1.6634269517368239e-09
well O 0 3.815155125153069e-08
known O 0 5.406028549259645e-07
. O 0 1.2588676554514677e-06

We O 0 1.8465805169398664e-06
searched O 0 2.6295685984223383e-06
for O 0 2.0604117523248533e-08
such O 0 4.2801204358511313e-08
germline O 0 2.6484431145945564e-05
mutations O 0 5.7046150914175087e-08
in O 0 1.7369446325687932e-08
48 O 0 1.1195534170838073e-06
French O 0 0.13836556673049927
melanoma B-Disease 1 1.0
- O 0 0.1608017385005951
prone O 0 3.9087399272830226e-06
families O 0 4.115756624401001e-09
selected O 0 7.232463516970711e-09
according O 0 8.678112450866138e-09
to O 0 1.330694443524294e-09
two O 0 1.989221454223866e-09
major O 0 2.0531579991711624e-08
criteria O 0 1.0993642440837448e-08
families O 0 3.0152613739176104e-09
with O 0 1.2511953695337752e-09
at O 0 1.2974142293842306e-07
least O 0 3.640958645689807e-09
three O 0 2.7268947100367313e-09
affected O 0 1.6640933075962039e-09
members O 0 1.6632492050305814e-09
( O 0 4.687395804836569e-09
n O 0 6.333684154924413e-08
= O 0 1.1783308195845166e-07
20 O 0 1.9404163609237912e-08
) O 0 2.174712854241534e-09
or O 0 9.660506838926608e-10
families O 0 2.2371807184562442e-10
with O 0 1.9687396157763715e-10
two O 0 9.972639380961823e-10
affected O 0 3.6347485021792636e-09
members O 0 1.9719952337737823e-09
, O 0 2.2385688858150843e-09
one O 0 3.5039744439302467e-09
of O 0 5.109369372036099e-09
them O 0 3.882453913917061e-09
affected O 0 5.546316295124143e-09
before O 0 2.414256350391497e-08
the O 0 5.618187870481961e-08
age O 0 1.5758038784952078e-07
of O 0 9.223087005238995e-08
50 O 0 6.524785334249827e-08
( O 0 2.0894960428563536e-08
n O 0 9.478904416937439e-08
= O 0 1.0637578640171341e-07
28 O 0 6.001428687341104e-08
) O 0 2.9085225339287035e-09
, O 0 1.2742070731874833e-09
and O 0 6.386861040041936e-10
one O 0 2.8150231035084516e-09
additional O 0 2.494515882744963e-08
minor O 0 7.602304208376154e-07
criterion O 0 5.1759507186943665e-05
. O 0 3.8346379369613715e-06

Sixteen O 0 7.213468779809773e-05
different O 0 7.427287869177235e-07
p16 O 0 0.00012989575043320656
germline O 0 2.3006332412478514e-05
mutations O 0 3.9991636668901265e-08
were O 0 2.151059241839448e-08
found O 0 1.2898254020399236e-08
in O 0 1.7249863759616346e-08
21 O 0 1.6444033690277138e-07
families O 0 2.0120145549640256e-08
, O 0 1.4573574347309659e-08
while O 0 4.8350397463536865e-08
one O 0 1.2474029631448502e-07
germline O 0 1.8882170479628257e-05
mutation O 0 8.417858765596975e-08
, O 0 3.0118371796561405e-08
Arg24His O 0 0.00028379919240251184
, O 0 3.3456352355187846e-08
was O 0 6.325951176222588e-07
detected O 0 3.987951799899747e-07
in O 0 8.775220550205631e-08
the O 0 1.070611915565678e-06
CDK4 O 1 0.9280547499656677
gene O 0 1.7285656213061884e-05
. O 0 3.5990340165881207e-06

The O 0 2.9107386581017636e-06
frequency O 0 1.347639454252203e-06
of O 0 5.776655029876565e-07
p16 O 0 1.1653815818135627e-05
gene O 0 1.4382652580025024e-07
mutation O 0 9.65553770271299e-09
in O 0 2.4498802986272494e-09
our O 0 8.608312285218744e-09
sample O 0 1.0935899297237484e-08
( O 0 1.6908671796045383e-08
44 O 0 4.6113921570167804e-08
% O 0 1.1353375128919652e-08
) O 0 1.3200669446433722e-09
is O 0 6.440196154144928e-10
among O 0 2.061309872791739e-10
the O 0 3.086595423695826e-09
highest O 0 3.3295293633273104e-08
rates O 0 8.149750208019668e-09
yet O 0 5.6330993203346225e-09
reported O 0 1.4969113948382073e-08
and O 0 1.330039856028975e-09
the O 0 2.6775524020195007e-08
CDK4 O 0 0.00019341296865604818
mutation O 0 1.6156972648673218e-08
is O 0 2.5026209993228576e-09
the O 0 4.219133487026738e-09
second O 0 2.7136291436136162e-08
mutation O 0 1.174152952643226e-08
detected O 0 2.757130346253689e-08
in O 0 2.5155613148086786e-09
this O 0 1.0615177181705349e-08
gene O 0 1.4267679659951682e-07
worldwide O 0 5.1179359417119485e-08
. O 0 3.8939884916544543e-07

In O 0 3.833102255157428e-06
summary O 0 1.2250976396899205e-05
, O 0 1.948498180581737e-07
our O 0 2.119383708532041e-07
results O 0 7.868487728046603e-08
show O 0 1.3513572127976659e-07
frequent O 0 6.231827143210467e-08
involvement O 0 1.4718590080065042e-07
of O 0 1.0593741706088622e-07
the O 0 5.717255362469587e-07
p16 O 0 0.00023896123457234353
gene O 0 7.83349037192238e-07
in O 0 1.6780232670043915e-07
familial B-Disease 0 0.024465765804052353
melanoma I-Disease 1 0.9995570778846741
and O 0 3.994543718022214e-08
confirm O 0 9.17980571557564e-07
the O 0 2.275858150824206e-07
role O 0 9.875428759187344e-07
of O 0 3.9854310784903646e-07
the O 0 4.400187947339873e-07
CDK4 O 0 0.13610289990901947
gene O 0 1.31590397245418e-07
as O 0 4.2367233277218475e-08
a O 0 1.1406638122934964e-06
melanoma B-Disease 1 0.9918558597564697
- O 0 0.0011358356568962336
predisposing O 0 0.0010656426893547177
gene O 0 1.631744680707925e-06
. O 0 2.1355133128508896e-07
. O 0 1.4396708820640924e-06

Progression O 0 0.007486619986593723
of O 0 2.061044506262988e-05
somatic O 0 0.002873529214411974
CTG O 1 0.9999703168869019
repeat O 0 1.2541232536023017e-05
length O 0 1.4321705066322465e-06
heterogeneity O 0 2.1361131530284183e-06
in O 0 4.00948962919756e-08
the O 0 1.0095497771089867e-07
blood O 0 1.5859117411309853e-05
cells O 0 4.28700222983025e-05
of O 1 0.7473149299621582
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.004749629646539688
. O 0 3.468089289526688e-06

The O 0 4.8348456402891316e-06
genetic O 0 3.4913721265183995e-06
basis O 0 2.2856600025988882e-06
of O 0 0.0002712321875151247
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999953508377075
DM B-Disease 1 1.0
) O 0 6.761223403373151e-07
is O 0 1.930938964278539e-08
the O 0 1.6267986069351537e-08
expansion O 0 2.2393267329334776e-07
of O 0 1.7331164769984753e-07
an O 0 8.671428872730758e-07
unstable O 0 0.018475722521543503
CTG O 1 0.9999164342880249
repeat O 0 1.004224850476021e-05
in O 0 1.3268990528558788e-07
the O 0 2.691518545816507e-07
34 O 0 8.272575655610126e-07
UTR O 0 0.00019013267592526972
of O 0 4.3502268454176374e-07
the O 0 1.7605210587134934e-06
DM B-Disease 1 1.0
protein O 0 4.728381099994294e-06
kinase O 0 2.781716830213554e-06
gene O 0 8.906476267611652e-08
on O 0 1.0239234171649514e-07
chromosome O 0 4.781335519510321e-06
19 O 0 5.649404101859545e-06
. O 0 4.004161837656284e-06

One O 0 4.551857728074538e-06
of O 0 5.59866407456866e-07
the O 0 4.558485500183451e-07
principal O 0 8.0731306297821e-06
features O 0 2.854037575161783e-07
of O 0 5.532583031708782e-07
the O 0 5.833822797285393e-06
DM B-Disease 1 1.0
mutation O 0 3.328402726765489e-07
is O 0 1.142392846986695e-08
an O 0 2.3351574895968952e-08
extraordinarily O 0 4.4639688212555484e-07
high O 0 2.4806195142446086e-07
level O 0 4.4391845221980475e-07
of O 0 4.271858529136807e-07
somatic O 0 3.4499164030421525e-05
mosaicism O 0 0.2298579216003418
, O 0 1.538090543817816e-08
due O 0 3.562483641417202e-08
to O 0 5.40149214245389e-09
an O 0 3.451619789984761e-08
extremely O 0 8.395586803544575e-08
high O 0 4.7649482581846314e-08
degree O 0 4.637261952211702e-07
of O 0 1.1334511640370692e-07
somatic O 0 2.3104862520995084e-06
instability O 0 3.2855592735359096e-07
both O 0 3.9971790322113065e-09
within O 0 1.4550243676580976e-08
and O 0 1.076270006450386e-08
between O 0 9.256606858798477e-08
different O 0 1.0701294428372421e-07
tissues O 0 4.498217094806023e-06
. O 0 2.2193530639924575e-06

This O 0 2.9126294975867495e-06
instability O 0 7.216190169856418e-06
appears O 0 4.22180818304696e-07
to O 0 8.349591240630616e-09
be O 0 1.469947896737267e-08
biased O 0 2.1601584876407287e-07
towards O 0 4.314076562650371e-08
further O 0 1.4323597419263479e-08
expansion O 0 3.862572128809916e-08
and O 0 3.619079480543519e-09
continuous O 0 1.9522479988154373e-07
throughout O 0 1.0793412386078671e-08
the O 0 9.418456237142436e-09
life O 0 1.4415027393965829e-08
of O 0 9.660658051302562e-09
an O 0 4.620334781435531e-09
individual O 0 1.2322133313702466e-09
, O 0 9.311244553167342e-10
features O 0 3.7088208060254146e-09
that O 0 3.151622296471146e-10
could O 0 6.229254334577661e-10
be O 0 2.6750652803997355e-09
associated O 0 2.0750867690821906e-08
with O 0 4.010481724492365e-09
the O 0 1.5065160141602973e-07
progressive O 0 2.8156046028016135e-06
nature O 0 6.542368851114588e-07
of O 0 4.275791809504881e-07
the O 0 1.9830681594612543e-06
disease O 0 4.862723289988935e-05
. O 0 1.8884677501773695e-06

Although O 0 2.4355374534934526e-06
increasing O 0 6.088396276027197e-07
measured O 0 7.070534024933295e-07
allele O 0 1.4368175982326647e-07
size O 0 3.901638123693374e-08
between O 0 3.7878344016917254e-08
patients O 0 3.176356244694034e-08
clearly O 0 9.981726378782696e-08
correlates O 0 5.50503045815276e-07
with O 0 1.0345841960912594e-09
an O 0 7.5101365126784e-09
increased O 0 1.3372851270787578e-08
severity O 0 6.03405965193815e-08
of O 0 2.3816459915337873e-08
symptoms O 0 4.9459245587968326e-08
and O 0 7.729133999490045e-10
an O 0 3.654177183065599e-09
earlier O 0 9.564621983315647e-09
age O 0 3.730760056441795e-08
of O 0 3.911876333972941e-08
onset O 0 7.806829671608284e-06
, O 0 2.6948940856641457e-09
this O 0 1.9424593045158645e-09
correlation O 0 2.3172283647454606e-08
is O 0 6.087960691125716e-10
not O 0 3.208038001911717e-10
precise O 0 1.0406327355383382e-08
and O 0 9.652125765313713e-10
measured O 0 2.936338638903635e-08
allele O 0 3.650359570173123e-09
length O 0 2.7713906725068682e-09
cannot O 0 8.119259153893665e-10
be O 0 5.575630512844043e-10
used O 0 2.789746211817601e-09
as O 0 2.7571078753396705e-09
an O 0 1.0953476348163349e-08
accurate O 0 1.0911376193689648e-06
predictor O 0 6.233483418327523e-06
of O 0 4.6211301452103726e-08
age O 0 7.693370207562111e-07
of O 0 2.428426569167641e-06
onset O 1 0.9984221458435059
. O 0 5.910656000196468e-06

In O 0 9.053806593328773e-07
order O 0 6.046882816690413e-08
to O 0 1.1916267972367223e-08
further O 0 4.122146179952324e-08
characterize O 0 6.076389240661229e-07
the O 0 1.6018377380078164e-07
dynamics O 0 2.47607513301773e-05
of O 0 9.417875844519585e-05
DM B-Disease 1 1.0
CTG O 1 0.9999998807907104
repeat O 0 1.62736887432402e-05
somatic O 0 1.8555604128778214e-06
instability O 0 2.4738531578805123e-07
, O 0 3.64200025693151e-09
we O 0 2.7185182993605395e-09
have O 0 1.0216536505680551e-09
studied O 0 5.380149303846338e-08
repeat O 0 6.368789939870112e-08
length O 0 1.1363731289293355e-08
changes O 0 2.0226680330637237e-09
over O 0 2.4253179464750474e-09
time O 0 2.212848926319566e-08
in O 0 9.509164300425255e-08
111 O 0 0.001443233573809266
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 7.367254539758505e-08
with O 0 2.524617181975941e-09
varying O 0 5.365126298784162e-08
clinical O 0 1.913000232889317e-06
severity O 0 1.887761868601956e-06
and O 0 3.4619918665157456e-07
CTG O 1 0.9974048733711243
repeat O 0 1.4179090612742584e-06
size O 0 3.208506527130339e-08
over O 0 3.8211251940367674e-09
time O 0 8.274570362232225e-09
intervals O 0 4.806544495750131e-08
of O 0 3.329275344299276e-08
1 O 0 1.5058581936955306e-07
- O 0 3.4524370562394324e-07
7 O 0 4.379297990908526e-07
years O 0 2.903320250879915e-07
. O 0 9.999836265706108e-07

We O 0 1.0082178505399497e-06
have O 0 1.4703572581709068e-08
found O 0 3.077156662811831e-08
a O 0 4.2228467833638206e-08
direct O 0 1.669494622547063e-07
progression O 0 2.571458480815636e-06
of O 0 4.978615564255051e-08
the O 0 5.8447099604563846e-08
size O 0 1.7474891933488834e-07
heterogeneity O 0 2.5041410367521166e-07
over O 0 1.1971466484794746e-08
time O 0 4.6275516751848045e-08
related O 0 6.63904913267288e-08
to O 0 4.611576898128078e-08
initial O 0 6.919825864315499e-06
CTG O 0 0.04097029194235802
repeat O 0 1.1706799796229461e-06
size O 0 2.5616769150360597e-08
and O 0 1.8465351470098312e-09
the O 0 4.669923114875019e-09
time O 0 1.3349584548905113e-08
interval O 0 1.4959601912778453e-07
and O 0 5.748520326420703e-09
always O 0 4.406469855666728e-08
biased O 0 2.292820084903724e-07
towards O 0 9.394884159519279e-08
further O 0 1.015774842016981e-07
expansion O 0 4.213673491904046e-06
. O 0 1.6654807950544637e-06

Attempts O 0 4.841655936616007e-06
to O 0 5.181238194040816e-08
mathematically O 0 1.1377999271644512e-06
model O 0 1.8738596452294587e-07
the O 0 4.386344798490427e-08
dynamics O 0 9.403208309777256e-07
have O 0 4.180466639525093e-09
proved O 0 2.378981633910371e-07
only O 0 1.294708162902225e-08
partially O 0 4.084649560809339e-07
successful O 0 6.258866847019817e-08
suggesting O 0 3.826786709737462e-08
that O 0 7.840884053145203e-10
individual O 0 5.43806277786274e-10
specific O 0 1.1474016181622915e-09
genetic O 0 2.200495785587009e-08
and O 0 4.7322670226890295e-09
/ O 0 1.2729362424579449e-05
or O 0 1.046894340106519e-07
environmental O 0 2.212131846590637e-07
factors O 0 3.3972067825516206e-08
also O 0 2.666293186237567e-09
play O 0 2.0408359446832947e-08
a O 0 1.0920979320871993e-07
role O 0 4.786317617799796e-07
in O 0 4.709848155926011e-07
somatic O 0 3.262772224843502e-05
mosaicism O 0 0.0020953533239662647
. O 0 7.67881999763631e-07
. O 0 3.3088390409830026e-06

Aspartylglucosaminuria B-Disease 1 0.9999997615814209
among O 0 1.9793194951489568e-05
Palestinian O 0 0.002040234860032797
Arabs O 0 0.0001808262604754418
. O 0 2.4786126232356764e-05

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9996935129165649
AGU B-Disease 1 1.0
) O 0 3.6524761526379734e-06
is O 0 1.4246100477066648e-07
a O 0 4.560268109798926e-07
rare O 0 5.865129423909821e-06
disorder B-Disease 1 0.9999890327453613
of I-Disease 1 0.999962568283081
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 1.0
caused O 0 1.2522685210569762e-05
by O 0 4.861783509113593e-08
the O 0 1.2567828662213287e-06
deficiency B-Disease 1 0.9366447329521179
of I-Disease 0 9.425785719940905e-06
the I-Disease 0 2.5756020477274433e-05
lysosomal I-Disease 1 0.9999991655349731
enzyme I-Disease 0 9.089924424188212e-05
aspartylglucosaminidase I-Disease 0 0.18232113122940063
( O 0 3.6416946386452764e-05
AGA O 1 0.999945878982544
) O 0 6.43218845652882e-06
. O 0 2.2932799765840173e-06

AGU B-Disease 1 1.0
is O 0 9.885503459372558e-06
inherited O 0 0.00035698185092769563
as O 0 1.2108906730645685e-06
an O 0 2.68908406724222e-05
autosomal O 1 0.9999804496765137
recessive O 1 0.9977682828903198
trait O 0 0.004957383032888174
and O 0 2.1718460629926994e-07
occurs O 0 3.2767226798569027e-07
with O 0 2.636317297799451e-08
a O 0 1.2440709724614862e-06
high O 0 1.6584134527874994e-06
frequency O 0 2.7430735372035997e-07
in O 0 2.7351838127742667e-08
Finland O 0 6.689970746265317e-07
because O 0 3.3495684448325846e-08
of O 0 1.8087777675646066e-07
a O 0 6.992132739469525e-07
founder O 0 5.7897588703781366e-05
effect O 0 2.347023155380157e-06
. O 0 1.5638374861737248e-06

While O 0 2.953653165604919e-06
very O 0 1.5803065878117195e-07
few O 0 8.147205932118595e-08
patients O 0 3.857352126601654e-08
with O 0 6.664207319317939e-08
AGU B-Disease 1 1.0
have O 0 3.3723512871119965e-08
been O 0 5.1161592296011804e-08
reported O 0 4.022312083407087e-08
from O 0 2.09809041251674e-08
non O 0 7.36916490495787e-07
- O 0 5.405812544267974e-07
Finnish O 0 6.229240625543753e-06
origin O 0 6.837981914031843e-08
, O 0 1.5885317949937416e-08
we O 0 6.375608307962466e-08
diagnosed O 0 1.4949198885005899e-05
the O 0 3.122218856788095e-07
disorder O 0 0.04499218612909317
in O 0 1.5264666330949694e-07
8 O 0 4.5276301534613594e-06
patients O 0 2.6390441831836142e-08
originating O 0 1.1277280975718895e-07
from O 0 2.8284203423822873e-08
3 O 0 1.5888356585946894e-07
unrelated O 0 5.226638108979387e-07
families O 0 9.346747376071107e-09
, O 0 3.881935661809166e-09
all O 0 1.101418867222037e-08
Palestinian O 0 2.5117589757428505e-05
Arabs O 0 6.167818469293707e-07
from O 0 4.1203616518714625e-08
the O 0 8.947339580345215e-08
region O 0 5.039089501224225e-07
of O 0 1.1896985370185575e-06
Jerusalem O 0 0.004252876620739698
. O 0 4.770299710799009e-06

The O 0 1.795363459677901e-05
clinical O 0 0.010683017782866955
diagnosis O 1 0.9997250437736511
of O 1 0.9431756734848022
AGU B-Disease 1 1.0
is O 0 1.5865628029132495e-06
often O 0 1.8597980044887663e-08
difficult O 0 9.97430333882221e-08
, O 0 1.3044943791840069e-08
in O 0 9.076005724750758e-09
particular O 0 1.583833508789212e-08
early O 0 6.409369746052107e-08
in O 0 1.1975920699569542e-08
the O 0 3.2420452100723196e-08
course O 0 6.717218070662057e-07
of O 0 8.321533329080921e-08
the O 0 1.5260387442594947e-07
disease O 0 3.267559350206284e-06
, O 0 3.4706371110360124e-09
and O 0 1.8495311948640847e-09
most O 0 2.1498318680812645e-09
of O 0 1.4532160363955882e-08
the O 0 9.813656731694209e-08
patients O 0 4.0149615188056487e-08
are O 0 8.44403391653259e-09
diagnosed O 0 2.03287218027981e-05
after O 0 9.162872061097005e-07
the O 0 1.0802751830851776e-06
age O 0 9.02012652659323e-06
of O 0 1.6752071587688988e-06
5 O 0 1.2694139286395512e-06
years O 0 6.987639835642767e-07
. O 0 1.3254284567665309e-06

However O 0 2.5255105811083922e-06
, O 0 7.87707676863647e-08
since O 0 3.041915874746337e-08
these O 0 7.13665038176714e-09
patients O 0 2.1521836757187884e-08
excrete O 0 4.614872466390807e-07
early O 0 4.4380328745319275e-08
large O 0 1.7587066025726017e-08
amounts O 0 3.428026928986583e-08
of O 0 1.0405518224843036e-07
aspartylglucosamine O 0 3.3491036447230726e-05
in O 0 1.7880351421695195e-08
urine O 0 6.408843944427645e-08
, O 0 1.203880906075483e-08
biochemical O 0 4.6654653829136805e-07
screening O 0 4.2609951123040446e-08
is O 0 6.333173985240137e-09
easy O 0 3.289885697199679e-08
by O 0 2.3461803166924255e-08
urine O 0 7.411962315018172e-07
chromatography O 0 7.044069934636354e-05
. O 0 7.603609333273198e-07
. O 0 2.629929667818942e-06

Detection O 0 0.00011775133316405118
of O 0 3.670304977276828e-06
heterozygous O 0 3.4456061257515103e-06
carriers O 0 3.6833733929597656e-07
of O 0 3.2007108075049473e-07
the O 0 8.74744637258118e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.010911159217357635
ATM O 0 0.014586648903787136
) O 0 6.088964710215805e-08
gene O 0 2.9676888502194743e-08
by O 0 2.7398307622661378e-08
G2 O 0 0.00016896952001843601
phase O 0 1.890903695311863e-05
chromosomal O 0 0.0002611387462820858
radiosensitivity O 0 0.003512637922540307
of O 0 0.00013358956493902951
peripheral O 1 0.999326229095459
blood O 1 0.9449270963668823
lymphocytes O 0 0.1802370697259903
. O 0 2.626901004987303e-05

In O 0 0.00015183468349277973
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999814033508301
telangiectasia I-Disease 1 1.0
( O 1 0.9968189001083374
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.307082915351202e-07
patients O 0 1.2965566398293049e-08
, O 0 1.220943790514184e-09
mutations O 0 2.4118615993273806e-09
in O 0 1.1638445762685024e-09
a O 0 2.2651089892633536e-08
single O 0 2.1395491600628702e-08
gene O 0 9.577107995539791e-09
, O 0 4.415461773987772e-09
ATM O 0 2.8751966965501197e-05
, O 0 2.7946671643519494e-09
result O 0 1.2674063576412209e-08
in O 0 4.6893031679928754e-08
an O 0 0.004518540110439062
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.487132005375315e-07
embraces O 0 1.7751905261320644e-06
a O 0 7.522297096329567e-08
variety O 0 1.3203144355600216e-08
of O 0 2.1740758882060618e-07
clinical O 0 1.2494889233494177e-05
features O 0 2.768846059097996e-07
and O 0 1.861721621310153e-08
manifests O 0 1.2103467952329083e-06
extreme O 0 2.295448211953044e-06
radiosensitivity O 0 0.025784462690353394
and O 0 1.0314916920606265e-07
a O 0 1.2723737654596334e-06
strong O 0 8.10650590210571e-07
pre O 0 0.0009308657608926296
- O 0 5.465928552439436e-05
disposition O 0 6.649250281043351e-05
to O 0 3.2125287816597847e-06
malignancy B-Disease 1 0.9998207688331604
. O 0 1.6185822460101917e-05

Heterozygotes O 0 0.00025010446552187204
for O 0 2.853242904166109e-07
the O 0 6.147903945930011e-07
ATM O 0 0.00020157881954219192
gene O 0 9.980412585264276e-08
have O 0 3.79046305454267e-09
no O 0 2.3174537844283805e-08
clinical O 0 2.652005264280888e-07
expression O 0 9.739440542944067e-08
of O 0 3.7573215649899794e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 7.521289369094575e-09
may O 0 1.6801170232838558e-08
be O 0 6.526553164576399e-08
cancer B-Disease 0 1.9209168385714293e-05
prone O 0 4.464965002171084e-07
with O 0 5.57043522420031e-09
a O 0 2.2605776450745907e-07
moderate O 0 9.711763482300739e-08
increase O 0 2.036830615281815e-08
in O 0 2.9650070842990317e-08
in O 0 1.5402402198105847e-07
vitro O 0 2.438222691125702e-05
radiosensitivity O 0 0.0006579134496860206
. O 0 4.770586656377418e-06

We O 0 3.275890321674524e-06
performed O 0 4.109996098122792e-06
a O 0 1.3923313417762984e-06
blind O 0 7.905885468062479e-06
chromosomal O 0 8.41023756947834e-06
analysis O 0 6.948631607883726e-07
on O 0 1.0572481414783397e-06
G2 O 1 0.6737769246101379
- O 0 4.53274515166413e-06
phase O 0 5.775003501184983e-06
lymphocytes O 0 3.548730660440924e-07
from O 0 2.859283831924131e-08
7 O 0 3.1469468808609236e-07
unrelated O 0 2.025626145041315e-06
A B-Disease 1 0.9999842643737793
- I-Disease 1 0.9996711015701294
T I-Disease 1 0.9999997615814209
patients O 0 4.2611493000777045e-08
, O 0 1.3946416466126266e-08
13 O 0 3.207895247214765e-07
obligate O 0 2.223626552222413e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
heterozygotes O 0 8.616645573056303e-06
( O 0 1.1519611042842826e-08
parents O 0 1.1735052929395806e-09
of O 0 3.4296532280819747e-09
the O 0 8.735272061244359e-09
patients O 0 4.52958692775951e-09
) O 0 8.160234266085808e-09
, O 0 4.574142398183767e-09
and O 0 5.458163254701276e-09
14 O 0 2.1704133246203128e-07
normal O 0 3.9015716879475804e-07
controls O 0 4.8144904951641365e-08
following O 0 1.8477761543067572e-08
X O 0 1.6043434243329102e-06
- O 0 1.1655205156557713e-07
irradiation O 0 1.1071799832507168e-07
with O 0 1.6898057397796151e-09
1 O 0 1.3830712930484879e-07
Gy O 0 1.3070457498542964e-05
in O 0 2.2887416406547345e-09
order O 0 7.785061484355538e-10
to O 0 6.950242603664947e-10
evaluate O 0 6.058404977693499e-08
this O 0 1.888235345859357e-08
cytogenetic O 0 3.673638730106177e-06
method O 0 6.401928942523227e-08
as O 0 1.3571064272355216e-08
a O 0 1.7546190278494578e-08
tool O 0 1.8522545985888428e-07
for O 0 9.306490689198199e-09
detection O 0 5.482622214003641e-07
of O 0 1.2700969591605826e-06
ATM O 0 0.0020559760741889477
carriers O 0 3.5660912089952035e-06
. O 0 2.1129085325810593e-06

Both O 0 2.2175987396622077e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.46930205821990967
and O 0 3.319447898775252e-07
heterozygotes O 0 4.920326318824664e-05
showed O 0 5.558905513680656e-07
significantly O 0 5.195449048756018e-08
increased O 0 1.0879601219926371e-08
levels O 0 3.207013676842507e-08
of O 0 7.96448915707515e-08
radiation O 0 0.0009220395586453378
- O 0 6.728048174409196e-05
induced O 0 6.773181667085737e-05
chromatid O 1 0.6640908122062683
damage O 0 1.8526551457398455e-06
relative O 0 1.272889136316735e-07
to O 0 2.584713332254296e-09
that O 0 5.27306687203577e-09
of O 0 1.0654412108124234e-07
normal O 0 3.1137255973590072e-06
controls O 0 2.4776738882792415e-06
. O 0 1.6460897995784762e-06

These O 0 5.995107699163782e-07
results O 0 2.715271136821684e-07
show O 0 1.667996940568628e-07
that O 0 3.511804180789113e-08
the O 0 6.928607945155818e-07
G2 O 1 0.5740671753883362
- O 0 2.8013402697979473e-05
phase O 0 8.546271419618279e-05
chromosomal O 0 0.00016788035281933844
radiosensitivity O 0 4.494050517678261e-05
assay O 0 3.174679079620546e-07
can O 0 2.483424799137879e-09
be O 0 3.2874063471410864e-09
used O 0 2.8686559794266486e-09
for O 0 1.6140023761934685e-09
the O 0 2.8572120669423384e-08
detection O 0 6.675497274954978e-07
of O 0 4.121661277167732e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 0.9999998807907104
heterozygotes O 0 0.00028624103288166225
. O 0 5.4351667131413706e-06

In O 0 9.893208243738627e-07
combination O 0 3.633090841503872e-07
with O 0 3.068084453161646e-08
molecular O 0 5.722247806261294e-06
genetic O 0 6.004096348988242e-07
analyses O 0 1.3248934749299224e-07
, O 0 3.7917358142181e-09
this O 0 1.426439966145665e-09
test O 0 6.280366449118446e-09
may O 0 5.60899771073764e-09
be O 0 2.7697577564822495e-09
of O 0 1.3165975865092605e-08
value O 0 2.8998382362033226e-08
in O 0 7.103296617572141e-09
studies O 0 5.268475078423762e-08
of O 0 1.0717329246290319e-07
familial B-Disease 0 9.381287782161962e-06
and I-Disease 0 3.3464264248550535e-08
sporadic I-Disease 0 0.19674310088157654
cancers I-Disease 1 0.6825863122940063
aimed O 0 1.986507641049684e-06
at O 0 3.2945237649073533e-07
determination O 0 2.9050754690729264e-08
of O 0 1.170957020235619e-08
the O 0 7.542824143058624e-09
potential O 0 1.8130602796873063e-08
involvement O 0 5.798374047571997e-08
of O 0 9.480007889806075e-08
ATM O 0 0.0001562008255859837
mutations O 0 6.310916234042452e-08
in O 0 6.301090138549625e-08
tumor B-Disease 0 0.07620230317115784
risk O 0 4.422054757924343e-07
or O 0 1.218336080910376e-07
development O 0 4.002745299658272e-06
. O 0 1.8988703232025728e-07
. O 0 1.3092673043502145e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 2.8749652756232535e-06
identification O 0 5.087870817988005e-07
and O 0 2.5073331855196557e-08
detection O 0 2.383997070865007e-06
of O 0 2.9697273475903785e-06
founder O 0 0.45720139145851135
- O 0 8.25490405986784e-06
effect O 0 8.471413792676685e-08
mutations O 0 7.039017813070814e-09
in O 0 4.763200944779555e-09
the O 0 4.2313772041779885e-08
ATM O 0 0.0001005857702693902
gene O 0 4.37442224665574e-08
in O 0 1.599101828730909e-08
ethnic O 0 1.293987708095301e-07
populations O 0 2.398394940428261e-07
. O 0 7.695601311752398e-07

To O 0 7.811065643181792e-07
facilitate O 0 8.849611390360224e-07
the O 0 1.1886897510748895e-07
evaluation O 0 1.4069553344597807e-06
of O 0 2.2582817109650932e-06
ATM O 1 0.9974096417427063
heterozygotes O 0 1.1657083632599097e-05
for O 0 1.0032780828339583e-08
susceptibility O 0 2.0615601670215256e-07
to O 0 2.594270576139479e-09
other O 0 3.0080578028446325e-09
diseases O 0 1.6831014363560826e-05
, O 0 5.842945682843492e-09
such O 0 4.964398669926595e-09
as O 0 4.050621669193788e-07
breast B-Disease 1 0.9930758476257324
cancer I-Disease 0 0.0031656359788030386
, O 0 3.494525202540899e-08
we O 0 1.7759656856242145e-08
have O 0 3.239052359660377e-09
attempted O 0 2.0048706517172832e-07
to O 0 9.382130627955121e-09
define O 0 4.917122709002797e-08
the O 0 9.837791914435456e-09
most O 0 1.2331324850123337e-09
common O 0 2.784461994309595e-09
mutations O 0 3.123985958808362e-09
and O 0 9.325392680281652e-10
their O 0 3.917534296959957e-09
frequencies O 0 4.283248600245315e-08
in O 0 1.9842097742639453e-07
ataxia B-Disease 1 0.999975323677063
- I-Disease 1 0.9920468330383301
telangiectasia I-Disease 1 1.0
( O 0 0.0011077324161306024
A B-Disease 1 1.0
- I-Disease 1 0.9999434947967529
T I-Disease 1 0.9999995231628418
) O 0 4.2473999428693787e-07
homozygotes O 0 3.3352964692312526e-06
from O 0 4.864065061838119e-08
10 O 0 7.67206529417308e-08
ethnic O 0 7.743278018779165e-08
populations O 0 1.2653030978526658e-07
. O 0 7.772603680678003e-07

Both O 0 1.6362794212909648e-06
genomic O 0 1.87815439858241e-05
mutations O 0 3.4216324706903833e-07
and O 0 1.257720771974391e-08
their O 0 2.1788492787777614e-08
effects O 0 4.814564249500108e-07
on O 0 3.492070561605942e-07
cDNA O 0 1.400048040522961e-05
were O 0 1.844748283019726e-07
characterized O 0 1.7388342712365557e-06
. O 0 1.3394558209256502e-06

Protein O 0 0.00044933322351425886
- O 0 2.0703662812593393e-05
truncation O 0 1.928133497131057e-05
testing O 0 2.608595082165266e-07
of O 0 1.6498492527716735e-07
the O 0 1.6170143624094635e-07
entire O 0 2.875105110433651e-06
ATM O 0 6.163003126857802e-05
cDNA O 0 3.5282378121337388e-06
detected O 0 1.1347014350349127e-07
92 O 0 1.339346908935113e-07
( O 0 3.261856207359415e-08
66 O 0 2.7172242766937416e-07
% O 0 2.9441954652043023e-08
) O 0 1.05624842205998e-08
truncating O 0 3.747709627077711e-07
mutations O 0 1.5066159875232188e-08
in O 0 8.244905203014241e-09
140 O 0 1.1940230137952312e-07
mutant O 0 5.605278374787304e-07
alleles O 0 1.644265239519882e-07
screened O 0 1.5819153986740275e-06
. O 0 1.0961334737658035e-06

The O 0 2.9377722967183217e-05
haplotyping O 0 0.0019663807470351458
of O 0 5.986560154269682e-06
patients O 0 3.035233930859249e-07
with O 0 2.4449846591778623e-08
identical O 0 1.1296316415609908e-06
mutations O 0 2.815943389578024e-07
indicates O 0 2.936907890216389e-07
that O 0 1.8490374786850339e-09
almost O 0 8.627378811354447e-09
all O 0 6.542624775285333e-10
of O 0 3.022435857147343e-09
these O 0 1.8435227788771158e-09
represent O 0 1.5474538983539787e-08
common O 0 1.681556405230822e-08
ancestry O 0 5.083825271867681e-08
and O 0 3.3323106496396804e-09
that O 0 3.752603561224532e-09
very O 0 8.904977200074882e-09
few O 0 2.275536203910633e-08
spontaneously O 0 1.6704467498129816e-06
recurring O 0 5.19949862791691e-05
ATM O 0 0.0006673055468127131
mutations O 0 8.322714393216302e-07
exist O 0 1.74538865849172e-06
. O 0 3.246908590881503e-06

Assays O 0 1.2607186363311484e-05
requiring O 0 2.341330684885179e-07
minimal O 0 5.915495080444089e-07
amounts O 0 4.496225969319312e-08
of O 0 5.904453814764565e-08
genomic O 0 5.313312385624158e-07
DNA O 0 2.3641177904210053e-07
were O 0 1.1755220796771937e-08
designed O 0 2.1012340312154265e-08
to O 0 2.6750446302514774e-09
allow O 0 1.117697401298301e-08
rapid O 0 3.5112324781039206e-07
screening O 0 3.7125026608464395e-08
for O 0 6.724201639940475e-09
common O 0 3.0720958221763794e-08
ethnic O 0 1.9254119365541555e-07
mutations O 0 6.450356409004598e-07
. O 0 5.655709856000612e-07

These O 0 1.0076727221530746e-06
rapid O 0 6.424414550565416e-06
assays O 0 2.389810788372415e-06
detected O 0 7.795943588462251e-07
mutations O 0 3.6612391340895556e-08
in O 0 1.2971749896451001e-08
76 O 0 3.056403556911391e-07
% O 0 1.5465863256736156e-08
of O 0 1.607385691215768e-08
Costa O 0 9.82028467433338e-08
Rican O 0 3.253518343626638e-07
patients O 0 4.247158180703536e-09
( O 0 4.270430675745729e-09
3 O 0 9.101073672468374e-09
) O 0 2.405874832689392e-09
, O 0 1.6855759010780957e-09
50 O 0 8.924122774089938e-09
% O 0 3.1729396887669736e-09
of O 0 3.4380565061553625e-09
Norwegian O 0 3.8531061363755725e-06
patients O 0 7.3979626868947435e-09
( O 0 5.918454615283508e-09
1 O 0 2.399826648513681e-08
) O 0 4.357041394342787e-09
, O 0 1.49140755301147e-09
25 O 0 1.2623929457333816e-08
% O 0 3.3563072321385334e-09
of O 0 8.03654209846627e-09
Polish O 0 2.3842790142225567e-06
patients O 0 3.742348297919307e-08
( O 0 2.0314686821620853e-08
4 O 0 5.45139258179006e-08
) O 0 6.7709842177521296e-09
, O 0 1.8007627611282828e-09
and O 0 8.248250971121251e-10
14 O 0 1.5164586031346516e-08
% O 0 6.259700757738074e-09
of O 0 4.163406508439493e-09
Italian O 0 1.154114741552803e-07
patients O 0 7.178821981312922e-09
( O 0 7.152075820471282e-09
1 O 0 1.9514507343387777e-08
) O 0 2.877742266704786e-09
, O 0 7.525245426798222e-10
as O 0 8.32730551181271e-10
well O 0 1.1984093717387623e-09
as O 0 1.976853347684937e-09
in O 0 5.928623370010655e-09
patients O 0 1.3589247060963316e-08
of O 0 6.6603371351448e-07
Amish O 1 0.9962449669837952
/ O 0 0.155446395277977
Mennonite O 0 0.00040750185144133866
and O 0 3.7148897291672256e-08
Irish O 0 5.256708845990943e-06
English O 0 5.615687314275419e-06
backgrounds O 0 5.009840151615208e-06
. O 0 2.6294133022020105e-06

Additional O 0 1.6249739474005764e-06
mutations O 0 3.4973666629412037e-07
were O 0 1.3857619762802642e-07
observed O 0 4.603360252986022e-07
in O 0 8.718114941075328e-08
Japanese O 0 7.24799156159861e-06
, O 0 1.0057922139594666e-07
Utah O 0 1.1401307347114198e-05
Mormon O 0 2.7360244985175086e-06
, O 0 6.527147711210546e-09
and O 0 6.060818069641982e-09
African O 0 5.353841174837726e-07
American O 0 3.248543862355291e-06
patients O 0 4.378082678613282e-07
. O 0 1.4033479374120361e-06

These O 0 1.5611611559052108e-07
assays O 0 2.966003478377388e-07
should O 0 1.8533741652504432e-08
facilitate O 0 1.3075164417841734e-07
screening O 0 1.443451225213721e-07
for O 0 1.9210685309190012e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 1.4946290320949629e-05
in O 0 3.696646899697953e-08
the O 0 2.7278064251845535e-08
populations O 0 1.4836825101838258e-08
studied O 0 3.6540120618155925e-07
. O 0 1.0771945113674519e-07
. O 0 7.188347126430017e-07

The O 0 0.00011246646317886189
von B-Disease 1 0.9990597367286682
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9999955892562866
Lindau I-Disease 1 0.9999998807907104
tumor I-Disease 1 0.9998286962509155
suppressor O 0 6.212593143573031e-05
gene O 0 8.622875924402251e-08
is O 0 5.746788378502288e-09
required O 0 1.0540608386122585e-08
for O 0 3.065528275669749e-08
cell O 0 7.451747023878852e-06
cycle O 0 9.310999303124845e-06
exit O 0 1.3654262147611007e-06
upon O 0 7.852323733459343e-07
serum O 0 2.8441811082302593e-05
withdrawal O 0 3.105126597802155e-05
. O 0 1.042079475155333e-05

The O 0 1.8537102732807398e-05
inactivation O 0 7.182142144301906e-05
of O 0 3.9723390727886e-06
the O 0 4.263175469532143e-06
von B-Disease 1 0.999936580657959
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999969005584717
Lindau I-Disease 1 0.9999998807907104
( I-Disease 0 0.00018656931933946908
VHL I-Disease 1 0.9999911785125732
) I-Disease 0 3.511398608679883e-05
tumor I-Disease 1 0.9767018556594849
suppressor O 0 0.0062769739888608456
gene O 0 1.7256697901757434e-06
predisposes O 0 4.054434612044133e-06
affected O 0 2.9605315532421628e-08
individuals O 0 4.733422542813059e-09
to O 0 1.654469983236595e-08
the O 0 2.4033779482124373e-06
human O 1 0.9991011619567871
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 4.909166761990491e-08
is O 0 5.750738907295272e-08
associated O 0 1.4759127964225627e-07
with O 0 9.55394199309012e-08
sporadic B-Disease 1 0.9993547797203064
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.997658371925354
RCC B-Disease 1 1.0
) O 0 6.7540258896769956e-06
and O 0 1.0571473012532806e-06
brain B-Disease 1 0.9899458289146423
hemangioblastomas I-Disease 1 0.9992344379425049
. O 0 5.780959691037424e-05

VHL O 1 0.9950436353683472
- O 0 0.0002980479330290109
negative O 0 8.839870133670047e-06
786 O 0 0.0001388578675687313
- O 0 4.2577568819979206e-05
0 O 0 2.179179091399419e-06
RCC B-Disease 1 0.9780358076095581
cells O 0 8.791183176981576e-07
are O 0 1.8767742915315466e-08
tumorigenic O 0 4.1835708543658257e-05
in O 0 3.9168568832792516e-07
nude O 0 0.022666234523057938
mice O 0 5.216041927269544e-07
which O 0 2.9719415817197614e-09
is O 0 3.7368401706316945e-09
suppressed O 0 6.187707413118915e-08
by O 0 8.276638041593287e-09
the O 0 1.1783644993101916e-07
reintroduction O 0 4.059898401465034e-06
of O 0 2.8658248538704356e-06
VHL B-Disease 0 0.016892386600375175
. O 0 6.169210337247932e-06

Remarkably O 0 0.0015309586888179183
, O 0 1.4906525791502645e-07
this O 0 3.772203527319107e-08
occurs O 0 8.24445294256293e-08
without O 0 4.84984532533872e-08
affecting O 0 9.425900060477943e-08
the O 0 5.603248354191237e-08
growth O 0 2.104218452814166e-07
rate O 0 9.106893372745617e-08
and O 0 1.6743777919714375e-08
cell O 0 2.3333959688898176e-06
cycle O 0 7.949279279273469e-07
profile O 0 1.3481360916500762e-08
of O 0 3.993033459437356e-09
these O 0 2.1649992909544835e-09
cells O 0 5.1691760205585524e-08
in O 0 5.763806498748636e-08
culture O 0 5.386666089179926e-06
. O 0 2.4720754936424782e-06

The O 0 1.6743011656217277e-05
786 O 0 0.00011551702482393011
- O 0 2.010024581977632e-05
0 O 0 7.030700430732395e-07
cell O 0 7.95972539435752e-07
line O 0 6.629166193761193e-08
, O 0 4.029328426469192e-09
like O 0 6.449554224019494e-09
many O 0 4.078839044296956e-09
cancer B-Disease 0 7.258125606313115e-06
cells O 0 6.707116995130491e-07
, O 0 2.0596298000441493e-08
fails O 0 3.0638801717941533e-07
to O 0 4.068973069593085e-08
exit O 0 1.4124094604994752e-06
the O 0 3.1736922778691223e-07
cell O 0 2.0162306100246496e-06
cycle O 0 4.5506669721362414e-07
upon O 0 4.3580999431469536e-07
serum O 0 1.3766992196906358e-05
withdrawal O 0 8.043850357353222e-06
. O 0 4.122282462049043e-06

Here O 0 4.213347892800812e-06
, O 0 4.333390535293802e-08
it O 0 7.4458670340504796e-09
is O 0 5.63778579376617e-09
shown O 0 7.402507939957559e-09
that O 0 2.4825439481901412e-09
reintroduction O 0 6.27462100055709e-08
of O 0 2.1319273457720556e-08
the O 0 5.22667811253541e-08
wild O 0 3.7590100987472397e-07
- O 0 8.94174172572093e-06
type O 0 9.874047464109026e-06
VHL B-Disease 1 0.6205390095710754
gene O 0 5.20725507158204e-07
restores O 0 1.1511922366480576e-06
the O 0 3.5897670613849186e-08
ability O 0 5.6716118024269235e-08
of O 0 1.796347305571544e-06
VHL O 1 0.9999994039535522
- O 1 0.7881519198417664
negative O 0 1.765935667208396e-05
RCC B-Disease 1 0.9999995231628418
cancer I-Disease 0 1.3887331078876741e-05
cells O 0 4.7292019189626444e-08
to O 0 5.034456407315702e-09
exit O 0 1.5498412153647223e-07
the O 0 5.1799833755694635e-08
cell O 0 4.257672685525904e-07
cycle O 0 2.7701696581061697e-07
and O 0 1.268806748555562e-08
enter O 0 2.968634362332523e-06
G0 O 1 0.9999939203262329
/ O 0 0.0013526800321415067
quiescence O 0 0.00017425282567273825
in O 0 3.097127034834557e-07
low O 0 2.5148704025923507e-06
serum O 0 2.841077366610989e-05
. O 0 3.5217965432821075e-06

Both O 0 2.5518866095808335e-05
VHL O 1 0.5962834358215332
- O 0 5.1334889576537535e-05
positive O 0 7.063961788844608e-07
and O 0 4.6742030690438696e-07
VHL O 1 0.9996337890625
- O 0 0.0008273610146716237
negative O 0 5.13983286509756e-06
RCC B-Disease 1 0.985993504524231
cells O 0 5.546349939322681e-07
exit O 0 3.061409188376274e-07
the O 0 6.709023381290535e-08
cell O 0 5.215584337747714e-07
cycle O 0 2.8551212949423643e-07
by O 0 5.9248279171697504e-08
contact O 0 3.892365384672303e-06
inhibition O 0 1.1633961548795924e-05
. O 0 1.4909951460140292e-06

The O 0 3.8902460801182315e-05
cyclin O 0 0.0007482239743694663
- O 0 2.1037636543042026e-05
dependent O 0 5.037878054281464e-06
kinase O 0 6.405339718185132e-06
inhibitor O 0 9.367647066937934e-07
, O 0 3.1528763599908416e-08
p27 O 0 3.4074905670422595e-06
, O 0 2.1385085702263495e-08
accumulates O 0 1.3250830477318232e-07
upon O 0 6.117380024761587e-08
serum O 0 1.155263589680544e-06
withdrawal O 0 2.7423047299635073e-07
, O 0 8.17331891056483e-09
only O 0 1.3479219962420075e-09
in O 0 2.099354245999052e-09
the O 0 9.521157195990781e-09
presence O 0 3.735295450724152e-08
of O 0 4.967120048604556e-07
VHL B-Disease 1 0.9916900396347046
, O 0 2.56397445497214e-08
as O 0 9.586977434139499e-09
a O 0 1.750641054343305e-08
result O 0 6.232514060400263e-09
of O 0 6.076211978012225e-09
the O 0 1.2225500611862117e-08
stabilization O 0 5.865649654879235e-07
of O 0 1.4755580934888712e-07
the O 0 6.367484388647426e-07
protein O 0 2.2632013951806584e-06
. O 0 7.1712429416948e-07

We O 0 2.4184471385524375e-06
propose O 0 1.3878242270948249e-06
that O 0 5.6018375715893853e-08
the O 0 1.5247250928496214e-07
loss O 0 9.568929044689867e-07
of O 0 1.52196480485145e-06
wild O 0 1.8036351320915855e-05
- O 0 0.02636129781603813
type O 0 0.0010396016295999289
VHL B-Disease 1 0.9997653365135193
gene O 0 1.359653793997495e-07
results O 0 1.4734735209742666e-08
in O 0 3.3228537699159233e-09
a O 0 1.200359012187846e-08
specific O 0 1.7734979707029197e-08
cellular O 0 1.9850531316478737e-06
defect O 0 4.3175256791982974e-07
in O 0 3.0592083533065306e-08
serum O 0 0.02599116787314415
- O 0 0.46545717120170593
dependent O 0 6.241883056645747e-06
growth O 0 1.5784088702730514e-07
control O 0 2.8723970757482675e-08
, O 0 3.298869399870341e-09
which O 0 1.7321069023523705e-09
may O 0 2.037615587369146e-08
initiate O 0 1.8137506003768067e-06
tumor B-Disease 0 0.006383207626640797
formation O 0 4.27106351708062e-05
. O 0 5.283134669298306e-06

This O 0 1.707736259959347e-06
is O 0 1.7870438284717238e-07
corrected O 0 1.0301640713805682e-06
by O 0 1.8398703005573225e-08
the O 0 3.310033491743525e-08
reintroduction O 0 3.0361138669832144e-07
of O 0 1.1568000957140612e-07
wild O 0 9.929125326380017e-07
- O 0 0.00015523438923992217
type O 0 0.0027480870485305786
VHL B-Disease 1 0.9999998807907104
, O 0 6.084570031816838e-06
implicating O 1 0.9933659434318542
VHL B-Disease 1 0.960608720779419
as O 0 1.1145193923312036e-07
the O 0 5.636251287910454e-08
first O 0 5.774066380581644e-07
tumor B-Disease 0 0.00013742264127358794
suppressor O 0 7.111241757229436e-06
involved O 0 6.973021271505786e-08
in O 0 9.234085496245825e-09
the O 0 3.625838829179884e-08
regulation O 0 1.847385533437773e-07
of O 0 3.2083204359878437e-07
cell O 0 7.251829629240092e-06
cycle O 0 4.440070824784925e-06
exit O 0 4.320623077092023e-07
, O 0 4.12793443871351e-09
which O 0 9.623321028939813e-10
is O 0 1.5960934796055426e-09
consistent O 0 1.1075703909568801e-08
with O 0 1.2595878784438241e-09
its O 0 1.8317958705438286e-08
gatekeeper O 0 3.4573238281154772e-06
function O 0 8.66387566134108e-08
in O 0 3.1257993526878636e-08
the O 0 4.996842903892684e-07
kidney O 0 0.0009898857679218054
. O 0 7.303413553927385e-07
. O 0 3.863408437609905e-06

Piebaldism B-Disease 1 1.0
with O 0 0.000822225701995194
deafness B-Disease 1 1.0
: O 0 8.149369932652917e-06
molecular O 0 6.95740309311077e-05
evidence O 0 1.4063195976632414e-06
for O 0 5.27984269638182e-08
an O 0 8.827122996990511e-07
expanded O 0 3.798874604399316e-05
syndrome O 1 0.999813973903656
. O 0 6.437428965000436e-06

In O 0 5.358685939427232e-06
a O 0 2.8114941414969508e-06
South O 0 7.490621101169381e-06
African O 0 7.68694189900998e-06
girl O 0 2.3460237571271136e-05
of O 0 9.63101501838537e-06
Xhosa O 1 0.9999974966049194
stock O 0 7.1862964432511944e-06
with O 0 8.380659721751726e-08
severe O 0 0.00036203741910867393
piebaldism B-Disease 1 0.9999955892562866
and O 0 3.281122917542234e-05
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.00013388747174758464
identified O 0 2.2119675122667104e-05
a O 0 1.7073911067200243e-06
novel O 0 9.332852641819045e-07
missense O 0 1.4732087265656446e-06
substitution O 0 1.0287037355283246e-07
at O 0 2.4036935997173714e-07
a O 0 6.564118137930564e-08
highly O 0 9.64287920623974e-08
conserved O 0 5.12814722242183e-07
residue O 0 1.5366615571110742e-06
in O 0 4.516751772598582e-08
the O 0 1.790892554254242e-07
intracellular O 0 1.0771821507660206e-05
kinase O 0 1.568078801028605e-06
domain O 0 2.025970786689868e-07
of O 0 7.297607851342036e-08
the O 0 3.0643943205177493e-07
KIT O 0 0.002712778514251113
proto O 0 0.0060923341661691666
- O 0 0.0012713740579783916
oncogene O 0 0.0054507190361619
, O 0 1.0723910008891835e-06
R796G O 0 0.00015682465163990855
. O 0 5.457121005747467e-06

Though O 0 8.249157690443099e-05
auditory B-Disease 0 0.30637070536613464
anomalies I-Disease 0 0.0007355556008405983
have O 0 7.505757793069279e-08
been O 0 1.1318093129375484e-07
observed O 0 4.4573067725650617e-07
in O 0 1.1939864918986132e-07
mice O 0 3.007362749940512e-07
with O 0 1.6434274385801473e-08
dominant O 0 2.4766109163465444e-06
white O 0 8.375336619792506e-07
spotting O 0 0.11773829162120819
( O 0 5.175091791898012e-05
W O 1 0.6769590377807617
) O 0 1.0883362477898118e-07
due O 0 9.513699694707611e-08
to O 0 4.804363129551348e-08
KIT O 1 0.8712225556373596
mutations O 0 5.867731670150533e-05
, O 0 2.637202305777464e-05
deafness B-Disease 1 1.0
is O 0 4.4075378013985755e-07
not O 0 6.118722239989438e-08
typical O 0 1.8687641158976476e-06
in O 0 2.076891405522474e-07
human O 0 1.885561459857854e-06
piebaldism B-Disease 0 0.00671922042965889
. O 0 5.2169252739986405e-06

Thus O 0 8.48469244374428e-06
, O 0 1.610959117215316e-07
the O 0 2.3934640580591804e-07
occurrence O 0 8.115082891890779e-05
of O 0 0.10237764567136765
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 0.00015243059897329658
this O 0 1.1024161494788132e-06
patient O 0 5.927794063609326e-06
extends O 0 1.9200393808205263e-07
considerably O 0 5.705659944510444e-08
the O 0 1.4207766518836706e-08
phenotypic O 0 1.2149328654231795e-07
range O 0 3.3336341687117965e-08
of O 0 7.212133112943775e-08
piebaldism B-Disease 0 3.7857073493796634e-06
due O 0 1.133466298597341e-07
to O 0 3.900432687942157e-08
KIT O 0 0.00013856872101314366
gene O 0 3.5096422834612895e-07
mutation O 0 3.9293151843367013e-08
in O 0 1.3761816575197372e-08
humans O 0 6.937495555803253e-08
and O 0 1.1359937879262816e-08
tightens O 0 6.528009066641971e-07
the O 0 3.836608897245242e-08
clinical O 0 2.8854717584181344e-06
similarity O 0 7.391554959212954e-07
between O 0 2.762684800927673e-07
piebaldism B-Disease 0 0.00010979109356412664
and O 0 7.08321934439482e-09
the O 0 1.1561940738147314e-08
various O 0 1.3042853908018515e-08
forms O 0 7.177757055387701e-08
of O 0 6.282069080043584e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 9.812905545913964e-07
. O 0 2.895947318393155e-06

Cycloheximide O 0 0.18071818351745605
facilitates O 0 1.432784029020695e-05
the O 0 3.1344569606517325e-07
identification O 0 4.63027532759952e-07
of O 0 6.015863505126617e-07
aberrant O 0 1.1509328032843769e-05
transcripts O 0 8.5941746874596e-06
resulting O 0 2.6985199497175927e-07
from O 0 7.352977604568878e-08
a O 0 3.1586009185957664e-07
novel O 0 7.851364784983161e-07
splice O 0 7.0506157499039546e-06
- O 0 6.083346875129791e-07
site O 0 2.386707933510479e-07
mutation O 0 3.7831988208836265e-08
in O 0 2.03526955289135e-08
COL17A1 O 0 0.004816262051463127
in O 0 6.887854198112109e-08
a O 0 2.66898695144846e-07
patient O 0 4.5057899455969164e-07
with O 0 1.2530281878753158e-07
generalized O 0 0.0010591723257675767
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999994039535522
. O 0 6.780063267797232e-05

Patients O 0 4.175798312644474e-05
with O 0 1.245521616510814e-06
generalized O 0 0.11789306253194809
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 9.178544928545307e-07
show O 0 1.1427107438066741e-06
decreased O 0 2.8252497941139154e-06
expression O 0 1.4422650451706431e-07
of O 0 7.556375862804998e-07
type O 0 5.507398600457236e-05
XVII O 1 0.9999998807907104
collagen O 1 0.5568000674247742
, O 0 1.0542225936660543e-06
a O 0 5.654724645864917e-06
transmembrane O 0 0.00013785637565888464
hemidesmosomal O 0 0.00013540827785618603
protein O 0 1.9551559944375185e-06
encoded O 0 1.5824646197870607e-06
by O 0 7.371730816885247e-07
COL17A1 O 0 0.0027942941524088383
. O 0 5.531419446924701e-06

This O 0 3.3369919947290327e-06
report O 0 1.091732997338113e-06
documents O 0 1.0982220146615873e-06
a O 0 3.59439553676566e-07
novel O 0 2.439461468384252e-06
splice O 0 1.954686376848258e-05
- O 0 1.8290677417098777e-06
site O 0 4.658334091800498e-07
mutation O 0 4.5260225789434116e-08
in O 0 1.496186463612048e-08
COL17A1 O 0 0.07145015895366669
in O 0 4.3611347422256586e-08
a O 0 2.329895210095856e-07
patient O 0 2.798240359425108e-07
with O 0 3.0697762554154906e-08
generalized O 0 0.030613455921411514
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 9.590273464255006e-08
and O 0 9.50442746727731e-09
applies O 0 1.798607840441946e-08
a O 0 8.944537555066745e-09
new O 0 2.575009983019072e-09
methodology O 0 6.368097160702746e-08
to O 0 2.8444815391992506e-09
define O 0 3.936681736149694e-08
and O 0 1.020801043694064e-08
characterize O 0 8.087201877060579e-07
the O 0 1.5137746345317282e-07
resulting O 0 5.908712523705617e-07
mRNA O 0 5.366101049730787e-06
splice O 0 9.430154932488222e-06
variants O 0 9.384117447552853e-07
. O 0 1.3923818187322468e-06

Mutational O 0 0.00646290834993124
analysis O 0 1.0942681910819374e-05
of O 0 4.406438165460713e-06
COL17A1 O 0 0.011316783726215363
identified O 0 3.043128344870638e-06
a O 0 6.26366841061099e-07
maternally O 0 8.04875344329048e-06
inherited O 0 1.570784479554277e-05
G O 0 7.705802272539586e-05
- O 0 1.0357740393374115e-05
to O 0 8.843502996569441e-07
- O 0 0.0004440390330273658
T O 0 0.00029132753843441606
transversion O 0 3.517930963425897e-05
at O 0 3.3763294027266966e-07
the O 0 1.0286977669693442e-07
- O 0 1.5316578583224327e-07
1 O 0 1.1101002428404172e-07
position O 0 2.7318790785102465e-07
of O 0 4.245917750722583e-07
exon O 0 8.150893336278386e-06
32 O 0 1.1732158782251645e-06
. O 0 5.828756570736005e-07

This O 0 9.824845619732514e-06
acceptor O 0 2.123172816936858e-05
splice O 0 0.0001161822656285949
- O 0 1.6443716958747245e-05
site O 0 1.847015596467827e-06
mutation O 0 1.640074458464369e-07
led O 0 7.510998756288245e-08
to O 0 9.911433451748053e-09
the O 0 6.140901120943454e-08
formation O 0 2.253552793263225e-06
of O 0 1.9376407180971e-06
aberrant O 0 8.690431059221737e-06
transcripts O 0 3.191111545675085e-06
present O 0 1.1365317931222307e-07
at O 0 5.483495328917343e-07
extremely O 0 3.85315416906451e-07
low O 0 8.279506005237636e-07
levels O 0 1.2961766060470836e-06
. O 0 2.034669705608394e-06

Based O 0 3.892695531249046e-06
on O 0 2.686356594949757e-07
our O 0 1.3091732853354188e-07
recent O 0 4.670896203151642e-08
finding O 0 2.635415512486361e-07
that O 0 5.6217675847847204e-08
cycloheximide O 0 0.00023608066840097308
stabilized O 0 0.0004790457896888256
mutant O 0 7.221796840894967e-05
COL17A1 O 0 0.08554370701313019
transcripts O 0 7.995620762812905e-06
in O 0 1.864687675379173e-07
keratinocytes O 0 1.468303935325821e-06
homozygous O 0 2.3623914557902026e-07
for O 0 2.4861986247515233e-08
a O 0 3.9712222132948227e-07
frameshift O 0 7.141729838622268e-06
mutation O 0 5.170447892055563e-08
, O 0 1.0089197921558934e-08
the O 0 2.2301874125219e-08
effects O 0 3.041846809992421e-07
of O 0 2.5239211254302063e-07
the O 0 3.8473928043458727e-07
splice O 0 1.5328532754210755e-05
- O 0 1.0557730547589017e-06
site O 0 1.6398961122376932e-07
mutation O 0 7.599838092176014e-09
on O 0 1.262927540324199e-08
splicing O 0 1.646678811084712e-07
of O 0 7.848911565133676e-08
COL17A1 O 0 5.987336771795526e-05
transcripts O 0 4.173605816504278e-07
were O 0 9.946202084165634e-09
determined O 0 2.1172658293266977e-08
using O 0 1.811245731175859e-08
reverse O 0 2.906861311657849e-07
transcriptase O 0 1.2568008287416887e-06
polymerase O 0 5.444772455120983e-07
chain O 0 6.169029376223989e-08
reaction O 0 5.8292988214248e-09
of O 0 2.2709143010501975e-08
total O 0 3.2305274544341955e-07
RNA O 0 6.897450475662481e-06
from O 0 8.947527163627456e-08
keratinocytes O 0 7.271625008797855e-07
incubated O 0 7.8778487022646e-07
for O 0 3.290017502877163e-08
2 O 0 7.844666356504604e-07
. O 0 9.079115557142359e-07

5 O 0 1.9964953025919385e-05
h O 0 9.516286809230223e-06
in O 0 8.42238776499471e-08
the O 0 1.3557513511841535e-07
presence O 0 2.5837496764324897e-07
or O 0 1.685053518940549e-07
absence O 0 1.8789788782669348e-06
of O 0 5.610184416582342e-06
10 O 0 1.0508415471122134e-05
microg O 0 0.01311575248837471
cycloheximide O 0 0.00297905458137393
per O 0 2.6944107958115637e-05
ml O 0 6.687659333692864e-05
. O 0 2.008080855375738e-06

Using O 0 2.5419515168323414e-06
this O 0 1.718779998327591e-07
approach O 0 4.041353349748533e-07
, O 0 3.434761453036117e-08
an O 0 1.9150543550949806e-07
abnormally O 0 1.3432893865683582e-05
spliced O 0 8.977493052952923e-06
transcript O 0 8.477550181851257e-06
was O 0 4.558737600746099e-07
identified O 0 4.163614875096755e-08
that O 0 9.738986284091311e-10
contains O 0 2.0383219556663335e-09
an O 0 4.452274104949083e-09
extra O 0 2.0923835108987987e-08
264 O 0 1.4518506930016883e-07
bases O 0 3.71462753889773e-08
upstream O 0 5.231949558037741e-07
from O 0 2.9523100408823666e-08
exon O 0 4.052159283673973e-07
32 O 0 2.5564446559656062e-08
, O 0 6.826758269795619e-09
resulting O 0 1.553314810109896e-08
in O 0 1.5742440240273936e-08
a O 0 2.3381754488127626e-07
premature O 0 2.8434521937015234e-06
termination O 0 3.4825065995391924e-06
codon O 0 9.037330528371967e-06
27 O 0 3.925801593140932e-06
bp O 0 8.514927685610019e-06
downstream O 0 2.0769814454979496e-06
from O 0 1.0138084149957649e-07
the O 0 4.099752857200656e-07
cryptic O 0 1.2448350389604457e-05
splice O 0 2.461032272549346e-05
site O 0 8.829608304949943e-06
. O 0 1.354468395220465e-06

Three O 0 1.5543469089607242e-06
other O 0 1.0448196974266466e-07
splice O 0 2.245490804853034e-06
variants O 0 1.9852734567393782e-07
, O 0 1.498737134397743e-08
including O 0 1.5944388920274832e-08
one O 0 3.2985187914391645e-08
derived O 0 1.003621079576078e-07
from O 0 6.795024631855995e-08
the O 0 2.2787422437886562e-07
skipping O 0 2.1298967567418003e-06
of O 0 5.20817366123083e-07
exon O 0 3.3524338505230844e-06
32 O 0 2.3395830339723034e-07
, O 0 1.3533324683123737e-08
were O 0 5.616987408529894e-08
also O 0 8.386784600133979e-08
identified O 0 1.0873231985897291e-06
. O 0 2.733210521910223e-06

These O 0 8.374369713237684e-07
results O 0 3.6264410141484404e-07
indicate O 0 2.953288174012414e-07
the O 0 5.230208088846666e-08
usefulness O 0 1.1865315627801465e-06
of O 0 1.0800294347745876e-07
cycloheximide O 0 6.663304520770907e-05
treatment O 0 5.689858184609875e-08
in O 0 9.134741851823946e-09
evaluating O 0 1.7743109026469028e-07
the O 0 4.807599296441367e-08
abnormal O 0 8.449094934803725e-07
processing O 0 1.4345721410791157e-07
of O 0 7.216495845341342e-08
mRNA O 0 2.8846741884080984e-07
due O 0 3.551018679104345e-08
to O 0 1.1160463664339204e-08
splice O 0 1.1090575071648345e-06
- O 0 1.3060781611784478e-07
site O 0 5.990312246240137e-08
mutations O 0 3.0587050670050075e-09
, O 0 1.524162462906986e-09
because O 0 3.5153477906391117e-09
( O 0 6.579259093086876e-08
i O 0 6.220687964741956e-07
) O 0 2.431554264603619e-07
aberrant O 0 1.0113091093444382e-06
splicing O 0 6.48738364361634e-07
often O 0 1.2151108563784874e-08
generates O 0 5.899230970385361e-08
a O 0 8.243839033639233e-08
premature O 0 4.5994900688128837e-07
termination O 0 7.488982873837813e-07
codon O 0 1.3761102763965027e-06
, O 0 5.0148791785886715e-08
( O 0 8.000405671282351e-08
ii O 0 1.2112545846321154e-05
) O 0 2.2998365523108077e-07
transcripts O 0 1.8872506188927218e-06
with O 0 3.9732977796802516e-08
premature O 0 5.134017555974424e-06
termination O 0 3.928868864022661e-06
codons O 0 7.458107234015188e-07
can O 0 1.0280265527740085e-08
occur O 0 4.187300106650582e-08
at O 0 7.018080054876918e-07
low O 0 7.629795391039806e-07
or O 0 5.2307370879134396e-08
undetectable O 0 2.921723989857128e-06
levels O 0 4.201692860306139e-08
due O 0 1.3042505742077992e-08
to O 0 6.760957127482925e-09
nonsense O 0 5.689711315426393e-07
- O 0 1.8912997745701432e-07
mediated O 0 1.7741722047048825e-07
mRNA O 0 1.3965161826945405e-07
decay O 0 3.700244732840474e-08
, O 0 8.851850363811309e-10
and O 0 1.3309660040761173e-09
( O 0 1.6837452321283308e-08
iii O 0 6.347228236336377e-07
) O 0 1.9799182737756382e-08
the O 0 8.723533007071183e-09
levels O 0 2.0496599972830154e-08
of O 0 7.219301156879965e-09
these O 0 2.6625783799971714e-09
transcripts O 0 1.6475269148941152e-07
can O 0 2.2776978081395782e-09
be O 0 8.339245738397949e-09
increased O 0 4.9957662895394606e-08
by O 0 1.7548674691170163e-07
cycloheximide O 0 0.00029447328415699303
. O 0 2.9962750431877794e-06

A O 0 4.452534994925372e-05
deletion O 0 4.28696112066973e-05
mutation O 0 1.1383328910596902e-06
in O 0 4.903047283733031e-07
COL17A1 O 1 0.7704536318778992
in O 0 9.527754940563682e-08
five O 0 9.452437410573111e-08
Austrian O 0 3.3574884582776576e-05
families O 0 5.293091831504171e-08
with O 0 6.23420461920432e-08
generalized O 0 0.0005290567642077804
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999997615814209
represents O 0 4.537892436928814e-06
propagation O 0 3.6173676107864594e-06
of O 0 6.870219522170373e-07
an O 0 1.3295694998305407e-06
ancestral O 0 0.00014063304115552455
allele O 0 1.6116433471324854e-05
. O 0 8.920312211557757e-06

Patients O 0 7.926332909846678e-05
with O 0 2.5126337277470157e-06
generalized O 0 0.01931905932724476
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 1.081717414308514e-06
a O 0 2.952496629404777e-07
usually O 0 4.989805191257801e-08
nonlethal O 0 2.884321474994067e-06
form O 0 5.748424314333533e-07
of O 0 0.003211954375728965
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 4.994866458218894e-07
have O 0 3.779361890110522e-08
generalized O 0 1.099678797800152e-06
blistering B-Disease 0 1.646273631195072e-05
, O 0 1.057118993230688e-06
nail B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999996423721313
, O 0 0.0002552910300437361
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 0.0001318279973929748
and O 0 0.0016162190586328506
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9857648015022278

Skin B-Disease 1 0.9999561309814453
fragility I-Disease 1 0.9997037053108215
in O 0 4.3699776597350137e-07
most O 0 1.512062652864188e-08
cases O 0 8.45354186651548e-09
is O 0 7.31305727086351e-09
due O 0 1.9839481169015016e-08
to O 0 5.118831136741164e-09
mutations O 0 8.837532483596533e-09
in O 0 7.4094010926728515e-09
the O 0 6.10048545013342e-08
gene O 0 1.0070284872654156e-07
encoding O 0 3.993036159499752e-07
type O 0 5.595447419182165e-06
XVII O 1 0.9999886751174927
collagen O 1 0.9919523596763611
( O 0 0.0010815946152433753
COL17A1 O 1 0.9999308586120605
) O 0 1.0832290172402281e-05
. O 0 3.885548267135164e-06

Recently O 0 2.438962292217184e-05
, O 0 2.862678911697003e-07
we O 0 1.0448455611822283e-07
reported O 0 3.5171476042705763e-07
five O 0 7.791931722067602e-08
Austrian O 0 6.980705620662775e-06
families O 0 3.020777583628842e-08
with O 0 6.05522743057918e-08
generalized O 0 0.0004180798423476517
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 8.170537739715655e-07
share O 0 5.011312396163703e-07
the O 0 2.6197915303782793e-07
same O 0 1.0446896112625836e-06
COL17A1 O 0 0.19188375771045685
mutation O 0 4.253404767950997e-06
. O 0 2.600371090011322e-06

Affected O 0 7.237789759528823e-06
individuals O 0 9.593346561587168e-08
in O 0 2.5010189474983235e-08
three O 0 1.5996844737742322e-08
families O 0 4.554649990495818e-09
are O 0 3.3968809987072746e-09
homozygous O 0 9.526010558147391e-08
for O 0 3.300092288327505e-08
4003delTC O 0 2.6692398023442365e-05
, O 0 4.1129101902015464e-08
whereas O 0 4.086503579969758e-08
those O 0 1.8931749501405193e-09
in O 0 2.31278973750193e-09
two O 0 3.0116691362991332e-09
others O 0 1.6463859608961684e-08
are O 0 2.0989388005432374e-08
compound O 0 5.2857885748380795e-05
heterozygotes O 0 3.206805558875203e-05
. O 0 2.9071513836242957e-06

To O 0 1.1866254681081045e-06
determine O 0 9.382184771311586e-07
if O 0 1.0622675716831509e-07
the O 0 1.4757425503830746e-07
occurrence O 0 2.5065019144676626e-06
of O 0 6.03236912866123e-07
4003delTC O 0 1.9358607460162602e-05
in O 0 3.508048607159253e-08
these O 0 1.0884209089567776e-08
unrelated O 0 4.990814090888307e-07
families O 0 1.3081819183469179e-08
signifies O 0 2.634812403812248e-07
propagation O 0 2.502451081909385e-07
of O 0 4.516872564863661e-08
an O 0 6.118371942420708e-08
ancestral O 0 5.088713805889711e-06
allele O 0 9.176552140388594e-08
or O 0 4.2671679523209605e-08
a O 0 4.2727225491034915e-07
mutational O 0 1.7819222193793394e-05
hot O 0 6.724633863086638e-07
spot O 0 7.037758109618153e-07
, O 0 4.3115594650089406e-08
haplotypes O 0 3.3104566909969435e-07
were O 0 4.246868812174398e-08
determined O 0 1.3993104630571906e-07
for O 0 7.327077611307686e-08
polymorphisms O 0 1.8004840285357204e-06
both O 0 9.452256932718228e-08
within O 0 9.942713177224505e-07
and O 0 1.3068996622678242e-06
flanking O 0 0.035220917314291
COL17A1 O 1 0.999996542930603
. O 0 7.993616600288078e-05

Five O 0 7.098717469489202e-05
intragenic O 0 0.001480981707572937
polymorphisms O 0 4.103462924831547e-05
were O 0 6.74735531447368e-07
chosen O 0 9.679268941908958e-07
based O 0 5.113281531521352e-07
on O 0 6.895280080243538e-07
their O 0 6.567886998709582e-07
informativeness O 0 0.0015830323100090027
. O 0 1.1439709851401858e-05

One O 0 2.409937451375299e-06
of O 0 1.5223973548472713e-07
these O 0 7.2161623343447445e-09
, O 0 1.0141019579634758e-08
not O 0 7.3399433198062525e-09
previously O 0 1.3700146439532546e-07
reported O 0 1.6098593391689064e-07
, O 0 2.260206244386609e-08
was O 0 1.684836320237082e-06
2988 O 0 5.5785571021260694e-05
A O 0 1.995007323785103e-06
or O 0 4.8288647747085633e-08
C O 0 2.031435769822565e-06
that O 0 3.312008223232965e-09
introduces O 0 3.1112861620385956e-08
a O 0 1.0769516833875059e-08
new O 0 8.892383718261954e-09
restriction O 0 4.875564130202292e-08
site O 0 1.8922921185549058e-07
for O 0 1.0905866787425111e-07
Eco0109 O 0 0.00010079893399961293
I O 0 0.00020126765593886375
. O 0 1.2051156772940885e-05

All O 0 2.644572305143811e-06
the O 0 1.0271522796756472e-06
4003delTC O 0 3.204409222234972e-05
alleles O 0 5.34716662059509e-07
showed O 0 2.2621303230607737e-07
the O 0 3.347881971649258e-08
same O 0 8.290133735044947e-08
haplotype O 0 5.52032417999726e-07
for O 0 6.459686119342223e-09
these O 0 1.1123295173831593e-08
five O 0 2.418035762730142e-07
polymorphic O 0 4.552378413791303e-06
markers O 0 1.6045289157773368e-05
. O 0 5.001504632673459e-06

Fourteen O 0 0.0002779146016109735
microsatellite O 0 0.0003367825993336737
polymorphisms O 0 7.907362487458158e-06
were O 0 1.4201513920397701e-07
selected O 0 1.1838884006465378e-07
based O 0 9.067427697573294e-08
on O 0 5.966526117617832e-08
their O 0 3.307666673890708e-08
high O 0 1.3912535905546974e-06
heterozygosity O 0 0.0009641704382374883
and O 0 3.935495485052343e-08
their O 0 4.0093521391781906e-08
location O 0 1.5082569007063285e-06
within O 0 7.987290473465691e-07
10q23 O 0 0.0006419988931156695
- O 0 0.00026746472576633096
q25 O 0 0.003700139233842492
near O 0 0.00033439300023019314
COL17A1 O 0 0.02938423492014408
. O 0 5.627202426694566e-06

Three O 0 4.680832716985606e-06
families O 0 4.132664344069781e-07
shared O 0 2.038480261035147e-06
microsatellite O 0 0.0010660478146746755
polymorphisms O 0 2.563377347541973e-05
covering O 0 3.058786751353182e-05
at O 0 1.3837556252838112e-05
most O 0 4.997748703772231e-08
19 O 0 6.460625172621803e-07
cM O 0 2.263266424051835e-06
, O 0 1.5005962694658592e-08
whereas O 0 4.36426326189121e-08
the O 0 2.1878152622889502e-08
others O 0 9.130143752145159e-09
shared O 0 2.7883219289037697e-08
smaller O 0 1.0429854313542819e-08
regions O 0 4.217821647500841e-09
consistent O 0 4.3432539342802556e-08
with O 0 4.364477668161726e-09
cross O 0 2.0147820123384008e-07
- O 0 4.334940797434683e-07
over O 0 3.04470226808462e-08
events O 0 2.610777016798238e-08
during O 0 4.8872209390538046e-08
passage O 0 5.983621065297484e-08
of O 0 8.664813755387968e-09
this O 0 3.4625902145535292e-09
mutation O 0 5.748673981287311e-09
through O 0 7.765667220382966e-09
several O 0 2.5433518402451227e-08
generations O 0 5.42794850844075e-07
. O 0 8.539368536730763e-07

These O 0 1.3412146699920413e-06
results O 0 8.795057624411129e-07
indicate O 0 1.3063389587841812e-06
that O 0 6.26354861310574e-08
4003delTC O 0 3.7515503663598793e-06
occurs O 0 7.10683707438875e-08
on O 0 9.002855705375623e-08
a O 0 2.522347415379045e-07
single O 0 4.6329566316671844e-07
ancestral O 0 6.898325409565587e-06
allele O 0 8.539595910406206e-07
. O 0 2.8161531417936203e-07
. O 0 1.4778003105675452e-06

The O 0 3.666379416245036e-05
haptoglobin O 0 0.0015885601751506329
- O 0 5.122046422911808e-05
gene O 0 8.247927212323702e-07
deletion O 0 2.547027861510287e-06
responsible O 0 1.39952555855416e-06
for O 0 7.229390348584275e-07
anhaptoglobinemia B-Disease 1 0.9817383885383606
. O 0 3.144074435112998e-05

We O 0 2.4150058379746042e-06
have O 0 6.76632652130138e-08
found O 0 9.504812226168724e-08
an O 0 7.779175348332501e-08
allelic O 0 2.9479770091711544e-06
deletion O 0 2.5502993139525643e-06
of O 0 8.523299470653001e-07
the O 0 1.1039385299227433e-06
haptoglobin O 0 0.0044557685032486916
( O 0 2.4751657292654272e-06
Hp O 0 2.2427941530622775e-06
) O 0 1.187501919019951e-08
gene O 0 8.970165055188772e-09
from O 0 7.910166743840819e-09
an O 0 1.901368662515779e-08
individual O 0 5.188585916471311e-08
with O 0 1.1743235717176503e-07
anhaptoglobinemia B-Disease 1 0.8410539031028748
. O 0 2.5135366740869358e-05

The O 0 3.394298255443573e-05
Hp O 0 5.013152622268535e-05
gene O 0 6.004875103826635e-07
cluster O 0 4.799445036951511e-07
consists O 0 1.780620095814811e-07
of O 0 8.752083999752358e-07
coding O 0 1.2474743925849907e-05
regions O 0 7.192200968120233e-08
of O 0 3.1527895316685317e-07
the O 0 9.687838655736414e-07
alpha O 0 1.9903851352864876e-05
chain O 0 6.174415716486692e-07
and O 0 1.525236292820864e-08
beta O 0 7.605059408888337e-07
chain O 0 1.5258423502473306e-07
of O 0 2.931671261308111e-08
the O 0 1.24540605384027e-07
haptoglobin O 0 3.708835720317438e-05
gene O 0 3.6587056229109294e-07
( O 0 1.5573648681765917e-07
Hp O 0 5.046033493272262e-07
) O 0 6.354699877419989e-09
and O 0 1.9413779472898796e-09
of O 0 3.784151303420913e-08
the O 0 9.83734480541898e-08
alpha O 0 2.4670682705618674e-06
chain O 0 3.206041867542808e-07
and O 0 1.874878030605487e-08
beta O 0 8.987223054646165e-07
chain O 0 2.3025930317999155e-07
of O 0 4.020609267740838e-08
the O 0 8.033602938439799e-08
haptoglobin O 0 2.3642949599889107e-05
- O 0 9.56099256654852e-07
related O 0 3.005135340572451e-07
gene O 0 1.1523593457241077e-07
( O 0 1.1598832116987978e-07
Hpr O 0 1.794709351088386e-05
) O 0 3.4279157290484363e-08
, O 0 5.697913696423029e-09
in O 0 1.3338919302441354e-08
tandem O 0 4.5270931536833814e-07
from O 0 4.025658739692517e-08
the O 0 1.0212668399844915e-07
5 O 0 4.7138925651779573e-07
side O 0 3.5752373150899075e-07
. O 0 8.478395443489717e-07

Southern O 0 4.01091092498973e-05
blot O 0 3.9946873584995046e-05
and O 0 3.452397550063324e-07
PCR O 0 5.658079771819757e-06
analyses O 0 5.82161192141939e-07
have O 0 8.864543765696453e-09
indicated O 0 4.2678841793986066e-08
that O 0 2.0512624931967594e-09
the O 0 8.283713270884618e-09
individual O 0 3.4367584333949708e-09
with O 0 3.6957708005047607e-09
anhaptoglobinemia B-Disease 0 1.595821595401503e-05
was O 0 6.901253186697431e-07
homozygous O 0 4.55565185575324e-08
for O 0 1.3730164782899124e-09
the O 0 1.0868443034439679e-08
gene O 0 2.114166619548996e-08
deletion O 0 3.99137540796346e-08
and O 0 1.2187684195197335e-09
that O 0 1.5652759088879975e-09
the O 0 1.4327258490709482e-08
gene O 0 2.4051512781397832e-08
deletion O 0 9.244891430171265e-08
was O 0 1.0427432073356613e-07
included O 0 3.500342060647199e-08
at O 0 1.5972324263202609e-07
least O 0 8.02034083591252e-09
from O 0 1.2105261681938373e-08
the O 0 5.6902273115611024e-08
promoter O 0 5.589660759142134e-06
region O 0 4.908333721687086e-07
of O 0 1.3020478490943788e-06
Hp O 0 5.731559667765396e-06
to O 0 4.3180939712783584e-08
Hpr O 0 3.1814779504202306e-05
alpha O 0 3.413861975332111e-07
but O 0 4.732573888333036e-09
not O 0 6.5186629427671505e-09
to O 0 5.0924434447097155e-08
Hpr O 0 5.7668748922878876e-05
beta O 0 3.5949001357948873e-06
( O 0 5.259158228909655e-07
Hpdel O 0 9.7034135251306e-05
) O 0 5.814343921883847e-07
. O 0 7.095811156432319e-07

In O 0 1.1553011063369922e-06
addition O 0 1.5173620226960338e-07
, O 0 2.9293348191572477e-08
we O 0 1.5903113492754528e-08
found O 0 1.399053672912487e-08
seven O 0 1.5759292537609326e-08
individuals O 0 7.783075517409088e-09
with O 0 6.994397949711129e-09
hypohaptoglobinemia B-Disease 0 0.00865859817713499
in O 0 3.674040982559745e-08
three O 0 3.2424658513718896e-08
families O 0 9.552479696139926e-09
, O 0 3.2064857435898375e-09
and O 0 3.197276443600572e-09
the O 0 7.334656260127304e-08
genotypes O 0 3.783430315706937e-07
of O 0 5.108183387392273e-08
six O 0 3.027208350658839e-08
of O 0 2.5903412748107257e-08
the O 0 1.764788848390708e-08
seven O 0 1.2112974623335049e-08
individuals O 0 1.3117942287976803e-09
were O 0 4.74177230813666e-09
found O 0 8.872138579363309e-09
to O 0 2.1518880899407122e-08
be O 0 8.002463687262207e-07
Hp2 O 1 0.9999239444732666
/ O 1 0.8195436000823975
Hpdel O 1 0.9904119372367859
. O 0 7.680507223994937e-06

The O 0 1.377551416226197e-05
phenotypes O 0 2.1681385987903923e-05
and O 0 1.7317351819201576e-07
genotypes O 0 1.9748133581742877e-06
in O 0 3.0936462280806154e-08
one O 0 1.9603481504759657e-08
of O 0 1.8150533520611134e-08
these O 0 2.7119306800216236e-09
three O 0 1.53865968854916e-08
families O 0 2.0586870874694796e-08
showed O 0 1.311230164446897e-07
the O 0 7.673997259871612e-08
father O 0 4.85986959120055e-07
to O 0 4.6310834278529e-08
be O 0 2.5676064296931145e-07
hypohaptoglobinemic B-Disease 0 0.00021492154337465763
( O 0 1.5150816352615948e-06
Hp2 O 0 0.00025738211115822196
) O 0 1.0448455611822283e-07
and O 0 5.453441431768624e-08
Hp2 O 0 0.03459382802248001
/ O 0 4.356462159194052e-05
Hpdel O 0 0.014708138071000576
, O 0 4.1677306938936454e-08
the O 0 7.699919279957612e-08
mother O 0 2.2062833693325956e-07
to O 0 2.6069256975347344e-08
be O 0 9.790585409064079e-08
Hp2 O 0 0.0009441030560992658
- O 0 4.4936809899809305e-06
1 O 0 4.192147002868296e-07
and O 0 5.088550025789118e-08
Hp1 O 0 0.3082718253135681
/ O 0 1.971091842278838e-05
Hp2 O 0 0.0005773883312940598
, O 0 1.6234880106935634e-08
one O 0 6.476513991771071e-09
of O 0 1.0556341578649153e-08
the O 0 7.314786554246666e-09
two O 0 3.338392229323972e-09
children O 0 5.345909492859846e-09
to O 0 5.9238534078076555e-09
be O 0 7.445870409128474e-08
hypohaptoglobinemic B-Disease 0 0.00044074698234908283
( O 0 2.2866931885801023e-06
Hp2 O 0 0.001176810241304338
) O 0 5.225372490258451e-08
and O 0 3.046159946507032e-08
Hp2 O 0 0.13150599598884583
/ O 0 6.694129115203395e-05
Hpdel O 0 0.04044847562909126
, O 0 1.1987186354645019e-08
and O 0 3.6780358758647935e-09
the O 0 1.0873232980657122e-08
other O 0 1.984957531675491e-09
child O 0 2.0135232148277282e-08
to O 0 6.075771885605263e-09
be O 0 8.727981537504093e-08
Hp1 O 0 0.4670965075492859
and O 0 7.801745027791185e-07
Hp1 O 1 0.9999998807907104
/ O 1 0.9107241034507751
Hpdel O 1 0.9828282594680786
, O 0 7.327999895778703e-08
showing O 0 4.6861870828251995e-07
an O 0 9.7526942965942e-08
anomalous O 0 1.308416267420398e-05
inheritance O 0 7.72204566601431e-06
of O 0 1.2721814528049435e-05
Hp O 0 0.00027142130420543253
phenotypes O 0 2.5354918307129992e-06
in O 0 8.150873753720589e-08
the O 0 4.969626843376318e-07
child O 0 2.6868076474784175e-06
with O 0 1.394908395013772e-06
Hp1 O 1 0.9999932050704956
. O 0 3.808653855230659e-05

The O 0 0.0003063648473471403
Hp2 O 1 0.9999953508377075
/ O 1 0.9280160665512085
Hpdel O 1 0.9714128971099854
individuals O 0 2.3318158071106154e-07
had O 0 2.9884392915846547e-07
an O 0 1.1366336849505387e-07
extremely O 0 3.4370884804957313e-07
low O 0 3.481011674466572e-07
level O 0 3.44526682738433e-07
of O 0 1.6534106350718503e-07
Hp O 0 6.410947435142589e-07
( O 0 1.8911331167714707e-08
mean O 0 1.0488030000033177e-07
+ O 0 1.8157568604237895e-07
/ O 0 1.5102187944648904e-07
- O 0 1.988676814335122e-07
SD O 0 1.9634505861176876e-06
= O 0 1.855537874462243e-07
0 O 0 9.210443963070247e-09
. O 0 2.587771996687138e-09
049 O 0 9.7782844932226e-07
+ O 0 8.375450732955869e-08
/ O 0 6.099949700910656e-08
- O 0 4.467043268618909e-08
0 O 0 1.5590018165312358e-08
. O 0 5.335142549967031e-09
043 O 0 6.686851747872424e-07
mg O 0 1.9611285040355142e-07
/ O 0 7.413136415834742e-08
ml O 0 4.666675579301227e-08
; O 0 8.996959843798891e-10
n O 0 2.3780556190899915e-08
= O 0 3.760085220960718e-08
6 O 0 7.180917194204994e-09
) O 0 1.7863538426254877e-09
, O 0 6.806329944097911e-10
compared O 0 2.7847062433750125e-09
with O 0 2.678045007975527e-10
the O 0 3.8278216152320965e-09
level O 0 2.695805534358442e-08
( O 0 4.493343475076017e-09
1 O 0 4.927504182461462e-09
. O 0 5.395764390847546e-10
64 O 0 1.5238695638686295e-08
+ O 0 1.943979910379312e-08
/ O 0 7.735066809289037e-09
- O 0 5.815328218972127e-09
1 O 0 4.6759036642640694e-09
. O 0 1.5011450971158524e-09
07 O 0 1.4573232931525126e-07
mg O 0 2.05491403448832e-07
/ O 0 9.892965380231544e-08
ml O 0 6.849951716958458e-08
) O 0 6.639347405190676e-10
obtained O 0 4.088754668174488e-09
from O 0 3.5396294784106885e-09
52 O 0 1.28058914583562e-07
healthy O 0 8.88847111468749e-08
volunteers O 0 9.835749636977198e-08
having O 0 3.3766127671697177e-07
phenotype O 0 3.0250037070800317e-06
Hp2 O 0 0.0002706349769141525
, O 0 2.7809180735971495e-08
whereas O 0 9.495678909843264e-08
the O 0 6.633606375316958e-08
serum O 0 5.124391009303508e-06
Hp O 0 1.539425170449249e-06
level O 0 1.1341496275463214e-07
of O 0 1.6515659950755435e-08
an O 0 1.674895244718755e-08
individual O 0 8.035284437823975e-09
with O 0 2.7490804299645788e-08
Hp1 O 0 0.4665428400039673
/ O 0 0.0002294620790053159
Hpdel O 0 0.0007599566015414894
was O 0 5.339917152014095e-06
0 O 0 1.3478309028869262e-06
. O 0 4.72496878956008e-07

50 O 0 1.5640967831132002e-05
mg O 0 2.5950794224627316e-05
/ O 0 2.710084299906157e-05
ml O 0 1.0483751793799456e-05
, O 0 4.2096903740684866e-08
which O 0 3.8127963009060295e-09
was O 0 5.333395591833323e-08
approximately O 0 2.6916078255112552e-08
half O 0 1.6849369899318845e-08
the O 0 2.3060511722405863e-08
level O 0 1.6562275106934976e-07
of O 0 1.3643870033774874e-07
Hp O 0 8.550026677767164e-07
in O 0 1.4103600953774276e-08
control O 0 2.6439471412231796e-07
sera O 0 6.095988737797597e-06
from O 0 7.502050181074083e-08
the O 0 1.0651445592202435e-07
Hp1 O 0 2.5356042897328734e-05
phenotype O 0 1.9740591028494237e-07
( O 0 8.94979379495453e-09
1 O 0 1.045674569155608e-08
. O 0 1.1550738143739636e-09
26 O 0 3.010556426374933e-08
+ O 0 6.91345434233881e-08
/ O 0 3.6094991884283445e-08
- O 0 1.7293018572672736e-08
0 O 0 1.913132319231181e-09
. O 0 3.9584072131226833e-10
33 O 0 7.523800249487067e-09
mg O 0 2.813993837946782e-08
/ O 0 2.755563599521338e-08
ml O 0 2.9249465072211933e-08
; O 0 7.838745763599775e-10
n O 0 3.3074520899845083e-08
= O 0 6.82542022900634e-08
9 O 0 2.4484286598180915e-08
) O 0 2.7522424339565532e-09
, O 0 1.7291492682147691e-09
showing O 0 2.0517566312605595e-08
a O 0 2.9911248589087336e-08
gene O 0 4.941322728768682e-08
- O 0 2.303928425817503e-07
dosage O 0 5.42709472028946e-07
effect O 0 6.858206802462519e-07
. O 0 8.563793585381063e-07

The O 0 2.5891811219480587e-06
other O 0 6.614414616024078e-08
allele O 0 4.952740368935338e-07
( O 0 9.505715752311517e-07
Hp2 O 0 0.0009403523290529847
) O 0 1.3660067565979261e-07
of O 0 9.660846700398906e-08
individuals O 0 2.486919470356952e-08
with O 0 8.586293631651642e-08
Hp2 O 1 1.0
/ O 1 0.9988768696784973
Hpdel O 1 0.9973937273025513
was O 0 8.059060974119348e-07
found O 0 9.256603483720482e-09
to O 0 1.1708268798926724e-09
have O 0 4.658258223599887e-10
, O 0 1.63578972589562e-09
in O 0 4.5974437590246e-09
all O 0 4.9223189968472525e-09
exons O 0 1.099509248092545e-07
, O 0 6.398484853065156e-09
no O 0 1.385912096196762e-08
mutation O 0 8.152984065645796e-09
, O 0 3.099946965789968e-09
by O 0 2.3096344392570245e-08
DNA O 0 1.7425379610358505e-06
sequencing O 0 5.54988127987599e-06
. O 0 2.054909145954298e-06

On O 0 4.1132034311885945e-06
the O 0 1.1964498014549463e-07
basis O 0 2.6104987682629144e-07
of O 0 5.0267061624253984e-08
the O 0 1.6512762712750373e-08
present O 0 2.3821776551358198e-08
study O 0 3.117154534493238e-08
, O 0 3.6278362536279474e-09
the O 0 1.3071294269195732e-08
mechanism O 0 5.136967615726462e-07
of O 0 2.2021841061814484e-07
anhaptoglobinemia B-Disease 0 0.00011235026613576338
and O 0 1.4265060244156302e-08
the O 0 3.483737387455221e-08
mechanism O 0 4.5194408926363394e-07
of O 0 2.50807033808087e-07
anomalous O 0 2.7327823772793636e-05
inheritance O 0 7.481226020900067e-06
of O 0 6.308561296464177e-06
Hp O 0 2.4597582523711026e-05
phenotypes O 0 4.809672304872947e-07
were O 0 4.554505039777723e-08
well O 0 1.0451466181393698e-07
explained O 0 4.04416277888231e-06
. O 0 1.991093768083374e-06

However O 0 4.294489826861536e-06
, O 0 2.501649305486353e-07
the O 0 5.183625830795791e-07
mechanism O 0 7.035965154500445e-06
of O 0 7.20099114914774e-06
hypohaptoglobinemia B-Disease 1 0.7890987396240234
remains O 0 0.001257814117707312
unknown O 0 0.003203117987141013

ATM O 0 0.011072864755988121
mutations O 0 6.827145625720732e-06
and O 0 4.244500360073289e-07
phenotypes O 0 7.831083348719403e-05
in O 0 5.150317883817479e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.332561623712536e-06
in O 0 8.204576573689337e-08
the O 0 1.1239080066616225e-07
British O 0 1.4806597619099193e-06
Isles O 0 1.781484229468333e-06
: O 0 2.726729775304193e-08
expression O 0 2.3478412103372648e-08
of O 0 1.7403667840198978e-08
mutant O 0 1.4404165540327085e-06
ATM O 0 2.249999306513928e-05
and O 0 5.80181191978113e-09
the O 0 3.6486841992200425e-08
risk O 0 4.177320818143926e-07
of O 0 1.4670268683403265e-05
leukemia B-Disease 1 1.0
, O 1 0.9989895224571228
lymphoma B-Disease 1 1.0
, O 0 0.01469495240598917
and O 0 0.0007964433752931654
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 0.00010563043178990483

We O 0 1.7608098232813063e-06
report O 0 3.3156194945149764e-07
the O 0 5.1736243733557785e-08
spectrum O 0 7.718976746673434e-08
of O 0 2.747031828675972e-07
59 O 0 7.0824303293193225e-06
ATM O 0 0.00046658513019792736
mutations O 0 1.7065431734408776e-07
observed O 0 5.372088480726234e-07
in O 0 5.148144737177063e-07
ataxia B-Disease 1 0.999998927116394
- I-Disease 1 0.9992005228996277
telangiectasia I-Disease 1 1.0
( O 0 0.027243349701166153
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
) O 0 2.9388721145551244e-07
patients O 0 1.3809962062794057e-08
in O 0 1.017081174836676e-08
the O 0 2.6445977141520416e-07
British O 0 2.2520409402204677e-05
Isles O 0 5.902448174310848e-05
. O 0 2.554037791924202e-06

Of O 0 5.317366594681516e-05
51 O 0 0.00012429444177541882
ATM O 0 0.004378842655569315
mutations O 0 1.002681301542907e-06
identified O 0 3.615177206484077e-07
in O 0 4.5355804445534886e-08
families O 0 2.1338230737910635e-08
native O 0 1.845022268298635e-08
to O 0 5.537521996501482e-09
the O 0 5.003910530376743e-08
British O 0 2.2829542558611138e-06
Isles O 0 3.4642482660274254e-06
, O 0 2.7027970972426374e-08
11 O 0 8.554891195444725e-08
were O 0 4.349670490455537e-08
founder O 0 1.54642032157426e-06
mutations O 0 1.9019564589939364e-08
, O 0 4.804736608576832e-09
and O 0 2.8670206209113758e-09
2 O 0 5.2335810352133194e-08
of O 0 3.326000452830158e-08
these O 0 8.759630354404635e-09
11 O 0 8.575524645948462e-08
conferred O 0 2.0338846695722168e-07
a O 0 4.050558999324494e-08
milder O 0 4.0794326139348414e-08
clinical O 0 1.9580468801905226e-07
phenotype O 0 3.162223549679766e-08
with O 0 1.1266992894221062e-09
respect O 0 7.554716852098409e-09
to O 0 1.6012595693837284e-08
both O 0 6.103989562689094e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 2.394176817688276e-06
cellular O 0 0.00024324050173163414
features O 0 4.811066901311278e-06
. O 0 2.597040293039754e-06

We O 0 2.4697426397324307e-06
report O 0 6.062289230612805e-07
, O 0 4.66228939899338e-08
in O 0 1.8891720188207728e-08
two O 0 5.393145841026126e-08
A B-Disease 1 0.9986521601676941
- I-Disease 1 0.9224338531494141
T I-Disease 1 0.999980092048645
families O 0 4.025320521350295e-08
, O 0 7.045465100219417e-09
an O 0 3.4115242186771866e-08
ATM O 0 1.943548340932466e-06
mutation O 0 7.169011606578124e-09
( O 0 5.305916594977589e-09
7271T O 0 6.631138376178569e-07
- O 0 5.356016572477529e-07
- O 0 7.338384762078931e-07
> O 0 9.506912874712725e-07
G O 0 3.8090263387857703e-07
) O 0 2.7339408514848174e-09
that O 0 1.7629837867350062e-10
may O 0 7.122164524808738e-10
be O 0 4.99554175803496e-10
associated O 0 3.92809917926229e-09
with O 0 5.130714741952147e-10
an O 0 6.947277864099988e-09
increased O 0 2.2697538071270174e-08
risk O 0 1.336105128757481e-07
of O 0 7.251181841638754e-07
breast B-Disease 1 0.9926936626434326
cancer I-Disease 0 0.0001432152057532221
in O 0 4.632514816194089e-08
both O 0 4.88483529181849e-08
homozygotes O 0 1.2773153684975114e-05
and O 0 1.9822534724767138e-08
heterozygotes O 0 1.1823419754364295e-06
( O 0 2.253233333249227e-08
relative O 0 1.9022506592136779e-07
risk O 0 2.6979195766330122e-08
12 O 0 1.4947374893381493e-08
. O 0 1.317445930126837e-09
7 O 0 1.8743630647577447e-08
; O 0 3.261506398288816e-09
P O 0 1.4412520386031247e-06
= O 0 3.060912945329619e-07
. O 0 1.0658513183159357e-08
0025 O 0 2.813575520121958e-06
) O 0 3.9269454354950994e-09
, O 0 3.879698229347639e-10
although O 0 7.02332358937241e-10
there O 0 1.8279242564034348e-09
is O 0 2.327570136628765e-09
a O 0 1.5931135521896067e-08
less O 0 1.3523313135976878e-08
severe O 0 2.504733856767416e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 4.3022970430683927e-07
in O 0 4.736430359031374e-09
terms O 0 1.8575077476157276e-08
of O 0 3.2288145490610987e-08
the O 0 7.748034391852343e-08
degree O 0 1.3664403013535775e-05
of O 0 4.6338442189153284e-05
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 4.399929821374826e-05

This O 0 8.270374678431835e-07
mutation O 0 1.7000424179514084e-07
( O 0 1.215447582580964e-07
7271T O 0 2.674345296327374e-06
- O 0 2.213622792623937e-06
- O 0 4.574770173348952e-06
> O 0 3.1555287023365963e-06
G O 0 1.2195687304483727e-06
) O 0 1.7071153379788484e-08
also O 0 2.279457733678214e-09
allows O 0 1.2468713839197676e-09
expression O 0 2.984945179917986e-09
of O 0 6.113831663157043e-09
full O 0 7.58439000492217e-08
- O 0 1.0835697139555123e-06
length O 0 4.5736652509731357e-07
ATM O 0 2.066654087684583e-05
protein O 0 5.956634296921948e-08
at O 0 3.767242162666662e-08
a O 0 1.5277402454216826e-08
level O 0 3.659159020230618e-08
comparable O 0 2.4866729120276432e-08
with O 0 8.159234399229831e-10
that O 0 1.5917035467438723e-09
in O 0 1.9379751137194035e-08
unaffected O 0 7.594535986754636e-07
individuals O 0 6.753213455112927e-08
. O 0 7.600129379170539e-07

In O 0 7.569611284452549e-07
addition O 0 1.450605111585901e-07
, O 0 1.1447572667577788e-08
we O 0 1.2858533793291826e-08
have O 0 2.9555651259727256e-09
studied O 0 4.756054465815396e-07
18 O 0 6.647489044553367e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 7.270751467558512e-08
, O 0 4.570297029715675e-09
in O 0 5.615463649633057e-09
15 O 0 2.2242655717263915e-08
families O 0 2.713534730247602e-09
, O 0 2.4009148003045766e-09
who O 0 6.034679422839417e-09
developed O 0 5.116325496601348e-07
leukemia B-Disease 1 0.9999998807907104
, O 0 0.0005791023140773177
lymphoma B-Disease 1 1.0
, O 0 0.00040918425656855106
preleukemic O 1 1.0
T O 1 0.9999996423721313
- O 0 0.029840046539902687
cell O 0 0.0007586085703223944
proliferation O 0 0.0025077941827476025
, O 0 2.700154482226935e-07
or O 0 0.00013131748710293323
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.0077304068545345e-05
mostly O 0 9.203280342262588e-07
in O 0 1.111623191718536e-06
childhood O 0 0.0005719640175811946
. O 0 1.008383151201997e-05

A O 0 1.298620645684423e-05
wide O 0 3.713013541073451e-07
variety O 0 1.1633994745352538e-07
of O 0 6.450774776567414e-07
ATM O 0 0.00020650296937674284
mutation O 0 6.586743239722637e-08
types O 0 3.232758416515935e-08
, O 0 1.749586253652069e-08
including O 0 2.5867368691478987e-08
missense O 0 3.7118697946425527e-06
mutations O 0 4.048828827762918e-08
and O 0 1.1101188412965257e-08
in O 0 1.8526874612234678e-07
- O 0 1.2877040717285126e-05
frame O 0 3.835831375909038e-05
deletions O 0 2.8603591317732935e-07
, O 0 9.410231704976013e-09
were O 0 1.8247066080334662e-08
seen O 0 1.1481908046562239e-07
in O 0 1.29442661034318e-08
these O 0 3.550978178168407e-08
patients O 0 2.391396947132307e-07
. O 0 1.5899435084065772e-06

We O 0 1.8353441646468127e-06
also O 0 9.305163217732115e-08
show O 0 1.6522284340680926e-07
that O 0 1.3217984928814985e-08
25 O 0 9.541611944996475e-08
% O 0 2.9027825476646285e-08
of O 0 4.252908070156991e-08
all O 0 5.6520221392020176e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.6904193478903835e-08
carried O 0 7.869883233979635e-08
in O 0 1.3811468591029552e-07
- O 0 4.163752691965783e-06
frame O 0 7.4875360951409675e-06
deletions O 0 1.673551537351159e-07
or O 0 2.3640044588546516e-08
missense O 0 3.4424553518874745e-07
mutations O 0 5.773463929159561e-09
, O 0 1.4000727244223299e-09
many O 0 3.5019681599024466e-10
of O 0 2.2572153035582687e-09
which O 0 5.928462165627479e-10
were O 0 5.8923008694478085e-09
also O 0 3.5116820562564044e-09
associated O 0 1.2917531044820407e-08
with O 0 5.463099750357969e-09
expression O 0 9.57676533630547e-08
of O 0 3.8623372233814734e-07
mutant O 0 3.065000782953575e-05
ATM O 0 0.0015124385245144367
protein O 0 4.041668034915347e-06
. O 0 1.3178686231185566e-06

The O 0 3.6098015698371455e-05
DMPK O 1 0.9667151570320129
gene O 0 6.873050551803317e-06
of O 0 7.203429504443193e-06
severely O 1 0.9759746789932251
affected O 1 0.9280729293823242
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.6442111134529114
is O 0 3.934110736736329e-06
hypermethylated O 1 0.991834282875061
proximal O 0 0.00018412167264614254
to O 0 6.159047671872031e-08
the O 0 2.8633422743951087e-07
largely O 0 2.433057943562744e-06
expanded O 0 6.517573183373315e-06
CTG O 0 0.0020476856734603643
repeat O 0 3.920340896002017e-05
. O 0 5.83366727369139e-06

Using O 0 5.407893695519306e-06
methylation O 0 1.0993538126058411e-05
- O 0 3.7866534512431826e-06
sensitive O 0 9.06012928680866e-07
restriction O 0 7.215862041221044e-08
enzymes O 0 1.4507953949305374e-08
, O 0 4.079593995953701e-09
we O 0 1.3538023146963951e-08
characterized O 0 5.408092818015575e-08
the O 0 4.4636021101496226e-08
methylation O 0 2.415058304450213e-07
pattern O 0 1.0041399178817301e-07
on O 0 2.333795201536759e-08
the O 0 2.0642113796043304e-08
5 O 0 2.2657225429156824e-08
side O 0 7.3131682931659725e-09
of O 0 3.4579656471578346e-08
the O 0 3.3708150226630096e-07
CTG O 1 0.5054818987846375
repeat O 0 1.5197790617094142e-06
in O 0 4.3793562554128584e-08
the O 0 9.123653654796726e-08
DMPK O 0 0.00044257735135033727
gene O 0 8.57887840766125e-08
of O 0 2.2440035607473874e-08
normal O 0 1.1981065028976445e-07
individuals O 0 1.06760666973571e-09
and O 0 1.6837732319530119e-09
of O 0 2.3464271237116918e-07
patients O 0 2.2998409576757695e-07
affected O 0 2.927353079940076e-07
with O 0 2.4200449843192473e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.341273782098142e-07
showing O 0 9.436653840566578e-07
expansions O 0 3.1652680831939506e-07
of O 0 5.438431927018428e-08
the O 0 1.3888738692457991e-07
repetitive O 0 5.167429662833456e-06
sequence O 0 2.773537062239484e-06
. O 0 2.5118456505879294e-06

The O 0 2.3033029719954357e-05
gene O 0 1.0142092833120842e-05
segment O 0 5.756550308433361e-06
analyzed O 0 1.329958990936575e-06
corresponds O 0 1.0006332331613521e-06
to O 0 3.72815662785797e-08
the O 0 2.738013620273705e-07
genomic O 0 1.8878823539125733e-05
SacI O 1 0.5689976811408997
- O 0 1.4830940926913172e-05
HindIII O 0 0.00014082402049098164
fragment O 0 2.9465211355272913e-06
carrying O 0 2.3942386633279966e-06
exons O 0 2.523021521483315e-06
11 O 0 2.706992063394864e-06
- O 0 6.914244750078069e-06
15 O 0 6.64119079374359e-06
. O 0 4.8523247642151546e-06

There O 0 7.2652728704269975e-06
is O 0 9.147042874246836e-07
constitutive O 0 2.691341796889901e-05
methylation O 0 1.4458099940384272e-05
in O 0 1.2117050118831685e-06
intron O 0 0.00025881105102598667
12 O 0 1.0743686971181887e-06
at O 0 4.770568011736032e-07
restriction O 0 8.00857407057265e-08
sites O 0 3.711044271881292e-08
of O 0 1.1236400609959674e-07
SacII O 0 0.00022319363779388368
and O 0 1.2327008391821437e-07
HhaI O 0 0.0036207546945661306
, O 0 7.143952984733914e-08
localized O 0 1.6569781280395546e-07
1 O 0 5.720370310768885e-08
, O 0 1.423494566665795e-08
159 O 0 5.2702841202290074e-08
- O 0 7.704547044795618e-08
1 O 0 5.2699022035085363e-08
, O 0 1.0830160768193764e-08
232 O 0 1.8834860782135365e-07
bp O 0 5.781951699646015e-07
upstream O 0 5.652485128848639e-07
of O 0 4.5868741693766424e-08
the O 0 6.931542628763054e-08
CTG O 0 0.0006310677854344249
repeat O 0 4.291597690553317e-07
, O 0 5.78795189554171e-09
whereas O 0 8.947489860133828e-09
most O 0 5.123556579000876e-10
, O 0 4.0916706134375147e-10
if O 0 4.3569894914163854e-10
not O 0 6.808809627223411e-10
all O 0 1.7026919874041369e-09
, O 0 4.452070268001762e-09
of O 0 7.129793200277845e-09
the O 0 1.4129342140734025e-08
other O 0 1.931534709953553e-09
sites O 0 2.58649031081859e-08
of O 0 1.1928644028103008e-07
SacII O 0 0.18504267930984497
, O 0 2.4781365937087685e-07
HhaI O 0 0.09440335631370544
, O 0 3.050864094689132e-08
and O 0 1.689384454550691e-08
HpaII O 0 8.433842594968155e-05
in O 0 1.0822437168656052e-08
this O 0 4.493977634467683e-09
region O 0 1.751609524092146e-08
are O 0 2.0484864915459866e-09
unmethylated O 0 2.949698000520584e-06
, O 0 1.7811899510888907e-08
in O 0 1.0417926077366246e-08
normal O 0 1.869208290372626e-07
individuals O 0 1.7493384518729727e-09
and O 0 1.2158243301030325e-09
most O 0 1.6377876832507354e-09
of O 0 3.9988581335137496e-08
the O 0 3.4847550978156505e-07
patients O 0 4.4317903302726336e-07
. O 0 1.8575274225440808e-06

In O 0 1.6506046449649148e-06
a O 0 2.445607947265671e-07
number O 0 1.9938491746529508e-08
of O 0 8.188035849343578e-08
young O 0 1.888498815105777e-07
and O 0 8.856080313535131e-08
severely O 0 8.237028669100255e-05
affected O 0 1.5629339600309322e-07
patients O 0 2.5939701941979365e-08
, O 0 5.0576511867461704e-09
however O 0 1.0727285726375158e-08
, O 0 9.923160071423354e-09
complete O 0 1.9997989397779747e-07
methylation O 0 1.8998105133505305e-07
of O 0 1.559667950346011e-08
these O 0 1.761646828413177e-09
restriction O 0 2.5751978327548386e-08
sites O 0 1.3071069560055548e-08
was O 0 4.5502329015789655e-08
found O 0 1.035518426562021e-08
in O 0 5.92561599788155e-09
the O 0 5.914101919302084e-08
mutated O 0 4.179943005055975e-07
allele O 0 5.801526867799112e-07
. O 0 6.813167487962346e-07

In O 0 1.0992803254339378e-06
most O 0 1.614070832545167e-08
of O 0 1.6719971185352733e-08
these O 0 5.137278158429126e-09
patients O 0 1.68586282711658e-08
, O 0 1.2404057336823371e-08
the O 0 2.4873517645573884e-07
onset O 1 0.9995161294937134
of O 0 2.5669562091934495e-05
the O 0 0.0008055430371314287
disease O 1 0.999998927116394
was O 1 0.9999984502792358
congenital O 1 1.0
. O 0 6.502853648271412e-05

Preliminary O 0 8.483124838676304e-05
in O 0 4.739938958664425e-06
vivo O 0 0.0005596312112174928
footprinting O 0 0.0010343376779928803
data O 0 2.9287465963534487e-07
gave O 0 3.259281555756388e-08
evidence O 0 2.9755106822904054e-08
for O 0 7.205599672488461e-09
protein O 0 1.882026339217191e-07
- O 0 5.621102445729775e-07
DNA O 0 4.801972295354062e-07
contact O 0 1.4357244992879714e-07
in O 0 1.6613032727264e-08
normal O 0 7.323653790081153e-07
genes O 0 3.357403954851179e-08
at O 0 1.6659748780512018e-07
an O 0 1.382920942205601e-07
Sp1 O 0 8.03950933914166e-06
consensus O 0 7.676793245536828e-08
binding O 0 2.494273232400701e-08
site O 0 1.651799834689882e-07
upstream O 0 4.892075935458706e-07
of O 0 4.734797798278123e-08
the O 0 1.4525181768476614e-07
CTG O 0 0.010513964109122753
repeat O 0 5.314350914886745e-07
and O 0 4.1472461020930496e-09
for O 0 4.3294225982037915e-09
a O 0 1.6703076255453198e-08
significant O 0 1.0129189043084352e-08
reduction O 0 2.4805146381368104e-08
of O 0 1.2592161979796401e-08
this O 0 4.862838132169145e-09
interaction O 0 2.7793696233402443e-08
in O 0 3.7331497892978405e-09
cells O 0 1.1189046134063574e-08
with O 0 3.3766103246790635e-09
a O 0 7.105860504452721e-07
hypermethylated O 0 0.004768673330545425
DMPK O 1 0.9883986115455627
gene O 0 2.216187112935586e-06
. O 0 2.2638742791514233e-07
. O 0 1.026680251925427e-06

The O 0 0.0025390908122062683
hemochromatosis B-Disease 1 1.0
gene O 0 0.00012599922774825245
product O 0 2.209278136433568e-06
complexes O 0 2.1395219391706632e-06
with O 0 4.1039143638954556e-08
the O 0 9.204474054058664e-07
transferrin O 0 0.004530312959104776
receptor O 0 1.3744617035627016e-06
and O 0 1.5359825411564998e-08
lowers O 0 2.1631394986343366e-07
its O 0 5.4417177430821084e-09
affinity O 0 6.821047549010473e-08
for O 0 1.491820889043538e-08
ligand O 0 9.304601462645223e-07
binding O 0 3.955947818212735e-07
. O 0 7.089080895639199e-07

We O 0 1.0655265214154497e-05
recently O 0 2.755101832008222e-06
reported O 0 6.543280051118927e-07
the O 0 7.374425337047796e-08
positional O 0 1.833822011576558e-06
cloning O 0 6.623466219934926e-07
of O 0 1.2523018710908218e-07
a O 0 3.551520819655707e-07
candidate O 0 1.2779994449374499e-06
gene O 0 6.403482984751463e-06
for O 0 2.0903406038996764e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 0.00017911623581312597

The O 0 4.85064992972184e-06
gene O 0 1.3217048717706348e-06
product O 0 1.4176168861013139e-07
, O 0 4.3309775321631605e-08
a O 0 1.240742335539835e-07
member O 0 1.2329454079917923e-07
of O 0 1.0950513740226597e-07
the O 0 1.328788385990265e-07
major O 0 3.654483180071111e-06
histocompatibility O 1 0.9940696954727173
complex O 0 0.0012761821271851659
class O 0 6.677950750599848e-06
I O 0 8.970763883553445e-05
- O 0 8.746078492549714e-06
like O 0 9.672554313056025e-08
family O 0 9.491695607266593e-08
, O 0 1.1117186282660896e-08
was O 0 2.6039694489554677e-07
found O 0 1.2867219290058074e-08
to O 0 4.211438753287666e-09
have O 0 3.998810615968296e-09
a O 0 6.37530419567156e-08
mutation O 0 2.9979101867638747e-08
, O 0 2.4563245659692257e-08
Cys O 0 7.848024688428268e-05
- O 0 2.449905878165737e-06
282 O 0 2.6148193228436867e-06
- O 0 4.021992936031893e-06
- O 0 4.719974640465807e-06
> O 0 2.426338596706046e-06
Tyr O 0 4.922048901789822e-06
( O 0 3.846918872341121e-08
C282Y O 0 8.834955451675341e-07
) O 0 1.247319136865599e-08
, O 0 5.14813658369917e-09
in O 0 1.2415229733164779e-08
85 O 0 1.9689751695750601e-07
% O 0 9.267613165775401e-08
of O 0 3.4305458029848523e-07
patient O 0 6.549725185323041e-06
chromosomes O 0 1.8699833162827417e-05
. O 0 3.662248900582199e-06

This O 0 7.468865078408271e-06
mutation O 0 2.643503421495552e-06
eliminates O 0 3.4015815799648408e-06
the O 0 2.9111001254022995e-07
ability O 0 3.990515722307464e-07
of O 0 3.439847205299884e-06
HFE O 1 0.9999152421951294
to O 0 3.9786601746527595e-07
associate O 0 6.61420244796318e-06
with O 0 1.6181866158149205e-07
beta2 O 0 0.25767937302589417
- O 0 0.0004957669298164546
microglobulin O 0 0.074494369328022
( O 0 1.0217924000244238e-06
beta2m O 0 1.559678821649868e-05
) O 0 5.7624212956852716e-08
and O 0 1.8244037391923484e-08
prevents O 0 3.774233618969447e-07
cell O 0 1.1120939234388061e-05
- O 0 5.283512109599542e-06
surface O 0 1.5572146367048845e-05
expression O 0 4.361726951174205e-06
. O 0 2.7461671834316803e-06

A O 0 3.2278101571137086e-05
second O 0 1.5128091490623774e-06
mutation O 0 1.838106697960029e-07
that O 0 5.609789965888012e-09
has O 0 4.095834338357918e-09
no O 0 1.3470744519850086e-08
effect O 0 7.467047424825068e-08
on O 0 3.347537926856603e-07
beta2m O 0 0.005107658449560404
association O 0 1.8552913161329343e-06
, O 0 1.7065545421246497e-07
H63D O 1 0.7366364598274231
, O 0 2.4774459816967465e-08
was O 0 2.406322039405495e-07
found O 0 1.0702393637984642e-08
in O 0 2.990638181543659e-09
eight O 0 3.4827856154606707e-09
out O 0 1.2296869078554096e-09
of O 0 1.4136782411355853e-08
nine O 0 6.67336550463915e-08
patients O 0 1.0480107448529452e-08
heterozygous O 0 4.015597099282786e-08
for O 0 1.5341790060574567e-08
the O 0 8.585685122852738e-07
C282Y O 0 0.00045012158807367086
mutant O 0 2.788067467918154e-05
. O 0 2.3782313292031176e-06

In O 0 1.0033154467237182e-06
this O 0 4.2185881454770424e-08
report O 0 1.3153305644664215e-07
, O 0 1.207325528440606e-08
we O 0 3.036733176031703e-08
demonstrate O 0 3.270039314884343e-07
in O 0 1.1090505580568788e-07
cultured O 0 1.0142005521629471e-05
293 O 0 1.0674711120373104e-05
cells O 0 2.3157278974395012e-06
overexpressing O 0 1.893280386866536e-05
wild O 0 3.5606197457127564e-07
- O 0 1.9504927877278533e-06
type O 0 8.947438914219674e-07
or O 0 2.0459931704408518e-07
mutant O 0 2.6378513211966492e-05
HFE O 1 0.8852744102478027
proteins O 0 2.5046182017263163e-08
that O 0 1.4581963414528332e-09
both O 0 1.867182852777205e-09
the O 0 1.1129746901872295e-08
wild O 0 6.947465891471438e-08
- O 0 1.3425392353383359e-06
type O 0 1.3515173122868873e-06
and O 0 2.505517215922737e-07
H63D O 1 0.9999995231628418
HFE O 1 0.9998917579650879
proteins O 0 2.0135928480158327e-07
form O 0 6.049224765547478e-08
stable O 0 2.8183071663079318e-06
complexes O 0 2.0727637206618965e-07
with O 0 1.772825086732155e-08
the O 0 5.369609539229714e-07
transferrin O 0 0.00017693129484541714
receptor O 0 5.674842668668134e-06
( O 0 4.3808603322759154e-07
TfR O 0 0.0002009746531257406
) O 0 4.1889578028531105e-07
. O 0 7.659227208023367e-07

The O 0 2.5432716938667e-05
C282Y O 0 0.00032708962680771947
mutation O 0 1.0346715271225548e-06
nearly O 0 3.260902303736657e-07
completely O 0 9.58904479375633e-07
prevents O 0 1.5503349004575284e-07
the O 0 5.558975146868761e-08
association O 0 1.0447161002957728e-07
of O 0 1.7235993254871573e-07
the O 0 1.8951649281007121e-06
mutant O 0 0.0005620999145321548
HFE O 1 0.999874472618103
protein O 0 1.2971943306183675e-06
with O 0 9.72295808310264e-08
the O 0 4.648420599551173e-06
TfR O 1 0.9948306679725647
. O 0 8.869916200637817e-06

Studies O 0 2.4525508706574328e-05
on O 0 4.093028110219166e-06
cell O 0 7.710697536822408e-05
- O 0 4.311705197324045e-06
associated O 0 1.2866111092080246e-06
transferrin O 0 2.744985067693051e-05
at O 0 5.143065209267661e-07
37 O 0 1.3723631298034888e-07
degrees O 0 9.889946994690035e-08
C O 0 4.4010064925714687e-07
suggest O 0 1.7238845018141546e-08
that O 0 9.564034009201805e-10
the O 0 1.093072832247799e-08
overexpressed O 0 1.72669535913883e-06
wild O 0 1.9727681888070947e-07
- O 0 4.067645477334736e-06
type O 0 7.067917067615781e-06
HFE O 1 0.995137631893158
protein O 0 1.2291339999137563e-06
decreases O 0 2.2517023978707584e-07
the O 0 2.11141841788276e-08
affinity O 0 1.2270919569346006e-07
of O 0 1.058818668298045e-07
the O 0 5.230866690908442e-07
TfR O 0 0.046624913811683655
for O 0 1.1536111514942604e-06
transferrin O 0 0.0007112709572538733
. O 0 8.771923603489995e-06

The O 0 0.00019488281395751983
overexpressed O 1 0.99072265625
H63D O 1 0.9986937642097473
protein O 0 3.981536337960279e-06
does O 0 9.948327495123976e-09
not O 0 1.3612639904181378e-09
have O 0 2.6058391555672245e-10
this O 0 9.066606909691188e-10
effect O 0 1.1280158140891672e-08
, O 0 5.276487247130035e-09
providing O 0 2.6261643526481748e-08
the O 0 7.290272829862943e-09
first O 0 4.93512253285644e-09
direct O 0 5.121995272361346e-09
evidence O 0 7.703587989738025e-09
for O 0 2.197361625988492e-09
a O 0 3.7888820969556036e-08
functional O 0 3.7906826833022933e-07
consequence O 0 3.025777459697565e-07
of O 0 1.7868494239792199e-07
the O 0 6.267623575695325e-07
H63D O 0 0.011550807394087315
mutation O 0 2.220109081463306e-06
. O 0 1.2008923704343033e-06

Addition O 0 4.666988388635218e-06
of O 0 2.054734750345233e-06
soluble O 0 1.0910087439697236e-05
wild O 0 5.638376023853198e-06
- O 0 0.000248170254053548
type O 0 0.13063062727451324
HFE O 1 1.0
/ O 1 0.9999368190765381
beta2m O 1 0.7254324555397034
heterodimers O 0 7.51424377085641e-05
to O 0 3.349741461988742e-07
cultured O 0 0.00010468832624610513
cells O 0 1.038760615301726e-06
also O 0 1.620660228240922e-08
decreased O 0 6.181715548336797e-07
the O 0 3.767766898477021e-08
apparent O 0 4.6614979964942904e-07
affinity O 0 9.109134424534204e-08
of O 0 9.799796174547737e-08
the O 0 2.3374553848043433e-07
TfR O 0 0.0002008633455261588
for O 0 1.3560248923738527e-08
its O 0 5.024997307145895e-09
ligand O 0 6.873719371469633e-08
under O 0 2.747785465828656e-08
steady O 0 2.8211090921104187e-06
- O 0 1.313984085982156e-07
state O 0 8.061320500019065e-09
conditions O 0 1.8338164764486464e-08
, O 0 3.2347859946213475e-09
both O 0 1.5225556371234461e-09
in O 0 6.725010326391612e-09
293 O 0 1.309267076976539e-07
cells O 0 2.8495383830318133e-08
and O 0 6.204451619140627e-09
in O 0 3.1774840181242325e-07
HeLa O 1 0.6915668845176697
cells O 0 6.105262400524225e-06
. O 0 1.1877757515321719e-06

Furthermore O 0 2.4891960492823273e-05
, O 0 1.8399657619738718e-07
at O 0 3.0154848218444386e-07
4 O 0 7.770485410674155e-08
degrees O 0 1.0799305272257698e-07
C O 0 2.614026470837416e-07
, O 0 2.365270646009776e-09
the O 0 7.095943832524654e-09
added O 0 1.2772449053954915e-07
soluble O 0 1.4281116591519094e-06
complex O 0 3.27852762893599e-06
of O 0 4.315756996220443e-06
HFE O 1 0.9999995231628418
/ O 0 0.41184568405151367
beta2m O 0 0.0026314761489629745
inhibited O 0 3.1653421501687262e-06
binding O 0 1.1365132479568274e-07
of O 0 1.9590555666582077e-07
transferrin O 0 1.793026240193285e-05
to O 0 5.741356403632381e-07
HeLa O 1 0.9999566078186035
cell O 0 0.00029154345975257456
TfR O 0 0.0005954160587862134
in O 0 3.201097698024569e-08
a O 0 1.57825525093358e-07
concentration O 0 9.504912668489851e-06
- O 0 1.3042849786870647e-06
dependent O 0 4.1238413928113005e-07
manner O 0 9.220129868481308e-07
. O 0 6.702628638777242e-07

Scatchard O 0 0.0009711338207125664
plots O 0 6.060836312826723e-06
of O 0 1.492965822080805e-07
these O 0 1.0855887744298798e-08
data O 0 1.2921823611122818e-07
indicate O 0 8.48106580519925e-08
that O 0 8.136082918497323e-09
the O 0 1.3083820249448763e-07
added O 0 7.196042588475393e-07
heterodimer O 0 1.922892806760501e-05
substantially O 0 3.755656337034452e-07
reduced O 0 5.645977907420274e-08
the O 0 7.963456027937355e-08
affinity O 0 2.454372349802725e-07
of O 0 5.883869107492501e-07
TfR O 0 0.002758336951956153
for O 0 1.5578237935187644e-06
transferrin O 0 0.0003625588142313063
. O 0 7.328891570068663e-06

These O 0 6.904294878040673e-07
results O 0 5.940103164903121e-07
establish O 0 1.5558863424303127e-06
a O 0 1.0125974085894995e-06
molecular O 0 2.8615115297725424e-05
link O 0 7.525793535023695e-06
between O 0 1.0247454156342428e-06
HFE O 1 0.9997100234031677
and O 0 4.066466985364059e-08
a O 0 3.1102896969059657e-07
key O 0 9.018896776069596e-07
protein O 0 1.6086976017959387e-07
involved O 0 5.7646310835934855e-08
in O 0 2.0389373744933437e-08
iron O 0 0.00026107081794179976
transport O 0 2.3709964807494543e-05
, O 0 3.273380855262076e-07
the O 0 1.6201893231482245e-06
TfR O 1 0.9999226331710815
, O 0 1.7150853182101855e-08
and O 0 2.856022973674044e-09
raise O 0 9.598688066603245e-09
the O 0 9.141261081424545e-09
possibility O 0 3.9613265556681654e-08
that O 0 1.840757546389682e-09
alterations O 0 6.835895050016916e-08
in O 0 4.1950678486557536e-09
this O 0 7.85208253972769e-09
regulatory O 0 6.977664668283978e-08
mechanism O 0 1.6837202565511689e-07
may O 0 1.4023879835178832e-08
play O 0 8.102280446564691e-08
a O 0 2.2428723411849205e-07
role O 0 3.101939398675313e-07
in O 0 8.402106743687909e-08
the O 0 1.715255848466768e-06
pathogenesis O 1 0.9999997615814209
of O 1 0.9997826218605042
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.11023498326539993
. O 0 3.1883453630143777e-05

Genomic O 0 0.00013094872701913118
organization O 0 1.4668580661236774e-06
of O 0 1.872931875368522e-06
the O 0 6.9179518504824955e-06
UBE3A O 1 0.9999388456344604
/ O 1 0.6848032474517822
E6 O 0 0.006500896532088518
- O 0 6.341355037875473e-05
AP O 0 0.00012007463374175131
gene O 0 2.5682871296339727e-07
and O 0 3.653830660255153e-08
related O 0 1.3666782479049289e-06
pseudogenes O 0 4.164568235864863e-05
. O 0 9.53373728407314e-06

The O 0 0.00018616380111780018
UBE3A O 0 0.02103176899254322
gene O 0 1.8957769498229027e-05
encodes O 0 8.818053174763918e-06
the O 0 1.7881958456200664e-06
E6 O 0 7.668197940802202e-05
- O 0 2.6854530005948618e-05
AP O 0 0.0005687327939085662
ubiquitin O 0 6.293065962381661e-05
- O 0 2.6818084734259173e-05
protein O 0 1.0909179763984866e-06
ligase O 0 2.7026997031498468e-06
and O 0 4.860983615628811e-09
has O 0 2.319504366354863e-09
recently O 0 7.193158513274511e-09
been O 0 3.881225119073406e-09
shown O 0 3.859035757614038e-09
to O 0 3.557470762416415e-09
be O 0 2.56794869812893e-08
mutated O 0 2.0145546386629576e-06
in O 0 5.2158069593133405e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0002327205438632518
who O 0 9.120771551351936e-07
lack O 0 0.0007876952295191586
15q11 O 1 0.9999971389770508
- O 1 0.8847537040710449
q13 O 0 0.0064697666093707085
deletions O 0 5.5140076256066095e-06
or O 0 8.44457588300429e-07
chromosome O 0 8.630568481748924e-05
15 O 0 4.091919254278764e-05
paternal O 1 0.9988089799880981
uniparental B-Disease 1 0.9999998807907104
disomy I-Disease 1 0.9999898672103882
. O 0 7.445242226822302e-05

Previous O 0 0.00026020430959761143
UBE3A O 0 0.009140809997916222
cDNA O 0 8.174194226739928e-05
analysis O 0 9.79779315457563e-07
has O 0 1.0077851442247265e-08
shown O 0 3.748963806060601e-08
a O 0 1.0732405542057677e-07
coding O 0 1.1281771321591805e-06
region O 0 2.567787475982186e-07
of O 0 3.559726735602453e-07
approximately O 0 2.0613983906514477e-06
2 O 0 5.041020358476089e-06
. O 0 2.288508540004841e-06

6 O 0 0.00011570111382752657
kb O 0 0.00013045732339378446
and O 0 1.3077308835818258e-07
a O 0 6.410269293155579e-07
3 O 0 9.174641490972135e-07
- O 0 2.01445072889328e-06
untranslated O 0 2.1842934074811637e-05
region O 0 8.9510751877242e-07
( O 0 3.025269847967138e-07
UTR O 0 3.177629696438089e-05
) O 0 3.629893541301499e-08
of O 0 1.097669510841115e-07
< O 0 4.735633410746232e-06
50 O 0 1.7738135227318708e-07
bp O 0 5.341045721252158e-07
, O 0 7.546033131689e-09
whereas O 0 1.853685382968706e-08
Northern O 0 2.7195465435170263e-08
analysis O 0 2.1335260669275158e-08
has O 0 1.3616014982176239e-09
indicated O 0 1.0168833775026087e-08
mRNA O 0 4.389558938555638e-08
sizes O 0 1.1075703909568801e-08
of O 0 3.7460903712371874e-08
5 O 0 2.3039945062919287e-07
- O 0 1.3590150729214656e-06
8 O 0 2.7999885787721723e-06
kb O 0 6.997025047894567e-05
. O 0 1.7076467884180602e-06

We O 0 9.64434775596601e-07
have O 0 1.82361752365523e-08
analyzed O 0 1.568238872096117e-07
additional O 0 1.2962715345565812e-07
cDNA O 0 5.6379244597337674e-06
clones O 0 2.6743478542812227e-07
and O 0 2.1779422709755636e-09
provide O 0 4.474033143964107e-09
evidence O 0 2.5837390893457268e-08
for O 0 3.5905736162078483e-09
an O 0 2.8573429844414022e-08
additional O 0 1.0473636535834885e-07
0 O 0 3.214712194221647e-07
. O 0 2.2787509124100325e-07

5 O 0 6.052706157788634e-05
kb O 0 0.000149951025377959
of O 0 6.537680746987462e-06
5 O 0 1.5408411854878068e-05
- O 0 3.493522308417596e-05
UTR O 0 0.0003451093507464975
and O 0 3.33986577061296e-07
> O 0 2.077060571537004e-06
2 O 0 3.4614933497323364e-07
kb O 0 5.909827450523153e-06
of O 0 6.377894692377595e-07
3 O 0 3.752144266400137e-06
- O 0 4.06953549827449e-05
UTR O 0 0.003714470425620675
. O 0 5.952447736490285e-06

We O 0 1.933111434482271e-06
have O 0 5.1280686363952555e-08
established O 0 2.733286237344146e-07
the O 0 1.55503471432894e-07
genomic O 0 2.8013880637445254e-06
organization O 0 2.4195443870667077e-07
of O 0 6.447871783166192e-07
UBE3A O 0 0.004303509369492531
and O 0 2.1173791608930514e-08
the O 0 9.029854908249035e-08
sequence O 0 5.541918994822481e-07
of O 0 9.811819836613722e-07
intron O 0 0.0013637440279126167
- O 0 5.813005554955453e-05
exon O 0 4.04109523515217e-05
borders O 0 1.5125292520679068e-06
. O 0 1.061110879163607e-06

We O 0 1.374814360133314e-06
have O 0 3.4574775042983674e-08
also O 0 1.4771118550527262e-08
mapped O 0 1.4951686466702085e-07
two O 0 6.55148202355349e-09
highly O 0 1.0288096063959529e-07
homologous O 0 4.7028734684317897e-07
processed O 0 1.856918601106372e-07
pseudogenes O 0 2.970534524138202e-06
, O 0 1.6257460799806722e-07
UBE3AP1 O 1 0.7885581254959106
and O 0 3.0406457085518923e-07
UBE3AP2 O 1 0.9953204989433289
, O 0 8.129788398036908e-08
to O 0 1.9541623430541222e-08
chromosomes O 0 1.4408792026188166e-07
2 O 0 2.946453747654232e-08
and O 0 2.9506983523219787e-09
21 O 0 1.0373831571541814e-07
, O 0 1.1106759068013616e-08
respectively O 0 8.913783489106208e-08
, O 0 6.08632699794498e-09
and O 0 2.492987594138185e-09
determined O 0 5.2904571390399724e-08
their O 0 5.8670931224469314e-08
genomic O 0 2.5566553176759044e-06
organization O 0 7.682394880248467e-07
. O 0 2.0755203422595514e-06

These O 0 3.75083828885181e-07
results O 0 8.312554200529121e-08
will O 0 4.098163142174371e-09
form O 0 4.749574511464516e-09
the O 0 9.904987940956289e-09
basis O 0 3.031727047186905e-08
for O 0 3.0520266314226774e-09
studies O 0 4.712759604785788e-08
of O 0 3.2702597962952495e-08
mutation O 0 4.476135018194327e-08
and O 0 1.9433718634331854e-08
imprinting O 0 3.066292993025854e-05
of O 0 2.257069900224451e-05
UBE3A O 1 0.9999125003814697
. O 0 2.2627249563811347e-05

Mutation O 0 6.814831976953428e-06
spectrum O 0 1.0435803687869338e-06
and O 0 1.7444803290800337e-07
genotype O 0 1.1690149221976753e-05
- O 0 1.3685425983567256e-05
phenotype O 0 2.8627191568375565e-06
analyses O 0 1.162398461929115e-06
in O 0 3.4351648992014816e-07
Cowden B-Disease 1 0.9999679327011108
disease I-Disease 0 0.00014052620099391788
and O 0 7.477335657313233e-07
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
, O 0 2.4148553734448797e-07
two O 0 5.918807346461108e-07
hamartoma B-Disease 1 0.9999768733978271
syndromes I-Disease 0 0.04267391562461853
with O 0 1.1985847777395975e-05
germline O 1 0.9999998807907104
PTEN O 1 0.9999988079071045
mutation O 0 2.3291595425689593e-05
. O 0 4.929837814415805e-06

The O 0 0.0007519466453231871
tumour B-Disease 1 1.0
suppressor O 1 0.9999728202819824
gene O 0 0.00020559041877277195
PTEN O 0 0.003174510784447193
, O 0 7.49377022657427e-08
which O 0 1.1747913752913064e-08
maps O 0 6.634732017118949e-07
to O 0 2.673098435934662e-07
10q23 O 0 0.0003941380127798766
. O 0 1.0403079613752197e-05

3 O 0 5.158871772437124e-06
and O 0 1.7454689782425703e-07
encodes O 0 1.2436771612556186e-06
a O 0 1.9200649603590136e-07
403 O 0 7.76145611780521e-07
amino O 0 5.208545985624369e-07
acid O 0 4.067747454428172e-07
dual O 0 1.8763358866635826e-06
specificity O 0 2.8571387247211533e-06
phosphatase O 0 0.1472916603088379
( O 0 2.911438059527427e-06
protein O 0 1.9622168565547327e-06
tyrosine O 0 2.1979553821438458e-06
phosphatase O 0 5.883291123609524e-06
; O 0 1.4169716067158333e-08
PTPase O 0 2.6820081984624267e-05
) O 0 3.2902875091167516e-08
, O 0 3.950308968825311e-09
was O 0 7.19126802550818e-08
shown O 0 1.6111489031800375e-08
recently O 0 1.9762811831469662e-08
to O 0 3.751451593814181e-09
play O 0 6.795569618134323e-08
a O 0 1.0787179860471952e-07
broad O 0 7.498488940882453e-08
role O 0 5.083127803118259e-07
in O 0 1.7685837860881293e-07
human O 0 3.598182502173586e-06
malignancy B-Disease 1 0.9809982180595398
. O 0 6.244919859454967e-06

Somatic O 1 0.9893671870231628
PTEN O 1 0.8314346671104431
deletions O 0 4.346496552898316e-06
and O 0 5.878563413830307e-08
mutations O 0 5.490094423521441e-08
were O 0 2.9111713928386962e-08
observed O 0 9.960976399270294e-08
in O 0 6.672220109749105e-08
sporadic B-Disease 0 0.0007729358621872962
breast I-Disease 1 0.9966040849685669
, I-Disease 0 1.1318668839521706e-05
brain I-Disease 1 1.0
, I-Disease 0 2.3803781004971825e-05
prostate I-Disease 1 1.0
and I-Disease 1 0.8973559141159058
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.999998927116394
lines O 0 5.392486741584435e-07
and O 0 4.270666931205369e-09
in O 0 9.289536251344543e-09
several O 0 2.9306537641105024e-08
primary O 0 0.004811608698219061
tumours B-Disease 1 1.0
such O 0 1.305587602473679e-07
as O 0 0.0020580205600708723
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999992847442627
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999997615814209
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.4391138553619385

In O 0 2.830217454174999e-06
addition O 0 6.878899512230419e-07
, O 0 9.712520068205777e-07
PTEN O 0 0.000489638710860163
was O 0 1.3163637504476355e-06
identified O 0 1.4775267231925682e-07
as O 0 1.9275645968264143e-08
the O 0 3.2821638740188064e-08
susceptibility O 0 1.9017501529106084e-07
gene O 0 2.1445947240295027e-08
for O 0 1.240192837315135e-08
two O 0 1.3804768741465523e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.999675989151001
( O 0 5.130904355610255e-06
CD B-Disease 0 3.867736813845113e-05
; O 0 3.6684920701191004e-07
MIM O 0 0.017353776842355728
158350 O 0 8.351586438948289e-05
) O 0 2.705923805024213e-07
and O 0 1.0754126122947127e-07
Bannayan B-Disease 0 0.21963724493980408
- I-Disease 0 0.03698268160223961
Zonana I-Disease 1 0.9999920129776001
( I-Disease 0 2.431057691865135e-05
BZS I-Disease 1 0.7959326505661011
) I-Disease 0 4.555243435788725e-07
or I-Disease 0 2.5678266979412e-07
Ruvalcaba I-Disease 0 0.00017810937424656004
- I-Disease 0 1.3185386706027202e-05
Riley I-Disease 0 0.0003331034386064857
- I-Disease 0 0.001600565854460001
Smith I-Disease 0 0.4994143545627594
syndrome I-Disease 1 0.9999971389770508
( O 0 0.00033950398210436106
MIM O 1 0.9999994039535522
153480 O 1 0.9992958307266235
) O 0 1.8937822460429743e-05
. O 0 7.91465845395578e-06

Constitutive O 0 0.0005929534672759473
DNA O 0 3.88479238608852e-05
from O 0 1.1175416148034856e-06
37 O 0 2.712685272854287e-06
CD B-Disease 0 5.923600838286802e-06
families O 0 5.222393184567409e-08
and O 0 3.277709836879694e-08
seven O 0 1.9567471554182703e-06
BZS B-Disease 1 0.9979403614997864
families O 0 1.608597983704385e-07
was O 0 1.7705224308883771e-06
screened O 0 2.0846571260335622e-06
for O 0 1.0132688430530834e-06
germline O 0 0.00820996519178152
PTEN O 0 0.06908758729696274
mutations O 0 6.421621492336271e-06
. O 0 3.5969819691672456e-06

PTEN O 0 0.06119187921285629
mutations O 0 2.5226702291547554e-06
were O 0 3.8559403492399724e-07
identified O 0 4.913185875921044e-07
in O 0 5.5078196226077125e-08
30 O 0 9.447263948914042e-08
of O 0 1.345599827118349e-07
37 O 0 3.102474863680982e-07
( O 0 7.521980904812153e-08
81 O 0 4.5100202328285377e-07
% O 0 3.701684647694492e-08
) O 0 1.0765655922284623e-08
CD B-Disease 0 1.7996757151195197e-07
families O 0 2.4762873973571686e-09
, O 0 2.173373481184626e-09
including O 0 6.014202913462441e-09
missense O 0 3.199346565452288e-07
and O 0 8.831432474210033e-09
nonsense O 0 5.266529115033336e-06
point O 0 9.046755167219089e-07
mutations O 0 2.1598077992734943e-08
, O 0 5.4320947739938674e-09
deletions O 0 1.0068882971836501e-07
, O 0 1.6369140709571184e-08
insertions O 0 6.584048151125899e-07
, O 0 3.243820501097616e-08
a O 0 4.109441249511292e-07
deletion O 0 1.9119472199236043e-05
/ O 0 5.3800114983459935e-05
insertion O 0 1.2068224350514356e-05
and O 0 8.274990364043333e-07
splice O 0 0.0002445982245262712
site O 0 2.9754181014141068e-05
mutations O 0 2.9786590403091395e-06
. O 0 2.3203347154776566e-06

These O 0 4.4814572675022646e-07
mutations O 0 2.3768454582295817e-07
were O 0 1.1875895467028386e-07
scattered O 0 1.1800423749264155e-07
over O 0 1.8415766689372504e-08
the O 0 8.489449498938484e-08
entire O 0 1.0076238368128543e-06
length O 0 8.878759558683669e-07
of O 0 1.7047991605068091e-06
PTEN O 0 0.0007162398542277515
, O 0 1.2628312617835036e-08
with O 0 3.545575388841371e-09
the O 0 2.581428759640403e-08
exception O 0 3.845385876388718e-08
of O 0 2.2689919276785986e-08
the O 0 2.541402466249565e-08
first O 0 1.2467178578390303e-07
, O 0 6.444859224075117e-08
fourth O 0 1.1885236972375424e-06
and O 0 7.266731216759581e-08
last O 0 2.085671212626039e-06
exons O 0 1.755061384756118e-05
. O 0 3.9861906770966016e-06

A O 0 9.567967208568007e-05
hot O 0 1.3072016372461803e-05
spot O 0 7.922541954030748e-06
for O 0 5.577667252509855e-07
PTEN O 0 0.0003386397729627788
mutation O 0 2.1064631994249794e-07
in O 0 4.478679827002452e-08
CD B-Disease 0 1.2775387858710019e-06
was O 0 2.2453741621575318e-07
identified O 0 9.661952304895749e-08
in O 0 3.9879054725133756e-08
exon O 0 7.261354539878084e-07
5 O 0 3.945476478861565e-08
that O 0 1.6571692906808266e-09
contains O 0 1.3416896926798927e-08
the O 0 7.828457881942086e-08
PTPase O 0 0.002674305345863104
core O 0 9.030903129314538e-06
motif O 0 5.114979444442724e-07
, O 0 5.571423766781436e-09
with O 0 1.5978600664823261e-09
13 O 0 2.6195758451308393e-08
of O 0 1.807528882125098e-08
30 O 0 3.7023909271738376e-08
( O 0 1.9295987030432116e-08
43 O 0 6.626752480087816e-08
% O 0 1.9221824132387155e-08
) O 0 7.487880537837555e-09
CD B-Disease 0 1.0089202362451033e-07
mutations O 0 5.438864469908822e-09
identified O 0 1.7406291519250772e-08
in O 0 1.7860957157722623e-08
this O 0 2.935452130259364e-07
exon O 0 3.352551721036434e-05
. O 0 2.672731397979078e-06

Seven O 0 2.2106372853158973e-05
of O 0 5.200706254981924e-06
30 O 0 1.8958987766382052e-06
( O 0 2.691798783871491e-07
23 O 0 8.680348173584207e-07
% O 0 4.2587444681885245e-08
) O 0 6.449750955539457e-09
were O 0 8.553124430932257e-09
within O 0 1.908672153660973e-08
the O 0 9.153634294989388e-08
core O 0 2.0421889530553017e-06
motif O 0 2.1202468758474424e-07
, O 0 1.6310106598638185e-09
the O 0 5.1206670015346845e-09
majority O 0 2.668145260287247e-09
( O 0 4.660002161926968e-09
five O 0 4.136478271021815e-09
of O 0 1.9092329495151716e-08
seven O 0 2.9661270772862736e-08
) O 0 9.602862505175835e-09
of O 0 9.09305608587374e-09
which O 0 2.4447595059484684e-09
were O 0 3.941151760500361e-08
missense O 0 1.3369073030844447e-06
mutations O 0 2.4563572509350706e-08
, O 0 8.30855650946205e-09
possibly O 0 2.380127739343152e-07
pointing O 0 1.274065084544418e-06
to O 0 1.2310768404688588e-08
the O 0 7.929020995334213e-08
functional O 0 8.221994107771025e-07
significance O 0 6.544546522491146e-07
of O 0 1.5759600557885278e-07
this O 0 7.368730337020679e-08
region O 0 1.4674247950097197e-06
. O 0 2.292580120411003e-06

Germline O 1 0.999982476234436
PTEN O 1 0.654577374458313
mutations O 0 2.0571426375681767e-06
were O 0 1.6336865371613385e-07
identified O 0 2.009286532711485e-07
in O 0 2.1762907920219732e-08
four O 0 1.5420617671679793e-08
of O 0 3.02824219033937e-08
seven O 0 7.056374329295068e-08
( O 0 2.7569942062655173e-07
57 O 0 5.009577307646396e-06
% O 0 1.694692173259682e-06
) O 0 1.7962718175112968e-06
BZS B-Disease 1 0.652535080909729
families O 0 2.51292590291996e-07
studied O 0 7.404963525914354e-06
. O 0 3.8635562304989435e-06

Interestingly O 0 5.9789490478578955e-05
, O 0 1.2617506683909596e-07
none O 0 1.5835955480270059e-07
of O 0 5.339767383816252e-08
these O 0 1.4466726483419734e-08
mutations O 0 8.713692523087957e-08
was O 0 1.1341512617946137e-06
observed O 0 5.77160562897916e-07
in O 0 1.8212074337498052e-07
the O 0 2.2838776203570887e-06
PTPase O 1 0.9994845390319824
core O 0 0.00033129219082184136
motif O 0 5.3497959015658125e-05
. O 0 4.0592399273009505e-06

It O 0 5.476544515659043e-07
is O 0 8.689428199204485e-08
also O 0 2.931089859714575e-08
worthy O 0 3.680894451463246e-07
of O 0 1.3077982430331758e-07
note O 0 1.4622111166318064e-07
that O 0 5.081438381182579e-09
a O 0 3.406342230505288e-08
single O 0 4.310917844918549e-08
nonsense O 0 9.70272594713606e-07
point O 0 2.2290055312623736e-07
mutation O 0 2.0493395425091876e-08
, O 0 7.886725050809673e-09
R233X O 0 1.3912588201492326e-06
, O 0 1.2224568024521432e-08
was O 0 1.5897752803084586e-07
observed O 0 4.198496128537954e-08
in O 0 5.738463926263648e-09
the O 0 6.060299995169771e-08
germline O 0 4.183407327218447e-06
DNA O 0 3.8383885225812264e-07
from O 0 2.3454019171254004e-08
two O 0 1.2527265447204172e-08
unrelated O 0 8.980968004834722e-07
CD B-Disease 0 3.0682772376167122e-06
families O 0 5.2146990725532305e-08
and O 0 8.924075700633693e-08
one O 0 3.658263040051679e-06
BZS B-Disease 1 0.999660849571228
family O 0 3.881451993947849e-05
. O 0 8.344311936525628e-06

Genotype O 0 0.0007002961938269436
- O 0 3.8245812902459875e-05
phenotype O 0 1.8339444523007842e-06
studies O 0 7.550672620482146e-08
were O 0 1.6735221208818984e-08
not O 0 2.426021161738845e-09
performed O 0 5.347737896954641e-08
on O 0 3.659270575440132e-08
this O 0 1.4901486267149266e-08
small O 0 3.9332743284603566e-08
group O 0 8.493482539506658e-08
of O 0 2.0787449557246873e-06
BZS B-Disease 1 0.9999502897262573
families O 0 2.839542048604926e-06
. O 0 4.15814929510816e-06

However O 0 2.7576936645345995e-06
, O 0 5.147413162376324e-07
genotype O 0 3.99416194341029e-06
- O 0 1.6715925994503777e-06
phenotype O 0 6.049618264114542e-07
analysis O 0 1.5101812778084422e-07
inthe O 0 4.316860668041045e-06
group O 0 4.327534597337035e-08
of O 0 5.950161963141909e-08
CD B-Disease 0 2.7967594178335276e-06
families O 0 9.692477043188319e-09
revealed O 0 6.898372362229566e-08
two O 0 3.0618219071243402e-09
possible O 0 1.640164271066169e-08
associations O 0 1.2255946479911017e-08
worthy O 0 2.8239307425792504e-07
of O 0 1.675010850021863e-07
follow O 0 1.97192164819171e-07
- O 0 6.078278715904162e-07
up O 0 8.47810639470481e-08
in O 0 4.177902113156051e-08
independent O 0 2.3863393039391667e-07
analyses O 0 2.5528786409267923e-06
. O 0 2.526146545278607e-06

The O 0 3.6114317936153384e-06
first O 0 4.973888962922501e-07
was O 0 1.4956607401472866e-06
an O 0 1.3795896336432634e-07
association O 0 1.365300761335675e-07
noted O 0 8.850052779507678e-08
in O 0 1.4743450904575184e-08
the O 0 3.199889064831041e-08
group O 0 3.763177502946746e-08
of O 0 1.05248211923481e-07
CD B-Disease 0 1.1928844287467655e-05
families O 0 7.08219545231259e-08
with O 0 4.5955349037285487e-07
breast B-Disease 1 0.9999996423721313
disease I-Disease 1 0.999956488609314
. O 0 3.173051300109364e-05

A O 0 4.107115091755986e-05
correlation O 0 4.522063136391807e-06
was O 0 5.744785198658064e-07
observed O 0 1.4876006559916277e-07
between O 0 1.7151572606621812e-08
the O 0 3.627367206604504e-08
presence O 0 3.4222719591525674e-07
/ O 0 6.096755896578543e-06
absence O 0 1.289170654672489e-06
of O 0 1.4216461750038434e-06
a O 0 6.499845312646357e-06
PTEN O 0 0.0029345888178795576
mutation O 0 1.4571739370694559e-08
and O 0 9.777755272111222e-10
the O 0 5.405614622588928e-09
type O 0 2.0277569490190217e-07
of O 0 1.1060440101573477e-06
breast O 1 0.6798902750015259
involvement O 1 0.7715449929237366
( O 0 0.0006337562226690352
unaffected O 0 0.0007596969953738153
versus O 0 0.001583712175488472
benign O 0 0.19051864743232727
versus O 0 0.0011915108188986778
malignant O 1 0.999535322189331
) O 0 4.693491518992232e-06
. O 0 3.7281961340340786e-06

Specifically O 0 2.8679573915724177e-06
and O 0 3.876077769859876e-08
more O 0 5.455373486284998e-09
directly O 0 5.728340823907274e-08
, O 0 1.3205159632434516e-08
an O 0 3.654499636240871e-08
association O 0 4.1218630286721236e-08
was O 0 4.357152363354544e-07
also O 0 1.105915359289611e-08
observed O 0 3.914981760999581e-08
between O 0 1.0473711675729191e-08
the O 0 1.1109005271237038e-08
presence O 0 2.492342332516273e-08
of O 0 5.779085654467053e-08
a O 0 1.1316556083329488e-06
PTEN O 1 0.6325768828392029
mutation O 0 6.080788921281055e-07
and O 0 6.37077050669177e-07
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 9.81738994596526e-05

Secondly O 0 0.0009986602235585451
, O 0 4.4990699166191916e-07
there O 0 1.0237593528472644e-07
appeared O 0 1.7596704537936603e-07
to O 0 1.3902647921781863e-08
be O 0 1.4143686222212182e-08
an O 0 1.0804085803783892e-07
interdependent O 0 6.926824880792992e-06
association O 0 6.253210926843167e-08
between O 0 1.0636441771794125e-07
mutations O 0 1.8377456001417158e-07
upstream O 0 1.5962668840074912e-06
and O 0 9.028473968442086e-09
within O 0 1.0789567284064105e-07
the O 0 5.802489795314614e-07
PTPase O 1 0.9984968900680542
core O 0 2.7073456294601783e-05
motif O 0 1.2027629736621748e-06
, O 0 1.039232344623997e-08
the O 0 2.7895877607875263e-08
core O 0 3.0127682748570805e-07
motif O 0 1.611207949281379e-07
containing O 0 1.5610787329478626e-08
the O 0 1.3214481064949268e-08
majority O 0 5.5289728351226586e-09
of O 0 6.597014845510785e-08
missense O 0 2.4861735710146604e-06
mutations O 0 5.269228608995036e-08
, O 0 1.4270285397799398e-08
and O 0 3.45890049935349e-09
the O 0 5.5384010266834593e-08
involvement O 0 5.507041578312055e-07
of O 0 5.324116258975664e-08
all O 0 7.41965378026066e-09
major O 0 3.444314131684223e-07
organ O 0 0.2085420936346054
systems O 0 6.233244494069368e-05
( O 0 7.3663231887621805e-06
central O 0 0.0016323017189279199
nervous O 0 0.0028088039252907038
system O 0 1.0332081501474022e-06
, O 0 2.1778660084237345e-06
thyroid O 1 1.0
, O 0 0.021869756281375885
breast O 1 1.0
, O 0 0.02011490985751152
skin O 1 0.9999992847442627
and O 1 0.7741199731826782
gastrointestinal O 1 1.0
tract O 1 1.0
) O 1 0.9237844944000244
. O 0 0.0001779830636223778

However O 0 1.1286140306765446e-06
, O 0 3.756665734044873e-08
these O 0 4.679026055498525e-09
observations O 0 1.9325017319715698e-07
would O 0 6.790306539272706e-09
need O 0 6.81404888069892e-09
to O 0 4.334512304637883e-09
be O 0 6.234677663030652e-09
confirmed O 0 1.616279732274961e-08
by O 0 5.192543284238127e-09
studying O 0 1.0179179810165806e-07
a O 0 1.2753115896657619e-08
larger O 0 3.2748335154764163e-09
number O 0 2.4604307480302623e-09
of O 0 2.1186961518537828e-08
CD B-Disease 0 1.4683486142530455e-06
families O 0 1.6895720023057947e-07
. O 0 1.0782011941046221e-06

Molecular O 1 0.9999922513961792
defects O 1 0.9828961491584778
leading O 0 2.7635674086923245e-06
to O 0 6.333164748184572e-08
human O 0 1.045016574607871e-06
complement B-Disease 0 0.4459751844406128
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.920644135429029e-07
an O 0 1.756039438305379e-07
African O 0 4.5154697545513045e-06
- O 0 5.299958957039053e-06
American O 0 1.877930912996817e-06
family O 0 8.294023245980497e-07
. O 0 8.50950073072454e-07

Complement B-Disease 1 0.6868230700492859
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.008043133653700352
C6D B-Disease 1 0.9999995231628418
) O 0 1.5523130514338845e-06
was O 0 5.227742349234177e-06
diagnosed O 0 3.5860625757777598e-06
in O 0 1.9206980894637127e-08
a O 0 1.3564444145686139e-07
16 O 0 2.5818826543400064e-07
- O 0 2.921432269431534e-07
year O 0 1.23780409921892e-07
- O 0 4.843799388254411e-07
old O 0 5.627438895317027e-06
African O 0 2.421192402835004e-05
- O 0 1.3388387742452323e-05
American O 0 1.4835460433459957e-06
male O 0 2.8587774636434915e-07
with O 0 6.564468435499293e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.754341039690189e-05

The O 0 2.4975848646136e-05
patients O 0 1.6104288533824729e-06
father O 0 3.1912211397866486e-06
and O 0 7.210840635707427e-08
two O 0 1.4573579676380177e-07
brothers O 0 6.059786755940877e-05
also O 0 3.664820553694881e-07
had O 0 3.419542053961777e-06
C6D B-Disease 1 0.9999794960021973
, O 0 8.898580716731885e-08
but O 0 1.2133369864386623e-08
gave O 0 8.370722781592121e-08
no O 0 1.0875000100440957e-07
history O 0 1.752162916091038e-06
of O 0 2.305935777258128e-05
meningitis B-Disease 1 0.9999991655349731
or O 0 1.630357473914046e-05
other O 0 2.491528448445024e-06
neisserial B-Disease 1 1.0
infection I-Disease 1 0.9999144077301025
. O 0 2.1502452000277117e-05

By O 0 1.8946842601508251e-06
using O 0 6.770223990315571e-07
exon O 0 7.184191872511292e-06
- O 0 3.476177994343743e-07
specific O 0 4.176794732302369e-08
polymerase O 0 1.138407696998911e-06
chain O 0 8.903690229544736e-08
reaction O 0 1.4283575211493371e-08
( O 0 1.949951489166324e-08
PCR O 0 7.74383863699768e-08
) O 0 1.6998049190419806e-08
/ O 0 1.6567283012136613e-07
single O 0 3.988460761661372e-08
- O 0 1.7942123520242603e-07
strand O 0 2.4373818519052293e-07
conformation O 0 7.302676152676213e-08
polymorphism O 0 3.2510612868463795e-08
as O 0 1.585709674678526e-09
a O 0 9.020401314785431e-09
screening O 0 8.74755912150249e-09
step O 0 1.4219043720231639e-08
and O 0 2.8066646784452587e-09
nucleotide O 0 4.690260482220765e-07
sequencing O 0 1.0183607912495063e-07
of O 0 3.486549360331992e-08
target O 0 6.123251949929909e-08
exons O 0 4.1560692665143506e-08
, O 0 1.5175283252233385e-09
we O 0 2.7344730924028227e-09
determined O 0 1.2716850683602843e-08
that O 0 7.027400439341136e-09
the O 0 6.140046338032334e-08
proband O 0 2.7019239496439695e-05
was O 0 2.655388698258321e-06
a O 0 1.1559823178686202e-06
compound O 0 1.0056759492726997e-05
heterozygote O 0 2.1789298898511333e-06
for O 0 6.097623383993778e-08
two O 0 2.989790175433882e-07
C6 O 0 0.0018556170398369431
gene O 0 2.8353720153972972e-06
mutations O 0 1.7134769905169378e-06
. O 0 2.457065875205444e-06

The O 0 9.096118446905166e-06
first O 0 9.193052505906962e-07
, O 0 2.7170923999619845e-07
1195delC O 0 9.696263077785261e-06
located O 0 6.295732077887806e-07
in O 0 9.816221080427567e-08
exon O 0 2.849587417586008e-06
7 O 0 3.2226225243903173e-07
, O 0 9.604768536064512e-09
is O 0 3.733491293900215e-09
a O 0 6.597855595202873e-09
novel O 0 3.699736339513038e-08
mutation O 0 6.959426368524646e-09
, O 0 2.05053485302642e-09
while O 0 4.6539088138786155e-09
the O 0 2.2889960149541366e-08
second O 0 1.826911386615393e-07
, O 0 4.769949413230279e-08
1936delG O 0 1.6012954802135937e-06
in O 0 1.1008963696212959e-07
exon O 0 8.566154861000541e-07
12 O 0 8.050015054550386e-08
, O 0 4.385940943762989e-09
has O 0 1.3360172967935569e-09
been O 0 3.259193137594707e-09
described O 0 2.1438792074945923e-08
before O 0 7.354380215929268e-08
to O 0 8.573218224228185e-08
cause O 0 2.6693992367654573e-06
C6D B-Disease 1 0.9692708849906921
in O 0 1.0249218007629679e-07
an O 0 1.329181174014593e-07
unrelated O 0 2.212664412581944e-06
African O 0 4.029471710964572e-06
- O 0 7.036401711957296e-06
American O 0 2.3908960429253057e-06
individual O 0 3.8548083125533594e-07
. O 0 9.836375056693214e-07

Both O 0 7.780687383274199e-07
mutations O 0 4.416769456838665e-07
result O 0 1.4003838089138299e-07
in O 0 3.162681991852878e-07
premature O 0 2.8749498596880585e-05
termination O 0 5.620420051855035e-05
codons O 0 2.816044980136212e-05
and O 0 2.014831352425972e-06
C6 O 0 0.08994081616401672
null O 0 5.0269019993720576e-05
alleles O 0 6.063559339963831e-06
. O 0 3.3154565244331025e-06

Allele O 0 1.5303223335649818e-05
- O 0 2.986740355481743e-06
specific O 0 1.1093361251823808e-07
PCR O 0 8.664650295031606e-07
indicated O 0 7.278868707771835e-08
that O 0 5.918748158251219e-09
the O 0 6.703319144207853e-08
probands O 0 3.172342985635623e-05
two O 0 6.434038368752226e-08
brothers O 0 3.763841959880665e-06
also O 0 5.501604150026651e-08
inherited O 0 2.0584691355907125e-06
the O 0 1.9460914302271703e-07
1195delC O 0 3.83167707695975e-06
mutation O 0 2.2050038239740388e-08
from O 0 5.170504469020898e-09
their O 0 3.8086822584659785e-09
heterozygous O 0 1.0170835906819775e-07
mother O 0 1.2128653281706647e-07
and O 0 7.3718204873785e-09
the O 0 2.3012472638583858e-07
1936delG O 0 6.209512775967596e-06
mutation O 0 7.302718074697623e-08
from O 0 2.0830338343102994e-08
their O 0 2.8940146279410328e-08
homozygous O 0 5.288692364047165e-07
father O 0 5.236814558884362e-06
. O 0 5.77753098696121e-07
. O 0 2.9050479497527704e-06

PAX6 O 0 0.4932717978954315
mutations O 0 0.00011031014582840726
reviewed O 0 0.00014452420873567462
. O 0 3.3137883292511106e-05

Mutations O 0 6.341221887851134e-05
in O 0 2.505345264580683e-06
PAX6 O 0 0.011736162938177586
are O 0 1.1047984571632696e-07
responsible O 0 6.619411578867584e-07
for O 0 1.4224082178770914e-07
human O 0 2.08721321541816e-05
aniridia B-Disease 1 1.0
and O 0 4.525237073949029e-08
have O 0 4.111974760689918e-09
also O 0 4.812771070561439e-09
been O 0 4.3632706336893534e-09
found O 0 7.119207445782649e-09
in O 0 8.880010504697111e-09
patients O 0 9.114553556344163e-09
with O 0 4.058772518078513e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 7.479050509573426e-06
with O 0 0.005510789342224598
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.000354523683199659
with O 0 0.0006958942976780236
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999895095825195
keratitis I-Disease 1 0.9999985694885254
, O 0 5.800498001917731e-07
and O 0 2.5606860276639054e-07
with O 0 1.4254665984481107e-05
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.4979776442050934

No O 0 2.1910864234087057e-05
locus O 0 2.3933778720675036e-05
other O 0 3.577327234438599e-08
than O 0 5.0348333502370224e-08
chromosome O 0 8.46216244099196e-06
11p13 O 0 5.0417078455211595e-05
has O 0 5.0622865899185854e-08
been O 0 1.321534313092343e-07
implicated O 0 5.4236675168795045e-06
in O 0 1.3324853398444247e-06
aniridia B-Disease 1 1.0
, O 0 6.594466981368896e-07
and O 0 2.1353503143473063e-07
PAX6 O 1 0.9943431615829468
is O 0 8.784363814129392e-08
clearly O 0 7.12066281494117e-08
the O 0 1.7510684457988646e-08
major O 0 4.693669808375489e-08
, O 0 5.25858379063493e-09
if O 0 2.184682434958063e-09
not O 0 2.5562578720439433e-09
only O 0 1.009863215273299e-08
, O 0 5.192179486357418e-08
gene O 0 6.109673336140986e-07
responsible O 0 4.553120561467949e-06
. O 0 6.166057119116886e-06

Twenty O 0 0.00011233121040277183
- O 0 6.085625955165597e-06
eight O 0 2.5818184212766937e-07
percent O 0 1.341292374945624e-07
of O 0 6.413124253867863e-08
identified O 0 5.685952260137128e-07
PAX6 O 0 7.919564086478204e-05
mutations O 0 4.628637384485046e-08
are O 0 7.587829919941669e-09
C O 0 2.457298614899628e-05
- O 0 6.061203021090478e-05
T O 0 1.0611324796627741e-05
changes O 0 4.1372143044782206e-08
at O 0 1.180050730908988e-06
CpG O 0 2.236010186607018e-05
dinucleotides O 0 4.56303177998052e-06
, O 0 1.2515181779804152e-08
20 O 0 1.6909286415511815e-08
% O 0 2.336689064463826e-09
are O 0 1.50131337917081e-10
splicing O 0 1.5517040097279278e-08
errors O 0 3.0983997589828505e-08
, O 0 1.7781137673367198e-09
and O 0 1.0307669162656907e-09
more O 0 7.1658906586336e-10
than O 0 1.3010869048812879e-09
30 O 0 3.045945007329465e-08
% O 0 1.51481067689474e-08
are O 0 2.189279202369221e-09
deletion O 0 3.699264254919399e-07
or O 0 8.688019903502209e-08
insertion O 0 2.3236341348820133e-06
events O 0 3.96563928006799e-06
. O 0 2.5476206246821675e-06

There O 0 1.0099141945829615e-05
is O 0 8.381408633795218e-07
a O 0 7.796627414791146e-07
noticeably O 0 3.865118742396589e-06
elevated O 0 3.262247446400579e-06
level O 0 4.0642382259648e-07
of O 0 6.499521276737141e-08
mutation O 0 4.6449372348433826e-08
in O 0 1.5217318960480952e-08
the O 0 3.003427551107052e-08
paired O 0 1.4942051507205178e-07
domain O 0 1.5544388531907316e-07
compared O 0 9.067234074677799e-09
with O 0 1.1677001587884206e-09
the O 0 1.5597512614817788e-08
rest O 0 3.899279477082018e-08
of O 0 1.5165547040396632e-07
the O 0 4.916790317111008e-07
gene O 0 1.440169285160664e-06
. O 0 1.0743440270744031e-06

Increased O 0 2.2233924028114416e-05
mutation O 0 1.1451828640929307e-06
in O 0 2.0805886435937282e-07
the O 0 3.103871506482392e-07
homeodomain O 0 8.568311750423163e-05
is O 0 5.971524075221168e-08
accounted O 0 4.0082898067339556e-07
for O 0 1.2324676390562672e-08
by O 0 4.8538151276034114e-08
the O 0 1.1263603028055513e-06
hypermutable O 0 0.0008576329564675689
CpG O 0 0.00031315512023866177
dinucleotide O 0 0.00013564748223870993
in O 0 8.881909820956935e-07
codon O 0 2.281855086039286e-05
240 O 0 7.3614210123196244e-06
. O 0 2.275259930684115e-06

Very O 0 1.98589009414718e-06
nearly O 0 2.6832535127141455e-07
all O 0 1.1262679677770393e-08
mutations O 0 2.9514653832052318e-08
appear O 0 3.3406298172167226e-08
to O 0 2.0834429292904133e-08
cause O 0 1.7013413753375062e-06
loss O 0 6.201778433023719e-06
of O 0 2.292820681759622e-06
function O 0 1.7195371810885263e-06
of O 0 1.5357913696334435e-07
the O 0 6.417321429807998e-08
mutant O 0 1.9491859859499527e-07
allele O 0 1.0770339287091701e-08
, O 0 4.6315029589294454e-10
and O 0 1.5152022692088707e-10
more O 0 1.690485113003959e-10
than O 0 5.058691243675639e-10
80 O 0 1.4504523804248493e-08
% O 0 6.072088165609557e-09
of O 0 3.471327403303803e-08
exonic O 0 4.896271093457472e-06
substitutions O 0 1.2412488104018848e-07
result O 0 1.1875986416498563e-07
in O 0 1.977465728941752e-07
nonsense O 0 2.2085845557739958e-05
codons O 0 1.9820961824734695e-05
. O 0 5.867770596523769e-06

In O 0 2.449382691338542e-06
a O 0 9.243953513760061e-07
gene O 0 6.370138549982585e-08
with O 0 4.589961299927836e-09
such O 0 4.707294998240741e-09
extraordinarily O 0 1.6696632201274042e-06
high O 0 1.526695285747337e-07
sequence O 0 9.259079547518922e-08
conservation O 0 1.3606676674271512e-08
throughout O 0 1.2336101029575275e-09
evolution O 0 1.5885076365407258e-08
, O 0 6.077252590053206e-10
there O 0 2.0182786553135657e-09
are O 0 1.3146196353730488e-09
presumed O 0 1.2022927649013582e-06
undiscovered O 0 0.00020493964257184416
missense O 0 2.0883701381535502e-06
mutations O 0 7.835685877921605e-09
, O 0 8.167891918375858e-10
these O 0 2.4825000388695173e-10
are O 0 3.9919881289485204e-10
hypothesized O 0 3.0915639825934704e-08
to O 0 1.9872041789881223e-09
exist O 0 1.7648797978608854e-08
in O 0 2.32799326482791e-08
as O 0 7.190966044845482e-08
- O 0 1.2806482345695258e-06
yet O 0 2.6659392915462377e-07
unidentified O 0 1.4542062672262546e-05
phenotypes O 0 1.0602519751046202e-06
. O 0 7.331691165290977e-08
. O 0 4.2202944428026967e-07

Genetic O 0 0.003039967268705368
heterogeneity O 0 5.4934567742748186e-05
and O 0 2.6240920192321937e-07
penetrance O 0 3.649948484962806e-05
analysis O 0 3.4912548585452896e-07
of O 0 2.5576986217856756e-07
the O 0 1.0309169056199607e-06
BRCA1 O 0 1.5148595593927894e-05
and O 0 1.4354330346577626e-07
BRCA2 O 0 7.372480467893183e-05
genes O 0 3.607094868129934e-06
in O 0 4.9893469622475095e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 2.6200259526376612e-05
. O 0 2.4941884475992993e-05

The O 0 0.23789182305335999
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9999966621398926
Consortium O 0 0.0012579041067510843
. O 0 1.1138941772514954e-05

The O 0 2.6911516215477604e-06
contribution O 0 2.869834588636877e-06
of O 0 2.5994413590524346e-06
BRCA1 O 0 2.2621165044256486e-05
and O 0 2.1250323811727867e-07
BRCA2 O 0 0.0006652516894973814
to O 0 7.171131528593833e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.3479556143283844
assessed O 0 1.002232920654933e-06
by O 0 1.482437816946458e-08
linkage O 0 2.784501305086451e-07
and O 0 6.384303641304712e-10
mutation O 0 2.558325995494215e-09
analysis O 0 7.249727485003632e-09
in O 0 4.900398753449053e-09
237 O 0 9.261658107106996e-08
families O 0 7.0030616861060935e-09
, O 0 4.073808845816984e-09
each O 0 2.1401969085843575e-09
with O 0 2.5606108344788936e-09
at O 0 1.8838686344224698e-07
least O 0 3.5902858463998655e-09
four O 0 4.530494202015234e-09
cases O 0 1.983591291221387e-09
of O 0 3.5369086504033476e-07
breast B-Disease 1 0.9978612065315247
cancer I-Disease 0 0.0004599852836690843
, O 0 1.1383428422107045e-08
collected O 0 4.0121214794908155e-08
by O 0 2.825228229141885e-08
the O 0 5.48655270904419e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.595444917678833
Consortium O 0 2.651076101756189e-05
. O 0 1.5595096556353383e-06

Families O 0 1.2759339824697236e-06
were O 0 2.0163371061698854e-07
included O 0 1.5053670665565733e-07
without O 0 1.3466691939356679e-07
regard O 0 2.292872522957623e-07
to O 0 2.7669553759324117e-08
the O 0 1.5144691190016601e-07
occurrence O 0 2.2312133296509273e-05
of O 0 0.0005502488347701728
ovarian B-Disease 1 1.0
or I-Disease 0 0.00010664412548067048
other I-Disease 0 4.516598437476205e-06
cancers I-Disease 1 0.9998018145561218
. O 0 1.5197852007986512e-05

Overall O 0 0.0007779125007800758
, O 0 5.0357643885945436e-06
disease O 0 0.00013789793592877686
was O 0 1.582679760758765e-05
linked O 0 8.78263745107688e-06
to O 0 6.18757738379827e-08
BRCA1 O 0 1.4088432180869859e-06
in O 0 1.197379617678962e-08
an O 0 1.987178599449635e-08
estimated O 0 7.025982995401137e-08
52 O 0 8.347604563141431e-08
% O 0 1.1362408791626422e-08
of O 0 9.051026594875111e-09
families O 0 2.8790378969745234e-09
, O 0 3.6837224381969236e-09
to O 0 6.907664662492152e-09
BRCA2 O 0 1.7644698857566254e-07
in O 0 1.1736222660374551e-08
32 O 0 7.289691694722933e-08
% O 0 1.1400159038998936e-08
of O 0 1.323953391363375e-08
families O 0 2.627280393241449e-09
, O 0 1.2886025579916804e-09
and O 0 5.662667001971045e-10
to O 0 2.1839074992868746e-09
neither O 0 5.199364494501424e-08
gene O 0 1.11413429593199e-08
in O 0 4.018905208624801e-09
16 O 0 2.926280195936215e-08
% O 0 7.894957576581874e-09
( O 0 8.171261001166386e-09
95 O 0 2.257750431056138e-08
% O 0 4.020193067333366e-09
confidence O 0 5.36532098749376e-08
interval O 0 8.376446771762858e-07
[ O 0 2.599934532554471e-06
CI O 0 0.001150748343206942
] O 0 4.576706373882189e-07
6 O 0 1.2321180520302732e-07
% O 0 2.989824210430925e-08
- O 0 4.162749434044599e-08
28 O 0 5.938245806191844e-08
% O 0 1.0756173729475904e-08
) O 0 3.390615122000895e-09
, O 0 1.0140395190205709e-09
suggesting O 0 3.609788379321799e-08
other O 0 8.468034273789726e-09
predisposition O 0 5.048025286669144e-06
genes O 0 1.6987926301226253e-06
. O 0 1.9051859680985217e-06

The O 0 5.118412445881404e-06
majority O 0 2.2831166290870897e-07
( O 0 4.541510350009048e-07
81 O 0 1.0904635701081133e-06
% O 0 1.0488449930790011e-07
) O 0 1.6177942541162338e-08
of O 0 4.6419966537314394e-08
the O 0 6.146741270640632e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.588485017440689e-07
were O 0 4.375866069494805e-08
due O 0 1.0425404184388753e-07
to O 0 2.006400201537417e-08
BRCA1 O 0 3.611276326864754e-07
, O 0 2.3515507319160633e-09
with O 0 5.33434629801377e-10
most O 0 9.453312577178963e-10
others O 0 4.36683400550919e-09
( O 0 1.7842740618334574e-08
14 O 0 1.391732382671762e-07
% O 0 5.730100127721016e-08
) O 0 2.4848237245578275e-08
due O 0 1.4575776674519147e-07
to O 0 2.6566249289317057e-07
BRCA2 O 0 2.705846054595895e-05
. O 0 2.5153647129627643e-06

Conversely O 0 9.590640547685325e-05
, O 0 2.189118077922103e-07
the O 0 7.655605571699198e-08
majority O 0 2.0094832464678802e-08
of O 0 8.026251663295625e-08
families O 0 2.7320030682176366e-08
with O 0 4.131528541506668e-08
male B-Disease 0 0.0004065337125211954
and I-Disease 0 5.581727009484894e-07
female I-Disease 1 0.9940081834793091
breast I-Disease 1 0.9998633861541748
cancer I-Disease 0 0.006808998063206673
were O 0 1.8459732586961763e-07
due O 0 3.6789779755963536e-07
to O 0 5.677424042005441e-08
BRCA2 O 0 1.8362651417191955e-06
( O 0 1.5537450792635354e-07
76 O 0 1.1694503427861491e-06
% O 0 1.812469605511069e-07
) O 0 1.74322806856253e-07
. O 0 4.606820880326268e-07

The O 0 3.136216946586501e-06
largest O 0 7.524089937760436e-07
proportion O 0 9.118869570556853e-08
( O 0 3.230015721555901e-08
67 O 0 1.3227372619439848e-07
% O 0 2.541189125793153e-08
) O 0 4.089495853065728e-09
of O 0 9.574551818047894e-09
families O 0 2.631533213559578e-09
due O 0 1.3307155377617619e-08
to O 0 4.7650545731414695e-09
other O 0 3.0392579564164635e-09
genes O 0 1.622144729651609e-08
was O 0 1.743874946669166e-07
found O 0 2.1825842466682843e-08
in O 0 9.015344026863659e-09
families O 0 3.962896677478511e-09
with O 0 2.0261430311308004e-09
four O 0 2.054631131898077e-08
or O 0 2.414214783641455e-08
five O 0 1.4262720782198812e-08
cases O 0 9.368076092641786e-09
of O 0 4.804666332347551e-06
female O 1 0.9998974800109863
breast B-Disease 1 0.9999890327453613
cancer I-Disease 0 0.3428848385810852
only O 0 1.1293471970930113e-06
. O 0 3.872479283018038e-06

These O 0 3.01307267136508e-07
estimates O 0 3.9628918102607713e-07
were O 0 2.924600828180246e-08
not O 0 5.964669202995765e-09
substantially O 0 1.884932601114997e-07
affected O 0 1.9355368863216427e-08
either O 0 8.536859219532289e-09
by O 0 6.152763631916969e-09
changing O 0 1.2691364759120916e-07
the O 0 5.7174254664005275e-08
assumed O 0 1.1042586720577674e-06
penetrance O 0 3.5054849831794854e-06
model O 0 1.2887095124369807e-07
for O 0 2.4486157101932804e-08
BRCA1 O 0 2.452065359648259e-07
or O 0 4.710025258702899e-09
by O 0 3.4231051326827355e-09
including O 0 9.259622402169043e-09
or O 0 1.1331474780718054e-07
excluding O 0 1.177276953967521e-05
BRCA1 O 0 8.207961400330532e-06
mutation O 0 3.014791616351431e-07
data O 0 6.337248805721174e-07
. O 0 4.2291338786526467e-07

Among O 0 1.1893797591255861e-06
those O 0 7.750784192239735e-08
families O 0 7.263474799401592e-08
with O 0 8.615296565039898e-08
disease O 0 0.002252505160868168
due O 0 2.6702396098698955e-06
to O 0 3.9374671700898034e-07
BRCA1 O 0 2.7290768684906652e-06
that O 0 3.1913542919426163e-09
were O 0 5.900206545561559e-09
tested O 0 4.255104713024593e-09
by O 0 8.554099095725576e-10
one O 0 1.2814163063978867e-09
of O 0 1.3656095143588232e-09
the O 0 3.2498446156381533e-09
standard O 0 7.694938908286986e-09
screening O 0 3.005213633500148e-09
methods O 0 2.97748470323711e-09
, O 0 1.4725906050117032e-09
mutations O 0 2.0307935333363503e-09
were O 0 6.800882523805285e-09
detected O 0 4.7273619685483936e-08
in O 0 4.88453455460558e-09
the O 0 3.104279855392633e-08
coding O 0 4.771032422468124e-07
sequence O 0 2.636976716985373e-07
or O 0 2.1298950159120977e-08
splice O 0 3.583508032534155e-07
sites O 0 8.092206904564136e-09
in O 0 1.1999304883048012e-09
an O 0 2.762387429910973e-09
estimated O 0 1.1846537084636566e-08
63 O 0 8.799909068102352e-08
% O 0 1.5067080028074997e-08
( O 0 2.1534811267542864e-08
95 O 0 7.052781825223065e-08
% O 0 3.49700535196007e-08
CI O 0 6.339625542750582e-05
51 O 0 2.7785594625129306e-07
% O 0 2.805745680234395e-08
- O 0 9.601748729437531e-08
77 O 0 1.7126276929957385e-07
% O 0 5.5941605126008653e-08
) O 0 6.56309140367739e-08
. O 0 1.0232029978851642e-07

The O 0 7.337906026805285e-06
estimated O 0 2.1202054085733835e-06
sensitivity O 0 5.317868954080041e-07
was O 0 2.854374940852722e-07
identical O 0 2.556980938095421e-08
for O 0 4.458188485045866e-09
direct O 0 3.98953368119237e-08
sequencing O 0 1.3833245304795128e-07
and O 0 5.305106576258822e-09
other O 0 1.0903948854945611e-08
techniques O 0 2.699070364542422e-06
. O 0 1.9486185465211747e-06

The O 0 3.154414662276395e-05
penetrance O 0 0.0003158528124913573
of O 0 7.73712781665381e-06
BRCA2 O 0 2.4736678824410774e-05
was O 0 2.989507493111887e-06
estimated O 0 3.9204559243444237e-07
by O 0 6.123415374759134e-08
maximizing O 0 2.8723588911816478e-06
the O 0 3.081203772126173e-07
LOD O 0 0.0002987315529026091
score O 0 1.0941160866195787e-07
in O 0 8.381043414829037e-08
BRCA2 O 0 2.807210194077925e-06
- O 0 8.143194918375229e-07
mutation O 0 1.689458528630894e-08
families O 0 1.9839017095790723e-09
, O 0 1.9850296961720915e-09
over O 0 3.6058642738368007e-09
all O 0 1.2242161950837271e-08
possible O 0 3.3218231010323507e-07
penetrance O 0 2.989203312608879e-05
functions O 0 3.6247820389689878e-06
. O 0 2.055644245047006e-06

The O 0 5.912347205594415e-06
estimated O 0 2.1659252524841577e-06
cumulative O 0 8.521116797055583e-06
risk O 0 1.828486915655958e-06
of O 0 5.51672656001756e-06
breast B-Disease 1 0.9705376029014587
cancer I-Disease 0 0.0006339948740787804
reached O 0 1.149192303273594e-05
28 O 0 1.635121975596121e-06
% O 0 4.1703309250351595e-08
( O 0 1.715697095505675e-08
95 O 0 5.8493160537409494e-08
% O 0 3.2655538717563104e-08
CI O 0 2.2895255824550986e-05
9 O 0 2.0839644321313244e-07
% O 0 1.3544712906821132e-08
- O 0 2.1881280787283686e-08
44 O 0 8.519681848895289e-09
% O 0 1.957287443232758e-09
) O 0 2.986378644376231e-10
by O 0 2.609928106966919e-10
age O 0 3.607666831939582e-09
50 O 0 2.3861916886858126e-09
years O 0 1.001522420551737e-09
and O 0 3.9256406458854087e-10
84 O 0 1.6897001131610523e-08
% O 0 5.850540496510348e-09
( O 0 5.483906662107074e-09
95 O 0 5.8893039778240563e-08
% O 0 1.584440845192603e-08
CI O 0 7.150494639063254e-06
43 O 0 5.326279151063318e-08
% O 0 6.2278795454062674e-09
- O 0 1.7383099404355562e-08
95 O 0 4.523148433577262e-08
% O 0 2.955362177203824e-09
) O 0 1.2760212886320232e-09
by O 0 1.2701983909124692e-09
age O 0 4.4066378990237354e-08
70 O 0 1.3281548660870612e-07
years O 0 2.2649928155260568e-07
. O 0 4.538159146250109e-07

The O 0 3.54943513229955e-05
corresponding O 1 0.9971283078193665
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0027140143793076277
were O 0 4.36052914665197e-06
0 O 0 2.5647723305155523e-06
. O 0 1.0468369282534695e-06

4 O 0 5.95761594013311e-06
% O 0 3.0704967457495513e-07
( O 0 8.737141854453512e-08
95 O 0 2.679371959857235e-07
% O 0 6.143314124074095e-08
CI O 0 2.8191487217554823e-05
0 O 0 2.5613642762323252e-08
% O 0 8.634408743546373e-09
- O 0 1.494321288930678e-08
1 O 0 9.133225731261518e-09
% O 0 2.9491793451796866e-09
) O 0 1.0086615986892866e-09
by O 0 4.807970133136052e-10
age O 0 9.220410213117702e-09
50 O 0 3.977663087795236e-09
years O 0 2.2955530809554148e-09
and O 0 1.9529913242166685e-09
27 O 0 9.954500512776576e-08
% O 0 2.267711352033075e-08
( O 0 1.3637777129815731e-08
95 O 0 6.426875387433029e-08
% O 0 1.9163325148952026e-08
CI O 0 4.228467332723085e-06
0 O 0 1.3859438929841872e-08
% O 0 5.322102758498204e-09
- O 0 1.4546302828932767e-08
47 O 0 2.833193235574072e-08
% O 0 4.58429161298568e-09
) O 0 1.532663218561936e-09
by O 0 1.2826976147906066e-09
age O 0 6.169523913968078e-08
70 O 0 2.2478231187506026e-07
years O 0 2.8041895916430803e-07
. O 0 7.373840276159171e-07

The O 0 1.481428807892371e-05
lifetime O 0 8.214673289330676e-05
risk O 0 7.140143861761317e-05
of O 0 0.004772156942635775
breast B-Disease 1 1.0
cancer I-Disease 1 0.9995031356811523
appears O 0 1.7964483731702785e-06
similar O 0 6.896291093738682e-09
to O 0 3.4428273565367817e-09
the O 0 4.5354678235298707e-08
risk O 0 2.3423088180152263e-07
in O 0 5.605535591257649e-08
BRCA1 O 0 9.187126579490723e-07
carriers O 0 1.382248004944131e-08
, O 0 2.2782278286115343e-09
but O 0 1.0685947682276264e-09
there O 0 2.9281883584530988e-09
was O 0 5.072241648917952e-08
some O 0 1.4155256966574825e-09
suggestion O 0 2.7992136608645524e-08
of O 0 1.351918754721737e-08
a O 0 3.8817006497993134e-08
lower O 0 6.737864310935038e-08
risk O 0 6.15890698441035e-08
in O 0 5.579295603297396e-08
BRCA2 O 0 1.007690116239246e-06
carriers O 0 8.681194429982497e-08
< O 0 7.91387356002815e-06
50 O 0 1.4285745919551118e-07
years O 0 5.050289431096644e-08
of O 0 1.7524558870718465e-07
age O 0 5.157022314961068e-06
. O 0 3.2758121051301714e-06

Eye B-Disease 1 0.9997509121894836
movement I-Disease 0 0.00013637739175464958
abnormalities I-Disease 1 0.7513972520828247
correlate O 0 9.291998139815405e-06
with O 0 1.5417714394061477e-07
genotype O 0 2.328091431991197e-05
in O 0 4.2846072574320715e-06
autosomal O 1 0.8994707465171814
dominant O 1 0.7651928067207336
cerebellar B-Disease 1 0.9999998807907104
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999998807907104
. O 0 0.0006386223249137402

We O 0 7.254139745782595e-06
compared O 0 4.329369403421879e-06
horizontal O 0 1.364156742056366e-05
eye O 0 1.1421527233324014e-05
movements O 0 7.610443049088644e-07
( O 0 7.143257221287058e-07
visually O 0 1.4555261032001e-06
guided O 0 1.011470885714516e-05
saccades O 0 0.00012761002290062606
, O 0 1.74344762626788e-07
antisaccades O 0 3.483369073364884e-05
, O 0 5.802478852956483e-08
and O 0 2.898035766918383e-08
smooth O 0 1.7611894236324588e-06
pursuit O 0 1.6464226064272225e-05
) O 0 9.308801907081943e-08
in O 0 1.812506944531833e-08
control O 0 7.739349427993147e-08
subjects O 0 2.721866962929198e-07
( O 0 1.3007679910970182e-07
n O 0 6.91239847583347e-07
= O 0 5.289126079333073e-07
14 O 0 8.917592708712618e-08
) O 0 8.504712489809663e-09
and O 0 1.5647146911490495e-09
patients O 0 1.5724456181587243e-09
with O 0 6.228126347984642e-10
three O 0 3.0119848837273366e-09
forms O 0 3.8192176532447775e-08
of O 0 2.766719444480259e-05
autosomal O 1 0.9027939438819885
dominant O 0 0.2545571029186249
cerebellar B-Disease 1 0.9999983310699463
ataxias I-Disease 1 0.9999998807907104
type I-Disease 1 0.9999855756759644
I I-Disease 1 0.9998766183853149
spinocerebellar B-Disease 1 0.9999978542327881
ataxias I-Disease 0 0.020860575139522552
1 I-Disease 0 9.084978387363662e-07
and I-Disease 0 2.9572863269322625e-08
2 I-Disease 0 1.977352752646766e-07
( O 0 1.1446659442526652e-07
SCA1 B-Disease 0 1.7414782632840797e-05
, O 0 4.072443360314537e-08
n O 0 5.58856072530034e-07
= O 0 4.1810392303887056e-07
11 O 0 9.86696022664546e-08
; O 0 8.310347077156166e-09
SCA2 B-Disease 0 7.958572496136185e-06
, O 0 1.8529252798771267e-08
n O 0 2.048687406386307e-07
= O 0 2.518544590657257e-07
10 O 0 2.354635419976603e-08
) O 0 1.3161958634100301e-08
and O 0 1.7818219788523493e-08
SCA3 B-Disease 1 0.9999998807907104
/ O 0 0.00026127672754228115
Machado B-Disease 0 3.075024869758636e-05
- I-Disease 0 5.8438013184058946e-06
Joseph I-Disease 0 0.0004471523279789835
disease I-Disease 0 0.0021842706482857466
( O 0 2.1063719941594172e-06
MJD B-Disease 1 0.9999998807907104
) O 0 6.224818207556382e-07
( O 0 1.5531851715877565e-07
n O 0 6.575445468115504e-07
= O 0 1.5848116845518234e-06
16 O 0 7.640747412551718e-07
) O 0 6.657498374806892e-07
. O 0 9.305772437073756e-07

In O 0 5.7195058616343886e-05
SCA1 B-Disease 1 0.9953472018241882
, O 0 2.8627873689401895e-06
saccade O 0 0.0005228070076555014
amplitude O 0 2.7167602638655808e-06
was O 0 8.108632414405292e-07
significantly O 0 1.4510035839521152e-07
increased O 0 4.189240954133311e-08
, O 0 2.9423933511907308e-08
resulting O 0 1.859688438798912e-07
in O 0 2.3830418172110512e-07
hypermetria B-Disease 0 0.0006227229023352265
. O 0 5.091490038466873e-06

The O 0 6.01688188908156e-05
smooth O 0 0.00013300159480422735
pursuit O 0 0.0008040943648666143
gain O 0 0.0001107408752432093
was O 0 7.734469545539469e-05
decreased O 0 0.00020543893333524466
. O 0 5.47284025742556e-06

In O 0 7.925034151412547e-05
SCA2 B-Disease 1 0.7903605103492737
, O 0 1.1182686648680829e-05
saccade O 0 0.0008678602753207088
velocity O 0 2.8041198675055057e-05
was O 0 2.507754834368825e-05
markedly O 0 2.3345053705270402e-05
decreased O 0 2.925853186752647e-05
. O 0 4.291419827495702e-06

The O 0 1.1213785910513252e-05
percentage O 0 4.615220859705005e-06
of O 0 3.2146263606591674e-07
errors O 0 3.3088831514760386e-06
in O 0 3.793239216065558e-07
antisaccades O 1 0.8642308115959167
was O 0 4.170601096120663e-05
greatly O 0 4.2910082242997305e-07
increased O 0 3.94373103063117e-08
and O 0 1.0749651835340046e-08
was O 0 3.2009336337068817e-07
significantly O 0 9.442544524063123e-08
correlated O 0 2.0735029693241813e-07
with O 0 6.465602719885055e-09
age O 0 2.4360765564779285e-06
at O 0 0.00042493216460570693
disease O 0 0.21294139325618744
onset O 1 0.9853448271751404
. O 0 5.793488071503816e-06

In O 0 2.3610316475242143e-06
addition O 0 4.092526069143787e-07
, O 0 7.628436549111939e-08
a O 0 1.8852885830256128e-07
correlation O 0 3.229529568216094e-07
between O 0 1.0352207624464427e-07
smooth O 0 1.8371443957221345e-06
pursuit O 0 3.5539440432330593e-05
gain O 0 2.5910385375027545e-06
and O 0 1.644995428762286e-08
the O 0 5.2329820476870736e-08
number O 0 3.618108479486182e-08
of O 0 3.7688167253691063e-07
trinucleotide O 0 0.0003744231362361461
repeats O 0 4.683270617533708e-06
was O 0 3.5236510029790225e-06
found O 0 7.48228671909601e-07
. O 0 1.440694063603587e-06

In O 0 0.00028504873625934124
SCA3 B-Disease 1 1.0
, O 0 2.5288334654760547e-05
gaze B-Disease 1 0.7342382669448853
- I-Disease 0 0.0013153132749721408
evoked I-Disease 0 2.6524516215431504e-05
nystagmus I-Disease 0 8.456990326521918e-05
was O 0 9.253673169951071e-07
often O 0 1.105938629564207e-08
present O 0 2.703204238230228e-08
as O 0 6.441013056246447e-08
was O 0 6.816327186243143e-06
saccade O 0 0.0013397664297372103
hypometria O 0 0.00010543187818257138
and O 0 3.048418477646919e-07
smooth O 0 1.3497678992280271e-05
pursuit O 0 0.00040486609213985503
gain O 0 7.367496436927468e-05
was O 0 4.154575435677543e-05
markedly O 0 1.7196231056004763e-05
decreased O 0 2.034006865869742e-05
. O 0 2.169890876757563e-06

Three O 0 1.6891351606318494e-06
major O 0 8.413514365201991e-07
criteria O 0 3.65659190038059e-07
, O 0 1.740487221013609e-07
saccade O 0 5.942501229583286e-05
amplitude O 0 2.605554300316726e-06
, O 0 6.448720313301237e-08
saccade O 0 1.3539771316573024e-05
velocity O 0 6.744139113834535e-07
, O 0 9.727517458202328e-09
and O 0 3.1410560819011835e-09
presence O 0 7.70153505413873e-08
of O 0 7.09748917415709e-07
gaze B-Disease 0 0.04897928610444069
- I-Disease 0 0.00047885262756608427
evoked I-Disease 0 1.196557695948286e-05
nystagmus I-Disease 0 1.0810917046910618e-05
, O 0 2.2088341822268376e-08
permitted O 0 2.6912484685226445e-08
the O 0 1.5473299086465886e-08
correct O 0 1.2672303739691415e-07
assignment O 0 1.7702105026273784e-07
of O 0 1.1277366240847186e-07
90 O 0 2.0808742817735038e-07
% O 0 4.0739973172776445e-08
of O 0 3.1561373958766126e-08
the O 0 9.93354163369986e-08
SCA1 B-Disease 0 0.0035771464463323355
, O 0 4.622064864179265e-08
90 O 0 8.553748642725623e-08
% O 0 1.4777515211505943e-08
of O 0 1.938281890545568e-08
the O 0 5.507284228656317e-08
SCA2 B-Disease 0 0.0004476855101529509
, O 0 5.5677049637381515e-09
and O 0 2.0659947086443253e-09
93 O 0 2.1303709729636466e-07
% O 0 8.164157350165624e-09
of O 0 7.3163493041761285e-09
the O 0 3.441568452444699e-08
patients O 0 1.118336978578327e-08
with O 0 1.7948792674360448e-08
SCA3 B-Disease 1 1.0
to O 0 3.073373378015276e-08
their O 0 9.742149309488468e-09
genetically O 0 1.2088602119320058e-08
confirmed O 0 1.0893679736057038e-08
patient O 0 2.5100796108290524e-08
group O 0 3.3751295092088185e-09
and O 0 1.092899215571208e-09
, O 0 4.295714450819332e-09
therefore O 0 3.586728070104073e-08
, O 0 1.693933882052079e-08
may O 0 5.1688115121351075e-08
help O 0 1.8615250496623048e-07
orient O 0 0.007973543368279934
diagnoses O 0 4.1078565118368715e-06
of O 0 1.103978661376459e-06
SCA1 B-Disease 1 0.9999804496765137
, O 0 6.395486025212449e-07
SCA2 B-Disease 1 0.9883507490158081
, O 0 8.989437105810794e-08
and O 0 4.803501596484239e-08
SCA3 B-Disease 1 1.0
at O 0 2.2954986889089923e-06
early O 0 2.661270457338105e-07
clinical O 0 3.9981574673220166e-07
stages O 0 3.419277163629886e-07
of O 0 2.2590992898585682e-07
the O 0 8.859710760589223e-07
diseases O 0 0.0004032122087664902
. O 0 5.730667567149794e-07
. O 0 4.710351731773699e-06

Genetic O 0 1.251425601367373e-05
basis O 0 5.173895942789386e-07
and O 0 4.1736331723996045e-08
molecular O 0 4.814454314328032e-06
mechanism O 0 2.8655940695898607e-05
for O 0 9.006832988234237e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0004230958875268698

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999918937683105
causes O 0 3.8883249544596765e-06
more O 0 4.091346639256699e-08
than O 0 3.777127943749292e-08
300 O 0 1.8809103607964062e-07
, O 0 4.8125716745062164e-08
000 O 0 1.2055753586537321e-06
sudden O 0 1.2533967037597904e-06
deaths O 0 3.2032598795694867e-08
each O 0 2.1922625936809936e-09
year O 0 1.0675806905169338e-08
in O 0 1.511318714619847e-08
the O 0 2.39931011947192e-07
USA O 0 6.752847184543498e-06
alone O 0 2.3876193608884932e-06
. O 0 1.6513192804268328e-06

In O 0 4.719605385616887e-06
approximately O 0 1.7943166312761605e-06
5 O 0 3.059357425172493e-07
- O 0 3.277935434198298e-07
12 O 0 9.797123112775807e-08
% O 0 3.880055388094661e-09
of O 0 1.1382446096774856e-09
these O 0 4.048647528342997e-10
cases O 0 1.5092382898984624e-09
, O 0 2.2826818213417255e-09
there O 0 8.375574012120524e-09
are O 0 5.164689120817911e-09
no O 0 1.825817577127964e-07
demonstrable O 0 0.002353654010221362
cardiac O 1 0.9992846846580505
or O 0 1.8939579149446217e-06
non O 1 0.9839116334915161
- O 1 0.9997796416282654
cardiac O 1 0.9999788999557495
causes O 0 7.095026433034946e-08
to O 0 3.4781919566739816e-09
account O 0 2.098158269348005e-08
for O 0 3.129227987841432e-09
the O 0 3.057353126223461e-08
episode O 0 3.722749397638836e-07
, O 0 2.3246067293314354e-09
which O 0 4.476924664320592e-10
is O 0 8.440487198058122e-10
therefore O 0 6.231943405765605e-09
classified O 0 2.6098715011357854e-07
as O 0 8.671362934364879e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999923706054688
IVF B-Disease 1 1.0
) O 0 4.487746628001332e-05
. O 0 9.09484333533328e-06

A O 0 1.3767792552243918e-05
distinct O 0 6.661360316684295e-07
group O 0 2.713381661578751e-07
of O 0 8.744294063944835e-06
IVF B-Disease 1 1.0
patients O 0 2.6884660542236816e-07
has O 0 2.5583455354194484e-09
been O 0 2.6877280401294e-09
found O 0 2.7031619165285292e-09
to O 0 2.469909832214512e-09
present O 0 2.7539558189459967e-08
with O 0 2.1987546006130287e-08
a O 0 1.1475716519271373e-06
characteristic O 0 4.361726951174205e-06
electrocardiographic O 0 0.004534163512289524
pattern O 0 7.351327076321468e-05
. O 0 7.665594239369966e-06

Because O 0 1.6637502540106652e-06
of O 0 2.6738709379969805e-07
the O 0 9.813319223894723e-08
small O 0 3.612977650391258e-08
size O 0 6.000444585652076e-08
of O 0 4.257883290392783e-08
most O 0 1.3752318395177099e-08
pedigrees O 0 6.602049893444928e-07
and O 0 1.4484784038870657e-08
the O 0 1.7678418373634486e-07
high O 0 3.871460194204701e-06
incidence O 0 1.1827710295619909e-05
of O 0 2.957761466859665e-07
sudden B-Disease 0 6.68253778712824e-06
death I-Disease 0 2.107721002175822e-07
, O 0 5.803206803989269e-09
however O 0 7.2396675321328985e-09
, O 0 6.950644504399861e-09
molecular O 0 2.1580829923095735e-07
genetic O 0 5.744380615624323e-08
studies O 0 6.513656103379617e-08
of O 0 6.120905595707882e-07
IVF B-Disease 1 0.9999998807907104
have O 0 4.752510829320045e-09
not O 0 8.59135163011615e-09
yet O 0 4.635944250708235e-08
been O 0 1.1660542043046007e-07
done O 0 6.84036820075562e-07
. O 0 1.5407792943733511e-06

Because O 0 0.000240863228100352
IVF B-Disease 1 1.0
causes O 0 0.012279259972274303
cardiac O 1 1.0
rhythm O 1 0.9999725818634033
disturbance O 0 0.31291061639785767
, O 0 5.175578721150487e-08
we O 0 2.9567056358814625e-08
investigated O 0 8.308098244924622e-07
whether O 0 2.3329413068040594e-07
malfunction O 1 0.9921414852142334
of O 0 8.480724318360444e-07
ion O 0 2.0207069610478356e-05
channels O 0 5.640487756863877e-07
could O 0 4.178667367682465e-08
cause O 0 2.1116807147336658e-07
the O 0 1.0594044397294056e-07
disorder O 0 2.5336692033306463e-06
by O 0 7.460323914187938e-09
studying O 0 4.529649686446646e-07
mutations O 0 1.5987632551173192e-08
in O 0 9.302230985497317e-09
the O 0 1.790892554254242e-07
cardiac O 0 0.0004823710769414902
sodium O 0 1.5017766372693586e-06
channel O 0 1.3036361451668199e-05
gene O 0 9.661906005931087e-06
SCN5A O 0 0.02453017048537731
. O 0 8.275477739516646e-06

We O 0 1.2977882306586253e-06
have O 0 4.0620790286993724e-08
now O 0 6.408636465948803e-08
identified O 0 9.392948641107068e-08
a O 0 1.1491263762763992e-07
missense O 0 1.1993976158919395e-06
mutation O 0 2.3753807809612226e-08
, O 0 7.93640175800192e-09
a O 0 1.8536029244842211e-07
splice O 0 4.217448349663755e-06
- O 0 6.687865834464901e-07
donor O 0 4.9207820040919614e-08
mutation O 0 1.90380013975755e-08
, O 0 5.711841666311557e-09
and O 0 7.652390721091251e-09
a O 0 2.3757350220421358e-07
frameshift O 0 3.6599797113012755e-06
mutation O 0 2.2881666339458206e-08
in O 0 5.595192753560241e-09
the O 0 4.5611031396219914e-08
coding O 0 2.3745078578940593e-06
region O 0 3.2007687877921853e-07
of O 0 1.1256730658715242e-06
SCN5A O 1 0.9998557567596436
in O 0 5.582967332884436e-07
three O 0 2.1243504306767136e-06
IVF B-Disease 1 1.0
families O 0 4.3398964066909684e-07
. O 0 1.2718664947897196e-06

We O 0 1.58169223141158e-06
show O 0 6.98737324000831e-07
that O 0 1.753240930213451e-08
sodium O 0 4.7781810508240596e-08
channels O 0 3.489875766149453e-08
with O 0 2.756350703236876e-09
the O 0 5.080956100300682e-08
missense O 0 1.3531359854823677e-06
mutation O 0 2.9913529431269126e-08
recover O 0 2.1797477245399932e-07
from O 0 4.511663220796436e-08
inactivation O 0 7.011951311142184e-06
more O 0 4.04929823005773e-09
rapidly O 0 5.8332833674512585e-08
than O 0 4.195476410728816e-09
normal O 0 3.758543698495487e-08
and O 0 1.178723119110714e-09
that O 0 2.9676761048591516e-09
the O 0 5.557332016792316e-08
frameshift O 0 4.606861239153659e-06
mutation O 0 2.6246171458410572e-08
causes O 0 9.181660765023025e-09
the O 0 1.1050255821487553e-08
sodium O 0 1.0465324606911963e-08
channel O 0 1.658406389992706e-08
to O 0 7.8662892866177e-10
be O 0 9.372293163778522e-09
non O 0 5.547630053115427e-07
- O 0 2.9945811093057273e-06
functional O 0 4.892523065791465e-06
. O 0 1.5295063349185511e-06

Our O 0 4.709192580776289e-06
results O 0 2.8257491635486076e-07
indicate O 0 1.294938272167201e-07
that O 0 3.872706155760852e-09
mutations O 0 1.147949468816023e-08
in O 0 2.7390052892428685e-08
cardiac O 0 0.00015193229774013162
ion O 0 1.6930744095589034e-05
- O 0 0.0004360535240266472
channel O 0 1.2475021549107623e-06
genes O 0 2.2866919024977506e-08
contribute O 0 4.570898326505812e-09
to O 0 1.4205374654352454e-09
the O 0 1.2343026156713677e-08
risk O 0 5.543929049167673e-08
of O 0 1.942509015862015e-07
developing O 0 3.307051883894019e-05
IVF B-Disease 1 1.0
. O 0 2.786164259305224e-07
. O 0 7.56388942591002e-07

Molecular O 0 0.002954092575237155
heterogeneity O 0 0.00017886125715449452
in O 0 1.5077707757882308e-06
mucopolysaccharidosis B-Disease 0 0.22694800794124603
IVA I-Disease 1 0.98087078332901
in O 0 1.359770607223254e-07
Australia O 0 4.5272400939211366e-08
and O 0 4.056703861721189e-09
Northern O 0 4.565376343634853e-08
Ireland O 0 2.4233354878333557e-08
: O 0 6.624575998870341e-09
nine O 0 1.6772800037756497e-08
novel O 0 6.456510703856111e-08
mutations O 0 1.837801022475105e-08
including O 0 1.2719858055731947e-08
T312S O 0 3.357834430062212e-05
, O 0 3.344920784797978e-08
a O 0 7.065398222039221e-08
common O 0 1.143118666391274e-08
allele O 0 4.6752106186431774e-08
that O 0 8.480075308625601e-09
confers O 0 3.4695673889473255e-07
a O 0 4.978953143108811e-07
mild O 0 3.4525335195212392e-06
phenotype O 0 9.307910659117624e-06
. O 0 1.3226782584752073e-06

Mucopolysaccharidosis B-Disease 1 0.9997251629829407
IVA I-Disease 1 0.9999948740005493
( O 0 0.0005750659038312733
MPS B-Disease 1 0.999993085861206
IVA I-Disease 1 1.0
) O 0 1.4192971775628394e-06
is O 0 6.009378239468788e-08
an O 0 4.90934496610862e-07
autosomal B-Disease 1 0.9976263642311096
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.12073177844285965
by O 0 7.560499284409161e-07
a O 0 0.0002803723909892142
genetic B-Disease 1 0.9999986886978149
defect I-Disease 1 0.9999762773513794
in O 0 1.683850086919847e-06
N O 0 0.0012739719823002815
- O 0 6.768519233446568e-05
acetylgalactosamine O 0 0.006496192421764135
- O 0 7.432586426148191e-05
6 O 0 3.7428635550895706e-05
- O 0 3.643257514340803e-05
sulfate O 0 4.8276950110448524e-05
sulfatase O 0 0.06665802747011185
( O 0 1.4347940123116132e-05
GALNS O 1 0.6349287629127502
) O 0 4.98471490573138e-06
. O 0 4.410449037095532e-06

Previous O 0 7.664848453714512e-06
studies O 0 5.74806222175539e-07
of O 0 9.962610647562542e-08
patients O 0 1.1793039433882768e-08
from O 0 1.2792192194410745e-08
a O 0 1.4596349728890345e-07
British O 0 7.615745744260494e-06
- O 0 9.50282901612809e-06
Irish O 0 2.976407358801225e-06
population O 0 8.386797034631854e-09
showed O 0 1.2601195642503171e-08
that O 0 1.0556013840812284e-09
the O 0 1.0201411271282268e-08
I113F O 0 1.470049710405874e-06
mutation O 0 6.751665893034442e-09
is O 0 1.18422149864017e-09
the O 0 1.8601944429263995e-09
most O 0 8.195621958861921e-10
common O 0 1.6175680794816572e-09
single O 0 7.36409067059185e-09
mutation O 0 8.504938975306686e-09
among O 0 1.4992602714869463e-08
MPS B-Disease 1 0.9999936819076538
IVA I-Disease 1 1.0
patients O 0 8.974392358140904e-07
and O 0 1.1593785487207242e-08
produces O 0 3.951953431169386e-08
a O 0 1.0877323575186892e-07
severe O 0 1.0658928886186914e-06
clinical O 0 1.2909649740322493e-05
phenotype O 0 9.095086170418654e-06
. O 0 2.184474624300492e-06

We O 0 1.6146301504704752e-06
studied O 0 5.370770395529689e-06
mutations O 0 9.39955953072058e-07
in O 0 1.5001475617282267e-07
the O 0 5.491915544553194e-07
GALNS O 0 0.26354140043258667
gene O 0 2.404594567906315e-07
from O 0 5.979000405886836e-08
23 O 0 3.6342447629067465e-07
additional O 0 2.864033206151362e-07
MPS B-Disease 1 0.9992926120758057
IVA I-Disease 1 1.0
patients O 0 1.6387345169732725e-07
( O 0 7.848668381882362e-09
15 O 0 7.111675248694382e-09
from O 0 1.8567736237429244e-09
Australia O 0 5.873595387839714e-09
, O 0 7.979474303532186e-10
8 O 0 4.865138958365378e-09
from O 0 1.4487595567658218e-09
Northern O 0 7.608627505817367e-09
Ireland O 0 4.210185977626679e-09
) O 0 1.869406629495529e-09
, O 0 2.8908780924652433e-10
with O 0 2.517739350338388e-10
various O 0 3.0562090636010453e-09
clinical O 0 1.1603871143961442e-06
phenotypes O 0 1.4796814866713248e-06
( O 0 1.2853854514105478e-07
severe O 0 2.6744217507257417e-07
, O 0 6.7840666417851025e-09
16 O 0 2.975556157025494e-08
cases O 0 2.106975927063104e-09
; O 0 1.2948654370958934e-09
intermediate O 0 1.6022639215407253e-07
, O 0 5.519321444324987e-09
4 O 0 1.9649151639100637e-08
cases O 0 1.652838310661764e-09
; O 0 1.2874380450611511e-09
mild O 0 3.061671804971411e-08
, O 0 7.959230607923473e-09
3 O 0 8.613078250618855e-08
cases O 0 3.660429470642157e-08
) O 0 1.82504635404257e-07
. O 0 2.2645046726665896e-07

We O 0 1.812165123737941e-06
found O 0 1.7612721592286107e-07
two O 0 1.5513192508365137e-08
common O 0 1.0832907904045896e-08
mutations O 0 9.188492633427359e-09
that O 0 8.946648977214977e-10
together O 0 1.2626145462490967e-08
accounted O 0 4.780587801178626e-07
for O 0 9.631148323308025e-09
32 O 0 2.75973548014008e-07
% O 0 1.896146351043626e-08
of O 0 1.0446338905012453e-08
the O 0 2.058043335750881e-08
44 O 0 6.317853973314413e-08
unrelated O 0 1.2803437243746885e-07
alleles O 0 5.2567985520113325e-09
in O 0 4.069661940775404e-09
these O 0 1.0845973896778105e-08
patients O 0 1.6944096614679438e-07
. O 0 9.316117370872234e-07

One O 0 4.930256181978621e-06
is O 0 2.5948466486624966e-07
the O 0 2.5428286676287826e-07
T312S O 0 4.0646715206094086e-05
mutation O 0 2.802700294068927e-07
, O 0 3.4037704210732045e-08
a O 0 6.5262412363154e-08
novel O 0 1.970350069768756e-07
mutation O 0 2.335433713085422e-08
found O 0 1.1909814467969682e-08
exclusively O 0 4.986275214946545e-08
in O 0 3.901653045090825e-08
milder O 0 5.894692094443599e-07
patients O 0 6.231363727238204e-07
. O 0 1.8930729765997967e-06

The O 0 3.1945767204888398e-06
other O 0 4.4182691283367603e-08
is O 0 3.191453146200729e-08
the O 0 3.8308254346475223e-08
previously O 0 5.759915211456246e-07
described O 0 1.431866053280828e-06
I113F O 0 1.753557262418326e-05
that O 0 3.3695609857886666e-08
produces O 0 1.278290397976889e-07
a O 0 6.764815339010966e-07
severe O 0 5.438365860754857e-06
phenotype O 0 2.0314151697675698e-05
. O 0 5.018581305193948e-06

The O 0 5.4274820286082104e-05
I113F O 0 0.000498918117955327
and O 0 1.3704918728763005e-06
T312S O 0 0.00010229672625428066
mutations O 0 4.6863078750902787e-07
accounted O 0 1.3932212823419832e-06
for O 0 5.0245109406432675e-08
8 O 0 5.743886504205875e-07
( O 0 5.3743235639558407e-08
18 O 0 1.1476194572423992e-07
% O 0 1.0901578306743431e-08
) O 0 2.5809596682080382e-09
and O 0 9.995224647951773e-10
6 O 0 4.732251568384527e-08
( O 0 2.6971786581952983e-08
14 O 0 6.131070051651477e-08
% O 0 1.1188746817936135e-08
) O 0 3.6339373732374725e-09
of O 0 1.8167018112080768e-08
44 O 0 8.221620362292015e-08
unrelated O 0 4.696616429100686e-07
alleles O 0 4.0967741199438024e-08
, O 0 3.073707688372451e-08
respectively O 0 1.0516118891246151e-06
. O 0 1.5196601452771574e-06

The O 0 7.088207894412335e-06
relatively O 0 2.0304130430304212e-06
high O 0 5.746194801758975e-06
residual O 0 0.0001993573532672599
GALNS O 1 0.9998263716697693
activity O 0 8.463784979539923e-06
seen O 0 2.4202182657973026e-07
when O 0 2.004564159108213e-08
the O 0 7.87341178920542e-08
T312S O 0 9.527020665700547e-06
mutant O 0 1.1179913599335123e-06
cDNA O 0 4.121838173887227e-06
is O 0 1.799232229870995e-08
overexpressed O 0 7.81403116434376e-07
in O 0 4.332545433527457e-09
mutant O 0 1.4706607487369183e-07
cells O 0 1.8146034008736933e-08
provides O 0 1.2806784521757208e-09
an O 0 8.963969566622154e-10
explanation O 0 1.0984105180966708e-08
for O 0 1.8520305289371208e-09
the O 0 3.625499900294926e-08
mild O 0 3.2626658708068135e-07
phenotype O 0 2.6475527192815207e-07
in O 0 1.1210300243646998e-08
patients O 0 3.0820244134588393e-09
with O 0 1.4080961951989934e-09
this O 0 4.6226908523294696e-08
mutation O 0 2.6871049385590595e-07
. O 0 5.983199002912443e-07

The O 0 2.194503622376942e-06
distribution O 0 1.9886084601239418e-07
and O 0 2.1448974152349365e-08
relative O 0 7.058245046209777e-07
frequencies O 0 1.155410842557103e-07
of O 0 6.506628125180214e-08
the O 0 1.584468662940708e-07
I113F O 0 3.778781683649868e-05
and O 0 5.638509037453332e-08
T312S O 0 3.347692472743802e-05
mutations O 0 4.863285951728358e-08
in O 0 8.977114163144506e-09
Australia O 0 2.122643927293666e-08
corresponded O 0 4.859817792635113e-08
to O 0 1.3166873147341107e-09
those O 0 1.674856031641525e-09
observed O 0 1.749846489929041e-08
in O 0 4.084833804540722e-09
Northern O 0 3.290262284849632e-08
Ireland O 0 1.2951823613605029e-08
and O 0 9.098482522951201e-10
are O 0 1.580883202123573e-10
unique O 0 1.2233705160014097e-09
to O 0 1.653777254029265e-10
these O 0 3.69620584139696e-10
two O 0 9.155459723686477e-10
populations O 0 2.6389723739583815e-09
, O 0 1.3444966251441315e-09
suggesting O 0 2.0027909997111237e-08
that O 0 5.66123037337718e-10
both O 0 7.499182386183634e-10
mutations O 0 1.3990529845742117e-09
were O 0 4.521214513886207e-09
probably O 0 1.7465254131820984e-08
introduced O 0 2.454477954216827e-09
to O 0 1.9265160577930374e-09
Australia O 0 8.705979936962649e-09
by O 0 4.950357457289556e-09
Irish O 0 3.7025927213107934e-07
migrants O 0 5.765950561453792e-08
during O 0 1.0747891820983568e-07
the O 0 1.5510195794377069e-07
19th O 0 5.367324320104672e-06
century O 0 1.8178850950789638e-05
. O 0 3.761078914976679e-06

Haplotype O 0 0.00033977144630625844
analysis O 0 2.204025804530829e-06
using O 0 4.824556185667461e-07
6 O 0 1.5464262332898215e-06
RFLPs O 0 8.399563375860453e-05
provides O 0 1.6285493842360665e-08
additional O 0 9.60432888774676e-09
data O 0 2.6490091897812817e-08
that O 0 2.2751531769671374e-09
the O 0 3.80268829758279e-08
I113F O 0 9.312242582382169e-06
mutation O 0 4.781025353395307e-08
originated O 0 3.0647919402326806e-07
from O 0 4.4807304533378556e-08
a O 0 3.6948992487850774e-07
common O 0 4.105410198462778e-07
ancestor O 0 2.779079477477353e-05
. O 0 4.873872057942208e-06

The O 0 4.502749561652308e-06
other O 0 1.170308792097785e-07
9 O 0 7.81407607064466e-07
novel O 0 5.048190132583841e-07
mutations O 0 5.411931525145519e-08
identified O 0 3.192208097857474e-08
in O 0 4.642365603046983e-09
these O 0 2.0565276148687417e-09
23 O 0 2.1606324196454807e-07
patients O 0 6.589228274123116e-09
were O 0 9.931302891175164e-09
each O 0 6.918265960109693e-09
limited O 0 1.509204494709593e-08
to O 0 1.4988428276296872e-08
a O 0 5.261205160422833e-07
single O 0 5.16091574809252e-07
family O 0 6.772529559384566e-07
. O 0 6.955606295377947e-07

These O 0 3.212573176369915e-07
data O 0 3.1769809538673144e-07
provide O 0 1.9127940120711173e-08
further O 0 9.043761295401964e-09
evidence O 0 6.206596481206361e-08
for O 0 1.0817155171594095e-08
extensive O 0 6.10513041010563e-07
allelic O 0 3.918119091395056e-06
heterogeneity O 0 4.266518772055861e-06
in O 0 2.185313405789202e-07
MPS B-Disease 0 0.15760135650634766
IVA I-Disease 1 0.9999991655349731
in O 0 1.245142442485303e-07
British O 0 2.1351966097427066e-06
- O 0 7.605806899846357e-07
Irish O 0 3.6567035976986517e-07
patients O 0 4.726043556502191e-09
and O 0 8.847512722454098e-10
provide O 0 2.767946316595271e-09
evidence O 0 3.311125595928388e-08
for O 0 6.399522245459366e-09
their O 0 7.149034253473019e-09
transmission O 0 7.297579429632606e-08
to O 0 3.2188516296827174e-09
Australia O 0 2.3129318904580032e-08
by O 0 8.528688866249468e-09
British O 0 1.1330863571856753e-06
- O 0 5.778060199190804e-07
Irish O 0 1.0430072734379792e-06
migrants O 0 2.700788002130139e-07
. O 0 5.261776436782384e-08
. O 0 5.57156397462677e-07

Identification O 0 1.875628913694527e-05
of O 0 3.764710527320858e-06
constitutional O 0 3.211316652595997e-05
WT1 O 1 0.9999656677246094
mutations O 0 1.034232468555274e-06
, O 0 3.014181615412781e-08
in O 0 3.180272400982176e-08
patients O 0 1.501793178704247e-08
with O 0 2.278980737457914e-08
isolated O 0 0.05576144531369209
diffuse B-Disease 1 0.9999994039535522
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.7207397224060514e-08
and O 0 4.334545611328622e-09
analysis O 0 5.967186211819353e-08
of O 0 2.0335160400009045e-07
genotype O 0 1.0862652743526269e-05
/ O 0 1.829108441597782e-05
phenotype O 0 6.543954214066616e-07
correlations O 0 2.142693915629934e-07
by O 0 5.634238409157888e-09
use O 0 8.269978479802376e-09
of O 0 6.894925519418393e-08
a O 0 4.449865969036182e-07
computerized O 0 1.1312561582599301e-05
mutation O 0 7.963013786138617e-07
database O 0 2.1419350559881423e-06
. O 0 8.47731996600487e-07

Constitutional O 0 2.8506357921287417e-05
mutations O 0 1.8502714738133363e-06
of O 0 8.701649107933918e-07
the O 0 1.6827231092975126e-06
WT1 O 0 0.10950794816017151
gene O 0 4.3415147388259356e-07
, O 0 2.083224437399167e-08
encoding O 0 2.401997676315659e-07
a O 0 6.514532628898451e-07
zinc O 0 0.002851234981790185
- O 0 9.600001794751734e-05
finger O 0 0.0001422147179255262
transcription O 0 0.00024833731004036963
factor O 0 7.521901466134295e-07
involved O 0 1.552915591673809e-07
in O 0 3.1705158676231804e-07
renal O 1 1.0
and O 0 1.389832164022664e-06
gonadal O 1 1.0
development O 1 0.5289223790168762
, O 0 1.1648045195045142e-08
are O 0 5.832632155033934e-10
found O 0 3.025365735709329e-09
in O 0 1.948002648077818e-09
most O 0 2.2973749569388247e-09
patients O 0 3.789588198799265e-09
with O 0 3.164926454246597e-08
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.2505331039428711
DDS B-Disease 1 1.0
) O 0 7.104830501702963e-07
, O 0 8.057495648472468e-08
or O 0 2.101027121170773e-06
diffuse B-Disease 1 0.9993682503700256
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 1 0.9995090961456299
DMS B-Disease 1 1.0
) O 0 9.798036444408353e-07
associated O 0 4.932838351123792e-07
with O 0 1.558195350526148e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 6.25617103651166e-05
/ O 1 0.9999935626983643
or O 1 0.8131042718887329
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 1 0.9913580417633057
WT B-Disease 1 1.0
) O 0 8.23537920950912e-05
. O 0 1.1209369404241443e-05

Most O 0 2.225213165729656e-06
mutations O 0 3.687510570671293e-06
in O 0 3.005656481036567e-06
DDS B-Disease 1 1.0
patients O 0 1.5079152035468724e-05
lie O 0 0.0008282416383735836
in O 0 3.304241317891865e-06
exon O 0 3.85251478292048e-05
8 O 0 2.3145353225118015e-06
or O 0 2.453192848861363e-07
exon O 0 3.164436520819436e-06
9 O 0 8.179059136637079e-07
, O 0 8.38022842231112e-08
encoding O 0 1.9068729670834728e-06
zinc O 0 0.0005170663935132325
finger O 0 0.00021275340986903757
2 O 0 1.582574077474419e-05
or O 0 6.907206170581048e-06
zinc O 1 0.6347305178642273
finger O 0 0.00016841557226143777
3 O 0 1.0390192528575426e-06
, O 0 3.066066156520719e-08
respectively O 0 1.2628581202989153e-07
, O 0 4.4315937586247856e-09
with O 0 2.7531561475058197e-09
a O 0 6.545926112266898e-08
hot O 0 2.8937174079146644e-07
spot O 0 7.465913540727342e-07
( O 0 1.9075481816344109e-07
R394W O 0 7.29822340872488e-06
) O 0 1.545092089827449e-07
in O 0 2.65830777834708e-07
exon O 0 1.2773372873198241e-05
9 O 0 1.3892482456867583e-05
. O 0 3.973892489739228e-06

We O 0 3.033849907296826e-06
analyzed O 0 1.7047519804691547e-06
a O 0 2.545303345868888e-07
series O 0 1.3734839399148768e-07
of O 0 1.1658696053018502e-07
24 O 0 4.956534667144297e-07
patients O 0 2.6767915883851856e-08
, O 0 6.301172028599922e-09
10 O 0 2.7343441288962822e-08
with O 0 2.0561168767585514e-08
isolated B-Disease 0 5.4978849220788106e-05
DMS I-Disease 1 0.9999992847442627
( O 0 1.9747229089261964e-05
IDMS B-Disease 1 0.9943374991416931
) O 0 5.1497107023124045e-08
, O 0 7.925041956013956e-09
10 O 0 1.775342539644953e-08
with O 0 1.964004781029871e-08
DDS B-Disease 1 1.0
, O 0 6.217224068905125e-08
and O 0 1.8340472252020845e-08
4 O 0 5.557479880735627e-07
with O 0 1.437664707282238e-07
urogenital B-Disease 1 0.9976916313171387
abnormalities I-Disease 1 0.9971327781677246
and O 0 1.7085483705159277e-05
/ O 1 0.9999994039535522
or O 1 0.9853089451789856
WT B-Disease 1 1.0
. O 0 0.00015768806042615324

We O 0 2.1852809368283488e-05
report O 0 3.453145473031327e-05
WT1 O 0 0.003522654762491584
heterozygous O 0 3.034457677131286e-06
mutations O 0 1.6118627854666556e-07
in O 0 4.518216556448351e-08
16 O 0 4.265313009454985e-07
patients O 0 6.54959748658257e-08
, O 0 4.941436060335036e-08
4 O 0 3.8256817447290814e-07
of O 0 4.344869921624195e-07
whom O 0 4.802292892236437e-07
presented O 0 5.578822765528457e-06
with O 0 4.7842186177149415e-06
IDMS B-Disease 1 0.9999982118606567
. O 0 1.8851296772481874e-05

One O 0 1.259742657566676e-05
male O 0 2.460832092765486e-06
and O 0 5.599604691042259e-08
two O 0 2.2062411630940915e-07
female O 0 0.00037381111178547144
IDMS B-Disease 1 1.0
patients O 0 2.8996894343435997e-06
with O 0 1.6414213632742758e-06
WT1 O 1 1.0
mutations O 0 0.0002140348224202171
underwent O 1 0.972162127494812
normal O 0 0.15278957784175873
puberty O 1 0.986265242099762
. O 0 1.0704918167903088e-05

Two O 0 2.202315499744145e-06
mutations O 0 2.2842782527732197e-06
associated O 0 1.7504827383163502e-06
with O 0 5.017319040234725e-07
IDMS B-Disease 1 0.9999983310699463
are O 0 8.673064932906982e-09
different O 0 2.5315221030552948e-09
from O 0 1.8896406217550066e-08
those O 0 2.313293734346189e-08
described O 0 1.5727275695098797e-06
in O 0 7.029084372334182e-06
DDS B-Disease 1 1.0
patients O 0 1.1648226973193232e-05
. O 0 6.199998097144999e-06

No O 0 0.00012253627937752753
WT1 O 0 0.13173967599868774
mutations O 0 6.462744863711123e-07
were O 0 2.0540655043532752e-07
detected O 0 2.460732844156155e-07
in O 0 8.916840599226816e-09
the O 0 2.8955385644735543e-08
six O 0 4.9656417644428075e-08
other O 0 6.154515119760617e-08
IDMS B-Disease 1 1.0
patients O 0 9.6030476015585e-07
, O 0 3.585278562923122e-08
suggesting O 0 2.9830455332557904e-06
genetic O 0 4.972398528479971e-06
heterogeneity O 0 3.3221347166545456e-06
of O 0 6.893997692714038e-07
this O 0 1.6161183111762512e-06
disease O 0 0.0008835205226205289
. O 0 4.736180017061997e-06

We O 0 4.099724264960969e-06
analyzed O 0 1.4776305761188269e-05
genotype O 0 5.34646023879759e-05
/ O 0 6.390411726897582e-05
phenotype O 0 2.1591258700937033e-06
correlations O 0 1.0024747325587668e-06
, O 0 2.042253299805452e-08
on O 0 1.3819738242659696e-08
the O 0 6.360144411132751e-09
basis O 0 3.5752194094129663e-08
of O 0 1.129876281424913e-08
the O 0 9.226444497301145e-09
constitution O 0 1.437963081940552e-08
of O 0 1.0544593465056096e-07
a O 0 8.29543125746568e-07
WT1 O 0 0.00022974313469603658
mutation O 0 4.990937441107235e-08
database O 0 8.985990973542357e-08
of O 0 3.471565790391651e-08
84 O 0 1.2223237035868806e-06
germ O 1 0.9999948740005493
- O 0 0.0012753740884363651
line O 0 9.245028991244908e-07
mutations O 0 1.0454870746912093e-08
, O 0 1.5637002803714495e-09
to O 0 1.3210744720382195e-09
compare O 0 1.9752562252506323e-08
the O 0 9.364324426996973e-09
distribution O 0 1.8632206888469227e-08
and O 0 3.2086393542130054e-09
type O 0 1.2286729145216668e-07
of O 0 1.0474815326233511e-07
mutations O 0 3.0767047576318873e-08
, O 0 3.984983454330404e-09
according O 0 8.653467276076299e-09
to O 0 1.137808292028808e-09
the O 0 1.1471747107805186e-08
different O 0 1.0748647305547365e-08
symptoms O 0 1.1779874284911784e-06
. O 0 9.821790172281908e-07

This O 0 1.944134055520408e-06
demonstrated O 0 1.27495366086805e-06
( O 0 2.1117692483585415e-07
1 O 0 1.7390021866958705e-07
) O 0 2.170951063362736e-08
the O 0 1.054784881659998e-08
association O 0 2.0750750451270505e-08
between O 0 2.939498955356612e-08
mutations O 0 2.6590120327796285e-08
in O 0 3.82464868664556e-08
exons O 0 1.9361081626811938e-07
8 O 0 1.1023588086800373e-07
and O 0 1.2044275798928084e-08
9 O 0 4.527801138465293e-07
and O 0 2.710277335893352e-08
DMS B-Disease 0 0.0021275104954838753
; O 0 6.367184557376504e-09
( O 0 1.0575527120693096e-08
2 O 0 1.1343244565864552e-08
) O 0 1.3668368659125463e-09
among O 0 2.799040166312494e-10
patients O 0 1.0893882462781335e-09
with O 0 5.646933143310662e-09
DMS B-Disease 1 0.9987454414367676
, O 0 1.3994647218851242e-08
a O 0 1.8453883754432354e-08
higher O 0 1.8995743644723007e-08
frequency O 0 2.8989092015763163e-08
of O 0 2.046652092246859e-08
exon O 0 3.0025742603356775e-07
8 O 0 2.4259390940528647e-08
mutations O 0 3.5453455726752736e-09
among O 0 8.704532095116235e-10
46 O 0 4.070206927053732e-08
, O 0 2.8442388000371466e-08
XY O 1 0.9991829991340637
patients O 0 6.999485435699171e-08
with O 0 1.363327761794153e-08
female O 0 3.984275281254668e-06
phenotype O 0 1.287228030832921e-07
than O 0 1.079754619048856e-09
among O 0 8.304701926142855e-10
46 O 0 2.5666068381724472e-08
, O 0 2.333884019378729e-08
XY O 1 0.999321460723877
patients O 0 4.068973069593085e-08
with O 0 6.455461498688919e-09
sexual O 0 6.210966034814192e-07
ambiguity O 0 2.928530420831521e-06
or O 0 1.0254200333292829e-06
male O 0 1.027176836032595e-06
phenotype O 0 4.446887302833602e-08
; O 0 6.544859099122391e-10
and O 0 1.7039363253701367e-09
( O 0 8.887601765650288e-09
3 O 0 1.2456406572880496e-08
) O 0 3.149400518154266e-09
statistically O 0 4.655151819576986e-09
significant O 0 2.3740753807288684e-09
evidence O 0 1.3277389854238208e-08
that O 0 2.8346240910082088e-09
mutations O 0 1.3254743969071114e-08
in O 0 1.8431720150147157e-08
exons O 0 1.749443470089318e-07
8 O 0 1.4363079969825776e-07
and O 0 1.840635555083736e-08
9 O 0 4.236186441630707e-07
preferentially O 0 2.4503964368705056e-07
affect O 0 5.8228344812505384e-08
amino O 0 4.10792395655335e-08
acids O 0 6.39749631048403e-09
with O 0 5.090127208617901e-10
different O 0 2.114706187938964e-09
functions O 0 1.2081564193522354e-07
. O 0 5.7976556888661435e-08
. O 0 8.652363021610654e-07

The O 0 6.2925013480708e-05
185delAG O 0 0.0008643305627629161
BRCA1 O 0 5.20861976838205e-05
mutation O 0 2.2041170666398102e-07
originated O 0 3.057062372135988e-07
before O 0 6.690009968224331e-08
the O 0 3.735359754841738e-08
dispersion O 0 6.577928957085533e-07
of O 0 1.4326799657737865e-07
Jews O 0 4.872896397500881e-07
in O 0 2.8699219001282472e-08
the O 0 6.434394350662842e-08
diaspora O 0 8.167805987113752e-08
and O 0 6.678481767607991e-09
is O 0 1.9582628851821937e-08
not O 0 1.5553485610553253e-08
limited O 0 2.171467059497445e-07
to O 0 5.982651600788813e-07
Ashkenazim O 0 0.0016856581205502152
. O 0 1.1651615750452038e-05

The O 0 1.643208452151157e-05
185delAG O 0 6.007021147524938e-05
mutation O 0 1.0711847835409571e-06
in O 0 7.188676676150862e-08
BRCA1 O 0 1.1696956789819524e-06
is O 0 2.379040076050387e-08
detected O 0 3.0136189366203325e-07
in O 0 3.3491723172573984e-08
Ashkenazi O 0 1.6630501704639755e-05
Jews O 0 4.831517799175344e-07
both O 0 1.9579529109137184e-08
in O 0 3.85643346589859e-07
familial B-Disease 1 0.9999368190765381
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.154218110372312e-06
in O 0 3.083537762904598e-07
the O 0 2.9881258001296374e-07
general O 0 2.9926482056907844e-06
population O 0 6.832218559793546e-07
. O 0 1.7578853430677555e-06

All O 0 2.406382463959744e-06
tested O 0 3.0329240416904213e-06
Ashkenazi O 0 6.269997538765892e-05
mutation O 0 6.397803531399404e-07
carriers O 0 3.762367271065159e-07
share O 0 2.180026115183864e-07
the O 0 1.0658070692670663e-07
same O 0 2.3711355368050135e-07
allelic O 0 5.460650754685048e-06
pattern O 0 4.739437372336397e-06
at O 0 3.4444628909113817e-06
the O 0 2.0233364921296015e-06
BRCA1 O 0 6.274232146097347e-05
locus O 0 2.528490949771367e-05
. O 0 2.5635349629737902e-06

Our O 0 5.92952983424766e-06
previous O 0 9.655924486651202e-07
study O 0 1.682115282619634e-07
showed O 0 9.761404129449147e-08
that O 0 2.5400441749923175e-09
this O 0 7.567219739712527e-09
Ashkenazi O 0 2.8687481972156093e-06
mutation O 0 1.0606191480633242e-08
also O 0 3.966299733093592e-09
occurs O 0 1.082024958520833e-08
in O 0 1.1937515864701709e-08
Iraqi O 0 1.2370621334412135e-05
Jews O 0 3.1800666988601733e-07
with O 0 1.0405176276151451e-08
a O 0 1.1690695345123459e-07
similar O 0 6.365681315401162e-08
allelic O 0 3.6118176467425656e-06
pattern O 0 8.561110007576644e-06
. O 0 2.9669531613762956e-06

We O 0 1.6487230141137843e-06
extended O 0 5.388600357036921e-07
our O 0 5.8798192981157626e-08
analysis O 0 4.661195873723045e-08
to O 0 9.843966530809212e-09
other O 0 6.52494458464048e-09
non O 0 8.765248367126333e-07
- O 0 1.7006404959829524e-06
Ashkenazi O 0 5.209169557929272e-06
subsets O 0 5.310556048243598e-07
354 O 0 4.0447153537570557e-07
of O 0 3.779564039518846e-08
Moroccan O 0 1.375683837068209e-06
origin O 0 5.912297140753253e-08
, O 0 2.0739552297754926e-08
200 O 0 2.313263394171372e-07
Yemenites O 0 4.5630972635990474e-06
and O 0 3.5252938346275187e-08
150 O 0 5.546455668081762e-07
Iranian O 0 9.123163181357086e-06
Jews O 0 4.5675469664274715e-06
. O 0 2.3700013116467744e-06

Heteroduplex O 0 0.0020558733958750963
analysis O 0 4.724640348285902e-06
complemented O 0 2.034848193943617e-06
by O 0 3.163972905895207e-08
direct O 0 1.2575557661875791e-07
DNA O 0 1.048578496920527e-06
sequencing O 0 8.317627475662448e-07
of O 0 3.9288661923819745e-07
abnormally O 0 1.7512040358269587e-05
migrating O 0 4.779498112839065e-07
bands O 0 4.428452484717127e-07
were O 0 5.955520236966549e-07
employed O 0 1.6289415725623257e-05
. O 0 6.484034202003386e-06

Four O 0 4.7120229282882065e-06
of O 0 1.6575959307374433e-06
Moroccan O 0 1.6443655113107525e-05
origin O 0 2.89671049813478e-07
( O 0 7.716091232623512e-08
1 O 0 4.018922794557511e-08
. O 0 3.3302900437348626e-09
1 O 0 1.8683309122025094e-08
% O 0 9.092449460013086e-09
) O 0 2.456548076068543e-09
and O 0 8.91644535983005e-10
none O 0 2.9444818139268136e-08
of O 0 4.1797193262027577e-08
the O 0 3.0045879384488217e-07
Yemenites O 0 0.0002059571270365268
or O 0 2.4059548309196543e-07
Iranians O 0 9.77568333837553e-07
was O 0 3.2111856285155227e-07
a O 0 8.081490676659087e-08
carrier O 0 1.7783935390980332e-07
of O 0 9.978547410582905e-08
the O 0 3.459932145233324e-07
185delAG O 0 4.449216430657543e-05
mutation O 0 2.5807942165556597e-06
. O 0 1.14073998247477e-06

BRCA1 O 0 0.0013323778985068202
allelic O 0 3.951777034671977e-05
patterns O 0 8.474369224131806e-07
were O 0 8.642172844020024e-08
determined O 0 1.105409737078844e-07
for O 0 9.557874491861185e-09
four O 0 1.1903773078358881e-08
of O 0 1.7428813947617527e-08
these O 0 1.2352534550785776e-09
individuals O 0 8.986943411670723e-10
and O 0 1.269120808444768e-09
for O 0 6.294229137893126e-09
12 O 0 9.857216554109982e-08
additional O 0 5.330812413717467e-08
non O 0 2.3335851437877864e-06
- O 0 2.504745680198539e-06
Ashkenazi O 0 3.586196044125245e-06
185delAG O 0 1.93128721548419e-06
mutation O 0 2.0707693337840283e-08
carriers O 0 1.8720051286891248e-08
who O 0 2.2951514466740264e-08
had O 0 1.7807500626076944e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003811588976532221

Six O 0 4.514702595770359e-05
non O 0 0.000643051287624985
- O 0 0.0006642763037234545
Ashkenazi O 0 0.00013382607721723616
individuals O 0 5.741992836760801e-08
shared O 0 2.917125243584451e-07
the O 0 1.9568260256619396e-07
common O 0 3.088888433921966e-07
Ashkenazi O 0 0.00013865847722627223
haplotype O 0 7.297869160538539e-06
, O 0 4.024376565325838e-08
four O 0 4.289690735959084e-08
had O 0 8.420605013270688e-08
a O 0 1.4445721774336562e-07
closely O 0 1.1529002108545683e-07
related O 0 2.0084071650217084e-07
pattern O 0 1.1649621001197374e-06
, O 0 2.064420279168644e-08
and O 0 7.32226901334343e-09
the O 0 7.327762574504959e-08
rest O 0 1.9033431897241826e-07
( O 0 1.5665348485072172e-07
n O 0 1.0169918596147909e-06
= O 0 1.1186718893441139e-06
6 O 0 2.4655344077473274e-07
) O 0 2.2418774392463092e-08
displayed O 0 1.5180972923189984e-07
a O 0 3.2450000730932516e-07
distinct O 0 5.528859787773399e-07
BRCA1 O 0 7.63473963161232e-06
allelic O 0 1.6830997992656194e-05
pattern O 0 3.976439984398894e-05
. O 0 1.0676116289687343e-05

We O 0 3.6112701309320983e-06
conclude O 0 8.598331987741403e-06
that O 0 1.5885477466781595e-07
the O 0 7.470464993275527e-07
185delAG O 0 0.0001202111816382967
BRCA1 O 0 7.248067959153559e-06
mutation O 0 5.252411483525066e-08
occurs O 0 1.5967183131238016e-08
in O 0 6.017037090799704e-09
some O 0 7.999714668471825e-09
non O 0 3.23555195791414e-06
- O 0 2.000730273721274e-05
Ashkenazi O 0 5.542910730582662e-05
populations O 0 4.7444341788605016e-08
at O 0 1.9176495413830708e-07
rates O 0 2.9193786943437772e-08
comparable O 0 4.3607435884496226e-08
with O 0 2.6396467234235388e-09
that O 0 2.028282253263569e-08
of O 0 8.299514320242452e-07
Ashkenazim O 0 0.0001677629043115303
. O 0 3.974234004999744e-06

The O 0 7.03108889865689e-06
majority O 0 3.701967727920419e-07
of O 0 1.3572173429565737e-06
Jewish O 0 4.6833436499582604e-05
185delAG O 0 0.00014635758998338133
mutation O 0 6.888168968544051e-07
carriers O 0 5.7869723235626225e-08
have O 0 5.181917117624835e-09
a O 0 7.23431554661147e-08
common O 0 3.539313908618169e-08
allelic O 0 1.4126653695711866e-06
pattern O 0 2.705567339944537e-06
, O 0 3.811838311662541e-08
supporting O 0 4.4087528294767253e-07
the O 0 1.9896899061677686e-07
founder O 0 4.758626801049104e-06
effect O 0 5.5189559589052806e-08
notion O 0 9.3328374362045e-08
, O 0 4.502608508261119e-09
but O 0 1.221509782212138e-09
dating O 0 1.0798852656535018e-07
the O 0 8.738904710980933e-09
mutations O 0 4.707708445295111e-09
origin O 0 6.795281670690656e-09
to O 0 2.9048854433000315e-09
an O 0 8.855080224634548e-09
earlier O 0 3.7031817612387385e-08
date O 0 1.3062276593700517e-07
than O 0 8.260141903804197e-09
currently O 0 4.5538968151959125e-08
estimated O 0 3.586461900795257e-07
. O 0 7.136461590562249e-07

However O 0 4.445812010089867e-06
, O 0 1.1530013921401405e-07
the O 0 7.311763283723849e-08
different O 0 1.7953311726159882e-08
allelic O 0 2.241395577584626e-06
pattern O 0 2.001620259761694e-06
at O 0 4.349473783804569e-06
the O 0 1.7708618997858139e-06
BRCA1 O 0 2.5053645003936253e-05
locus O 0 1.6114996697069728e-06
even O 0 2.957234235267947e-09
in O 0 1.227329793351828e-09
some O 0 1.1736619454083552e-09
Jewish O 0 1.1018752843483526e-07
mutation O 0 1.1950591627396534e-08
carriers O 0 1.4913599244437137e-08
, O 0 4.8228607774092325e-09
might O 0 1.8903685727877928e-08
suggest O 0 8.03141233518545e-08
that O 0 5.3325384108404705e-09
the O 0 3.3152268485991954e-08
mutation O 0 1.583196329590919e-08
arose O 0 1.4055564179216162e-07
independently O 0 2.1358778212743346e-07
. O 0 6.947147568325818e-08
. O 0 4.6882837523298804e-07

Crystal O 1 0.9607939124107361
structure O 0 0.00035641802242025733
of O 0 0.00011921827535843477
the O 0 0.45044639706611633
hemochromatosis B-Disease 1 1.0
protein O 1 1.0
HFE O 1 1.0
and O 0 4.417873356032942e-07
characterization O 0 1.1466875548649114e-05
of O 0 3.665019789877988e-07
its O 0 6.163713095475032e-08
interaction O 0 3.8767734622524586e-07
with O 0 9.928977107165338e-08
transferrin O 0 0.0002495490189176053
receptor O 0 1.3256180864118505e-05
. O 0 1.8430617956255446e-06

HFE O 1 0.9998993873596191
is O 0 3.386026719454094e-06
an O 0 3.2842042401171057e-06
MHC O 0 0.032885342836380005
- O 0 0.00035706593189388514
related O 0 6.240537913981825e-06
protein O 0 5.984192057439941e-07
that O 0 3.766521761150443e-09
is O 0 6.862790780104433e-09
mutated O 0 1.714411546061001e-08
in O 0 1.3108495622304872e-08
the O 0 6.479185117314046e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9998266100883484

HFE O 1 0.9991469383239746
binds O 0 4.6611636207671836e-05
to O 0 8.869347993822885e-07
transferrin O 0 0.0003210972063243389
receptor O 0 2.7646306989481673e-05
( O 0 2.3480797608499415e-06
TfR O 0 0.02937125787138939
) O 0 9.388470800786308e-08
and O 0 1.1600376659259837e-08
reduces O 0 4.647506912647259e-08
its O 0 5.692037063909083e-09
affinity O 0 4.288250821105066e-08
for O 0 4.204795445161835e-08
iron O 0 0.4055270850658417
- O 0 0.0007171643665060401
loaded O 0 8.852329483488575e-05
transferrin O 0 0.0018480619182810187
, O 0 6.996061756581184e-07
implicating O 0 0.0018703287933021784
HFE O 1 0.9999263286590576
in O 0 5.6895487432484515e-06
iron O 1 0.996696949005127
metabolism O 1 0.5037742853164673
. O 0 1.3148056495992932e-05

The O 0 0.00014130634372122586
2 O 0 6.13161755609326e-05
. O 0 1.3033676623308565e-05

6 O 0 0.0004535997286438942
A O 0 0.0003825988678727299
crystal O 0 0.03805597499012947
structure O 0 0.0003764463763218373
of O 0 0.00020434203906916082
HFE O 1 0.9999998807907104
reveals O 0 4.289545904612169e-05
the O 0 4.532708999249735e-07
locations O 0 1.1450562169557088e-06
of O 0 2.360582038818393e-05
hemochromatosis B-Disease 1 1.0
mutations O 0 2.034726639976725e-05
and O 0 4.551777976757876e-07
a O 0 4.085914042661898e-05
patch O 0 0.023944420740008354
of O 0 3.8260772271314636e-05
histidines O 1 0.9138997197151184
that O 0 2.030492574078835e-08
could O 0 1.6830419724556123e-08
be O 0 1.418826833798903e-08
involved O 0 1.8814736790773168e-07
in O 0 3.254663454299589e-07
pH O 0 0.011176597326993942
- O 0 8.91864110599272e-05
dependent O 0 3.2224518236034783e-06
interactions O 0 1.8236577261632192e-06
. O 0 1.0012537359216367e-06

We O 0 1.9017116983377491e-06
also O 0 1.283839452526081e-07
demonstrate O 0 1.0561899443928269e-06
that O 0 2.1979897724122566e-07
soluble O 0 0.0012050805380567908
TfR O 1 0.9999731779098511
and O 0 1.6284350294881733e-06
HFE O 1 0.9999897480010986
bind O 0 4.300506589061115e-06
tightly O 0 6.190863587107742e-06
at O 0 4.987397801414772e-07
the O 0 4.992584834440095e-08
basic O 0 2.675881205504993e-07
pH O 0 5.654129608956282e-07
of O 0 4.670878439583248e-08
the O 0 6.275411124079255e-08
cell O 0 5.333090484782588e-07
surface O 0 7.54230953248225e-08
, O 0 5.329772623241524e-09
but O 0 2.496166162657687e-09
not O 0 5.62223645417248e-09
at O 0 2.0522659838206891e-07
the O 0 1.737032988557985e-07
acidic O 0 3.848196683975402e-06
pH O 0 1.0601585017866455e-05
of O 0 2.76776904684084e-06
intracellular O 0 0.00010670578194549307
vesicles O 0 0.00018957654538098723
. O 0 5.266905191092519e-06

TfR O 1 0.9999861717224121
HFE O 1 0.9992609620094299
stoichiometry O 0 0.00037670883466489613
( O 0 6.0616230257437564e-06
2 O 0 1.7608198277230258e-06
1 O 0 3.9171709431684576e-07
) O 0 4.054246005580353e-08
differs O 0 5.7915986673151565e-08
from O 0 1.56967828957022e-07
TfR O 0 0.0005895747453905642
transferrin O 0 1.103485919884406e-05
stoichiometry O 0 1.0695126775317476e-06
( O 0 4.584748936053984e-08
2 O 0 6.533053920065868e-08
2 O 0 5.5171668122966366e-08
) O 0 1.273051264405467e-08
, O 0 3.641764223516475e-09
implying O 0 7.351897579610522e-08
a O 0 7.1945174262566525e-09
different O 0 1.3836135570599595e-09
mode O 0 8.555755925954145e-08
of O 0 2.99640099399312e-08
binding O 0 7.267354362738843e-08
for O 0 2.9341336471588875e-07
HFE O 1 0.9999136924743652
and O 0 4.5591025354951853e-07
transferrin O 0 0.0008404427208006382
to O 0 4.355648286491487e-07
TfR O 1 0.9995381832122803
, O 0 2.5806459191812792e-08
consistent O 0 9.043402826591773e-08
with O 0 2.4234221296381975e-09
our O 0 6.37972021877431e-08
demonstration O 0 1.4388842828338966e-06
that O 0 1.0785925042000599e-07
HFE O 0 0.20881687104701996
, O 0 1.9736486933652486e-07
transferrin O 0 3.221481529180892e-05
, O 0 4.9681240454901854e-08
and O 0 8.297505615928458e-08
TfR O 0 0.0018230079440400004
form O 0 3.0638861403531337e-07
a O 0 3.6396800169313792e-06
ternary O 0 5.042001066613011e-05
complex O 0 6.077379293856211e-05
. O 0 3.8184934965102e-06

Identification O 0 1.2514470654423349e-05
of O 0 5.419243507276406e-07
three O 0 8.025210007645e-08
novel O 0 5.374384386414022e-07
mutations O 0 3.809977755508953e-08
and O 0 6.277108610674986e-09
a O 0 4.9692612691387694e-08
high O 0 7.534861623526012e-08
frequency O 0 5.896238519653707e-08
of O 0 3.1059972371849653e-08
the O 0 8.465227097076422e-08
Arg778Leu O 0 0.003355849301442504
mutation O 0 4.854426194356165e-08
in O 0 2.457561620872184e-08
Korean O 0 0.04301159083843231
patients O 0 3.9018910769073045e-08
with O 0 3.4428751405357616e-08
Wilson B-Disease 0 0.2705865800380707
disease I-Disease 0 0.07451288402080536
. O 0 4.188029834040208e-06

Four O 0 4.396481472213054e-06
mutations O 0 1.3812327779305633e-06
- O 0 1.1023038496205118e-05
- O 0 2.5900089895003475e-05
R778L O 0 5.335143214324489e-05
, O 0 2.0651771137636388e-07
A874V O 0 1.02395906651509e-05
, O 0 8.20271424117891e-08
L1083F O 0 5.417112333816476e-06
, O 0 2.98095805817411e-08
and O 0 1.6900610688708184e-08
2304delC O 0 1.726851792227535e-06
- O 0 1.9491001239657635e-06
- O 0 5.773989641966182e-07
in O 0 1.687355499768728e-08
the O 0 2.615951011364359e-08
copper O 0 6.2230769799498376e-06
- O 0 6.459663950408867e-07
transporting O 0 1.506977241660934e-06
enzyme O 0 2.024981853310237e-07
, O 0 1.3304464197005927e-08
P O 0 2.9391735552053433e-06
- O 0 3.520812015267438e-07
type O 0 8.604094432484999e-07
ATPase O 0 0.00028287453460507095
( O 0 2.7710697736438306e-08
ATP7B O 0 7.112856110325083e-06
) O 0 6.680188846530655e-09
, O 0 7.565080784033285e-10
were O 0 2.0100840991688074e-09
identified O 0 1.6081003195722587e-08
in O 0 1.5936150177253694e-08
Korean O 0 0.018480176106095314
Patients O 0 9.168661563307978e-08
with O 0 2.8803027518620183e-08
Wilson B-Disease 0 0.292209655046463
disease I-Disease 0 0.09877248108386993
. O 0 2.637779289216269e-06

Arg778Leu O 1 0.5387787222862244
, O 0 8.76529838933493e-07
the O 0 1.096560424684867e-07
most O 0 1.1908451114095442e-08
frequently O 0 3.663684466914674e-08
reported O 0 3.508563750642679e-08
mutation O 0 3.7176171030495198e-09
of O 0 4.8917883077592705e-09
this O 0 4.504421280415727e-09
enzyme O 0 5.370921485337021e-08
, O 0 3.830494588186184e-09
was O 0 1.030704979143593e-07
found O 0 9.566281988782066e-09
in O 0 4.0713850069096225e-09
six O 0 1.3587744263077184e-08
of O 0 2.3767903201132867e-08
eight O 0 5.9018642417640876e-08
unrelated O 0 7.772025583108189e-07
patients O 0 1.0525581295439679e-08
studied O 0 2.743303753049986e-07
, O 0 1.470901445088657e-08
an O 0 2.697230172543641e-08
allele O 0 6.70785951228936e-08
frequency O 0 8.288742492368328e-08
of O 0 1.7054401268978836e-07
37 O 0 3.420533630560385e-06
. O 0 1.7499586419944535e-06

5 O 0 1.0590186320769135e-05
% O 0 5.034180503571406e-07
, O 0 1.1579376568704447e-08
which O 0 3.2609093203461725e-09
is O 0 4.4310102254030426e-09
considerably O 0 2.027334744525433e-08
higher O 0 1.2488784228992245e-08
than O 0 7.872413276821533e-10
those O 0 7.268858848163973e-10
in O 0 4.871378855852981e-09
other O 0 4.55325199766321e-09
Asian O 0 1.6590320228715427e-06
populations O 0 1.220514178612575e-07
. O 0 4.6088510430308816e-07

The O 0 1.7966950736081344e-06
novel O 0 1.5578165175611502e-06
single O 0 3.883093313561403e-07
nucleotide O 0 4.310418262321036e-06
deletion O 0 1.8336995708523318e-06
, O 0 4.775138151558167e-08
2304delC O 0 2.980679482789128e-06
, O 0 4.0871739770409476e-08
was O 0 2.543100379170937e-07
found O 0 3.6934402203314676e-08
in O 0 2.824721967442656e-08
one O 0 2.0591041050010972e-07
patient O 0 2.2932799765840173e-06
. O 0 2.2160495518619427e-06

Since O 0 7.856826414354146e-06
a O 0 1.4640531844634097e-06
mutation O 0 3.15398068551076e-07
at O 0 1.2972487866136362e-06
cDNA O 0 1.9485594748402946e-05
nucleotide O 0 1.4667527466372121e-05
2302 O 0 0.0003120432374998927
( O 0 1.3648738672600302e-07
2302insC O 0 1.2085279195162002e-06
) O 0 1.7072064650847096e-08
had O 0 9.351615481989484e-09
been O 0 8.607393020554355e-09
previously O 0 3.3298341861609515e-08
described O 0 5.120054780149985e-08
, O 0 4.038715584187003e-09
this O 0 3.507551804560194e-09
region O 0 2.5414607307538972e-08
of O 0 5.1432422765174124e-08
the O 0 4.7502342681582377e-07
ATP7B O 1 0.9999921321868896
gene O 0 1.6663720714404917e-07
may O 0 1.166514262962437e-08
be O 0 1.547813965885325e-08
susceptible O 0 1.5795531282947195e-07
to O 0 4.454026125699784e-08
gene O 0 2.1635285065713106e-06
rearrangements O 0 0.0002243444905616343
causing O 0 0.05900450795888901
Wilson B-Disease 1 0.9999662637710571
disease I-Disease 1 0.9924709796905518
. O 0 1.3362036042963155e-05

Disruption O 0 0.0008804136887192726
of O 0 3.580253633117536e-06
splicing O 0 9.013573617266957e-06
regulated O 0 3.5995719827042194e-07
by O 0 4.186900781633085e-08
a O 0 1.1395134151825914e-06
CUG O 0 0.0036027897149324417
- O 0 6.444640348490793e-06
binding O 0 8.38428661609214e-07
protein O 0 5.4375464060285594e-06
in O 0 4.363757398095913e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.486916441237554e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999982118606567
DM B-Disease 1 1.0
) O 0 4.19107818743214e-05
is O 0 3.3245899544454005e-07
caused O 0 5.020827984481002e-07
by O 0 1.0692011187529715e-07
a O 0 5.099148438603152e-06
CTG O 1 0.7905116677284241
expansion O 0 2.7570308702706825e-06
in O 0 6.500860649794049e-08
the O 0 1.0287644869322321e-07
3 O 0 3.5873000570063596e-07
untranslated O 0 1.6221858459175564e-05
region O 0 3.7636914385075215e-07
of O 0 6.834994792370708e-07
the O 0 6.5561116571188904e-06
DM B-Disease 1 1.0
gene O 0 4.6458353608613834e-05
. O 0 5.247312401479576e-06

One O 0 5.610719199466985e-06
model O 0 5.047437753091799e-06
of O 0 4.5531232899520546e-05
DM B-Disease 1 1.0
pathogenesis O 1 1.0
suggests O 0 5.1952683861600235e-06
that O 0 3.9322465283930796e-08
RNAs O 0 4.980927315045847e-06
from O 0 1.8742985830044745e-08
the O 0 1.2058135823167504e-08
expanded O 0 4.093274696970184e-08
allele O 0 1.9584646793191496e-08
create O 0 8.951637653353828e-09
a O 0 5.493917853982566e-08
gain O 0 3.7367141203503706e-07
- O 0 3.4190196629424463e-07
of O 0 2.1357291757340136e-07
- O 0 8.95920607035805e-07
function O 0 6.95222510671556e-08
mutation O 0 4.426144784019925e-09
by O 0 1.2007981275985458e-09
the O 0 7.097094467667375e-09
inappropriate O 0 8.085314107120212e-08
binding O 0 1.0435545760856257e-08
of O 0 1.989556430714856e-08
proteins O 0 2.5722036056663455e-08
to O 0 2.381614372382046e-08
the O 0 1.1723514035111293e-06
CUG O 1 0.9687477946281433
repeats O 0 6.454860704252496e-05
. O 0 7.146233656385448e-06

Data O 0 1.3774778381048236e-05
presented O 0 1.3937527683083317e-06
here O 0 3.2770853408692346e-07
indicate O 0 1.903895139321321e-07
that O 0 5.300555550036279e-09
the O 0 3.951893390308214e-08
conserved O 0 6.6603820414457e-07
heterogeneous O 0 1.1244787856412586e-06
nuclear O 0 5.229902671999298e-05
ribonucleoprotein O 0 0.006951536517590284
, O 0 1.1640265284995621e-07
CUG O 0 0.0001502432714914903
- O 0 3.8249703493420384e-07
binding O 0 4.6293525457485885e-08
protein O 0 8.879947444029312e-08
( O 0 3.5744694315553716e-08
CUG O 0 2.620610575831961e-05
- O 0 2.857247864085366e-06
BP O 0 1.0423587809782475e-05
) O 0 1.7013748632166426e-08
, O 0 4.204921744133117e-09
may O 0 8.505199211583658e-09
mediate O 0 1.0168275110800096e-07
the O 0 9.540683976183573e-08
trans O 0 7.690399570492445e-07
- O 0 2.5338263185403775e-06
dominant O 0 2.7703040927917755e-07
effect O 0 4.083114291120182e-08
of O 0 7.035463767124384e-08
the O 0 4.140258056395396e-07
RNA O 0 2.7829728423967026e-05
. O 0 1.1423774139984744e-06

CUG O 1 0.9997908473014832
- O 0 0.00883422326296568
BP O 0 0.00047084165271371603
was O 0 2.640434558998095e-06
found O 0 1.421327340267453e-07
to O 0 2.7549750925004446e-08
bind O 0 9.472344686400902e-08
to O 0 1.859677389859371e-08
the O 0 2.112881247740006e-07
human O 0 2.395743877059431e-06
cardiac O 1 0.9997103810310364
troponin O 1 0.998297393321991
T O 0 0.35907143354415894
( O 0 1.13123041955987e-06
cTNT O 0 3.618983464548364e-05
) O 0 2.6263631980327773e-07
pre O 0 7.526022727688542e-06
- O 0 2.3426132429449353e-06
messenger O 0 3.5190100788895506e-06
RNA O 0 5.353524556994671e-07
and O 0 3.4397029669008816e-09
regulate O 0 3.81383102876498e-08
its O 0 1.1095241170266945e-08
alternative O 0 2.867132309347653e-07
splicing O 0 6.24533686277573e-06
. O 0 1.5103727264431654e-06

Splicing O 0 0.0004303752793930471
of O 0 2.325142668269109e-05
cTNT O 0 0.0018735745688900352
was O 0 8.230072853621095e-05
disrupted O 0 0.0008017554064281285
in O 0 5.7799617934506387e-05
DM B-Disease 1 1.0
striated O 1 0.9985204339027405
muscle O 0 2.5230638129869476e-05
and O 0 7.194245199571014e-08
in O 0 2.14413915955447e-07
normal O 0 1.9371680537005886e-05
cells O 0 5.981116828479571e-07
expressing O 0 1.4381308233168966e-07
transcripts O 0 1.0247356385661988e-06
that O 0 1.7575901622990386e-08
contain O 0 5.671340659318957e-07
CUG O 0 0.0028195595368742943
repeats O 0 3.264543192926794e-05
. O 0 3.846864274237305e-06

Altered O 0 3.261138772359118e-05
expression O 0 1.1399808954593027e-06
of O 0 6.789298367948504e-07
genes O 0 6.343924496832187e-07
regulated O 0 9.0981495759479e-07
posttranscriptionally O 0 1.4764895240659826e-05
by O 0 4.3807014549201995e-07
CUG O 1 0.9999785423278809
- O 0 0.0003119471075478941
BP O 0 2.7753210815717466e-05
therefore O 0 8.503045734187253e-08
may O 0 2.7526587231818667e-08
contribute O 0 2.508560896785639e-07
to O 0 2.1661753635271452e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999927282333374
. O 0 1.5357474012489547e-06
. O 0 3.3070343761210097e-06

Identification O 0 2.0553839931380935e-05
of O 0 1.3045959121882333e-06
a O 0 8.37542472709174e-07
novel O 0 1.9908525246137287e-06
nonsense O 0 1.078808509191731e-05
mutation O 0 1.235070783422998e-07
and O 0 8.566382270203121e-09
a O 0 1.9512467019922042e-07
missense O 0 1.1597564935073024e-06
substitution O 0 1.2808615679205104e-07
in O 0 4.440335743538526e-08
the O 0 2.2355285977937456e-07
vasopressin O 0 1.1719786016328726e-05
- O 0 4.870443262916524e-06
neurophysin O 0 0.00011924965656362474
II O 0 0.05379673093557358
gene O 0 9.664237410333953e-08
in O 0 1.3063518267131258e-08
two O 0 9.131014166996465e-09
Spanish O 0 1.1907222869922407e-06
kindreds O 0 3.06677829939872e-05
with O 0 6.098484277572425e-07
familial B-Disease 1 0.999993085861206
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 0.00010173677583225071

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9999973773956299
FNDI B-Disease 1 1.0
) O 0 9.551001312502194e-06
is O 0 1.440028967181206e-07
an O 0 6.951083832973382e-07
autosomal B-Disease 1 0.9996826648712158
dominant I-Disease 1 0.9992827773094177
disease I-Disease 1 0.9999935626983643
caused O 0 0.02967056632041931
by O 0 1.4192311027727555e-05
deficiency O 1 1.0
in O 0 2.4784017114143353e-06
the O 0 2.4412101993220858e-05
antidiuretic O 0 0.20266127586364746
hormone O 0 4.622761935024755e-06
arginine O 0 6.393810963345459e-06
vasopressin O 0 8.911775694286916e-06
( O 0 6.687432119178993e-07
AVP O 0 1.733734825393185e-05
) O 0 1.6829618587621553e-08
encoded O 0 1.6006488579023426e-08
by O 0 7.0169940968867195e-09
the O 0 1.9311826804369048e-07
AVP O 0 0.00031062058405950665
- O 0 6.903992471052334e-06
neurophysin O 0 0.0007607840816490352
II O 1 0.9999971389770508
( O 0 0.00031432945979759097
AVP O 1 0.9985637068748474
- O 0 9.855998359853402e-05
NPII O 0 0.11145560443401337
) O 0 4.006000722256431e-07
gene O 0 1.7871835211735743e-07
on O 0 3.494319287256076e-07
chromosome O 0 5.8310673921369016e-05
20p13 O 0 0.0007048383704386652
. O 0 1.4800674762227573e-05

In O 0 1.0129538168257568e-06
this O 0 6.365231541849425e-08
study O 0 9.255335697844203e-08
, O 0 1.0652131621213812e-08
we O 0 1.4555350702494252e-08
analyzed O 0 1.1671912858446376e-07
two O 0 9.439480308515158e-09
families O 0 2.5831379701912738e-08
with O 0 3.696661110552668e-08
FNDI B-Disease 1 1.0
using O 0 2.2506053198867448e-07
direct O 0 2.3508486890477798e-07
automated O 0 4.596959684022295e-07
fluorescent O 0 1.9357290881316658e-08
, O 0 1.9061501266293135e-09
solid O 0 1.794393256204785e-08
phase O 0 5.89986122179198e-08
, O 0 5.288165016992252e-09
single O 0 1.2346464295376336e-08
- O 0 4.6965357825001774e-08
stranded O 0 9.765947339701597e-08
DNA O 0 2.6285949417115262e-08
sequencing O 0 4.111341667112356e-08
of O 0 3.9923044425904664e-08
PCR O 0 1.6580702322244179e-06
- O 0 3.0251017051341478e-06
amplified O 0 1.992006946238689e-05
AVP O 0 0.0007657649694010615
- O 0 2.2443055058829486e-05
NPII O 0 0.0008677940932102501
DNA O 0 3.5364613722776994e-05
. O 0 4.210351562505821e-06

In O 0 2.0750057956320234e-06
one O 0 1.0877032963207967e-07
of O 0 1.161246814262995e-07
the O 0 9.50178460357165e-08
families O 0 4.440657619397825e-08
, O 0 2.5913394097187847e-08
affected O 0 4.515907647828499e-08
individuals O 0 6.053816559159486e-09
presented O 0 1.9860158317897003e-07
a O 0 2.277312773912854e-07
novel O 0 3.6854112295259256e-07
nonsense O 0 1.3616382830150542e-06
mutation O 0 1.9123962857747756e-08
in O 0 1.0268644601296728e-08
exon O 0 3.312756007289863e-07
3 O 0 2.368910934080759e-08
of O 0 9.731637717891317e-09
the O 0 9.981055981711506e-09
gene O 0 8.128591133527152e-09
, O 0 1.7558837717146503e-09
consisting O 0 1.9823820807118864e-08
in O 0 1.7641662353184984e-08
a O 0 2.409500154954003e-07
G O 0 2.23275105781795e-06
to O 0 8.267616635748709e-08
T O 0 5.444209818961099e-05
transition O 0 4.904711659037275e-06
at O 0 8.195290320145432e-06
nucleotide O 0 3.2820429623825476e-05
2101 O 0 1.6480109479743987e-05
, O 0 7.006494939787444e-09
which O 0 1.0056877552955257e-09
produces O 0 2.2213391126513216e-09
a O 0 1.3881131799564628e-08
stop O 0 6.558636300724174e-08
signal O 0 2.5183285856655857e-07
in O 0 4.907940365228569e-08
codon O 0 2.788324991342961e-06
82 O 0 4.994488790543983e-06
( O 0 2.552095111241215e-06
Glu O 0 0.0009478623978793621
) O 0 6.776282930331945e-07
of O 0 2.6520885967329377e-06
NPII O 0 0.011274718679487705
. O 0 1.2884042916994076e-05

The O 0 4.2128773202421144e-05
premature O 0 9.731286991154775e-05
termination O 0 1.3085635146126151e-05
eliminates O 0 2.273602603963809e-06
part O 0 2.3615446309577237e-07
of O 0 3.0305452014545153e-07
the O 0 4.283035934804502e-07
C O 0 0.0011716679437085986
- O 0 7.16977083357051e-05
terminal O 0 1.9379958757781424e-05
domain O 0 7.333103440032573e-07
of O 0 1.5465752767340746e-07
NPII O 0 0.1831837147474289
, O 0 3.0636694958730004e-08
including O 0 1.517621761593091e-08
a O 0 5.105865241716856e-08
cysteine O 0 7.508721466820134e-08
residue O 0 1.7606070912279392e-07
in O 0 4.654423957362042e-09
position O 0 3.208310772606637e-08
85 O 0 6.907891503260544e-08
, O 0 2.708425927977487e-09
which O 0 7.043378658089239e-10
could O 0 1.3944122523312785e-09
be O 0 5.961279470056979e-09
involved O 0 4.813966825167881e-08
in O 0 3.165107997915584e-08
the O 0 3.241823094413121e-07
correct O 0 1.1279392310825642e-05
folding O 0 6.153208232717589e-05
of O 0 2.8179899800306885e-06
the O 0 5.315153430274222e-06
prohormone O 0 0.26804670691490173
. O 0 5.443995632958831e-06

In O 0 3.3072426504077157e-06
the O 0 8.373499440494925e-07
second O 0 2.178310523959226e-06
family O 0 6.207720844031428e-07
, O 0 6.413539921368283e-08
a O 0 3.042682408249675e-07
G279A O 0 3.987224772572517e-06
substitution O 0 1.528341329048999e-07
at O 0 5.436460241980967e-07
position O 0 3.313451202302531e-07
- O 0 2.2183684222909505e-07
1 O 0 5.833205563021693e-08
of O 0 1.4460492359091859e-08
the O 0 1.536342963959214e-08
signal O 0 1.6475458153308864e-07
peptide O 0 5.897296162515886e-08
was O 0 4.0605296902640475e-08
observed O 0 1.950487060753403e-08
in O 0 2.78709744172545e-09
all O 0 5.472089448232964e-09
affected O 0 3.398399073262226e-08
individuals O 0 4.755342075668523e-08
. O 0 7.470593459402153e-07

This O 0 5.917034286540002e-06
missense O 0 4.3928779632551596e-05
mutation O 0 9.470552981838409e-07
, O 0 5.5521933717272987e-08
which O 0 3.659996394844711e-08
replaces O 0 1.1519869985932019e-05
Ala O 0 0.25921252369880676
with O 0 2.618976964186004e-07
Thr O 1 0.9987008571624756
, O 0 8.764348535805766e-08
is O 0 3.8826630799349005e-08
frequent O 0 1.37783288778337e-07
among O 0 8.79061516911861e-08
FNDI B-Disease 1 1.0
patients O 0 6.425343599403277e-07
and O 0 2.260016707111845e-08
is O 0 7.684367631100031e-08
thought O 0 1.1964714019541134e-07
to O 0 8.649622351697417e-09
reduce O 0 5.359102317470388e-08
the O 0 2.310846838327052e-07
efficiency O 0 1.1104958730356884e-06
of O 0 6.612282277274062e-07
cleavage O 0 5.870132099516923e-06
by O 0 1.7648063987962814e-07
signal O 0 7.0787509685033e-06
peptidases O 0 5.533890362130478e-05
. O 0 3.623419502218894e-07
. O 0 1.421460524397844e-06

Genetic O 0 0.0006430914509110153
heterogeneity O 0 0.00019516472821123898
of O 0 0.0006870681536383927
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.5750122151512187e-07
due O 0 1.493989884693292e-06
to O 0 4.3244526182206755e-07
TWIST O 0 0.001059859641827643
and O 0 1.9175045053998474e-06
FGFR O 1 0.9999899864196777
mutations O 0 2.5340621505165473e-05
. O 0 8.091984454949852e-06

Thirty O 0 0.0004292060330044478
- O 0 2.3011072698864155e-05
two O 0 1.789250205774806e-07
unrelated O 0 1.7455884062655969e-06
patients O 0 1.9803639617066437e-08
with O 0 4.343102766313223e-09
features O 0 3.726514705704176e-07
of O 0 0.0001179243772639893
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 4.079113224975117e-08
a O 0 2.561477288054448e-07
common O 0 3.0130038908282586e-07
autosomal B-Disease 0 0.0038705782499164343
dominant I-Disease 0 6.499760638689622e-05
condition I-Disease 0 0.11299698054790497
of O 1 0.9902965426445007
craniosynostosis B-Disease 1 1.0
and O 0 0.44929763674736023
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999955892562866
, O 0 8.993224582809489e-07
were O 0 3.093974214607442e-07
screened O 0 3.4418383165757405e-07
for O 0 5.581051709668827e-08
mutations O 0 1.6891789300643723e-07
in O 0 3.227989964216249e-07
TWIST O 0 0.0015123492339625955
, O 0 2.9908276246715104e-06
FGFR2 O 1 0.999996542930603
, O 0 2.243900325993309e-06
and O 0 3.5671998830366647e-06
FGFR3 O 1 0.9999967813491821
. O 0 5.805908949696459e-05

Nine O 0 1.1602041013247799e-05
novel O 0 3.3168764730362454e-06
and O 0 1.3867654047317046e-07
three O 0 3.929874310415471e-07
recurrent O 0 5.445669012260623e-05
TWIST O 0 9.8734388302546e-05
mutations O 0 2.866924546651717e-07
were O 0 1.4111975588093628e-07
found O 0 1.5119594820589555e-07
in O 0 2.001993237854549e-07
12 O 0 3.5172786283510504e-06
families O 0 1.2095218835384003e-06
. O 0 4.381780854600947e-06

Seven O 0 8.332933248311747e-06
families O 0 1.2211499722525332e-07
were O 0 8.762509651205619e-08
found O 0 3.5064630310444045e-08
to O 0 9.462805650173323e-09
have O 0 1.3711852098197141e-08
the O 0 5.01375552630634e-07
FGFR3 O 1 0.9999843835830688
P250R O 0 0.0008989348425529897
mutation O 0 7.263253110068035e-08
, O 0 5.87899773307754e-09
and O 0 1.1790020071344998e-09
one O 0 2.5444957252318545e-09
individual O 0 1.493072665503803e-09
was O 0 4.8400959684613554e-08
found O 0 4.531842456856339e-09
to O 0 2.3779636038057106e-09
have O 0 1.0013987861157148e-08
an O 0 4.3846807784575503e-07
FGFR2 O 1 0.8993892669677734
VV269 O 0 0.0024083994794636965
- O 0 0.00010684528388082981
270 O 0 1.7888893125928007e-05
deletion O 0 1.6582962416578084e-05
. O 0 2.8492233923316235e-06

To O 0 1.5227502672132687e-06
date O 0 2.7975888770015445e-06
, O 0 9.866809591585479e-08
our O 0 8.917712079892226e-08
detection O 0 3.5715055446416955e-07
rate O 0 1.2809043425932032e-07
for O 0 2.675229637816301e-08
TWIST O 0 2.513707113394048e-05
or O 0 5.129321039021306e-07
FGFR O 0 0.34322428703308105
mutations O 0 8.143150864725612e-08
is O 0 1.9736443590545605e-08
68 O 0 1.909426430302119e-07
% O 0 1.666708371317327e-08
in O 0 8.394446027182312e-09
our O 0 2.95119065185645e-07
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999996423721313
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 7.997643791668452e-08
, O 0 6.981949240980612e-09
including O 0 6.7412297966029655e-09
our O 0 5.5835535306414386e-08
five O 0 4.042262347070391e-08
patients O 0 1.4622801636221539e-08
elsewhere O 0 4.188873603538923e-08
reported O 0 2.020057365825778e-07
with O 0 2.6753165016657476e-08
TWIST O 0 5.779355706181377e-05
mutations O 0 1.2989100923732622e-06
. O 0 9.602094905858394e-07

More O 0 2.0156987545760785e-07
than O 0 1.8188584860467927e-08
35 O 0 3.765180522918854e-08
different O 0 2.055264847200533e-09
TWIST O 0 3.9070525303941395e-07
mutations O 0 6.587569600924326e-09
are O 0 7.066065510485942e-10
now O 0 4.879022519332921e-09
known O 0 2.7632793830889568e-08
in O 0 3.405263981903772e-08
the O 0 2.4677126475580735e-07
literature O 0 4.605714366334723e-06
. O 0 1.4259695717555587e-06

The O 0 1.6330476455550524e-06
most O 0 1.72864886849311e-08
common O 0 1.007448879875028e-08
phenotypic O 0 5.425893618848932e-07
features O 0 2.0448695181585208e-07
, O 0 1.3090305728269414e-08
present O 0 4.168573397578257e-08
in O 0 8.811444018874681e-09
more O 0 1.7668962959405121e-09
than O 0 1.4609635723417114e-09
a O 0 9.859732585937309e-09
third O 0 2.775724716741479e-08
of O 0 1.3235494478180954e-08
our O 0 4.07559852533268e-08
patients O 0 9.317965066202305e-09
with O 0 3.101253920334557e-09
TWIST O 0 2.1539352019317448e-05
mutations O 0 4.4395822129672524e-08
, O 0 1.0408392370209185e-08
are O 0 1.527967619097126e-08
coronal B-Disease 0 0.00020935064821969718
synostosis I-Disease 0 0.00995553843677044
, O 0 4.758781528835243e-07
brachycephaly B-Disease 0 0.0271766297519207
, O 0 8.389046115553356e-07
low B-Disease 0 0.00021363665291573852
frontal I-Disease 1 0.999984860420227
hairline I-Disease 1 1.0
, O 0 6.393000603566179e-06
facial B-Disease 1 0.9952421188354492
asymmetry I-Disease 1 0.9999979734420776
, O 0 4.206706216791645e-05
ptosis B-Disease 1 0.9999996423721313
, O 0 1.4854182154522277e-05
hypertelorism B-Disease 1 0.9999775886535645
, O 0 2.553753120082547e-06
broad B-Disease 0 1.604903991392348e-05
great I-Disease 0 0.0005475259968079627
toes I-Disease 0 0.191913902759552
, O 0 2.7899154702026863e-06
and O 0 7.89073692430975e-06
clinodactyly B-Disease 1 0.9999302625656128
. O 0 0.00026073993649333715

Significant O 0 0.00010422823834232986
intra O 0 0.005479781422764063
- O 0 4.8447545850649476e-05
and O 0 2.4481258265041106e-07
interfamilial O 0 0.0003784251748584211
phenotypic O 0 1.3029375622863881e-05
variability O 0 5.9009294091083575e-06
is O 0 3.805561732406204e-08
present O 0 2.3194525411440736e-08
for O 0 8.498777681609226e-09
either O 0 2.0574944414875063e-07
TWIST O 0 7.491406722692773e-05
mutations O 0 1.4954067637518165e-06
or O 0 1.3851822586730123e-06
FGFR O 1 0.9998741149902344
mutations O 0 7.191019903984852e-06
. O 0 3.010332420672057e-06

The O 0 5.954627795290435e-06
overlap O 0 2.331145196876605e-06
in O 0 9.807293821495477e-08
clinical O 0 6.229592486306501e-07
features O 0 6.017268816549404e-08
and O 0 4.2958294699246835e-09
the O 0 2.8053175782360995e-08
presence O 0 6.027181598255993e-08
, O 0 7.847530625326726e-09
in O 0 4.503330153227125e-09
the O 0 8.245188531930125e-09
same O 0 7.625727604931853e-09
genes O 0 8.821364971822732e-09
, O 0 5.163465210955565e-10
of O 0 1.4068612941287029e-09
mutations O 0 5.253347756806193e-10
for O 0 1.559217199798013e-10
more O 0 1.6029752525348329e-10
than O 0 6.249056827556387e-10
one O 0 5.61077406757704e-09
craniosynostotic B-Disease 0 3.833870323433075e-06
condition I-Disease 0 1.2174793937447248e-06
- O 0 1.3676361731995712e-07
such O 0 4.058452685029579e-09
as O 0 5.552945481213101e-08
Saethre B-Disease 0 0.017759758979082108
- I-Disease 0 2.3191721993498504e-05
Chotzen I-Disease 0 0.0008113764342851937
, I-Disease 0 1.292995932544727e-07
Crouzon I-Disease 0 0.00014485105930361897
, I-Disease 0 9.13911932798328e-08
and I-Disease 0 2.0255554034065426e-07
Pfeiffer I-Disease 1 0.9992330074310303
syndromes I-Disease 0 0.00030124495970085263
- O 0 4.636272478819592e-06
support O 0 9.150841151495115e-08
the O 0 1.0944334150053692e-07
hypothesis O 0 3.2701106533750135e-07
that O 0 9.716725202224552e-09
TWIST O 0 1.1092130307588377e-06
and O 0 1.6432643690222903e-08
FGFRs O 0 6.818609836045653e-05
are O 0 4.842596101894969e-09
components O 0 1.5536947728378436e-07
of O 0 4.963160904480901e-08
the O 0 3.862248121322409e-08
same O 0 9.758890939792764e-08
molecular O 0 4.801807790499879e-06
pathway O 0 4.979698928764265e-07
involved O 0 2.0711484083335563e-08
in O 0 7.702765536521383e-09
the O 0 3.719200236673714e-08
modulation O 0 1.226190533998306e-06
of O 0 7.576609846182691e-07
craniofacial O 1 0.9999991655349731
and O 0 1.9944177438446786e-06
limb O 1 0.9999995231628418
development O 0 0.0020828288979828358
in O 0 6.112109076639172e-07
humans O 0 8.64494040797581e-07
. O 0 1.8674016644126823e-07
. O 0 7.931695904517255e-07

Mutation O 0 2.6110863473149948e-05
analysis O 0 5.630036866932642e-06
of O 0 7.079237093421398e-06
UBE3A O 1 1.0
in O 1 0.9981471300125122
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9887963533401489
. O 0 4.7333709517261013e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.999742329120636
AS B-Disease 1 1.0
) O 0 8.107340363494586e-06
is O 0 1.3544176624691318e-07
caused O 0 4.1712863207976625e-07
by O 0 2.534734733217192e-07
chromosome O 0 0.006244335789233446
15q11 O 1 0.9996613264083862
- O 1 0.9855449795722961
q13 O 1 0.9578681588172913
deletions O 0 6.62157935948926e-06
of O 0 1.7400055867256015e-06
maternal O 0 5.378872810979374e-05
origin O 0 1.4687660723211593e-06
, O 0 3.097312912814232e-07
by O 0 1.1393221939215437e-06
paternal O 1 0.9991914629936218
uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
( O 1 0.9874699115753174
UPD B-Disease 1 1.0
) O 0 1.7264698044527904e-06
15 O 0 2.0887216578557855e-07
, O 0 2.105675278585295e-08
by O 0 8.13340292893372e-08
imprinting O 1 0.6578759551048279
defects O 0 0.46572810411453247
, O 0 5.2210584300382834e-08
and O 0 2.5533259062626712e-08
by O 0 8.262036743644785e-08
mutations O 0 2.0785616072771518e-07
in O 0 4.305502727675048e-07
the O 0 9.965544450096786e-06
UBE3A O 1 0.9999305009841919
gene O 0 4.4448479457059875e-05
. O 0 4.574154900183203e-06

UBE3A O 1 0.9841083884239197
encodes O 0 0.00016610242892056704
a O 0 1.0297150765836705e-05
ubiquitin O 0 0.00011919894313905388
- O 0 7.455566810676828e-05
protein O 0 3.214122216377291e-06
ligase O 0 1.6197280274354853e-05
and O 0 5.987308071553343e-08
shows O 0 1.0648677744029555e-06
brain O 0 0.00032498501241207123
- O 0 8.132305993058253e-06
specific O 0 8.92657624262938e-07
imprinting O 0 0.00023979635443538427
. O 0 6.662619853159413e-06

Here O 0 6.858998858660925e-06
we O 0 6.486356483037525e-07
describe O 0 1.0773958820209373e-05
UBE3A O 1 0.5613857507705688
coding O 0 0.0004623604763764888
- O 0 7.2029620241664816e-06
region O 0 2.2196212512426428e-07
mutations O 0 8.899004910745134e-08
detected O 0 8.053409317199112e-08
by O 0 1.9355702818302234e-08
SSCP O 0 0.01390249002724886
analysis O 0 1.881821702909292e-07
in O 0 2.3303520890749496e-08
13 O 0 3.8379783973141457e-07
AS B-Disease 0 0.0040457905270159245
individuals O 0 6.793728601905968e-08
or O 0 5.291477123137156e-07
families O 0 9.294800520365243e-07
. O 0 3.13430041387619e-06

Two O 0 2.3330044314207043e-06
identical O 0 2.002635937969899e-06
de O 0 2.7284910174785182e-05
novo O 0 2.1450756321428344e-05
5 O 0 7.499398634536192e-06
- O 0 1.8464483218849637e-05
bp O 0 2.5755873139132746e-05
duplications O 0 2.027818663918879e-05
in O 0 9.515039778307255e-07
exon O 0 1.1478724445623811e-05
16 O 0 1.5866294234001543e-06
were O 0 6.588966243725736e-07
found O 0 1.1131380688311765e-06
. O 0 2.53714142672834e-06

Among O 0 8.721505651010375e-07
the O 0 1.9539766071829945e-07
other O 0 8.966128284271235e-09
11 O 0 1.3797605902254872e-07
unique O 0 6.394924412234104e-08
mutations O 0 1.7609826485909252e-08
, O 0 8.4585742854415e-09
8 O 0 1.1561901658296847e-07
were O 0 8.375977245123067e-08
small O 0 7.777395438779422e-08
deletions O 0 5.446745490189642e-07
or O 0 2.6332324409850116e-07
insertions O 0 5.417293323262129e-06
predicted O 0 3.726617933352827e-06
to O 0 1.0503504199732561e-07
cause O 0 2.675761152204359e-06
frameshifts O 0 0.0010975772747769952
, O 0 2.1108391479174315e-07
1 O 0 3.3268131005570467e-07
was O 0 3.290570305125584e-07
a O 0 3.099522771776719e-08
mutation O 0 3.382192526046879e-09
to O 0 1.643354341496206e-09
a O 0 4.6437143907951395e-08
stop O 0 1.2125855164413224e-07
codon O 0 4.96589336762554e-07
, O 0 1.0296395736020258e-08
1 O 0 3.217085620121907e-08
was O 0 8.440946430710028e-08
a O 0 3.7272464226134616e-08
missense O 0 2.3228089673921204e-07
mutation O 0 6.344829550641862e-09
, O 0 1.3758292283228002e-09
and O 0 1.3077171567843493e-09
1 O 0 3.013227711790023e-08
was O 0 2.1053324417152908e-07
predicted O 0 1.29720518771137e-07
to O 0 6.177858224987176e-09
cause O 0 1.4320050922833616e-07
insertion O 0 1.2739448038701084e-06
of O 0 7.142671734072792e-07
an O 0 6.192536829985329e-07
isoleucine O 0 0.001052314881235361
in O 0 1.1508855379815941e-07
the O 0 2.3246084879247064e-07
hect O 0 2.3636095647816546e-05
domain O 0 7.012807827777578e-07
of O 0 1.0264790972769333e-07
the O 0 1.8841562621219055e-07
UBE3A O 0 0.003932572901248932
protein O 0 1.8480376695606537e-07
, O 0 3.85763732069222e-09
which O 0 3.626750011420654e-09
functions O 0 4.630641825542625e-08
in O 0 4.781609064252734e-08
E2 O 0 1.067497578333132e-05
binding O 0 1.7407029417881859e-07
and O 0 1.3894806727421383e-07
ubiquitin O 0 8.22170295577962e-06
transfer O 0 4.82136874779826e-06
. O 0 5.835347565152915e-06

Eight O 0 1.0702202416723594e-05
of O 0 8.134206836984958e-07
the O 0 2.6184923740402155e-07
cases O 0 9.918925769625275e-08
were O 0 5.738838808611035e-07
familial O 0 0.00018448052287567407
, O 0 3.054512376365892e-07
and O 0 1.0812290440753713e-07
five O 0 5.217783609623439e-07
were O 0 1.7401996501575923e-06
sporadic O 0 4.328719660406932e-05
. O 0 4.439283657120541e-06

In O 0 3.256422360209399e-06
two O 0 3.3167580681947584e-07
familial O 0 1.0980525985360146e-05
cases O 0 6.800379992455419e-08
and O 0 2.454638448057267e-08
one O 0 9.779163434586735e-08
sporadic O 0 2.7377002425055252e-06
case O 0 4.033167897432577e-07
, O 0 2.3497995016441564e-07
mosaicism O 0 0.1790899932384491
for O 0 5.310161554916704e-07
UBE3A O 1 0.9993657469749451
mutations O 0 1.856552103163267e-07
was O 0 6.911212153681845e-07
detected O 0 1.5303015743484139e-07
in O 0 9.674487877475713e-09
the O 0 3.113363788997958e-08
mother O 0 2.446996063554252e-07
of O 0 1.4929258895790554e-07
three O 0 9.851915194758476e-08
AS B-Disease 1 0.9999927282333374
sons O 1 0.9076690077781677
, O 0 2.045216547230666e-07
in O 0 8.024812103712975e-08
the O 0 5.555339157581329e-07
maternal O 0 9.648587729316205e-05
grandfather O 0 0.0003074310370720923
of O 0 1.5901770211712574e-06
two O 0 7.080656416746933e-08
AS B-Disease 1 0.7972573041915894
first O 0 1.2809766758437036e-06
cousins O 0 4.131334208068438e-06
, O 0 3.0361540837020584e-08
and O 0 1.1449538206420584e-08
in O 0 5.6589261276940306e-08
the O 0 3.7431911437124654e-07
mother O 0 3.308535951873637e-06
of O 0 3.947429831896443e-06
an O 0 2.1339801605790854e-05
AS B-Disease 1 0.9999998807907104
daughter O 1 0.9999855756759644
. O 0 9.921837772708386e-05

The O 0 5.682900336978491e-07
frequencies O 0 8.412946783664665e-08
with O 0 2.444022983993932e-09
which O 0 1.9563803910216393e-09
we O 0 8.335636181300288e-09
detected O 0 3.6718692086878946e-08
mutations O 0 3.2367177826841953e-09
were O 0 1.630980150935102e-08
5 O 0 4.6537159903436986e-08
( O 0 2.564815559935596e-08
14 O 0 5.583191509117569e-08
% O 0 8.52743564649927e-09
) O 0 2.081618877269875e-09
of O 0 4.32237667880031e-09
35 O 0 1.7007257824275257e-08
in O 0 2.7994684348442433e-09
sporadic O 0 4.8959353904365344e-08
cases O 0 1.7261637674792496e-09
and O 0 1.2704334251267824e-09
8 O 0 3.4329797671261986e-08
( O 0 1.3716638491700905e-08
80 O 0 4.3672446992104597e-08
% O 0 7.589624928527883e-09
) O 0 2.429800138870064e-09
of O 0 6.806566865691366e-09
10 O 0 2.432824786069432e-08
in O 0 2.7967375970661124e-08
familial O 0 1.7296617897955002e-06
cases O 0 1.1953514444940083e-07
. O 0 4.114488092454849e-07
. O 0 3.373012305019074e-06

The O 0 0.0008477144292555749
hemochromatosis B-Disease 1 0.9999990463256836
845 O 0 0.00063183723250404
G O 0 0.0001618473615963012
- O 0 2.8947026294190437e-05
- O 0 6.413787104975199e-06
> O 0 1.321276386079262e-06
A O 0 1.1959762957758358e-07
and O 0 3.28022853324228e-09
187 O 0 3.4906349810626125e-08
C O 0 1.9085744895619428e-07
- O 0 1.965110669743808e-07
- O 0 4.111393252514972e-07
> O 0 7.078737667143287e-07
G O 0 4.276579090856103e-07
mutations O 0 1.2903346835457796e-08
: O 0 8.957666608466752e-09
prevalence O 0 8.400375861583598e-08
in O 0 1.0771325165137569e-08
non O 0 1.7732564856487443e-06
- O 0 2.7232556021772325e-05
Caucasian O 0 8.631375385448337e-05
populations O 0 4.4300918489170726e-07
. O 0 8.736290055821883e-07

Hemochromatosis B-Disease 1 1.0
, O 0 3.4270651667611673e-05
the O 0 0.04562873765826225
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 2.4128299628500827e-05
leads O 0 3.894347173627466e-05
, O 0 2.733932547016593e-07
if O 0 5.096417794447916e-07
untreated O 1 0.6844455599784851
, O 0 2.8703661314466444e-07
to O 0 1.487927079324436e-06
progressive O 1 0.9999979734420776
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 2.454727109579835e-05
premature B-Disease 1 0.6810449957847595
death I-Disease 0 0.0004143866244703531
. O 0 1.9379460354684852e-05

The O 0 0.0017113888170570135
hemochromatosis B-Disease 1 1.0
gene O 0 0.04105675220489502
, O 0 9.496993698121514e-06
HFE O 1 0.9999998807907104
, O 0 1.9181688060143642e-07
recently O 0 1.323668499253472e-07
has O 0 2.16542472841752e-09
been O 0 5.585489404325017e-09
identified O 0 2.6966384680804367e-08
, O 0 4.372026296550757e-09
and O 0 5.649713141764323e-09
characterization O 0 6.516322059724189e-07
of O 0 7.067878016187024e-08
this O 0 2.7777584676869083e-08
gene O 0 2.502679308236111e-08
has O 0 9.431070369103622e-10
shown O 0 1.9776604798238395e-09
that O 0 1.6598890317798265e-10
it O 0 1.5738731151682117e-10
contains O 0 7.952549729850489e-10
two O 0 3.5680428056572566e-10
mutations O 0 6.371384531078661e-10
that O 0 1.1951992173742099e-10
result O 0 1.868098342683311e-09
in O 0 3.3021241296893322e-09
amino O 0 3.3441104108078434e-08
acid O 0 1.377731262408588e-08
substitutions O 0 2.2638303676103533e-08
- O 0 1.2277791938686278e-07
cDNA O 0 4.6370232098524866e-07
nucleotides O 0 3.251346569754787e-08
845 O 0 1.4133605930055637e-07
G O 0 1.255195343219384e-07
- O 0 7.12370606947843e-08
- O 0 1.7245660899334325e-07
> O 0 1.2986805586479022e-07
A O 0 1.9569118592244195e-07
( O 0 1.4348671584230033e-08
C282Y O 0 2.2030663160421682e-07
) O 0 1.2120549008898251e-09
and O 0 7.879112917663633e-10
187 O 0 1.0719226395394799e-08
C O 0 5.5189772751873534e-08
- O 0 9.689597391115967e-08
- O 0 4.868604150942701e-07
> O 0 1.5491364138142671e-06
G O 0 4.999110842618393e-06
( O 0 6.954730906727491e-07
H63D O 0 0.00022331647051032633
) O 0 9.673768772699987e-07
. O 0 1.272656504625047e-06

Although O 0 0.013509633019566536
hemochromatosis B-Disease 1 1.0
is O 0 3.0019266432645964e-06
common O 0 5.54387554529967e-07
in O 0 3.644660750978801e-07
Caucasians O 0 1.6466519809910096e-05
, O 0 1.2581747910189733e-07
affecting O 0 6.484501113845909e-07
> O 0 9.160111176242935e-07
= O 0 8.821223786981136e-07
1 O 0 2.1436260055907042e-07
/ O 0 2.511584114017751e-07
300 O 0 1.40016425120848e-08
individuals O 0 6.027383592233093e-10
of O 0 2.689235722996841e-09
northern O 0 4.3627963464132336e-09
European O 0 3.939789383622383e-09
origin O 0 9.473768436407681e-09
, O 0 1.3410648147527127e-09
it O 0 2.5923849178433045e-10
has O 0 2.876292259923474e-10
not O 0 3.2012900663680455e-10
been O 0 3.1025020330588404e-09
recognized O 0 4.1292973484985396e-09
in O 0 6.368593652439358e-09
other O 0 8.977353971317825e-09
populations O 0 1.1666015353739567e-07
. O 0 6.529229494844913e-07

The O 0 1.948245198946097e-06
present O 0 1.8064351081648056e-07
study O 0 5.488136523013054e-08
used O 0 3.782448487754664e-08
PCR O 0 1.875697677178323e-07
and O 0 4.688514021466972e-09
restriction O 0 1.838260885733689e-07
- O 0 4.1922709215214127e-07
enzyme O 0 1.2733821108668053e-07
digestion O 0 7.628028697581613e-08
to O 0 2.0305379599960816e-09
analyze O 0 3.58797365151986e-08
the O 0 6.082798709172721e-09
frequency O 0 1.008944838787329e-08
of O 0 7.781977728882339e-09
the O 0 3.7065170488403965e-08
845 O 0 5.615519285129267e-07
G O 0 4.6843416612318833e-07
- O 0 1.9640482662452996e-07
- O 0 1.6996436613680999e-07
> O 0 1.2341618571554136e-07
A O 0 3.1875355688271156e-08
and O 0 8.457715083842743e-10
187 O 0 9.99511584609536e-09
C O 0 5.898792210246029e-08
- O 0 6.782930483950622e-08
- O 0 2.2493050266803039e-07
> O 0 3.218712834041071e-07
G O 0 3.0503323955599626e-07
mutations O 0 1.535300242494486e-08
in O 0 1.3960469225082761e-08
HLA O 0 2.1527027911361074e-06
- O 0 8.110598770372235e-08
typed O 0 1.0112861303923637e-07
samples O 0 4.931528518881123e-09
from O 0 4.5605963450157105e-09
non O 0 1.7172267519072193e-07
- O 0 4.0179190818889765e-07
Caucasian O 0 6.946365260773746e-07
populations O 0 3.129992043326979e-09
, O 0 1.7750673153571483e-09
comprising O 0 3.421500949229994e-08
Australian O 0 9.410160828338121e-07
Aboriginal O 0 1.9290744148747763e-06
, O 0 3.4256736114457453e-08
Chinese O 0 2.7089961918136396e-07
, O 0 1.3891753525285822e-08
and O 0 1.9835015407920764e-08
Pacific O 0 4.544761395663954e-06
Islanders O 0 7.002569418546045e-06
. O 0 1.5264171224771417e-06

Results O 0 7.850280780985486e-06
showed O 0 1.1891835356436786e-06
that O 0 2.307512048105309e-08
the O 0 7.641396848612203e-08
845 O 0 1.9180606614099815e-06
G O 0 3.890428160957526e-06
- O 0 7.64939613873139e-06
- O 0 5.805013188364683e-06
> O 0 1.5382246374429087e-06
A O 0 2.1001648065066547e-07
mutation O 0 9.138157786026113e-09
was O 0 1.1609674110957258e-08
present O 0 2.8886968372887623e-09
in O 0 7.61435747786976e-10
these O 0 3.942403625778468e-10
populations O 0 1.1014897882688501e-09
( O 0 1.5226253591293926e-09
allele O 0 1.6234066313458584e-09
frequency O 0 1.6461024765490606e-09
0 O 0 7.032492366221277e-10
. O 0 1.8204462937099208e-10
32 O 0 5.311566297905301e-09
% O 0 1.8433469195500152e-09
) O 0 7.622203979096298e-10
, O 0 4.5197981468625414e-10
and O 0 5.00970154249103e-10
, O 0 2.6104469696974775e-09
furthermore O 0 1.5509140638414465e-08
, O 0 2.1707926567415825e-09
it O 0 2.1559956042693784e-09
was O 0 1.1539187738662804e-07
always O 0 5.7766833094774483e-08
seen O 0 5.883656228888867e-08
in O 0 1.222433443359705e-08
conjunction O 0 2.3003849491942674e-07
with O 0 1.2077589417458512e-07
HLA O 1 0.9831686019897461
haplotypes O 0 4.462982360564638e-06
common O 0 2.114255437390966e-08
in O 0 2.1803957750421432e-08
Caucasians O 0 7.031143240965321e-07
, O 0 9.230704201002027e-09
suggesting O 0 6.228606963532002e-08
that O 0 6.831708532217817e-09
845 O 0 7.769564831505704e-07
G O 0 1.3342655620363075e-06
- O 0 1.8789644400385441e-06
- O 0 2.76592732006975e-06
> O 0 6.365298759192228e-07
A O 0 7.390195833067992e-08
may O 0 2.6115922757696808e-09
have O 0 1.6091510068871884e-10
been O 0 5.972395356046434e-10
introduced O 0 8.080435209834036e-10
into O 0 5.970117733511415e-10
these O 0 5.431532446031895e-10
populations O 0 3.4282079397485177e-09
by O 0 1.839477370424447e-08
Caucasian O 0 3.074039705097675e-05
admixture O 0 1.9963126760558225e-05
. O 0 2.4079524791886797e-06

187 O 0 4.417031959746964e-06
C O 0 7.700528840359766e-06
- O 0 2.5656531761342194e-06
- O 0 4.406992957228795e-06
> O 0 3.963938070228323e-06
G O 0 2.2840517885924783e-06
was O 0 4.1696355879139446e-07
present O 0 4.694547328654153e-08
at O 0 1.111312073476256e-07
an O 0 1.1914540465340906e-08
allele O 0 1.945114824764005e-08
frequency O 0 5.217992082862111e-08
of O 0 1.0879688971954238e-07
2 O 0 1.4026001053935033e-06
. O 0 1.7086127854781807e-06

68 O 0 8.711335976840928e-05
% O 0 4.4771084617423185e-07
in O 0 1.0174344033941907e-08
the O 0 9.470443096404324e-09
two O 0 2.328795822847951e-09
populations O 0 2.7656612555659876e-09
analyzed O 0 4.349239191014931e-08
( O 0 4.429575639619543e-08
Australian O 0 1.125822223002615e-06
Aboriginal O 0 1.7582390228199074e-06
and O 0 3.1253584609203244e-08
Chinese O 0 2.4115606720442884e-06
) O 0 2.0858394123024482e-07
. O 0 2.533180918362632e-07

In O 0 1.113794155571668e-06
the O 0 2.9261082090670243e-07
Australian O 0 1.171910867014958e-06
Aboriginal O 0 6.083741368456685e-07
samples O 0 2.0169903081068696e-08
, O 0 4.313382984122427e-09
187 O 0 6.180087552820623e-08
C O 0 2.7384106715544476e-07
- O 0 3.1105952302823425e-07
- O 0 6.8779024786636e-07
> O 0 3.896618636645144e-07
G O 0 1.380537213435673e-07
was O 0 2.2178559433427836e-08
found O 0 1.761582990589261e-09
to O 0 6.638878891074285e-10
be O 0 2.031413481873301e-09
associated O 0 6.407561414789598e-08
with O 0 2.2066031135636877e-07
HLA O 1 0.9999834299087524
haplotypes O 0 5.64891388421529e-06
common O 0 1.2682551009390863e-08
in O 0 2.5587276297756034e-08
Caucasians O 0 1.8518178421800258e-06
, O 0 1.319045761505322e-08
suggesting O 0 8.002420059938231e-08
that O 0 2.9855544703139003e-09
it O 0 1.4957290961348235e-09
was O 0 3.275266280411415e-08
introduced O 0 5.1413757695684126e-09
by O 0 1.6965916671551895e-08
recent O 0 1.7734312507400318e-07
admixture O 0 3.7956635878799716e-06
. O 0 9.553901918479824e-07

In O 0 2.5073820779653033e-06
the O 0 3.1987181614567817e-07
Chinese O 0 2.7646271405501466e-07
samples O 0 8.59751470017045e-09
analyzed O 0 2.4924469599341137e-08
, O 0 5.2176609699472465e-09
187 O 0 2.5190868058189153e-08
C O 0 1.313236168698495e-07
- O 0 1.6868253283064405e-07
- O 0 3.617805077738012e-07
> O 0 5.259088311504456e-07
G O 0 2.968267551750614e-07
was O 0 7.956047198831584e-08
present O 0 2.6147736420512047e-08
in O 0 9.980713144841502e-09
association O 0 1.0331648425676576e-08
with O 0 1.0792521321079107e-09
a O 0 2.223111827959201e-08
wide O 0 2.1638982161675813e-08
variety O 0 1.4656811764268696e-08
of O 0 1.3670978660229594e-06
HLA O 1 0.9733592867851257
haplotypes O 0 1.5635632735211402e-06
, O 0 6.798470675306589e-09
showing O 0 3.101095913393692e-08
this O 0 1.4500644018866637e-09
mutation O 0 9.250562538198892e-10
to O 0 4.859423974323818e-10
be O 0 2.134017407229294e-09
widespread O 0 1.0414607842790247e-08
and O 0 2.3642150459579625e-09
likely O 0 1.540392169374627e-08
to O 0 1.102903102179198e-08
predate O 0 9.66482389230805e-07
the O 0 1.3085762695652647e-08
more O 0 8.65110261205615e-10
genetically O 0 2.7742623753823636e-09
restricted O 0 6.279072817250153e-09
845 O 0 2.039241309148565e-07
G O 0 4.30285155061938e-07
- O 0 6.211665208866179e-07
- O 0 1.1662159522529691e-06
> O 0 1.7908223526319489e-06
A O 0 4.605068397722789e-07
mutation O 0 1.7117231720931159e-07
. O 0 2.063100197347012e-07

Genotype O 0 0.003245933912694454
- O 0 0.0002829001459758729
phenotype O 0 1.9326971596456133e-05
correlations O 0 2.455968024150934e-05
in O 0 8.022047950362321e-06
attenuated B-Disease 1 0.8779588341712952
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999997615814209
. O 0 0.0002002884866669774

Germ O 1 0.9999996423721313
- O 0 0.0008789841085672379
line O 0 2.8116012344980845e-06
mutations O 0 1.3181811198137439e-07
of O 0 1.0372684045023561e-07
the O 0 7.959376375765714e-07
tumor B-Disease 1 0.9920599460601807
suppressor O 0 0.010512014850974083
APC O 0 9.492376193520613e-06
are O 0 1.8081012242987526e-08
implicated O 0 3.970862053392921e-06
in O 0 2.4579119326517684e-06
attenuated B-Disease 1 0.9958482980728149
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9999995231628418
AAPC B-Disease 1 1.0
) O 0 7.999068657227326e-06
, O 0 1.9445108989657456e-07
a O 0 1.2606336667886353e-06
variant O 0 1.8403483409201726e-05
of O 0 0.004676372744143009
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 1.0
FAP B-Disease 1 1.0
) O 0 0.0005476215155795217
. O 0 3.6770736187463626e-05

AAPC B-Disease 1 1.0
is O 0 1.4571594419976464e-06
recognized O 0 1.0872656019955684e-07
by O 0 1.0722948751151762e-08
the O 0 3.7855951262599774e-08
occurrence O 0 8.93107255706127e-07
of O 0 8.258655270765303e-07
< O 1 0.7525644302368164
100 O 0 0.00011042317055398598
colonic B-Disease 1 0.999546229839325
adenomas I-Disease 0 0.0004960924270562828
and O 0 5.571104466639554e-09
a O 0 5.2451230914130065e-08
later O 0 3.7941620689707634e-07
onset O 1 0.9554608464241028
of O 1 0.9990547299385071
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.002403130754828453
age O 0 0.0012763196136802435
> O 0 9.439062523597386e-06
40 O 0 3.237201440242643e-07
years O 0 2.4832800704643887e-07
) O 0 2.280703341739354e-07
. O 0 7.048410566312668e-07

The O 0 5.687812972610118e-06
aim O 0 1.674903614912182e-06
of O 0 9.350227259119492e-08
this O 0 1.4527614666803856e-08
study O 0 1.9934118355990904e-08
was O 0 5.851547513202604e-08
to O 0 8.563669773309357e-09
assess O 0 1.1863110103149666e-06
genotype O 0 1.490421527705621e-05
- O 0 2.963897532026749e-05
phenotype O 0 1.028623682941543e-05
correlations O 0 1.7812086298363283e-05
in O 0 5.1109445848851465e-06
AAPC B-Disease 1 1.0
families O 0 6.597583251277683e-06
. O 0 6.498704806290334e-06

By O 0 3.6090459616389126e-06
protein O 0 4.629627255781088e-06
- O 0 1.0890314570133341e-06
truncation O 0 9.379194125358481e-06
test O 0 6.088263262427063e-07
( O 0 1.0229663303107372e-06
PTT O 0 3.6870947951683775e-05
) O 0 2.2446201342063432e-08
assay O 0 5.3727656990076866e-08
, O 0 1.6328938201581877e-09
the O 0 4.4827626055621295e-09
entire O 0 2.0466058003876242e-07
coding O 0 4.5970867290634487e-07
region O 0 7.607106766727156e-08
of O 0 1.3478074833983555e-07
the O 0 6.312096729743644e-07
APC B-Disease 0 1.1685579011100344e-05
gene O 0 4.944716991417408e-08
was O 0 1.4665094738575135e-07
screened O 0 9.565373915165765e-08
in O 0 1.1065356630979295e-08
affected O 0 1.1487335527249343e-08
individuals O 0 3.929732983465328e-09
from O 0 1.7433960408652638e-07
11 O 0 0.0019328383496031165
AAPC B-Disease 1 1.0
kindreds O 0 0.058336175978183746
, O 0 6.022171561426148e-08
and O 0 4.391373487067085e-09
their O 0 4.581127477365499e-09
phenotypic O 0 2.434636030557158e-07
differences O 0 1.5693339605604706e-07
were O 0 5.53538541225862e-07
examined O 0 1.0503566954866983e-05
. O 0 4.559930403047474e-06

Five O 0 9.113441592489835e-06
novel O 0 3.2347190426662564e-05
germ O 1 0.9990609288215637
- O 0 0.001170421834103763
line O 0 1.985709968721494e-05
APC B-Disease 0 8.600932233093772e-06
mutations O 0 5.741609498954858e-08
were O 0 6.032828991919814e-08
identified O 0 3.5685945931618335e-07
in O 0 1.5040971845792228e-07
seven O 0 3.0294495445559733e-06
kindreds O 0 0.00033141730818897486
. O 0 8.672961484990083e-06

Mutations O 0 2.458590461174026e-05
were O 0 1.5732646261312766e-06
located O 0 6.452460183936637e-07
in O 0 2.0843613057763832e-08
three O 0 2.4860740133192394e-09
different O 0 1.350758171980715e-09
regions O 0 7.859275008570421e-09
of O 0 8.941522366967547e-08
the O 0 5.388410500017926e-07
APC B-Disease 0 1.1266727597103454e-05
gene O 0 7.147060188117393e-08
( O 0 1.8442447569100295e-08
1 O 0 2.9345637031497063e-08
) O 0 7.99247068528075e-09
at O 0 4.3480284261931956e-08
the O 0 1.6906673394601057e-08
5 O 0 4.6612310455884653e-08
end O 0 1.836974661273416e-07
spanning O 0 4.996290385861357e-07
exons O 0 9.520397270534886e-08
4 O 0 2.4406887177974568e-08
and O 0 2.2911788022383917e-09
5 O 0 1.1402420341255493e-08
, O 0 3.3969844714931696e-09
( O 0 5.3546957978767296e-09
2 O 0 1.745759270477265e-08
) O 0 4.240294337876094e-09
within O 0 9.092363306706375e-09
exon O 0 6.43542534817243e-08
9 O 0 2.3873994337009208e-08
, O 0 1.0265642780282747e-09
and O 0 1.186423626009514e-09
( O 0 6.595917589891087e-09
3 O 0 2.2236164909372746e-08
) O 0 4.767309214059878e-09
at O 0 2.9526310285632462e-08
the O 0 1.8863419271042403e-08
3 O 0 1.4798395397974673e-07
distal O 0 9.922935078066075e-07
end O 0 2.9096486287016887e-07
of O 0 2.935213956334337e-07
the O 0 1.5584926131850807e-06
gene O 0 3.3530316159158247e-06
. O 0 1.825551066758635e-06

Variability O 0 0.0001871583517640829
in O 0 2.6358907234680373e-07
the O 0 1.3746331717356952e-07
number O 0 1.246418293021634e-07
of O 0 0.00039269617991521955
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.44196292757987976
most O 0 2.6355730042837422e-08
apparent O 0 1.8033969695352425e-07
in O 0 7.403411217410394e-09
individuals O 0 2.643304464200469e-09
with O 0 2.2098740615206225e-09
mutations O 0 1.0643256054265748e-08
in O 0 1.4002337067609005e-08
region O 0 1.4750010279840353e-07
1 O 0 9.115701686823741e-07
, O 0 3.7516105777513076e-08
and O 0 2.7472927044414064e-08
upper O 0 0.22584529221057892
- O 1 0.8214114904403687
gastrointestinal O 0 0.00704260915517807
manifestations O 0 1.1964424629695714e-05
were O 0 3.609517023051012e-07
more O 0 1.9215518065607284e-08
severe O 0 5.604519515145512e-07
in O 0 1.2237239843670977e-07
them O 0 3.0371188586286735e-07
. O 0 3.269760100010899e-06

In O 0 1.5759706002427265e-06
individuals O 0 4.766020822444261e-08
with O 0 1.4130796976985494e-08
mutations O 0 6.370636640440352e-08
in O 0 2.6347185766439907e-08
either O 0 6.575897515403994e-08
region O 0 5.32303943145962e-07
2 O 0 4.206030723707954e-07
or O 0 4.533634268000242e-08
region O 0 8.518060923279336e-08
3 O 0 5.643103406782757e-08
, O 0 2.8983551114691863e-09
the O 0 6.923202899855596e-09
average O 0 1.634362156721636e-08
number O 0 2.8790434480896465e-09
of O 0 3.943904047787328e-08
adenomas B-Disease 0 2.3930377210490406e-05
tended O 0 1.881376121559697e-08
to O 0 1.575988561874908e-09
be O 0 4.693291533186539e-09
lower O 0 2.3230965595644193e-08
than O 0 1.1142932132557348e-09
those O 0 8.417577745944982e-10
in O 0 2.111522068304339e-09
individuals O 0 1.0642012826522773e-09
with O 0 6.471064795121606e-10
mutations O 0 7.2338979251185265e-09
in O 0 3.528843661726455e-09
region O 0 3.087945188440244e-08
1 O 0 3.452324293107267e-08
, O 0 2.6647068995799827e-09
although O 0 3.2855822507116272e-09
age O 0 6.803792018672539e-08
at O 0 4.660511194742867e-07
diagnosis O 0 1.977134843400563e-06
was O 0 6.166335992929817e-07
similar O 0 1.0012558959715534e-07
. O 0 9.351803100798861e-07

In O 0 1.764306034601759e-05
all O 0 1.464558135921834e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.0804872214794159
, O 0 1.1078323041147087e-06
a O 0 1.5683571064073476e-06
predominance O 0 4.405483923619613e-05
of O 0 1.4937853848095983e-05
right O 0 0.12587083876132965
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.7895787954330444
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999194145202637
sparing O 0 6.020831278874539e-05
was O 0 1.6677977328072302e-05
observed O 0 7.5990524237568025e-06
. O 0 3.6250933135306695e-06

No O 0 0.0031019446905702353
desmoid B-Disease 1 0.9999998807907104
tumors I-Disease 1 1.0
were O 0 1.806801833481586e-06
found O 0 3.133127108867484e-07
in O 0 1.3414215516149852e-07
these O 0 2.221340622554635e-07
kindreds O 0 0.00019319658167660236
. O 0 9.254950782633387e-06

Our O 0 8.244928721978795e-06
data O 0 1.2557501349874656e-06
suggest O 0 2.9739570095443923e-07
that O 0 3.152431560238256e-08
, O 0 1.0059898869485551e-07
in O 0 1.4741278846486239e-06
AAPC B-Disease 1 1.0
families O 0 2.3495665857353742e-07
, O 0 3.2728369347978514e-08
the O 0 6.007189057299911e-08
location O 0 5.405771048572205e-07
of O 0 1.6271343383778003e-07
the O 0 5.581168238677492e-07
APC B-Disease 0 2.4011347704799846e-05
mutation O 0 6.135948638075206e-08
may O 0 4.31628208730217e-08
partially O 0 9.075271236724802e-07
predict O 0 2.923508475305425e-07
specific O 0 8.012133179136072e-08
phenotypic O 0 3.872069555654889e-06
expression O 0 1.8372073782302323e-06
. O 0 1.6292008240270661e-06

This O 0 6.292958687481587e-07
should O 0 7.461707696165831e-08
help O 0 4.4480493954779377e-08
in O 0 9.987988214277266e-09
the O 0 1.6413409298365877e-08
design O 0 1.6415499715094484e-07
of O 0 8.703444365210089e-08
tailored O 0 3.031499318240094e-07
clinical O 0 2.3955697542987764e-05
- O 0 9.84221333055757e-06
management O 0 5.002059424441541e-07
protocols O 0 7.537865798212806e-08
in O 0 3.8555039161281e-09
this O 0 6.02569683039178e-09
subset O 0 2.683488844468229e-07
of O 0 2.4106699925141584e-07
FAP B-Disease 0 2.1000474589527585e-05
patients O 0 1.0385610949015245e-07
. O 0 1.1428400625845825e-07
. O 0 1.1650532769635902e-06

Wilms B-Disease 1 0.9999998807907104
' I-Disease 0 0.0005608844803646207
tumor I-Disease 0 0.0004698163247667253
1 O 0 1.0267331163049676e-06
and O 0 1.3224320127847022e-07
Dax O 0 0.05015760660171509
- O 0 2.6923582936433377e-06
1 O 0 2.4854833213794336e-07
modulate O 0 4.7012139248181484e-07
the O 0 2.1029460839372405e-08
orphan O 0 6.224402682164509e-07
nuclear O 0 2.8057406780135352e-06
receptor O 0 4.326331691117957e-06
SF O 0 7.081733201630414e-05
- O 0 1.0252581006398032e-07
1 O 0 1.3763129302901689e-08
in O 0 2.238812468746687e-09
sex O 0 1.101851765383799e-08
- O 0 2.203549165358254e-08
specific O 0 2.038447455277037e-08
gene O 0 2.774974063868285e-07
expression O 0 4.7100994038373756e-07
. O 0 6.675083454865671e-07

Products O 0 8.59643751027761e-06
of O 0 7.912273758847732e-06
steroidogenic O 0 0.0004977239295840263
factor O 0 5.329324721969897e-06
1 O 0 9.434458547730173e-07
( O 0 4.810580094272154e-07
SF O 0 0.00029491435270756483
- O 0 5.607449224953598e-07
1 O 0 1.0093590674387087e-07
) O 0 2.080742511623157e-08
and O 0 1.6239649625049424e-08
Wilms B-Disease 1 0.9990956783294678
tumor I-Disease 0 0.0002491557679604739
1 O 0 8.118335586004832e-07
( O 0 3.1314749548982945e-07
WT1 O 0 3.1673553166911006e-05
) O 0 6.415397546533086e-09
genes O 0 1.4664103265005224e-09
are O 0 2.5731036745746394e-10
essential O 0 1.051482545477711e-08
for O 0 2.0787473076211427e-08
mammalian O 0 5.036340553488117e-06
gonadogenesis O 0 3.8606722227996215e-05
prior O 0 1.095844936571666e-06
to O 0 1.6137329339471762e-07
sexual O 0 6.8459817157418e-06
differentiation O 0 5.268195673124865e-05
. O 0 3.011544094988494e-06

In O 0 7.313363767025294e-06
males O 0 2.960864776468952e-06
, O 0 1.4917831094862777e-06
SF O 1 0.9999873638153076
- O 0 2.604689507279545e-05
1 O 0 5.506569209501322e-07
participates O 0 1.6912646572109225e-07
in O 0 8.832510722811548e-09
sexual O 0 1.7618527081708635e-08
development O 0 1.8107586541304954e-08
by O 0 3.4809526372470145e-09
regulating O 0 8.258302841568366e-08
expression O 0 1.751836897767589e-08
of O 0 1.6420203863276583e-08
the O 0 1.7311803901520761e-07
polypeptide O 0 7.78933972469531e-05
hormone O 0 7.630183063156437e-06
Mullerian O 0 0.0012017738772556186
inhibiting O 0 7.971303602971602e-06
substance O 0 2.9504687972803367e-06
( O 0 3.0548872018698603e-06
MIS O 0 0.0037526243831962347
) O 0 1.6150584087881725e-06
. O 0 1.705514705463429e-06

Here O 0 1.0900062989094295e-05
, O 0 1.787756218618597e-07
we O 0 1.1530651278235382e-07
show O 0 5.402189344749786e-07
that O 0 2.945437813650642e-07
WT1 O 0 0.4713573455810547
- O 0 0.017972173169255257
KTS O 1 0.9975741505622864
isoforms O 0 8.916093747757259e-07
associate O 0 1.448704438189452e-06
and O 0 2.4836486645085643e-08
synergize O 0 6.053200195310637e-06
with O 0 1.5841121125959035e-07
SF O 1 0.9993054866790771
- O 0 7.682280738663394e-06
1 O 0 3.4240153468090284e-07
to O 0 4.0027501313488756e-08
promote O 0 1.0662456588761415e-06
MIS O 0 0.004916651174426079
expression O 0 3.948265202780021e-06
. O 0 2.3519974092778284e-06

In O 0 5.122846687299898e-06
contrast O 0 3.1433703497896204e-06
, O 0 9.124590860665194e-07
WT1 O 0 0.05221324786543846
missense O 0 1.5934765542624518e-05
mutations O 0 1.659179105217845e-07
, O 0 2.1269803696100098e-08
associated O 0 7.0767136151062e-08
with O 0 7.93110785934914e-08
male B-Disease 0 0.013157106935977936
pseudohermaphroditism I-Disease 1 1.0
in O 0 6.767944432795048e-05
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.182394602343265e-07
fail O 0 9.515829333395232e-07
to O 0 1.3745032845235983e-07
synergize O 0 0.00012468047498259693
with O 0 3.227932893423713e-06
SF O 1 0.9999998807907104
- O 0 0.0009348575258627534
1 O 0 1.3737718290940393e-05
. O 0 1.0928246183539159e-06

Additionally O 0 7.022135832812637e-06
, O 0 1.714958557386126e-07
the O 0 1.2515353375874838e-07
X O 0 2.3065582354320213e-05
- O 0 5.134859748068266e-06
linked O 0 9.034349091052718e-07
, O 0 1.8422722902755595e-08
candidate O 0 4.8639353877888425e-08
dosage O 0 8.696389386386727e-07
- O 0 8.670875217831053e-07
sensitive O 0 5.224285928306927e-07
sex O 0 8.065783418942374e-08
- O 0 7.777706656497685e-08
reversal O 0 2.820714541940106e-07
gene O 0 2.4433438383653083e-08
, O 0 1.272769711846422e-08
Dax O 0 0.00023994455114006996
- O 0 3.8720145312254317e-07
1 O 0 8.551546670787502e-08
, O 0 1.898042434334002e-08
antagonizes O 0 9.011915267365112e-07
synergy O 0 5.143938892615552e-07
between O 0 1.604195034587974e-07
SF O 0 0.0003017359122168273
- O 0 4.3102519953208684e-07
1 O 0 7.498588416865459e-08
and O 0 1.520574244295858e-08
WT1 O 0 1.5353345588664524e-05
, O 0 6.373502614565041e-09
most O 0 1.2877794386412234e-09
likely O 0 3.2064615407279007e-09
through O 0 2.7534710067556034e-09
a O 0 1.4668110281945701e-08
direct O 0 2.95620914414485e-08
interaction O 0 4.47692052318871e-08
with O 0 4.707028011807779e-08
SF O 1 0.9280800223350525
- O 0 1.7212292732438073e-05
1 O 0 2.7392461561248638e-06
. O 0 6.386050586115743e-07

We O 0 5.10187692270847e-06
propose O 0 4.971967427991331e-06
that O 0 6.096821607570746e-07
WT1 O 0 0.000327780784573406
and O 0 1.073594262379629e-06
Dax O 1 0.9998319149017334
- O 0 4.757649730890989e-05
1 O 0 1.4696361176902428e-06
functionally O 0 1.7412189663446043e-06
oppose O 0 1.9263739048369644e-08
each O 0 2.8688311726199345e-09
other O 0 1.816531258747034e-09
in O 0 1.9821777996753553e-08
testis O 0 3.844436832878273e-06
development O 0 7.672782231793462e-08
by O 0 2.69193130009171e-08
modulating O 0 4.514647116593551e-06
SF O 0 0.0016296732937917113
- O 0 1.8825769529939862e-06
1 O 0 5.304158321450814e-07
- O 0 8.785073646322417e-07
mediated O 0 1.4284603366832016e-06
transactivation O 0 1.0600159839668777e-05
. O 0 6.727899659608738e-08
. O 0 4.537523068393057e-07

A O 0 6.182415381772444e-05
mouse O 0 7.84029998612823e-06
model O 0 1.8172064528698684e-06
for O 0 1.2551969348351122e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999959468841553
- O 1 0.9850024580955505
centre O 0 0.0010224295547232032
mutations O 0 5.993803370074602e-06
. O 0 2.0504558051470667e-06

Imprinting O 0 0.0018901340663433075
in O 0 3.0867054192640353e-06
the O 0 3.2651046240061987e-06
15q11 O 0 0.01626303605735302
- O 0 0.0007598066586069763
q13 O 0 0.0004018419422209263
region O 0 8.020036261768837e-07
involves O 0 3.7958048437758407e-07
an O 0 7.631303589050731e-08
imprinting O 0 4.2136930460401345e-06
centre O 0 5.419355147751048e-06
( O 0 7.921800602161966e-07
IC O 0 4.528868157649413e-05
) O 0 3.752290211878062e-08
, O 0 8.882822477573882e-09
mapping O 0 2.2673485489121958e-07
in O 0 1.4791107005862614e-08
part O 0 4.409025677887257e-08
to O 0 2.6228056171362368e-08
the O 0 4.6629386929453176e-07
promoter O 0 4.151783650740981e-05
and O 0 2.21313214865404e-07
first O 0 5.0911939979414456e-06
exon O 0 6.452522939071059e-05
of O 0 1.2038981367368251e-05
SNRPN O 1 0.7565752267837524
. O 0 1.2512836292444263e-05

Deletion O 0 0.0005944515578448772
of O 0 1.5075485862325877e-05
this O 0 3.3583826279937057e-06
IC O 0 0.000824762275442481
abolishes O 0 9.590778063284233e-06
local O 0 3.64792612117526e-07
paternally O 0 5.37024243385531e-06
derived O 0 2.6534294761404453e-07
gene O 0 5.615220288746059e-08
expression O 0 1.9285060659512965e-08
and O 0 4.439884460083476e-09
results O 0 8.608151347289095e-08
in O 0 1.926612867464428e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999990463256836
PWS B-Disease 1 1.0
) O 0 0.00013124212273396552
. O 0 8.28833526611561e-06

We O 0 9.17528893751296e-07
have O 0 2.230178886009071e-08
created O 0 6.130158425321497e-08
two O 0 2.3127730841565608e-08
deletion O 0 1.2838312386520556e-06
mutations O 0 1.039782020484381e-07
in O 0 8.62723510408614e-08
mice O 0 1.5771373682582635e-06
to O 0 2.102098335399205e-07
understand O 0 0.0005253917770460248
PWS B-Disease 1 1.0
and O 0 2.1647430514804e-07
the O 0 4.316809452120651e-07
mechanism O 0 1.167812001767743e-06
of O 0 2.823246916250355e-07
this O 0 7.9668268426758e-07
IC O 0 0.00026251524104736745
. O 0 4.214995442453073e-06

Mice O 0 0.31261146068573
harbouring O 0 0.04579693824052811
an O 0 1.920190925375209e-06
intragenic O 0 0.002209422877058387
deletion O 0 2.2764950699638575e-05
in O 0 1.942520100328693e-07
Snrpn O 1 0.8467426896095276
are O 0 5.640800537776158e-08
phenotypically O 0 3.707407086039893e-05
normal O 0 1.710259311948903e-06
, O 0 1.3985681057704369e-08
suggesting O 0 6.376313876899076e-08
that O 0 2.589786607387623e-09
mutations O 0 1.850220243682088e-08
of O 0 1.5433911926265864e-07
SNRPN O 1 0.9542151093482971
are O 0 1.8284447733663e-08
not O 0 2.3684952665803394e-08
sufficient O 0 1.2131828270867118e-06
to O 0 2.184537152061239e-06
induce O 0 0.005973262246698141
PWS B-Disease 1 1.0
. O 0 8.490020991303027e-05

Mice O 0 0.00010845813812920824
with O 0 4.971346712068225e-08
a O 0 1.9125265282582404e-07
larger O 0 1.0891066182239229e-07
deletion O 0 4.806700530934904e-07
involving O 0 2.3441904772880662e-07
both O 0 6.198787616540358e-08
Snrpn O 0 0.007282611448317766
and O 0 6.327839940922786e-08
the O 0 1.5764727550049429e-06
putative O 1 0.90899258852005
PWS O 1 1.0
- O 1 0.9964559674263
IC O 0 0.014625590294599533
lack O 0 2.565031707035814e-07
expression O 0 3.395496506186646e-08
of O 0 3.508884915959243e-08
the O 0 1.391371569070543e-07
imprinted O 0 1.159459770860849e-05
genes O 0 1.6739359125494957e-06
Zfp127 O 0 0.02012614719569683
( O 0 1.9324588720337488e-06
mouse O 0 1.187268480862258e-06
homologue O 0 2.102105327139725e-06
of O 0 3.3871560845000204e-07
ZNF127 O 1 0.8434299826622009
) O 0 6.819173563599179e-07
, O 0 3.7671026120733586e-07
Ndn O 0 0.19228661060333252
and O 0 1.2189461529032997e-07
Ipw O 0 0.0015153620624914765
, O 0 4.253370633477971e-08
and O 0 1.8289643577418246e-08
manifest O 0 1.6647755956000765e-06
several O 0 5.2636639935599305e-08
phenotypes O 0 2.866532895495766e-06
common O 0 5.55911242372531e-07
to O 0 1.0350985576224048e-05
PWS B-Disease 1 1.0
infants O 1 0.999981164932251
. O 0 2.133312591467984e-05

These O 0 1.0855587788682897e-06
data O 0 8.82713948158198e-07
demonstrate O 0 3.226660396649095e-07
that O 0 1.219750345171633e-08
both O 0 8.15273537568828e-09
the O 0 4.0967503167621544e-08
position O 0 1.7323958445558674e-07
of O 0 1.3758619843429187e-07
the O 0 6.82211350522266e-07
IC O 0 0.00011096401431132108
and O 0 8.998920719704984e-09
its O 0 1.0883710821474324e-08
role O 0 7.025152370943033e-08
in O 0 9.917029863970583e-09
the O 0 8.111941340871454e-09
coordinate O 0 3.276359450410382e-08
expression O 0 1.662203352736924e-08
of O 0 1.9640159720779593e-08
genes O 0 1.6829650562044662e-08
is O 0 4.736439240815571e-09
conserved O 0 1.2001866878108558e-07
between O 0 1.7717095346370115e-08
mouse O 0 7.056858919440856e-08
and O 0 1.1052274651035532e-09
human O 0 7.43632933009053e-09
, O 0 3.022654793127799e-09
and O 0 2.853529190716131e-09
indicate O 0 7.882366759304205e-08
that O 0 2.379034302890659e-09
the O 0 1.3717946778513124e-08
mouse O 0 4.382096818744685e-08
is O 0 1.389956483244248e-09
a O 0 4.530191777263326e-09
suitable O 0 2.41906388254165e-08
model O 0 2.0436521808164798e-08
system O 0 7.436159243923157e-09
in O 0 1.4445323825995615e-09
which O 0 7.477144459144824e-10
to O 0 2.2459378801187313e-09
investigate O 0 7.786790945374378e-08
the O 0 7.213949260176378e-08
molecular O 0 2.3478044113289798e-06
mechanisms O 0 5.622485446110659e-07
of O 0 1.6875686981165927e-07
imprinting O 0 2.0463141936488682e-06
in O 0 1.0019088669821485e-08
this O 0 3.5234364315073208e-09
region O 0 1.420595019396842e-08
of O 0 2.0367838970969387e-08
the O 0 5.4272405236588384e-08
genome O 0 3.1150690915637824e-07
. O 0 6.005848263157532e-08
. O 0 5.045687316851399e-07

Mutations O 0 1.1125203855044674e-05
of O 0 2.1639743863488548e-06
the O 0 1.6717168591640075e-06
ATM O 0 0.0003146844683215022
gene O 0 3.928371370420791e-07
detected O 0 5.505665967575624e-07
in O 0 2.0552744217638974e-07
Japanese O 1 0.9999655485153198
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 6.621813099627616e-06
: O 0 4.482029680730193e-08
possible O 0 2.267335617034405e-07
preponderance O 0 4.9743128329282627e-05
of O 0 2.1078497525195417e-07
the O 0 1.0955757545616507e-07
two O 0 6.427022469779331e-08
founder O 0 1.3200924513512291e-05
mutations O 0 9.677146408648696e-07
4612del165 O 0 3.893044049618766e-05
and O 0 1.251164690074802e-06
7883del5 O 0 0.0024635836016386747
. O 0 2.0384790332172997e-05

The O 0 2.9796574381180108e-05
ATM O 0 0.0004887932445853949
( O 0 4.212777184875449e-06
A O 1 0.9995377063751221
- O 1 0.7846852540969849
T O 1 0.9976467490196228
, O 0 5.629063792866873e-08
mutated O 0 4.4330838022688113e-07
) O 0 8.696524389506521e-08
gene O 0 7.635379972725787e-08
on O 0 1.985780926361258e-07
human O 0 8.797071018307179e-07
chromosome O 0 9.060138836503029e-05
11q22 O 0 0.0038403470534831285
. O 0 1.4218375326890964e-05

3 O 0 3.889103936671745e-06
has O 0 2.8859558298677257e-08
recently O 0 2.7651246625737258e-08
been O 0 7.604202600930421e-09
identified O 0 1.943802097059688e-08
as O 0 5.243900425000447e-09
the O 0 8.637488946305893e-09
gene O 0 1.1408642919263912e-08
responsible O 0 1.4292240280155966e-08
for O 0 5.9762390591799885e-09
the O 0 5.419512376647617e-07
human O 0 0.0014272931730374694
recessive B-Disease 1 0.9999986886978149
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.980233371257782
A B-Disease 1 1.0
- I-Disease 1 0.9999901056289673
T I-Disease 1 0.9999988079071045
) O 0 4.589247055264423e-06
. O 0 2.347690042370232e-06

In O 0 1.2487209914979758e-06
order O 0 7.454495687397866e-08
to O 0 1.684307271432317e-08
define O 0 1.42529088975607e-07
the O 0 3.518924884815533e-08
types O 0 7.677745372802747e-08
of O 0 5.890185093448963e-06
disease O 1 0.999881386756897
- O 1 0.9014036059379578
causing O 0 0.00010495610331417993
ATM O 0 0.0012253770837560296
mutations O 0 1.0396368210763285e-08
in O 0 8.972355303171753e-09
Japanese O 0 2.7083013264928013e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.999439537525177
T I-Disease 1 0.9999964237213135
patients O 0 2.7159940962917517e-09
as O 0 7.010368396898059e-10
well O 0 3.9447878297238503e-10
as O 0 9.65321267365482e-10
to O 0 1.1576410940961068e-09
look O 0 6.440813660191225e-09
for O 0 3.802556047816097e-09
possible O 0 1.1417191103646473e-07
mutational O 0 9.299657904193737e-06
hotspots O 0 3.6870144981548947e-07
, O 0 1.0940426342642695e-08
reverse O 0 1.5754221749375574e-07
- O 0 2.8274851615606167e-07
transcribed O 0 1.5402297321998049e-06
RNA O 0 5.451714173432265e-07
derived O 0 1.3627974304597501e-08
from O 0 3.105740775666277e-09
ten O 0 5.264527302983879e-08
patients O 0 5.160248228719411e-09
belonging O 0 6.42680149098851e-08
to O 0 9.558640101658966e-09
eight O 0 1.287671267391488e-07
unrelated O 0 3.193583779648179e-06
Japanese O 0 0.011057967320084572
A B-Disease 1 1.0
- I-Disease 1 0.9996862411499023
T I-Disease 1 0.9938311576843262
families O 0 1.5314453705173037e-08
was O 0 3.566420048173313e-08
analyzed O 0 2.1871183975008535e-08
for O 0 1.366492807797215e-09
mutations O 0 2.349721528460691e-09
by O 0 9.149838109401287e-10
the O 0 1.2104614199870412e-08
restriction O 0 6.347288916686011e-08
endonuclease O 0 8.664815709380491e-07
fingerprinting O 0 4.820306571673427e-07
method O 0 4.621465734544472e-07
. O 0 7.101998562575318e-07

As O 0 1.6162756537596579e-06
has O 0 2.7891410070424172e-08
been O 0 2.1361278967901853e-08
reported O 0 2.089974415753204e-08
by O 0 2.6842137401672517e-09
others O 0 7.753235387042423e-09
, O 0 8.548410868058909e-09
mutations O 0 2.3185283026805337e-08
that O 0 6.304898381159774e-09
lead O 0 1.6061008523138298e-07
to O 0 1.4048890761841903e-07
exon O 0 6.461622979259118e-05
skipping O 0 1.2951254575455096e-05
or O 0 5.499169333234022e-07
premature O 0 3.157470700898557e-06
protein O 0 5.736130219702318e-07
truncation O 0 7.099559297785163e-06
were O 0 2.1488003199010564e-07
also O 0 4.91929910140243e-08
predominant O 0 5.760711587754486e-07
in O 0 7.571323834554278e-08
our O 0 6.453678906837013e-07
mutants O 0 6.6343673097435385e-06
. O 0 2.24612472266017e-06

Six O 0 9.537288860883564e-07
different O 0 1.1724096360410385e-08
mutations O 0 3.7174132216932776e-08
were O 0 2.827621869982977e-08
identified O 0 8.636899195835213e-08
on O 0 1.005600438475085e-07
12 O 0 1.6711926775769825e-07
of O 0 8.556033037621091e-08
the O 0 1.2584891351252736e-07
16 O 0 8.824479778013483e-07
alleles O 0 3.4895870726359135e-07
examined O 0 2.8649394607782597e-06
. O 0 2.7871258225786733e-06

Four O 0 2.448364512019907e-06
were O 0 5.834428975504125e-07
deletions O 0 1.6966456541922526e-06
involving O 0 1.5041515553093632e-06
a O 0 1.445011889700254e-06
loss O 0 7.684713636990637e-06
of O 0 4.92992739964393e-06
a O 0 5.035649337514769e-06
single O 0 2.600891775728087e-06
exon O 0 1.5319998055929318e-05
exon O 0 5.5020677791617345e-06
7 O 0 1.1820601457657176e-06
, O 0 8.931346684448727e-08
exon O 0 1.4886537655911525e-06
16 O 0 5.676724867953453e-07
, O 0 1.9247987381731946e-07
exon O 0 7.031545010249829e-06
33 O 0 2.378024873905815e-06
or O 0 1.0523070841372828e-06
exon O 0 1.7618529454921372e-05
35 O 0 6.617583494517021e-06
. O 0 1.9818166947516147e-06

The O 0 2.7739047254726756e-06
others O 0 1.587420968007791e-07
were O 0 1.704620586906458e-07
minute O 0 3.6849053230980644e-07
deletions O 0 9.184017244479037e-07
, O 0 1.805238127872144e-07
4649delA O 0 1.0411149560241029e-05
in O 0 5.544901000575919e-07
exon O 0 1.2114937817386817e-05
33 O 0 2.0137363208050374e-06
and O 0 1.7634452831316594e-07
7883del5 O 0 6.0456284700194374e-05
in O 0 1.4878305591992103e-06
exon O 0 6.67083149892278e-05
55 O 0 9.71375538938446e-06
. O 0 3.139942919005989e-06

The O 0 7.278268640220631e-06
mutations O 0 2.3225686618388863e-06
4612del165 O 0 4.19635689468123e-05
and O 0 1.3769673046226671e-07
7883del5 O 0 2.6455627448740415e-05
were O 0 1.6434343308446842e-07
found O 0 3.983055663070445e-08
in O 0 6.231444693582944e-09
more O 0 6.074262204336378e-10
than O 0 1.0538471206800182e-09
two O 0 1.678924443915264e-09
unrelated O 0 6.78384921570796e-08
families O 0 3.759860867091902e-09
; O 0 1.8187397143876183e-09
44 O 0 6.675694663726972e-08
% O 0 2.0646879761443415e-08
( O 0 7.597967588424126e-09
7 O 0 2.908135776635845e-08
of O 0 2.0505046549601502e-08
16 O 0 4.338302872497479e-08
) O 0 5.879054132407191e-09
of O 0 6.8388135154862084e-09
the O 0 1.954598438658195e-08
mutant O 0 2.8728638312713883e-07
alleles O 0 7.776754351596082e-09
had O 0 8.78375683299737e-09
one O 0 8.46399661469377e-09
of O 0 2.361485407220698e-08
the O 0 4.5219064048751534e-08
two O 0 7.54105755618184e-08
mutations O 0 4.7663209556958464e-07
. O 0 1.2974034007129376e-06

The O 0 2.456134279782418e-05
4612del165 O 0 0.00021627578826155514
mutations O 0 4.4313171088106174e-07
in O 0 2.5188899854811098e-08
three O 0 9.793663657831075e-09
different O 0 3.405119519683808e-09
families O 0 4.477217263598732e-09
were O 0 1.5278859066825135e-08
all O 0 1.749799771744165e-08
ascribed O 0 3.583378145322058e-07
to O 0 1.1660448606676255e-08
the O 0 5.451007822898646e-08
same O 0 1.14147198360115e-07
T O 0 2.9177394935686607e-06
- O 0 9.602021009413875e-07
- O 0 1.4349486718856497e-06
> O 0 3.4756874356389744e-07
A O 0 7.06379452708461e-08
substitution O 0 4.792437735545718e-08
at O 0 7.78092683617615e-08
the O 0 3.745304510971437e-08
splice O 0 9.190790137836302e-07
donor O 0 1.1060296856157947e-07
site O 0 4.157378725722083e-07
in O 0 3.948044309254328e-07
intron O 0 0.00013467404642142355
33 O 0 1.731485826894641e-05
. O 0 3.085178150286083e-06

Microsatellite O 0 0.2860995829105377
genotyping O 0 0.00031695832149125636
around O 0 4.2417873373779e-06
the O 0 1.583113771630451e-06
ATM O 0 0.002385104540735483
locus O 0 4.170906777289929e-06
also O 0 1.0701821651082355e-08
indicated O 0 3.0680084250889195e-08
that O 0 5.347980280845377e-09
a O 0 6.483276848712194e-08
common O 0 3.6734242314651055e-08
haplotype O 0 8.402713547184248e-07
was O 0 1.6091134114049055e-07
shared O 0 4.5936769055288096e-08
by O 0 5.996654728335216e-09
the O 0 2.7169749117206266e-08
mutant O 0 2.429753465094109e-07
alleles O 0 1.6008749881279982e-08
in O 0 1.4353433996916465e-08
both O 0 3.302661255588646e-08
mutations O 0 8.125879844556039e-07
. O 0 1.5941416222631233e-06

This O 0 1.6603868289166712e-06
suggests O 0 6.75265994232177e-07
that O 0 8.880247648335171e-09
these O 0 5.162817728887603e-09
two O 0 1.5009369747076562e-08
founder O 0 8.273677849501837e-06
mutations O 0 7.344035424239337e-08
may O 0 6.868909707691273e-08
be O 0 5.850230522241873e-08
predominant O 0 1.0220117019343888e-06
among O 0 1.231495332376653e-07
Japanese O 0 3.34970754920505e-05
ATM O 0 0.00025299613480456173
mutant O 0 1.2588636309374124e-05
alleles O 0 8.322230087287608e-07
. O 0 1.3463292134474614e-06

W474C O 0 0.001086615608073771
amino O 0 1.8148466551792808e-05
acid O 0 2.809483930832357e-06
substitution O 0 7.769276066937891e-07
affects O 0 1.1576089775644505e-07
early O 0 7.175607663612027e-08
processing O 0 1.180296678171544e-07
of O 0 4.65413307892959e-08
the O 0 3.45170541038442e-08
alpha O 0 3.855874410874094e-07
- O 0 3.664830217076087e-08
subunit O 0 6.789104389781642e-08
of O 0 1.95676950198731e-08
beta O 0 2.0288962332415394e-07
- O 0 1.1427768953353734e-07
hexosaminidase O 0 1.2016759001198807e-06
A O 0 7.864646534017083e-08
and O 0 2.440957436178337e-09
is O 0 4.972653400159288e-09
associated O 0 2.3669732840403412e-08
with O 0 3.771944534491922e-08
subacute O 0 0.0019506568787619472
G B-Disease 1 0.8732395172119141
( I-Disease 0 0.00034432951360940933
M2 I-Disease 1 0.9999401569366455
) I-Disease 0 2.116268433383084e-06
gangliosidosis I-Disease 0 7.223822467494756e-05
. O 0 2.461155872879317e-06

Mutations O 0 9.413811312697362e-06
in O 0 3.197726812231849e-07
the O 0 6.821215947638848e-07
HEXA O 0 0.0015355568611994386
gene O 0 1.1752759832006632e-07
, O 0 6.737001179146773e-09
encoding O 0 1.4981853979634252e-08
the O 0 2.885229299920411e-08
alpha O 0 1.5217993620808556e-07
- O 0 3.5241036755451205e-08
subunit O 0 9.133700729080374e-08
of O 0 1.9861364108919588e-08
beta O 0 2.86508765157123e-07
- O 0 1.1197760585446304e-07
hexosaminidase O 0 3.7746331145172007e-06
A O 0 6.818132760599838e-07
( O 0 4.8440856659226483e-08
Hex O 0 1.271644578082487e-06
A O 0 2.011358901654603e-07
) O 0 9.036760673097888e-09
, O 0 1.7679009367554954e-09
that O 0 1.7599273149926375e-09
abolish O 0 1.4025435746134463e-07
Hex O 0 7.045278834993951e-06
A O 0 7.414436709041183e-07
enzyme O 0 5.793294235445501e-07
activity O 0 1.2204670838400489e-06
cause O 0 7.015599112492055e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9994890689849854
( O 0 5.473936198541196e-06
TSD B-Disease 1 0.9997872710227966
) O 0 9.333175654546721e-08
, O 0 1.0399481276124334e-08
the O 0 4.876978110246455e-08
fatal O 0 2.5445369828958064e-06
infantile B-Disease 0 1.1800867696365458e-06
form I-Disease 0 2.3458717635094217e-08
of I-Disease 0 3.4813576803571777e-06
G I-Disease 0 0.008886394090950489
( I-Disease 0 5.404901094152592e-05
M2 I-Disease 1 0.9999978542327881
) I-Disease 0 5.348630907064944e-07
gangliosidosis I-Disease 0 1.4908579032635316e-05
, I-Disease 0 1.5164158639890957e-07
Type I-Disease 0 7.108787031029351e-06
1 I-Disease 0 7.024969363556011e-06
. O 0 3.7191834962868597e-06

Less O 0 1.5679586795158684e-05
severe O 0 2.55558861681493e-05
, O 0 1.0517833288758993e-06
subacute O 1 0.9996065497398376
( O 0 0.016160467639565468
juvenile O 1 0.9999996423721313
- O 1 0.9996771812438965
onset O 1 1.0
) O 0 8.543864851162652e-07
and O 0 5.842380446097195e-08
chronic O 1 0.9725946187973022
( O 0 2.7792427772510564e-06
adult O 0 2.4174913050956093e-05
- O 0 0.0004803654155693948
onset O 1 0.9939951300621033
) O 0 4.328665426100997e-08
variants O 0 1.0795244698158513e-08
are O 0 6.50049458705837e-10
characterized O 0 1.2236045066060797e-08
by O 0 3.784221824787437e-09
a O 0 3.831263839515486e-08
broad O 0 3.892050060017027e-08
spectrum O 0 5.0947363661180134e-08
of O 0 8.073386936757743e-08
clinical O 0 8.338615771208424e-06
manifestations O 0 2.47012189902307e-06
and O 0 1.4939223191845485e-08
are O 0 4.663470054566687e-09
associated O 0 9.655209254333386e-08
with O 0 2.6870578651028154e-08
residual O 0 7.833989366190508e-05
levels O 0 1.6629508081678068e-06
of O 0 8.552791541660554e-07
Hex O 0 8.148279448505491e-05
A O 0 2.714478569032508e-06
enzyme O 0 1.266862000193214e-06
activity O 0 8.556511943424994e-07
. O 0 6.38222161342128e-07

We O 0 5.496105131896911e-06
identified O 0 3.0722474093636265e-06
a O 0 1.9169633560522925e-06
1422 O 0 3.429994103498757e-05
G O 0 4.38729193774634e-06
- O 0 1.5458895177289378e-06
- O 0 1.1270092272752663e-06
> O 0 9.555860742693767e-07
C O 0 9.743358759806142e-07
( O 0 3.520858626870904e-08
amino O 0 4.225537608704144e-08
acid O 0 3.26016440510557e-08
W474C O 0 4.772469992531114e-07
) O 0 7.701810744720206e-09
substitution O 0 2.079504746177463e-08
in O 0 4.875245540603146e-09
the O 0 7.436585125475403e-09
first O 0 2.5660781943770417e-08
position O 0 1.242615610408393e-07
of O 0 2.5436364126107947e-07
exon O 0 2.3335871901508654e-06
13 O 0 5.3455045190276e-07
of O 0 5.144664783074404e-07
HEXA O 0 0.3324831426143646
of O 0 2.899463424910209e-07
a O 0 3.015234710801451e-07
non O 0 3.922751602658536e-06
- O 0 5.697585493180668e-06
Jewish O 0 4.164094207226299e-06
proband O 0 7.179828389780596e-05
who O 0 1.5446840961885755e-07
manifested O 0 2.4023786409088643e-06
a O 0 7.176387271101703e-07
subacute O 0 2.233090708614327e-05
variant O 0 9.192631296173204e-07
of O 0 4.050338247907348e-06
G B-Disease 0 0.0012529095401987433
( I-Disease 0 0.00011709407408488914
M2 I-Disease 1 0.999972939491272
) I-Disease 0 8.951357813202776e-06
gangliosidosis I-Disease 0 0.0003509353846311569
. O 0 9.734620107337832e-06

On O 0 7.355638899753103e-06
the O 0 8.595843610237353e-07
second O 0 1.9828319182124687e-06
maternally O 0 2.5446934159845114e-05
inherited O 0 7.713228114880621e-06
allele O 0 1.6836752081417217e-07
, O 0 1.05739133005045e-08
we O 0 1.385032089018523e-08
identified O 0 1.6572387551150314e-07
the O 0 2.070631950346069e-07
common O 0 2.079545993183274e-06
infantile O 1 0.9999815225601196
disease O 1 0.9995425939559937
- O 0 0.0033430084586143494
causing O 0 1.7690370441414416e-05
4 O 0 4.336154233897105e-06
- O 0 4.376861397759058e-06
bp O 0 2.566783678048523e-06
insertion O 0 8.945792728809465e-07
, O 0 2.139467909501036e-07
+ O 0 9.033857168105897e-06
TATC O 0 0.0019631744362413883
1278 O 0 0.0002342358638998121
, O 0 2.2796203325015085e-07
in O 0 3.405732229566638e-07
exon O 0 2.1027908587711863e-05
11 O 0 6.661882707703626e-06
. O 0 2.504561962268781e-06

Pulse O 0 0.00953302439302206
- O 0 6.16125762462616e-05
chase O 0 1.2557797163026407e-05
analysis O 0 6.429720542655559e-07
using O 0 2.3484621181069087e-07
proband O 0 3.8003636291250587e-05
fibroblasts O 0 4.120097401028033e-06
revealed O 0 4.88769671846967e-07
that O 0 4.6852597357371906e-09
the O 0 2.277585764431933e-08
W474C O 0 8.715019816918357e-07
- O 0 1.360901791258584e-07
containing O 0 6.22110292169964e-08
alpha O 0 2.4883578930712247e-07
- O 0 5.1548408208645924e-08
subunit O 0 1.6507605948845594e-07
precursor O 0 9.902404229933381e-08
was O 0 1.822796846795427e-08
normally O 0 4.664768571416289e-09
synthesized O 0 2.0117957078014115e-08
, O 0 8.171101573140049e-10
but O 0 4.5390116665267044e-10
not O 0 8.224403935663815e-10
phosphorylated O 0 1.1183738024556078e-07
or O 0 1.0273366157775854e-08
secreted O 0 3.412956317561111e-08
, O 0 1.6518298950884969e-09
and O 0 2.037979784930144e-09
the O 0 4.066730596719026e-08
mature O 0 4.840982228415669e-07
lysosomal O 0 7.404933421639726e-05
alpha O 0 2.066285333057749e-06
- O 0 1.243751341917232e-07
subunit O 0 1.6078188025403506e-07
was O 0 9.266251765893685e-08
not O 0 1.7802864960003717e-08
detected O 0 1.2416317076713312e-06
. O 0 6.342556844174396e-07

When O 0 8.178051757568028e-06
the O 0 1.2976199741387973e-06
W474C O 0 1.2611587408173364e-05
- O 0 1.0018096645580954e-06
containing O 0 3.5755269323090033e-07
alpha O 0 1.1413395668569137e-06
- O 0 3.622897679633752e-07
subunit O 0 7.032726330180594e-07
was O 0 5.578214654633484e-07
transiently O 0 3.51089170180785e-06
co O 0 1.3618083585242857e-06
- O 0 1.317864359862142e-07
expressed O 0 1.3268200760307991e-08
with O 0 2.577938973402638e-09
the O 0 3.216361577074167e-08
beta O 0 1.932170050622517e-07
- O 0 5.088840993039412e-08
subunit O 0 9.069970019481843e-08
to O 0 4.005390685790644e-09
produce O 0 1.8848458793740974e-08
Hex O 0 2.692722773645073e-06
A O 0 7.468021294698701e-07
( O 0 6.165112154121744e-08
alphabeta O 0 2.7171229248779127e-06
) O 0 2.6065528402341442e-08
in O 0 3.681153515344704e-08
COS O 0 0.00014530826592817903
- O 0 1.58252203164011e-06
7 O 0 2.2520997333685955e-07
cells O 0 1.5860885937968305e-08
, O 0 1.32921817996845e-09
the O 0 3.347037758061333e-09
mature O 0 1.701562979405935e-08
alpha O 0 6.385941020425889e-08
- O 0 1.5560400967729038e-08
subunit O 0 1.655243231368786e-08
was O 0 8.196829881512713e-09
present O 0 3.730779685184871e-09
, O 0 1.3865275594326931e-09
but O 0 5.055025842359839e-10
its O 0 1.628694623612148e-09
level O 0 3.1943276468382464e-08
was O 0 4.623316840479674e-08
much O 0 9.675594547786659e-09
lower O 0 1.1696534407690251e-08
than O 0 4.802278574800312e-10
that O 0 1.6863500873487425e-10
from O 0 1.1818253042861215e-09
normal O 0 4.3727123255621336e-08
alpha O 0 2.122948075111708e-07
- O 0 4.224901317684271e-08
subunit O 0 1.1018648393701369e-07
transfections O 0 1.8875319085509545e-07
, O 0 8.893973890700124e-10
although O 0 8.132541862160281e-10
higher O 0 4.780156714900841e-09
than O 0 2.954357591899992e-10
in O 0 6.466142066230418e-10
those O 0 2.1202108957396604e-09
cells O 0 2.0934773914405014e-08
transfected O 0 1.7311637634520594e-07
with O 0 7.594052053860878e-10
an O 0 5.768576727405161e-09
alpha O 0 1.696200939704795e-07
- O 0 1.1107950115274434e-07
subunit O 0 2.303401203107569e-07
associated O 0 4.546935983285039e-08
with O 0 7.10832850359111e-08
infantile O 0 0.00037660449743270874
TSD B-Disease 1 0.9019182324409485
. O 0 8.681948202138301e-06

Furthermore O 0 3.2933738111751154e-05
, O 0 2.4952208832473843e-07
the O 0 1.432267282552857e-07
precursor O 0 3.044199502255651e-06
level O 0 3.126259287000721e-07
of O 0 5.3544532363503095e-08
the O 0 8.034736964646072e-08
W474C O 0 2.750638714132947e-06
alpha O 0 7.883222110649513e-07
- O 0 9.473265549786447e-08
subunit O 0 7.78999975636907e-08
was O 0 1.5866907787653872e-08
found O 0 1.90420590406859e-09
to O 0 1.3740433235653882e-09
accumulate O 0 5.788131218764647e-08
in O 0 1.2681123706670405e-08
comparison O 0 3.4937919224375946e-08
to O 0 6.604402802423692e-09
the O 0 3.825195804552095e-08
normal O 0 2.8945177632522245e-07
alpha O 0 1.4492558193524019e-06
- O 0 4.2730280824798683e-07
subunit O 0 1.2913351383758709e-06
precursor O 0 1.5695301271989592e-06
levels O 0 3.407857036563655e-07
. O 0 4.289003641133604e-07

We O 0 2.960356368930661e-06
conclude O 0 5.434456397779286e-06
that O 0 1.007305101552447e-07
the O 0 2.5470737341493077e-07
1422 O 0 2.1547117285081185e-05
G O 0 1.1163569979544263e-05
- O 0 3.676951109810034e-06
- O 0 3.0396854526770767e-06
> O 0 2.0684128685388714e-06
C O 0 8.146628260874422e-07
mutation O 0 1.5348668114256725e-08
is O 0 2.676239008181369e-09
the O 0 1.1617204087599475e-08
cause O 0 7.02200395608088e-08
of O 0 3.968833084400103e-07
Hex B-Disease 1 0.8846297860145569
A I-Disease 1 0.9961674809455872
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.787125362781808e-07
the O 0 2.2271665329753887e-06
proband O 0 0.0020860456861555576
. O 0 7.66575521993218e-06

The O 0 9.198961379297543e-06
resulting O 0 7.570147772639757e-06
W474C O 0 5.0532697059679776e-05
substitution O 0 1.7111467514041578e-06
clearly O 0 7.23692267001752e-07
interferes O 0 2.696978640415182e-07
with O 0 5.717901707669171e-09
alpha O 0 7.76643844346836e-07
- O 0 1.0355110191540007e-07
subunit O 0 1.424038202912925e-07
processing O 0 6.422145304441074e-08
, O 0 2.059589387926053e-09
but O 0 8.645296700748872e-10
because O 0 1.3156580269679807e-09
the O 0 8.987770527824068e-09
base O 0 9.9563031596972e-08
substitution O 0 1.8051795791507175e-07
falls O 0 2.3857028281781822e-06
at O 0 1.3011563737563847e-07
the O 0 1.686306561055062e-08
first O 0 2.8663277973350887e-08
position O 0 1.2009137151380855e-07
of O 0 1.408215695164472e-07
exon O 0 1.4933232250768924e-06
13 O 0 1.3108362395541917e-07
, O 0 1.4331877906670343e-08
aberrant O 0 3.523616953771125e-07
splicing O 0 2.1286408014020708e-07
may O 0 1.297655050080948e-08
also O 0 9.019764490858506e-09
contribute O 0 6.466986945952158e-08
to O 0 1.0217384271982155e-07
Hex B-Disease 1 0.7603744864463806
A I-Disease 0 0.02170090191066265
deficiency I-Disease 0 0.17572547495365143
in O 0 1.5866444869061525e-07
this O 0 3.5760385230787506e-07
proband O 0 0.0001295633555855602
. O 0 5.687069233317743e-07
. O 0 1.6323050431310548e-06

Two O 0 5.850096840731567e-06
frequent O 0 5.1529764277802315e-06
missense O 0 0.00012505958147812635
mutations O 0 1.6561658412683755e-05
in O 0 6.587965617654845e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0011256288271397352

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00040785278542898595
an O 1 0.9995551705360413
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999995231628418
by O 0 0.00010571930761216208
early O 1 0.9999961853027344
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999973773956299
goiter B-Disease 1 1.0
. O 1 0.9987793564796448

A O 0 3.964497227570973e-05
century O 0 3.827630280284211e-06
after O 0 4.593515257056424e-07
its O 0 1.4741510234728139e-08
recognition O 0 3.275485127574029e-08
as O 0 2.4943016541101315e-08
a O 0 4.842182761422009e-07
syndrome O 0 3.616527465055697e-05
by O 0 5.396973890015033e-08
Vaughan O 0 4.796682333108038e-05
Pendred O 1 0.7225337624549866
, O 0 4.757592364512675e-08
the O 0 1.206554856025832e-07
disease O 0 1.4648529941041488e-05
gene O 0 9.28223983009957e-07
( O 0 2.808878434734652e-06
PDS O 0 0.0007518907659687102
) O 0 6.132415109050271e-08
was O 0 3.7620441162289353e-07
mapped O 0 3.7190199009273783e-07
to O 0 1.1155955803587858e-07
chromosome O 0 3.0690520361531526e-05
7q22 O 0 0.007383148651570082
- O 0 0.03605731576681137
q31 O 0 0.1590627282857895
. O 0 1.191768933495041e-05

1 O 0 4.067005193064688e-06
and O 0 7.920375111325484e-08
, O 0 4.9593001705261486e-08
recently O 0 1.069654018692745e-07
, O 0 1.5159148603061112e-08
found O 0 1.2623833534064488e-08
to O 0 2.026422230017033e-08
encode O 0 6.681159447907703e-07
a O 0 1.2924032262162655e-06
putative O 0 4.539180372375995e-05
sulfate O 0 0.0001648471225053072
transporter O 0 0.1590348333120346
. O 0 1.4803526937612332e-05

We O 0 1.1750063322324422e-06
performed O 0 1.039237190525455e-06
mutation O 0 1.6377455835936416e-07
analysis O 0 1.4660886904493964e-07
of O 0 1.2679072369792266e-07
the O 0 6.105001943979005e-07
PDS B-Disease 0 0.15385094285011292
gene O 0 2.18847105770692e-07
in O 0 4.134413700285222e-08
patients O 0 1.9864621947363048e-08
from O 0 1.0995847787853563e-07
14 O 0 2.007006150961388e-05
Pendred B-Disease 1 0.999967098236084
families O 0 3.211653520907021e-08
originating O 0 3.855211971881545e-08
from O 0 3.532776959858097e-09
seven O 0 3.347740085146711e-09
countries O 0 1.5043173651196895e-10
and O 0 1.99043981297109e-09
identified O 0 5.9217324377414116e-08
all O 0 3.52221505295347e-08
mutations O 0 2.659418214534526e-07
. O 0 6.401465384442417e-07

The O 0 5.10606787429424e-06
mutations O 0 3.09402423681604e-07
include O 0 3.2668246774392173e-08
three O 0 2.6520728724221954e-08
single O 0 7.127837875486875e-08
base O 0 2.6538344854998286e-07
deletions O 0 6.184216090332484e-07
, O 0 6.769953841967435e-08
one O 0 1.5973725453477527e-07
splice O 0 3.3043297662516125e-06
site O 0 2.812143691244273e-07
mutation O 0 1.862453125056618e-08
and O 0 1.018914197459253e-08
10 O 0 3.9216263303387677e-07
missense O 0 2.173681241401937e-05
mutations O 0 2.2099313810031163e-06
. O 0 2.280989065184258e-06

One O 0 2.230417521786876e-05
missense O 0 4.841581903747283e-05
mutation O 0 7.054368893477658e-07
( O 0 3.9917185290505586e-07
L236P O 0 1.276862167287618e-05
) O 0 1.31953953541597e-07
was O 0 2.976743473936949e-07
found O 0 4.5040110308036674e-08
in O 0 2.3450395403301627e-08
a O 0 1.0644844650187224e-07
homozygous O 0 1.4511918777770916e-07
state O 0 2.4452086577753107e-08
in O 0 1.4193086705915903e-08
two O 0 2.503949581011966e-08
consanguineous O 0 0.0007354027475230396
families O 0 2.8572884502864326e-08
and O 0 8.790175698436542e-09
in O 0 4.106451001462119e-08
a O 0 1.4695447703161335e-07
heterozygous O 0 3.3471287963493523e-08
state O 0 2.039418633970058e-09
in O 0 1.440463082147403e-09
five O 0 3.2089699786297388e-09
additional O 0 1.768340140984037e-08
non O 0 7.699411980865989e-06
- O 0 7.870447734603658e-05
consanguineous O 0 0.0008417073986493051
families O 0 3.8381614331228775e-07
. O 0 8.5040488784216e-07

Another O 0 4.1607883758842945e-05
missense O 0 6.390362977981567e-05
mutation O 0 1.672292455623392e-06
( O 0 7.091467750797165e-07
T416P O 0 1.4620573892898392e-05
) O 0 9.910869636087227e-08
was O 0 2.9865873329981696e-07
found O 0 2.2670885613251812e-08
in O 0 1.213376243924813e-08
a O 0 3.883300436768877e-08
homozygous O 0 7.3784768517271e-08
state O 0 1.294157492282011e-08
in O 0 1.4828506422759347e-08
one O 0 3.297285999792621e-08
family O 0 3.518696800597354e-08
and O 0 4.045368928728976e-09
in O 0 2.145040767231876e-08
a O 0 1.6746690789659624e-07
heterozygous O 0 1.0257510041356e-07
state O 0 1.638141533533144e-08
in O 0 2.0484328899783577e-08
four O 0 1.0077086187720852e-07
families O 0 2.7866053642355837e-07
. O 0 1.5467743423869251e-06

Pendred B-Disease 1 0.9995859265327454
patients O 0 2.7433504783402896e-06
in O 0 9.284917013019367e-08
three O 0 1.6873498509539786e-07
non O 0 0.00010440519690746441
- O 0 0.00035443261731415987
consanguineous O 0 0.021583659574389458
families O 0 6.6736940418365975e-09
were O 0 5.81748027528306e-09
shown O 0 5.8057088025975645e-09
to O 0 4.051924573644783e-09
be O 0 7.563919268704922e-08
compound O 0 1.851300839916803e-05
heterozygotes O 0 2.931280050688656e-06
for O 0 1.8160372405873204e-07
L236P O 0 8.178655843948945e-05
and O 0 8.142612273331906e-07
T416P O 0 0.000585679488722235
. O 0 7.573108632641379e-06

In O 0 2.610678166092839e-06
total O 0 5.31962939476216e-07
, O 0 4.7353033494346164e-08
one O 0 1.686042949700095e-08
or O 0 5.111708833993589e-09
both O 0 1.7836776500246287e-09
of O 0 6.889441017676745e-09
these O 0 1.7195652679546924e-09
mutations O 0 7.2376793447404e-09
were O 0 1.3421606048780177e-08
found O 0 1.5379496787204516e-08
in O 0 6.496011728529538e-09
nine O 0 1.1327865934163128e-07
of O 0 1.0759768542811798e-07
the O 0 1.010942867196718e-07
14 O 0 5.122868174112227e-07
families O 0 6.493573323496094e-08
analyzed O 0 1.2667629789575585e-06
. O 0 1.3963165201857919e-06

The O 0 3.6270191685616737e-06
identification O 0 1.1086905260526692e-06
of O 0 5.089181058792747e-07
two O 0 1.0954692442055602e-07
frequent O 0 8.339303008142451e-07
PDS B-Disease 0 0.00011786905815824866
mutations O 0 3.108409529772871e-08
will O 0 5.347980280845377e-09
facilitate O 0 1.6591664575571485e-07
the O 0 4.2779248587976326e-07
molecular O 0 0.0013039004988968372
diagnosis O 1 0.9266489148139954
of O 1 0.9781967997550964
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.390291234012693e-05

Insertional O 0 0.003598896088078618
mutation O 0 3.169553110637935e-06
by O 0 2.515479593512282e-07
transposable O 0 4.5755481551168486e-05
element O 0 7.730873221589718e-06
, O 0 4.792227628058754e-07
L1 O 0 0.001208631438203156
, O 0 8.100256110310511e-08
in O 0 5.371525801933785e-08
the O 0 7.508305657211167e-07
DMD B-Disease 1 0.9999998807907104
gene O 0 3.4230490086883947e-07
results O 0 2.107371415149828e-07
in O 0 4.631268950561207e-07
X B-Disease 1 0.9675080180168152
- I-Disease 1 0.9995112419128418
linked I-Disease 1 0.9981775283813477
dilated I-Disease 1 0.9999701976776123
cardiomyopathy I-Disease 1 1.0
. O 0 3.366671080584638e-05

X B-Disease 1 0.9999837875366211
- I-Disease 1 0.9999872446060181
linked I-Disease 1 0.9999054670333862
dilated I-Disease 1 0.9999985694885254
cardiomyopathy I-Disease 1 1.0
( O 0 0.009166039526462555
XLDCM B-Disease 1 0.9999998807907104
) O 0 5.757131020800443e-07
is O 0 3.1249410170630654e-08
a O 0 9.633852471324644e-08
clinical O 0 2.9129766971891513e-06
phenotype O 0 2.8874976578663336e-06
of O 0 9.265692142435e-07
dystrophinopathy B-Disease 1 0.6168361902236938
which O 0 3.2459311682941916e-08
is O 0 1.144418870779873e-08
characterized O 0 3.091988531878087e-08
by O 0 1.5142445519700232e-08
preferential O 0 5.193692686589202e-06
myocardial B-Disease 1 1.0
involvement I-Disease 0 4.346786681708181e-06
without O 0 9.362077690866499e-08
any O 0 6.194828472416702e-08
overt O 0 1.9167603113601217e-06
clinical O 0 1.9858558516716585e-05
signs O 0 1.3223669157014228e-05
of O 0 0.025095408782362938
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.04123213142156601

To O 0 1.0776276440083166e-06
date O 0 1.007496962301957e-06
, O 0 2.4656937824829583e-08
several O 0 6.888061676590951e-09
mutations O 0 2.2601071236749704e-08
in O 0 2.8975438937095532e-08
the O 0 4.618003003997728e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999980926513672
gene O 0 6.667015986749902e-05
, O 0 2.8157014639873523e-06
DMD O 1 1.0
, O 0 3.965529771221554e-08
have O 0 1.699437812696658e-09
been O 0 6.629859772289137e-09
identified O 0 2.3950068595013363e-08
in O 0 1.495952339780615e-08
patients O 0 7.240413602005447e-09
with O 0 1.5951780341083577e-08
XLDCM B-Disease 1 1.0
, O 0 1.062087235936815e-07
but O 0 8.216161084817486e-09
a O 0 2.4286428867981158e-08
pathogenic O 0 2.8791712125553204e-08
correlation O 0 4.111545237606151e-08
of O 0 3.6297049810229964e-09
these O 0 2.9822135871881983e-09
cardiospecific O 0 1.0606044270389248e-05
mutations O 0 1.1586782022732223e-07
in O 0 1.446638862034888e-07
DMD O 1 1.0
with O 0 6.945823116666361e-08
the O 0 4.521588834904833e-06
XLDCM B-Disease 1 0.9999979734420776
phenotype O 0 2.131103656211053e-06
has O 0 8.55622506179543e-09
remained O 0 1.281102299799386e-07
to O 0 1.737255850287056e-08
be O 0 3.4746668120533286e-07
elucidated O 0 0.00018889269267674536
. O 0 5.249324658507248e-06

We O 0 2.0382547063491074e-06
report O 0 7.253726721501152e-07
here O 0 9.506099019063186e-08
the O 0 4.112839491199338e-08
identification O 0 4.869736969226324e-08
of O 0 4.442402712356852e-08
a O 0 9.865924965879458e-08
unique O 0 1.8906216325831338e-07
de O 0 2.0645935364882462e-05
novo O 0 4.51768355560489e-05
L1 O 0 0.0007902036304585636
insertion O 0 2.532601456550765e-06
in O 0 7.715119920703728e-08
the O 0 2.414657558347244e-07
muscle O 0 1.176807359115628e-06
exon O 0 5.818420959258219e-06
1 O 0 8.351950668838981e-07
in O 0 4.4115452624282625e-07
DMD O 1 1.0
in O 0 1.3677430388270295e-07
three O 0 2.822546889547084e-07
XLDCM B-Disease 1 0.9999394416809082
patients O 0 1.0683511675324553e-07
from O 0 3.049700580959325e-08
two O 0 5.619398635303696e-08
unrelated O 0 5.536855496757198e-06
Japanese O 0 0.00016142323147505522
families O 0 1.0244581289953203e-06
. O 0 2.1843870854354464e-06

The O 0 1.7112810382968746e-05
insertion O 0 1.7200658476212993e-05
was O 0 7.623790224897675e-06
a O 0 3.045479843422072e-06
5 O 0 1.5040798189147608e-06
- O 0 6.999885613367951e-07
truncated O 0 3.9183029798550706e-07
form O 0 1.8372157128965227e-08
of O 0 1.0741887734866395e-07
human O 0 2.5074294285332144e-07
L1 O 0 0.0011338983895257115
inversely O 0 3.0691726351506077e-06
integrated O 0 1.40852466756769e-06
in O 0 1.708890806639829e-08
the O 0 2.4763830097640493e-08
5 O 0 8.13068794514038e-08
- O 0 2.0722279714391334e-07
untranslated O 0 3.536855047059362e-06
region O 0 6.189442558479641e-08
in O 0 2.8700805287940057e-08
the O 0 6.750573788849579e-08
muscle O 0 1.783175775926793e-07
exon O 0 5.466228572004184e-07
1 O 0 3.898960088122294e-08
, O 0 1.9095451886386172e-09
which O 0 7.141003899313603e-10
affected O 0 1.5163189592826143e-09
the O 0 1.1138453714920615e-08
transcription O 0 6.179157594488061e-07
or O 0 1.0173139664004793e-08
the O 0 2.5934854264164642e-08
stability O 0 5.352156335902691e-07
of O 0 1.0733183586353334e-07
the O 0 1.7184882494802878e-07
muscle O 0 1.7324900625226292e-07
form O 0 1.5274867593007002e-08
of O 0 4.806590823136503e-07
dystrophin O 0 3.22584091918543e-05
transcripts O 0 1.1992717645625817e-06
but O 0 2.7445994366104287e-09
not O 0 9.020534319503781e-10
that O 0 1.0332018574032986e-09
of O 0 2.0355644281266905e-08
the O 0 4.3153028173037455e-07
brain O 0 0.27079036831855774
or O 0 5.9767940001620445e-06
Purkinje O 1 0.9999995231628418
cell O 0 7.880255725467578e-05
form O 0 2.3496333767525357e-08
, O 0 2.121308106950437e-08
probably O 0 8.32056485933208e-08
due O 0 4.369027450934482e-08
to O 0 4.050016322310057e-09
its O 0 2.886460848117167e-09
unique O 0 1.2312295183392052e-08
site O 0 1.9618562419054797e-07
of O 0 6.462190782485777e-08
integration O 0 1.3713626003664103e-06
. O 0 2.4281209789478453e-06

We O 0 5.269568646326661e-06
speculate O 0 5.3668122745875735e-06
that O 0 3.5665763675751805e-08
this O 0 6.396900431582253e-08
insertion O 0 1.2932490562889143e-06
of O 0 3.818810512257187e-07
an O 0 4.06912874950649e-07
L1 O 0 0.021577632054686546
sequence O 0 7.6716132753063e-06
in O 0 1.3500101658792119e-06
DMD O 1 1.0
is O 0 9.011255741597779e-08
responsible O 0 7.089237641366708e-08
for O 0 2.8257549633536883e-09
some O 0 2.089702411112171e-09
of O 0 1.1716540626593996e-08
the O 0 2.0125710875618097e-08
population O 0 8.436532361599802e-09
of O 0 4.4599257620348e-08
Japanese O 0 8.493338100379333e-06
patients O 0 4.803474240588912e-08
with O 0 6.297666033105997e-08
XLDCM B-Disease 1 0.9998708963394165
. O 0 8.27611870590772e-07
. O 0 1.6785975276434328e-06

Severe O 0 0.00232867943122983
early O 0 0.0008696424774825573
- O 1 0.9999953508377075
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9998114705085754
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.00018809149332810193
red O 0 0.4970727264881134
hair O 1 0.9999630451202393
pigmentation O 1 0.9830307960510254
caused O 0 0.00022432481637224555
by O 0 5.943961696175393e-06
POMC O 1 1.0
mutations O 0 1.4148523632684373e-06
in O 0 3.477995278444723e-07
humans O 0 2.583296236480237e-06
. O 0 1.1135647355331457e-06

Sequential O 0 0.0008825697004795074
cleavage O 0 0.00021421245764940977
of O 0 3.2287302929034922e-06
the O 0 1.255091660823382e-06
precursor O 0 1.0855539585463703e-05
protein O 0 1.1653421552182408e-06
pre O 0 1.0535408364376053e-05
- O 0 1.1295765034446958e-05
pro O 0 1.6171750758076087e-05
- O 0 1.9030658222618513e-05
opiomelanocortin O 0 0.00042211016989313066
( O 0 2.540458581279381e-06
POMC O 0 0.0007871718844398856
) O 0 6.495518078963869e-08
generates O 0 7.210785213374038e-08
the O 0 7.22455197887939e-08
melanocortin O 0 2.1818366803927347e-05
peptides O 0 5.970470624561131e-07
adrenocorticotrophin O 0 2.4483071683789603e-05
( O 0 9.147244099949603e-07
ACTH O 0 5.4485157306771725e-05
) O 0 9.335330020121546e-08
, O 0 3.276659654716241e-08
melanocyte O 0 4.144061676925048e-05
- O 0 8.984430678538047e-06
stimulating O 0 2.808878434734652e-06
hormones O 0 2.55523644909772e-07
( O 0 4.516527951636817e-08
MSH O 0 3.042310027012718e-06
) O 0 5.979249095844352e-09
alpha O 0 2.634628337716549e-08
, O 0 6.99091340372604e-10
beta O 0 5.566951788438246e-09
and O 0 2.2886530171017938e-10
gamma O 0 7.312736194364788e-09
as O 0 3.680560300978186e-10
well O 0 5.837796357432978e-10
as O 0 9.892674457390171e-10
the O 0 9.36435995413376e-09
opioid O 0 2.896182991207752e-07
- O 0 3.19247050128979e-07
receptor O 0 2.6298241095901176e-07
ligand O 0 5.519881938198523e-07
beta O 0 1.759181714078295e-06
- O 0 2.661872031239909e-06
endorphin O 0 0.00013538361235987395
. O 0 1.300293320127821e-06

While O 0 3.401834646865609e-06
a O 0 2.398317349161516e-07
few O 0 2.509151109109098e-08
cases O 0 1.4110812074363821e-08
of O 0 8.610350050730631e-07
isolated O 1 0.9882493019104004
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999574422836304
have O 0 2.5285315174983225e-08
been O 0 1.9612426171988773e-07
reported O 0 1.5815971892152447e-06
( O 0 2.116201812896179e-06
OMIM O 1 0.7994198203086853
201400 O 0 6.102519910200499e-05
) O 0 1.46603412076729e-07
, O 0 3.847792484634738e-08
an O 0 6.292358989412605e-07
inherited O 1 0.9999973773956299
POMC O 1 1.0
defect O 1 0.9943715333938599
has O 0 7.446168837077494e-08
not O 0 1.3843322044237993e-08
been O 0 1.0756321700000626e-07
described O 0 3.3597683568586945e-07
so O 0 1.663756705738706e-07
far O 0 5.714404665013717e-07
. O 0 2.338162857995485e-06

Recent O 0 2.6456823434273247e-06
studies O 0 7.209794716800388e-07
in O 0 4.074525605801682e-08
animal O 0 1.0199859445947368e-07
models O 0 6.450897416243606e-08
elucidated O 0 3.506856046442408e-06
a O 0 9.894549890532289e-08
central O 0 1.8195008522070566e-07
role O 0 2.2549407674432587e-07
of O 0 3.611462204844429e-07
alpha O 0 3.976466541644186e-05
- O 0 2.378415229031816e-05
MSH O 0 0.0005445567076094449
in O 0 8.46843750679227e-09
the O 0 1.4037635054364728e-08
regulation O 0 2.0146220691685812e-08
of O 0 2.081254635299956e-08
food O 0 4.211762316685963e-08
intake O 0 9.409895085354947e-08
by O 0 4.33783764464124e-09
activation O 0 9.728504579697983e-08
of O 0 3.8819521819277725e-08
the O 0 1.6355821230717993e-07
brain O 0 3.6499482121143956e-06
melanocortin O 0 1.5265732145053335e-05
- O 0 8.65682011408353e-07
4 O 0 2.7083791565019055e-07
- O 0 3.80516326003999e-07
receptor O 0 1.7784613248750247e-07
( O 0 1.9933283468276386e-08
MC4 O 0 5.6356611821684055e-06
- O 0 2.475538281032641e-07
R O 0 8.584522106502845e-07
; O 0 1.1714618608493765e-08
refs O 0 2.0115699328471237e-07
3 O 0 4.8661622287227146e-08
- O 0 7.183577821479048e-08
5 O 0 4.680037335447196e-08
) O 0 3.4448635055639443e-09
and O 0 1.162766216644684e-09
the O 0 1.5827977151161576e-08
linkage O 0 9.500504916104546e-07
of O 0 8.291968356388679e-08
human O 0 4.697028259670333e-07
obesity B-Disease 1 0.9494627714157104
to O 0 2.3846780550229596e-08
chromosome O 0 2.9531854579545325e-06
2 O 0 1.2913791636037786e-07
in O 0 3.722102803749294e-08
close O 0 3.283999490122369e-07
proximity O 0 1.609616901987465e-07
to O 0 6.182031331292137e-09
the O 0 1.4911572066012013e-07
POMC O 1 0.8135886192321777
locus O 0 1.0771539109555306e-06
, O 0 3.77316577981901e-09
led O 0 8.038472998350699e-09
to O 0 1.3682611710308379e-09
the O 0 6.409563102494076e-09
proposal O 0 1.2884950884028967e-08
of O 0 4.041599410697927e-08
an O 0 7.214761410523352e-08
association O 0 1.8742598228982388e-07
of O 0 2.265728198835859e-06
POMC O 1 0.9999793767929077
with O 0 2.669353591500112e-07
human O 0 0.00015127369260881096
obesity B-Disease 1 1.0
. O 0 8.392323252337519e-06

The O 0 5.743959263782017e-06
dual O 0 7.450070825143484e-06
role O 0 2.0653437786677387e-06
of O 0 6.620487056352431e-06
alpha O 0 0.02077747881412506
- O 0 0.019039211794734
MSH O 1 0.9932987689971924
in O 0 1.0131665817425528e-07
regulating O 0 7.552615670647356e-07
food O 0 1.6968353122592816e-07
intake O 0 4.4481771510618273e-07
and O 0 1.825761408724702e-08
influencing O 0 4.143224214203656e-05
hair O 0 0.00020571924687828869
pigmentation O 0 0.00015974459529388696
predicts O 0 1.4261763681133743e-06
that O 0 4.043155144017874e-09
the O 0 2.4736166892580513e-08
phenotype O 0 1.4886181531892362e-07
associated O 0 2.287102063291968e-08
with O 0 4.422600508036112e-09
a O 0 5.2554685225914e-07
defect O 0 1.9826880816253833e-05
in O 0 2.3605402077464532e-07
POMC O 1 0.9999892711639404
function O 0 4.2110798403882654e-07
would O 0 1.0748052226006166e-08
include O 0 3.310753697860491e-07
obesity B-Disease 1 1.0
, O 0 1.2609278599029494e-07
alteration O 0 0.0003244515974074602
in O 0 1.4686693248222582e-06
pigmentation O 0 0.15670163929462433
and O 0 5.7589342759456486e-05
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.424304668442346e-05

The O 0 8.400443221034948e-06
observation O 0 8.293492282973602e-05
of O 0 5.556673841056181e-07
these O 0 4.34757190248547e-08
symptoms O 0 2.3506361230829498e-06
in O 0 2.0725403260257735e-07
two O 0 1.910395610593696e-07
probands O 0 0.021536916494369507
prompted O 0 2.5632905931161076e-07
us O 0 4.581864132546798e-08
to O 0 4.7179553597231916e-09
search O 0 4.638580364257905e-08
for O 0 7.020126258083792e-09
mutations O 0 3.070092091661536e-08
within O 0 7.670997348441233e-08
their O 0 3.403426944714738e-07
POMC O 1 0.9992110729217529
genes O 0 3.354298314661719e-06
. O 0 1.1344562835802208e-06

Patient O 0 9.57213924266398e-05
1 O 0 1.5229767313940101e-06
was O 0 7.469837441931304e-07
found O 0 2.0331510697246813e-08
to O 0 4.0906424914055606e-09
be O 0 1.12562599241528e-08
a O 0 2.0361223107556725e-07
compound O 0 5.8581085795594845e-06
heterozygote O 0 8.609257520220126e-07
for O 0 1.8673680379777124e-09
two O 0 1.4706033057976242e-09
mutations O 0 4.517834994999248e-09
in O 0 1.1536277710888498e-08
exon O 0 5.972065650894365e-07
3 O 0 2.3572333418542257e-07
( O 0 9.985249249666595e-08
G7013T O 0 3.545747404132271e-06
, O 0 6.453998935285199e-08
C7133delta O 0 0.00010719408601289615
) O 0 5.790273149841596e-08
which O 0 3.515032487300118e-09
interfere O 0 1.1683334300016668e-08
with O 0 7.916954314346469e-10
appropriate O 0 6.097856442011107e-08
synthesis O 0 7.528266792178329e-07
of O 0 5.755346705882403e-07
ACTH O 0 4.283831367501989e-05
and O 0 9.044247661904592e-08
alpha O 0 4.614362842403352e-05
- O 0 5.842237806064077e-05
MSH O 0 0.0011420849477872252
. O 0 1.6544373693250236e-06

Patient O 0 0.00011605537292780355
2 O 0 2.290731345055974e-06
was O 0 1.3577662230090937e-06
homozygous O 0 1.8466951701157086e-07
for O 0 6.1828329123159165e-09
a O 0 5.0703746978797426e-08
mutation O 0 1.7210034286563314e-08
in O 0 3.7221312254587247e-08
exon O 0 2.0959798803232843e-06
2 O 0 9.697258747110027e-07
( O 0 7.910152248769009e-07
C3804A O 0 2.5993100280174986e-05
) O 0 2.611876084301912e-07
which O 0 1.2625716294678568e-07
abolishes O 0 1.763394357112702e-05
POMC O 0 0.007015853188931942
translation O 0 6.188591942191124e-05
. O 0 4.331467607698869e-06

These O 0 3.8917460187803954e-07
findings O 0 2.3071032728694263e-07
represent O 0 4.560920530138901e-08
the O 0 1.97901215415186e-08
first O 0 2.1383373294270314e-08
examples O 0 3.247727065058825e-08
of O 0 9.03766022020136e-08
a O 0 2.170377229049336e-06
genetic B-Disease 1 0.999998927116394
defect I-Disease 1 0.9999842643737793
within O 0 8.119140488815901e-07
the O 0 3.072771960432874e-06
POMC O 1 0.9999804496765137
gene O 0 1.0660183846766813e-07
and O 0 5.923175283584214e-09
define O 0 1.3466100767800526e-07
a O 0 1.8419987668494286e-07
new O 0 9.39961296353431e-07
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9999871253967285
resulting O 0 8.668454938742798e-06
in O 0 5.292718583405076e-07
early O 0 0.058763179928064346
- O 1 0.9999991655349731
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9932975172996521
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.0003571609267964959
red O 0 0.1258762776851654
hair O 1 0.9952175617218018
pigmentation O 1 0.6056689620018005
. O 0 1.3336725714907516e-05
. O 0 2.0435358237591572e-05

A O 0 1.8296597772859968e-05
European O 0 2.3179106847237563e-06
multicenter O 0 0.001909357961267233
study O 0 5.888634859729791e-06
of O 0 6.80445518810302e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 6.682523121526174e-07
classification O 0 8.664617325848667e-07
of O 0 3.2714333997319045e-07
105 O 0 8.040399279707344e-07
mutations O 0 1.552870543264362e-08
and O 0 2.744856120173722e-09
a O 0 3.838717077542242e-08
general O 0 4.080132853800933e-08
system O 0 3.175932050680785e-08
for O 0 1.219415501907406e-08
genotype O 0 9.045685942510318e-07
- O 0 1.5624511888745474e-06
based O 0 1.258448349972241e-07
prediction O 0 2.1142004698049277e-06
of O 0 5.953850745754607e-07
metabolic O 0 0.0003495493729133159
phenotype O 0 1.5107305443962105e-05
. O 0 2.516144377295859e-06

Phenylketonuria B-Disease 1 0.9999990463256836
( O 0 0.006613688077777624
PKU B-Disease 1 0.9999673366546631
) O 0 1.9727972357941326e-06
and O 0 2.1297594798852515e-07
mild B-Disease 0 0.001102319685742259
hyperphenylalaninemia I-Disease 1 1.0
( O 1 1.0
MHP B-Disease 1 1.0
) O 0 0.00014124950394034386
are O 0 2.2796812970682367e-07
allelic B-Disease 0 0.052950531244277954
disorders I-Disease 1 0.9998987913131714
caused O 0 3.125241619272856e-06
by O 0 4.641624329337901e-08
mutations O 0 2.6199005631610817e-08
in O 0 1.8471139284770288e-08
the O 0 1.9156681219101301e-07
gene O 0 1.0000494512496516e-06
encoding O 0 2.4539558580727316e-06
phenylalanine O 0 9.35131247388199e-05
hydroxylase O 0 0.001112973433919251
( O 0 9.425960888620466e-05
PAH O 1 0.9999995231628418
) O 0 2.5585877665434964e-05
. O 0 7.019176791800419e-06

Previous O 0 1.3300780665304046e-05
studies O 0 8.41466203382879e-07
have O 0 1.1652133480311022e-08
suggested O 0 4.0899113429304634e-08
that O 0 2.0242347797960747e-09
the O 0 1.2588703413030089e-08
highly O 0 8.893506731055822e-08
variable O 0 1.410738832419156e-06
metabolic O 0 0.0068171098828315735
phenotypes O 0 0.0001393506390741095
of O 1 0.866500973701477
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.22391723096370697
with O 0 3.772081254282966e-05
PAH O 1 1.0
genotypes O 0 0.0034754350781440735
. O 0 1.7328306057606824e-05

We O 0 2.283577032358153e-06
identified O 0 7.917307129901019e-07
both O 0 1.025950595590075e-07
causative O 0 2.026500260399189e-05
mutations O 0 4.4742657223650895e-07
in O 0 2.6631516902853036e-07
686 O 0 4.09851927543059e-05
patients O 0 5.883847009613419e-08
from O 0 8.009428853483769e-08
seven O 0 4.1560704744370014e-07
European O 0 1.3637148867928772e-06
centers O 0 2.6752074973046547e-06
. O 0 1.901425093819853e-06

On O 0 3.421160045036231e-06
the O 0 1.67379099025311e-07
basis O 0 1.8001391310917825e-07
of O 0 5.19387342023947e-08
the O 0 4.005690712460819e-08
phenotypic O 0 5.460684633362689e-07
characteristics O 0 1.448694604277989e-07
of O 0 2.407586805475148e-07
297 O 0 6.8265662775957026e-06
functionally O 0 9.926170605467632e-05
hemizygous O 0 0.0004757597343996167
patients O 0 7.04237734794333e-08
, O 0 1.1596482885067871e-08
105 O 0 1.4318808894131507e-07
of O 0 3.781864421625869e-08
the O 0 2.80716427880634e-08
mutations O 0 5.682339931922797e-09
were O 0 9.169584203050363e-09
assigned O 0 5.032317673681064e-08
to O 0 5.987260465190047e-09
one O 0 1.359640311449084e-08
of O 0 4.4370001006655e-08
four O 0 6.433192112353936e-08
arbitrary O 0 2.6392160634713946e-07
phenotype O 0 1.2626068155441317e-06
categories O 0 1.6443042341052205e-06
. O 0 1.8343362171435729e-06

We O 0 1.7008059103318374e-06
proposed O 0 3.1558369073536596e-07
and O 0 3.4703344198305786e-08
tested O 0 7.076214103562961e-08
a O 0 4.434766864847006e-08
simple O 0 1.5191567115380167e-08
model O 0 1.4648259494265403e-08
for O 0 5.779193124055837e-09
correlation O 0 1.9004085061169462e-07
between O 0 6.901544225001999e-08
genotype O 0 2.8334292778708914e-07
and O 0 1.213619338358285e-08
phenotypic O 0 1.92638322005223e-06
outcome O 0 6.145427960291272e-06
. O 0 3.934106644010171e-06

The O 0 1.4620070942328312e-05
observed O 0 1.0571660823188722e-05
phenotype O 0 7.5821417340193875e-06
matched O 0 8.122431722767942e-07
the O 0 1.8413243196846452e-07
predicted O 0 1.0992761190209421e-06
phenotype O 0 2.2304729441202653e-07
in O 0 2.3745837296473837e-08
79 O 0 3.8193567775124393e-07
% O 0 2.0060406669131225e-08
of O 0 1.0388122362314789e-08
the O 0 5.170651906638568e-09
cases O 0 1.2982632746627587e-09
, O 0 8.550444796640022e-10
and O 0 6.646747041649803e-10
in O 0 1.511349823068997e-09
only O 0 1.684794859180272e-09
5 O 0 1.756206025049778e-08
of O 0 1.1910132435843934e-08
184 O 0 6.192335888499656e-08
patients O 0 4.313893242624545e-09
was O 0 2.33784476222354e-08
the O 0 6.434895283291553e-09
observed O 0 2.128075848872868e-08
phenotype O 0 5.97377702860058e-09
more O 0 1.1048726517026708e-10
than O 0 2.9737373674620926e-10
one O 0 1.4093000100245945e-09
category O 0 1.474879507412652e-08
away O 0 7.778029775806772e-09
from O 0 8.007744689564333e-09
that O 0 6.956347053943546e-09
expected O 0 2.672035464001965e-07
. O 0 1.0188459782511927e-06

Among O 0 4.995628160031629e-07
the O 0 1.263077393787171e-07
seven O 0 1.0608866318762011e-07
contributing O 0 4.213614772652363e-07
centers O 0 6.79857663499206e-08
, O 0 5.756068954809734e-09
the O 0 1.827287299249747e-08
proportion O 0 8.540624918396134e-08
of O 0 8.132859363740863e-08
patients O 0 1.325087684023174e-08
for O 0 4.933654373928675e-09
whom O 0 7.231873411228662e-08
the O 0 4.616593685113912e-08
observed O 0 2.45682656441204e-07
phenotype O 0 6.286720832804349e-08
did O 0 3.580110652379176e-09
not O 0 2.356035810890944e-09
match O 0 2.6093134763982562e-08
the O 0 4.685798415948739e-08
predicted O 0 2.1351711154693476e-07
phenotype O 0 3.4932856607383656e-08
was O 0 4.491717575660914e-08
4 O 0 2.6241366413159994e-08
% O 0 5.173582007245159e-09
- O 0 1.2182995945408948e-08
23 O 0 4.202918901796693e-08
% O 0 8.01237387548781e-09
( O 0 6.565855859008707e-09
P O 0 9.199752071253897e-07
< O 0 2.2701527768731466e-07
. O 0 2.927367237504086e-09
0001 O 0 2.9837510737706907e-06
) O 0 6.4220451179153315e-09
, O 0 9.404809153679139e-10
suggesting O 0 4.403863052004908e-09
that O 0 1.5949605525200639e-10
differences O 0 1.6138360647843797e-09
in O 0 7.991415307273542e-10
methods O 0 2.1593784538254113e-09
used O 0 3.232645706674475e-09
for O 0 2.3445152486090137e-09
mutation O 0 6.844492617119613e-08
detection O 0 4.865559617428517e-07
or O 0 4.6586183799490755e-08
phenotype O 0 7.69131645483867e-07
classification O 0 2.0240801745785575e-07
may O 0 1.7413828601320347e-08
account O 0 1.54431649690423e-08
for O 0 1.7388264161866118e-09
a O 0 1.976175667550706e-08
considerable O 0 1.2356989032014098e-07
proportion O 0 1.6005580505407124e-07
of O 0 2.1543239370203082e-07
genotype O 0 2.7201228931517107e-06
- O 0 7.442905825882917e-06
phenotype O 0 2.7120102004118962e-06
inconsistencies O 0 7.625601028848905e-06
. O 0 1.5900982361927163e-06

Our O 0 1.0742091944848653e-05
data O 0 2.613495553305256e-06
indicate O 0 8.676955189912405e-07
that O 0 8.660703088025912e-08
the O 0 1.855190589594713e-06
PAH O 1 0.9999996423721313
- O 0 4.3376334360800683e-05
mutation O 0 2.291768481654799e-07
genotype O 0 1.3517941965801583e-07
is O 0 3.254211344838609e-09
the O 0 7.788154121612934e-09
main O 0 2.56246465824006e-07
determinant O 0 1.915271241159644e-06
of O 0 1.6991266704735608e-07
metabolic O 0 0.00019439210882410407
phenotype O 0 1.86597020501722e-07
in O 0 7.031945692403951e-09
most O 0 1.7769144378121382e-08
patients O 0 2.0922723820149258e-07
with O 0 9.417716682946775e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.000278907100437209

In O 0 7.69781820508797e-07
the O 0 8.037005017058618e-08
present O 0 1.0583905662997495e-07
study O 0 6.385904782746366e-08
, O 0 5.276688863631307e-09
the O 0 2.0950992052348738e-08
classification O 0 2.6113502826774493e-07
of O 0 1.0628933750922442e-06
105 O 0 0.3807269334793091
PAH O 1 1.0
mutations O 0 1.7550348729855614e-07
may O 0 1.8560982084636635e-08
allow O 0 8.862650169305653e-09
the O 0 3.409943616361488e-08
prediction O 0 7.188058930296393e-07
of O 0 2.029408285864065e-08
the O 0 3.769233103412262e-08
biochemical O 0 2.076601049338933e-06
phenotype O 0 1.782716765319492e-07
in O 0 3.386131552929328e-08
> O 0 2.3624861000826058e-07
10 O 0 2.7932724577794943e-08
, O 0 6.178895617381386e-09
000 O 0 2.7900463805963227e-07
genotypes O 0 1.0988509302478633e-07
, O 0 2.215660321880364e-09
which O 0 4.122975294507114e-10
may O 0 7.136973234622701e-10
be O 0 9.825147362363396e-10
useful O 0 2.1758632229307295e-08
for O 0 4.760939642522999e-09
the O 0 7.165036208789388e-08
management O 0 1.6613054185654619e-06
of O 0 5.595964921667473e-06
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.1472979167592712e-05
newborns O 0 3.034662404388655e-05
. O 0 2.4522951207472943e-06

Somatic O 0 0.0014128506882116199
instability O 0 7.283154991455376e-05
of O 0 5.476128990267171e-06
the O 0 1.7020234736264683e-05
CTG O 1 0.9999992847442627
repeat O 0 2.717682764341589e-05
in O 0 2.721295686569647e-07
mice O 0 1.1503713039928698e-06
transgenic O 0 5.893146521884773e-07
for O 0 4.997052727162554e-08
the O 0 4.424995859153569e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 3.2720186027290765e-06
is O 0 4.6679751619649323e-08
age O 0 9.489595953482421e-08
dependent O 0 3.810493609535115e-08
but O 0 1.7128352070017172e-09
not O 0 1.7732840751349954e-09
correlated O 0 7.640916521722829e-08
to O 0 5.970200778193657e-09
the O 0 4.8665892649069065e-08
relative O 0 4.38125880464213e-06
intertissue O 0 0.0005388785502873361
transcription O 0 1.720874752209056e-05
levels O 0 1.9323874766996596e-07
and O 0 1.3087839079162222e-07
proliferative O 0 0.03895000368356705
capacities O 0 7.735089457128197e-05
. O 0 9.207263246935327e-06

A O 0 0.00108423363417387
( O 0 5.561653961194679e-05
CTG O 1 0.9921443462371826
) O 0 2.795871068883571e-06
nexpansion O 0 3.071461105719209e-05
in O 0 1.1152509671319422e-07
the O 0 1.9662803651954164e-07
3 O 0 8.124717396640335e-07
- O 0 1.34540766794089e-06
untranslated O 0 3.635469693108462e-05
region O 0 1.0055023267341312e-06
( O 0 6.731723942721146e-07
UTR O 0 0.0002816374762915075
) O 0 5.966855809447225e-08
of O 0 7.027551163218959e-08
the O 0 6.85357122165442e-07
DM O 1 0.9999998807907104
protein O 0 4.010066277260194e-06
kinase O 0 1.7960799141292227e-06
gene O 0 4.925664853772105e-08
( O 0 9.468279671409618e-08
DMPK O 0 0.0004665804444812238
) O 0 5.8528200952423504e-08
is O 0 1.6260974788906424e-08
responsible O 0 1.5338051184698998e-07
for O 0 2.749123098055861e-07
causing O 1 0.9770212769508362
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999986886978149
DM B-Disease 1 1.0
) O 0 2.6789506591740064e-05
. O 0 6.425376795959892e-06

Major O 0 0.00013915941235609353
instability O 0 0.00011379745410522446
, O 0 1.0763812241521009e-07
with O 0 1.527478055152187e-08
very O 0 7.829026316130694e-08
large O 0 1.1762693929995294e-07
expansions O 0 9.106760785471124e-07
between O 0 9.500715947297067e-08
generations O 0 6.35561150374997e-08
and O 0 8.798108908081304e-09
high O 0 1.2991165476705646e-07
levels O 0 1.0298010977294325e-07
of O 0 1.7741349722655286e-07
somatic O 0 9.889482498692814e-06
mosaicism O 0 0.0005900355172343552
, O 0 3.515959434707838e-08
is O 0 2.201599791362696e-08
observed O 0 1.8314626970550307e-07
in O 0 1.5112100015812757e-07
patients O 0 3.615208186147356e-07
. O 0 1.1091188980572042e-06

There O 0 9.549179594614543e-06
is O 0 6.147605517980992e-07
a O 0 7.307537543965736e-07
good O 0 2.64939899352612e-07
correlation O 0 5.972914323137957e-07
between O 0 1.4609872778237332e-07
repeat O 0 7.107839792297455e-07
size O 0 1.7150402698007383e-07
( O 0 4.701823996811072e-08
at O 0 8.907088044907141e-08
least O 0 8.296220599390836e-09
in O 0 5.1693209712766475e-09
leucocytes O 0 6.367530659190379e-06
) O 0 3.247764013281085e-08
, O 0 8.544515317510104e-09
clinical O 0 1.6468514729695016e-07
severity O 0 4.1810474726844404e-07
and O 0 4.429483269063894e-08
age O 0 1.3167656106816139e-05
of O 0 2.6207155315205455e-05
onset O 1 0.9999566078186035
. O 0 9.118118214246351e-06

The O 0 0.0001260843127965927
trinucleotide O 1 0.9791700839996338
repeat O 0 0.00013070646673440933
instability O 0 0.00011833280586870387
mechanisms O 0 3.0378099836525507e-05
involved O 0 3.439263309701346e-05
in O 0 3.343927164678462e-05
DM B-Disease 1 1.0
and O 0 7.39338190669514e-08
other O 0 2.436028623264974e-08
human O 0 5.694771061826032e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.873669302516646e-07
unknown O 0 0.03581948205828667
. O 0 7.771412128931843e-06

We O 0 2.616500523799914e-06
studied O 0 7.884133083280176e-06
somatic O 0 1.4425155313801952e-05
instability O 0 2.8466865842347033e-06
by O 0 1.3761376749243937e-07
measuring O 0 5.637435970129445e-05
the O 0 2.2832459762867074e-06
CTG O 1 0.9977376461029053
repeat O 0 2.626425839480362e-06
length O 0 2.1335326039206848e-07
at O 0 4.9008963998176114e-08
several O 0 1.0116827375838966e-09
ages O 0 1.0081965484687316e-08
in O 0 1.1171128466713753e-09
various O 0 4.752420235121235e-09
tissues O 0 1.0314287379742382e-07
of O 0 2.887520338390459e-07
transgenic O 0 1.0133449904969893e-05
mice O 0 5.5577606872248e-07
carrying O 0 5.38842527930683e-07
a O 0 7.980103191584931e-07
( O 0 1.8008945517067332e-06
CTG O 1 0.810184895992279
) O 0 5.51071934751235e-07
55expansion O 0 1.0794649824674707e-05
surrounded O 0 1.5710380694144988e-06
by O 0 3.200267428837833e-08
45 O 0 2.8126262918704015e-07
kb O 0 4.24922063757549e-06
of O 0 1.0407880779439438e-07
the O 0 2.9561539349742816e-07
human O 0 1.1379778470654855e-06
DM B-Disease 1 1.0
region O 0 1.9117513261335262e-07
, O 0 6.881180958373534e-09
using O 0 1.4753211985407688e-08
small O 0 7.464483786634446e-08
- O 0 9.793309345695889e-07
pool O 0 5.616222551907413e-06
PCR O 0 1.2432536095730029e-05
. O 0 9.793393473955803e-07

These O 0 3.1443928492080886e-06
mice O 0 3.8494331420224626e-06
have O 0 1.2425747542010868e-08
been O 0 1.9792310013144743e-08
shown O 0 1.8599539686192657e-08
to O 0 4.374745454782669e-09
reproduce O 0 1.1397663257639579e-07
the O 0 9.085310637146904e-08
intergenerational O 0 6.100588507251814e-06
and O 0 1.7134111018890508e-08
somatic O 0 1.1588211918933666e-06
instability O 0 4.650397613659152e-07
of O 0 1.6276494818612264e-07
the O 0 4.3639059299493965e-07
55 O 0 1.101354973798152e-05
CTG O 1 0.9894982576370239
repeat O 0 1.5666438457628828e-06
suggesting O 0 1.1618106299238207e-07
that O 0 1.5680549081409367e-09
surrounding O 0 1.5426884658609197e-08
sequences O 0 2.047745262245826e-08
and O 0 3.431021022848313e-09
the O 0 2.4905462581159554e-08
chromatin O 0 8.546619483240647e-07
environment O 0 1.0932921412631913e-07
are O 0 7.660394096831169e-09
involved O 0 1.1281863265821812e-07
in O 0 1.8767748599657352e-07
instability O 0 2.0709348973468877e-05
mechanisms O 0 2.6786823582369834e-05
. O 0 5.838910510647111e-06

As O 0 1.1359167046975926e-06
observed O 0 6.436874286919192e-07
in O 0 2.4996502645535656e-08
some O 0 7.642938726348802e-09
of O 0 5.597511787414078e-08
the O 0 1.1805286703747697e-07
tissues O 0 1.6133202507262467e-06
of O 0 0.0133201964199543
DM B-Disease 1 1.0
patients O 0 2.0249508452252485e-05
, O 0 1.8978976612515908e-08
there O 0 2.9596506578855042e-08
is O 0 1.1023562507261886e-08
a O 0 1.422040085685694e-08
tendency O 0 1.4575352480505899e-08
for O 0 2.2198227700442885e-09
repeat O 0 1.7533152174564748e-07
length O 0 7.070453733604154e-08
and O 0 1.8214448616049594e-08
somatic O 0 5.732029876526212e-06
mosaicism O 0 6.635359022766352e-05
to O 0 2.2473532368394444e-08
increase O 0 2.8954667996572425e-08
with O 0 4.936374864428217e-09
the O 0 8.227440417840626e-08
age O 0 4.818946308660088e-07
of O 0 3.617473964823148e-07
the O 0 6.266111540753627e-07
mouse O 0 3.204927452316042e-06
. O 0 5.355250323191285e-07

Furthermore O 0 1.4501541045319755e-05
, O 0 1.1136481958828881e-07
we O 0 3.448454677368318e-08
observed O 0 1.6805054769974959e-07
no O 0 5.139221315175746e-08
correlation O 0 9.486193874863602e-08
between O 0 1.0164877828344743e-08
the O 0 1.6916930078991754e-08
somatic O 0 2.385051516284875e-07
mutation O 0 3.403776815957826e-08
rate O 0 4.7632124022811695e-08
and O 0 1.6977118377781153e-08
tissue O 0 1.1075111615355127e-05
proliferation O 0 0.3539218604564667
capacity O 0 0.00015318508667405695
. O 0 7.604126494697994e-06

The O 0 2.546469204389723e-06
somatic O 0 5.200259693083353e-06
mutation O 0 7.669812163157985e-08
rates O 0 1.1666499766249672e-08
in O 0 9.602235673256132e-10
different O 0 7.223360798391809e-10
tissues O 0 2.080405181459355e-08
were O 0 1.9029831932471097e-08
also O 0 6.101902094712841e-09
not O 0 4.989259672072421e-09
correlated O 0 9.219463947829354e-08
to O 0 4.045083379367043e-09
the O 0 2.0523671651062614e-08
relative O 0 8.625143550489156e-07
inter O 0 2.6126204829779454e-05
- O 0 5.479727406054735e-05
tissue O 0 1.3136185543771717e-06
difference O 0 9.505700404588424e-08
in O 0 1.4136619874705048e-08
transcriptional O 0 3.480052441773296e-07
levels O 0 1.2698744278338836e-08
of O 0 3.6800564817696113e-09
the O 0 2.8872924051626114e-09
three O 0 3.5659626362871677e-09
genes O 0 3.3254295317419746e-08
( O 0 3.598198716758816e-08
DMAHP O 0 0.00022952639847062528
, O 0 1.0178927567494611e-07
DMPK O 0 0.0003125362272839993
and O 0 3.3973879709492394e-08
59 O 0 7.047073040666874e-07
) O 0 6.22236129288467e-08
surrounding O 0 1.366856423601348e-07
the O 0 7.07336695882077e-08
repeat O 0 8.710500196684734e-07
. O 0 1.4519697799642017e-07
. O 0 1.0018630973718246e-06

A O 0 2.5307150281150825e-05
novel O 0 1.0021163689089008e-05
missense O 0 3.0675273592351004e-05
mutation O 0 2.8097844051444554e-07
in O 0 5.4568229046481065e-08
patients O 0 3.2900238977617846e-08
from O 0 7.5557146317351e-08
a O 0 3.547942469595e-06
retinoblastoma B-Disease 1 0.9965720176696777
pedigree O 0 0.0002334060991415754
showing O 0 1.0676498050088412e-06
only O 0 1.620314016292923e-08
mild O 0 9.905521380915161e-08
expression O 0 2.749494498743843e-08
of O 0 8.047957322787624e-08
the O 0 7.710881391176372e-07
tumor B-Disease 0 0.047437310218811035
phenotype O 0 1.1786408322222997e-05
. O 0 2.1124592421983834e-06

We O 0 8.956625379141769e-07
have O 0 2.8988043965227916e-08
used O 0 1.0620933466043425e-07
single O 0 1.4607726939175336e-07
strand O 0 7.435176030412549e-07
conformation O 0 1.8216209696220176e-07
polymorphism O 0 5.99688618763139e-08
analysis O 0 1.0945874429069136e-08
to O 0 2.3918373948106364e-09
study O 0 1.14943938811507e-08
the O 0 1.751656242277022e-08
27 O 0 4.7492420662820223e-07
exons O 0 2.0695065927611722e-07
of O 0 6.939030328112494e-08
the O 0 2.4502841711182555e-07
RB1 O 1 0.8229180574417114
gene O 0 3.3794986364910073e-08
in O 0 6.599416124686286e-09
individuals O 0 2.813149935221304e-09
from O 0 1.3880761429163613e-08
a O 0 8.742325974253617e-08
family O 0 1.2502087542998197e-07
showing O 0 4.293046629300079e-07
mild O 0 1.429809515229863e-07
expression O 0 5.601655672649031e-08
of O 0 1.457763971757231e-07
the O 0 1.296574623665947e-06
retinoblastoma B-Disease 0 0.0017268008086830378
phenotype O 0 2.367114939261228e-05
. O 0 1.2581726878124755e-06

In O 0 1.9874246390827466e-06
this O 0 1.9037933896015602e-07
family O 0 3.243898447635729e-07
affected O 0 4.32529816407623e-08
individuals O 0 8.185238264957206e-09
developed O 0 8.800614637038962e-08
unilateral B-Disease 0 2.5385828848811798e-05
tumors I-Disease 1 1.0
and O 0 7.769285303993456e-08
, O 0 1.4843222650995358e-08
as O 0 3.5568057388246643e-09
a O 0 5.150562643052581e-09
result O 0 1.7910346539196098e-09
of O 0 7.845226690506024e-09
linkage O 0 2.5460778374508664e-07
analysis O 0 2.0595042116156037e-08
, O 0 7.436471438637682e-09
unaffected O 0 1.523413999393597e-07
mutation O 0 7.81499753799153e-09
carriers O 0 3.991876162956487e-09
were O 0 5.204273012537897e-09
also O 0 5.5168061230403964e-09
identified O 0 5.5757851669113734e-08
within O 0 1.3275140986479528e-07
the O 0 5.751812750531826e-07
pedigree O 0 1.9719944248208776e-05
. O 0 3.265011400799267e-06

A O 0 3.0768438591621816e-05
single O 0 9.066507686839032e-07
band O 0 1.7586584135642624e-06
shift O 0 1.0478437388883322e-06
using O 0 3.1202125683194026e-07
SSCP O 0 0.00040625716792419553
was O 0 1.5683630181229091e-06
identified O 0 4.047763866310561e-07
in O 0 1.0720047782797337e-07
exon O 0 2.795164846247644e-06
21 O 0 2.0037275305639923e-07
which O 0 8.29851565242734e-09
resulted O 0 5.192486796090634e-08
in O 0 1.0041089737455877e-08
a O 0 4.271019449220148e-08
missense O 0 3.084826118993078e-07
mutation O 0 8.317213584518868e-09
converting O 0 9.973067705004723e-08
a O 0 1.2334052712503762e-07
cys O 0 1.8059723515762016e-05
- O 0 6.648979251622222e-06
- O 0 6.496611149486853e-06
> O 0 4.2241867959091906e-06
arg O 0 8.562348057239433e-07
at O 0 1.3922500841090368e-07
nucleotide O 0 4.3295409568600007e-07
position O 0 5.828668037111129e-08
28 O 0 1.571089001117798e-07
in O 0 4.383635143767606e-08
the O 0 6.944139840925345e-07
exon O 0 2.2780241124564782e-05
. O 0 1.7998179373535095e-06

The O 0 1.2512108696682844e-05
mutation O 0 6.031648354110075e-06
destroyed O 0 4.475988680496812e-05
an O 0 1.5132217185964691e-06
NdeI O 0 0.0018484137253835797
restriction O 0 3.5205239328206517e-06
enzyme O 0 9.369878171128221e-06
site O 0 5.632093689200701e-06
. O 0 2.753840817604214e-06

Analysis O 0 1.05837043520296e-05
of O 0 6.019461693540507e-07
all O 0 8.862755151994861e-08
family O 0 1.9935797013204137e-07
members O 0 1.5785014184643842e-08
demonstrated O 0 4.8099469296403186e-08
that O 0 3.918363855603957e-09
the O 0 4.20224566255456e-08
missense O 0 2.246557642138214e-06
mutation O 0 1.2749630684538715e-07
co O 0 1.2321019312366843e-05
- O 0 3.2553227356402203e-05
segregated O 0 1.2242006732776645e-06
with O 0 1.100746960247534e-08
patients O 0 6.272108521443442e-08
with O 0 1.8559218517566478e-07
tumors B-Disease 1 1.0
or O 0 0.0001220577978529036
who O 0 5.447571993499878e-07
, O 0 4.877573189787654e-08
as O 0 1.9630046921292887e-08
a O 0 5.641252087684734e-08
result O 0 2.0005765932751274e-08
of O 0 3.065563447535169e-08
linkage O 0 6.757342703167524e-07
analysis O 0 3.5004891429935014e-08
had O 0 2.0128243960471082e-08
been O 0 1.66610121254962e-08
predicted O 0 4.4206799998391944e-08
to O 0 5.0721227218275544e-09
carry O 0 1.1070343930441595e-07
the O 0 1.1164145234943135e-06
predisposing O 0 0.00021012536308262497
mutation O 0 3.29551789945981e-06
. O 0 3.4112754292436875e-06

These O 0 8.168364615812607e-07
observations O 0 2.372373273828998e-06
point O 0 7.509580655096215e-07
to O 0 1.5585975177145883e-08
another O 0 8.876272516999961e-08
region O 0 1.108200535782089e-07
of O 0 2.8070016355741245e-07
the O 0 2.2541978523804573e-06
RB1 O 1 0.9995704293251038
gene O 0 8.71520526857239e-08
where O 0 7.733031104351085e-09
mutations O 0 2.0809043377312264e-09
only O 0 7.840404991910077e-10
modify O 0 5.116429946383505e-09
the O 0 5.848944883979357e-09
function O 0 2.398398812886171e-08
of O 0 8.826750885759793e-09
the O 0 1.905656610290407e-08
gene O 0 1.1062276428219775e-08
and O 0 1.5289901567072661e-09
raise O 0 5.179249473741265e-09
important O 0 5.126354452045234e-09
questions O 0 7.802992918470864e-09
for O 0 4.062480574162919e-09
genetic O 0 1.0429555459268158e-06
counseling O 0 2.84204872968985e-07
in O 0 9.941840239946487e-09
families O 0 3.479532217909309e-09
with O 0 2.94813307100128e-09
these O 0 1.1720876713638972e-08
distinctive O 0 1.9194992262328014e-07
phenotypes O 0 7.927204137558874e-07
. O 0 1.4206145237949386e-07
. O 0 6.495840239040263e-07

Maternal B-Disease 1 0.9994311928749084
disomy I-Disease 1 0.9997560381889343
and O 0 0.0003076134016737342
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.000251994002610445
with O 0 4.429170417097339e-07
gamete O 1 0.594517707824707
complementation O 0 0.00017986929742619395
in O 0 5.977643269261534e-08
a O 0 1.7440994781736663e-07
case O 0 1.4731874387052812e-07
of O 0 1.7547916968396748e-06
familial O 0 0.00016901335038710386
translocation O 0 0.00034815253457054496
( O 0 2.0760585357493255e-06
3 O 0 4.278039114069543e-07
; O 0 2.91858803791456e-08
15 O 0 3.7269623476277047e-07
) O 0 2.4300427980961103e-07
( O 0 3.130191146283323e-07
p25 O 0 8.458628144580871e-06
; O 0 7.218519471052787e-08
q11 O 0 7.644299330422655e-06
. O 0 1.114925538558964e-07
2 O 0 1.514995005891251e-06
) O 0 5.764218258264009e-07
. O 0 1.2564509006551816e-06

Maternal B-Disease 1 0.9999963045120239
uniparental I-Disease 1 0.9999998807907104
disomy I-Disease 1 0.9999997615814209
( I-Disease 1 0.9994340538978577
UPD I-Disease 1 1.0
) I-Disease 0 2.3806935587344924e-06
for I-Disease 0 9.607813211687244e-08
chromosome I-Disease 0 5.640564722853014e-06
15 I-Disease 0 3.137704993605439e-07
is O 0 2.8957593656286917e-08
responsible O 0 8.317121569234587e-08
for O 0 1.2636070856331116e-08
an O 0 1.2850716757384362e-07
estimated O 0 2.471007292115246e-07
30 O 0 2.3328789211518597e-07
% O 0 2.265247012189775e-08
of O 0 1.419582051909174e-08
cases O 0 1.5068803094209215e-08
of O 0 1.236508887814125e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9997316002845764
PWS B-Disease 1 1.0
) O 0 1.7113887224695645e-05
. O 0 3.0994219741842244e-06

We O 0 5.4076463129604235e-06
report O 0 8.061459766395274e-07
on O 0 9.807612144641098e-08
an O 0 4.5300215134602695e-08
unusual O 0 1.552005102212206e-07
case O 0 2.7318191087033483e-07
of O 0 2.2210429051483516e-06
maternal B-Disease 0 0.20541131496429443
disomy I-Disease 1 0.9999474287033081
15 I-Disease 0 0.00018793212075252086
in O 0 1.3573605428973678e-05
PWS B-Disease 1 1.0
that O 0 3.0415328922117624e-08
is O 0 1.0732688515702193e-08
most O 0 1.7833647891762894e-09
consistent O 0 1.470581612039723e-08
with O 0 2.282585898072398e-09
adjacent O 0 3.760387130569143e-07
- O 0 6.466869422183663e-07
1 O 0 2.2531436627559742e-07
segregation O 0 3.1107168751987047e-07
of O 0 9.409212964328617e-08
a O 0 2.5223329203072353e-07
paternal O 0 1.7331739172732341e-06
t O 0 1.7596067891645362e-07
( O 0 1.749669564787837e-08
3 O 0 3.24089555192586e-08
; O 0 3.4407658944246577e-09
15 O 0 5.984385609281162e-08
) O 0 4.731195701879187e-08
( O 0 7.053158412873017e-08
p25 O 0 1.5918992630759021e-06
; O 0 5.912812905961573e-09
q11 O 0 1.2933550124216708e-06
. O 0 1.1067847971446554e-08
2 O 0 4.438608414147893e-08
) O 0 5.433617999983653e-09
with O 0 3.437361506541947e-09
simultaneous O 0 1.2031919141008984e-06
maternal O 0 2.336282705073245e-05
meiotic O 0 0.000983772217296064
nondisjunction O 0 0.006350892595946789
for O 0 2.132703684765147e-06
chromosome O 0 6.985857908148319e-05
15 O 0 4.372956027509645e-06
. O 0 2.8319129796727793e-06

The O 0 1.1652326065814123e-05
patient O 0 3.7570637232420268e-06
( O 0 4.7600886432519474e-07
J O 0 3.4512429465394234e-06
. O 0 1.653983972005335e-08
B O 0 7.657124001525517e-07
. O 0 6.062113033777905e-09
) O 0 1.1860803894592209e-08
, O 0 4.1054311061827775e-09
a O 0 4.094219363537377e-08
17 O 0 2.45318801717076e-07
- O 0 2.2160129731219058e-07
year O 0 1.0660814808716168e-07
- O 0 1.825697268031945e-06
old O 0 2.4911958007578505e-06
white O 0 5.908098046347732e-07
male O 0 5.360028012546536e-07
with O 0 4.346519233422441e-08
PWS B-Disease 1 1.0
, O 0 6.958911313859062e-08
was O 0 3.8212732533793314e-07
found O 0 9.042278037441065e-09
to O 0 2.1467669863994843e-09
have O 0 4.198101866137449e-09
47 O 0 2.5146519533336686e-07
chromosomes O 0 3.0592670441365044e-07
with O 0 1.7783825967399025e-08
a O 0 8.321762265950383e-07
supernumerary O 0 0.011398989707231522
, O 0 6.928172524567344e-08
paternal O 0 2.5887243282340933e-06
der O 0 9.517674334347248e-05
( O 0 8.589700684069612e-08
15 O 0 2.9130545087241444e-08
) O 0 4.0658134636828436e-09
consisting O 0 1.4734061082322114e-08
of O 0 2.442663493695818e-08
the O 0 3.9364117299101054e-08
short O 0 4.197955831841682e-07
arm O 0 1.249064825969981e-05
and O 0 7.912885990890572e-08
the O 0 3.951199687435292e-06
proximal O 1 0.9988555908203125
long O 0 4.805509524885565e-05
arm O 0 0.01727171242237091
of O 0 5.5076296121114865e-05
chromosome O 0 0.0012139559257775545
15 O 0 5.044492809247458e-06
, O 0 2.6398123509352445e-07
and O 0 9.184008717966208e-07
distal O 1 0.9982920289039612
chromosome O 1 0.9999932050704956
arm O 1 0.9999997615814209
3p O 1 1.0
. O 0 0.0011072540655732155

The O 0 2.065814442175906e-05
t O 0 6.278587534325197e-06
( O 0 1.5300737743473292e-07
3 O 0 6.518640560670974e-08
; O 0 2.661821651983587e-09
15 O 0 3.120866765016217e-08
) O 0 8.864273759456864e-09
was O 0 7.228204879083933e-08
present O 0 2.537483823061848e-08
in O 0 1.1553851209100685e-08
the O 0 1.8590956329944675e-08
balanced O 0 6.141475239473948e-08
state O 0 5.496587629494343e-09
in O 0 6.00289151719835e-09
the O 0 4.9833655424436074e-08
patients O 0 2.2096307006336247e-08
father O 0 1.036639901030867e-06
and O 0 2.1591328902559326e-07
a O 0 1.605089164513629e-05
sister O 0 0.00018949052901007235
. O 0 4.44419265477336e-06

Fluorescent O 0 5.348020567907952e-05
in O 0 5.112989356348407e-07
situ O 0 1.3983506505610421e-05
hybridization O 0 1.2757466265611583e-06
analysis O 0 3.821174914264702e-07
demonstrated O 0 1.751831035790019e-07
that O 0 1.9479179158565785e-08
the O 0 5.598861889666296e-07
PWS B-Disease 1 1.0
critical O 0 5.7351135183125734e-06
region O 0 4.6737486059100775e-07
resided O 0 1.507629804109456e-06
on O 0 5.515736134498184e-08
the O 0 3.466351827796643e-08
derivative O 0 9.884832934403676e-07
chromosome O 0 5.910695790589671e-07
3 O 0 3.265622439130311e-08
and O 0 2.12468420635048e-09
that O 0 8.375346527422778e-10
there O 0 5.324509277926381e-09
was O 0 2.882158298689319e-07
no O 0 7.989761030557929e-08
deletion O 0 1.5583558479193016e-06
of O 0 1.4941808785806643e-06
the O 0 3.040691080968827e-05
PWS B-Disease 1 1.0
region O 0 4.685156000050483e-06
on O 0 2.3554086681087938e-07
the O 0 1.745736994962499e-07
normal O 0 4.4511816099657153e-07
pair O 0 2.7734657237488136e-07
of O 0 3.7147771081436076e-07
15s O 0 8.218395123549271e-06
present O 0 1.1779503665820812e-06
in O 0 1.8278087736689486e-06
J O 0 0.0002004755224334076
. O 0 5.112792223371798e-06

B O 0 0.011452746577560902
. O 0 0.00016008020611479878

Methylation O 0 8.771987631917e-05
analysis O 0 5.0574212764331605e-06
at O 0 2.2809867914475035e-06
exon O 0 2.9276425266289152e-06
alpha O 0 5.340358484318131e-07
of O 0 2.3206297328215442e-08
the O 0 1.913505442985297e-08
small O 0 6.65371615582444e-08
nuclear O 0 1.0047077012131922e-05
ribonucleoprotein O 0 0.0008697691955603659
- O 0 2.3018076262815157e-06
associated O 0 6.423235845431918e-07
polypeptide O 0 4.287182036932791e-06
N O 0 3.832996299024671e-06
( O 0 2.3182435882063146e-07
SNRPN O 0 0.00019016492296941578
) O 0 1.2367799229195953e-07
gene O 0 9.861616234729809e-08
showed O 0 1.2521752523753094e-07
a O 0 6.680917863377545e-08
pattern O 0 2.8729184009534947e-07
characteristic O 0 7.322969963752257e-08
of O 0 7.391506073872733e-08
only O 0 4.197775638203893e-08
the O 0 2.861917209884268e-07
maternal O 0 1.2000122296740301e-05
chromosome O 0 4.284243459551362e-06
15 O 0 1.3820285857946146e-06
in O 0 1.3347339518077206e-06
J O 0 0.0006743540288880467
. O 0 4.076425739185652e-06

B O 0 0.014256814494729042
. O 0 0.00024076887348201126

Maternal B-Disease 1 0.7929232120513916
disomy I-Disease 0 0.0022025147918611765
was O 0 8.384419743379112e-06
confirmed O 0 3.824248153705412e-07
by O 0 8.568281373300124e-08
polymerase O 0 5.833422164869262e-06
chain O 0 3.970631610172859e-07
reaction O 0 4.147516818875374e-08
analysis O 0 6.503291416493084e-08
of O 0 1.0708767916867146e-07
microsatellite O 0 7.59918975745677e-06
repeats O 0 8.213577871174493e-07
at O 0 4.333126355504646e-07
the O 0 1.5939288289246178e-07
gamma O 0 2.5514332264719997e-06
- O 0 1.0730906296885223e-06
aminobutyric O 0 1.1331240784784313e-05
acid O 0 5.797323296974355e-07
receptor O 0 4.2422058754709724e-07
beta3 O 0 3.3693215755192796e-06
subunit O 0 2.3577824777021306e-06
( O 0 4.5581725771626225e-07
GABRB3 O 0 0.000122663943329826
) O 0 9.758553005667636e-07
locus O 0 2.2246096705202945e-05
. O 0 1.3782853329757927e-06

A O 0 0.00011137151886941865
niece O 0 9.401114220963791e-05
( O 0 1.2672028333327034e-06
B O 0 5.253997187537607e-06
. O 0 2.0775184239596456e-08
B O 0 7.934494874461961e-07
. O 0 5.6431219697117285e-09
) O 0 3.626901889930423e-09
with O 0 1.3655234720744147e-09
45 O 0 2.1891301216214742e-08
chromosomes O 0 3.078935506550806e-08
and O 0 1.1834718760539431e-09
the O 0 1.4121043889758766e-08
derivative O 0 1.580273334411686e-07
3 O 0 1.4015002491873929e-08
but O 0 7.52415518778804e-10
without O 0 4.644172157952653e-09
the O 0 2.1575598196932333e-08
der O 0 1.0512425433262251e-05
( O 0 4.679296594645166e-08
15 O 0 3.836104411902852e-08
) O 0 8.46180192581869e-09
demonstrated O 0 1.4640997747505935e-08
a O 0 1.453296327724729e-08
phenotype O 0 6.493982596111891e-08
consistent O 0 1.525067538921121e-08
with O 0 1.3035932333593792e-09
that O 0 2.4177801982716574e-09
reported O 0 6.989372991483833e-08
for O 0 2.4480552696104496e-08
haploinsufficiency O 0 8.83011452970095e-05
of O 0 6.206991201906931e-06
distal O 0 6.509443483082578e-05
3 O 0 1.3835167919751257e-05
p O 0 0.0001686586911091581
. O 0 2.8957099402759923e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 4.060556966578588e-05
with O 0 1.0221773436569492e-06
unbalanced O 0 0.0005172291421331465
segregation O 0 1.925347896758467e-05
of O 0 3.7767936191812623e-06
non O 0 0.004200885538011789
- O 0 0.1542080193758011
Robertsonian O 1 0.9998573064804077
translocations O 0 4.777325102622854e-06
has O 0 7.43102690492492e-09
been O 0 5.463172580988385e-09
reported O 0 1.3521868957866445e-08
previously O 0 1.116823522551158e-08
but O 0 8.58965953920432e-10
has O 0 5.619917864407853e-10
not O 0 4.790129959353351e-10
, O 0 1.8270319701585436e-09
to O 0 6.049234002603043e-09
our O 0 6.457200640852534e-08
knowledge O 0 7.712036449447623e-07
, O 0 2.1435889507870343e-08
been O 0 2.766359230577109e-08
observed O 0 1.0202641931300604e-07
in O 0 2.3611701038817046e-08
a O 0 1.8422834102693741e-07
case O 0 8.471476462545979e-07
of O 0 2.997722003783565e-05
PWS B-Disease 1 1.0
. O 0 6.740275421179831e-05

Furthermore O 0 6.667308480245993e-05
, O 0 3.1966138180905546e-07
our O 0 1.8120098843610322e-07
findings O 0 1.5558048005459568e-07
are O 0 7.862903217414896e-09
best O 0 6.461068835506012e-08
interpreted O 0 2.626934190175234e-07
as O 0 1.0067135036706532e-07
true O 0 2.284086576764821e-06
gamete O 0 0.0005228576483204961
complementation O 0 0.00015124169294722378
resulting O 0 1.998217612708686e-06
in O 0 1.8826523273673956e-06
maternal B-Disease 1 0.9976525902748108
UPD I-Disease 1 1.0
15 I-Disease 0 0.0035390041302889585
and O 0 5.635861452901736e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999687671661377
- I-Disease 1 0.9999978542327881
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999954700469971
type I-Disease 0 0.0001508599816588685
2 I-Disease 0 1.9932725990656763e-05
and O 0 2.282923560414929e-06
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999991655349731
: O 0 1.3957465228031651e-07
a O 0 1.2753558564781997e-07
case O 0 7.031157167602942e-08
for O 0 4.2057095583913906e-08
" O 0 1.7084498722397257e-06
lumping O 0 2.91878568532411e-05
" O 0 1.2043929928040598e-05
. O 0 3.899640432791784e-06

Recent O 0 1.0600513633107767e-05
studies O 0 1.5786600897627068e-06
demonstrated O 0 3.54354995124595e-07
the O 0 6.702116905898947e-08
existence O 0 4.4801709009334445e-07
of O 0 9.473338025145495e-08
a O 0 1.2168230512088485e-07
genetically O 0 4.3910493019438945e-08
distinct O 0 1.0819857010346823e-08
, O 0 4.254779639722983e-09
usually O 0 4.511996554157349e-09
lethal O 0 7.591043349464144e-09
form O 0 5.255174517770911e-09
of O 0 6.535321972478414e-08
the O 0 2.908413989644032e-07
Schwartz B-Disease 1 0.8857479691505432
- I-Disease 1 0.997627317905426
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.0002710499393288046
SJS B-Disease 1 1.0
) O 0 9.204965181197622e-07
of O 0 4.2902906898234505e-06
myotonia B-Disease 1 0.9999984502792358
and O 0 4.2569412471493706e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 0.9999998807907104
, O 0 4.3878762312488107e-07
which O 0 9.950323232033043e-08
we O 0 5.721046250073414e-07
called O 0 3.729150557774119e-05
SJS B-Disease 1 0.9999948740005493
type I-Disease 0 4.129458102397621e-05
2 I-Disease 0 2.338817466807086e-05
. O 0 5.938233243796276e-06

This O 0 3.251754606026225e-05
disorder O 1 0.9793545007705688
is O 0 5.387110491028579e-07
reminiscent O 0 1.202550993184559e-05
of O 0 8.716765478311572e-07
another O 0 9.706751598059782e-07
rare O 0 5.938755407441931e-07
condition O 0 1.087043528968934e-05
, O 0 2.4193505510083924e-07
the O 0 8.30758835945744e-06
Stuve B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.3701865077018738
SWS B-Disease 1 0.9999996423721313
) O 0 2.6616865511641663e-07
, O 0 2.8018632747262018e-08
which O 0 2.3992773989789384e-08
comprises O 0 6.997022410359932e-07
campomelia B-Disease 0 0.0038706776686012745
at O 0 6.878524436615407e-05
birth O 0 0.00046436573029495776
with O 0 2.7818450689665042e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.26450321078300476
contractures B-Disease 1 1.0
, O 0 4.484198143472895e-06
and O 0 3.461268818227836e-07
early B-Disease 0 1.700333086773753e-05
death I-Disease 0 0.00010714206291595474
. O 0 1.0065087735711131e-05

To O 0 3.904125094322808e-07
test O 0 1.2673017124598118e-07
for O 0 3.710548668323099e-08
possible O 0 5.757702297159994e-07
nosologic O 0 0.29397448897361755
identity O 0 4.3568118712755677e-07
between O 0 7.425504122693383e-08
these O 0 1.3232490658765528e-08
disorders O 0 0.00014541637210641056
, O 0 4.557631161361542e-09
we O 0 7.671008717125005e-09
reviewed O 0 4.392766683736227e-08
the O 0 1.0855308651969153e-08
literature O 0 4.568582312458602e-08
and O 0 1.893969647781546e-09
obtained O 0 3.873165965728731e-08
a O 0 3.1288475810242744e-08
follow O 0 1.2866237852904305e-08
- O 0 5.239753875230235e-08
up O 0 1.9278219909324434e-08
of O 0 1.050360065590894e-08
the O 0 6.805164876055869e-09
only O 0 2.7051629825081136e-09
two O 0 1.8284298519688491e-09
surviving O 0 2.6810230338014662e-06
patients O 0 2.9300501580564742e-08
, O 0 1.0741863398777696e-08
one O 0 4.43138432615342e-08
with O 0 7.913156707672897e-08
SJS B-Disease 1 0.9999904632568359
type I-Disease 0 4.044155048177345e-06
2 I-Disease 0 5.546508532461303e-07
at O 0 4.813140890291834e-07
age O 0 1.0826447294220998e-07
10 O 0 1.0190113641783682e-08
years O 0 5.385207835217898e-09
and O 0 1.1619281092833944e-09
another O 0 6.466419222306286e-08
with O 0 7.901181930947132e-08
SWS B-Disease 1 0.9848626255989075
at O 0 1.3011045894018025e-06
age O 0 9.344180966763815e-07
7 O 0 7.254162710523815e-07
years O 0 3.497673617403052e-07
. O 0 8.227445960073965e-07

Patients O 0 1.6571737432968803e-05
reported O 0 1.3629816066895728e-06
as O 0 8.555086594697059e-08
having O 0 1.0836565706995316e-06
either O 0 0.00016593874897807837
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.6639893651008606
SWS B-Disease 1 0.9999966621398926
presented O 0 2.1649928783062933e-07
a O 0 4.907434814072076e-08
combination O 0 1.9545165486078986e-08
of O 0 1.3238775409263326e-08
a O 0 5.903338973212158e-08
severe O 0 1.0380308594903909e-06
, O 0 9.645754062148626e-07
prenatal O 1 1.0
- O 1 1.0
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999555349349976
with O 1 0.9592968821525574
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 0 3.320817631902173e-05
feeding O 1 0.9994788765907288
difficulties O 1 0.9999972581863403
, O 0 2.753888111328706e-06
tendency O 0 3.300808430140023e-06
to O 0 2.704429959976551e-07
hyperthermia B-Disease 1 0.9999998807907104
, O 0 1.8630967701938062e-07
and O 0 5.155804316814283e-08
frequent O 0 3.423587600082101e-07
death O 0 1.1059976259275572e-06
in O 0 2.975324377985089e-07
infancy O 0 0.049381207674741745
) O 0 4.7840995165415734e-08
with O 0 7.781858712974099e-09
a O 0 4.922002290186356e-07
distinct O 0 1.784190999387647e-06
campomelic B-Disease 1 0.9999961853027344
- I-Disease 1 0.9999998807907104
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 0.9999998807907104
. O 0 0.00022547673142980784

The O 0 9.94017409539083e-06
similarity O 0 5.67715915167355e-06
of O 0 4.989091166862636e-07
the O 0 4.241437352447974e-07
clinical O 0 2.7436895834398456e-05
and O 0 8.920213190322102e-08
radiographic O 0 0.0028352055232971907
findings O 0 9.367450957142864e-07
is O 0 1.3841686019588906e-08
so O 0 3.6572032069415172e-09
extensive O 0 5.0101370163702086e-08
that O 0 3.4478215837907555e-09
these O 0 1.8475894592029363e-08
disorders O 0 9.821771527640522e-05
appear O 0 1.5104434680779377e-07
to O 0 3.893512712238589e-08
be O 0 1.5352071613961016e-07
a O 0 8.584980832893052e-07
single O 0 8.941672717810434e-07
entity O 0 4.786002591572469e-06
. O 0 2.084601646856754e-06

The O 0 8.155971045198385e-06
follow O 0 4.036079189972952e-06
- O 0 4.728705789602827e-06
up O 0 3.113435411705723e-07
observation O 0 4.029771389468806e-06
of O 0 1.1811727773647362e-07
an O 0 6.014377618157596e-08
identical O 0 1.0366848357534764e-07
and O 0 6.658944506909847e-09
unique O 0 6.257459261860276e-08
pattern O 0 1.5470517382709659e-06
of O 0 1.8257587726111524e-05
progressive O 1 0.9999983310699463
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999933242797852
in O 0 2.2325649240428902e-07
the O 0 2.7678484570969886e-07
two O 0 6.599280055752388e-08
patients O 0 3.654304592259905e-08
( O 0 4.6569390121931065e-08
one O 0 4.8912873751305597e-08
with O 0 1.1243002973060356e-07
SJS B-Disease 1 0.999995231628418
type I-Disease 0 3.778638074436458e-06
2 I-Disease 0 2.9852773764105223e-07
, O 0 1.0075006606768966e-08
one O 0 1.2427691764571591e-08
with O 0 2.8003940499843338e-08
SWS B-Disease 1 0.9997307658195496
) O 0 1.394098347873296e-07
surviving O 0 1.714780410111416e-05
beyond O 0 1.4825983498667483e-06
infancy O 0 5.031578439229634e-06
adds O 0 7.421681402774993e-08
to O 0 4.242948214994158e-09
the O 0 1.4718948726510916e-08
evidence O 0 1.2330959009432263e-07
in O 0 2.1746309641912376e-08
favor O 0 6.871753299719785e-08
of O 0 2.859156609247293e-07
identity O 0 4.7710050239402335e-06
. O 0 2.7597352527664043e-06

The O 0 5.2456312005233485e-06
hypothesis O 0 9.099632734432817e-06
that O 0 8.740739758650307e-07
SWS B-Disease 0 0.2047109603881836
and O 0 9.643766816225252e-07
SJS B-Disease 1 0.9999887943267822
type I-Disease 0 4.929678198095644e-06
2 I-Disease 0 2.819305109369452e-07
are O 0 2.9298812265210472e-09
the O 0 1.4316850815987436e-08
same O 0 8.43656877691501e-08
disorder O 0 5.001114004699048e-06
should O 0 1.036510433038984e-08
be O 0 1.9501856129977568e-08
testable O 0 3.27537009070511e-07
by O 0 6.048761491683763e-09
molecular O 0 1.5228505390041391e-07
methods O 0 4.5410512683474735e-08
. O 0 2.9080247543333826e-08
. O 0 3.8512291666847887e-07

A O 0 8.826830890029669e-05
mouse O 0 1.0674263648979831e-05
model O 0 7.464988698302477e-07
of O 0 1.3415716466624872e-06
severe O 0 0.22215509414672852
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9975624084472656
defects O 1 0.9999998807907104
in O 0 0.00010297202243236825
hemostasis O 1 1.0
and O 0 0.00022918308968655765
thrombosis B-Disease 1 1.0
. O 0 0.0012027621269226074

von B-Disease 1 0.9997972846031189
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.8979580998420715
( I-Disease 0 0.03283002972602844
vWf I-Disease 1 0.9999994039535522
) I-Disease 0 0.008036003448069096
deficiency I-Disease 1 0.9999998807907104
causes O 0 0.1465834379196167
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.008768308907747269
humans O 0 0.00037711590994149446
. O 0 4.917797923553735e-06

We O 0 2.6090453957294812e-06
generated O 0 1.3153799045539927e-06
a O 0 2.900198978750268e-07
mouse O 0 1.5871940206579893e-07
model O 0 1.690183637492737e-08
for O 0 2.374491714363103e-09
this O 0 8.777694127104496e-09
disease O 0 6.127434915015328e-08
by O 0 8.43289704732797e-09
using O 0 8.175052812475769e-08
gene O 0 5.438471930574451e-07
targeting O 0 1.062062437995337e-06
. O 0 4.703366585090407e-07

vWf B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999953508377075
deficient I-Disease 1 0.9989691972732544
mice O 0 2.1806801669299603e-05
appeared O 0 8.873781780494028e-07
normal O 0 9.364387096866267e-07
at O 0 2.854062017831893e-07
birth O 0 9.24847185501676e-08
; O 0 2.7072224462187933e-09
they O 0 4.807835018993956e-09
were O 0 1.0916085102508077e-07
viable O 0 3.0396536203625146e-06
and O 0 4.1390777028027514e-07
fertile O 0 0.0001185150831588544
. O 0 6.640025731030619e-06

Neither O 0 0.0036066228058189154
vWf O 0 0.05249078944325447
nor O 0 0.0004314934485591948
vWf O 0 0.011568156071007252
propolypeptide O 0 0.004611988551914692
( O 0 2.202029099862557e-05
von B-Disease 1 0.7379996180534363
Willebrand I-Disease 1 0.9999970197677612
antigen O 0 4.057170372107066e-05
II O 1 0.9703606963157654
) O 0 1.6388048607041128e-07
were O 0 3.32847527317881e-08
detectable O 0 4.0648853882885305e-07
in O 0 2.9003363266610904e-08
plasma O 0 1.9991268800367834e-06
, O 0 2.3969171536464273e-08
platelets O 0 2.1127373202034505e-06
, O 0 2.65935700127784e-08
or O 0 2.6837244604394073e-07
endothelial O 0 1.9185736164217815e-05
cells O 0 7.676383262378295e-08
of O 0 3.959272021347715e-08
the O 0 2.388885036452848e-07
homozygous O 0 6.499349638033891e-06
mutant O 0 5.944972872384824e-05
mice O 0 5.62793275094009e-06
. O 0 7.092116902640555e-07

The O 0 5.029184467275627e-05
mutant O 0 0.0038124576676636934
mice O 0 0.0002026508591370657
exhibited O 0 3.2701645977795124e-05
defects O 1 0.9917681217193604
in O 0 1.0839718243005336e-06
hemostasis O 1 0.9999918937683105
with O 0 1.6950657766301447e-07
a O 0 4.987805823475355e-06
highly O 0 1.216264263348421e-05
prolonged O 1 0.9964313507080078
bleeding O 1 0.7744396328926086
time O 0 6.744466531927173e-07
and O 0 2.1478722089796065e-07
spontaneous O 0 0.00018350579193793237
bleeding O 0 0.026914063841104507
events O 0 2.7431940452515846e-07
in O 0 4.368544281874165e-08
approximately O 0 3.5430801403890655e-07
10 O 0 1.8659773104445776e-07
% O 0 2.0679914314314374e-07
of O 0 1.3643705187860178e-06
neonates O 0 7.176883809734136e-05
. O 0 3.9160340747912414e-06

As O 0 2.6846048513107235e-06
in O 0 8.820124008934727e-08
the O 0 1.3022450673361163e-07
human O 0 4.4088912432016514e-07
disease O 0 4.9081550059781875e-06
, O 0 2.5275864956597616e-08
the O 0 5.865402954441379e-07
factor O 0 1.2816602975362912e-05
VIII O 0 0.20538650453090668
level O 0 1.918056796057499e-06
in O 0 8.98915875069406e-09
these O 0 4.507644035811609e-09
mice O 0 4.042856005526119e-08
was O 0 3.471737741733705e-08
reduced O 0 5.012878112609087e-09
strongly O 0 3.4788618652470404e-09
as O 0 1.7978867283829914e-09
a O 0 3.134191794984531e-09
result O 0 2.782672758883109e-09
of O 0 6.056242174423687e-09
the O 0 1.4812083115600672e-08
lack O 0 5.986120754641888e-08
of O 0 7.310620020462011e-08
protection O 0 2.9935307566120173e-07
provided O 0 3.017800622728828e-07
by O 0 4.704842524461128e-07
vWf O 0 0.00018553507106844336
. O 0 2.447505266900407e-06

Defective O 1 0.999961256980896
thrombosis B-Disease 1 0.9999818801879883
in O 0 7.190512405941263e-06
mutant O 0 0.09341821074485779
mice O 0 4.125254417886026e-05
was O 0 9.420487003808375e-07
also O 0 1.8457471995247943e-08
evident O 0 1.131751048433216e-07
in O 0 8.77143513378087e-09
an O 0 8.82927686518542e-09
in O 0 2.0329570915578188e-08
vivo O 0 3.296222303106333e-06
model O 0 6.589946792701085e-07
of O 0 5.633667569782119e-06
vascular B-Disease 1 0.999998927116394
injury I-Disease 1 0.977489173412323
. O 0 0.00024139547895174474

In O 0 7.980643772498297e-07
this O 0 6.355163151283705e-08
model O 0 3.0274108553385304e-07
, O 0 2.640111240737042e-08
the O 0 2.298341144069127e-07
exteriorized O 0 0.00022500105842482299
mesentery O 0 0.0002088760957121849
was O 0 6.098593530623475e-06
superfused O 0 0.00013124238466843963
with O 0 1.3077034566322254e-07
ferric O 1 0.9963304400444031
chloride O 0 3.178320548613556e-05
and O 0 7.217982300744552e-08
the O 0 6.73664317218936e-07
accumulation O 0 0.0001337869034614414
of O 0 7.424027444358217e-06
fluorescently O 0 0.002474105218425393
labeled O 0 8.722721759113483e-06
platelets O 0 6.919060524523957e-06
was O 0 7.923953830868413e-07
observed O 0 3.04034443843193e-07
by O 0 1.0560574992268812e-07
intravital O 0 6.937633588677272e-05
microscopy O 0 1.62731757882284e-05
. O 0 2.8712579478451516e-06

We O 0 3.371883622094174e-06
conclude O 0 1.0215791007794905e-05
that O 0 2.8563729159714057e-08
these O 0 1.9205002033118035e-08
mice O 0 6.353460548780276e-07
very O 0 4.280544985135748e-08
closely O 0 5.737820742979238e-07
mimic O 0 0.0001021374628180638
severe O 0 0.00018943380564451218
human O 0 0.004740833304822445
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 5.7632538741358985e-09
will O 0 1.3386319830388516e-09
be O 0 1.0450879051049355e-09
very O 0 2.3642332536155664e-09
useful O 0 2.2860989545847588e-08
for O 0 5.2507060921413995e-09
investigating O 0 2.2483419570562546e-07
the O 0 5.318128160070046e-08
role O 0 7.721949941696948e-07
of O 0 1.2927681609653519e-06
vWf O 0 0.00039936459506861866
in O 0 7.779650701422725e-08
normal O 0 1.907673322421033e-06
physiology O 0 6.388234396581538e-06
and O 0 1.2883033306820835e-08
in O 0 7.492312903423226e-08
disease O 0 5.680403319274774e-06
models O 0 1.1249245090994009e-07
. O 0 8.837400855554733e-08
. O 0 1.3876521052225144e-06

Oral O 1 0.9998526573181152
contraceptives O 0 0.0022551550064235926
and O 0 2.5347517862428504e-07
the O 0 7.132120458663849e-07
risk O 0 7.587551226606593e-05
of O 1 0.9997175335884094
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9978838562965393

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9999998807907104
Study O 0 0.005470996722579002
Group O 0 1.546977728139609e-05
. O 0 1.8030306137006846e-06

BACKGROUND O 0 0.00047985243145376444
Women O 0 1.1778492989833467e-06
with O 0 2.3165611651165818e-08
mutations O 0 6.612548020257236e-08
in O 0 1.5169328904107715e-08
either O 0 7.683751590548127e-08
the O 0 4.65872517452226e-07
BRCA1 O 0 5.107061042508576e-06
or O 0 1.3510968699392834e-07
the O 0 4.9574276772546e-07
BRCA2 O 0 1.151870583271375e-05
gene O 0 5.193437857542449e-08
have O 0 2.4160744516166233e-09
a O 0 6.086305859298591e-08
high O 0 2.705856729789957e-07
lifetime O 0 2.3625409539818065e-06
risk O 0 0.00011421818635426462
of O 1 0.9999914169311523
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0009512215037830174

Oral O 1 0.9999279975891113
contraceptives O 1 0.9963501691818237
protect O 0 0.00013345717161428183
against O 1 0.9991274476051331
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.5173026213233243e-06
general O 0 1.1841858622574364e-06
, O 0 1.4059822639467257e-08
but O 0 1.022751328072502e-09
it O 0 4.053437863138498e-10
is O 0 1.0521420401587989e-09
not O 0 3.5700031819629885e-10
known O 0 4.760621674648746e-09
whether O 0 3.6147060900049155e-09
they O 0 5.0470121415457925e-09
also O 0 1.856558462520752e-08
protect O 0 7.464370099796724e-08
against O 0 1.625170966690348e-07
hereditary B-Disease 1 0.9331499338150024
forms I-Disease 0 3.52651986759156e-05
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00029200801509432495

METHODS O 0 1.6124318790389225e-05
We O 0 1.0508769037187449e-06
enrolled O 0 3.5867055885319132e-06
207 O 0 2.215377662651008e-06
women O 0 1.0566257202526685e-07
with O 0 5.00853673202073e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.4844124456867576e-05
161 O 0 3.398678018129431e-05
of O 0 1.2933390962643898e-06
their O 0 6.545327124740652e-08
sisters O 0 6.760192718502367e-06
as O 0 9.213908924721181e-08
controls O 0 2.3406163052186457e-07
in O 0 3.130596581968348e-08
a O 0 1.6263587099274446e-07
case O 0 5.47565150554874e-07
- O 0 4.233441813994432e-06
control O 0 2.4706660042284057e-06
study O 0 1.5198920664261095e-06
. O 0 1.6468230796817807e-06

All O 0 7.367816010628303e-07
the O 0 2.816958897255972e-07
patients O 0 7.76700375126893e-08
carried O 0 5.677109626844867e-08
a O 0 5.3162011681706645e-08
pathogenic O 0 4.940399378483562e-08
mutation O 0 7.893075526510529e-09
in O 0 4.759804550502622e-09
either O 0 5.5522146880093715e-08
BRCA1 O 0 8.635183803562541e-07
( O 0 1.14819748375794e-07
179 O 0 4.918079525850771e-07
women O 0 5.798009539148552e-08
) O 0 3.800817793830902e-08
or O 0 6.644837924341118e-08
BRCA2 O 0 1.708309696368815e-06
( O 0 4.058641138726671e-07
28 O 0 6.037645107426215e-06
women O 0 1.0026908512372756e-06
) O 0 8.39733047541813e-07
. O 0 1.8997793631569948e-06

The O 0 9.981104994949419e-06
control O 0 3.739847898032167e-06
women O 0 1.2670237481415825e-07
were O 0 7.95723096302936e-08
enrolled O 0 5.074689966022561e-07
regardless O 0 1.4487110888694588e-07
of O 0 5.970772321006734e-08
whether O 0 1.5618054405308612e-08
or O 0 1.5777519735138412e-08
not O 0 2.9691482605898045e-09
they O 0 8.820725483360548e-09
had O 0 1.7948147501556377e-07
either O 0 7.806939947840874e-07
mutation O 0 1.4150588185657398e-06
. O 0 1.893361968541285e-06

Lifetime O 0 0.00013398402370512486
histories O 0 1.3141951967554633e-05
of O 0 4.516572062129853e-06
oral O 1 0.6780441999435425
- O 1 0.6330304145812988
contraceptive O 0 4.386560613056645e-05
use O 0 1.6157898130586545e-08
were O 0 3.4706456375488415e-08
obtained O 0 7.196935314368602e-08
by O 0 2.1933178828703603e-08
interview O 0 1.8104363164184178e-07
or O 0 1.0920308213258068e-08
by O 0 2.443943714069974e-09
written O 0 9.191402305930296e-09
questionnaire O 0 1.4468272802048432e-08
and O 0 1.922826786682208e-09
were O 0 1.2041243557803227e-08
compared O 0 4.9199936569266356e-08
between O 0 5.749751608163933e-08
patients O 0 1.3000233778370784e-08
and O 0 1.0701453945216599e-08
control O 0 9.229233910446055e-06
women O 0 2.3664864556849352e-07
, O 0 9.280433310721037e-09
after O 0 5.128059044068323e-08
adjustment O 0 9.590581839802326e-07
for O 0 1.0404243688810766e-08
year O 0 3.6084600196772953e-08
of O 0 1.0348495749212816e-07
birth O 0 1.016919100038649e-06
and O 0 3.0531057859661814e-07
parity O 0 3.419656786718406e-05
. O 0 1.7100439890782582e-06

RESULTS O 0 3.5555236536310986e-05
The O 0 2.9343259484448936e-06
adjusted O 0 1.4560298041033093e-05
odds O 0 1.2034113751724362e-05
ratio O 0 4.105694642930757e-06
for O 0 4.75726528748055e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.108004539673857e-06
with O 0 9.274523371516352e-09
any O 0 1.3329000125850143e-08
past O 0 1.1173605152237087e-08
use O 0 4.638046835481191e-09
of O 0 5.416557513626685e-08
oral O 0 7.926660146040376e-06
contraceptives O 0 3.41943850798998e-05
was O 0 1.6696103557478637e-05
0 O 0 2.268768184876535e-06
. O 0 9.234385061063222e-07

5 O 0 6.905296231707325e-06
( O 0 1.143528379543568e-06
95 O 0 7.650108955203905e-07
percent O 0 8.54789377058296e-08
confidence O 0 1.918787404520117e-07
interval O 0 3.7771283700749336e-07
, O 0 2.5889534072121023e-08
0 O 0 1.3802615050906297e-08
. O 0 1.325693665954475e-09
3 O 0 7.313364136507516e-09
to O 0 2.159510126276132e-09
0 O 0 8.556926722746994e-09
. O 0 3.728794606416841e-09
8 O 0 1.4982946083819115e-07
) O 0 9.720324811723913e-08
. O 0 2.608540228266065e-07

The O 0 4.504210301092826e-05
risk O 0 2.968352782772854e-05
decreased O 0 3.439105967117939e-06
with O 0 1.3629169792750417e-08
increasing O 0 7.075013286339527e-08
duration O 0 3.544252820120164e-07
of O 0 3.891233291142271e-08
use O 0 5.220806897909824e-09
( O 0 1.2202995947063755e-08
P O 0 3.001829895765695e-07
for O 0 2.64473687394684e-09
trend O 0 4.019734944904485e-08
, O 0 3.870416875884075e-09
< O 0 1.3631762385557522e-07
0 O 0 4.3327519350100374e-09
. O 0 2.1748702838664258e-09
001 O 0 2.1465884003646352e-07
) O 0 1.0527583249597683e-09
; O 0 1.0736280614542792e-10
use O 0 1.819974032590821e-10
for O 0 6.160087995255026e-10
six O 0 4.176386347864991e-09
or O 0 4.786789631339161e-09
more O 0 6.693539056357167e-10
years O 0 6.135396635187362e-09
was O 0 1.9950593355133606e-07
associated O 0 2.228010487215215e-08
with O 0 2.8776214744397066e-09
a O 0 4.370077633097935e-08
60 O 0 1.1525935406098142e-07
percent O 0 3.410151450111698e-08
reduction O 0 6.959269427397885e-08
in O 0 6.173019784228018e-08
risk O 0 1.0287325267199776e-06
. O 0 9.942144743035897e-07

Oral O 1 0.9976323843002319
- O 0 0.02336522564291954
contraceptive O 0 6.319044041447341e-05
use O 0 1.1244375741625845e-07
protected O 0 2.445101381454151e-05
against O 0 0.025338266044855118
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 2.552254407817145e-08
for O 0 8.448448163278499e-09
carriers O 0 1.6888785481228297e-08
of O 0 2.8977153121445554e-08
the O 0 1.1326925886123718e-07
BRCA1 O 0 6.759321422578068e-07
mutation O 0 1.0597415389668186e-08
( O 0 1.8370300836068054e-08
odds O 0 2.772164862108184e-07
ratio O 0 5.0415597030450954e-08
, O 0 1.762231582880247e-09
0 O 0 2.5250217472461145e-09
. O 0 4.2083053708452667e-10
5 O 0 3.2699276619752027e-09
; O 0 3.311905472092036e-10
95 O 0 3.2412785344604345e-08
percent O 0 6.921275108595637e-09
confidence O 0 3.3873586602339856e-08
interval O 0 8.917984217760022e-08
, O 0 5.294593652394042e-09
0 O 0 3.0407423246003873e-09
. O 0 4.208449977394224e-10
3 O 0 1.5577495959817611e-09
to O 0 7.432638948756676e-10
0 O 0 1.8293682124692623e-09
. O 0 5.552410198284008e-10
9 O 0 1.2297743268163686e-08
) O 0 1.0928344895688724e-09
and O 0 2.747971572514274e-10
for O 0 9.941190093343266e-10
carriers O 0 1.352676992638635e-08
of O 0 3.1631159913558804e-08
the O 0 2.0755567220476223e-07
BRCA2 O 0 3.1048002711031586e-06
mutation O 0 6.483882941665797e-08
( O 0 2.4373020934831402e-08
odds O 0 4.07418440317997e-07
ratio O 0 4.727271729620952e-08
, O 0 1.9091590530706526e-09
0 O 0 1.932455973019387e-09
. O 0 4.2937137179066553e-10
4 O 0 1.9878787504978845e-09
; O 0 2.963149725587755e-10
95 O 0 1.1227227147969643e-08
percent O 0 2.0280144230611086e-09
confidence O 0 1.2756764533605747e-08
interval O 0 3.9837622978211584e-08
, O 0 3.1032303393629945e-09
0 O 0 2.3939461524236094e-09
. O 0 6.411760566926716e-10
2 O 0 1.870405164083877e-09
to O 0 5.262273394812667e-10
1 O 0 1.3792877062712705e-08
. O 0 9.561995639728593e-09
1 O 0 1.0952477680348238e-07
) O 0 1.2960624928837206e-07
. O 0 2.7889609555131756e-07

CONCLUSIONS O 0 0.00023788894759491086
Oral O 1 0.9951410293579102
- O 0 0.018326882272958755
contraceptive O 0 3.674416075227782e-05
use O 0 3.31816885079661e-08
may O 0 2.096322226918801e-08
reduce O 0 2.020043332606747e-08
the O 0 4.513720597287829e-08
risk O 0 3.089542587986216e-05
of O 1 0.9999561309814453
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.402658184219035e-07
women O 0 1.381886782780839e-08
with O 0 8.014433561243095e-10
pathogenic O 0 1.4684542470888573e-08
mutations O 0 5.4724229592295615e-09
in O 0 9.922914046001097e-09
the O 0 2.5713529794302303e-07
BRCA1 O 0 1.0744007340690587e-05
or O 0 2.855343609553529e-06
BRCA2 O 0 0.0002118829288519919
gene O 0 8.135406824294478e-05

A O 0 0.000684285769239068
Japanese O 0 0.001078987494111061
family O 0 9.633788977225777e-06
with O 0 8.209286193050502e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 6.04052047492587e-07
a O 0 3.780195129365893e-06
codon O 0 1.1370339962013531e-05
291 O 0 6.218961630111153e-07
deletion O 0 7.431738140439847e-07
: O 0 2.3374838065137737e-08
a O 0 4.6910564321933634e-08
clinical O 0 3.519771496485191e-07
, O 0 2.844249635813867e-08
biochemical O 0 0.00013634956849273294
, O 0 3.7600679547722393e-07
pathological O 0 0.49630019068717957
, O 0 8.638975401709104e-08
and O 0 8.590011901787875e-08
genetic O 0 2.0678999135270715e-05
report O 0 9.753801350598224e-06
. O 0 4.662014816858573e-06

We O 0 8.13272527011577e-06
report O 0 2.716146354941884e-06
a O 0 8.991586355477921e-07
Japanese O 0 1.1640097909548786e-05
family O 0 7.863549171815976e-07
with O 0 1.0938935020021745e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 1 1.0
ALD B-Disease 1 1.0
) O 0 1.6744245385780232e-06
with O 0 2.046628466700895e-08
a O 0 2.506145619918243e-07
three O 0 6.551246656272269e-08
base O 0 3.472394496384368e-07
pair O 0 9.549020205668057e-07
deletion O 0 1.6625972421024926e-05
( O 0 2.9315735901036533e-06
delGAG O 0 9.611158020561561e-05
291 O 0 2.089407871608273e-06
) O 0 1.0067883948750023e-07
in O 0 5.521694035337532e-08
the O 0 2.906466761487536e-06
ALD B-Disease 1 1.0
gene O 0 0.0002900413528550416
. O 0 1.339497794106137e-05

A O 0 2.1837060558027588e-05
variety O 0 6.365790454765374e-07
of O 0 7.538095019299362e-07
phenotypes O 0 3.4261163364135427e-06
were O 0 2.9334316309359565e-07
observed O 0 6.584004381693376e-07
within O 0 3.0893863822711864e-07
this O 0 1.82954764227361e-07
family O 0 2.203239773734822e-06
. O 0 1.4969321000535274e-06

While O 0 9.40905465540709e-06
the O 0 1.6297229876727215e-06
proband O 0 9.660814248491079e-05
( O 0 8.168076419678982e-07
patient O 0 3.826590102562477e-07
1 O 0 1.8058908324292133e-07
) O 0 4.071682369044538e-08
was O 0 2.21866883975963e-07
classified O 0 1.1898534779675174e-07
as O 0 6.075424607843161e-09
having O 0 2.0751107498995225e-08
a O 0 2.525331233016459e-08
rare O 0 2.7170733218895293e-08
intermediate O 0 3.062002065234992e-07
type O 0 1.3599961334875843e-07
of O 0 2.2502318586248293e-07
adult O 0 2.3283321297640214e-06
cerebral O 0 0.0043829274363815784
and O 0 5.805395630886778e-07
cerebello O 1 1.0
- O 1 1.0
brain O 1 0.9995976090431213
stem O 0 1.6678903875799733e-06
forms O 0 3.15628199132334e-08
, O 0 2.4640106843776266e-08
his O 0 1.2826302508983645e-07
younger O 0 2.731748907081055e-07
brother O 0 3.6238106986274943e-06
( O 0 2.199174531369863e-07
patient O 0 1.5814131870683923e-07
2 O 0 5.659239121769133e-08
) O 0 1.6068094410570666e-08
and O 0 1.0776092018716099e-08
nephew O 0 0.000816866522654891
( O 0 3.941068825952243e-06
patient O 0 2.2948420337343123e-06
3 O 0 1.2373005802146508e-06
) O 0 2.239322469677063e-07
had O 0 1.0034120805357816e-06
a O 0 3.1805524486117065e-05
childhood O 1 0.9999959468841553
ALD B-Disease 1 1.0
type O 1 0.9999748468399048
. O 0 7.21682736184448e-05

Another O 0 0.00013027258682996035
nephew O 0 0.0007802815525792539
( O 0 4.99644193041604e-06
patient O 0 1.961326461241697e-06
4 O 0 7.660469236725476e-07
) O 0 1.0281623019636754e-07
of O 0 2.7869032237504143e-07
patient O 0 7.522998544118309e-07
1 O 0 8.293089877042803e-07
was O 0 3.871966328006238e-06
classified O 0 9.968320000552922e-07
as O 0 2.8124432560616697e-08
having O 0 1.0841863229416049e-07
an O 0 3.2181233677874843e-07
adolescent O 0 2.2139385691843927e-05
form O 0 1.1887107120855944e-06
. O 0 9.079470146389212e-06

The O 0 1.4901898794050794e-05
tau O 0 2.2222138795768842e-05
level O 0 5.215037504058273e-07
in O 0 2.2557143708468175e-08
the O 0 6.308943056865246e-08
cerebrospinal O 0 1.1106875717814546e-05
fluid O 0 2.4348535589524545e-05
( O 0 2.43918093474349e-05
CSF O 1 0.9998512268066406
) O 0 4.626483871561504e-07
in O 0 1.0681331019668505e-07
patient O 0 4.5047198682368617e-07
1 O 0 1.8251543565384054e-07
was O 0 4.1958705310207733e-07
as O 0 1.8512757549160597e-08
high O 0 4.424593669227761e-08
as O 0 2.5402333569957136e-09
that O 0 8.435016018992769e-10
of O 0 3.045213148311632e-08
patients O 0 4.677360010418852e-08
with O 0 4.812580982616055e-07
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999994039535522
( O 0 2.5786743208300322e-05
AD B-Disease 0 0.0001554537593619898
) O 0 5.043656869929691e-07
. O 0 3.6876406284136465e-07

His O 0 6.0127873439341784e-05
brain O 0 0.00036602202453650534
magnetic O 0 4.131954847252928e-05
resonance O 0 1.973218604689464e-05
image O 0 4.869941676588496e-06
( O 0 1.8008240658673458e-06
MRI O 0 0.03089357540011406
) O 0 2.978375050588511e-06
showed O 0 1.8700335203902796e-05
abnormalities B-Disease 0 0.00797807052731514
in I-Disease 0 1.559632920589138e-07
the I-Disease 0 1.1261863619438373e-06
bilateral I-Disease 0 0.05180610343813896
cerebellar I-Disease 1 0.9999998807907104
hemispheres I-Disease 0 0.004384459927678108
and O 0 4.4819060462941707e-07
brain O 1 0.988344669342041
stem O 0 1.1061463737860322e-05
, O 0 1.1642936392775027e-08
but O 0 2.926635822575463e-09
not O 0 2.820800704128601e-09
in O 0 1.1907725472326547e-08
the O 0 4.819571017833368e-07
cerebral O 0 0.02553568221628666
white O 0 4.3248940073681297e-07
matter O 0 8.689474952916498e-07
, O 0 2.3874086707564857e-08
where O 0 2.4933218156775183e-08
marked O 0 1.2390655967919884e-07
reductions O 0 1.1868502269862802e-07
of O 0 7.905011045750143e-08
the O 0 3.0168223474902334e-07
cerebral O 0 0.00030855595832690597
blood O 0 6.782012860639952e-06
flow O 0 3.4466445413272595e-06
and O 0 7.848642269436823e-08
oxygen O 0 2.436856084386818e-05
metabolism O 0 1.619388240214903e-05
were O 0 4.730257430196616e-08
clearly O 0 9.524902111479605e-08
demonstrated O 0 5.19848200042361e-08
by O 0 1.2366686341636068e-08
positron O 0 7.074249879224226e-07
emission O 0 6.199178415045026e-08
tomography O 0 7.155488788157527e-07
( O 0 1.8300694648587523e-07
PET O 0 3.143382400594419e-06
) O 0 2.7568233917918405e-07
. O 0 4.889794809059822e-07

In O 0 2.0772172319993842e-06
patients O 0 2.3544249927454075e-07
2 O 0 2.0635056330320367e-07
and O 0 1.688540329780608e-08
3 O 0 9.485397356456815e-08
, O 0 6.7713976648065e-09
the O 0 3.679658178157297e-08
autopsy O 0 1.2730764638035907e-06
findings O 0 5.901492272641917e-07
showed O 0 3.940621809306322e-06
massive O 0 0.0002600490697659552
demyelination B-Disease 1 1.0
of I-Disease 0 2.2997293854132295e-05
the I-Disease 0 1.2605490155692678e-05
cerebral I-Disease 0 0.013870238326489925
white I-Disease 0 2.6985301815329876e-07
matter I-Disease 0 1.0187687848883797e-07
with O 0 7.653909506188938e-09
sparing O 0 3.443965681526606e-07
of O 0 3.1199806471704505e-07
the O 0 3.1243564535543555e-06
U O 1 0.9999990463256836
- O 0 0.0016680116532370448
fibers O 0 4.737354174721986e-06
, O 0 4.671003139833374e-08
compatible O 0 1.0852475895717362e-07
with O 0 3.0745443968527297e-09
the O 0 6.517359452118399e-08
findings O 0 4.5886815769335954e-07
of O 0 4.4978742153034545e-06
childhood O 1 0.999990701675415
ALD B-Disease 1 1.0
. O 0 0.0002080119593301788

Oleic O 0 0.014364258386194706
and O 0 5.9171306929783896e-06
erucic O 0 0.0029156748205423355
acids O 0 5.9494341257959604e-06
( O 0 1.5656328287150245e-06
Lorenzos O 0 0.00030170942773111165
Oil O 0 3.818915502051823e-06
) O 0 1.9897955283454394e-08
were O 0 5.231472588462793e-09
administered O 0 1.7126204454598337e-08
to O 0 4.3653765047224624e-09
patients O 0 6.840535693442007e-09
1 O 0 2.56523637887085e-08
and O 0 4.103599238192146e-09
4 O 0 4.625054117468608e-08
, O 0 4.1135672645964405e-09
but O 0 2.049057146180644e-09
sufficient O 0 1.0396928473710432e-07
effectiveness O 0 3.365040015523846e-07
was O 0 4.789541208083392e-07
not O 0 7.859952688704652e-08
obtained O 0 2.531273366912501e-06
. O 0 2.3614729798282497e-06

The O 0 6.156808467494557e-06
findings O 0 1.6296498870360665e-06
in O 0 6.162878207760514e-08
this O 0 2.1633699276435436e-08
family O 0 7.857808981270864e-08
suggest O 0 1.2916230218706914e-07
that O 0 2.06725729867685e-08
delGAG291 O 0 5.646565568895312e-06
is O 0 4.346883741845886e-08
part O 0 5.7239063266933954e-08
of O 0 1.6250470480372314e-07
the O 0 2.1074195899473125e-07
cause O 0 8.978536811810045e-07
of O 0 6.130116616986925e-06
Japanese O 1 0.9999456405639648
ALD B-Disease 1 1.0
with O 0 2.086802197709403e-07
phenotypic O 0 1.0849918908206746e-05
variations O 0 3.614126399043016e-06
. O 0 2.8111242045270046e-06

Moreover O 0 3.973214188590646e-05
, O 0 8.171202381390685e-08
although O 0 7.826603365401752e-09
the O 0 8.123523187464343e-09
scale O 0 1.5560080157683842e-07
of O 0 2.419013256371727e-08
the O 0 9.546687884665062e-09
study O 0 1.0842024167345699e-08
is O 0 1.6768250121756978e-09
limited O 0 1.5500584149563679e-09
, O 0 1.8825596637128683e-09
there O 0 4.645209106257653e-09
is O 0 4.9160515658286386e-09
a O 0 1.3143544919103078e-08
possibility O 0 8.685054098123146e-08
that O 0 1.1926409193563359e-08
PET O 0 3.670969874747243e-07
can O 0 6.221183568300148e-09
detect O 0 4.189377307284303e-07
an O 0 2.9426132641674485e-07
insidious B-Disease 0 4.176061338512227e-05
lesion I-Disease 0 0.00010884687799261883
which O 0 4.201105685552875e-09
is O 0 3.084306143819049e-09
undetectable O 0 9.677647483385954e-08
by O 0 6.283745079826986e-09
computed O 0 2.6757254545373144e-07
tomogram O 0 2.2146277842693962e-06
( O 0 9.759895647221128e-08
CT O 0 6.664729880867526e-06
) O 0 7.829350501253884e-09
or O 0 6.309638589385713e-09
MRI O 0 8.119062613332062e-07
analysis O 0 3.925921632230711e-08
, O 0 2.498671713979661e-09
and O 0 1.4813235083011023e-09
that O 0 1.7024971432633151e-09
the O 0 1.7368021687502733e-08
higher O 0 9.23026703958385e-08
level O 0 2.0305201076098456e-07
of O 0 5.103791167471172e-08
tau O 0 5.32518754425837e-07
reflects O 0 2.4947965471255884e-08
the O 0 8.866369860527357e-09
process O 0 3.3238695351656133e-08
of O 0 1.029592453960504e-06
neuronal B-Disease 1 0.9995530247688293
degeneration I-Disease 1 0.9999964237213135
in O 0 4.1645122109912336e-05
ALD B-Disease 1 1.0
. O 0 5.619128933176398e-05

Lorenzos O 0 0.016381265595555305
Oil O 0 1.5365563740488142e-05
should O 0 4.3352756051717733e-08
be O 0 1.0028916364035467e-08
given O 0 8.930149952846023e-09
in O 0 1.3652429409205524e-08
the O 0 6.003237729146349e-08
early O 0 3.3978943747570156e-07
stage O 0 1.8573591660242528e-06
. O 0 3.2505843705621373e-07
. O 0 1.461540705349762e-06

Nonsense O 0 0.0013452221173793077
mutation O 0 8.553757652407512e-06
in O 0 1.4395815242096432e-06
exon O 0 8.448977496300358e-06
4 O 0 1.1917879874090431e-06
of O 0 2.3179451602572954e-07
human O 0 3.04681719853761e-07
complement O 0 5.885468453925569e-06
C9 O 1 0.9996936321258545
gene O 0 5.587953069152718e-07
is O 0 2.9906569665172356e-08
the O 0 2.704143042819851e-08
major O 0 1.3642569740568433e-07
cause O 0 3.7353100879045087e-07
of O 0 1.9402184534556e-06
Japanese O 1 0.6346049308776855
complement B-Disease 0 0.3481202721595764
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999973773956299
. O 0 1.618085298105143e-05

Deficiency B-Disease 1 0.9999997615814209
of I-Disease 0 5.2443763706833124e-05
the I-Disease 0 9.285045052820351e-06
ninth I-Disease 0 0.00020407079136930406
component I-Disease 0 3.274233313277364e-05
of I-Disease 0 5.946349119767547e-07
human I-Disease 0 3.406141502182436e-07
complement I-Disease 0 6.9942129812261555e-06
( O 0 1.818481359805446e-05
C9 O 1 0.999685525894165
) O 0 2.313556990429788e-07
is O 0 1.1054092752260658e-08
the O 0 1.292975682076758e-08
most O 0 5.197478003537981e-09
common O 0 5.644362488510524e-08
complement B-Disease 1 0.9999845027923584
deficiency I-Disease 1 1.0
in O 0 1.7041375031112693e-06
Japan O 0 9.168376891466323e-06
but O 0 5.5224598227709976e-09
is O 0 3.6203360309627897e-09
rare O 0 2.8631350623697926e-09
in O 0 1.8040492433257782e-09
other O 0 1.3360479389490365e-09
countries O 0 8.76909300728812e-09
. O 0 8.353352427548089e-07

We O 0 1.1315681831547408e-06
studied O 0 1.3498466842065682e-06
the O 0 1.627345369570321e-07
molecular O 0 1.5161888313741656e-06
basis O 0 7.836882218725805e-07
of O 0 1.9562659872462973e-05
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999778270721436
in O 0 2.8672579333033354e-07
four O 0 5.028979330745642e-07
Japanese O 0 0.143459290266037
C9 B-Disease 1 1.0
- I-Disease 1 0.9998575448989868
deficient I-Disease 0 0.2546086311340332
patients O 0 4.928108054969016e-08
who O 0 2.4626997330301492e-08
had O 0 5.433857950265519e-07
suffered O 0 0.2784157395362854
from O 0 0.0021486894693225622
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.0001037208057823591

Direct O 0 1.912880725285504e-05
sequencing O 0 9.364929610455874e-06
of O 0 2.822190708684502e-06
amplified O 0 2.21836435230216e-05
C9 O 0 0.00040233871550299227
cDNA O 0 1.0526852747716475e-05
and O 0 2.9687193148220103e-08
DNA O 0 5.135194669492193e-07
revealed O 0 3.7250933360155614e-07
a O 0 1.1294587665133804e-07
nonsense O 0 1.2754181852869806e-06
substitution O 0 1.6559290827444784e-07
( O 0 1.4303455486697203e-07
CGA O 0 3.8793132262071595e-06
- O 0 2.1820967504027067e-06
- O 0 5.778264949185541e-06
> O 0 7.473182904504938e-06
TGA O 0 1.5140276445890777e-05
) O 0 5.1094797726136676e-08
at O 0 1.1595558646604331e-07
codon O 0 7.571250080218306e-07
95 O 0 1.9568334153063915e-07
in O 0 4.594413027803057e-08
exon O 0 9.74489125837863e-07
4 O 0 7.745315855345325e-08
in O 0 1.155682660680668e-08
the O 0 4.039279843937038e-08
four O 0 3.311953662432643e-07
C9 B-Disease 1 0.9998631477355957
- I-Disease 1 0.9541433453559875
deficient I-Disease 0 0.0005276757874526083
individuals O 0 3.1539232736577105e-07
. O 0 1.2821867585444124e-06

An O 0 3.311648470116779e-06
allele O 0 1.2124610293540172e-06
- O 0 8.060898721851117e-07
specific O 0 5.3457487325658803e-08
polymerase O 0 9.050681910593994e-06
chain O 0 4.988525006410782e-07
reaction O 0 1.3430441647699354e-08
system O 0 1.5297871414077235e-08
designed O 0 2.0685744672732653e-08
to O 0 8.164500187035628e-09
detect O 0 2.5931669256351597e-07
exclusively O 0 4.707190015551532e-08
only O 0 4.979952450412384e-09
one O 0 3.6272758130451166e-09
of O 0 7.982705163556147e-09
the O 0 8.03307820262944e-09
normal O 0 4.629105632147912e-08
and O 0 1.894381318479077e-09
mutant O 0 7.013503733332982e-08
alleles O 0 3.546245075369825e-09
indicated O 0 3.119097868875542e-09
that O 0 1.7629400717034116e-10
all O 0 2.1400692329365256e-10
the O 0 1.8136749879715808e-09
four O 0 3.942510762300344e-09
patients O 0 1.2695274831386882e-09
were O 0 3.298366024750976e-09
homozygous O 0 1.9088869152028565e-08
for O 0 2.34313368707717e-09
the O 0 2.0983945248076452e-08
mutation O 0 7.466487872420657e-09
in O 0 9.881213181017756e-09
exon O 0 3.7132824104446627e-07
4 O 0 4.084524363179298e-08
and O 0 1.406668115322418e-09
that O 0 5.34946642538614e-10
the O 0 5.878224573763191e-09
parents O 0 5.974552408360978e-09
of O 0 3.6030748162829696e-08
patient O 0 2.2696526968957187e-07
2 O 0 2.693395515507291e-07
were O 0 5.280880372993124e-07
heterozygous O 0 3.200987066520611e-06
. O 0 6.52034430004278e-07

The O 0 5.388561930885771e-06
common O 0 3.7561110843853385e-07
mutation O 0 2.6289239940524567e-07
at O 0 7.30170029328292e-07
codon O 0 2.0961399513907963e-06
95 O 0 4.841517693421338e-07
in O 0 3.472320742048396e-08
exon O 0 7.692893291277869e-07
4 O 0 3.1328784899642415e-08
might O 0 8.422512465244836e-09
be O 0 4.360117600299418e-09
responsible O 0 3.48098083691184e-08
for O 0 1.3963718181742024e-08
most O 0 8.058955813794455e-08
Japanese O 0 0.2140396237373352
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999774694442749
. O 0 8.795485086920962e-07
. O 0 1.8712252085606451e-06

BRCA1 O 0 2.6025443730759434e-05
required O 0 3.9731392575959035e-07
for O 0 3.06573355146611e-07
transcription O 0 0.0006216538022272289
- O 0 3.839615601464175e-05
coupled O 0 1.50689311340102e-05
repair O 0 1.845526094257366e-05
of O 0 2.3616307771590073e-06
oxidative O 0 0.0012932090321555734
DNA O 0 0.0778191015124321
damage O 0 0.0016452355775982141
. O 0 6.469833351729903e-06

The O 0 0.00011025292769772932
breast B-Disease 1 0.9999591112136841
and I-Disease 0 0.24759531021118164
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9999998807907104
gene O 0 0.0020118248648941517
BRCA1 O 0 0.00018699478823691607
encodes O 0 3.3385456390533363e-06
a O 0 5.710177219953039e-07
zinc O 0 0.00022954435553401709
finger O 0 2.066860906779766e-05
protein O 0 1.3459697356665856e-06
of O 0 1.1016646794814733e-06
unknown O 0 0.00012796474038623273
function O 0 1.1862195606227033e-05
. O 0 2.0273366772016743e-06

Association O 0 3.242956518079154e-05
of O 0 3.6026463021698873e-06
the O 0 2.9394764169410337e-06
BRCA1 O 0 1.0654005563992541e-05
protein O 0 1.3960074340957362e-07
with O 0 4.382512575062947e-09
the O 0 1.3533123421893833e-07
DNA O 0 0.0003638833877630532
repair O 1 0.8312166929244995
protein O 0 0.0002625001943670213
Rad51 O 0 0.08396605402231216
and O 0 6.684267361833918e-09
changes O 0 3.941353021730265e-09
in O 0 3.1242124443053854e-09
the O 0 2.1025048368983335e-08
phosphorylation O 0 1.0707665154541246e-07
and O 0 8.174612986522334e-09
cellular O 0 6.101870440033963e-07
localization O 0 1.0652231594576733e-06
of O 0 2.4745936855197215e-08
the O 0 2.8949695973778944e-08
protein O 0 5.3162516167049034e-08
after O 0 3.967474171417962e-08
exposure O 0 2.2523444442867913e-07
to O 0 1.586315612200906e-08
DNA O 0 6.121567275840789e-05
- O 0 9.903583304549102e-06
damaging O 0 7.280659133357403e-07
agents O 0 2.08237427301583e-08
are O 0 1.5231946814964203e-09
consistent O 0 2.0242319820340526e-08
with O 0 1.0585673448915145e-09
a O 0 1.8480442065538227e-08
role O 0 8.866238232485557e-08
for O 0 4.9071726238025803e-08
BRCA1 O 0 1.7294191820838023e-06
in O 0 1.824818411932938e-07
DNA O 0 7.034483860479668e-05
repair O 0 0.003513172036036849
. O 0 1.2167654858785681e-05

Here O 0 5.2758791753149126e-06
, O 0 7.858019301920649e-08
it O 0 3.915920476771362e-09
is O 0 8.37896152461326e-09
shown O 0 1.7147778308412853e-08
that O 0 7.134881130355097e-09
mouse O 0 4.971233806827513e-07
embryonic O 0 2.722006684052758e-06
stem O 0 1.6419991879956797e-05
cells O 0 1.8383118003839627e-05
deficient B-Disease 0 9.374758519697934e-06
in I-Disease 0 3.681546800748947e-08
BRCA1 I-Disease 0 3.9169765386759536e-07
are O 0 2.1128272464920883e-09
defective O 0 1.0923729121259385e-07
in O 0 3.16073234252201e-09
the O 0 1.1473715311183241e-08
ability O 0 1.0279442186345022e-08
to O 0 3.3616507355560543e-09
carry O 0 3.6516428991717476e-08
out O 0 1.1244697617485144e-07
transcription O 0 7.98243418103084e-05
- O 0 3.811478791249101e-06
coupled O 0 2.9883985916967504e-06
repair O 0 4.542135229712585e-06
of O 0 2.9123444278411625e-07
oxidative O 0 1.189963222714141e-05
DNA O 0 2.5102790459641255e-05
damage O 0 2.207462785008829e-06
, O 0 7.0352865755296534e-09
and O 0 3.4675273763440373e-09
are O 0 4.7056611940377024e-09
hypersensitive O 0 1.0776872159112827e-06
to O 0 2.7862167684133965e-08
ionizing O 0 3.940754686482251e-05
radiation O 0 1.304591387452092e-05
and O 0 5.380426060241916e-08
hydrogen O 0 9.48496051478287e-07
peroxide O 0 9.075505658984184e-06
. O 0 1.7575684978510253e-06

These O 0 5.939938887422613e-07
results O 0 3.4972430285051814e-07
suggest O 0 5.700410952158563e-07
that O 0 6.446064304554966e-08
BRCA1 O 0 3.579918711693608e-06
participates O 0 7.67843232551968e-07
, O 0 3.8160870019510185e-08
directly O 0 8.62527755884912e-08
or O 0 3.5951046584159485e-08
indirectly O 0 2.0878731277207407e-07
, O 0 1.552447059793849e-08
in O 0 6.68507311729627e-08
transcription O 0 2.737826798693277e-05
- O 0 3.932677827833686e-06
coupled O 0 2.6669717954064254e-06
repair O 0 5.5108953347371425e-06
of O 0 4.845471721637296e-07
oxidative O 0 6.0826961998827755e-05
DNA O 0 0.00011607618216658011
damage O 0 3.127138188574463e-05
. O 0 2.8715871280837746e-07
. O 0 1.3147176787242643e-06

Truncation O 0 0.004716595634818077
mutations O 0 1.1681923751893919e-05
in O 0 8.041158139349136e-07
the O 0 1.5763193914608564e-06
transactivation O 0 0.00036924780579283834
region O 0 2.621155999804614e-06
of O 0 5.518584202945931e-06
PAX6 O 1 0.9944186210632324
result O 0 1.0875803582166554e-06
in O 0 2.867947159757023e-07
dominant O 0 2.8769591153832152e-06
- O 0 2.9021541649854043e-06
negative O 0 8.574613730161218e-07
mutants O 0 3.836642463284079e-06
. O 0 7.300217248484842e-07

PAX6 O 1 0.685418426990509
is O 0 4.532641469268128e-06
a O 0 3.1104609661269933e-06
transcription O 0 2.5192630346282385e-05
factor O 0 3.2516510373170604e-07
with O 0 3.897396627650096e-09
two O 0 1.3124306086353954e-08
DNA O 0 1.7243833099200856e-06
- O 0 7.718997494521318e-07
binding O 0 1.1721685666543635e-07
domains O 0 4.925054213344993e-07
( O 0 4.351379701006408e-08
paired O 0 1.5214075688163575e-07
box O 0 4.3504178393050097e-07
and O 0 3.5518855412419725e-08
homeobox O 0 7.584832019347232e-06
) O 0 3.0137332629465163e-08
and O 0 7.641363986010674e-09
a O 0 1.8543437363405246e-07
proline O 0 1.956195092134294e-06
- O 0 1.6798915112303803e-06
serine O 0 3.5543164358387003e-06
- O 0 3.087358891207259e-06
threonine O 0 6.568070602952503e-06
( O 0 8.253072678598983e-07
PST O 0 9.229766146745533e-05
) O 0 8.043612638175546e-07
- O 0 2.302020675415406e-06
rich O 0 1.3986128806209308e-06
transactivation O 0 0.00019954088202212006
domain O 0 1.4879759874020237e-05
. O 0 3.6672959140560124e-06

PAX6 O 1 0.9999996423721313
regulates O 0 0.005582010373473167
eye O 0 0.0006069222581572831
development O 0 2.426866103633074e-06
in O 0 4.890465987728021e-08
animals O 0 3.66263606110806e-08
ranging O 0 7.900473519839579e-08
from O 0 6.629735338492537e-08
jellyfish O 0 1.6538332658910804e-07
to O 0 1.4122848668307597e-08
Drosophila O 0 9.831629768086714e-07
to O 0 6.507534067168308e-08
humans O 0 1.7147194739663973e-06
. O 0 1.4926455378372339e-06

Heterozygous O 0 4.4900880311615765e-05
mutations O 0 5.906182423132122e-07
in O 0 5.866668217890947e-08
the O 0 1.1033242941493882e-07
human O 0 4.3065091404059785e-07
PAX6 O 1 0.9580569863319397
gene O 0 1.702555607607792e-07
result O 0 1.6237665434459814e-08
in O 0 3.6710130491002246e-09
various O 0 5.076265185977036e-09
phenotypes O 0 2.361530988537197e-07
, O 0 1.6218166365433717e-08
including O 0 1.0042951004152201e-07
aniridia B-Disease 1 1.0
, O 0 1.0672033567971084e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.5204290068359114e-06
autosomal B-Disease 0 0.05524613335728645
dominant I-Disease 0 0.0005267960950732231
keratitis I-Disease 1 0.9478455781936646
, O 0 9.417172464054602e-07
and O 0 1.5534827980445698e-05
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.4115923345088959

It O 0 1.0952682032439043e-06
is O 0 1.679765233575381e-07
believed O 0 4.6300681333377725e-07
that O 0 1.6421020987422708e-08
the O 0 6.405141306231599e-08
mutated O 0 3.219731752324151e-07
allele O 0 3.373690162788989e-07
of O 0 3.1629477348360524e-07
PAX6 O 0 0.020078390836715698
produces O 0 8.709887566737962e-08
an O 0 5.996039931233099e-08
inactive O 0 9.120710160459566e-07
protein O 0 5.447629405352927e-07
and O 0 7.581814998047776e-08
aniridia B-Disease 1 1.0
is O 0 4.043797616759548e-07
caused O 0 4.221260496706236e-07
due O 0 3.205045118193084e-07
to O 0 2.857564425085002e-07
genetic O 0 0.00019430022803135216
haploinsufficiency O 1 0.7908995151519775
. O 0 1.2809455256501678e-05

However O 0 2.016411372096627e-06
, O 0 8.077052626731529e-08
several O 0 2.6684721987635385e-08
truncation O 0 4.070551767654251e-06
mutations O 0 2.9932991196801595e-08
have O 0 2.2440451719063503e-09
been O 0 7.019604009173008e-09
found O 0 4.947167120405993e-09
to O 0 3.0228912706320443e-09
occur O 0 1.0964597230156414e-08
in O 0 1.2352352918298948e-08
the O 0 2.731011363721336e-07
C O 0 0.007280525751411915
- O 0 3.220333019271493e-05
terminal O 0 4.068789621669566e-06
half O 0 6.505611338525341e-08
of O 0 1.403240617037227e-07
PAX6 O 0 0.006109482608735561
in O 0 6.107680405875726e-08
patients O 0 2.0487414431613615e-08
with O 0 1.8804863444188413e-08
Aniridia B-Disease 1 1.0
resulting O 0 7.33331319224817e-07
in O 0 1.774746749561018e-08
mutant O 0 1.371565048202683e-07
proteins O 0 5.232670297061759e-09
that O 0 5.533021263381954e-10
retain O 0 7.298648796449925e-09
the O 0 3.260357317458329e-08
DNA O 0 2.0914194465149194e-06
- O 0 2.786278514577134e-07
binding O 0 3.4999082743070176e-08
domains O 0 4.418151178242624e-08
but O 0 2.164793011516508e-09
have O 0 2.3565795981284055e-09
lost O 0 2.2533542676228535e-07
most O 0 1.4503361178697105e-08
of O 0 1.9591358579873486e-07
the O 0 1.2030978950861027e-06
transactivation O 0 0.0003903148462995887
domain O 0 2.0063784177182242e-05
. O 0 2.3019526906864485e-06

It O 0 5.393890774030297e-07
is O 0 4.357492500162152e-08
not O 0 6.250573392208025e-09
clear O 0 1.516152003944171e-08
whether O 0 1.943950245220094e-08
such O 0 1.4211642529460278e-08
mutants O 0 3.984419436164899e-06
really O 0 8.057647846726468e-07
behave O 0 2.2391174070435227e-07
as O 0 4.130764352794358e-08
loss O 0 1.6241651792370249e-06
- O 0 1.7489708170614904e-06
of O 0 1.2986648698642966e-06
- O 0 5.98366068516043e-06
function O 0 3.344736114740954e-07
mutants O 0 1.6832899518703925e-07
as O 0 1.3632445394762271e-08
predicted O 0 4.509142570441327e-07
by O 0 2.1416602180579503e-07
haploinsufficiency O 0 0.00010984419350279495
. O 0 5.076643901702482e-06

Contrary O 0 1.271360360988183e-05
to O 0 6.178166955805864e-08
this O 0 2.611902694127366e-08
theory O 0 2.779198098323832e-07
, O 0 7.932875689675711e-09
our O 0 1.0506084890948841e-08
data O 0 2.5961679028796425e-08
showed O 0 1.2562582973885128e-08
that O 0 5.927116575321634e-10
these O 0 7.474207364133179e-10
mutants O 0 2.6062345170885237e-08
are O 0 2.069552307304434e-09
dominant O 0 1.571958279100727e-07
- O 0 9.527864364144989e-08
negative O 0 4.424813582204479e-08
in O 0 2.5673706716133893e-08
transient O 0 2.5666859073680826e-06
transfection O 0 2.470548224664526e-06
assays O 0 6.04207528454026e-08
when O 0 4.943677023305781e-09
they O 0 2.167589885360144e-09
are O 0 1.9698298547865534e-09
coexpressed O 0 1.2786480283466517e-06
with O 0 1.601485699609384e-08
wild O 0 1.1898936236320878e-06
- O 0 5.304411388351582e-05
type O 0 7.829604874132201e-05
PAX6 O 1 0.7122843265533447
. O 0 1.7932434275280684e-05

We O 0 1.7884294720715843e-06
found O 0 2.344543759136286e-07
that O 0 1.9486501301457793e-08
the O 0 9.948388424163568e-08
dominant O 0 9.883249276754213e-07
- O 0 3.858287414004735e-07
negative O 0 4.065753245185988e-08
effects O 0 3.984940022405681e-08
result O 0 5.736822128454833e-09
from O 0 3.0933082761919195e-09
the O 0 7.235940735483837e-09
enhanced O 0 3.407719972869927e-08
DNA O 0 3.8756638787162956e-08
binding O 0 4.532542785540272e-09
ability O 0 4.853942581206638e-09
of O 0 3.7684785070268845e-08
these O 0 3.7796507257326084e-08
mutants O 0 8.686958608450368e-06
. O 0 1.4746650549568585e-06

Kinetic O 0 0.0002377544587943703
studies O 0 4.194393113721162e-06
of O 0 3.730063156126562e-07
binding O 0 2.2295625967672095e-07
and O 0 3.390784897305821e-08
dissociation O 0 4.9776795094658155e-06
revealed O 0 8.696621875969868e-07
that O 0 1.4161556372016548e-08
various O 0 2.872446458468403e-08
truncation O 0 3.0160047117533395e-06
mutants O 0 3.783892168485181e-07
have O 0 9.037656845123365e-09
3 O 0 8.90112730189685e-08
- O 0 4.502293506902788e-07
5 O 0 2.4067421122708765e-07
- O 0 2.1429147523122083e-07
fold O 0 1.0054776566903456e-07
higher O 0 1.7335553437192175e-08
affinity O 0 4.530935182600615e-09
to O 0 4.4747647254261835e-10
various O 0 1.4550067817253876e-09
DNA O 0 1.700961860251482e-07
- O 0 3.312452179216052e-08
binding O 0 6.279934794406472e-09
sites O 0 7.525077450054596e-09
when O 0 2.6055619883891268e-09
compared O 0 5.067558817017925e-09
with O 0 3.745872223515079e-10
the O 0 1.9632894421306446e-08
wild O 0 2.793086650854093e-07
- O 0 3.946812284993939e-06
type O 0 1.0081129403261002e-05
PAX6 O 0 0.002395168412476778
. O 0 4.167995939496905e-06

These O 0 6.43909686459665e-07
results O 0 3.247597533118096e-07
provide O 0 6.905849403437969e-08
a O 0 5.0044832278217655e-08
new O 0 2.0812386480884015e-08
insight O 0 4.2065201455443457e-07
into O 0 1.640602498298449e-08
the O 0 3.4736721943318116e-08
role O 0 2.9563062753368285e-07
of O 0 7.7044131785442e-07
mutant O 0 9.80844342848286e-05
PAX6 O 1 0.9995437264442444
in O 0 1.7637510154600022e-06
causing O 0 0.0001092773163691163
aniridia B-Disease 1 0.9999998807907104
. O 0 2.765204499155516e-06
. O 0 3.814482397501706e-06

Reversal O 0 0.0051004644483327866
of O 0 0.0004913381417281926
severe O 1 0.9999996423721313
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 3.460404695942998e-05
excellent O 0 0.00044799025636166334
neuropsychologic O 0 0.28667500615119934
outcome O 0 3.142831019431469e-06
in O 0 1.3774585738701717e-07
very B-Disease 0 1.959924418315495e-07
- I-Disease 0 2.873389121305081e-06
long I-Disease 0 1.4154110203890014e-06
- I-Disease 0 4.894552603218472e-06
chain I-Disease 0 2.437017656120588e-06
acyl I-Disease 0 1.701560336186958e-06
- I-Disease 0 5.659547696268419e-06
coenzyme I-Disease 0 2.0119041437283158e-05
A I-Disease 0 0.0016628986923024058
dehydrogenase I-Disease 0 0.040531449019908905
deficiency I-Disease 0 0.062277741730213165
. O 0 3.265163741161814e-06

Very B-Disease 0 1.9398561562411487e-05
- I-Disease 0 2.735593261604663e-05
long I-Disease 0 3.9245774132723454e-06
- I-Disease 0 3.1496360861638095e-06
chain I-Disease 0 5.712213919650821e-07
acyl I-Disease 0 4.593800042584917e-07
- I-Disease 0 5.674809244737844e-07
coenzyme I-Disease 0 1.4426532288780436e-06
A I-Disease 0 4.582782821671572e-06
dehydrogenase I-Disease 0 6.043982011760818e-06
( I-Disease 0 2.786225365980499e-07
VLCAD I-Disease 1 0.9966000914573669
) I-Disease 0 1.7597219539311482e-06
deficiency I-Disease 0 0.0018572729313746095
is O 0 2.914243601992439e-08
a O 0 4.7263526425922464e-07
disorder O 0 0.006263847462832928
of O 0 1.5442272342625074e-05
fatty O 0 0.02882690355181694
acid O 0 0.00011791357974288985
beta O 0 4.177697974228067e-06
oxidation O 0 9.196175909664817e-08
that O 0 4.7511874434746915e-09
reportedly O 0 1.349263385463928e-07
has O 0 4.574701062409758e-09
high O 0 3.8678948044434946e-08
rates O 0 4.738592096487082e-08
of O 0 9.138700818311918e-08
morbidity O 0 4.055248064105399e-05
and O 0 2.338159958981123e-07
mortality O 0 0.0004730789514724165
. O 0 2.159842324545025e-06

We O 0 1.2693993767243228e-06
describe O 0 1.0841196171895717e-06
the O 0 1.9677474938362138e-07
outcome O 0 6.091108843975235e-07
of O 0 2.3200260557132424e-07
a O 0 3.9372605442622444e-07
5 O 0 3.6787994872611307e-07
- O 0 4.399302611091116e-07
year O 0 1.35261942091347e-07
- O 0 9.807936294237152e-07
old O 0 3.4378599593765102e-06
girl O 0 1.3846215551893692e-05
with O 0 1.5972963183230604e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.520663317933213e-06
was O 0 7.653395186935086e-06
first O 0 4.5961050432197226e-07
seen O 0 5.068170594313415e-07
at O 0 5.398239295573148e-07
5 O 0 8.641644910767354e-08
months O 0 2.2574232261263205e-08
of O 0 3.326933040170843e-08
age O 0 8.20448065042001e-07
with O 0 3.4085883271472994e-07
severe O 1 0.9999929666519165
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9998743534088135
hepatomegaly B-Disease 1 1.0
, O 1 0.9964259266853333
encephalopathy B-Disease 1 0.9999996423721313
, O 0 4.965394509781618e-06
and O 0 2.736965507210698e-05
hypotonia B-Disease 1 0.9999431371688843
. O 0 0.00013514024612959474

Biochemical O 0 0.40127769112586975
studies O 0 0.0013131878804415464
indicated O 1 0.9955447912216187
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 4.0544204239267856e-05
by O 0 1.0853449339265353e-07
a O 0 3.794747840402124e-07
stable O 0 1.761485009410535e-06
yet O 0 3.5807238418783527e-07
inactive O 0 1.1159696441609412e-05
enzyme O 0 1.3377681170823053e-05
. O 0 1.9444789813860552e-06

Molecular O 0 0.0021494359243661165
genetic O 0 2.1122612452018075e-05
analysis O 0 1.388361624776735e-06
of O 0 1.1865304259117693e-06
her O 0 6.304603630269412e-06
VLCAD O 1 0.9999980926513672
gene O 0 5.1076799536531325e-06
revealed O 0 8.690547474543564e-06
a O 0 3.2859961720532738e-06
T1372C O 0 0.00022985863324720412
( O 0 4.112105216336204e-06
F458L O 0 0.00019776099361479282
) O 0 9.540135579300113e-07
missense O 0 6.361776286212262e-06
mutation O 0 2.0889865481876768e-07
and O 0 8.767591452851775e-08
a O 0 1.079040885088034e-05
1668 O 1 0.9998651742935181
ACAG O 1 0.9999997615814209
1669 O 1 0.9997960925102234
splice O 0 0.002026865491643548
site O 0 4.0062772313831374e-05
mutation O 0 4.823581093660323e-06
. O 0 2.607391479614307e-06

After O 0 3.892721906595398e-06
initial O 0 1.5571257563351537e-06
treatment O 0 2.5221405053343915e-07
with O 0 8.810590657049033e-08
intravenous O 0 6.955624849069864e-05
glucose O 0 0.0003228579298593104
and O 0 1.303104681937839e-07
carnitine O 0 0.01207963190972805
, O 0 3.3877206817578553e-08
the O 0 4.8478938197149546e-08
patient O 0 1.734118342255897e-07
has O 0 6.409636377213701e-09
thrived O 0 2.0522072929907154e-07
on O 0 2.1231782554309575e-08
a O 0 1.5510980233557348e-07
low O 0 9.111529379879357e-07
- O 0 1.1311419712001225e-06
fat O 0 1.2028851870127255e-07
diet O 0 2.954799960264154e-08
supplemented O 0 5.523115831351788e-08
with O 0 3.569269546588316e-09
medium O 0 1.0542969448579242e-06
- O 0 4.465788606466958e-06
chain O 0 5.756455720984377e-07
triglyceride O 0 5.827789664181182e-07
oil O 0 2.968091905586334e-07
and O 0 6.526179419097389e-08
carnitine O 0 4.361791434348561e-05
and O 0 1.5359570681994228e-07
avoidance O 0 6.9947259362379555e-06
of O 0 3.269984745202237e-06
fasting O 0 0.00012421351857483387
. O 0 1.18690531962784e-05

Her O 0 0.45670944452285767
ventricular O 1 0.9999927282333374
hypertrophy O 1 0.8817117214202881
resolved O 0 1.652830178500153e-05
significantly O 0 5.147383603798517e-07
over O 0 3.236984724708236e-08
1 O 0 2.756572925477485e-08
year O 0 7.572966254087987e-09
, O 0 3.5171787704513235e-09
and O 0 4.618731619387972e-09
cognitively O 0 1.3759550711256452e-05
, O 0 1.7949751907053724e-08
she O 0 6.004485442190344e-08
is O 0 6.611788450072709e-09
in O 0 2.488868444672221e-09
the O 0 9.032159908883841e-09
superior O 0 2.2502854335471056e-07
range O 0 1.3675422394499037e-07
for O 0 6.673594299400065e-08
age O 0 1.3713332009501755e-05
. O 0 2.848717940651113e-06

Clinical O 0 0.017514949664473534
recognition O 0 4.5224423956824467e-05
of O 1 0.9998161196708679
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.2061702111386694e-05
important O 0 4.849359243053186e-07
because O 0 5.661881186114215e-09
it O 0 1.453021258868148e-09
is O 0 3.206229060026544e-09
one O 0 2.5110027390695677e-09
of O 0 3.740369791671583e-09
the O 0 1.1461030346993084e-08
few O 0 2.1983856512974853e-08
directly O 0 2.2620181994170707e-07
treatable O 0 0.005294687580317259
causes O 0 3.221407268938492e-06
of O 0 0.01199253834784031
cardiomyopathy B-Disease 1 1.0
in O 0 1.589419844094664e-05
children O 0 4.658592388295801e-06
. O 0 8.024434805520286e-07
. O 0 2.9294690193637507e-06

Cloning O 0 7.675696542719379e-05
of O 0 8.747470019443426e-07
a O 0 4.6282931975838437e-07
novel O 0 4.5139444182495936e-07
member O 0 1.6306839256685635e-07
of O 0 7.751508235287474e-08
the O 0 2.2429557589020988e-07
low O 0 1.6452910131192766e-05
- O 0 0.00015297284699045122
density O 0 2.2837184587842785e-05
lipoprotein O 0 0.0007326439954340458
receptor O 0 5.785763278254308e-06
family O 0 1.465893205931934e-06
. O 0 9.279265782424773e-07

A O 0 2.423747537250165e-05
gene O 0 1.2243945093359798e-06
encoding O 0 3.823208771791542e-07
a O 0 2.5091327415793785e-07
novel O 0 1.8592892274682526e-06
transmembrane O 0 7.954718057590071e-06
protein O 0 1.8789792477491574e-07
was O 0 1.2688072104083403e-07
identified O 0 2.5582592044770536e-08
by O 0 1.9239274617888213e-09
DNA O 0 2.1250945891893025e-08
sequence O 0 2.3497676693295944e-08
analysis O 0 9.938996292646607e-09
within O 0 6.3818355044986674e-09
the O 0 4.3847055763990284e-08
insulin B-Disease 0 6.5836798057716805e-06
- I-Disease 0 0.00035896067856810987
dependent I-Disease 0 0.18759630620479584
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 0.014783850871026516
IDDM B-Disease 1 0.9999996423721313
) O 0 2.7458763725007884e-06
locus O 0 1.1193420505151153e-05
IDDM4 O 0 9.109744860325009e-05
on O 0 2.08088545150531e-06
chromosome O 0 5.6475953897461295e-05
11q13 O 0 0.00016141538799274713
. O 0 9.410211532667745e-06

Based O 0 2.8980307433812413e-06
on O 0 5.323568075255025e-07
its O 0 4.8183945722257704e-08
chromosomal O 0 1.8874919760492048e-06
position O 0 2.62217611179949e-07
, O 0 1.766930957103341e-08
this O 0 1.70898868390168e-08
gene O 0 2.656720710092486e-08
is O 0 5.559226856632904e-09
a O 0 2.8555231068594367e-08
candidate O 0 2.1020637674951104e-08
for O 0 1.9494084568805192e-08
conferring O 0 3.1384759040520294e-06
susceptibility O 0 2.8568132620421238e-05
to O 0 1.888663973659277e-06
diabetes B-Disease 1 0.9999493360519409
. O 0 1.6869580576894805e-05

The O 0 5.323655841493746e-06
gene O 0 9.30477824567788e-07
, O 0 7.172515381625999e-08
termed O 0 4.160791831964161e-06
low O 0 1.6880185285117477e-05
- O 0 9.111343388212845e-05
density O 0 5.639150458591757e-06
lipoprotein O 0 2.7875466912519187e-05
receptor O 0 4.012569547739986e-07
related O 0 3.301174800185436e-08
protein O 0 4.61643487881247e-08
5 O 0 4.4436401225311783e-08
( O 0 5.897948085475946e-08
LRP5 O 0 7.353010005317628e-05
) O 0 2.5281842397362198e-08
, O 0 7.741413732276214e-09
encodes O 0 5.756665188982879e-08
a O 0 1.0981215048389004e-08
protein O 0 3.267572523668605e-08
of O 0 3.961235961469356e-08
1615 O 0 4.67644385935273e-05
amino O 0 3.098270440204942e-07
acids O 0 1.7566282650705034e-08
that O 0 7.62860385972175e-10
contains O 0 4.935988506815647e-09
conserved O 0 9.714320015064004e-08
modules O 0 1.320566838103332e-07
which O 0 1.1867178351110397e-09
are O 0 4.213935589358897e-10
characteristic O 0 4.8537942554105484e-09
of O 0 2.12001385335725e-08
the O 0 4.212437332284935e-08
low O 0 1.7591079313206137e-06
- O 0 2.068266439891886e-05
density O 0 3.1487829801335465e-06
lipoprotein O 0 9.103335469262674e-05
( O 0 2.078255420201458e-06
LDL O 0 4.166462167631835e-05
) O 0 2.789003303860227e-07
receptor O 0 7.487311677323305e-07
family O 0 3.427419699164602e-07
. O 0 4.3095042201457545e-07

These O 0 9.087699481824529e-07
modules O 0 5.7456795730104204e-06
include O 0 1.743627109362933e-07
a O 0 6.078464025449648e-07
putative O 0 6.258775556489127e-06
signal O 0 5.042651878284232e-07
peptide O 0 8.750701141480022e-08
for O 0 4.602954017940419e-09
protein O 0 5.3304056280012446e-08
export O 0 4.9155101322639894e-08
, O 0 6.537800523176429e-09
four O 0 2.4844208468266515e-08
epidermal O 0 4.8694355427869596e-06
growth O 0 2.2871593330364703e-07
factor O 0 3.903700758201012e-07
( O 0 1.3100226681217464e-07
EGF O 0 2.2064605218474753e-05
) O 0 1.343910227546985e-08
repeats O 0 6.505636207521093e-08
with O 0 4.003374520777925e-09
associated O 0 1.895751040592586e-07
spacer O 0 1.7234004189958796e-05
domains O 0 8.493188943248242e-07
, O 0 6.5923735803608e-08
three O 0 1.6547483028261922e-07
LDL O 0 6.436458352254704e-05
- O 0 4.650043138099136e-06
receptor O 0 1.282810558222991e-06
( O 0 7.88083411862317e-08
LDLR O 0 8.478992822347209e-05
) O 0 3.058099906638745e-08
repeats O 0 7.39494723234202e-08
, O 0 6.732608248682936e-09
a O 0 3.4350559730000896e-08
single O 0 8.017453723141443e-08
transmembrane O 0 2.4917114842537558e-06
spanning O 0 1.616940039639303e-06
domain O 0 1.086346856027376e-06
, O 0 2.190892800513211e-08
and O 0 2.5822412652587445e-08
a O 0 1.017845761452918e-06
cytoplasmic O 0 2.9176640964578837e-05
domain O 0 2.3071190298651345e-05
. O 0 2.8711619961541146e-06

The O 0 5.4028519116400275e-06
encoded O 0 2.312576043550507e-06
protein O 0 4.70664673457577e-07
has O 0 7.946489688492875e-09
a O 0 2.1981801268111667e-08
unique O 0 3.107881951791569e-08
organization O 0 9.6155496009942e-08
of O 0 3.0915959996491438e-06
EGF O 1 0.9998270869255066
and O 0 3.443138325565087e-07
LDLR O 1 0.9992979764938354
repeats O 0 1.9364586023584707e-06
; O 0 1.68282365820005e-08
therefore O 0 1.2011015826374205e-07
, O 0 5.403081360100259e-08
LRP5 O 0 0.002407171530649066
likely O 0 9.97232589838859e-08
represents O 0 5.8578457640123816e-08
a O 0 2.9272126056412162e-08
new O 0 1.1985014758408852e-08
category O 0 5.708707249141298e-07
of O 0 3.405615132123785e-07
the O 0 2.8252391075511696e-06
LDLR O 1 0.9998865127563477
family O 0 2.3407610569847748e-05
. O 0 6.318091891444055e-06

Both O 0 2.8043280053680064e-06
human O 0 8.219485607696697e-07
and O 0 2.9343965479711187e-07
mouse O 0 3.120426117675379e-05
LRP5 O 1 0.9999641180038452
cDNAs O 0 0.005594740621745586
have O 0 8.611859669827027e-09
been O 0 1.6649257972289888e-08
isolated O 0 3.325023456568488e-08
and O 0 9.823049040846854e-10
the O 0 4.939680664506341e-09
encoded O 0 2.272565247096736e-08
mature O 0 7.49079465123259e-09
proteins O 0 2.383121699978119e-09
are O 0 8.543304952368658e-10
95 O 0 4.7428056149101394e-08
% O 0 1.4818271942829142e-08
identical O 0 2.570173052163227e-08
, O 0 3.602798059887391e-09
indicating O 0 1.1061815996527002e-07
a O 0 2.7469994279272214e-08
high O 0 3.960646566270043e-08
degree O 0 3.492073972211074e-07
of O 0 8.175130972176703e-08
evolutionary O 0 7.68794336636347e-07
conservation O 0 8.728130751478602e-08
. O 0 3.6922287449669966e-08
. O 0 4.0519583421883e-07

The O 0 3.0402763513848186e-05
APC B-Disease 0 0.0001573477202327922
variants O 0 3.0746155061933678e-06
I1307K O 0 4.2849427700275555e-05
and O 0 8.70273026976065e-08
E1317Q O 0 2.3691882233833894e-05
are O 0 3.27463531846206e-08
associated O 0 3.835537881968776e-06
with O 1 0.9179416298866272
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0013839119346812367
but O 0 4.358772898171992e-08
not O 0 2.472560112209976e-08
always O 0 8.220193592478608e-08
with O 0 1.649837422235123e-08
a O 0 5.22398238445021e-07
family O 0 1.125135327129101e-06
history O 0 1.3062245670880657e-05
. O 0 3.7765232718811603e-06

Classical O 1 0.9999814033508301
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999998807907104
FAP B-Disease 1 0.9999967813491821
) O 0 3.517345703585306e-06
is O 0 1.2914111380268878e-07
a O 0 6.266787409003882e-07
high O 0 0.014705367386341095
- O 1 0.9999986886978149
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999911785125732
disease I-Disease 1 0.9973078966140747
that O 0 8.617729463367141e-08
predisposes O 0 6.700126687064767e-05
to O 0 5.0142190843871504e-08
hundreds O 0 2.132135250576539e-07
or O 0 1.7295830900820874e-07
thousands O 0 1.194340029542218e-06
of O 1 0.999984860420227
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999876022338867
carcinoma I-Disease 1 1.0
and O 0 1.1230936536321678e-07
that O 0 1.2051444286953483e-08
results O 0 2.617029082330191e-08
from O 0 3.1059972371849653e-08
truncating O 0 3.139218506476027e-06
mutations O 0 3.5824758271019164e-08
in O 0 6.145670283785876e-08
the O 0 8.408501344092656e-07
APC B-Disease 0 6.870309880468994e-05
gene O 0 4.140173587074969e-06
. O 0 1.7729707906255499e-06

A O 0 4.3943189666606486e-05
variant O 0 2.103398583130911e-05
of O 0 1.6412792319897562e-05
FAP B-Disease 0 0.05424953252077103
is O 0 1.7131473214249127e-05
attenuated B-Disease 1 0.9987309575080872
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.999984860420227
, O 0 8.939184112932708e-07
which O 0 6.393423745976179e-08
results O 0 1.4451894969624846e-07
from O 0 3.0628257263742853e-07
germ O 1 0.9999914169311523
- O 0 0.0005067494348622859
line O 0 1.6062861050158972e-06
mutations O 0 2.5792878943775577e-08
in O 0 8.37410496501434e-09
the O 0 1.909925018139802e-08
5 O 0 5.044176276669532e-08
and O 0 6.0867448858914486e-09
3 O 0 3.147090410493547e-08
regions O 0 1.0309229026006506e-08
of O 0 5.969531002847361e-08
the O 0 9.510811764812388e-07
APC B-Disease 0 3.886496779159643e-05
gene O 0 2.4981402475532377e-06
. O 0 1.12176576294587e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 3.030067637155298e-05
have O 0 2.051858416507457e-08
" O 0 9.213449061462597e-07
multiple O 0 1.725735819491092e-05
" O 1 0.9999994039535522
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 7.008154170762282e-06
typically O 0 2.106117058531254e-08
fewer O 0 4.122851837706776e-09
than O 0 3.424554861908291e-09
100 O 0 2.529824527641722e-08
) O 0 3.3646332386894073e-09
without O 0 9.76080372083743e-09
the O 0 1.2170343666184635e-07
florid O 0 2.3804621378076263e-05
phenotype O 0 2.1626765374094248e-06
of O 0 1.8804416868078988e-06
classical O 0 0.00011642580648185685
FAP B-Disease 0 0.0001890646235551685
. O 0 5.656067514792085e-06

Another O 0 2.7206024242332205e-05
group O 0 7.656072398276592e-07
of O 0 3.035598581391241e-07
patients O 0 8.47986925123223e-08
with O 0 1.4058937125582815e-08
multiple O 0 8.015754247026052e-06
adenomas B-Disease 1 0.9983482360839844
has O 0 1.4594936814660286e-08
no O 0 2.0705165582057816e-08
mutations O 0 7.052388895090189e-09
in O 0 1.1608920935657352e-08
the O 0 1.765681787446738e-07
APC B-Disease 0 1.2039623470627703e-05
gene O 0 6.478764902340117e-08
, O 0 4.019288457612902e-09
and O 0 2.1263302230067893e-09
their O 0 7.350857256227528e-09
phenotype O 0 1.4487470423318882e-07
probably O 0 5.526709045966527e-08
results O 0 1.1691895451804157e-08
from O 0 1.0336655087428426e-08
variation O 0 4.2435086555769885e-08
at O 0 1.2808457938717766e-07
a O 0 9.228682529283105e-08
locus O 0 2.0943764411640586e-07
, O 0 2.243681462843483e-09
or O 0 6.137292452024212e-09
loci O 0 2.7146180414661103e-08
, O 0 5.548644210762177e-09
elsewhere O 0 3.233720491380154e-08
in O 0 2.4599440706651876e-08
the O 0 5.704962404706748e-07
genome O 0 3.381612032171688e-06
. O 0 1.985043581953505e-06

Recently O 0 1.355015774606727e-05
, O 0 1.7085999104438088e-07
however O 0 7.872120733054544e-08
, O 0 6.378515848837196e-08
a O 0 1.826259961035248e-07
missense O 0 1.530161398477503e-06
variant O 0 4.486858244945324e-07
of O 0 1.3880888900530408e-06
APC B-Disease 0 0.00014468582230620086
( O 0 1.999982941924827e-06
I1307K O 0 0.0002129902713932097
) O 0 1.4538431969413068e-07
was O 0 3.6289043237047736e-07
described O 0 1.156575066829646e-07
that O 0 4.339434589439861e-09
confers O 0 7.79578144260995e-08
an O 0 1.5728483404586768e-08
increased O 0 1.31156284055578e-07
risk O 0 1.3261644198792055e-05
of O 1 0.9999997615814209
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0002815577026922256
including O 0 1.6947519725363236e-06
multiple O 0 1.181189509225078e-05
adenomas B-Disease 0 0.19031500816345215
, O 0 2.425144032258686e-07
in O 0 1.1626091236394132e-06
Ashkenazim O 0 0.0007010881672613323
. O 0 7.4601516644179355e-06

We O 0 2.1782400381198386e-06
have O 0 3.8454150086408845e-08
studied O 0 6.79594450048171e-07
a O 0 1.5689180088429566e-07
set O 0 9.946832335572253e-08
of O 0 7.752631603352711e-08
164 O 0 5.918886927247513e-07
patients O 0 3.656444746980014e-08
with O 0 3.8470879815122316e-08
multiple O 1 0.9991896748542786
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9334349632263184
/ I-Disease 1 1.0
or I-Disease 1 0.9188680052757263
carcinoma I-Disease 1 1.0
and O 0 2.786042045954673e-07
analyzed O 0 7.047980034258217e-06
codons O 0 4.73067711936892e-06
1263 O 0 9.056095586856827e-05
- O 0 1.0601473150018137e-05
1377 O 0 0.00011729589459719136
( O 0 1.3330343335837824e-06
exon O 0 6.659748578385916e-06
15G O 0 9.193128789775074e-06
) O 0 4.920040552747196e-08
of O 0 4.2797204002908984e-08
the O 0 1.1524495135972757e-07
APC B-Disease 0 5.962720024399459e-06
gene O 0 1.285586535004768e-07
for O 0 1.3315234070887527e-07
germ O 1 0.999998927116394
- O 1 0.8523681163787842
line O 0 4.818795059691183e-05
variants O 0 4.585816895996686e-06
. O 0 2.653910314620589e-06

Three O 0 6.51016807751148e-06
patients O 0 3.419150118588732e-07
with O 0 2.7786487777348157e-08
the O 0 4.568329643461766e-07
I1307K O 0 7.01334502082318e-05
allele O 0 2.5823652549661347e-07
were O 0 7.495414422464819e-08
detected O 0 2.342295459811794e-07
, O 0 1.7931819584759978e-08
each O 0 2.8818194053314983e-08
of O 0 7.938446060506976e-07
Ashkenazi O 0 0.0006616223254241049
descent O 0 0.0007538056233897805
. O 0 1.5002038708189502e-05

Four O 0 1.6095284081529826e-05
patients O 0 8.071522188402014e-07
had O 0 6.58269186715188e-07
a O 0 3.0967628390499158e-06
germ O 1 0.9999984502792358
- O 0 0.4181739091873169
line O 0 2.768281956377905e-05
E1317Q O 0 8.94589684321545e-05
missense O 0 3.86049168810132e-06
variant O 0 4.222754341753898e-07
of O 0 3.551181748662202e-07
APC O 0 1.8815790099324659e-06
that O 0 5.7705134004493175e-09
was O 0 1.3210983240696805e-07
not O 0 7.021130343787263e-09
present O 0 4.852075008443535e-08
in O 0 5.122252133560323e-08
controls O 0 1.880314783875292e-07
; O 0 2.8668729612491006e-09
one O 0 4.725935198734987e-09
of O 0 9.710573678489709e-09
these O 0 1.1858851678425708e-09
individuals O 0 3.144154936407517e-09
had O 0 3.431906492323833e-08
an O 0 2.0215813023582996e-08
unusually O 0 4.755197124950428e-08
large O 0 7.198882379100269e-09
number O 0 1.320236275859088e-08
of O 0 1.7089584503082733e-07
metaplastic B-Disease 0 0.0004765571793541312
polyps I-Disease 0 4.554879978968529e-06
of I-Disease 0 1.329634301328042e-06
the I-Disease 0 6.004009719617898e-06
colorectum I-Disease 0 0.021038083359599113
. O 0 1.90077716979431e-05

There O 0 2.92754748443258e-06
is O 0 8.584770938568909e-08
increasing O 0 3.251818014859964e-08
evidence O 0 6.308846423053183e-08
that O 0 2.7825612924914367e-09
there O 0 2.651824893007415e-08
exist O 0 1.0989432297492385e-07
germ O 0 0.4675140678882599
- O 0 7.34235072741285e-06
line O 0 2.3106881030798831e-07
variants O 0 1.9293263875397315e-08
of O 0 1.0818041573656956e-08
the O 0 3.9282809893848025e-08
APC B-Disease 0 1.810501771615236e-06
gene O 0 2.7362899501781612e-08
that O 0 1.1755506568178475e-09
predispose O 0 1.3156278555470635e-07
to O 0 2.1355646140364115e-09
the O 0 1.9726583033730094e-08
development O 0 4.333762717578793e-07
of O 0 2.040997514995979e-06
multiple O 1 0.9999556541442871
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998890161514282
carcinoma I-Disease 1 1.0
, O 0 2.002081060936689e-07
but O 0 6.659414353293869e-09
without O 0 2.8850257294266157e-08
the O 0 1.0235113734324841e-07
florid O 0 7.222386102512246e-06
phenotype O 0 3.563248753835069e-07
of O 0 7.484899811061041e-08
classical O 0 1.2067579518770799e-05
FAP B-Disease 0 9.798141036299057e-06
, O 0 8.649325700105237e-09
and O 0 3.3823732703552878e-09
possibly O 0 3.907208423470365e-08
with O 0 6.078623382421711e-09
importance O 0 2.495851913408842e-05
for O 1 0.9751940965652466
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.9994858503341675
in O 0 1.814814964973266e-07
the O 0 8.857956146357537e-08
general O 0 3.3204358373950527e-07
population O 0 8.718181732092489e-08
. O 0 1.0975251285572085e-07
. O 0 9.325494829681702e-07

Genomic O 0 0.00029057334177196026
structure O 0 6.61115018374403e-06
of O 0 1.1935190968870302e-06
the O 0 1.1181396075699013e-05
human O 1 0.9828532338142395
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 0.0008444447885267437
gene O 0 2.7922505978494883e-05
. O 0 4.3060877032985445e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 0.00030520340078510344
is O 0 1.84430149374748e-07
caused O 0 1.323095517591355e-07
by O 0 8.508574289578519e-09
mutations O 0 2.0633809327819108e-08
in O 0 1.4986142105044564e-08
a O 0 8.376073168392395e-08
gene O 0 3.4019009831354197e-08
which O 0 1.1839015101600125e-08
encodes O 0 6.287835958573851e-07
an O 0 2.432185226552974e-07
intestinal O 0 0.00025983716477639973
anion O 0 0.0193362757563591
transporter O 1 0.9497935771942139
. O 0 2.5785020625335164e-05

We O 0 3.0564899589080596e-06
report O 0 1.0973561757054995e-06
here O 0 1.6540634817374666e-07
the O 0 5.931430990813169e-08
complete O 0 7.7296266454141e-07
genomic O 0 3.748542667381116e-06
organization O 0 1.1355978557503477e-07
of O 0 1.8294255710316065e-07
the O 0 8.293675364257069e-07
human O 0 2.6087665901286528e-05
CLD B-Disease 1 1.0
gene O 0 1.6934901623244514e-06
which O 0 3.688969485438065e-08
spans O 0 7.936183124002127e-07
approximately O 0 1.8295617110197782e-07
39kb O 0 5.9995682022417895e-06
, O 0 2.2352635298261703e-08
and O 0 2.4315351510040273e-08
comprises O 0 6.426765253308986e-07
21 O 0 4.175244612270035e-06
exons O 0 1.0214124813501257e-05
. O 0 2.1908108465140685e-06

All O 0 4.2067626054631546e-05
exon O 0 0.0007090166909620166
/ O 0 0.0001842867786763236
intron O 0 9.861920989351347e-05
boundaries O 0 5.142134114066721e-07
conform O 0 3.826612271495833e-07
to O 0 6.1956669128449e-08
the O 0 8.086329899015254e-07
GT O 0 0.0007296388503164053
/ O 0 0.0012219889322295785
AG O 0 0.045084189623594284
rule O 0 5.0508128879300784e-06
. O 0 3.152809767925646e-06

An O 0 2.7949060950049898e-06
analysis O 0 1.6444469110865612e-06
of O 0 7.029232733657409e-07
the O 0 1.0427844472360448e-06
putative O 0 5.31675796082709e-05
promoter O 0 2.471531661285553e-05
region O 0 4.142632121784118e-07
sequence O 0 1.1949996405746788e-06
shows O 0 4.157616331212921e-07
a O 0 7.293918997675064e-07
putative O 0 4.295547478250228e-05
TATA O 0 0.0014268725644797087
box O 0 1.9285687358205905e-06
and O 0 4.119112517741996e-08
predicts O 0 1.747907163007767e-06
multiple O 0 2.9700825621148397e-07
transcription O 0 1.3667791790794581e-05
factor O 0 8.570027034693339e-07
binding O 0 3.6361376487548114e-07
sites O 0 1.7462043615523726e-06
. O 0 2.1949977053736802e-06

The O 0 7.1424660745833535e-06
genomic O 0 9.26121083466569e-06
structure O 0 1.606137516318995e-06
was O 0 4.0425678093924944e-07
determined O 0 6.010111519572092e-08
using O 0 2.3229855372619568e-08
DNA O 0 7.140791780102518e-08
from O 0 1.3844320134737131e-09
several O 0 1.1444095671109267e-09
sources O 0 8.652938809916577e-09
including O 0 9.954281843249646e-10
multiple O 0 5.785468104591018e-09
large O 0 5.456083940202916e-08
- O 0 1.7228446722583612e-06
insert O 0 2.2245747004490113e-06
libaries O 0 8.664866982144304e-06
and O 0 1.753655531899767e-08
genomic O 0 5.856192046849173e-07
DNA O 0 9.392121569362644e-07
from O 0 2.342800229371278e-07
Finnish O 1 0.9976708292961121
CLD B-Disease 1 0.9999998807907104
patients O 0 6.954730906727491e-07
and O 0 7.45903321330843e-08
controls O 0 2.2026054011803353e-06
. O 0 3.0034616429475136e-06

Exon O 0 0.0006247559795156121
- O 0 3.565098268154543e-06
specific O 0 1.3746763727340294e-07
primers O 0 7.596578939228493e-07
developed O 0 2.139120525157523e-08
in O 0 1.902964230637849e-09
this O 0 7.011665137390821e-10
study O 0 1.6904988520138886e-09
will O 0 3.287975447463509e-10
facilitate O 0 9.302178582970555e-09
mutation O 0 4.293404742838902e-09
screening O 0 9.261177602581938e-09
studies O 0 1.6284189996440546e-08
of O 0 3.237509460518595e-08
patients O 0 1.6178002937294877e-08
with O 0 9.325468397491932e-09
the O 0 1.0861564987862948e-05
disease O 1 0.9206758141517639
. O 0 2.6212510420009494e-06

Genomic O 0 0.00013040818157605827
sequencing O 0 9.29306224861648e-06
of O 0 6.121353180787992e-06
a O 0 4.4647546019405127e-05
BAC O 1 0.999998927116394
clone O 1 0.9999542236328125
H O 1 1.0
_ O 0 1.4778214563193615e-06
RG364P16 O 0 2.8895507057313807e-05
revealed O 0 6.449482725656708e-07
the O 0 2.820350353260892e-08
presence O 0 2.4396229036938166e-08
of O 0 2.626765471802628e-08
another O 0 7.184564765339019e-08
, O 0 8.612581758882243e-09
highly O 0 7.62064189530065e-08
homologous O 0 2.7917735678784084e-07
gene O 0 5.7013519239035304e-08
3 O 0 1.215544784827216e-07
of O 0 1.5386281404516922e-07
the O 0 8.895880228010355e-07
CLD B-Disease 1 0.9999916553497314
gene O 0 2.761960331554292e-07
, O 0 8.94979379495453e-09
with O 0 2.684034550171077e-09
a O 0 2.68152344773398e-08
similar O 0 9.736687900385732e-09
genomic O 0 2.623546606628224e-07
structure O 0 2.60250232031467e-07
, O 0 7.0963501741516666e-09
recently O 0 2.3055587661247046e-08
identified O 0 2.673393240115729e-08
as O 0 1.9044284371716458e-08
the O 0 1.32791342366545e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 3.168887269566767e-05
( O 0 2.1187392121646553e-05
PDS B-Disease 0 0.017025236040353775
) O 0 5.591780904978805e-07
. O 0 2.5504837708467676e-07
. O 0 1.865658646238444e-06

The O 0 4.067754343850538e-05
APCI1307K O 1 0.9755024313926697
allele O 0 6.5657600316626485e-06
and O 0 2.0736791839226498e-07
cancer B-Disease 0 0.003978589083999395
risk O 0 3.468155455266242e-06
in O 0 8.037204679567367e-08
a O 0 6.406290253835323e-07
community O 0 3.702729856058795e-08
- O 0 1.284881818719441e-07
based O 0 2.6540361020011005e-08
study O 0 5.40726752262799e-08
of O 0 1.6395676993852248e-07
Ashkenazi O 0 5.819784200866707e-05
Jews O 0 8.691267794347368e-06
. O 0 1.8041055227513425e-06

Mutations O 0 2.4719511202420108e-05
in O 0 9.243759109267558e-07
APC O 0 2.4975659471238032e-05
are O 0 5.4972929319774266e-08
classically O 0 4.2218696762574837e-05
associated O 0 3.4690817756199976e-06
with O 0 1.2178009455965366e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 1.0
FAP B-Disease 1 0.9999955892562866
) O 0 3.1555481427858467e-07
, O 0 2.6219852955478018e-08
a O 0 3.4203631571472215e-07
highly O 0 0.00016547752602491528
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9706476926803589
by O 0 6.647184818575624e-06
multiple O 0 0.20034022629261017
intestinal O 1 0.9999998807907104
polyps B-Disease 0 0.03156667202711105
and O 0 1.9218859392822196e-07
, O 0 2.693149099286529e-07
without O 0 2.0066315755684627e-06
surgical O 1 0.9999918937683105
intervention O 1 0.7254003286361694
, O 0 5.386103794080555e-07
the O 0 2.087258963001659e-06
development O 0 0.005470613017678261
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 1.0
CRC B-Disease 1 0.9999998807907104
) O 0 4.015120066469535e-05
. O 0 8.749673725105822e-06

APC B-Disease 0 0.0006480840966105461
is O 0 2.188551434301189e-06
a O 0 6.3464208324148785e-06
tumour O 1 1.0
- O 0 0.42218148708343506
suppressor O 0 0.0027905525639653206
gene O 0 2.185067415894082e-07
, O 0 1.4039241769125965e-08
and O 0 8.615605118222902e-09
somatic O 0 4.084492502443027e-06
loss O 0 2.996167131641414e-05
occurs O 0 1.533620888949372e-05
in O 0 2.2905061996425502e-05
tumours B-Disease 1 1.0
. O 0 5.2341289119794965e-05

The O 0 3.388661571079865e-05
germline O 0 0.0004993624752387404
T O 0 8.416296623181552e-05
- O 0 2.1381799797381973e-06
to O 0 9.306849335644074e-08
- O 0 2.489364760549506e-06
A O 0 3.856466264551273e-06
transversion O 0 9.50177764025284e-06
responsible O 0 1.4494213473881246e-07
for O 0 2.0852995774589544e-08
the O 0 4.7097404376472696e-07
APC O 0 1.2068615433236118e-05
I1307K O 0 6.915510766702937e-06
allele O 0 6.44364206436876e-08
converts O 0 2.903690443645246e-08
the O 0 1.7700005017218245e-08
wild O 0 5.834084504385828e-08
- O 0 2.2854891312817927e-07
type O 0 1.1526638132863809e-07
sequence O 0 1.1824666046322818e-07
to O 0 2.2357538043138447e-08
a O 0 3.6819403703702847e-07
homopolymer O 0 0.1016140729188919
tract O 0 0.05688602477312088
( O 0 1.2457813681976404e-05
A8 O 0 0.011932325549423695
) O 0 1.1601395399907233e-08
that O 0 2.1463983923553087e-09
is O 0 1.2716388830824599e-08
genetically O 0 7.13282943820559e-08
unstable O 0 2.300482265127357e-06
and O 0 5.5991563385759946e-08
prone O 0 5.729811164201237e-06
to O 0 2.871225888156914e-07
somatic O 0 6.887601193739101e-05
mutation O 0 6.667539764748653e-06
. O 0 2.3195468656922458e-06

The O 0 5.252083428786136e-05
I1307K O 0 0.000333590607624501
allele O 0 4.9090726861322764e-06
was O 0 2.932045845227549e-06
found O 0 4.541462601537205e-07
in O 0 1.063716808857862e-06
6 O 0 2.6279785743099637e-05
. O 0 7.94445259089116e-06

1 O 0 2.3744945792714134e-05
% O 0 3.0794899430475198e-06
of O 0 1.48256583543116e-06
unselected O 1 0.9995070695877075
Ashkenazi O 1 0.7618962526321411
Jews O 0 4.551323399937246e-06
and O 0 9.121721689098194e-08
higher O 0 4.305478285004938e-07
proportions O 0 1.377410058012174e-06
of O 0 1.478385229347623e-06
Ashkenazim O 0 0.00028860423481091857
with O 0 1.6647042855311156e-07
family O 0 2.9603959319501882e-06
or O 0 3.888726212153415e-07
personal O 0 8.983453881228343e-06
histories O 0 1.8199145415565e-05
of O 0 0.005114685278385878
CRC B-Disease 1 0.9999858140945435
( O 0 0.0001694912207312882
ref O 0 0.0022994973696768284
. O 0 1.8776144372623094e-07
2 O 0 1.7486572687630542e-06
) O 0 9.480836524744518e-07
. O 0 1.893493845273042e-06

To O 0 1.146946942753857e-06
evaluate O 0 2.111440153385047e-06
the O 0 2.6073738013110415e-07
role O 0 1.41750081184e-06
of O 0 2.702431629586499e-06
I1307K O 0 0.09266949445009232
in O 0 1.4739113112227642e-06
cancer B-Disease 0 8.160503057297319e-05
, O 0 6.309580413699223e-08
we O 0 2.2759145679174253e-07
genotyped O 0 0.002391807036474347
5 O 0 2.2591796096094185e-06
, O 0 4.480234849779663e-07
081 O 0 0.0017219990259036422
Ashkenazi O 0 2.4268258130177855e-05
volunteers O 0 6.281973696786736e-07
in O 0 9.670525003002695e-08
a O 0 3.7566232435892744e-07
community O 0 2.42686780893564e-07
survey O 0 3.6379935863806168e-06
. O 0 1.8465347011442645e-06

Risk O 0 0.000132207409478724
of O 0 1.0709952221077401e-05
developing O 1 0.9952632188796997
colorectal B-Disease 1 1.0
, I-Disease 0 0.0021497835405170918
breast I-Disease 1 0.9964118599891663
and I-Disease 0 7.696615256236328e-08
other I-Disease 0 3.516395352676227e-08
cancers I-Disease 0 0.00026204087771475315
were O 0 2.1085453738578508e-07
compared O 0 6.424228331525228e-07
between O 0 3.010729017205449e-07
genotyped O 0 0.00012504241021815687
I1307K O 0 1.2763995982822962e-05
carriers O 0 2.6927940766086067e-08
and O 0 3.6966802952065336e-09
non O 0 5.202321062824922e-07
- O 0 8.923716450226493e-07
carriers O 0 2.1146103534874783e-08
and O 0 2.385832198470439e-09
their O 0 4.7729686869502075e-09
first O 0 3.730361584075581e-07
- O 0 6.6247062022739556e-06
degree O 0 2.0900017261737958e-05
relatives O 0 4.36623849964235e-06
. O 0 1.625734967092285e-06

Sperm O 0 6.886741175549105e-05
DNA O 0 5.301854798744898e-06
analysis O 0 8.507456072948116e-07
in O 0 2.755895707196032e-07
a O 0 5.101045189803699e-06
Friedreich B-Disease 1 0.9999972581863403
ataxia I-Disease 1 0.999992847442627
premutation O 1 0.9999350309371948
carrier O 0 6.959194433875382e-05
suggests O 0 4.293769507057732e-06
both O 0 1.6638647082345415e-07
meiotic O 0 0.000194499283679761
and O 0 3.9499272475040925e-07
mitotic O 0 8.774682646617293e-05
expansion O 0 2.1176469999772962e-06
in O 0 1.911981257762818e-07
the O 0 1.4189872672432102e-06
FRDA B-Disease 1 0.9860513210296631
gene O 0 1.23109421110712e-05
. O 0 1.8399288137516123e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 1.5176879060163628e-05
usually O 0 5.926703465775063e-07
caused O 0 8.467745260531956e-07
by O 0 4.735429826041582e-08
an O 0 1.6428890603492619e-07
expansion O 0 1.5953294223436387e-06
of O 0 1.581037622599979e-06
a O 0 1.133545629272703e-05
GAA O 0 0.000811419275123626
trinucleotide O 0 0.0019293332006782293
repeat O 0 1.01059058579267e-05
in O 0 8.621368010608421e-07
intron O 0 7.54844440962188e-05
1 O 0 6.228511892913957e-07
of O 0 2.5817249138526677e-07
the O 0 9.287933835366857e-07
FRDA B-Disease 0 0.27333444356918335
gene O 0 1.0276558896293864e-05
. O 0 3.035800773432129e-06

Occasionally O 0 1.2094355952285696e-05
, O 0 1.7975794719404803e-07
a O 0 1.6982663453291025e-07
fully O 0 1.98705023990442e-07
expanded O 0 5.793300061895934e-08
allele O 0 2.2737401295103155e-08
has O 0 1.2452385789174514e-09
been O 0 3.1301055081200957e-09
found O 0 5.6938938008954665e-09
to O 0 5.460370378074231e-09
arise O 0 1.8116504918452847e-07
from O 0 1.6913905653836991e-07
a O 0 1.0196109769822215e-06
premutation O 0 9.369182225782424e-05
of O 0 1.847528096732276e-06
100 O 0 1.7802002503231051e-06
or O 0 1.6746052722282911e-07
less O 0 4.1361340663570445e-07
triplet O 0 4.3891304812859744e-05
repeats O 0 2.3531874830950983e-05
. O 0 4.798827376362169e-06

We O 0 2.0209952253935626e-06
have O 0 5.44821183723343e-08
examined O 0 9.278080597141525e-07
the O 0 2.4703592771402327e-07
sperm O 0 2.2734595859219553e-06
DNA O 0 1.2789114407496527e-06
of O 0 5.994587581881206e-07
a O 0 5.378873993322486e-06
premutation O 0 0.042653992772102356
carrier O 0 3.255248520872556e-05
. O 0 8.861233254719991e-06

This O 0 6.374821168719791e-06
mans O 0 7.89840123616159e-05
leucocyte O 0 0.00011676167923724279
DNA O 0 8.060466825554613e-06
showed O 0 7.969121043061023e-07
one O 0 6.654756390389593e-08
normal O 0 2.2747492778307787e-07
allele O 0 4.921363938592549e-08
and O 0 6.801207597106895e-09
one O 0 1.118405279498802e-08
allele O 0 3.221107292006309e-08
of O 0 5.906604982897079e-08
approximately O 0 4.27440568273596e-07
100 O 0 1.0221413049293915e-06
repeats O 0 4.356480985734379e-06
. O 0 1.4081272183830151e-06

His O 0 2.406464409432374e-05
sperm O 0 2.3052871256368235e-05
showed O 0 1.1384457820895477e-06
an O 0 1.2176681707387615e-07
expanded O 0 1.6607876318630588e-07
allele O 0 1.6246812606368621e-07
in O 0 2.3810056148931835e-08
a O 0 1.0101680203433716e-07
tight O 0 1.0855742402782198e-06
range O 0 2.0073194662018068e-07
centering O 0 6.812088599872368e-07
on O 0 5.786056433976228e-08
a O 0 8.229621784039409e-08
size O 0 6.231779536847171e-08
of O 0 1.1122916987460485e-07
approximately O 0 9.513261716165289e-07
320 O 0 5.337697075447068e-06
trinucleotide O 0 0.00024567614309489727
repeats O 0 1.9917295503546484e-05
. O 0 3.410315912333317e-06

His O 0 6.0880061937496066e-05
affected O 0 1.1836003068310674e-05
son O 0 0.0009592609130777419
has O 0 3.3253286346734967e-07
repeat O 0 2.2128986074676504e-06
sizes O 0 7.967358328642149e-07
of O 0 4.249694939062465e-06
1040 O 0 8.57253689900972e-05
and O 0 2.3455013433704153e-06
540 O 0 0.00010216551891062409
. O 0 1.0659697181836236e-05

These O 0 3.599544697863166e-07
data O 0 5.940505047874467e-07
suggest O 0 1.4209371101969737e-07
that O 0 1.0703618436025408e-08
expansion O 0 1.3183520763959677e-07
occurs O 0 3.194998043909436e-08
in O 0 5.0600057477367955e-09
two O 0 2.4424011701995596e-09
stages O 0 1.2794173187558044e-07
, O 0 1.8774294119339174e-08
the O 0 3.59832199592347e-08
first O 0 8.284001040692601e-08
during O 0 3.4837381690522307e-07
meiosis O 0 1.654014567975537e-06
followed O 0 9.432842063006319e-08
by O 0 1.363710033785992e-08
a O 0 1.9716395627256134e-07
second O 0 6.661651923423051e-07
mitotic O 0 1.4372206351254135e-05
expansion O 0 4.465520305529935e-06
. O 0 2.28171347771422e-06

We O 0 2.411776904409635e-06
also O 0 1.4415060434203042e-07
show O 0 5.038531725176654e-08
that O 0 2.7426947379893818e-09
in O 0 5.4046354058812085e-09
all O 0 5.965875349289718e-09
informative O 0 6.868856416986091e-07
carrier O 0 2.0176162252028007e-07
father O 0 2.7375460831535747e-07
to O 0 3.417365945779238e-08
affected O 0 1.048928979230368e-07
child O 0 1.139282062467828e-06
transmissions O 0 1.1548958127605147e-06
, O 0 5.989361895331058e-09
with O 0 1.504903535121116e-09
the O 0 1.9492746972105124e-08
notable O 0 3.763608091844617e-08
exception O 0 2.4598220349503208e-08
of O 0 3.941181958566631e-08
the O 0 1.01920413442258e-07
premutation O 0 1.0738977834989782e-05
carrier O 0 4.426890427566832e-07
, O 0 1.6374418265741042e-08
the O 0 4.1032958364439764e-08
expansion O 0 3.8538229318874073e-07
size O 0 3.230780123431032e-07
decreases O 0 5.617870897367538e-07
. O 0 1.0878589051799281e-07
. O 0 9.155316433862026e-07

The O 0 2.6647127015166916e-05
R496H O 0 0.00024789044982753694
mutation O 0 1.7741800775183947e-06
of O 0 2.3254428924701642e-06
arylsulfatase O 0 0.3217174708843231
A O 0 9.750960452947766e-05
does O 0 4.785788405570202e-07
not O 0 1.0469885864949902e-06
cause O 0 0.03319200128316879
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 0.0001371881371596828

Deficiency B-Disease 1 0.9999998807907104
of I-Disease 0 0.0005756671889685094
arylsulfatase I-Disease 1 0.9999057054519653
A I-Disease 1 0.9636069536209106
( O 0 0.0008039120002649724
ARSA O 1 0.9999973773956299
) O 0 6.9960274231561925e-06
enzyme O 0 9.174272236123215e-06
activity O 0 1.2630388482648414e-05
causes O 0 3.691950041684322e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 1 0.9999760389328003
MLD B-Disease 1 1.0
) O 0 0.0001032207437674515
. O 0 1.4082967936701607e-05

A O 0 6.877673058625078e-06
number O 0 3.642975343609578e-07
of O 0 2.451214641041588e-06
ARSA O 1 0.9994586110115051
gene O 0 2.4206437956308946e-06
mutations O 0 1.7939797203325725e-07
responsible O 0 7.491354381272686e-07
for O 0 8.196769840651541e-07
MLD B-Disease 1 1.0
have O 0 2.433484382891038e-07
been O 0 6.952184321562527e-07
identified O 0 3.3152005016745534e-06
. O 0 2.2020929009158863e-06

Recently O 0 1.9225113646825776e-05
, O 0 4.1468217659712536e-07
the O 0 1.015495513456699e-06
R496H O 0 5.832640817970969e-05
mutation O 0 9.921506034515915e-07
of O 0 2.0934048734488897e-06
ARSA O 1 0.999843955039978
was O 0 2.093758439514204e-06
proposed O 0 5.2908003311813445e-08
to O 0 1.2886081535157246e-08
be O 0 2.6091042215625748e-08
a O 0 3.140923467981338e-07
cause O 0 1.7713499573801528e-06
of O 0 0.00016539692296646535
MLD B-Disease 1 1.0
( O 0 0.0005200908053666353
Draghia O 1 0.6798468232154846
et O 0 9.137392771663144e-05
al O 0 1.940862784977071e-05
. O 0 4.7110159329122325e-08
, O 0 4.880271831098071e-08
1997 O 0 1.2516229617176577e-06
) O 0 7.473500431842695e-07
. O 0 7.812317335265107e-07

We O 0 1.9366725609870628e-06
have O 0 1.097096031799083e-07
investigated O 0 1.8291653987034806e-06
the O 0 4.012550220977573e-07
R496H O 0 3.5703746107174084e-05
mutation O 0 6.926613593805087e-08
and O 0 3.831356565342503e-09
found O 0 7.359990839006514e-09
this O 0 3.74348863019236e-09
mutation O 0 6.220305603932275e-09
at O 0 3.464408493414339e-08
a O 0 9.777126663834679e-09
relatively O 0 5.766992217104416e-09
high O 0 7.588264239188902e-09
frequency O 0 3.5947396170854518e-09
in O 0 9.110342480411759e-10
an O 0 2.6158497590245133e-09
African O 0 2.5485622501264515e-08
American O 0 2.2634029761547936e-08
population O 0 1.1744792915990843e-09
( O 0 3.11175929468277e-09
f O 0 3.289697403374703e-08
= O 0 7.818997715958176e-08
0 O 0 1.0221355317696634e-08
. O 0 2.0902843900216794e-09
09 O 0 2.0271072287414427e-07
, O 0 7.624214148904684e-09
n O 0 3.524978353652841e-07
= O 0 5.391185595726711e-07
61 O 0 3.146622873373417e-07
subjects O 0 8.263752420134551e-07
) O 0 5.905275770601293e-07
. O 0 7.815730214133509e-07

The O 0 0.0001717563281999901
ARSA O 1 0.9999890327453613
enzyme O 0 2.0001083612442017e-05
activity O 0 7.201109042398457e-07
in O 0 9.79373826481833e-09
subjects O 0 6.496422599866492e-08
with O 0 5.37749977880253e-09
and O 0 7.220031239540958e-09
without O 0 6.118231965501764e-08
the O 0 3.818643108388642e-07
R496H O 0 2.1315250705811195e-05
mutation O 0 1.7349977454728105e-08
was O 0 7.050871886349341e-08
determined O 0 3.303385653907753e-08
and O 0 3.880321841620571e-09
found O 0 8.41124325745568e-09
to O 0 1.147262196354859e-08
be O 0 1.8561253511961695e-07
normal O 0 1.41338532557711e-05
. O 0 2.772307425402687e-06

It O 0 6.852538945167908e-07
is O 0 1.077412363770236e-07
therefore O 0 8.059663514359272e-08
concluded O 0 4.180600967629289e-07
that O 0 1.4764725442262261e-08
the O 0 1.919171523923069e-07
R496H O 0 6.869668141007423e-05
mutation O 0 4.874625574302627e-07
of O 0 2.3289985620067455e-06
ARSA O 1 0.9999901056289673
does O 0 4.7981082218484516e-08
not O 0 1.8637610565974683e-08
negatively O 0 1.886443214971223e-07
influence O 0 1.288613589167653e-07
the O 0 7.000740254170523e-08
activity O 0 5.137633820595511e-07
of O 0 7.57814177632099e-07
ARSA O 1 0.999777615070343
and O 0 2.114646591167002e-08
is O 0 2.0980824189109626e-08
not O 0 1.3383670172117945e-08
a O 0 7.767423539917218e-07
cause O 0 6.570420282514533e-06
of O 0 0.000330111215589568
MLD B-Disease 1 1.0

Down O 0 0.0006352898781187832
- O 0 3.142401692457497e-05
regulation O 0 1.3346779041967238e-06
of O 0 5.362722390600538e-07
transmembrane O 0 7.106831617420539e-05
carbonic O 0 0.034923579543828964
anhydrases O 1 0.99906986951828
in O 0 0.00038012018194422126
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9921557307243347
lines O 0 5.144037231730181e-07
by O 0 3.055744102198332e-08
wild O 0 5.115886096973554e-07
- O 0 2.986979552588309e-06
type O 0 1.7605680113774724e-05
von B-Disease 1 0.9991092085838318
Hippel I-Disease 1 0.9999992847442627
- I-Disease 1 0.9908283948898315
Lindau I-Disease 1 0.9985766410827637
transgenes O 0 0.0015551066026091576
. O 0 1.3646511433762498e-05

To O 0 3.8588500501646195e-06
discover O 0 9.432763363292906e-06
genes O 0 7.21675689874246e-07
involved O 0 4.970702320861164e-07
in O 0 4.787604552802804e-07
von B-Disease 1 0.9987879395484924
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9998733997344971
Lindau I-Disease 1 0.9999972581863403
( O 0 1.0819282579177525e-05
VHL B-Disease 1 0.5672709941864014
) O 0 7.246557061080239e-07
- O 0 1.4603508589061676e-06
mediated O 0 2.1277282939990982e-06
carcinogenesis O 0 0.0004018538456875831
, O 0 1.3420786260098794e-08
we O 0 4.899167649341507e-08
used O 0 1.4772670510865282e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999998807907104
lines O 0 7.735649705864489e-05
stably O 0 0.0005033796769566834
transfected O 0 1.2143890671723057e-05
with O 0 1.819177697370833e-08
wild O 0 6.212222274371015e-07
- O 0 2.6542000341578387e-05
type O 0 9.80133845587261e-05
VHL O 1 0.9999793767929077
- O 0 0.00019433799025136977
expressing O 0 1.4844382349110674e-05
transgenes O 0 0.00043482278124429286
. O 0 7.613733941980172e-06

Large O 0 8.058053026616108e-06
- O 0 6.235528871911811e-06
scale O 0 6.297303116298281e-06
RNA O 0 2.4430759367533028e-05
differential O 0 5.145145678397967e-07
display O 0 5.760465526805092e-08
technology O 0 1.4007818549544027e-07
applied O 0 1.1513944464525139e-08
to O 0 3.006211279910076e-09
these O 0 4.5610053511779824e-09
cell O 0 2.4448780777674983e-07
lines O 0 1.0188597521221254e-08
identified O 0 1.101830715555252e-08
several O 0 2.9849167582085556e-09
differentially O 0 1.0688565765804015e-07
expressed O 0 3.7427962951142035e-09
genes O 0 4.4197672188772685e-09
, O 0 1.1690618473281233e-09
including O 0 2.7813409353427687e-09
an O 0 4.009979193142499e-08
alpha O 0 3.2893792649701936e-06
carbonic O 0 2.8901789846713655e-05
anhydrase O 0 6.320140528259799e-05
gene O 0 6.533247187689994e-07
, O 0 1.6766155397363036e-07
termed O 0 1.2042793969158083e-05
CA12 O 0 0.008036105893552303
. O 0 1.4931929399608634e-05

The O 0 6.221616786206141e-06
deduced O 0 1.6245870938291773e-05
protein O 0 8.549961876269663e-07
sequence O 0 4.142932255035703e-07
was O 0 3.401019625925983e-07
classified O 0 2.880127851767611e-07
as O 0 3.474632848110559e-08
a O 0 7.946857039087263e-08
one O 0 6.266799346121843e-08
- O 0 9.526007715976448e-07
pass O 0 1.0130910368388868e-06
transmembrane O 0 0.00018534198170527816
CA O 0 2.179690454795491e-05
possessing O 0 4.091982191312127e-06
an O 0 4.622012284016819e-07
apparently O 0 1.3044618754065596e-05
intact O 0 2.1400084733613767e-05
catalytic O 0 3.238663794036256e-06
domain O 0 8.636419579488575e-07
in O 0 3.471340548344415e-08
the O 0 3.681350619899604e-07
extracellular O 0 0.00014006280980538577
CA O 0 0.002160503529012203
module O 0 0.060471389442682266
. O 0 2.1340576495276764e-05

Reintroduced O 0 3.7110858102096245e-05
wild O 0 1.1676253961923067e-05
- O 0 7.953682506922632e-05
type O 0 3.2222898880718276e-05
VHL B-Disease 1 0.9567388892173767
strongly O 0 1.0999933692801278e-06
inhibited O 0 1.8575982494439813e-06
the O 0 1.4275926218942914e-07
overexpression O 0 6.526017841679277e-07
of O 0 5.208943676393574e-08
the O 0 8.99123762110321e-08
CA12 O 0 0.008570144884288311
gene O 0 9.221099617207074e-08
in O 0 1.6131474822600467e-08
the O 0 3.1778083098288334e-07
parental O 0 0.0002749866689555347
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.00024194431898649782
. O 0 4.106415417481912e-06

Similar O 0 1.6212899254242075e-06
results O 0 2.8448039302020334e-07
were O 0 8.281774199758729e-08
obtained O 0 2.9294699288584525e-07
with O 0 9.061117367537008e-08
CA9 O 1 0.9846758246421814
, O 0 1.4534064973759087e-07
encoding O 0 4.601722878305736e-07
another O 0 7.246785571624059e-07
transmembrane O 0 2.1807049051858485e-05
CA O 0 1.8068242297886172e-06
with O 0 1.8535722290380363e-08
an O 0 3.0750391033507185e-07
intact O 0 6.187641702126712e-05
catalytic O 0 2.1432904759421945e-05
domain O 0 2.6433559469296597e-05
. O 0 2.356496679567499e-06

Although O 0 2.0337424757599365e-06
both O 0 7.816372971092278e-08
domains O 0 7.985470347193768e-07
of O 0 5.499788358065416e-07
the O 0 2.9194984563218895e-06
VHL B-Disease 1 0.9999535083770752
protein O 0 3.6647190881922143e-06
contribute O 0 6.544553343701409e-08
to O 0 2.699546008955167e-08
regulation O 0 3.4271189974788285e-07
of O 0 6.356593758027884e-07
CA12 O 1 0.9880478382110596
expression O 0 2.6229764671370503e-07
, O 0 2.3025966910950046e-08
the O 0 7.466662310662286e-08
elongin O 0 7.565284704469377e-06
binding O 0 1.0852869536392973e-07
domain O 0 6.223880291145178e-07
alone O 0 1.3980539392832725e-07
could O 0 8.252948902054413e-08
effectively O 0 2.248842520202743e-06
regulate O 0 3.1607658456778154e-05
CA9 O 1 0.9999700784683228
expression O 0 2.30702444241615e-05
. O 0 5.399895144364564e-06

We O 0 2.7079498977400362e-05
mapped O 0 0.00016336167755071074
CA12 O 1 0.9880656003952026
and O 0 1.2268747923371848e-05
CA9 O 1 0.9999096393585205
loci O 0 6.274780389503576e-06
to O 0 2.0152873503320734e-07
chromosome O 0 1.0046386705653276e-05
bands O 0 3.1617369131708983e-06
15q22 O 0 0.0004474068700801581
and O 0 2.080704916807008e-06
17q21 O 0 0.02429378032684326
. O 0 1.3139695511199534e-05

2 O 0 1.015926682157442e-05
respectively O 0 2.6618110950948903e-06
, O 0 1.1027794499796073e-07
regions O 0 8.020037967071403e-08
prone O 0 6.217472900971188e-07
to O 0 2.833906620480775e-08
amplification O 0 3.0855076147418004e-06
in O 0 4.0674752455061025e-08
some O 0 6.37019965665786e-08
human O 0 1.6802118807390798e-06
cancers B-Disease 0 0.020384952425956726
. O 0 4.811479811905883e-06

Additional O 0 1.237883680005325e-06
experiments O 0 1.2709256225207355e-06
are O 0 1.7344616409786795e-08
needed O 0 4.618240367904036e-08
to O 0 8.567591081032333e-09
define O 0 1.3483396799074399e-07
the O 0 1.1040885539159717e-07
role O 0 3.483728960418375e-06
of O 0 1.5899413483566605e-05
CA O 0 0.025328872725367546
IX O 1 0.9788572788238525
and O 0 5.84985116347525e-07
CA O 0 0.0005430702003650367
XII O 0 0.011786703951656818
enzymes O 0 1.302889671705998e-07
in O 0 1.8979193328050314e-08
the O 0 2.9111102861634208e-08
regulation O 0 7.85081297749457e-08
of O 0 9.161791325595914e-08
pH O 0 1.7987266573982197e-06
in O 0 2.998356052330564e-08
the O 0 8.846019028396768e-08
extracellular O 0 6.28648376732599e-06
microenvironment O 0 3.922653831978096e-06
and O 0 1.985279718397237e-09
its O 0 1.6293097981900928e-09
potential O 0 7.299651105796556e-09
impact O 0 4.878094372884334e-08
on O 0 1.3487871797224216e-07
cancer B-Disease 0 3.984255454270169e-05
cell O 0 4.894414814771153e-05
growth O 0 3.7270444863679586e-06
. O 0 6.633643465647765e-07

A O 0 3.0873128707753494e-05
gene O 0 1.4525447795676882e-06
encoding O 0 1.0105050023412332e-06
a O 0 6.442376729864918e-07
transmembrane O 0 1.3747954653808847e-05
protein O 0 2.4297136747009063e-07
is O 0 6.216367864908534e-09
mutated O 0 2.1937028193974584e-08
in O 0 1.1526535281802808e-08
patients O 0 7.463743401103784e-08
with O 0 9.578457138559315e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 6.143483005871531e-06
. O 0 2.6653672193788225e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999681711196899
WFS B-Disease 1 1.0
; O 0 2.803280221996829e-05
OMIM O 1 1.0
222300 O 0 0.4314565360546112
) O 0 3.322960253626661e-07
is O 0 5.626552379567329e-08
an O 0 1.3997550922795199e-06
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 0.0001998321822611615
by O 0 9.224491464010498e-07
young O 0 0.00023021086235530674
- O 1 0.6821286082267761
onset O 1 0.9999997615814209
non O 1 0.9999920129776001
- O 1 0.9999818801879883
immune O 1 0.7898197174072266
insulin B-Disease 1 0.9978347420692444
- I-Disease 1 0.9999556541442871
dependent I-Disease 1 0.9999915361404419
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.16246271133422852
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999990463256836
. O 0 4.676336902775802e-05

Linkage O 0 0.0012394824298098683
to O 0 1.3289269418237382e-06
markers O 0 1.4014478438184597e-05
on O 0 2.0149773263256066e-06
chromosome O 0 0.0003088900411967188
4p O 1 0.999993085861206
was O 0 8.537075336789712e-05
confirmed O 0 1.0921110060735373e-06
in O 0 9.189846394974666e-08
five O 0 2.308199498202157e-07
families O 0 5.679102059730212e-07
. O 0 2.8633444344450254e-06

On O 0 2.608503109513549e-06
the O 0 1.973693883883243e-07
basis O 0 7.300955644495843e-07
of O 0 1.9045174894927186e-06
meiotic O 1 0.9763011336326599
recombinants O 1 0.9999634027481079
and O 0 6.334206773317419e-06
disease O 1 0.9996069073677063
- O 0 0.003999041859060526
associated O 0 2.1242663933662698e-05
haplotypes O 0 2.157746894226875e-05
, O 0 8.243084437253856e-08
the O 0 7.770410093144164e-07
WFS B-Disease 0 0.04294120892882347
gene O 0 1.9906350701148767e-07
was O 0 3.2644149428051605e-07
localized O 0 2.0453609295145725e-07
to O 0 3.9297649578884375e-08
a O 0 3.8088626297394512e-06
BAC O 1 0.9985941052436829
/ O 0 0.0013218037784099579
P1 O 0 0.021764229983091354
contig O 0 6.155550363473594e-05
of O 0 2.2251551001772896e-07
less O 0 5.03492927350635e-08
than O 0 4.8866525048651965e-08
250 O 0 1.62249932600389e-06
kb O 0 4.7804394853301346e-05
. O 0 1.6819594748085365e-06

Mutations O 0 9.240356121154036e-06
in O 0 2.059037456092483e-07
a O 0 1.7752435610418615e-07
novel O 0 9.761382671058527e-07
gene O 0 4.442385943548288e-07
( O 0 4.2751193518597574e-07
WFS1 O 0 0.022166050970554352
) O 0 2.804253824706393e-07
encoding O 0 2.0624942465019558e-07
a O 0 1.8457372163993568e-07
putative O 0 2.9558652840933064e-06
transmembrane O 0 2.6046996026707347e-06
protein O 0 5.84008539306069e-08
were O 0 7.025604542576502e-09
found O 0 4.769637573787122e-09
in O 0 1.647204816990211e-09
all O 0 4.007851384102423e-09
affected O 0 1.6609041253445866e-08
individuals O 0 7.81715936426508e-09
in O 0 5.585002682551021e-08
six O 0 3.217744961148128e-05
WFS B-Disease 1 1.0
families O 0 1.6730753671367893e-08
, O 0 2.7637891975018647e-09
and O 0 7.134646207163087e-10
these O 0 1.3884910998740452e-09
mutations O 0 6.7108385515268765e-09
were O 0 1.2989427311538293e-08
associated O 0 4.121532626299995e-08
with O 0 2.487052341848539e-08
the O 0 3.4120823784178356e-06
disease O 0 0.008480141870677471
phenotype O 0 1.9898083337466232e-05
. O 0 3.122441285086097e-06

WFS1 O 1 0.9863576889038086
appears O 0 2.9631328288814984e-06
to O 0 8.388287398020111e-08
function O 0 2.6925275165012863e-07
in O 0 7.354857700647699e-08
survival O 0 1.2675192010647152e-05
of O 0 5.600380518444581e-06
islet O 0 0.3230777978897095
beta O 0 0.00019475129374768585
- O 0 1.9739924027817324e-05
cells O 0 2.6525137286625977e-07
and O 0 2.271676713405668e-08
neurons O 0 1.6152863508978044e-06
. O 0 1.572921064507682e-07
. O 0 9.317085414295434e-07

Stable O 0 0.0019171102903783321
interaction O 0 3.198789954694803e-06
between O 0 1.662502171484448e-07
the O 0 3.982129115343014e-08
products O 0 1.006344518827973e-08
of O 0 5.043762385525952e-08
the O 0 3.563571624454198e-07
BRCA1 O 0 9.005204447021242e-06
and O 0 1.9106616377939645e-07
BRCA2 O 0 0.0014230337692424655
tumor B-Disease 1 0.990729033946991
suppressor O 0 5.7230310630984604e-05
genes O 0 1.0063487110301139e-07
in O 0 5.032337213606297e-08
mitotic O 0 1.073019393516006e-05
and O 0 2.247298169777423e-07
meiotic O 1 0.8213986754417419
cells O 0 0.00010585891868686303
. O 0 5.796528057544492e-06

BRCA1 O 0 0.002513509476557374
and O 0 1.1946715403610142e-06
BRCA2 O 0 1.2900885849376209e-05
account O 0 1.302719567775057e-07
for O 0 4.755031479675154e-09
most O 0 3.2478864042673194e-09
cases O 0 3.6921070645234977e-09
of O 0 2.4035102796915453e-07
familial O 0 0.008961953222751617
, O 0 3.05810914369431e-07
early O 0 0.00402139313519001
onset O 1 1.0
breast B-Disease 1 0.9999639987945557
and I-Disease 0 0.028312381356954575
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.3840198082325514e-06
encode O 0 7.523996714553505e-07
products O 0 4.3924565318320674e-08
that O 0 5.577387884869722e-09
each O 0 2.0191533778302073e-08
interact O 0 1.1449389347717442e-07
with O 0 1.1627427909388643e-07
hRAD51 O 0 0.00011473954509710893
. O 0 8.389442882617004e-06

Results O 0 5.34178161615273e-06
presented O 0 1.2417430070854607e-06
here O 0 2.1129093852323422e-07
show O 0 1.318928042337575e-07
that O 0 1.9274910556532632e-08
BRCA1 O 0 7.161933694987965e-07
and O 0 4.236375872324061e-08
BRCA2 O 0 8.372641786991153e-06
coexist O 0 1.1002294968420756e-06
in O 0 4.630226868584941e-08
a O 0 3.351550219576893e-07
biochemical O 0 5.507535024662502e-05
complex O 0 1.1522496606630739e-05
and O 0 5.183047235846061e-08
colocalize O 0 0.00041362608317285776
in O 0 1.9141559448598855e-07
subnuclear O 0 0.0007061764481477439
foci O 0 2.4672572180861607e-05
in O 0 6.157039678100773e-08
somatic O 0 8.959889328252757e-07
cells O 0 4.5867256659448685e-08
and O 0 4.09597511463744e-09
on O 0 3.440465690118799e-08
the O 0 4.0615368845919875e-08
axial O 0 1.1006381583911207e-07
elements O 0 6.924367568217349e-08
of O 0 4.025651207939518e-07
developing O 0 2.8761965040757786e-06
synaptonemal O 0 0.44203636050224304
complexes O 0 0.00010201909026363865
. O 0 5.172561941435561e-06

Like O 0 0.00012107248767279088
BRCA1 O 0 0.000364435778465122
and O 0 3.2624775485601276e-06
RAD51 O 1 0.9997941851615906
, O 0 4.881543191004312e-06
BRCA2 O 0 4.8550547944614664e-05
relocates O 0 1.3711187420994975e-05
to O 0 6.198114306243951e-07
PCNA O 1 0.9218127727508545
+ O 0 1.0366120477556251e-05
replication O 0 6.517789188364986e-07
sites O 0 1.4529832448317848e-08
following O 0 9.709685500070009e-09
exposure O 0 1.0736808064848447e-07
of O 0 2.2556763212833175e-07
S O 0 3.3006428566295654e-05
phase O 0 9.863853847491555e-06
cells O 0 4.062126492954121e-07
to O 0 1.1242231323649321e-07
hydroxyurea O 0 3.3662538044154644e-05
or O 0 1.1841768809972564e-06
UV O 0 0.0011122316354885697
irradiation O 0 5.751930802944116e-05
. O 0 3.1107990707823774e-06

Thus O 0 3.535328505677171e-05
, O 0 1.6257923789453343e-06
BRCA1 O 0 1.0261291208735202e-05
and O 0 9.13624376153166e-08
BRCA2 O 0 2.2723716028849594e-06
participate O 0 9.529990308010383e-08
, O 0 2.519721142846265e-08
together O 0 2.0986107074350002e-08
, O 0 1.3088907735436806e-08
in O 0 2.9638705711931834e-08
a O 0 1.6233988731073623e-07
pathway O 0 5.518008379112871e-07
( O 0 4.862024383101016e-08
s O 0 2.1717757192618592e-07
) O 0 8.441554122384787e-09
associated O 0 1.204484956218721e-08
with O 0 2.311105085084364e-09
the O 0 5.4351545486497344e-08
activation O 0 2.821959981247346e-07
of O 0 2.3739232801744947e-07
double O 0 1.100442545975966e-06
- O 0 7.445710252795834e-06
strand O 0 3.4820948258129647e-06
break O 0 1.7711203099679551e-06
repair O 0 1.8619810361997224e-05
and O 0 3.137423618682078e-07
/ O 0 0.0001356553693767637
or O 0 3.5247196592536056e-06
homologous O 0 5.172565579414368e-05
recombination O 0 3.74788542103488e-05
. O 0 7.000806363066658e-06

Dysfunction O 1 0.9999967813491821
of O 0 1.2058008906024043e-05
this O 0 1.1829691857201396e-06
pathway O 0 1.2041185982525349e-05
may O 0 3.424027639198357e-08
be O 0 1.3092304129713739e-08
a O 0 7.726326600732136e-08
general O 0 1.3644600471707236e-07
phenomenon O 0 8.239671842602547e-07
in O 0 7.1313976945930335e-09
the O 0 1.835713092646074e-08
majority O 0 4.73842698411886e-09
of O 0 6.171959654466264e-08
cases O 0 2.8710552157917846e-08
of O 0 8.978829100669827e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9999310970306396
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002953445946332067
. O 0 1.9925959350075573e-05

A O 0 8.234319102484733e-05
novel O 0 3.8304504414554685e-05
Arg362Ser O 0 0.0007377733709290624
mutation O 0 6.10599215633556e-07
in O 0 6.183778822332897e-08
the O 0 1.8732198725501803e-07
sterol O 0 3.6274550438974984e-06
27 O 0 5.6270737331942655e-06
- O 0 6.391732313204557e-06
hydroxylase O 0 9.756712643138599e-06
gene O 0 4.2631410224203137e-07
( O 0 1.464744201484791e-07
CYP27 O 0 0.00039767607813701034
) O 0 3.869016396151892e-08
: O 0 3.346214194621666e-09
its O 0 1.8174461935416275e-09
effects O 0 1.7385486827947716e-08
on O 0 5.339227371337074e-08
pre O 0 4.472150976653211e-06
- O 0 1.1110264495073352e-06
mRNA O 0 1.463348212382698e-06
splicing O 0 3.6278041193327226e-07
and O 0 1.334989008228149e-08
enzyme O 0 3.7209531456028344e-07
activity O 0 1.2821378732041921e-06
. O 0 1.0275971362716518e-06

A O 0 2.463920827722177e-05
novel O 0 5.661280283675296e-06
C O 0 7.997009561222512e-06
to O 0 9.839746439865849e-08
A O 0 1.8471828298061155e-06
mutation O 0 8.174757226697693e-08
in O 0 4.011631560274509e-08
the O 0 2.2309048119950603e-07
sterol O 0 2.2148367406771285e-06
27 O 0 2.6309583063266473e-06
- O 0 3.603739287427743e-06
hydroxylase O 0 5.8481391533860005e-06
gene O 0 2.0878155737591442e-07
( O 0 1.2154927730989584e-07
CYP27 O 0 4.453308065421879e-05
) O 0 2.7339112307345204e-08
was O 0 3.471075871175344e-08
identified O 0 8.20139689494681e-09
by O 0 1.19397922659914e-08
sequencing O 0 5.067614665676956e-07
amplified O 0 2.598013907118002e-06
CYP27 O 0 6.0424121329560876e-05
gene O 0 1.2889712763808348e-07
products O 0 1.2123329895530333e-08
from O 0 2.4504283047122044e-08
a O 0 2.176500970563211e-07
patient O 0 8.04496266937349e-07
with O 0 3.9124293493841833e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 0.401782363653183
CTX B-Disease 1 0.9999915361404419
) O 0 2.769342472674907e-06
. O 0 2.260115024910192e-06

The O 0 8.81947562447749e-06
mutation O 0 2.215595259258407e-06
changed O 0 1.3094072528474499e-06
the O 0 7.216673907350923e-07
adrenodoxin O 0 0.00012950001109857112
cofactor O 0 1.5223584341583773e-05
binding O 0 6.207756086951122e-07
residue O 0 5.5017953854985535e-06
362Arg O 0 8.42592453409452e-06
to O 0 3.282245870650513e-07
362Ser O 0 4.8522637371206656e-05
( O 0 4.893899131275248e-06
CGT O 0 0.0001588643208378926
362Arg O 0 2.6741368856164627e-05
to O 0 8.773067179390637e-07
AGT O 0 0.09041184931993484
362Ser O 0 9.015782779897563e-06
) O 0 5.1266113132442115e-08
, O 0 5.756573884241334e-09
and O 0 2.4428576939072855e-09
was O 0 2.851855640528811e-07
responsible O 0 4.98427880302188e-07
for O 0 3.5118989671900636e-07
deficiency O 1 0.9992305040359497
in O 0 7.348399435613828e-07
the O 0 6.119783392932732e-06
sterol O 0 2.6376852474641055e-05
27 O 0 8.002013601071667e-06
- O 0 1.1248015653109178e-05
hydroxylase O 0 8.316475032188464e-06
activity O 0 1.7630534898671613e-07
, O 0 2.886135996860162e-09
as O 0 1.5121427443531843e-09
confirmed O 0 2.5371489353887e-09
by O 0 1.6302953431690526e-09
expression O 0 1.162411944477526e-08
of O 0 1.7969172816378887e-08
mutant O 0 2.70337267238574e-07
cDNA O 0 9.659553370511276e-07
into O 0 1.0535004690837013e-07
COS O 0 0.00019519802299328148
- O 0 8.63289005792467e-06
1 O 0 3.3553410503373016e-06
cells O 0 1.321202034887392e-06
. O 0 9.010531698550039e-07

Quantitative O 0 1.80312435986707e-05
analysis O 0 1.1525894478836562e-06
showed O 0 1.8131335366433632e-07
that O 0 2.709500623865324e-09
the O 0 1.578712272021221e-08
expression O 0 5.01605583735909e-08
of O 0 1.7595311874174513e-07
CYP27 O 0 0.006054338999092579
gene O 0 3.1127527222452045e-07
mRNA O 0 5.018955562263727e-07
in O 0 1.6586627182846314e-08
the O 0 5.193427909944148e-08
patient O 0 8.626412295598129e-08
represented O 0 4.286173975742713e-07
52 O 0 5.512792995432392e-06
. O 0 2.325057039342937e-06

5 O 0 2.0045077690156177e-05
% O 0 1.1556713843674515e-06
of O 0 5.055368887951772e-07
the O 0 8.936235076362209e-07
normal O 0 1.3911680071032606e-05
level O 0 2.5506409656372853e-05
. O 0 4.165194241068093e-06

As O 0 1.4242978068068624e-06
the O 0 4.709524716872693e-07
mutation O 0 2.7934461854783876e-07
occurred O 0 4.188804723526118e-06
at O 0 7.482793193958059e-07
the O 0 2.795802060973074e-07
penultimate O 0 2.5389001166331582e-05
nucleotide O 0 3.754034196390421e-06
of O 0 5.397286599873041e-07
exon O 0 1.0537793286857777e-06
6 O 0 5.34202911239845e-07
( O 0 8.261374517815057e-08
- O 0 1.0799635674629826e-07
2 O 0 5.8666341118396304e-08
position O 0 6.181950595873786e-08
of O 0 1.2722325948288926e-07
exon O 0 1.963546083061374e-06
6 O 0 1.9046066199734923e-06
- O 0 7.079182978486642e-06
intron O 0 3.7013411201769486e-05
6 O 0 8.993224582809489e-07
splice O 0 2.25026724365307e-06
site O 0 1.8582667848932033e-07
) O 0 9.024944347402197e-09
of O 0 1.125789061973137e-08
the O 0 3.772160539483593e-08
gene O 0 3.9705554399915854e-08
, O 0 1.1744687888892713e-08
we O 0 3.321385122490028e-08
hypothesized O 0 4.27728878094058e-07
that O 0 6.270036934097334e-09
the O 0 2.6181174561656917e-08
mutation O 0 3.482016808220578e-08
may O 0 1.967574192462962e-08
partially O 0 5.977244654786773e-07
affect O 0 5.874237274383631e-08
the O 0 3.9691393283192156e-08
normal O 0 2.9239436116768047e-07
splicing O 0 1.7803110097247554e-07
efficiency O 0 2.1412841277879124e-08
in O 0 4.623279536986047e-09
exon O 0 1.5224236449284945e-07
6 O 0 2.1206933098483205e-08
and O 0 1.5901983063670855e-09
cause O 0 5.9737543800508774e-09
alternative O 0 1.1051267456707592e-08
splicing O 0 1.1760630513890646e-07
elsewhere O 0 1.2104845126259534e-08
, O 0 1.895154699838031e-09
which O 0 6.54266252286817e-10
resulted O 0 2.899440154635613e-08
in O 0 1.4363841671638511e-08
decreased O 0 3.036067028006073e-06
transcript O 0 4.469196937861852e-06
in O 0 4.4591093484314115e-08
the O 0 3.0597337286053516e-07
patient O 0 2.285500841026078e-06
. O 0 2.549404598539695e-06

Transfection O 1 0.6035357713699341
of O 0 1.4850839761493262e-05
constructed O 0 0.0006009807693772018
minigenes O 0 0.015693053603172302
, O 0 1.922960279898689e-07
with O 0 1.0299814334757684e-08
or O 0 2.7920044942675304e-08
without O 0 2.552556566115527e-08
the O 0 4.624269323016961e-08
mutation O 0 1.5993306234918236e-08
, O 0 6.32576124814932e-09
into O 0 8.463435818839571e-08
COS O 1 0.9948124885559082
- O 0 1.9990633518318646e-05
1 O 0 5.643947815769934e-07
cells O 0 3.820208860361163e-08
confirmed O 0 8.155068620396833e-09
that O 0 9.283969704121375e-10
the O 0 1.2742076727079166e-08
mutant O 0 4.646079787562485e-07
minigene O 0 4.380553036753554e-06
was O 0 1.529550104351074e-07
responsible O 0 4.604747871894688e-08
for O 0 5.205513797790218e-09
a O 0 7.200093676829056e-08
mRNA O 0 4.3517786707525374e-07
species O 0 3.789798252995524e-09
alternatively O 0 1.9465331035917188e-07
spliced O 0 9.623014420867548e-07
at O 0 4.600555882916524e-07
an O 0 1.5188720681180712e-07
activated O 0 2.879061639760039e-06
cryptic O 0 5.6232438510051e-06
5 O 0 1.0193095931754215e-06
splice O 0 5.282953225105302e-06
site O 0 9.505924936092924e-07
88 O 0 7.747634640509204e-07
bp O 0 1.7565363350513508e-06
upstream O 0 6.418251814466203e-07
from O 0 1.8885272012880705e-08
the O 0 4.0112031030048456e-08
3 O 0 1.6422812620930927e-07
end O 0 5.70228678498097e-07
of O 0 1.2807031453121454e-06
exon O 0 3.10262585117016e-05
6 O 0 1.1715953405655455e-05
. O 0 4.228660600347212e-06

Our O 0 5.686196800525067e-06
data O 0 1.1215047379664611e-06
suggest O 0 1.351112359770923e-07
that O 0 8.935943540677727e-09
the O 0 5.0646235649765003e-08
C O 0 6.355654136314115e-07
to O 0 2.0343845719139608e-08
A O 0 5.39257428044948e-07
mutation O 0 3.5011698429343596e-08
at O 0 6.717512945897397e-08
the O 0 3.343676624467662e-08
penultimate O 0 3.0258690912887687e-06
nucleotide O 0 4.443687089406012e-07
of O 0 1.4320050922833616e-07
exon O 0 1.2870184491475811e-06
6 O 0 1.4552442451076786e-07
of O 0 3.960661842938862e-08
the O 0 6.085424075763513e-08
CYP27 O 0 0.029988696798682213
gene O 0 7.188100425992161e-08
not O 0 5.031941086031111e-09
only O 0 1.5970199385151318e-08
causes O 0 1.335399417712324e-07
the O 0 5.786607744084904e-07
deficiency B-Disease 0 0.2989446222782135
in I-Disease 0 2.288743417011574e-07
the I-Disease 0 9.72128646026249e-07
sterol I-Disease 0 4.321399501350243e-06
27 I-Disease 0 2.705995711949072e-06
- I-Disease 0 2.1484163426066516e-06
hydroxylase I-Disease 0 9.87359271675814e-07
activity I-Disease 0 3.072013754490399e-08
, O 0 6.180376765918538e-10
but O 0 3.2227875923496185e-10
also O 0 8.467851975169083e-10
partially O 0 2.632629048093804e-08
leads O 0 5.498800526027026e-09
to O 0 1.7670547247661261e-09
alternative O 0 1.5959969346113212e-08
pre O 0 2.088999508487177e-06
- O 0 5.534936917683808e-07
mRNA O 0 5.003996648156317e-07
splicing O 0 2.5159951633213495e-07
of O 0 3.1912705367176386e-08
the O 0 1.1549272471711447e-07
gene O 0 9.319636546933907e-07
. O 0 6.087920496611332e-07

To O 0 1.4309105154097779e-06
our O 0 6.171513291519659e-07
knowledge O 0 2.337493924642331e-06
, O 0 2.935677834159378e-08
this O 0 8.654771121996419e-09
is O 0 4.5073518251115274e-09
the O 0 3.202482501407644e-09
first O 0 4.950621690369417e-09
report O 0 1.0849408482727085e-08
regarding O 0 1.7574157240574095e-08
effects O 0 2.436014767681627e-08
on O 0 2.169816681885095e-08
pre O 0 2.717327788559487e-06
- O 0 4.880281494479277e-07
mRNA O 0 3.3624672823862056e-07
splicing O 0 6.277769415419243e-08
of O 0 4.336182968245339e-09
a O 0 5.0652393390748784e-09
mutation O 0 1.6143287817627083e-09
at O 0 2.6915977002772706e-08
the O 0 3.106654844486911e-08
- O 0 2.756468688858149e-07
2 O 0 1.9244500037984835e-07
position O 0 2.9908909482401214e-07
of O 0 2.2065232485601882e-07
a O 0 8.464580218969786e-07
5 O 0 2.501725703041302e-06
splice O 0 2.5057011953322217e-05
site O 0 7.86648342909757e-06
. O 0 3.0978262657299638e-06

ATM O 0 0.01166178472340107
germline O 0 0.0005718506290577352
mutations O 0 2.0723043689940823e-06
in O 0 6.470712605732842e-07
classical O 1 0.9970113039016724
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 1.6828556908876635e-05
in O 0 3.18865431836457e-08
the O 0 1.8839908477730205e-07
Dutch O 0 0.00024009833578020334
population O 0 3.007930899912026e-07
. O 0 6.653233413089765e-07

Germline O 0 0.016538651660084724
mutations O 0 9.831695706452592e-07
in O 0 1.1364461016682981e-07
the O 0 2.9960696679154353e-07
ATM O 0 6.546551594510674e-05
gene O 0 2.857266601097308e-08
are O 0 8.361205061646615e-10
responsible O 0 2.8492449288819444e-08
for O 0 4.8989619472195045e-08
the O 1 0.9980904459953308
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999986886978149
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.7578251572558656e-05
. O 0 4.359664671937935e-06

In O 0 2.4550140551582444e-06
our O 0 4.888181592832552e-07
study O 0 2.351839754055618e-07
, O 0 1.3174567214946364e-08
we O 0 4.332958436492618e-09
have O 0 2.1987618392671493e-09
determined O 0 4.640704176495092e-08
the O 0 9.509254539352696e-08
ATM O 0 1.2297236025915481e-05
mutation O 0 9.43292821631303e-09
spectrum O 0 1.483187261897001e-08
in O 0 7.183218908579647e-09
19 O 0 1.8793825518059748e-07
classical O 0 1.1569733942451421e-05
A B-Disease 1 0.9999942779541016
- I-Disease 1 0.9954715967178345
T I-Disease 1 0.9999988079071045
patients O 0 1.995488929651401e-08
, O 0 1.2773143653888042e-09
including O 0 6.820599085521906e-10
some O 0 6.859686707549884e-10
immigrant O 0 1.5578187628761953e-08
populations O 0 2.1553376861049856e-09
, O 0 7.937244750344519e-10
as O 0 1.9471630974265963e-09
well O 0 2.891386907677429e-09
as O 0 4.299764100323955e-09
12 O 0 3.450547225725131e-08
of O 0 2.357812789455238e-08
Dutch O 0 1.2819863286495092e-06
ethnic O 0 2.4812820242914313e-07
origin O 0 1.930106918734964e-06
. O 0 1.618870442143816e-06

Both O 0 1.0692965588532388e-06
the O 0 7.023074886092218e-07
protein O 0 7.191083000179788e-07
truncation O 0 4.903392436972354e-06
test O 0 3.08955435457392e-07
( O 0 1.0529234941714094e-06
PTT O 0 2.734948975557927e-05
) O 0 1.2398002624536275e-08
and O 0 1.5596375302351362e-09
the O 0 8.995299616287866e-09
restriction O 0 5.0191562905865794e-08
endonuclease O 0 8.087733931461116e-07
fingerprinting O 0 4.5508315338338434e-07
( O 0 1.8641381416273362e-07
REF O 0 3.072298932238482e-05
) O 0 6.783626993467351e-09
method O 0 4.5174042284656934e-09
were O 0 2.4466069170614446e-09
used O 0 2.9771896059571645e-09
and O 0 2.11103068359364e-09
compared O 0 1.401885096896649e-08
for O 0 2.087344075363262e-09
their O 0 3.960614503029092e-09
detection O 0 1.1128816623795501e-07
efficiency O 0 3.722216490587016e-08
, O 0 3.261568570778195e-09
identifying O 0 8.682420116201683e-08
76 O 0 3.208886312222603e-07
% O 0 1.2069203414455387e-08
and O 0 1.1258357579535527e-09
60 O 0 2.657632869329518e-08
% O 0 3.821707839080091e-09
of O 0 5.885314457998447e-09
the O 0 1.0724094501313175e-08
mutations O 0 1.416160966272173e-08
, O 0 3.236793588712317e-08
respectively O 0 1.261790771422966e-06
. O 0 1.2639006854442414e-06

Most O 0 1.2111746627851971e-06
patients O 0 1.2626897216705402e-07
were O 0 8.510687621310353e-08
found O 0 8.446969701481066e-08
to O 0 1.008025876103602e-07
be O 0 1.3174990272091236e-06
compound O 0 0.0029258066788315773
heterozygote O 0 0.0010435247095301747
. O 0 8.97122754395241e-06

Seventeen O 0 4.38437782577239e-05
mutations O 0 7.633602763235103e-07
were O 0 2.308670588035966e-07
distinct O 0 1.0728393817771575e-07
, O 0 2.6350504001015906e-08
of O 0 8.962592090711041e-08
which O 0 1.4709407025748078e-08
10 O 0 3.61940593052168e-08
were O 0 4.374280493379956e-08
not O 0 5.10832975919584e-08
reported O 0 1.294890466851939e-06
previously O 0 2.5003710106830113e-06
. O 0 1.3423267546386342e-06

Mutations O 0 1.3732807019550819e-05
are O 0 7.839381055418926e-08
small O 0 2.033345509744322e-07
deletions O 0 1.0358266990806442e-06
or O 0 4.19493460412923e-07
point O 0 5.083130872662878e-06
mutations O 0 9.644751344239921e-07
frequently O 0 1.0157880296901567e-06
affecting O 0 4.359094873507274e-06
splice O 0 3.972963895648718e-05
sites O 0 3.943930096284021e-06
. O 0 3.178852239216212e-06

Moreover O 0 0.00015769107267260551
, O 0 1.7980526081373682e-06
a O 0 6.877423402329441e-06
16 O 0 1.3209714779804926e-05
. O 0 2.7945304736931575e-06

7 O 0 0.00014959370309952646
- O 0 5.761043576058e-05
kb O 0 0.00013721888535656035
genomic O 0 7.111743798304815e-06
deletion O 0 2.014687197515741e-06
of O 0 2.23471005256215e-07
the O 0 9.113687582384955e-08
3 O 0 1.1650449494027271e-07
end O 0 8.362584225096725e-08
of O 0 2.6173783140848172e-08
the O 0 3.647202007073247e-08
gene O 0 2.1131386418460352e-08
, O 0 2.16312945333641e-09
most O 0 8.289762765123498e-10
likely O 0 2.829023015848975e-09
a O 0 1.8535509127559635e-08
result O 0 1.3163966805507243e-08
of O 0 3.891159394697752e-08
recombination O 0 7.992824890834527e-08
between O 0 1.7844714150783147e-08
two O 0 8.48292192046074e-09
LINE O 0 2.5155969751722296e-07
elements O 0 3.216042543385811e-08
, O 0 2.5228565903034905e-08
was O 0 8.464708685096412e-07
identified O 0 2.0061399936821545e-06
. O 0 1.4631334579462418e-06

The O 0 2.1858229501958704e-06
most O 0 3.49777948827068e-08
frequently O 0 2.8969417087409965e-08
found O 0 1.1643602526589802e-08
mutation O 0 6.698587462494743e-09
, O 0 2.017235489759628e-09
identified O 0 2.7889175413520206e-08
in O 0 8.294907871686519e-09
three O 0 1.0840989439486748e-08
unrelated O 0 8.222779115385492e-07
Turkish O 0 2.825319825205952e-05
A B-Disease 1 1.0
- I-Disease 1 0.9993888139724731
T I-Disease 1 0.999879002571106
individuals O 0 5.053736096272132e-09
, O 0 3.064123843543598e-09
was O 0 4.9695838555408045e-08
previously O 0 1.5027760369434873e-08
described O 0 8.408355789413235e-09
to O 0 1.3691799916060177e-09
be O 0 2.554863876014224e-09
a O 0 5.690541726721676e-08
Turkish O 0 1.9921403691114392e-06
A B-Disease 1 0.9999270439147949
- I-Disease 1 0.8013834357261658
T I-Disease 1 0.9999039173126221
founder O 0 9.646076068747789e-05
mutation O 0 1.5261130101862364e-06
. O 0 7.572391496069031e-07

The O 0 4.462701781449141e-06
presence O 0 9.925206541083753e-07
of O 0 2.544327628584142e-07
a O 0 4.3487170842126943e-07
founder O 0 7.90143803897081e-06
mutation O 0 1.856848896863994e-08
among O 0 8.905754467214422e-10
relatively O 0 4.642082718220308e-09
small O 0 3.138510784594928e-09
ethnic O 0 5.0367421344788e-09
population O 0 1.372220670425861e-09
groups O 0 4.0173395166043235e-10
in O 0 2.0037451697874076e-09
Western O 0 4.6341057213794556e-08
Europe O 0 2.6098010863506715e-08
could O 0 7.556950620823955e-09
indicate O 0 5.415483173010216e-08
a O 0 2.8066770241252925e-08
high O 0 4.3672777394476725e-08
carrier O 0 3.4282557237474975e-08
frequency O 0 2.4345933269387388e-08
in O 0 5.7782671980532996e-09
such O 0 8.144809271470876e-09
communities O 0 6.949480280127318e-08
. O 0 8.163723350662622e-07

In O 0 3.1062190828379244e-06
patients O 0 2.7973038640993764e-07
of O 0 1.5948593556913693e-07
Dutch O 0 9.827244866755791e-06
ethnic O 0 1.0400180627812006e-07
origin O 0 1.2496414569795888e-07
, O 0 1.1871531313545347e-08
however O 0 1.264648741283736e-08
, O 0 7.571204996281722e-09
no O 0 3.3936316867766436e-08
significant O 0 7.483943420538708e-08
founder O 0 1.3861376828572247e-06
effect O 0 4.854426194356165e-08
could O 0 1.552201212007276e-08
be O 0 6.646701677937017e-08
identified O 0 3.0157514174788957e-06
. O 0 3.02640592053649e-06

The O 0 7.702064067416359e-06
observed O 0 8.790246283751912e-06
genetic O 0 1.1815905963885598e-05
heterogeneity O 0 4.599871772370534e-06
including O 0 7.38520711252022e-08
the O 0 1.1389796128469243e-07
relative O 0 5.391013928601751e-06
high O 0 1.700351958788815e-06
percentage O 0 5.642564815389051e-07
of O 0 3.285089462679025e-07
splice O 0 2.1356392608140595e-05
- O 0 3.778774726015399e-06
site O 0 4.2848580505960854e-07
mutations O 0 2.18461693179961e-08
had O 0 2.4744897686446166e-08
no O 0 5.840965400238929e-08
reflection O 0 5.23881453773356e-07
on O 0 2.541063963690249e-07
the O 0 6.854198772998643e-07
phenotype O 0 7.31696309230756e-06
. O 0 1.893181433842983e-06

All O 0 9.681751862444798e-07
patients O 0 1.7443622368773504e-07
manifested O 0 1.1731980293916422e-06
classical O 0 0.00030074131791479886
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9995197057723999
T I-Disease 1 0.9998138546943665
and O 0 5.7835187305954605e-08
increased O 0 5.235727940089419e-07
cellular O 0 5.807073193864198e-06
radioresistant O 0 5.675941065419465e-05
DNA O 0 2.3439461074303836e-05
synthesis O 0 1.6668389434926212e-05
. O 0 1.5664631973777432e-06

Determination O 0 2.0943711206200533e-05
of O 0 1.9125952803733526e-06
the O 0 7.702958555455552e-07
genomic O 0 3.8429848245868925e-06
structure O 0 7.421171517307812e-07
of O 0 4.091316441190429e-07
the O 0 1.4407215758183156e-06
COL4A4 O 1 0.9999003410339355
gene O 0 1.7677778885172302e-07
and O 0 9.10920050500863e-09
of O 0 3.0078820145718055e-07
novel O 0 1.497913763159886e-05
mutations O 0 1.918591806315817e-05
causing O 0 0.008149716071784496
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.026540860533714294

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.2067320717033e-05
a O 0 0.0005155594553798437
progressive O 1 0.9999969005584717
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.4694252610206604
by O 0 8.496289228787646e-05
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9971376657485962
abnormalities I-Disease 0 0.23915641009807587
and O 0 3.559671313269064e-08
associated O 0 3.002299138188391e-07
with O 0 3.7151803411461515e-08
mutations O 0 1.9573467113787046e-07
in O 0 1.1140029698708531e-07
either O 0 6.319408498711709e-07
the O 0 8.45199974719435e-06
COL4A3 O 1 0.9999997615814209
or O 0 1.665487161517376e-06
the O 0 2.6047368919535074e-06
COL4A4 O 1 0.999963641166687
gene O 0 4.757374654218438e-07
, O 0 1.328722021298745e-08
which O 0 4.890407634405847e-09
encode O 0 6.471083224823815e-08
the O 0 1.1818961809240136e-07
alpha3 O 0 9.322367986897007e-05
and O 0 4.4574261437446694e-07
alpha4 O 1 0.9040064811706543
type O 1 0.6729894876480103
IV O 1 1.0
collagen O 1 0.9999860525131226
chains O 0 0.0004608204762917012
, O 0 1.1952264458159334e-06
respectively O 0 2.0292231056373566e-05
. O 0 5.802129635412712e-06

To O 0 1.1168714308951166e-06
date O 0 2.3216894078359473e-06
, O 0 7.962970016706095e-08
mutation O 0 4.212854776142194e-08
screening O 0 3.992205321878828e-08
in O 0 3.641437817947235e-09
the O 0 8.06002908859682e-09
two O 0 5.052088081214379e-09
genes O 0 1.5757009919070697e-08
has O 0 2.7479727382484498e-09
been O 0 1.6962811599796623e-08
hampered O 0 5.946507712906168e-07
by O 0 1.1576902991805582e-08
the O 0 5.2202320688365944e-08
lack O 0 1.1405165167843734e-07
of O 0 1.0914981629639442e-07
genomic O 0 1.6874267885214067e-06
structure O 0 1.2873327932538814e-06
information O 0 1.1377467217243975e-06
. O 0 9.079660685529234e-07

We O 0 8.6034087871667e-06
report O 0 1.5968150819389848e-06
here O 0 3.1665149435866624e-07
the O 0 1.107727101157252e-07
complete O 0 7.759613254165743e-07
characterization O 0 2.9726231787208235e-06
of O 0 1.8112289978944318e-07
the O 0 2.6950786491397594e-07
48 O 0 1.2244132676642039e-06
exons O 0 3.7333870750444476e-07
of O 0 7.961102710396517e-08
the O 0 2.3869083065619634e-07
COL4A4 O 0 0.0363033264875412
gene O 0 1.3835898471370456e-07
, O 0 6.381239092689839e-09
a O 0 4.179448254149065e-08
comprehensive O 0 2.867209047963115e-07
gene O 0 6.236857075236912e-08
screen O 0 1.3597198744719208e-07
, O 0 3.9064169676805705e-09
and O 0 1.9129864359257454e-09
the O 0 1.2004414351451942e-08
subsequent O 0 1.343585296353922e-07
detection O 0 1.662308761751774e-07
of O 0 2.440083690657957e-08
10 O 0 1.1720966419659362e-08
novel O 0 5.816662707047726e-08
mutations O 0 5.117561929779413e-09
in O 0 3.1327156424509894e-09
eight O 0 6.257005225052126e-08
patients O 0 1.6795505075606343e-07
diagnosed O 0 7.069925050018355e-05
with O 0 9.73215173871722e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0014725903747603297

Furthermore O 0 1.4190063666319475e-05
, O 0 2.2491848028494132e-07
we O 0 1.1412694789214584e-07
identified O 0 4.029876663480536e-07
a O 0 2.0298968195220368e-07
glycine O 0 4.434639890860126e-07
to O 0 5.4645507674422333e-08
alanine O 0 1.5884112372077652e-06
substitution O 0 2.2787422437886562e-07
in O 0 7.115015421277349e-08
the O 0 2.505651082174154e-07
collagenous O 0 0.00015498251013923436
domain O 0 6.015742997078632e-07
that O 0 5.233548705518842e-09
is O 0 1.217161482713891e-08
apparently O 0 1.4905671719134261e-07
silent O 0 7.074951327012968e-07
in O 0 2.2199255766963688e-08
the O 0 5.4432991447583845e-08
heterozygous O 0 1.160706517566723e-07
carriers O 0 3.653356728250401e-08
, O 0 1.3156285838533677e-08
in O 0 5.544637105003858e-08
11 O 0 2.428894504191703e-06
. O 0 1.1174712426509359e-06

5 O 0 8.291402082249988e-06
% O 0 2.600381208139879e-07
of O 0 6.87450594227812e-08
all O 0 8.991542621572535e-09
control O 0 1.1107292863243856e-07
individuals O 0 8.43677394612996e-09
, O 0 7.671271617937236e-09
and O 0 6.992744161493647e-09
in O 0 1.5793236940453426e-08
one O 0 2.6598947044931265e-08
control O 0 3.583302543574973e-08
individual O 0 4.813377252332884e-09
homozygous O 0 2.1399774396968496e-08
for O 0 3.2708011854509778e-09
this O 0 2.018321865193684e-08
glycine O 0 1.2990005870960886e-06
substitution O 0 7.826112664588436e-07
. O 0 6.966041610212415e-07

There O 0 2.522080649214331e-06
has O 0 4.58453008889137e-08
been O 0 3.4527587899901846e-08
no O 0 2.608268445669637e-08
previous O 0 9.243515819434833e-08
finding O 0 1.5208215131679026e-07
of O 0 9.620300289725492e-08
a O 0 1.1244976860780298e-07
glycine O 0 4.1546832107997034e-07
substitution O 0 7.410534408336389e-08
that O 0 4.112892693086678e-09
is O 0 2.204321614129867e-09
not O 0 1.473042798849633e-09
associated O 0 7.751076225304132e-09
with O 0 1.8895818243436224e-09
any O 0 3.2354048329352736e-08
obvious O 0 6.927002118573e-07
phenotype O 0 5.85312648127001e-07
in O 0 5.433848926372775e-08
homozygous O 0 7.425347803291515e-07
individuals O 0 1.1529815679978128e-07
. O 0 1.8095971654474852e-06

Founder O 1 0.9031915068626404
BRCA1 O 0 0.0005644008633680642
and O 0 3.430608046528505e-07
BRCA2 O 0 6.982882496231468e-06
mutations O 0 1.593562615198607e-07
in O 0 6.10260357802872e-08
French O 0 1.0893162652791943e-05
Canadian O 1 0.7520698308944702
breast B-Disease 1 1.0
and I-Disease 1 0.9999910593032837
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.004880632273852825
. O 0 1.9028988390346058e-05

We O 0 1.5629608469680534e-06
have O 0 7.534832491273846e-08
identified O 0 1.484503968640638e-07
four O 0 4.8684462683468155e-08
mutations O 0 1.5622701354800483e-08
in O 0 2.9977598181574194e-09
each O 0 2.7346920283832787e-09
of O 0 4.387064578281752e-08
the O 0 7.754680154903326e-06
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999996423721313
- O 1 0.999123752117157
susceptibility O 0 0.0022043504286557436
genes O 0 2.383109887205137e-07
, O 0 2.5262274050419364e-08
BRCA1 O 0 3.6499130828815396e-07
and O 0 8.178277610682017e-09
BRCA2 O 0 2.818920563640859e-07
, O 0 5.583636220052313e-09
in O 0 5.6484417143565224e-09
French O 0 8.290496111840184e-07
Canadian O 0 0.0003705027629621327
breast B-Disease 1 0.9971467852592468
cancer I-Disease 0 0.0977923646569252
and O 0 0.0001565873681101948
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.433238584373612e-06
from O 0 5.537900960916886e-06
Quebec O 0 0.00014285498764365911
. O 0 6.159286840556888e-06

To O 0 1.309345975641918e-06
identify O 0 2.5437409476580797e-06
founder O 0 1.5496076230192557e-05
effects O 0 3.132591245957883e-06
, O 0 3.415443927679007e-08
we O 0 2.1712574849175326e-08
examined O 0 9.971184766754959e-08
independently O 0 1.248073999704502e-07
ascertained O 0 1.7667746305960463e-06
French O 0 1.5779196473886259e-06
Canadian O 0 1.1415341759857256e-05
cancer B-Disease 0 2.379590341661242e-06
families O 0 4.912629858466744e-09
for O 0 2.0974451064859068e-09
the O 0 1.079732481201745e-08
distribution O 0 8.903787929170903e-09
of O 0 2.1306915343188848e-08
these O 0 8.478102664355447e-09
eight O 0 2.0367185982195224e-07
mutations O 0 5.403998102337937e-07
. O 0 6.298362791312684e-07

Mutations O 0 1.3625991414301097e-05
were O 0 7.358659104284015e-07
found O 0 3.231714060802915e-07
in O 0 1.4582964524834097e-07
41 O 0 2.264181603095494e-06
of O 0 4.003318281320389e-06
97 O 0 0.00039143417961895466
families O 0 3.121973804809386e-06
. O 0 6.14960254097241e-06

Six O 0 6.348152055579703e-06
of O 0 8.039402246140526e-07
eight O 0 4.623837241979345e-07
mutations O 0 1.56174650101093e-07
were O 0 2.6926997520604345e-07
observed O 0 1.1796940952990553e-06
at O 0 1.552520302539051e-06
least O 0 4.6423241428783513e-07
twice O 0 2.906261443058611e-06
. O 0 1.9097810763923917e-06

The O 0 0.00015737848298158497
BRCA1 O 0 0.0013642156263813376
C4446T O 0 0.000489438942167908
mutation O 0 9.295811196352588e-07
was O 0 7.304653308892739e-07
the O 0 3.829079275874392e-08
most O 0 4.405736664381266e-09
common O 0 4.598443403835972e-09
mutation O 0 8.237643456254773e-09
found O 0 1.0086889545846134e-08
, O 0 3.531530401446048e-09
followed O 0 4.527412755805926e-08
by O 0 2.508902241515898e-08
the O 0 5.419656758931524e-07
BRCA2 O 0 1.3056740499450825e-05
8765delAG O 0 5.073936699773185e-05
mutation O 0 1.9023827917408198e-06
. O 0 1.9135550246573985e-06

Together O 0 3.0099533887550933e-06
, O 0 7.015966474455126e-08
these O 0 8.713555210704271e-09
mutations O 0 1.4769625522603747e-08
were O 0 2.741127147487532e-08
found O 0 3.5058945968557964e-08
in O 0 2.8840407395591683e-08
28 O 0 4.1587742316551157e-07
of O 0 2.5138271553259983e-07
41 O 0 5.766785875493952e-07
families O 0 1.0675806905169338e-08
identified O 0 5.6809984272376823e-08
to O 0 1.1217294648702136e-08
have O 0 2.0569995484720494e-08
a O 0 6.861039878458541e-07
mutation O 0 1.1575973530852934e-06
. O 0 9.19908529795066e-07

The O 0 1.345522832707502e-05
odds O 0 1.8769782400340773e-05
of O 0 4.923467145090399e-07
detection O 0 1.7771436660041218e-06
of O 0 1.523977886108696e-07
any O 0 7.278966052126634e-08
of O 0 1.8657816269751493e-07
the O 0 2.723816976413218e-07
four O 0 3.593264636947424e-07
BRCA1 O 0 4.581122539093485e-06
mutations O 0 1.8028021031568642e-07
was O 0 5.026911821914837e-06
18 O 0 1.2185399100417271e-05
. O 0 6.748141458956525e-06

7x O 1 0.6604582071304321
greater O 0 2.7162111564393854e-06
if O 0 5.638111133521306e-08
one O 0 1.96674498909033e-08
or O 0 4.765145611429489e-09
more O 0 9.721132787632314e-10
cases O 0 9.52791534558628e-09
of O 1 0.8982168436050415
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.0005366883124224842
also O 0 8.224161263115093e-08
present O 0 1.34045478716871e-07
in O 0 1.574762649170225e-07
the O 0 8.720914479454223e-07
family O 0 4.085049567947863e-06
. O 0 3.1010717975732405e-06

The O 0 9.807910828385502e-06
odds O 0 1.7257621948374435e-05
of O 0 5.198502321945853e-07
detection O 0 7.704369409111678e-07
of O 0 8.865055178830517e-08
any O 0 6.611046643456575e-08
of O 0 2.3231147849855915e-07
the O 0 2.2768784901927575e-07
four O 0 4.1249623450312356e-07
BRCA2 O 0 3.6904164062434575e-06
mutations O 0 2.084222927578594e-07
was O 0 2.3259708541445434e-06
5 O 0 2.974001290567685e-06
. O 0 2.3165052880358417e-06

3x O 0 0.0007774722762405872
greater O 0 7.634665166733612e-07
if O 0 3.373007473328471e-08
there O 0 3.052726427199559e-08
were O 0 3.347358656924371e-08
at O 0 1.1030928703803511e-07
least O 0 5.824719373492826e-09
five O 0 4.424186794693696e-09
cases O 0 7.513174082873775e-09
of O 0 2.540056357247522e-06
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9998518228530884
in O 0 1.069195059244521e-05
the O 0 9.604378283256665e-05
family O 0 3.493722397251986e-05
. O 0 3.3231140150746796e-06

Interestingly O 0 4.346659989096224e-05
, O 0 2.409734634056804e-07
the O 0 1.0314916920606265e-07
presence O 0 1.4273803117248463e-07
of O 0 3.94663260294692e-07
a O 0 1.4305231161415577e-05
breast B-Disease 1 0.9876008033752441
cancer I-Disease 0 0.003641177900135517
case O 0 7.414460469590267e-06
< O 0 0.1508760005235672
36 O 0 3.329104458771326e-07
years O 0 2.6186866008970355e-08
of O 0 4.022726329822035e-08
age O 0 2.029021999305769e-07
was O 0 3.6209809195497655e-07
strongly O 0 3.7858409740465504e-08
predictive O 0 9.515368759593912e-08
of O 0 1.2229441459510326e-08
the O 0 1.3691284550532146e-08
presence O 0 1.929532622568786e-08
of O 0 1.1118840070878377e-08
any O 0 1.3101596252340642e-08
of O 0 5.9557937248655435e-08
the O 0 5.824777815632842e-08
eight O 0 1.1046930126212828e-07
mutations O 0 7.336755203368739e-08
screened O 0 7.676755444663286e-07
. O 0 1.079227899936086e-06

Carriers O 0 1.0242402822768781e-05
of O 0 4.809772917724331e-07
the O 0 1.3779920493561804e-07
same O 0 6.595630708261524e-08
mutation O 0 2.848679869771331e-08
, O 0 2.1080051038069314e-09
from O 0 2.689902744990036e-09
different O 0 8.941565821096731e-10
families O 0 2.6210540404747462e-09
, O 0 2.746274985199193e-09
shared O 0 3.862248121322409e-08
similar O 0 1.1080732775781144e-08
haplotypes O 0 6.948022246433538e-07
, O 0 1.1199551508411787e-08
indicating O 0 1.3272305920963845e-07
that O 0 1.8164862947145366e-09
the O 0 1.8330959861145857e-08
mutant O 0 1.5992229407402192e-07
alleles O 0 8.954130770177926e-09
were O 0 8.121384453829705e-09
likely O 0 4.309600232232924e-09
to O 0 1.8069211682458786e-09
be O 0 2.5720845453491847e-09
identical O 0 9.081650986786372e-09
by O 0 3.724046848674334e-09
descent O 0 1.6412072056937177e-07
for O 0 4.54344872835577e-09
a O 0 6.285197429178879e-08
mutation O 0 1.4813552162706856e-08
in O 0 8.153233643781732e-09
the O 0 8.032239406929875e-08
founder O 0 1.198246445710538e-05
population O 0 1.3205894333623291e-07
. O 0 5.426390430329775e-07

The O 0 2.348321686440613e-06
identification O 0 1.3107228369335644e-06
of O 0 8.862862728165055e-07
common O 0 1.0628486961650196e-06
BRCA1 O 0 4.1643696022219956e-05
and O 0 2.1895104396207898e-07
BRCA2 O 0 3.583719808375463e-05
mutations O 0 8.598667022852169e-08
will O 0 1.7063536361661136e-08
facilitate O 0 3.961448271638801e-07
carrier O 0 2.9207359375504893e-07
detection O 0 5.349145908439823e-07
in O 0 2.157954881454316e-08
French O 0 2.6442094167578034e-06
Canadian O 0 0.0004778620204888284
breast B-Disease 1 0.9987982511520386
cancer I-Disease 0 0.10035344958305359
and O 0 0.0003104831848759204
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.907957089832053e-05
. O 0 5.889376097911736e-06

Are O 0 7.090736744430615e-06
Dp71 O 0 0.25646114349365234
and O 0 2.2239657937461743e-06
Dp140 O 1 0.9975457787513733
brain O 1 0.8088008761405945
dystrophin O 0 0.00015054529649205506
isoforms O 0 3.7627688698194106e-07
related O 0 1.4383557811470382e-07
to O 0 7.646324462484699e-08
cognitive B-Disease 1 0.503497838973999
impairment I-Disease 1 0.9999959468841553
in O 0 0.2613272964954376
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.0017045220592990518

Molecular O 0 0.00020973144273739308
study O 0 3.149445149119856e-07
and O 0 1.9948304341710354e-08
neuropsychological O 0 1.3682079043064732e-06
analysis O 0 7.020155834425168e-08
were O 0 4.1181223764397146e-08
performed O 0 1.046151751893376e-07
concurrently O 0 1.4275845217071037e-07
on O 0 7.071263041780185e-08
49 O 0 4.145540515310131e-07
patients O 0 4.110902551701656e-08
with O 0 1.3952886490642413e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9982814788818359
DMD B-Disease 1 1.0
) O 0 1.460884249127048e-07
in O 0 6.653231743314336e-09
order O 0 7.657413370054655e-09
to O 0 4.341495607462775e-09
find O 0 5.13001516821987e-08
a O 0 6.564518173490796e-08
molecular O 0 1.7359087678414653e-07
explanation O 0 2.513092844935727e-08
for O 0 2.2729758075712425e-09
the O 0 7.860042927632094e-08
cognitive B-Disease 0 7.77573513914831e-05
impairment I-Disease 0 0.0001918031193781644
observed O 0 7.644704851372808e-07
in O 0 1.215586706848626e-07
most O 0 3.318004644370376e-07
DMD B-Disease 1 1.0
patients O 0 5.999316726956749e-06
. O 0 4.919740149489371e-06

Complete O 0 1.6887559468159452e-05
analysis O 0 1.2605290748979314e-06
of O 0 5.693005959983566e-07
the O 0 5.909816991334083e-07
dystrophin O 0 3.1553143344353884e-05
gene O 0 2.2807316213402373e-07
was O 0 3.17518782821935e-07
performed O 0 1.1656583609465088e-07
to O 0 1.5537890973860158e-08
define O 0 1.3626888062390208e-07
the O 0 1.4221137689673924e-07
localization O 0 1.834432805480901e-05
of O 0 1.0950096651640706e-07
deletions O 0 2.3853564812270633e-07
and O 0 2.9832047943045836e-08
duplications O 0 5.663467163685709e-06
in O 0 8.338390244944094e-08
relation O 0 7.349037218773447e-07
to O 0 3.4248440528017454e-08
the O 0 3.351783561811317e-07
different O 0 8.682633279022411e-07
DMD B-Disease 1 1.0
promoters O 0 0.0007831988041289151
. O 0 9.788158422452398e-06

Qualitative O 0 5.020420212531462e-05
analysis O 0 1.496480990681448e-06
of O 0 3.6771120903722476e-07
the O 0 5.17880323513964e-07
Dp71 O 0 0.0014708525268360972
transcript O 0 6.6491629695519805e-06
and O 0 1.080138201103864e-08
testing O 0 1.9168004072867006e-08
for O 0 5.1269903877937395e-09
the O 0 3.2828150864361305e-08
specific O 0 2.1511002756824382e-08
first O 0 2.935275347226707e-07
exon O 0 3.290700306024519e-06
of O 0 4.014433727661526e-07
Dp140 O 0 1.376605996483704e-05
were O 0 1.5400991060232627e-07
also O 0 2.0408711165487148e-08
carried O 0 1.2114411163111072e-07
out O 0 2.2162410573400848e-07
. O 0 1.4521293678626535e-06

Neuropsychological O 0 0.00044976084609515965
analysis O 0 8.064788744377438e-06
assessed O 0 7.777462087688036e-06
verbal O 0 1.4333827493828721e-05
and O 0 1.2897289707325399e-06
visuospatial O 1 0.9925069212913513
intelligence O 0 0.0002130749635398388
, O 0 5.270384804134665e-07
verbal O 0 7.919443305581808e-05
memory O 1 0.754281759262085
, O 0 4.6841407197462104e-07
and O 0 3.2990195109050546e-07
reading O 0 0.00020678552391473204
skills O 0 0.015491505153477192
. O 0 3.2604548323433846e-05

Comparison O 0 5.00673231726978e-05
of O 0 3.1090580705495086e-06
molecular O 0 1.4431155250349548e-05
and O 0 1.6194589136375726e-07
psychometric O 0 8.741310011828318e-05
findings O 0 9.965096978703514e-07
demonstrated O 0 7.12571647909499e-07
that O 0 1.6206540109919843e-08
deletions O 0 2.083799444108081e-07
and O 0 2.2271267496876135e-08
duplications O 0 1.4002931720824563e-06
that O 0 1.1292472734680814e-08
were O 0 5.5945445609495437e-08
localized O 0 6.587772531929659e-07
in O 0 2.5190292518573187e-08
the O 0 1.4469713960352237e-07
distal O 0 3.4702861739788204e-06
part O 0 8.345789126451564e-08
of O 0 2.0003118095246464e-07
the O 0 2.625248782806011e-07
gene O 0 8.35314679648036e-08
seemed O 0 2.9246230326407385e-08
to O 0 2.452194447499778e-09
be O 0 7.290411829785626e-09
preferentially O 0 1.0702927966121933e-07
associated O 0 1.2116908010284533e-07
with O 0 1.2390182746457867e-07
cognitive B-Disease 1 0.822982668876648
impairment I-Disease 1 0.9929100871086121
. O 0 1.8019880371866748e-05

Two O 0 5.030992724641692e-06
altered O 0 1.7149603081634268e-05
Dp71 O 0 0.00034769478952512145
transcripts O 0 7.66653010941809e-06
and O 0 5.017022175479724e-08
two O 0 1.038101657968582e-07
deleted O 0 2.3202371721708914e-06
Dp140 O 0 4.095956228411524e-06
DNA O 0 1.746282976000657e-07
sequences O 0 3.7265923680251944e-08
were O 0 7.569775029026005e-09
found O 0 6.765007665165967e-09
in O 0 5.2297068897644294e-09
four O 0 3.414342941709947e-08
patients O 0 3.300797146721379e-08
with O 0 1.3288770617236878e-07
severe O 1 0.9999998807907104
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.0010451911948621273

These O 0 3.7120503293408547e-07
findings O 0 4.319379058870254e-07
suggest O 0 1.0837748476433262e-07
that O 0 1.4523645619490821e-09
some O 0 1.903639468281426e-09
sequences O 0 4.733659864086803e-08
located O 0 6.209094749465294e-08
in O 0 6.752180592428658e-09
the O 0 3.407960136314614e-08
distal O 0 9.344377076558885e-07
part O 0 4.681367471448539e-08
of O 0 8.592454037170683e-08
the O 0 9.211466078795638e-08
gene O 0 2.1058358612435768e-08
and O 0 1.7279688790949876e-09
, O 0 3.905775702861547e-09
in O 0 3.490526534477567e-09
particular O 0 8.601583445511096e-09
, O 0 5.154572324528317e-09
some O 0 1.3231582052242175e-08
DMD B-Disease 1 0.9999990463256836
isoforms O 0 2.7360707477441792e-08
expressed O 0 4.228889682877934e-09
in O 0 3.519997404666242e-09
the O 0 2.2340103100759734e-08
brain O 0 1.177290073428594e-06
may O 0 6.35324548525773e-09
be O 0 6.757333803619758e-09
related O 0 3.923114633153091e-08
to O 0 1.277790140363777e-08
the O 0 6.45210377570038e-07
cognitive B-Disease 1 0.9768633842468262
impairment I-Disease 1 0.6860861778259277
associated O 0 1.4795398783462588e-05
with O 0 2.0197949197608978e-06
DMD B-Disease 1 1.0
. O 0 2.417368023088784e-06
. O 0 3.858574018522631e-06

I1307K O 0 0.06834340840578079
APC O 0 0.0005076387315057218
and O 0 5.068697532806254e-07
hMLH1 O 0 1.2921129382448271e-05
mutations O 0 1.8737577534011507e-07
in O 0 3.4683029781490404e-08
a O 0 2.687258700007078e-07
non O 0 4.270937279216014e-05
- O 0 3.412519799894653e-05
Jewish O 0 9.283822691941168e-06
family O 0 1.4185906138663995e-07
with O 0 2.5178476192877497e-08
hereditary B-Disease 1 0.9999998807907104
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.3727473020553589

We O 0 2.7492042136145756e-06
describe O 0 1.692779733275529e-06
a O 0 7.12486723841721e-07
French O 0 2.382462753303116e-06
Canadian O 0 1.903171323647257e-05
hereditary B-Disease 1 0.9999938011169434
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 1.0
HNPCC B-Disease 1 1.0
) O 0 0.00019020917534362525
kindred O 0 0.00016838600276969373
which O 0 5.218758758473996e-08
carries O 0 2.5916961021721363e-07
a O 0 1.9084761504473136e-07
novel O 0 1.3591187553174677e-06
truncating O 0 2.2266473024501465e-05
mutation O 0 1.2522222050392884e-06
in O 0 1.0633677902660565e-06
hMLH1 O 0 0.00014159701822791249
. O 0 1.4042733710084576e-05

Interestingly O 0 7.352126704063267e-05
, O 0 5.929168196416867e-07
the O 0 7.118340477063612e-07
I1307K O 0 0.00011393035674700513
APC O 0 3.057276626350358e-05
polymorphism O 0 1.5781273532411433e-06
, O 0 2.6261593788490245e-08
associated O 0 4.924828544972115e-08
with O 0 4.367033845653623e-09
an O 0 4.993375313233628e-08
increased O 0 3.1606921879756555e-07
risk O 0 1.2043046808685176e-05
of O 1 0.9999473094940186
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.278365956153721e-06
is O 0 1.373882270172544e-07
also O 0 1.2246365699297712e-08
present O 0 3.90265775251919e-08
in O 0 5.973858918650876e-08
this O 0 1.5537541742105532e-07
family O 0 2.941405455203494e-06
. O 0 2.12469490179501e-06

The O 0 2.458672497596126e-05
I1307K O 0 0.00012643598893191665
polymorphism O 0 6.897108505654614e-06
has O 0 3.37444880926796e-08
previously O 0 5.5119606656717224e-08
only O 0 3.524377456542993e-09
been O 0 9.803962086607498e-09
identified O 0 2.595722214948637e-08
in O 0 8.429068998339062e-09
individuals O 0 6.172769850820714e-09
of O 0 5.329816303856205e-07
self O 0 0.000725471181795001
- O 0 0.0058494010008871555
reported O 0 1.6095898899948224e-05
Ashkenazi O 0 7.873711729189381e-05
Jewish O 0 9.052270797837991e-06
origins O 0 1.4244896192394663e-05
. O 0 2.096643584081903e-06

In O 0 1.9806377622444415e-06
addition O 0 2.679852286746609e-07
, O 0 3.403517112587906e-08
in O 0 1.6724053253369675e-08
this O 0 2.9000542411949937e-08
family O 0 1.0443554998573745e-07
, O 0 7.233925902738747e-09
there O 0 1.7102310678751564e-08
appears O 0 5.5505946505718384e-08
to O 0 4.6757433480593136e-09
be O 0 1.6404708702566495e-08
no O 0 7.097219878460237e-08
relationship O 0 2.0124794275488966e-07
between O 0 1.1556863910300308e-07
the O 0 2.8301155907684006e-07
I1307K O 0 2.3663520551053807e-05
polymorphism O 0 6.557159508702171e-07
and O 0 1.0278461637369674e-08
the O 0 4.6190685054625646e-08
presence O 0 7.980531790963141e-08
or O 0 4.462495439838676e-08
absence O 0 1.1503832411108306e-06
of O 0 9.064062396646477e-06
cancer B-Disease 0 0.008479386568069458
. O 0 6.297395316323673e-07
. O 0 1.981223249458708e-06

Identification O 0 1.4788288353884127e-05
of O 0 9.980685717891902e-07
a O 0 3.750037365080061e-07
novel O 0 6.315859764072229e-07
mutation O 0 7.160569026609664e-08
of O 0 9.0344023817579e-08
the O 0 6.477998795162421e-07
CPO O 0 0.001465509762056172
gene O 0 8.57953807553713e-07
in O 0 2.26005823833475e-07
a O 0 5.810968104924541e-06
Japanese O 1 0.619209349155426
hereditary B-Disease 1 0.9999992847442627
coproporphyria I-Disease 1 0.9999996423721313
family O 0 0.001042138203047216
. O 0 1.5480669389944524e-05

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 1 0.9994261264801025
HCP B-Disease 1 1.0
) O 0 1.5252183402481023e-05
is O 0 4.039966086111235e-07
an O 0 1.6785719481049455e-06
autosomal B-Disease 1 0.9999845027923584
dominant I-Disease 1 0.9995861649513245
disease I-Disease 1 0.9983391761779785
characterized O 0 3.8076168493716978e-06
by O 0 1.8169103555010224e-07
a O 0 3.19978607876692e-05
deficiency B-Disease 1 0.9973933696746826
of I-Disease 0 0.010801081545650959
coproporphyrinogen I-Disease 1 0.9999994039535522
oxidase I-Disease 0 0.0011845857370644808
( O 0 1.3508766642189585e-05
CPO O 0 0.01269560307264328
) O 0 1.6937504199177056e-07
caused O 0 9.153738744771545e-08
by O 0 8.823215935649387e-09
a O 0 6.093833349041233e-08
mutation O 0 3.246475799301152e-08
in O 0 3.2285129236697685e-08
the O 0 1.0133304613191285e-06
CPO O 0 0.0032335894647985697
gene O 0 1.5988500308594666e-05
. O 0 3.4047102417389397e-06

Only O 0 1.1332138001307612e-06
11 O 0 1.095909851756005e-06
mutations O 0 8.003061680028623e-08
of O 0 6.892545911796333e-08
the O 0 1.184242961471682e-07
gene O 0 1.0634798286446312e-07
have O 0 6.561323928622187e-09
been O 0 8.890318525800467e-08
reported O 0 1.3389220612225472e-06
in O 0 2.207029183409759e-06
HCP B-Disease 1 1.0
patients O 0 4.205129880574532e-05
. O 0 9.217982551490422e-06

We O 0 3.1886290798865957e-06
report O 0 1.150423940998735e-06
another O 0 2.2785900455346564e-07
mutation O 0 9.101180609150106e-08
in O 0 3.92732957266162e-08
a O 0 1.2125200328227947e-06
Japanese O 0 0.00011236935097258538
family O 0 6.085614131734474e-06
. O 0 2.449167823215248e-06

Polymerase O 0 0.0018230911809951067
chain O 0 2.1464180463226512e-05
reaction O 0 1.014774284158193e-06
- O 0 1.0693812555473414e-06
single O 0 2.5917478296832996e-07
strand O 0 8.134858262565103e-07
conformational O 0 1.2263667770184838e-07
polymorphism O 0 9.415388291245108e-08
and O 0 2.165474466409023e-09
direct O 0 2.017459799219523e-08
sequence O 0 4.0279470425730324e-08
analyses O 0 5.6793300728941176e-08
demonstrated O 0 3.755734567789659e-08
a O 0 3.5244262619471556e-08
C O 0 4.2956924062309554e-07
to O 0 2.1992075716070758e-08
T O 0 8.720789992366917e-07
substitution O 0 1.1202973837498575e-07
in O 0 4.7148724036105705e-08
exon O 0 7.780806186019618e-07
1 O 0 5.319081708421436e-08
of O 0 3.564916895015813e-08
the O 0 1.4740419373993063e-07
CPO O 0 9.248518836102448e-06
gene O 0 1.1019677970125485e-07
at O 0 1.94105723494431e-07
nucleotide O 0 3.287082677161379e-07
position O 0 1.0877551659405071e-07
85 O 0 1.7126686202573183e-07
, O 0 8.416474628347714e-09
which O 0 3.407679027844779e-09
lies O 0 7.620190700663443e-08
in O 0 1.057113063751558e-08
the O 0 6.769023741526325e-08
putative O 0 2.9582031402242137e-06
presequence O 0 4.694329163612565e-06
for O 0 3.988848717995097e-08
targeting O 0 2.916076766723563e-07
to O 0 1.179173878540496e-07
mitochondria O 0 1.0561462659097742e-05
. O 0 1.3552383961723535e-06

This O 0 1.649893192734453e-06
mutation O 0 2.0848948167895287e-07
changes O 0 2.7221723541970277e-08
the O 0 8.002999862810611e-08
codon O 0 1.234418959938921e-06
for O 0 3.81207136967987e-08
glutamine O 0 7.25594134109997e-07
to O 0 3.8192617068943946e-08
a O 0 2.3589829822867614e-07
termination O 0 9.318498541688314e-07
codon O 0 3.965329142374685e-06
at O 0 7.942990123410709e-07
amino O 0 7.774145842631697e-07
acid O 0 3.3085095196838665e-07
position O 0 1.0343617304897634e-06
29 O 0 9.774362297321204e-06
. O 0 1.9061019429500448e-06

MaeI O 0 0.004467667080461979
restriction O 0 2.999351181642851e-06
analysis O 0 3.851515373298753e-07
showed O 0 6.787162476484809e-08
two O 0 3.0683404705911244e-09
other O 0 1.837702101603611e-09
carriers O 0 1.964188278691381e-08
in O 0 1.6451773277026405e-08
the O 0 7.564956945316226e-07
family O 0 8.400619663007092e-06
. O 0 2.938652187367552e-06

The O 0 2.548491465859115e-05
C O 0 0.2788633108139038
- O 0 0.22072963416576385
T O 0 0.00022748495393898338
mutation O 0 1.6902585286970861e-07
is O 0 3.1752296791864865e-08
located O 0 5.7223779492687754e-08
within O 0 2.8854934441824298e-08
a O 0 3.8704484950358164e-08
recently O 0 6.332899005201398e-08
proposed O 0 2.4798334052889004e-08
putative O 0 3.044348204639391e-07
alternative O 0 3.7207399827821064e-08
translation O 0 9.822632591749425e-07
initiation O 0 9.701781209514593e-07
codon O 0 8.033577501009859e-07
( O 0 1.1589610693363284e-07
TIC O 0 5.583017355093034e-06
- O 0 2.2341963301641954e-07
1 O 0 8.602768275522976e-08
) O 0 1.021147610913431e-08
, O 0 1.622471823559124e-09
supporting O 0 1.6099846789074945e-08
that O 0 5.278923076446063e-09
TIC O 0 1.449534647690598e-05
- O 0 4.0378398580287467e-07
1 O 0 7.849944694271471e-08
is O 0 5.77435610438215e-09
the O 0 2.175900704060041e-08
real O 0 4.0168924897443503e-07
TIC O 0 1.1694787644955795e-05
rather O 0 7.76727020479484e-08
than O 0 6.71447750733023e-08
TIC O 0 3.088220182689838e-05
- O 0 1.742787276270974e-06
2 O 0 6.149259093035653e-07
. O 0 1.8825325298621465e-07
. O 0 8.372222168873122e-07

Human B-Disease 0 1.8349244783166796e-05
complement I-Disease 0 0.0001979419175768271
factor I-Disease 1 0.9867736101150513
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.4271853268146515
with O 1 0.78363037109375
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9187691807746887

This O 0 9.060837555807666e-07
study O 0 2.5062675490516995e-07
reports O 0 6.119795870063172e-08
on O 0 1.2523969417088665e-08
six O 0 1.6688746384829756e-08
cases O 0 1.4370966638921345e-08
of O 0 1.4154799146126607e-06
deficiency B-Disease 1 0.9999793767929077
in I-Disease 0 3.059955702156003e-07
the I-Disease 0 3.2190135357268446e-07
human I-Disease 0 6.017533138447106e-08
complement I-Disease 0 8.211042512584754e-08
regulatory I-Disease 0 1.6257754964499327e-07
protein I-Disease 0 3.021875727426959e-07
Factor I-Disease 0 1.8324478787690168e-06
H I-Disease 1 0.7385423183441162
( O 0 2.5064611008929205e-07
FH O 0 9.545076318318024e-05
) O 0 3.34642491495174e-09
in O 0 8.074287904946686e-10
the O 0 1.5832738453624984e-09
context O 0 3.797013548023642e-08
of O 0 6.347241310322715e-08
an O 0 2.3906040951260366e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.005032626446336508

Five O 0 2.8352260414976627e-06
of O 0 2.741658704508154e-07
the O 0 1.2536975191324018e-07
cases O 0 1.8936235690603098e-08
were O 0 4.8696161769612445e-08
observed O 0 2.832532288721268e-07
in O 0 5.1919222698870726e-08
children O 0 1.030524146017342e-07
presenting O 0 5.306877028488088e-06
with O 0 4.7524532419629395e-05
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 1 0.5627290606498718
. O 0 7.765553891658783e-05

Two O 0 1.2014926369374734e-06
of O 0 5.101017563902133e-07
the O 0 2.8182969913359557e-07
children O 0 1.851248043749365e-07
exhibited O 0 4.695040843216702e-06
a O 0 0.00016664815484546125
homozygous O 0 0.49513477087020874
deficiency O 1 0.9997366070747375
characterized O 0 8.533360187357175e-07
by O 0 2.051349667908653e-08
the O 0 4.7122920676656577e-08
absence O 0 2.3097693713225453e-07
of O 0 9.757010843713942e-08
the O 0 7.271042790080173e-08
150 O 0 2.5814023274506326e-07
- O 0 4.055290787619015e-07
kD O 0 2.2728507246938534e-05
form O 0 4.2949796608127144e-08
of O 0 6.383530148923455e-07
Factor O 0 2.1851978090126067e-05
H O 1 0.7452966570854187
and O 0 6.274355701663126e-09
the O 0 2.5452056462427208e-08
presence O 0 8.729396228090991e-08
, O 0 8.306765941767935e-09
upon O 0 7.382136857359001e-08
immunoblotting O 0 5.6186013352999e-06
, O 0 1.4004126747124701e-08
of O 0 2.6426203447726948e-08
the O 0 3.908356305259986e-08
42 O 0 3.653127294001024e-07
- O 0 1.0689233249649988e-06
kD O 0 0.0014478174271062016
Factor O 0 3.2280007872032e-05
H O 0 0.004045533016324043
- O 0 2.8014392228215e-07
like O 0 1.4177826024308615e-08
protein O 0 4.719956336884934e-08
1 O 0 3.785003244161089e-08
( O 0 3.8370629340533924e-08
FHL O 0 4.068603630003054e-06
- O 0 1.0426299468235811e-07
1 O 0 1.7837058052805332e-08
) O 0 2.182733105371426e-09
and O 0 7.598703333222545e-10
other O 0 3.0911260218147163e-09
FH O 0 2.6675195840653032e-05
- O 0 1.131987914959609e-06
related O 0 5.710297159566835e-07
protein O 0 1.069943323273037e-06
( O 0 6.866138733130356e-07
FHR O 0 0.0006956897559575737
) O 0 4.503890806972777e-07
bands O 0 2.2412589260056848e-06
. O 0 1.64892730936117e-06

Southern O 0 1.7704984202282503e-05
blot O 0 1.3288205991557334e-05
and O 0 1.3542806698296772e-07
PCR O 0 1.430076963515603e-06
analysis O 0 6.116680140166864e-08
of O 0 2.3208597710322465e-08
DNA O 0 2.8656069162025233e-07
of O 0 8.712944321587202e-08
one O 0 7.152679160071784e-08
patient O 0 3.113940181265207e-07
with O 0 4.726280167233199e-08
homozygous O 0 0.23118877410888672
deficiency O 1 0.9983939528465271
ruled O 0 2.4256436859104724e-07
out O 0 1.3395980325014989e-08
the O 0 1.2856669506788876e-08
presence O 0 2.1162243513117573e-08
of O 0 1.1712876890612733e-08
a O 0 1.1728973348112959e-08
large O 0 5.2881139467331195e-09
deletion O 0 1.0514428083752136e-07
of O 0 6.483215031494183e-08
the O 0 4.2197069660687703e-07
FH O 1 0.8926861882209778
gene O 0 7.801330070833501e-08
as O 0 1.1289112755719088e-08
the O 0 6.296428267660303e-08
underlying O 0 3.8795245927758515e-05
defect O 0 8.772315595706459e-06
for O 0 1.9163898912211152e-07
the O 0 5.08105949847959e-05
deficiency O 1 0.9999980926513672
. O 0 4.3942225602222607e-05

The O 0 2.1794076019432396e-06
other O 0 2.5236364109559872e-08
four O 0 1.5584845414196025e-08
children O 0 1.3688908673259448e-08
presented O 0 1.368143642821451e-07
with O 0 2.3312598784741567e-07
heterozygous O 0 0.00045285100350156426
deficiency O 1 0.9513586759567261
and O 0 4.4374910856959104e-08
exhibited O 0 1.2647564290091395e-05
a O 0 1.137845447374275e-05
normal O 0 4.670796624850482e-05
immunoblotting O 0 0.00017477566143497825
pattern O 0 1.1066475735788117e-06
of O 0 2.6704890387918567e-07
proteins O 0 2.1112940373768652e-07
of O 0 2.3404695639328565e-06
the O 0 8.094161603366956e-05
FH O 1 0.9999998807907104
family O 0 6.867067713756114e-05
. O 0 2.9812538286932977e-06

Factor B-Disease 1 0.9999997615814209
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
is O 0 4.5588851094180427e-07
the O 0 2.9905487508585793e-07
only O 0 6.085546147005516e-07
complement B-Disease 1 0.9999945163726807
deficiency I-Disease 1 1.0
associated O 0 0.0005626236088573933
with O 0 1.6951504221651703e-05
HUS B-Disease 1 1.0
. O 0 0.00010157683573197573

These O 0 8.562250286558992e-07
observations O 0 8.130655260174535e-06
suggest O 0 1.0333777709092828e-06
a O 0 2.2873990701555158e-07
role O 0 3.789840263834776e-07
for O 0 1.4823450555923046e-07
FH O 1 0.9903287291526794
and O 0 3.985465184541681e-07
/ O 0 0.02328740991652012
or O 0 5.121347385284025e-06
FH O 1 0.9996734857559204
receptors O 0 5.443495183499181e-07
in O 0 2.218761352423826e-08
the O 0 1.3299889189966052e-07
pathogenesis O 1 0.9775794148445129
of O 0 0.0006861814763396978
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 8.69120231072884e-06
. O 0 1.1749328223231714e-05

Further O 0 8.397778401558753e-07
evidence O 0 7.137122111089411e-07
for O 0 3.2690810058966235e-08
a O 0 2.1823559848144214e-07
major O 0 3.1424184498973773e-07
ancient O 0 3.21359584631864e-05
mutation O 0 3.41881241183728e-05
underlying O 1 0.9999445676803589
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.0608360500773415e-05
linkage O 0 0.03542318940162659
disequilibrium O 0 0.0011410578154027462
studies O 0 4.091550351859041e-07
in O 0 3.601934039920707e-08
the O 0 1.4357217992255755e-07
Japanese O 0 1.2891060578112956e-05
population O 0 2.276088082453498e-07
. O 0 4.250613017120486e-07

The O 0 0.0017791922437027097
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9995092153549194
DM B-Disease 1 1.0
) O 0 1.134895569521177e-06
mutation O 0 6.876617675288799e-08
is O 0 1.622070477935722e-08
an O 0 6.542119024288695e-08
unstable O 0 1.381055608362658e-05
( O 0 4.0879140215110965e-06
CTG O 1 0.9962202906608582
) O 0 7.212133255052322e-07
n O 0 1.2710032706308994e-06
repeat O 0 6.787109896322363e-07
, O 0 2.7565571159016145e-08
present O 0 7.545331470737437e-08
at O 0 3.425275849622267e-07
a O 0 8.16914536017066e-08
copy O 0 1.9719742283541564e-07
number O 0 1.2139619087747633e-08
of O 0 4.793004748648855e-08
5 O 0 1.8890247588387865e-07
- O 0 3.812860427387932e-07
37 O 0 1.4845605278424046e-07
repeats O 0 1.0083854107278967e-07
on O 0 3.080691968193605e-08
normal O 0 9.476464413182839e-08
chromosomes O 0 3.3885608985428917e-08
but O 0 2.7699478266640654e-09
amplified O 0 6.765938564967655e-08
to O 0 7.54591766849444e-09
50 O 0 1.806056104669551e-07
- O 0 3.765985638892744e-07
3000 O 0 4.868743985753099e-07
copies O 0 3.2895852086767263e-07
on O 0 8.455768920612172e-07
DM B-Disease 1 0.9034374356269836
chromosomes O 0 2.0298155504860915e-05
. O 0 2.0135403246968053e-06

Previous O 0 1.422219975211192e-05
findings O 0 2.4549017325625755e-06
in O 0 2.519649626719911e-07
Caucasian O 0 2.3318909370573238e-05
populations O 0 1.2003091853785008e-07
of O 0 1.1299172228973475e-06
a O 0 0.006552697625011206
DM B-Disease 1 1.0
founder O 1 0.9995493292808533
chromosome O 0 0.0001625867298571393
raise O 0 1.3850103641743772e-07
a O 0 1.0854650156488788e-07
question O 0 4.923504448584026e-08
about O 0 1.438745034221256e-08
the O 0 2.30204779683163e-08
molecular O 0 3.679150211155502e-07
events O 0 5.670464986451407e-08
involved O 0 4.61043363486624e-08
in O 0 2.8842828569963785e-08
the O 0 1.9030601094982558e-07
expansion O 0 3.327858394186478e-06
mutation O 0 1.5223495211103e-06
. O 0 1.3801978866467834e-06

To O 0 3.1538081657345174e-06
investigate O 0 2.1879334326513344e-06
whether O 0 4.928554631078441e-07
a O 0 1.0128919711860362e-06
founder O 0 1.388037981087109e-05
chromosome O 0 2.6424297630001092e-06
for O 0 8.189629596699888e-08
the O 0 7.184788955783006e-06
DM B-Disease 1 1.0
mutation O 0 2.406078749572771e-07
exists O 0 4.504225969981235e-08
in O 0 5.9877400815366855e-09
the O 0 1.2053789966159911e-08
Japanese O 0 1.188224473480659e-06
population O 0 4.856201663017146e-09
, O 0 3.1885007967247248e-09
we O 0 2.502507534529741e-08
genotyped O 0 1.181861080112867e-05
families O 0 3.0019268848491265e-08
using O 0 3.132962334007061e-08
polymorphic O 0 2.2657879128473724e-07
markers O 0 4.3508822500371025e-07
near O 0 9.542756060909596e-07
the O 0 2.339518232474802e-07
( O 0 1.5156264225879568e-06
CTG O 0 0.16758087277412415
) O 0 2.2610498717767769e-07
n O 0 1.303648218708986e-06
repeat O 0 1.1219701718800934e-06
region O 0 4.0265192069455225e-07
and O 0 1.9279769958302495e-07
constructed O 0 6.78298674756661e-05
haplotypes O 0 0.00013377492723520845
. O 0 7.824926797184162e-06

Six O 0 1.919559281304828e-06
different O 0 5.8094112631579264e-08
haplotypes O 0 9.942107226379449e-07
were O 0 6.271893226994507e-08
found O 0 1.3816712396419462e-07
and O 0 4.86663623178174e-07
DM B-Disease 1 1.0
alleles O 0 4.558259263376385e-07
were O 0 6.050200340723677e-07
always O 0 3.0176158816175302e-06
haplotype O 0 2.3764428988215514e-05
A O 0 2.6375846573500894e-05
. O 0 7.125701358745573e-06

To O 0 9.056449243871612e-07
find O 0 2.447775671043928e-07
an O 0 5.743405395719492e-08
origin O 0 7.818027825123863e-08
of O 0 2.748630265614338e-07
the O 0 9.342595035377599e-07
( O 0 8.98273447091924e-06
CTG O 1 0.9668499827384949
) O 0 3.0727116495654627e-07
n O 0 4.565202686990233e-07
repeat O 0 2.0762635699611565e-07
mutation O 0 1.2396371040779286e-08
and O 0 1.5312022760838317e-09
to O 0 4.392688879306661e-09
investigate O 0 1.050578859462803e-07
the O 0 4.3658950232838833e-08
mechanism O 0 5.871845019100874e-07
of O 0 5.0428777598199304e-08
the O 0 3.097637701898748e-08
expansion O 0 7.379082234137968e-08
mutation O 0 3.493070943605403e-09
in O 0 7.931221790435927e-10
the O 0 3.3487874695481423e-09
Japanese O 0 9.262806344167984e-08
population O 0 6.116674944323108e-10
we O 0 7.562137582795003e-10
have O 0 9.058810368500758e-10
studied O 0 1.0153700458204185e-07
90 O 0 6.945809332137287e-07
Japanese O 0 0.00014775065938010812
DM B-Disease 1 0.9999998807907104
families O 0 2.8886542935424586e-08
comprising O 0 5.882915488086837e-08
190 O 0 8.001642015642574e-08
affected O 0 6.78093581285566e-09
and O 0 6.235998384340746e-09
130 O 0 2.2208070049600792e-07
unaffected O 0 1.3900985322834458e-06
members O 0 2.4791154373815516e-07
. O 0 1.215512952512654e-06

The O 0 4.5464776121662e-06
results O 0 8.76423655427061e-07
suggest O 0 2.442365882870945e-07
that O 0 6.720919376590473e-09
a O 0 4.285887911237296e-08
few O 0 2.0545527945614595e-08
common O 0 2.621955275117216e-08
ancestral O 0 7.5788816502608825e-06
mutations O 0 7.899404863564996e-08
in O 0 4.451920077030991e-08
both O 0 4.756140725703517e-08
Caucasian O 0 0.00010978910722769797
and O 0 5.606893793697054e-08
Japanese O 0 3.1973882869351655e-05
populations O 0 1.59422910428475e-08
have O 0 1.280583195040208e-09
originated O 0 4.226287586561739e-08
by O 0 5.595406360470179e-09
expansion O 0 9.094187447544755e-08
of O 0 4.479525728129374e-08
an O 0 4.691271371370931e-08
ancestral O 0 8.481873123855621e-07
n O 0 4.5803611214978446e-07
= O 0 4.995380322725396e-07
5 O 0 3.524123570741722e-08
repeat O 0 3.487952682235118e-08
to O 0 7.293499582061713e-09
n O 0 2.5547390691826877e-07
= O 0 4.698238171840785e-07
19 O 0 3.745108756447735e-07
- O 0 3.5496583450367325e-07
37 O 0 5.056062946096063e-07
copies O 0 5.366604227674543e-07
. O 0 8.157699085131753e-07

These O 0 4.6847350176904e-07
data O 0 6.33498814295308e-07
support O 0 4.500979500221547e-08
multistep O 0 1.9102913029200863e-06
models O 0 2.1901662705658964e-07
of O 0 3.916793502867222e-07
triplet O 0 7.832771370885894e-05
repeat O 0 3.276540383012616e-06
expansion O 0 3.4062486520269886e-07
that O 0 2.3940647242426394e-09
have O 0 4.4474088300994197e-10
been O 0 1.8778045784983988e-09
proposed O 0 3.816834848180406e-09
for O 0 6.4964078561047245e-09
both O 0 2.0006285694762482e-07
DM B-Disease 1 1.0
and O 0 1.6883460602912237e-06
Friedreichs B-Disease 1 0.9999991655349731
ataxia I-Disease 0 0.4777570962905884
. O 0 1.0315629879187327e-06
. O 0 2.989772610817454e-06

The O 0 4.015010290459031e-06
molecular O 0 1.4551343156199437e-05
basis O 0 1.5843230357859284e-05
of O 1 0.7871751189231873
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.073433607729385e-07
the O 0 2.8753086667165917e-07
western O 0 2.700947732137138e-07
Cape O 0 2.0621553176169982e-06
, O 0 1.0202563771599671e-07
South O 0 2.2790231923863757e-06
Africa O 0 3.4472200240998063e-06
. O 0 2.4740495518926764e-06

Deficiency B-Disease 1 0.9999996423721313
of I-Disease 0 6.912420212756842e-05
the I-Disease 0 8.992076800495852e-06
sixth I-Disease 0 0.00019198094378225505
component I-Disease 0 3.504663982312195e-05
of I-Disease 0 1.8250287894261419e-06
human I-Disease 0 5.620174761133967e-07
complement I-Disease 0 9.09833124751458e-06
( O 0 1.208590401802212e-05
C6 O 1 0.9195446968078613
) O 0 4.356512306458171e-08
has O 0 2.9079454400005034e-09
been O 0 4.427090249947696e-09
reported O 0 1.5017100452041632e-08
in O 0 1.9333812328881095e-09
a O 0 4.678589071716033e-09
number O 0 2.184273872885001e-09
of O 0 1.3157013256659411e-08
families O 0 3.576500207103095e-09
from O 0 9.280308965742279e-09
the O 0 3.7990059098547135e-08
western O 0 1.2918027891828388e-07
Cape O 0 2.370005631746608e-06
, O 0 9.009657730985055e-08
South O 0 2.329442622794886e-06
Africa O 0 2.474150960551924e-06
. O 0 1.7190010339618311e-06

Meningococcal B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9995300769805908
is O 0 4.4250080577512563e-07
endemic O 0 4.355025566837867e-07
in O 0 3.5383621366236184e-08
the O 0 1.1239422548214861e-07
Cape O 0 8.293380233226344e-06
and O 0 1.62439857120944e-08
almost O 0 6.302148136683172e-08
all O 0 2.0317555637916485e-08
pedigrees O 0 1.1976945870628697e-06
of O 0 1.6073878441602574e-06
total O 1 0.9943482279777527
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.011887142434716225
C6Q0 O 1 0.9999992847442627
) O 0 6.141393527059336e-08
have O 0 3.2105618164024463e-09
been O 0 1.853650033467602e-08
ascertained O 0 9.77595277618093e-07
because O 0 6.223096704616182e-08
of O 0 1.9059420992562082e-06
recurrent O 1 0.9999948740005493
disease O 1 0.9999585151672363
. O 0 3.818069308181293e-05

We O 0 1.6874284938239725e-06
have O 0 2.993047942823068e-08
sequenced O 0 3.1606921879756555e-07
the O 0 4.1202909528692544e-08
expressed O 0 2.431168688588059e-08
exons O 0 3.434683719660825e-07
of O 0 2.504795588720299e-07
the O 0 6.435953423533647e-07
C6 O 0 0.01812414452433586
gene O 0 2.459859516079632e-08
from O 0 4.459923541588751e-09
selected O 0 4.3292742724077016e-09
cases O 0 2.104301177752177e-09
and O 0 8.426573328002007e-10
have O 0 1.1057524895718984e-09
found O 0 1.0641897141283607e-08
three O 0 4.613943715980895e-08
molecular O 0 0.05120882764458656
defects O 0 0.02348717488348484
leading O 0 9.458511840421124e-07
to O 0 4.9062929718957093e-08
total O 0 0.012995677068829536
deficiency O 1 1.0
879delG O 0 0.15621434152126312
, O 0 1.9306407139652038e-08
which O 0 1.448792752434258e-09
is O 0 1.5909021877646978e-09
the O 0 5.531779034839701e-09
common O 0 1.7189988099630682e-08
defect O 0 4.967167228642211e-07
in O 0 1.36420181817698e-08
the O 0 1.574475874122072e-07
Cape O 0 1.5969513697200455e-05
and O 0 5.0350731584103414e-08
hitherto O 0 9.095502718992066e-06
unreported O 0 3.947376626456389e-06
, O 0 1.976134100800664e-08
and O 0 1.524250414774997e-08
1195delC O 0 1.8429421970722615e-06
and O 0 2.0788187171660866e-08
1936delG O 0 6.4972050495271105e-06
, O 0 1.913257463570517e-08
which O 0 2.9882547547543936e-09
have O 0 9.009770152168528e-10
been O 0 6.4635434782189805e-09
previously O 0 4.1992972654725236e-08
reported O 0 4.761214356108212e-08
in O 0 2.8228690496234776e-08
African O 0 1.629112261980481e-06
- O 0 6.338079856504919e-06
Americans O 0 2.249743374704849e-06
. O 0 1.8153841665480286e-06

We O 0 4.509539849095745e-06
also O 0 2.8677010277533554e-07
show O 0 2.3868673793003836e-07
that O 0 1.7225632475970087e-08
the O 0 3.886019896981452e-07
879delG O 0 3.4535078157205135e-05
and O 0 6.314769507298479e-07
1195delC O 1 0.5002800822257996
defects O 0 0.012168158777058125
are O 0 8.102725601588645e-09
associated O 0 1.3322676295501878e-07
with O 0 9.462177530394911e-08
characteristic O 1 0.6881656646728516
C6 O 1 1.0
/ O 1 0.999936580657959
C7 O 1 0.988318920135498
region O 0 8.651224447930872e-07
DNA O 0 8.432146387349349e-06
marker O 0 4.519553840509616e-06
haplotypes O 0 8.248580343206413e-07
, O 0 5.0515969185482845e-09
although O 0 3.1445626103021596e-09
small O 0 1.2479807409704335e-08
variations O 0 3.62925653973889e-08
were O 0 2.563857606219244e-07
observed O 0 2.9668285606021527e-06
. O 0 2.386201231274754e-06

The O 0 8.519086259184405e-05
1936delG O 0 0.0013602891704067588
defect O 0 0.00038087231223471463
was O 0 8.17105046735378e-06
observed O 0 8.893589438230265e-07
only O 0 2.2558390710969434e-08
once O 0 8.485078950570824e-08
in O 0 1.7848595490477237e-08
the O 0 3.7601353142235894e-08
Cape O 0 1.558968278914108e-06
, O 0 7.720562855695334e-09
but O 0 1.8038152083121872e-09
its O 0 5.1433572956227636e-09
associated O 0 9.758592511843744e-08
haplotype O 0 5.693586899724323e-07
could O 0 2.3840685869913614e-08
be O 0 1.5570709877010813e-07
deduced O 0 1.755213634169195e-05
. O 0 1.975790837605018e-06

The O 0 3.1579434107698034e-06
data O 0 9.130196758633247e-07
from O 0 1.1218476458907389e-07
the O 0 1.3953179234249546e-07
haplotypes O 0 4.25557118433062e-06
indicate O 0 1.6956995807504427e-07
that O 0 2.300010182310075e-09
these O 0 1.7929896456436722e-09
three O 0 4.02450694991785e-08
molecular O 0 3.687889693537727e-05
defects O 0 9.549125024932437e-06
account O 0 5.5398277964968656e-08
for O 0 2.3290903428119236e-08
the O 0 1.6762523955549113e-06
defects O 0 7.437855674652383e-05
in O 0 2.5920858348627007e-08
all O 0 1.8422513292648546e-08
the O 0 1.5748062764942006e-07
38 O 0 1.6260496522590984e-06
unrelated O 0 5.342790245776996e-06
C6Q0 O 1 0.8044301271438599
individuals O 0 5.29788701797429e-09
we O 0 4.212170168216289e-09
have O 0 1.2903093038474367e-09
studied O 0 6.568438237763985e-08
from O 0 5.0367734871770153e-08
the O 0 4.436132883256505e-07
Cape O 0 3.257254138588905e-05
. O 0 2.700674485822674e-06

We O 0 3.324083763800445e-06
have O 0 7.335356144722027e-08
also O 0 5.97293663417986e-08
observed O 0 3.205534255812381e-07
the O 0 3.472649154900864e-07
879delG O 0 2.4699456844246015e-05
defect O 0 4.70095937998849e-06
in O 0 3.611730292618631e-08
two O 0 1.6015535209135123e-07
Dutch O 1 0.9999991655349731
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 0.9999997615814209
kindreds O 0 6.569609831785783e-05
, O 0 3.248358737550916e-08
but O 0 1.245621650269868e-08
the O 0 1.3324620340426918e-07
879delG O 0 1.4570578059647232e-05
defect O 0 3.452375494816806e-06
in O 0 3.3985870118158346e-08
the O 0 1.2908029134450771e-07
Cape O 0 1.8329288650420494e-05
probably O 0 5.982365678391943e-07
did O 0 5.484097442831626e-08
not O 0 8.602304646387893e-09
come O 0 2.5754827603918784e-08
from O 0 4.794842567434898e-08
The O 0 5.78490244151908e-07
Netherlands O 0 2.5077167720155558e-06
. O 0 3.8886892639311554e-07
. O 0 1.7096949704864528e-06

Complement B-Disease 1 0.9999998807907104
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.7576489881321322e-06
seven O 0 7.892587632341019e-07
further O 0 4.542311557997891e-07
molecular O 0 0.0018391379853710532
defects O 0 4.082794112036936e-05
and O 0 1.6136493030671772e-08
their O 0 7.050280004250453e-08
associated O 0 1.3482561371347401e-05
marker O 0 0.000552046753000468
haplotypes O 0 0.00010550861770752817
. O 0 4.308540155761875e-06

Seven O 0 7.724424904154148e-06
further O 0 1.151967580881319e-06
molecular O 0 9.880905054160394e-06
bases O 0 4.446117145562312e-06
of O 1 0.5626505017280579
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.4453308924421435e-06
described O 0 6.358540849760175e-05
. O 0 6.79515460433322e-06

All O 0 3.967009263305954e-07
these O 0 3.373264689798816e-08
new O 0 1.8924471589798486e-07
molecular O 0 2.6393261578050442e-05
defects O 0 1.480695755162742e-05
involve O 0 1.269784434043686e-06
single O 0 2.231520511486451e-06
- O 0 1.350270031252876e-05
nucleotide O 0 5.0928401833516546e-06
events O 0 6.297905486007949e-08
, O 0 3.0515026061550543e-09
deletions O 0 1.4154615257666592e-08
and O 0 1.1741299044132347e-09
substitutions O 0 2.6791818541482826e-08
, O 0 7.167398230478739e-09
some O 0 2.7117081913274887e-09
of O 0 2.5372807854751045e-08
which O 0 2.0753322615973957e-08
alter O 0 7.744280878796417e-07
splice O 0 3.4376041639916366e-06
sites O 0 9.037280790380464e-08
, O 0 2.1212354539557055e-08
and O 0 2.981862579076733e-08
others O 0 2.9776805376968696e-07
codons O 0 1.1658461517072283e-05
. O 0 2.423091927994392e-06

They O 0 2.776858707420615e-07
are O 0 9.616756280195204e-09
distributed O 0 7.276297786518171e-09
along O 0 1.0171959985427748e-07
the O 0 3.7734056945737393e-07
C7 O 0 0.0006618424667976797
gene O 0 1.9580431853682967e-07
, O 0 9.668197797907396e-09
but O 0 5.390839774577216e-09
predominantly O 0 2.0974821879349292e-08
towards O 0 1.5187053747922619e-07
the O 0 1.4799269365539658e-07
3 O 0 7.360371796494292e-07
end O 0 2.9980701583554037e-06
. O 0 2.363978637731634e-06

All O 0 1.3806138667860068e-06
were O 0 8.57710801938083e-07
found O 0 5.109499170430354e-07
in O 0 4.4679464394903334e-07
compound O 0 4.918942431686446e-05
heterozygous O 0 2.2312544842861826e-06
individuals O 0 3.856220303077862e-07
. O 0 2.034592171185068e-06

The O 0 0.0026761286426335573
C6 O 1 0.9999998807907104
/ O 1 0.9996641874313354
C7 O 1 0.9998132586479187
marker O 0 0.0002203303447458893
haplotypes O 0 4.0648654248798266e-05
associated O 0 7.62767854212143e-07
with O 0 1.341555844192044e-07
most O 0 1.8776676142806537e-06
C7 B-Disease 1 1.0
defects I-Disease 1 0.9446576237678528
are O 0 1.0380659176689733e-07
tabulated O 0 6.459195719799027e-05
. O 0 1.5196948197626625e-06
. O 0 5.913158929615747e-06

A O 0 4.041006832267158e-05
genome O 0 4.48244099970907e-06
- O 0 9.076976539290627e-07
wide O 0 1.1883475536933474e-07
search O 0 2.2897411611211282e-07
for O 0 3.886056276769523e-08
chromosomal O 0 0.0001748036447679624
loci O 0 2.0771003619302064e-06
linked O 0 4.364652340882458e-06
to O 0 1.1398250165939317e-07
mental O 1 0.9999990463256836
health O 0 0.007147659547626972
wellness O 1 0.8550482392311096
in O 0 1.2457064713089494e-07
relatives O 0 1.9309138110656932e-07
at O 0 6.532430916195153e-07
high O 0 9.756691952134133e-07
risk O 0 2.096491698466707e-06
for O 0 1.6733401935198344e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 3.4647101188056695e-07
the O 0 3.087650611632853e-06
Old O 0 0.001009841333143413
Order O 0 1.3361538549361285e-05
Amish O 0 0.0005551319918595254
. O 0 6.402298367902404e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 1.0
BPAD B-Disease 1 1.0
; O 1 0.9999998807907104
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 0.000910852337256074
is O 0 2.7320874096403713e-07
characterized O 0 3.5118250707455445e-07
by O 0 2.8028466658724938e-08
episodes O 0 9.453624443267472e-07
of O 0 1.9094763047178276e-05
mania B-Disease 1 0.9895427227020264
and O 0 0.00036144323530606925
/ O 1 1.0
or O 1 0.9999904632568359
hypomania B-Disease 1 1.0
interspersed O 0 0.49102017283439636
with O 0 8.956318424679921e-07
periods O 0 0.3251040279865265
of O 1 0.9708009958267212
depression B-Disease 1 1.0
. O 0 0.00021836362429894507

Compelling O 0 3.0499842978315428e-05
evidence O 0 1.9047663499804912e-06
supports O 0 1.4887999100210436e-07
a O 0 2.136922461204449e-08
significant O 0 3.192445419131218e-08
genetic O 0 3.486443631572911e-07
component O 0 5.444585440272931e-07
in O 0 1.536633220666772e-08
the O 0 9.450850768644159e-08
susceptibility O 0 1.0855452501346008e-06
to O 0 1.6272834102437628e-07
develop O 0 0.00010301966540282592
BPAD B-Disease 1 1.0
. O 0 8.195846749003977e-05

To O 0 5.250678896118188e-07
date O 0 1.2360812888800865e-06
, O 0 3.064879194880632e-08
however O 0 2.6902323924105076e-08
, O 0 2.4982250934613148e-08
linkage O 0 6.573225732608989e-07
studies O 0 3.024317152267031e-08
have O 0 1.3466653348004343e-09
attempted O 0 1.385902095307756e-07
only O 0 7.239736810049635e-09
to O 0 1.6278599801466953e-08
identify O 0 6.93424681230681e-07
chromosomal O 0 0.01391653809696436
loci O 0 1.059130227076821e-06
that O 0 1.8408954360893404e-08
cause O 0 2.62806906903279e-07
or O 0 3.042362450855762e-08
increase O 0 3.120712221971189e-08
the O 0 9.531098754678169e-08
risk O 0 7.05547904544801e-07
of O 0 1.7256072624149965e-06
developing O 0 0.00010772733367048204
BPAD B-Disease 1 1.0
. O 0 1.5453470041393302e-05

To O 0 2.3581101515901537e-07
determine O 0 2.585968275070627e-07
whether O 0 6.473329960954288e-08
there O 0 6.779063710382616e-08
could O 0 2.6475847292317667e-08
be O 0 6.312023970167502e-08
protective O 0 1.1947990969929378e-06
alleles O 0 6.043366340691136e-08
that O 0 7.051542016967005e-09
prevent O 0 5.747865827743226e-08
or O 0 2.6831248334246993e-08
reduce O 0 1.735348575948592e-08
the O 0 8.828708075725444e-08
risk O 0 5.2003861128469e-07
of O 0 2.6914236173070094e-07
developing O 0 2.5063609427888878e-05
BPAD B-Disease 1 1.0
, O 0 1.3008071064746218e-08
similar O 0 1.4465230124827144e-09
to O 0 4.267554087888925e-10
what O 0 7.259769452261366e-10
is O 0 8.307886600888992e-10
observed O 0 7.59307106079632e-09
in O 0 1.7571836208318814e-09
other O 0 1.2615648969926951e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.4152867322536622e-07
we O 0 1.4154271354982484e-07
used O 0 3.620149300331832e-06
mental O 1 0.9999610185623169
health O 0 5.48738353245426e-05
wellness O 0 0.2087807059288025
( O 0 3.4198478715552483e-07
absence O 0 1.8574269233795349e-07
of O 0 9.216228846753438e-08
any O 0 2.5191306463057117e-07
psychiatric B-Disease 1 0.999974250793457
disorder I-Disease 1 0.9998438358306885
) O 0 4.432039588664338e-07
as O 0 4.5063654141586085e-08
the O 0 1.632238166848765e-07
phenotype O 0 2.633915414662624e-07
in O 0 1.3593240311138288e-08
our O 0 1.0320230359184279e-07
genome O 0 7.095960086189734e-07
- O 0 1.1723647048711427e-06
wide O 0 2.9367259912760346e-07
linkage O 0 3.3592987165320665e-06
scan O 0 2.2778819186441979e-07
of O 0 4.4644025365414564e-08
several O 0 1.4194629471830922e-08
large O 0 1.3457601255595364e-07
multigeneration O 0 0.001967045245692134
Old O 0 6.443556776503101e-05
Order O 0 1.2882096598332282e-06
Amish O 0 5.002293619327247e-05
pedigrees O 0 2.953819375761668e-06
exhibiting O 0 4.4960287937101384e-07
an O 0 7.533898838119057e-08
extremely O 0 6.256479991861852e-07
high O 0 2.56757721217582e-06
incidence O 0 6.351970660034567e-05
of O 0 8.106984751066193e-05
BPAD B-Disease 1 1.0
. O 0 0.00015185988740995526

We O 0 7.710705176577903e-07
have O 0 2.6502929628691163e-08
found O 0 3.7640532468685706e-08
strong O 0 1.9494754255333646e-08
evidence O 0 1.1509832376077611e-07
for O 0 2.0938207612175574e-08
a O 0 4.719542232578533e-07
locus O 0 1.825558001655736e-06
on O 0 2.6927099838758295e-07
chromosome O 0 1.0949833267659415e-05
4p O 1 0.9205312728881836
at O 0 2.885499816329684e-05
D4S2949 O 0 8.137625263771042e-05
( O 0 6.615347842853225e-07
maximum O 0 1.2309662906773156e-06
GENEHUNTER O 0 0.0006891299271956086
- O 0 6.899464096932206e-06
PLUS O 0 4.5936776587041095e-06
nonparametric O 0 8.264041753136553e-06
linkage O 0 1.794275590327743e-06
score O 0 1.505535038859307e-07
= O 0 3.3753570960470825e-07
4 O 0 5.274598535720543e-08
. O 0 4.938474518212388e-09
05 O 0 5.46712044524611e-07
, O 0 1.738787602789671e-08
P O 0 9.759893373484374e-07
= O 0 9.029648140312929e-08
5 O 0 1.731311627395371e-08
. O 0 6.438574673417463e-10
22 O 0 5.201325592452122e-09
x O 0 5.785027124005637e-09
10 O 0 2.7031463734061845e-09
( O 0 3.4247902291895116e-09
- O 0 2.3076704991353836e-08
4 O 0 3.9616139702047803e-08
) O 0 1.5620972959595747e-08
; O 0 5.731332297642666e-09
SIBPAL O 0 9.479557775193825e-06
Pempirical O 0 4.7331545829365496e-06
value O 0 7.647695809964716e-08
< O 0 1.6305284589179792e-07
3 O 0 5.449944495694581e-09
x O 0 6.501713389894803e-09
10 O 0 3.508943802188469e-09
( O 0 1.6072071451489478e-09
- O 0 6.45394759857254e-09
5 O 0 6.581817313389138e-09
) O 0 3.171185092298856e-09
) O 0 1.0331880906377933e-09
and O 0 2.5988403096199875e-10
suggestive O 0 4.3205158561931967e-08
evidence O 0 2.0212342022318808e-08
for O 0 1.081379163991869e-08
a O 0 1.8932090029011306e-07
locus O 0 1.6621866052446421e-06
on O 0 2.3548921035398962e-07
chromosome O 0 2.261424197058659e-05
4q O 0 5.38897693331819e-05
at O 0 1.768065658325213e-06
D4S397 O 0 1.306463764194632e-05
( O 0 2.461385406604677e-07
maximum O 0 9.775449143489823e-07
GENEHUNTER O 0 0.0002066984015982598
- O 0 4.028833700431278e-06
PLUS O 0 3.4331615097471513e-06
nonparametric O 0 7.189085863501532e-06
linkage O 0 1.0320727596990764e-06
score O 0 1.2710066243926121e-07
= O 0 2.7816216174869624e-07
3 O 0 4.1716752718912176e-08
. O 0 4.710591028356248e-09
29 O 0 5.577805595180507e-08
, O 0 2.046160041402345e-08
P O 0 1.4928704104022472e-06
= O 0 1.7398697593762336e-07
2 O 0 1.7972702437418775e-08
. O 0 1.6631477306461306e-09
57 O 0 9.313557924883753e-09
x O 0 7.388430312005312e-09
10 O 0 5.3041051550906104e-09
( O 0 5.337972286412196e-09
- O 0 2.416306266184165e-08
3 O 0 2.6117431772831878e-08
) O 0 1.1340691941086334e-08
; O 0 6.688960496603613e-09
SIBPAL O 0 1.041205268847989e-05
Pempirical O 0 3.798074885708047e-06
value O 0 8.862163269895973e-08
< O 0 2.2944210797959386e-07
1 O 0 9.473279938276846e-09
x O 0 8.274775531447176e-09
10 O 0 4.097467254382536e-09
( O 0 2.7677879987919596e-09
- O 0 6.975745758808216e-09
3 O 0 8.993086275665974e-09
) O 0 1.9129497985659327e-09
) O 0 5.634503974505378e-10
that O 0 1.0564570052107314e-10
are O 0 4.4016607025909593e-10
linked O 0 5.365883382069114e-08
to O 0 5.524422164171483e-08
mental O 1 0.9938575625419617
health O 0 0.006359353195875883
wellness O 1 0.8662031292915344
. O 0 8.412034731009044e-06

These O 0 2.5798888714234636e-07
findings O 0 2.787376160995336e-07
are O 0 9.35186506012542e-09
consistent O 0 6.897057147625674e-08
with O 0 2.156678169384918e-09
the O 0 1.4286463567714236e-08
hypothesis O 0 2.9601361362097123e-08
that O 0 4.0626019215395104e-10
certain O 0 1.5409468145932692e-09
alleles O 0 4.360749539245035e-09
could O 0 3.64357055637754e-09
prevent O 0 4.0300911052781885e-08
or O 0 2.1205476485874897e-08
modify O 0 3.8833739779420284e-08
the O 0 8.194176359666017e-08
clinical O 0 6.061437943571946e-06
manifestations O 0 7.99380723037757e-06
of O 0 3.57527460437268e-05
BPAD B-Disease 1 1.0
and O 0 1.1202631355899939e-07
perhaps O 0 1.2433908125331072e-07
other O 0 2.0972182213085944e-08
related O 0 1.558318399474956e-05
affective B-Disease 1 0.9998737573623657
disorders I-Disease 1 0.9999998807907104
. O 0 9.896768460748717e-05

Segregation O 1 0.9292489290237427
distortion O 1 0.9256972074508667
in O 0 0.0012634829618036747
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0003772058116737753

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999935626983643
DM B-Disease 1 1.0
) O 0 1.49741817949689e-05
is O 0 2.1046881215625035e-07
an O 0 6.156206495688821e-07
autosomal B-Disease 1 0.9167497754096985
dominant I-Disease 1 0.6027016043663025
disease I-Disease 0 0.046598661690950394
which O 0 2.1513875125833692e-08
, O 0 2.6446777212640882e-08
in O 0 4.860124036554225e-08
the O 0 3.477265693163645e-07
typical O 0 1.4660366105090361e-05
pedigree O 0 3.506494749672129e-06
, O 0 1.3740780957505194e-08
shows O 0 6.385685225041016e-08
a O 0 1.653905741250128e-07
three O 0 1.6269403602109378e-07
generation O 0 5.595341008302057e-06
anticipation O 0 4.045429523102939e-05
cascade O 0 0.0003427228075452149
. O 0 6.763068540749373e-06

This O 0 1.1192951205885038e-06
results O 0 1.3880305687052896e-06
in O 0 1.285293933506182e-06
infertility B-Disease 1 0.9999877214431763
and O 0 0.3739182949066162
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999997615814209
CDM B-Disease 1 0.9999992847442627
) O 0 1.1486902451451897e-07
with O 0 9.337571604817185e-09
the O 0 8.126067996272468e-08
disappearance O 0 2.29298893827945e-05
of O 0 9.136121661867946e-05
DM B-Disease 1 1.0
in O 0 3.8036282603570726e-06
that O 0 1.477776322644786e-06
pedigree O 0 0.00017842554370872676
. O 0 1.3814863450534176e-05

The O 0 3.7737258935521822e-06
concept O 0 3.1275164928956656e-06
of O 0 1.918579982884694e-06
segregation O 0 5.008064545108937e-05
distortion O 0 6.847803160781041e-05
, O 0 1.0227542190932581e-07
where O 0 7.684792535656015e-08
there O 0 3.2989213138989726e-08
is O 0 2.9119766153939963e-08
preferential O 0 9.050719285141895e-08
transmission O 0 5.258175406197552e-07
of O 0 6.227288196214431e-08
the O 0 3.933634573627387e-08
larger O 0 2.0998237815206267e-08
allele O 0 2.978917912344059e-08
at O 0 2.4917443397498573e-07
the O 0 8.729435307941458e-07
DM B-Disease 1 1.0
locus O 0 2.9433474537654547e-06
, O 0 4.181344159803757e-09
has O 0 1.0439861197752975e-09
been O 0 2.26155072446943e-09
put O 0 4.782919837964528e-09
forward O 0 2.8678588392949678e-08
to O 0 2.8839254540002912e-08
explain O 0 5.795632205263246e-07
partially O 0 1.4455990822170861e-06
the O 0 1.6877909558843385e-07
maintenance O 0 2.414477785350755e-05
of O 0 1.5809495380381122e-05
DM B-Disease 1 1.0
in O 0 4.149895858063246e-07
the O 0 5.72358374029136e-07
population O 0 1.963716869113341e-07
. O 0 3.6791817592529696e-07

In O 0 3.5754117106989725e-06
a O 0 1.1929500942642335e-06
survey O 0 1.4054426173970569e-06
of O 0 1.1874993788296706e-06
DM B-Disease 1 1.0
in O 0 3.4810747706615075e-07
Northern O 0 5.768110895587597e-07
Ireland O 0 5.341061637409439e-07
, O 0 1.4312541907202103e-07
59 O 0 1.6963883808784885e-06
pedigrees O 0 4.406366315379273e-06
were O 0 5.687643920282426e-07
ascertained O 0 3.1662621040595695e-05
. O 0 2.5152808120765258e-06

Sibships O 0 0.024326931685209274
where O 0 1.8239866221847478e-06
the O 0 2.2885338069045247e-07
status O 0 1.3224118333710067e-07
of O 0 5.7686232679543537e-08
all O 0 6.4631495710898434e-09
the O 0 2.5347896226435296e-08
members O 0 8.875404411412546e-09
had O 0 1.805836902235569e-08
been O 0 8.376597193660018e-09
identified O 0 2.070121674080383e-08
were O 0 1.2363431167727867e-08
examined O 0 6.683148257025096e-08
to O 0 5.733737928892424e-09
determine O 0 5.303855132865465e-08
the O 0 8.03377204761091e-08
transmission O 0 7.551910243819293e-07
of O 0 1.7595597512354288e-07
the O 0 2.039615992543986e-06
DM B-Disease 1 1.0
expansion O 0 2.6713119041232858e-06
from O 0 6.591694301505413e-08
affected O 0 3.5523058272701746e-08
parents O 0 1.3436923573806325e-08
to O 0 1.6464268171034746e-08
their O 0 1.6620249709831114e-07
offspring O 0 4.628947408491513e-06
. O 0 1.9072566601607832e-06

Where O 0 1.2282363059057388e-05
the O 0 2.4505111468897667e-06
transmitting O 0 0.0038937905337661505
parent O 0 6.921423391759163e-06
was O 0 2.7466559913591482e-05
male O 0 7.1960212153499015e-06
, O 0 3.690694256874849e-07
58 O 0 1.4611053302360233e-05
. O 0 2.6648792754713213e-06

3 O 0 7.86159398558084e-06
% O 0 2.5056917252186395e-07
of O 0 9.590053906549656e-08
the O 0 4.9081464226219396e-08
offspring O 0 6.788224027332035e-08
were O 0 2.6624324078738937e-08
affected O 0 1.4702338901884104e-08
, O 0 2.9448792293607085e-09
and O 0 3.337367271427638e-09
in O 0 8.366217940647402e-09
the O 0 2.693939649134336e-08
case O 0 6.387414686059856e-08
of O 0 1.660318673657457e-07
a O 0 1.8298634358870913e-06
female O 0 6.289662451308686e-06
transmitting O 0 0.0002594386169221252
parent O 0 6.039812205926864e-07
, O 0 1.6905616462281614e-07
68 O 0 4.428386546351248e-06
. O 0 1.469661356168217e-06

7 O 0 0.0001264924358110875
% O 0 3.4229481116199167e-06
were O 0 1.9018713146579103e-06
affected O 0 3.55346219294006e-06
. O 0 4.8788760977913626e-06

Studies O 0 3.7758025428047404e-05
on O 0 3.3026979053829564e-06
meiotic O 0 0.00045539336861111224
drive O 0 5.704131126549328e-06
in O 0 1.1609981811488979e-06
DM B-Disease 1 1.0
have O 0 2.8990863043532045e-08
shown O 0 8.05499169587165e-08
increased O 0 6.916738470863493e-08
transmission O 0 9.588919880343383e-08
of O 0 9.504772080504154e-09
the O 0 1.6067358998839154e-08
larger O 0 1.548729322564668e-08
allele O 0 1.3107994689676161e-08
at O 0 6.956508968869457e-08
the O 0 1.9166073172982578e-07
DM B-Disease 1 0.9999982118606567
locus O 0 8.691290531714913e-07
in O 0 2.743564486706873e-08
non O 0 1.8796671383825014e-06
- O 0 0.00017967235180549324
DM O 1 1.0
heterozygotes O 0 1.7980602933675982e-05
for O 0 5.674705789715517e-07
CTGn O 0 0.00683252327144146
. O 0 6.631570613535587e-06

This O 0 7.70232645663782e-07
study O 0 2.8857090228484594e-07
provides O 0 2.5230397326936327e-08
further O 0 9.293647629249335e-09
evidence O 0 9.187112226527461e-08
that O 0 1.6164955596309483e-08
the O 0 1.3930352906754706e-06
DM B-Disease 1 1.0
expansion O 0 6.082365416659741e-06
tends O 0 2.823133797846822e-07
to O 0 2.4206702420315196e-08
be O 0 3.766279377259707e-08
transmitted O 0 1.4635812704000273e-06
preferentially O 0 2.8492343062680447e-06
. O 0 2.023604565692949e-06

Diagnosis O 1 0.9999994039535522
of O 1 0.9980849027633667
hemochromatosis B-Disease 1 1.0
. O 0 0.21612480282783508

If O 0 0.0011169129284098744
untreated O 1 1.0
, O 0 0.01005235780030489
hemochromatosis B-Disease 1 1.0
can O 0 3.5828721593134105e-05
cause O 1 0.9986780285835266
serious O 1 0.9999344348907471
illness O 1 0.9997791647911072
and O 0 8.13613283412451e-08
early B-Disease 0 2.278232386743184e-06
death I-Disease 0 1.2563957625388866e-06
, O 0 1.0139743267245649e-08
but O 0 4.646493856341749e-09
the O 0 2.018603595388413e-07
disease O 0 1.628988320589997e-05
is O 0 2.0113546383981884e-08
still O 0 4.334986059006951e-08
substantially O 0 2.9377932264651463e-07
under O 0 7.168642696342431e-06
- O 1 0.9299613833427429
diagnosed O 0 0.007947420701384544
. O 0 4.038188762933714e-06

The O 0 1.3966101505502593e-05
cornerstone O 0 0.0001314570545218885
of O 0 8.792138714852626e-07
screening O 0 5.654027290802333e-07
and O 0 1.7260527229723266e-08
case O 0 1.0008186990262402e-07
detection O 0 7.551707881248149e-07
is O 0 1.4325700625761328e-08
the O 0 5.005065517593721e-08
measurement O 0 4.800287570105866e-06
of O 0 1.1321326383040287e-06
serum O 0 0.07783358544111252
transferrin O 0 0.2042531967163086
saturation O 0 1.5022870684333611e-05
and O 0 4.7410871673037036e-08
the O 0 5.352034122552141e-07
serum O 0 6.364169530570507e-05
ferritin O 0 0.0003602316719479859
level O 0 1.0536755326029379e-05
. O 0 2.8932256554980995e-06

Once O 0 9.332771696790587e-06
the O 0 8.93217929842649e-07
diagnosis O 0 6.557360757142305e-05
is O 0 2.0355302865482372e-07
suspected O 0 1.2614799743460026e-05
, O 0 1.2144371908107132e-07
physicians O 0 1.7425382736746542e-07
must O 0 1.22973958127659e-07
use O 0 8.769361556915101e-07
serum O 1 0.9999785423278809
ferritin O 1 0.9999994039535522
levels O 0 3.5999557439936325e-05
and O 0 1.550198902577904e-07
hepatic O 0 0.23277369141578674
iron O 0 0.17614756524562836
stores O 0 2.214071486150715e-07
on O 0 8.755041136510044e-08
liver O 0 3.718491541349067e-07
biopsy O 0 2.2894508333592967e-07
specimens O 0 1.9912762994067634e-08
to O 0 3.452164776263089e-09
assess O 0 3.8662250290144584e-07
patients O 0 2.1830008023471237e-08
for O 0 8.759130309954344e-09
the O 0 2.1022447072027717e-07
presence O 0 2.1701287096220767e-06
of O 0 2.9279519367264584e-05
iron B-Disease 1 0.9999992847442627
overload I-Disease 1 0.9999892711639404
. O 0 1.8858489056583494e-05

Liver O 1 0.9999972581863403
biopsy O 1 0.8420056104660034
is O 0 3.1628871965949656e-07
also O 0 1.980537689405537e-08
used O 0 1.3284306099592413e-08
to O 0 8.309554822005794e-09
establish O 0 2.186806256077034e-07
the O 0 2.0974107428628486e-07
presence O 0 2.627234891861008e-07
or O 0 9.837813763624581e-08
absence O 0 3.83823817173834e-06
of O 0 8.606439951108769e-05
cirrhosis B-Disease 1 1.0
, O 0 6.738660829341825e-08
which O 0 8.802238937732909e-09
can O 0 1.041578023830425e-08
affect O 0 5.406328114077041e-07
prognosis O 0 0.014720340259373188
and O 0 3.625756335168262e-07
management O 0 0.0002115256356773898
. O 0 5.430203600553796e-06

A O 0 1.5508390788454562e-05
DNA O 0 5.1947035899502225e-06
- O 0 5.805168257211335e-07
based O 0 3.813772764260648e-08
test O 0 1.784873049359703e-08
for O 0 6.559258913796384e-09
the O 0 1.406870637765678e-07
HFE O 0 0.11858470737934113
gene O 0 5.1495241848442674e-08
is O 0 1.5209302706153949e-09
commercially O 0 6.1815357277339444e-09
available O 0 1.5635989170093012e-09
, O 0 1.013482631151419e-09
but O 0 1.0071851130888376e-09
its O 0 2.321018044426637e-09
place O 0 8.826245512238984e-09
in O 0 7.679353153378088e-09
the O 0 9.219094465606759e-08
diagnosis O 0 0.00041674013482406735
of O 0 0.00019338457786943763
hemochromatosis B-Disease 1 1.0
is O 0 2.3534557840321213e-06
still O 0 3.1431616775989824e-07
being O 0 5.002536340725783e-07
evaluated O 0 2.7680302991939243e-06
. O 0 1.6876747395144776e-06

Currently O 0 5.584029167948756e-06
, O 0 5.699090621646974e-08
the O 0 2.2469761162824398e-08
most O 0 3.882631549601001e-09
useful O 0 3.133601822469245e-08
role O 0 4.348542503862518e-08
for O 0 4.832565903001296e-09
this O 0 8.33423730028926e-09
test O 0 8.787912619823146e-09
is O 0 5.4107309743756105e-09
in O 0 9.707241233058994e-09
the O 0 5.794991153607043e-08
detection O 0 9.151937774731778e-06
of O 0 3.156024467898533e-05
hemochromatosis B-Disease 1 1.0
in O 0 2.1903260858380236e-06
the O 0 8.639063366899791e-07
family O 0 1.5297105449008086e-07
members O 0 5.460286889302779e-09
of O 0 6.995627899186729e-08
patients O 0 5.441437966879903e-09
with O 0 2.4038981916163493e-09
a O 0 4.12405796623716e-07
proven O 0 2.4652811134728836e-06
case O 0 8.30263502393791e-08
of O 0 2.2682850442379277e-07
the O 0 1.6923858083828236e-06
disease O 0 0.0003434153622947633
. O 0 2.221883960373816e-06

It O 0 6.406772854461451e-07
is O 0 2.195926072090515e-07
crucial O 0 4.544483545032563e-06
to O 0 2.1365635802794714e-06
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.9723291397094727
because O 0 2.501864173609647e-06
phlebotomy O 1 1.0
therapy O 0 0.052932173013687134
can O 0 8.118182392991002e-08
avert O 0 0.21656790375709534
serious O 1 1.0
chronic O 1 1.0
disease O 1 0.9999997615814209
and O 0 1.1852824854940991e-07
can O 0 4.3456736875668867e-08
even O 0 6.098239424545682e-08
lead O 0 5.925720643062959e-07
to O 0 1.340962398899137e-07
normal O 0 6.49268549750559e-05
life O 0 1.1773016922234092e-05
expectancy O 0 3.6070483474759385e-05
. O 0 2.755191417236347e-07
. O 0 1.8959276530949865e-06

Prevalence O 0 0.0036407834850251675
of O 0 2.5333358735224465e-06
the O 0 4.087387878826121e-06
I1307K O 0 0.01280536875128746
APC B-Disease 0 0.00016909942496567965
gene O 0 3.3639844332356006e-07
variant O 0 1.5552097920590313e-07
in O 0 1.67016427354838e-08
Israeli O 0 1.3736007531406358e-06
Jews O 0 1.3418693356470612e-07
of O 0 1.51253569669052e-08
differing O 0 4.304638423491269e-09
ethnic O 0 7.924301215211926e-09
origin O 0 2.4970530532186785e-08
and O 0 9.656936583724018e-09
risk O 0 2.7279111236566678e-06
for O 0 0.00047503350651822984
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.009524213150143623

BACKGROUND O 0 0.0037861515302211046
& O 0 0.0006546213990077376
AIMS O 0 4.722662197309546e-05
Israeli O 0 1.9773893654928543e-05
Jews O 0 6.161480428090726e-07
of O 0 1.0026146668451474e-07
European O 0 2.5799078429145084e-08
birth O 0 1.0175453013516744e-07
, O 0 8.267739382006312e-09
i O 0 4.21128021343975e-08
. O 0 5.543820069675576e-09
e O 0 6.335170610327623e-08
. O 0 1.981772523862446e-09
, O 0 3.995928921085579e-09
Ashkenazim O 0 1.5367760397566599e-06
, O 0 4.697939814946039e-09
have O 0 3.548877414161211e-09
the O 0 2.586663754300389e-07
highest O 1 0.9999980926513672
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9999939203262329
of O 0 2.0257789401512127e-06
any O 0 1.822465378609195e-07
Israeli O 0 5.229767339187674e-06
ethnic O 0 1.6904262167827255e-07
group O 0 3.2584244991085143e-07
. O 0 5.425826543614676e-07

The O 0 8.589393110014498e-05
I1307K O 0 0.0045914375223219395
APC B-Disease 0 0.0004568150616250932
gene O 0 1.8794646621245192e-06
variant O 0 1.0116139037563698e-06
was O 0 1.1558212236195686e-06
found O 0 2.2794073117893277e-07
in O 0 2.564999874721252e-07
6 O 0 1.743846405588556e-05
. O 0 4.224851181788836e-06

1 O 0 7.258984169311589e-06
% O 0 3.625147826369357e-07
of O 0 1.4590769126243686e-07
American O 0 4.271500415597984e-07
Jews O 0 4.1077760215557646e-07
, O 0 3.016758398644015e-08
28 O 0 3.329552384911949e-07
% O 0 4.429711353282073e-08
of O 0 6.589959866687423e-08
their O 0 1.411126390848949e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.0002758455229923129
, O 0 2.521480979567059e-08
but O 0 2.1011208328758357e-09
not O 0 4.073606785226502e-09
in O 0 4.397963948576944e-08
non O 0 7.537846613558941e-06
- O 0 1.495891046943143e-05
Jews O 0 9.594089533493388e-06
. O 0 3.2317032037099125e-06

We O 0 2.7610619781626156e-06
assessed O 0 4.248426648700843e-06
the O 0 1.855838263509213e-06
I1307K O 0 0.0007432840648107231
prevalence O 0 2.5159111828543246e-05
in O 0 9.209077234118013e-08
Israeli O 0 2.04814386961516e-06
Jews O 0 1.8195044049207354e-07
of O 0 2.0063696481997795e-08
differing O 0 2.452259950658231e-09
ethnic O 0 2.9808828738708826e-09
origin O 0 1.2192991505344253e-08
and O 0 1.1428897828125173e-08
risk O 0 2.8535362162074307e-06
for O 0 0.0001543786929687485
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0038223660085350275

METHODS O 0 1.3938903975940775e-05
DNA O 0 3.670007345135673e-06
samples O 0 1.314873969704422e-07
from O 0 9.193387029426958e-08
500 O 0 2.2354090845055907e-07
unrelated O 0 1.6630698951303202e-07
Jews O 0 5.944637138100006e-08
of O 0 3.155643923946627e-08
European O 0 2.077582017534496e-08
or O 0 3.0359224467702006e-08
non O 0 2.2664103482838982e-07
- O 0 9.670451817100911e-08
European O 0 6.516984285553917e-09
origin O 0 1.0052241705693632e-08
, O 0 1.8390134970402983e-09
with O 0 1.0007815687274046e-09
or O 0 7.869204843302668e-09
without O 0 1.7108966687828797e-08
a O 0 1.406932312875142e-07
personal O 0 4.5954999450259493e-07
and O 0 3.876269971669899e-08
/ O 0 4.7006058593979105e-05
or O 0 1.8954888503230904e-07
family O 0 1.1939864918986132e-07
history O 0 7.752216220069386e-07
of O 0 1.8493929019314237e-06
neoplasia B-Disease 1 0.9756137728691101
, O 0 3.110004698214652e-08
were O 0 4.211585391544759e-08
examined O 0 2.260937748133074e-07
for O 0 2.169046986466583e-08
the O 0 2.229464826086769e-07
I1307K O 0 7.640086550964043e-06
variant O 0 5.9579292610578705e-08
by O 0 8.61054516576587e-09
the O 0 2.290253675596432e-08
allele O 0 1.9197861078623646e-08
- O 0 6.131655538865743e-08
specific O 0 3.8847002059583247e-08
oligonucleotide O 0 3.7253316804708447e-06
( O 0 7.535952590842498e-07
ASO O 0 9.05181368580088e-05
) O 0 4.7527944957437285e-07
method O 0 1.9933906969527015e-06
. O 0 1.8667584527065628e-06

RESULTS O 0 2.7268935809843242e-05
In O 0 6.088373538659653e-07
persons O 0 5.520113859347475e-07
at O 0 1.028277438308578e-06
average O 0 1.2800705917470623e-06
risk O 0 9.393071422891808e-07
for O 0 3.4479660826036707e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.887227209517732e-05
I1307K O 0 0.29649338126182556
was O 0 2.688450422283495e-06
found O 0 9.48015284052417e-08
in O 0 6.286060738602828e-08
5 O 0 8.887756166586769e-07
. O 0 7.868695206525445e-07

0 O 0 5.673976829712046e-06
% O 0 5.417466013568628e-07
of O 0 2.490038752966939e-07
120 O 0 3.9119666439546563e-07
European O 0 1.3462684478326992e-07
and O 0 1.1358588380971923e-07
1 O 0 2.310631771251792e-06
. O 0 1.6987504523058305e-06

6 O 0 2.9243134122225456e-05
% O 0 6.915636276971782e-07
of O 0 2.5208467491211195e-07
188 O 0 2.910800560584903e-07
non O 0 2.391360283127142e-07
- O 0 2.232226279375027e-07
European O 0 5.015969861688063e-08
Jews O 0 1.7479959524280275e-07
( O 0 4.8169429334166125e-08
P O 0 1.8390551304037217e-06
= O 0 1.9506512671796372e-07
0 O 0 2.1620499168761853e-08
. O 0 8.724914124513816e-09
08 O 0 8.676756237946393e-07
) O 0 7.714384508972216e-08
. O 0 2.388014763710089e-07

It O 0 6.900595508341212e-06
occurred O 0 6.927837239345536e-05
in O 0 2.0857448816968827e-06
15 O 0 1.0132271199836396e-05
. O 0 7.480035037588095e-06

4 O 0 2.3588852855027653e-05
% O 0 8.393006964979577e-07
of O 0 3.9899984471958305e-07
52 O 0 2.392442411291995e-06
Ashkenazi O 0 3.487696449155919e-05
Israelis O 0 2.1039688817836577e-06
with O 0 7.227887977023784e-08
familial O 0 9.5799368864391e-05
cancer B-Disease 0 8.662675827508792e-05
( O 0 4.527016699285014e-06
P O 0 0.049188025295734406
= O 0 2.3307359242608072e-06
0 O 0 1.95998541840936e-08
. O 0 1.8846615379430887e-09
02 O 0 3.434166160332097e-07
) O 0 2.145547073340026e-09
and O 0 5.647447509637971e-10
was O 0 2.1591652910046832e-08
not O 0 1.9460788536207474e-09
detected O 0 1.916624903230968e-08
in O 0 3.8943799296475845e-09
51 O 0 1.6884669662431406e-07
non O 0 1.3411163308774121e-06
- O 0 6.186634209370823e-07
European O 0 3.141794735483927e-08
Jews O 0 1.6392019119848555e-07
at O 0 2.8045693056810705e-07
increased O 0 4.4181177827340434e-07
cancer B-Disease 0 1.4262565855460707e-05
risk O 0 1.4819227089901688e-06
. O 0 1.7599805914869648e-06

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
occurred O 1 0.9564051032066345
personally O 0 8.067045564530417e-05
or O 0 5.817039436806226e-07
in O 0 1.2047634356804338e-07
the O 0 2.9520154498641205e-07
families O 0 6.24566567353213e-08
of O 0 4.472026375879068e-07
13 O 0 1.2203215646877652e-06
of O 0 2.4496373498550383e-06
20 O 0 7.913209628895856e-06
Ashkenazi O 0 0.00019264181901235133
I1307K O 0 6.31783259450458e-05
carriers O 0 1.0160500352185409e-07
, O 0 2.3466773413360897e-08
8 O 0 1.3349156802178186e-07
of O 0 9.071544582184288e-08
whom O 0 1.0530604299674451e-07
also O 0 3.07621164097327e-08
had O 0 1.7904552862546552e-07
a O 0 2.2071028524806025e-06
personal O 0 2.1256160835037008e-05
or O 0 1.6726513649700792e-06
family O 0 2.5872013793559745e-06
history O 0 4.933825766784139e-05
of O 0 0.046068232506513596
noncolonic O 1 1.0
neoplasia B-Disease 1 1.0
. O 0 0.0002489071630407125

CONCLUSIONS O 0 0.00017190280777867883
The O 0 5.1213526603532955e-05
I1307K O 0 0.006092206574976444
APC O 0 7.519339851569384e-05
variant O 0 9.259199487132719e-07
may O 0 6.378053285516216e-08
represent O 0 4.214864190998924e-08
a O 0 2.321214651601622e-07
susceptibility O 0 4.281976089259842e-06
gene O 0 2.676475787666277e-07
for O 0 2.0709912007532694e-07
colorectal B-Disease 1 1.0
, I-Disease 0 2.291194505232852e-06
or I-Disease 0 5.027972065363429e-07
other I-Disease 0 2.4194653391873544e-08
, I-Disease 0 5.860169949301053e-07
cancers I-Disease 0 0.39721357822418213
in O 0 4.815794909518445e-07
Ashkenazi O 1 0.9775561690330505
Jews O 0 4.70109807793051e-06
, O 0 2.325170989081471e-08
and O 0 1.0960247820435143e-08
partially O 0 3.1688157378084725e-06
explains O 0 4.5077840127305535e-07
the O 0 3.940212423003686e-08
higher O 0 4.910506277155946e-07
incidence O 0 4.596312282956205e-05
of O 0 0.09903915226459503
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.0394521268608514e-05
European O 0 5.546992269955808e-06
Israelis O 0 2.0867573766736314e-05
. O 0 1.3784482462142478e-06

Systematic O 0 3.983556234743446e-05
analysis O 0 4.260736659489339e-06
of O 0 4.469746727409074e-06
coproporphyrinogen O 1 0.9647719264030457
oxidase O 0 0.18047313392162323
gene O 0 0.004746886435896158
defects O 1 0.9333186149597168
in O 0 4.4806756704929285e-06
hereditary B-Disease 1 0.9999997615814209
coproporphyria I-Disease 1 0.9999998807907104
and O 0 6.1617074607056566e-06
mutation O 0 1.3922456673753913e-05
update O 0 4.507734047365375e-05
. O 0 5.782867447123863e-06

Hereditary B-Disease 1 0.9999997615814209
coproporphyria I-Disease 1 0.9999990463256836
( O 0 0.07376986742019653
HC B-Disease 1 1.0
) O 0 5.797604899271391e-05
is O 0 5.456062126540928e-07
an O 0 3.5077991924481466e-06
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.15064939856529236
autosomal O 1 1.0
dominant O 1 0.9967124462127686
inheritance O 0 0.30017560720443726
caused O 0 9.525391942588612e-05
by O 0 1.1806305337813683e-06
deficient B-Disease 0 0.08972486108541489
activity I-Disease 0 8.526449164492078e-06
of I-Disease 0 1.75118420884246e-05
coproporphyrinogen I-Disease 1 0.997793436050415
III I-Disease 1 1.0
oxidase I-Disease 0 0.0019942419603466988
( O 0 3.811371425399557e-05
CPO O 0 0.004612920805811882
) O 0 1.2242485354363453e-05
. O 0 9.807153219298925e-06

Clinical O 1 0.5728071928024292
manifestations O 0 0.00033046447788365185
of O 0 8.73517547006486e-06
the O 0 2.52598911174573e-05
disease O 1 0.6626400947570801
are O 0 9.022500080391183e-09
characterized O 0 3.3765030593713163e-07
by O 0 6.36947063981097e-08
acute O 0 0.09693437814712524
attacks O 0 2.3227457859320566e-06
of O 0 0.15762414038181305
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 4.867271741204604e-07
precipitated O 0 9.59032968239626e-06
by O 0 4.8578161937484765e-08
drugs O 0 2.423428782094561e-07
, O 0 9.967856584580659e-08
fasting O 0 3.0206132578314282e-05
, O 0 4.0879038465391204e-07
cyclical O 1 0.977102518081665
hormonal O 0 0.050172533839941025
changes O 0 1.2261467929874925e-07
, O 0 3.265352006565081e-07
or O 0 8.371076546609402e-06
infectious B-Disease 1 0.9999991655349731
diseases I-Disease 1 0.9999997615814209
. O 0 0.0003349743492435664

Skin O 1 1.0
photosensitivity O 1 0.9999880790710449
may O 0 1.5800420442246832e-05
also O 0 4.404680566949537e-07
be O 0 3.4681184502005635e-07
present O 0 3.1431247862201417e-06
. O 0 6.9995644480513874e-06

The O 0 5.651920673699351e-06
seven O 0 6.927445497240114e-07
exons O 0 2.147396116924938e-06
, O 0 1.1533423105447582e-07
the O 0 8.632532626506872e-07
exon O 0 6.480178126366809e-05
/ O 0 5.323413643054664e-05
intron O 0 2.7521775336936116e-05
boundaries O 0 6.844675937145439e-08
and O 0 5.401471714350237e-09
part O 0 5.467105523848659e-08
of O 0 2.772981702037214e-07
3 O 0 8.416331525040732e-07
noncoding O 0 1.0093346645589918e-05
sequence O 0 6.379561909852782e-07
of O 0 3.3024352319444006e-07
the O 0 3.6933914770997944e-07
CPO O 0 2.535318890295457e-05
gene O 0 2.2542650413015508e-08
were O 0 1.3379663599266678e-08
systematically O 0 3.746876586774306e-08
analyzed O 0 8.883296764850002e-09
by O 0 1.2395111603780151e-09
an O 0 6.0520619626913685e-09
exon O 0 1.4179400409375376e-07
- O 0 7.129251855531038e-08
by O 0 6.558936149758665e-08
- O 0 1.872135499070282e-06
exon O 0 5.663267074851319e-06
denaturing O 0 2.084947300318163e-05
gradient O 0 5.852412414242281e-06
gel O 0 9.291076821682509e-06
electrophoresis O 0 6.676036718999967e-05
( O 0 2.3538575533166295e-06
DGGE O 0 0.014398310333490372
) O 0 5.9578727729103775e-08
strategy O 0 2.7557634396657704e-08
followed O 0 6.288636722473484e-09
by O 0 8.610770985129079e-10
direct O 0 7.791586931205075e-09
sequencing O 0 2.6927837737389382e-08
in O 0 5.141414849418879e-09
seven O 0 4.4031512658193606e-08
unrelated O 0 6.240188668016344e-07
heterozygous O 0 3.8382088973776263e-07
HC B-Disease 1 0.8324317336082458
patients O 0 6.43779500819619e-08
from O 0 3.3431984292064953e-08
France O 0 8.142327345694866e-08
, O 0 2.4155966116268246e-08
Holland O 0 5.816984298689931e-07
, O 0 2.407891486200242e-08
and O 0 1.3541303189867904e-08
Czech O 0 2.4529570055165095e-06
Republic O 0 1.435790636605816e-05
. O 0 6.531984581670258e-06

Seven O 0 6.190250132931396e-06
novel O 0 1.8307674736206536e-06
mutations O 0 1.5409541731514764e-07
and O 0 4.82532680479153e-09
two O 0 6.992103784853043e-09
new O 0 2.6677902553728927e-08
polymorphisms O 0 1.6154742752405582e-06
were O 0 6.08775792443339e-07
detected O 0 9.982656592910644e-06
. O 0 1.908353624457959e-06

Among O 0 3.2316921760866535e-07
these O 0 1.5785825979719448e-08
mutations O 0 1.7085389103499438e-08
two O 0 5.186782114918742e-09
are O 0 1.6458491458593016e-08
missense O 0 2.5028905383805977e-06
( O 0 6.290115379670169e-07
G197W O 0 2.9244723918964155e-05
, O 0 1.4232534795155516e-07
W427R O 0 4.807815003005089e-06
) O 0 5.429259175571133e-08
, O 0 3.5342189175224803e-09
two O 0 5.561294535993966e-09
are O 0 4.715463575166723e-09
nonsense O 0 2.595272462713183e-06
( O 0 4.952173640049295e-07
Q306X O 0 4.2260668124072254e-05
, O 0 1.0681697659720157e-07
Q385X O 0 1.658669498283416e-05
) O 0 4.2755349483059035e-08
, O 0 3.033866047275069e-09
two O 0 1.5448226031722356e-09
are O 0 8.186935573917253e-10
small O 0 2.791493258769151e-08
deletions O 0 5.367792255128734e-07
( O 0 1.053713049259386e-06
662de14bp O 0 8.865262498147786e-05
; O 0 1.6446949757664697e-07
1168del3bp O 0 5.308110121404752e-05
removing O 0 3.1943268368195277e-06
a O 0 1.0323956303182058e-06
glycine O 0 2.3809704998711823e-06
at O 0 1.2375461437841295e-06
position O 0 4.0226771602647204e-07
390 O 0 6.01608689976274e-07
) O 0 8.50448511613422e-09
, O 0 1.146627126580313e-09
and O 0 8.223949299335231e-10
one O 0 2.89444912482395e-09
is O 0 5.4043156616501165e-09
a O 0 4.3664449833613617e-08
splicing O 0 2.5641122647357406e-07
mutation O 0 4.419398180743883e-08
( O 0 6.149352316242584e-08
IVS1 O 0 5.6562403187854216e-05
- O 0 3.313648448965978e-06
15c O 0 1.299206542171305e-05
- O 0 1.1988601045231917e-06
- O 0 9.396404152539617e-07
> O 0 9.458890986024926e-07
g O 0 1.4495098810130003e-07
) O 0 4.74870498479163e-09
which O 0 8.150493058245445e-10
creates O 0 9.455354721410458e-09
a O 0 2.8644148386547386e-08
new O 0 5.65563489374199e-08
acceptor O 0 1.7848478819360025e-06
splice O 0 4.3781023123301566e-05
site O 0 1.5423804143210873e-05
. O 0 3.887460934492992e-06

The O 0 3.5210225178161636e-05
pathological O 0 0.0009733471088111401
significance O 0 1.3485237104760017e-05
of O 0 2.2675396849081153e-06
the O 0 1.38434108976071e-06
point O 0 6.9180437094473746e-06
mutations O 0 3.1839115877119184e-07
G197W O 0 1.6854384739417583e-05
, O 0 2.0157256130914902e-07
W427R O 0 2.874571509892121e-05
, O 0 4.729860236807326e-08
and O 0 8.90222651150907e-09
the O 0 8.551693042591069e-08
in O 0 2.4251718855339277e-07
- O 0 6.757485152775189e-06
frame O 0 2.539565866754856e-05
deletion O 0 2.3844677343731746e-06
390delGly O 0 1.0375082410973846e-06
were O 0 1.710211527949923e-08
assessed O 0 7.597261486580464e-08
by O 0 2.4328932202166698e-09
their O 0 1.5355249294302098e-09
respective O 0 2.213059957512087e-08
expression O 0 1.5358448735014463e-08
in O 0 7.612415586777388e-09
a O 0 3.7411350461979964e-08
prokaryotic O 0 1.0110971260246515e-07
system O 0 2.3286904848873746e-08
using O 0 2.3366679258174372e-08
site O 0 1.1259435268584639e-06
- O 0 1.7820398170442786e-06
directed O 0 1.6209900195462978e-06
mutagenesis O 0 3.4531123674241826e-05
. O 0 1.9350591173861176e-06

These O 0 9.890368346532341e-07
mutations O 0 7.694096666455152e-07
resulted O 0 3.7904368355157203e-07
in O 0 4.730320313228731e-08
the O 0 1.9637730019894661e-07
absence O 0 1.341621555184247e-06
or O 0 1.8088709907715383e-07
a O 0 5.091962975711795e-07
dramatic O 0 6.062617103452794e-06
decrease O 0 1.111599885916803e-05
of O 0 5.440845598059241e-06
CPO O 0 0.10613328963518143
activity O 0 3.2337382435798645e-05
. O 0 2.9741713660769165e-06

The O 0 1.5447797068190994e-06
two O 0 9.864702121831215e-08
polymorphisms O 0 1.9367391814739676e-06
were O 0 1.1126461174626456e-07
localized O 0 1.1073717587350984e-06
in O 0 1.1841684255387008e-07
noncoding O 0 8.869966222846415e-06
part O 0 1.7757835735210392e-07
of O 0 2.1088168011829111e-07
the O 0 1.0067289224480191e-07
gene O 0 1.26905597142013e-08
1 O 0 2.3013761563106527e-08
) O 0 5.860446794514473e-09
a O 0 2.7322323958856032e-08
C O 0 1.4886524013490998e-06
/ O 0 1.8095523728334229e-06
G O 0 1.6522897112736246e-06
polymorphism O 0 2.3958779138411046e-07
in O 0 3.706524154267754e-08
the O 0 1.5222637728129484e-07
promotor O 0 0.00010455973097123206
region O 0 5.551261210712255e-07
, O 0 1.2780331815065438e-07
142 O 0 1.0523432365516783e-06
bp O 0 3.3218652788491454e-06
upstream O 0 1.3788086334898253e-06
from O 0 2.1271018724178248e-08
the O 0 5.169994565790148e-08
transcriptional O 0 7.734855103080918e-07
initiation O 0 1.2887549871720694e-07
site O 0 1.4761437228116847e-07
( O 0 1.8081459884911055e-08
- O 0 9.134536327337628e-08
142C O 0 1.5925688785500824e-06
/ O 0 4.7234053113243135e-07
G O 0 6.978502824495081e-07
) O 0 1.3090954986694214e-08
, O 0 2.4755411054400156e-09
and O 0 1.4328070951918903e-09
2 O 0 2.9049093797084424e-08
) O 0 8.594302158826395e-09
a O 0 2.8372815208399516e-08
6 O 0 9.293864167148058e-08
bp O 0 2.5413692128495313e-07
deletion O 0 1.1550836376272855e-07
polymorphism O 0 5.10495965500013e-08
in O 0 4.370542150411438e-09
the O 0 2.026043510738873e-08
3 O 0 1.1398032739862174e-07
noncoding O 0 9.204878210766765e-07
part O 0 4.588720869946883e-08
of O 0 1.140597021276335e-07
the O 0 3.770905721012241e-07
CPO O 0 8.810231520328671e-05
gene O 0 5.206479727348778e-07
, O 0 5.843829598006778e-08
574 O 0 2.6208811050310032e-06
bp O 0 2.4840928745106794e-06
downstream O 0 1.1497592140585766e-06
of O 0 5.8389048263052246e-08
the O 0 4.263775466029074e-08
last O 0 5.8690627469104584e-08
base O 0 1.5942237041599583e-07
of O 0 6.647233874446101e-08
the O 0 9.052393323827346e-08
normal O 0 6.754746095793962e-07
termination O 0 6.262408192014846e-07
codon O 0 3.656539774965495e-06
( O 0 8.212559237108508e-07
+ O 0 1.9845138012897223e-06
574 O 0 3.9515689422842115e-06
delATTCTT O 0 2.1283582100295462e-05
) O 0 6.818301585553854e-07
. O 0 7.458299364770937e-07

Five O 0 3.1994197343010455e-05
intragenic O 0 0.02377905324101448
dimorphisms O 0 0.0018730494193732738
are O 0 5.4551787087575576e-08
now O 0 5.2127500538290406e-08
well O 0 1.846662911475505e-08
characterized O 0 1.3251083430532162e-07
and O 0 8.096576742389061e-09
the O 0 1.0899191948965381e-07
high O 0 4.035630070120533e-07
degree O 0 4.9187451622856315e-06
of O 0 1.0334939588574343e-06
allelic O 0 3.105401628999971e-05
heterogeneity O 0 5.18117485626135e-05
in O 0 5.295868845678342e-07
HC B-Disease 1 0.9999998807907104
is O 0 6.912807180015079e-07
demonstrated O 0 7.298721271808972e-08
with O 0 1.0902175828775285e-09
seven O 0 4.287430854787999e-09
new O 0 6.063404778267056e-10
different O 0 2.613474714419084e-10
mutations O 0 1.5275996023689231e-09
making O 0 4.102769679548146e-09
a O 0 1.382511616299098e-08
total O 0 4.522579288845918e-08
of O 0 1.4369518908097234e-07
nineteen O 0 4.4163749407744035e-05
CPO O 1 0.9242066740989685
gene B-Disease 0 3.1924097129376605e-05
defects I-Disease 0 3.5244349419372156e-05
reported O 0 2.5819218762990204e-07
so O 0 3.3919619113476074e-08
far O 0 1.1810804068090874e-07
. O 0 1.5135638875563018e-07
. O 0 9.263544598070439e-07

Coincidence O 0 0.00028034806018695235
of O 0 1.74387275819754e-06
two O 0 2.516935921903496e-07
novel O 0 3.4123131626984105e-06
arylsulfatase O 0 7.047429244266823e-05
A O 0 1.3136173038219567e-06
alleles O 0 6.124677298657843e-08
and O 0 1.377799563329063e-08
mutation O 0 1.3159603895473992e-07
459 O 0 9.679651157057378e-06
+ O 0 0.00013711386418435723
1G O 0 0.0009166236850433052
> O 0 1.3814989188176696e-06
A O 0 1.8252657696393726e-07
within O 0 4.220205696015e-08
a O 0 8.744744661726145e-08
family O 0 8.227910797131699e-08
with O 0 1.0977365150210971e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 6.435069508370361e-07
molecular O 0 1.330591999249009e-06
basis O 0 2.1034459507518477e-07
of O 0 3.1969278779797605e-07
phenotypic O 0 1.74294036696665e-05
heterogeneity O 0 4.682655708165839e-05
. O 0 9.432404112885706e-06

In O 0 1.166782749351114e-05
a O 0 4.51037840321078e-06
family O 0 3.9023419162731443e-07
with O 0 1.2357608270008313e-08
three O 0 6.532630436595355e-08
siblings O 0 6.55349651879078e-07
, O 0 1.415059358578219e-08
one O 0 2.371976215442828e-08
developed O 0 4.6479055271220204e-08
classical O 0 5.29125736647984e-06
late O 0 0.00019860416068695486
infantile O 1 0.9998052716255188
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.38807612657546997
MLD B-Disease 1 1.0
) O 0 7.466956503776601e-06
, O 0 2.114566513000682e-07
fatal O 0 4.915327372145839e-05
at O 0 7.515866400353843e-06
age O 0 7.867098247515969e-06
5 O 0 6.772096980967035e-07
years O 0 1.0068114164596409e-07
, O 0 2.899019868607411e-08
with O 0 6.244379591180405e-08
deficient O 0 0.012467998079955578
arylsulfatase O 1 0.8681641221046448
A O 0 0.08379200845956802
( O 0 8.165177860064432e-06
ARSA O 1 0.996672511100769
) O 0 6.054627021967462e-08
activity O 0 4.551013788045566e-08
and O 0 5.131901570365471e-09
increased O 0 1.9801267114871735e-07
galactosylsulfatide O 0 0.002834809012711048
( O 0 0.00010430439579067752
GS O 1 1.0
) O 0 5.134879302204354e-06
excretion O 0 1.7296177247771993e-05
. O 0 1.5627537095497246e-06

The O 0 3.7701647670473903e-06
two O 0 1.0108657022556145e-07
other O 0 3.571654971779026e-08
siblings O 0 7.46009902741207e-07
, O 0 1.0875290712419883e-07
apparently O 0 3.770883722609142e-06
healthy O 0 5.660015744979319e-07
at O 0 3.249195685839368e-07
12 O 0 9.435199643803571e-08
( O 0 2.2612585581782696e-08
1 O 0 4.367077721667556e-08
/ O 0 7.869643070534948e-08
2 O 0 1.548522732264246e-08
) O 0 1.6472363473241103e-09
and O 0 3.6418107418612067e-10
15 O 0 1.19307030921334e-09
years O 0 1.1917216102830253e-09
, O 0 2.2336685834289938e-09
respectively O 0 2.737166937549773e-08
, O 0 3.598574549457112e-09
and O 0 1.777055946838857e-09
their O 0 4.353295501857701e-09
father O 0 4.7473585595980694e-07
, O 0 2.989487768445542e-08
apparently O 0 6.227311928341805e-07
healthy O 0 3.4227021217247966e-08
as O 0 2.0312040938108566e-09
well O 0 4.954438193038868e-09
, O 0 8.08935229912322e-09
presented O 0 5.696101084140537e-07
ARSA O 1 0.9825459718704224
and O 0 3.322786028547853e-07
GS O 1 0.9996907711029053
values O 0 3.8087062392833104e-08
within O 0 2.3062007414864638e-08
the O 0 1.6432455396397927e-08
range O 0 1.2918705749598303e-07
of O 0 2.6552597773843445e-06
MLD B-Disease 1 1.0
patients O 0 3.210961585864425e-05
. O 0 4.160847311140969e-06

Mutation O 0 6.458016287069768e-06
screening O 0 5.770746724920173e-07
and O 0 2.4382785568377585e-08
sequence O 0 3.022434782451455e-07
analysis O 0 1.9844407006530673e-07
disclosed O 0 7.914007937870338e-07
the O 0 4.462001967908691e-08
involvement O 0 2.859644609998213e-07
of O 0 4.552889265596605e-08
three O 0 1.9577624854605347e-08
different O 0 4.289903543508444e-08
ARSA O 0 0.04038385674357414
mutations O 0 5.4818382722032766e-08
being O 0 3.288580785465456e-08
the O 0 4.274384934888076e-08
molecular O 0 3.717349841281248e-07
basis O 0 2.2928789178422448e-07
of O 0 7.944800586301426e-07
intrafamilial O 0 0.0006217159680090845
phenotypic O 0 7.66707889852114e-05
heterogeneity O 0 0.00018845086742658168
. O 0 1.1532059943419881e-05

The O 0 1.718862222332973e-05
late O 0 0.00024794533965177834
infantile O 1 0.986764132976532
patient O 0 0.00013703999866265804
inherited O 0 0.03956801816821098
from O 0 4.876359525951557e-06
his O 0 8.776131835475098e-06
mother O 0 1.476376928621903e-05
the O 0 3.439442934904946e-07
frequent O 0 1.3986380054120673e-07
0 O 0 6.391059059751569e-08
- O 0 1.3711503754620935e-07
type O 0 1.7527868578781636e-07
mutation O 0 1.3198780379752861e-07
459 O 0 5.247176886769012e-06
+ O 0 1.1819704013760202e-05
1G O 0 3.451558586675674e-05
> O 0 3.1348514539786265e-07
A O 0 1.137570606601912e-07
, O 0 3.4498475187660915e-09
and O 0 2.6864825919403756e-09
from O 0 8.603272760865366e-09
his O 0 7.09594729642049e-08
father O 0 1.1654310583253391e-06
a O 0 2.8878591251668695e-07
novel O 0 5.267149276733107e-07
, O 0 6.838412502929714e-08
single O 0 2.4542924847992253e-07
basepair O 0 2.0280102035030723e-05
microdeletion O 0 2.3029755539027974e-05
of O 0 8.658405477035558e-07
guanine O 0 4.347785761638079e-06
at O 0 1.5376321016447037e-06
nucleotide O 0 1.89592049082421e-06
7 O 0 4.030099773899565e-07
in O 0 3.593767772258616e-08
exon O 0 1.1084367770308745e-06
1 O 0 3.0217404400900705e-07
( O 0 2.6382446094430634e-07
7delG O 0 6.603248948522378e-06
) O 0 6.414684321498498e-07
. O 0 6.560612177963776e-07

The O 0 7.5257789831084665e-06
two O 0 1.3904285651733517e-06
clinically O 0 0.0008187048370018601
unaffected O 0 1.536658965051174e-05
siblings O 0 1.5366118759629899e-06
carried O 0 3.093310283475148e-07
the O 0 3.6097509337196243e-07
maternal O 0 9.164305083686486e-06
mutation O 0 6.205092404343304e-07
459 O 0 1.236251864611404e-05
+ O 0 3.527354056132026e-05
1G O 0 0.00011565446766326204
> O 0 9.237503491021926e-07
A O 0 1.8440270821429294e-07
and O 0 7.836402637906303e-09
, O 0 5.084501708552125e-09
on O 0 1.9364675196698045e-08
their O 0 1.3528059561451755e-08
paternal O 0 8.666715984873008e-07
allele O 0 5.438317884909338e-08
, O 0 7.78052289263087e-09
a O 0 4.056705549260187e-08
novel O 0 1.3531058584703715e-07
cytosine O 0 3.6915602663611935e-07
to O 0 3.148885951986813e-08
thymidine O 0 2.4977209704957204e-06
transition O 0 2.881171212720801e-06
at O 0 4.113485829293495e-06
nucleotide O 0 2.1215597371337935e-05
2435 O 0 0.00013374572154134512
in O 0 1.4417616966966307e-07
exon O 0 9.055231657839613e-07
8 O 0 8.95743070827848e-08
, O 0 4.238256856581302e-09
resulting O 0 1.1814607958626766e-08
in O 0 6.226062332359561e-09
substitution O 0 3.158823247417786e-08
of O 0 1.2384299452605774e-07
alanine O 0 1.884053290268639e-06
464 O 0 1.465473815187579e-06
by O 0 1.627363985789998e-07
valine O 0 3.996882514911704e-05
( O 0 1.3232561286713462e-06
A464V O 0 3.543294224073179e-05
) O 0 1.3880518281439436e-06
. O 0 1.1419568863857421e-06

The O 0 6.067668437026441e-05
fathers O 0 7.26656144252047e-05
genotype O 0 1.6846735888975672e-05
thus O 0 2.3670559130550828e-06
was O 0 3.08830822177697e-05
7delG O 0 0.0015854352386668324
/ O 0 0.011513406410813332
A464V O 0 0.004679403267800808
. O 0 1.8706952687352896e-05

Mutation O 0 4.776301284437068e-05
A464V O 0 0.00010784142068587244
was O 0 1.5317484667320969e-06
not O 0 1.9684788910012685e-08
found O 0 2.3853601760492893e-08
in O 0 6.769734284262086e-08
18 O 0 3.681860107462853e-06
unrelated O 0 0.25965142250061035
MLD B-Disease 1 1.0
patients O 0 9.348064850200899e-06
and O 0 2.0402917755291128e-07
50 O 0 4.479594736039871e-06
controls O 0 4.8807746679813135e-06
. O 0 2.057688107015565e-06

A464V O 0 0.0006286851712502539
, O 0 3.5483179772199946e-07
although O 0 2.446940072786674e-07
clearly O 0 2.824124067046796e-06
modifying O 0 1.7581052816240117e-05
ARSA O 1 0.9999868869781494
and O 0 1.5712070307927206e-05
GS O 1 1.0
levels O 0 4.927440386381932e-06
, O 0 6.950236297598167e-08
apparently O 0 5.930864972469863e-07
bears O 0 5.91206003264233e-07
little O 0 9.139711920624904e-08
significance O 0 3.316523873309052e-07
for O 0 1.5126683905464233e-08
clinical O 0 7.514060598623473e-06
manifestation O 0 0.003610241925343871
of O 0 0.00023518338275607675
MLD B-Disease 1 1.0
, O 0 2.282814875798067e-06
mimicking O 0 2.6994261133950204e-05
the O 0 1.7714276054903166e-06
frequent O 0 1.0316827683709562e-05
ARSA O 0 0.4896659851074219
pseudodeficiency O 0 0.0007427997188642621
allele O 0 2.5989555069827475e-05
. O 0 7.517659014411038e-06

Our O 0 9.932441571436357e-06
results O 0 6.541033599205548e-07
demonstrate O 0 4.034529297314293e-07
that O 0 7.160484205570583e-09
in O 0 8.082566615996711e-09
certain O 0 2.928865505680278e-08
genetic O 0 1.4954681546441861e-06
conditions O 0 6.451181252487004e-05
MLD B-Disease 1 1.0
- O 1 0.9999988079071045
like O 0 2.3126085579860955e-05
ARSA O 1 0.999998927116394
and O 0 4.668425219733763e-07
GS O 1 0.9999985694885254
values O 0 2.5024979422028082e-08
need O 0 4.349967053229875e-09
not O 0 9.889825625108983e-10
be O 0 1.8047099370477326e-09
paralleled O 0 8.481566737827961e-08
by O 0 5.469772634825176e-09
clinical O 0 9.3591970653506e-06
disease O 0 1.7479204643677804e-06
, O 0 4.869205039170765e-09
a O 0 1.8689013003836408e-08
finding O 0 3.7800685248612353e-08
with O 0 5.915904210951339e-09
serious O 0 9.984893267755979e-07
diagnostic O 0 8.34698585094884e-06
and O 0 3.495629243843723e-07
prognostic O 0 0.002459923969581723
implications O 0 2.3900158339529298e-05
. O 0 6.7109572228218894e-06

Moreover O 0 3.4656553907552734e-05
, O 0 8.306450922646036e-07
further O 0 2.6159616481891135e-06
ARSA O 1 0.9848783612251282
alleles O 0 1.7486306660430273e-06
functionally O 0 4.773353794007562e-06
similar O 0 4.776030593234282e-08
to O 0 4.233265826769639e-08
A464V O 0 1.744839573802892e-05
might O 0 6.417810283210201e-08
exist O 0 2.9474826135356125e-08
which O 0 1.9851622568012317e-09
, O 0 1.9778565452099883e-09
together O 0 3.6594502983433586e-09
with O 0 6.267633523293625e-09
0 O 0 7.998819029353399e-08
- O 0 4.125493830997584e-07
type O 0 2.5281514126618276e-07
mutations O 0 3.849803675848307e-08
, O 0 9.762015196201901e-09
may O 0 1.0463932653692609e-07
cause O 0 1.0483351616130676e-05
pathological O 1 0.9999990463256836
ARSA O 1 1.0
and O 0 5.639747541863471e-06
GS O 1 1.0
levels O 0 1.7020605014295143e-07
, O 0 1.9520491889579716e-09
but O 0 3.221540256781452e-10
not O 0 1.6890870924157753e-09
clinical O 0 2.2745389571809937e-07
outbreak O 0 2.3761292311519355e-07
of O 0 1.610863904488724e-07
the O 0 2.2793103653384605e-06
disease O 0 0.002156137255951762
. O 0 2.8715243161059334e-07
. O 0 1.8628388716024347e-06

Human O 1 0.9999780654907227
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.9988376498222351
to O 0 1.6973230231087655e-05
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 1.3796391613141168e-05
neurofibromatosis B-Disease 1 0.9999995231628418
type I-Disease 0 0.042452916502952576
1 I-Disease 0 0.0003027683706022799
. O 0 1.452263313694857e-05

Heterozygous O 0 0.0008721169433556497
germ O 1 0.9997127652168274
- O 0 8.880552923073992e-05
line O 0 8.402842013310874e-07
mutations O 0 6.478171599155758e-08
in O 0 9.281885482437247e-09
the O 0 8.447018728929834e-08
DNA O 0 6.33703893981874e-05
mismatch O 1 0.9997625946998596
repair O 1 0.9583527445793152
genes O 0 5.927025085838977e-06
lead O 0 6.32068986305967e-06
to O 0 3.4708457405940862e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.029517903923988342

The O 0 0.00012194867304060608
disease O 1 0.6911193132400513
susceptibility O 0 4.950193761033006e-05
of O 0 3.4587485515658045e-06
individuals O 0 3.224132001378166e-07
who O 0 4.969242581864819e-07
constitutionally O 0 3.2252373785013333e-06
lack O 0 1.6893561394226708e-07
both O 0 9.992866090158259e-09
wild O 0 2.1128954585947213e-07
- O 0 1.3251731161290081e-06
type O 0 3.953545331114583e-07
alleles O 0 6.459318768747835e-08
is O 0 5.479716236322929e-08
unknown O 0 8.831688319332898e-06
. O 0 2.4197988750529476e-06

We O 0 1.1438818319220445e-06
have O 0 2.3047761033012648e-08
identified O 0 1.787715291357017e-07
three O 0 3.701847006709613e-08
offspring O 0 3.82089410777553e-07
in O 0 1.0074011669303218e-07
a O 0 2.2064205040805973e-05
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.9999581575393677
who O 0 1.4851164451101795e-05
developed O 0 0.0005807721754536033
hematological B-Disease 1 1.0
malignancy I-Disease 1 0.9999997615814209
at O 0 8.964479093265254e-06
a O 0 8.386464145360151e-08
very O 0 6.446639222446038e-09
early O 0 3.848188967481292e-08
age O 0 2.3292864170798566e-07
, O 0 2.0187259863746476e-08
and O 0 1.2595741338827793e-08
at O 0 6.778080319236324e-07
least O 0 1.6049501283532663e-08
two O 0 3.178524554670048e-09
of O 0 1.7528462237237363e-08
them O 0 9.85943060527461e-09
displayed O 0 1.0690640692700981e-06
signs O 0 1.3181526128391852e-06
of O 0 4.758037448482355e-06
neurofibromatosis B-Disease 1 0.9996492862701416
type I-Disease 0 0.00442182132974267
1 I-Disease 0 0.00019215822976548225
( O 0 4.7399204049725085e-05
NF1 B-Disease 1 0.9896300435066223
) O 0 1.886412178464525e-06
. O 0 1.3333599326870171e-06

DNA O 0 5.591574335994665e-06
sequence O 0 5.922290711168898e-07
analysis O 0 2.0946681900113617e-07
and O 0 6.137994557064985e-09
allele O 0 6.185253198509599e-08
- O 0 1.1136226873986743e-07
specific O 0 1.6841047667526254e-08
amplification O 0 5.389648549680714e-07
in O 0 2.204280491469035e-08
two O 0 3.4671980841949335e-08
siblings O 0 1.1584565982047934e-06
revealed O 0 2.9691495910810772e-06
a O 0 1.6952983514784137e-06
homozygous O 0 6.16042689216556e-06
MLH1 O 0 0.0001893269072752446
mutation O 0 2.12758749285058e-07
( O 0 1.9014635199710028e-07
C676T O 0 9.679984032118227e-06
- O 0 1.7229960576514713e-05
- O 0 5.569934728555381e-05
> O 0 5.36532279511448e-05
Arg226Stop O 0 0.0006209636339917779
) O 0 2.150915406673448e-06
. O 0 1.4803505337113165e-06

Thus O 0 2.4302833480760455e-05
, O 0 6.971478114792262e-07
a O 0 1.6936452311711037e-06
homozygous O 0 1.1612081834755372e-05
germ O 1 0.9999995231628418
- O 1 0.9872817397117615
line O 0 0.000256427563726902
MLH1 O 1 0.9918906688690186
mutation O 0 5.055807150711189e-07
and O 0 7.521722267256337e-08
consequent O 0 0.039275046437978745
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 5.275998410070315e-05
in O 0 5.548445187741891e-07
a O 0 5.838620836584596e-06
mutator O 1 0.5447781085968018
phenotype O 0 2.4311609649885213e-06
characterized O 0 1.2634941981559678e-07
by O 0 5.6342628340644296e-08
leukemia B-Disease 1 0.8206112384796143
and O 0 4.755591817229288e-06
/ O 1 0.9999998807907104
or O 1 0.9995988011360168
lymphoma B-Disease 1 1.0
associated O 1 0.7843445539474487
with O 0 2.6425344913150184e-05
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.8133718371391296
1 I-Disease 0 7.066257967380807e-05
. O 0 1.2098414572392358e-06
. O 0 2.660087830008706e-06

Missense O 0 0.0018416973762214184
mutations O 0 3.1341510293714236e-06
in O 0 6.347639924797477e-08
the O 0 5.98947877961109e-08
most O 0 7.456895545487896e-09
ancient O 0 5.310272968017671e-07
residues O 0 9.358682291349396e-07
of O 0 2.5461676500526664e-07
the O 0 1.4847520333205466e-06
PAX6 O 1 0.9999762773513794
paired O 0 2.409789703960996e-05
domain O 0 6.286975803959649e-06
underlie O 0 3.1554477573081385e-06
a O 0 2.1501533353784907e-07
spectrum O 0 3.715003913384862e-07
of O 0 1.1008793080691248e-05
human O 1 0.9999682903289795
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9871533513069153

Mutations O 0 8.847249773680232e-06
of O 0 9.32269415443443e-07
the O 0 1.2904696404802962e-06
human O 0 1.011285712593235e-05
PAX6 O 1 0.9999992847442627
gene O 0 0.3554886281490326
underlie O 1 0.9999982118606567
aniridia B-Disease 1 1.0
( O 1 1.0
congenital B-Disease 1 1.0
absence I-Disease 0 0.03315415605902672
of I-Disease 0 0.0009659582865424454
the I-Disease 0 6.826410390203819e-05
iris I-Disease 0 0.39766690135002136
) O 0 1.6895572798603098e-06
, O 0 1.728920011601076e-07
a O 0 1.7535837741888827e-06
rare O 0 6.971901893848553e-05
dominant O 1 0.9999188184738159
malformation B-Disease 1 1.0
of I-Disease 1 0.9998767375946045
the I-Disease 1 0.9999911785125732
eye I-Disease 1 1.0
. O 0 0.00034527230309322476

The O 0 9.49844343267614e-06
spectrum O 0 5.979085926810512e-06
of O 0 5.377592060540337e-06
PAX6 O 1 0.9998393058776855
mutations O 0 3.320965788589092e-06
in O 0 5.012708470530924e-07
aniridia B-Disease 1 1.0
patients O 0 3.466342661795352e-07
is O 0 1.2446693453682656e-08
highly O 0 2.1643359104928095e-08
biased O 0 9.485506069495386e-08
, O 0 1.7486545544898036e-09
with O 0 1.2135075166952447e-09
92 O 0 3.396268084543408e-07
% O 0 9.239000675620446e-09
of O 0 5.204540798331436e-09
all O 0 1.5976285849816918e-09
reported O 0 7.712530702974618e-08
mutations O 0 9.430392466924786e-09
leading O 0 3.0410166829142327e-08
to O 0 1.526412063412863e-08
premature O 0 1.7844394051280688e-06
truncation O 0 5.753438472311245e-06
of O 0 2.0029976610658196e-07
the O 0 2.4898392325667373e-07
protein O 0 4.467222254334047e-07
( O 0 4.931511909944675e-08
nonsense O 0 1.1336624083924107e-06
, O 0 2.1818518547433996e-08
splicing O 0 3.449514451858704e-07
, O 0 2.301420032324586e-08
insertions O 0 1.9184213329026534e-07
and O 0 9.987911830933172e-09
deletions O 0 1.0299091712795416e-07
) O 0 2.3460865250513052e-08
and O 0 1.231828505865451e-08
just O 0 1.4903568512636411e-07
2 O 0 2.2890009176990134e-07
% O 0 5.4042359920458694e-08
leading O 0 2.2269569299737668e-08
to O 0 1.5081994542143207e-09
substitution O 0 1.3375503371548803e-08
of O 0 1.8206634422313073e-08
one O 0 7.51635553797314e-09
amino O 0 2.0808178291531476e-08
acid O 0 8.816150476320672e-09
by O 0 3.127229142307897e-09
another O 0 1.4812118820373144e-07
( O 0 2.0458759308894514e-07
missense O 0 2.9388597795332316e-06
) O 0 4.2281018863832287e-07
. O 0 1.0139007144971401e-06

The O 0 2.8253523396415403e-06
extraordinary O 0 1.666793195909122e-06
conservation O 0 7.340534011746058e-07
of O 0 2.0791445365375694e-07
the O 0 3.262924224145536e-07
PAX6 O 0 0.013554688543081284
protein O 0 6.078394108044449e-07
at O 0 1.20333154995933e-07
the O 0 2.988758041055917e-08
amino O 0 1.4668802350570331e-07
acid O 0 1.1061183613492176e-07
level O 0 1.002530609639507e-07
amongst O 0 1.1045055714475893e-07
vertebrates O 0 3.28636610902322e-06
predicts O 0 4.3430307528069534e-07
that O 0 1.3556266331704592e-08
pathological O 0 2.0955258150934242e-05
missense O 0 1.8113755686499644e-06
mutations O 0 4.034236411598613e-08
should O 0 4.219865346044571e-09
in O 0 8.801096740285175e-09
fact O 0 2.1709260167313005e-08
be O 0 4.939944453496992e-09
common O 0 4.946261622507109e-09
even O 0 4.607486392416149e-09
though O 0 6.7606862330649165e-09
they O 0 4.965128308498379e-09
are O 0 4.18296330906287e-09
hardly O 0 4.496749284044199e-07
ever O 0 3.8120205658742634e-07
seen O 0 1.4999974382590153e-06
in O 0 1.015685370475694e-06
aniridia B-Disease 1 1.0
patients O 0 1.004985642794054e-05
. O 0 3.5268146802991396e-06

This O 0 1.2620265579244005e-06
indicates O 0 1.5989880921551958e-06
that O 0 1.2020247019961516e-08
there O 0 3.395490111302024e-08
is O 0 4.299799272189375e-08
a O 0 3.043361118670873e-07
heavy O 0 1.7114947695517913e-05
ascertainment O 1 0.5299146771430969
bias O 0 1.0817608426805236e-06
in O 0 1.459048348806391e-08
the O 0 1.2127168602660277e-08
selection O 0 2.9738426832182085e-08
of O 0 5.105923506221188e-08
patients O 0 1.7212199665550543e-08
for O 0 1.8923454803143613e-08
PAX6 O 0 0.09637361764907837
mutation O 0 4.572365597255157e-08
analysis O 0 1.3949981614302942e-08
and O 0 8.433133635854517e-10
that O 0 1.4068398668243276e-09
the O 0 7.326448780986539e-08
missing O 0 1.8816110241459683e-05
PAX6 O 1 0.9962444305419922
missense O 0 5.850807065144181e-05
mutations O 0 3.7322334378586675e-07
frequently O 0 1.4399562076050643e-07
may O 0 2.2838287350168684e-07
underlie O 0 1.2300097296247259e-05
phenotypes O 0 3.2181401365960483e-06
distinct O 0 3.600121374347509e-07
from O 0 1.9267174593551317e-06
textbook O 0 0.0004960435326211154
aniridia B-Disease 1 0.9999995231628418
. O 0 4.929089845973067e-05

Here O 0 1.10684804894845e-05
we O 0 2.7516568934515817e-07
present O 0 2.7678194669533696e-07
four O 0 2.3180422203950002e-07
novel O 0 6.043278972356347e-06
PAX6 O 0 0.14082223176956177
missense O 0 1.963446629815735e-05
mutations O 0 1.358479551072378e-07
, O 0 9.250920030012821e-09
two O 0 5.915260725686267e-09
in O 0 2.013046973559085e-08
association O 0 4.3401236382578645e-08
with O 0 2.709243673848505e-08
atypical O 0 0.00012691928714048117
phenotypes O 0 0.0003737747319974005
ectopia B-Disease 1 0.9991706609725952
pupillae I-Disease 1 0.9991453886032104
( O 0 4.568461008602753e-06
displaced B-Disease 0 1.9866042748617474e-06
pupils I-Disease 0 1.2175211168141686e-06
) O 0 4.5304145146474184e-07
and O 0 5.360441832635843e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9723007082939148
( O 0 4.188161256024614e-05
searching B-Disease 0 0.0003110016114078462
gaze I-Disease 0 0.000582390814088285
) O 0 3.7130203622837143e-07
, O 0 3.833142159237468e-08
and O 0 1.971480934059855e-08
two O 0 3.332121423227363e-08
in O 0 1.23098104154451e-07
association O 0 2.866328543404961e-07
with O 0 5.080422837977494e-08
more O 0 2.068490374540488e-07
recognizable O 0 0.0006176613969728351
aniridia B-Disease 1 1.0
phenotypes O 0 0.001225436688400805
. O 0 1.5929874280118383e-05

Strikingly O 0 4.124908082303591e-05
, O 0 9.964947622620457e-08
all O 0 1.0865168320606244e-08
four O 0 2.3801520754318517e-08
mutations O 0 1.8476070451356463e-08
are O 0 2.5796995650750887e-09
located O 0 8.893167802170865e-08
within O 0 3.468481679647084e-08
the O 0 3.5878031212632777e-07
PAX6 O 0 0.20058345794677734
paired O 0 8.814765237730171e-07
domain O 0 2.5099225808844494e-07
and O 0 3.4483937927376473e-09
affect O 0 1.1916313269466627e-08
amino O 0 2.312517288771687e-08
acids O 0 2.279931576865124e-09
which O 0 2.8425328757464285e-10
are O 0 2.496698126019936e-10
highly O 0 4.948431886475646e-09
conserved O 0 4.03771593937563e-08
in O 0 4.30836788467559e-09
all O 0 6.406043251416804e-09
known O 0 1.4140481141566852e-07
paired O 0 1.1775078974096687e-06
domain O 0 2.7806956950371386e-06
proteins O 0 8.249673442151106e-07
. O 0 1.1363327985236538e-06

Our O 0 4.363866082712775e-06
results O 0 2.398701610673015e-07
support O 0 2.6036261147055484e-08
the O 0 3.2858597620588625e-08
hypothesis O 0 9.22511063095044e-08
that O 0 1.7541998964532013e-09
the O 0 7.636294263591026e-09
under O 0 5.501992461631744e-08
- O 0 3.274061555202934e-07
representation O 0 6.811738018086544e-08
of O 0 1.410254526490462e-07
missense O 0 2.7718633646145463e-06
mutations O 0 4.250239982184212e-08
is O 0 1.8731014961304027e-08
caused O 0 7.27556468405055e-08
by O 0 3.5541898313340425e-08
ascertainment O 0 0.3105769157409668
bias O 0 1.0347464467486134e-06
and O 0 1.4179881269171801e-08
suggest O 0 9.572728743023617e-08
that O 0 5.061299379605089e-09
a O 0 3.243480506398555e-08
substantial O 0 3.000087076543423e-07
burden O 0 1.5226514733512886e-06
of O 0 1.160449846793199e-05
PAX6 B-Disease 1 1.0
- I-Disease 0 0.19935943186283112
related I-Disease 0 0.0001710937067400664
disease I-Disease 0 0.0007947497069835663
remains O 0 4.162555740094831e-07
to O 0 9.828339031514588e-09
be O 0 3.844315443757296e-08
uncovered O 0 2.4080989533104002e-05
. O 0 3.338820988574298e-07
. O 0 1.1171579217261751e-06

The O 0 1.15260672828299e-05
chromosomal O 0 9.383649739902467e-05
order O 0 7.200875984381128e-07
of O 0 2.019563680732972e-06
genes O 0 3.2135951641976135e-06
controlling O 0 2.9436921977321617e-05
the O 0 1.8671146335691446e-06
major O 0 0.00014249380910769105
histocompatibility O 1 0.9999991655349731
complex O 0 0.003088804893195629
, O 0 2.1681954365249112e-07
properdin O 0 0.0004336344136390835
factor O 0 8.62853539729258e-06
B O 0 1.8984945199918002e-05
, O 0 4.924960350649599e-08
and O 0 6.571484334472188e-08
deficiency B-Disease 0 0.2662026286125183
of I-Disease 0 8.080694897216745e-06
the I-Disease 0 3.498945261526387e-06
second I-Disease 0 1.894432534754742e-05
component I-Disease 0 1.4135470337350853e-05
of I-Disease 0 1.7938649534698925e-06
complement I-Disease 0 9.688128557172604e-06
. O 0 7.640479452675208e-06

The O 0 4.088296009285841e-06
relationship O 0 9.576542652212083e-07
of O 0 1.499954436212647e-07
the O 0 1.6095984278763353e-07
genes O 0 1.5437430533893348e-07
coding O 0 5.190189540371648e-07
for O 0 8.139097928960837e-08
HLA O 0 0.00016375299310311675
to O 0 1.9227396563792354e-08
those O 0 2.2381305697649623e-08
coding O 0 6.192288992679096e-07
for O 0 3.751102539695239e-08
properdin O 0 0.000834620906971395
Factor O 0 6.840075366199017e-05
B O 0 2.0684796254499815e-05
allotypes O 0 8.277245797216892e-06
and O 0 9.90504567255357e-09
for O 0 5.730133167958229e-08
deficiency B-Disease 0 0.006084998603910208
of I-Disease 0 1.1722909221134614e-06
the I-Disease 0 6.080736625335703e-07
second I-Disease 0 1.6624577483526082e-06
component I-Disease 0 1.9222429727960844e-06
of I-Disease 0 1.4706468220992974e-07
complement I-Disease 0 9.169935424324649e-07
( O 0 8.195448231163027e-07
C2 O 0 4.4533164327731356e-05
) O 0 1.3047954716682852e-08
was O 0 4.43545999928574e-08
studied O 0 3.5297340161832835e-08
in O 0 5.126511215536311e-09
families O 0 4.801804731613402e-09
of O 0 5.8119049128890765e-08
patients O 0 7.406606528093107e-08
with O 0 2.128885398633429e-06
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.9866764545440674

Patients O 0 3.260020548623288e-06
were O 0 9.785245680404842e-08
selected O 0 5.1442523130162954e-08
because O 0 9.168902082024033e-09
they O 0 4.95768981423339e-09
were O 0 3.267435388920603e-08
heterozygous O 0 2.272184360663232e-07
or O 0 1.339626578555908e-07
homozygous O 0 5.4582974371442106e-06
for O 0 3.7254711060086265e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00011506267037475482

12 O 0 1.3959576790512074e-05
families O 0 2.423238925075566e-07
with O 0 5.2316348586600725e-08
15 O 0 8.727155318410951e-07
matings O 0 1.6895275621209294e-05
informative O 0 1.0236914931738283e-05
for O 0 1.0903598195000086e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 4.429552518558921e-06
found O 0 2.2147335130284773e-06
. O 0 2.6980794700648403e-06

Of O 0 3.05066514556529e-05
57 O 0 2.02186347451061e-05
informative O 0 2.4226012101280503e-05
meioses O 0 6.016239422024228e-05
, O 0 5.0740801782467315e-08
two O 0 1.2092246315376087e-08
crossovers O 0 7.446608663030929e-08
were O 0 1.7009270436574297e-08
noted O 0 4.0605918627534265e-08
between O 0 1.8936351864340395e-07
the O 0 1.0471201676409692e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.0922791204848181e-07
and O 0 5.3701301183650685e-09
the O 0 1.7855752787454549e-07
HLA O 0 0.00026638517738319933
- O 0 3.7822217109351186e-06
B O 0 9.430640602658968e-06
gene O 0 2.5661172742275085e-08
, O 0 2.476197469292174e-09
with O 0 1.4091332545262958e-09
a O 0 2.4943968668367233e-08
recombinant O 0 7.322229578221595e-08
fraction O 0 1.083508252008869e-07
of O 0 2.476426175235247e-07
0 O 0 3.7635763305843284e-07
. O 0 3.5930042940890417e-07

035 O 0 0.3684558570384979
. O 0 0.00045563391176983714

A O 0 0.0002410849410807714
lod O 0 0.0005869882879778743
score O 0 8.799579518381506e-07
of O 0 2.592454961813928e-07
13 O 0 3.173989000515576e-07
was O 0 3.8186576034604514e-07
calculated O 0 4.776800324179931e-07
for O 0 5.131875013830722e-08
linkage O 0 2.1519703295780346e-05
between O 0 1.704663191048894e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.19631090456096e-06
HLA O 1 0.8750728964805603
- O 0 8.072144737525377e-06
B O 0 8.163496204360854e-06
at O 0 1.2451744169084122e-07
a O 0 1.6897580223940167e-08
maximum O 0 1.653015679892178e-08
likelihood O 0 2.7038128180834065e-08
value O 0 8.55753068407239e-09
of O 0 5.903662891881822e-09
the O 0 1.038657693186451e-08
recombinant O 0 9.69985975984855e-08
fraction O 0 1.7306159350027883e-07
of O 0 2.3226715484270244e-07
0 O 0 5.571940846493817e-07
. O 0 7.247642201946292e-07

04 O 0 0.013356076553463936
. O 0 0.0002957410179078579

18 O 0 1.4489099157799501e-05
families O 0 1.1039263370093977e-07
with O 0 3.236133139239428e-08
21 O 0 1.2820743222619058e-06
informative O 0 1.0582972436168347e-06
matings O 0 8.294402960018488e-07
for O 0 7.996450612779427e-09
both O 0 2.487265682304951e-08
properdin O 0 2.309813498868607e-05
Factor O 0 6.645568646490574e-06
B O 0 2.772751713564503e-06
allotype O 0 7.081572675815551e-06
and O 0 1.3193583470183512e-07
HLA O 0 6.464218313340098e-05
- O 0 2.0236857380950823e-06
B O 0 3.6298015402280726e-06
were O 0 2.181099318931956e-07
found O 0 4.306513403662393e-07
. O 0 7.954087664074905e-07

Of O 0 4.332619209890254e-05
72 O 0 2.485557342879474e-05
informative O 0 2.0116240193601698e-05
meioses O 0 0.00010813645349116996
, O 0 1.1847399861153463e-07
three O 0 8.188911237994034e-08
recombinants O 0 7.168246611399809e-06
were O 0 8.15222591654674e-08
found O 0 6.098007077071088e-08
, O 0 1.983823061380008e-08
giving O 0 2.788513242535373e-08
a O 0 9.902668551831084e-08
recombinant O 0 2.0485157392613473e-07
fraction O 0 2.830579717283399e-07
of O 0 3.815672471318976e-07
0 O 0 9.87980001809774e-07
. O 0 8.556307307117095e-07

042 O 0 0.11785053461790085
. O 0 0.00036677654134109616

A O 0 0.00014698973973281682
lod O 0 0.0003371087950654328
score O 0 1.4741532368134358e-06
of O 0 4.882795678895491e-07
16 O 0 6.760081987522426e-07
between O 0 6.144768462945649e-07
HLA O 0 3.645544347818941e-05
- O 0 2.4939270133472746e-06
B O 0 5.947976205789018e-06
and O 0 3.423335570573727e-08
Factor O 0 4.122935024497565e-06
B O 0 2.5589874894649256e-06
allotypes O 0 5.470382347994018e-06
was O 0 3.234279120079009e-07
calculated O 0 3.8099781818345946e-07
at O 0 5.120611135112085e-08
a O 0 9.572543646640952e-09
maximum O 0 1.4775909384923125e-08
likelihood O 0 2.6737705383084176e-08
value O 0 5.608334685547334e-09
of O 0 4.6917878471219865e-09
the O 0 6.4654179787737576e-09
recombinant O 0 3.566453798953262e-08
fraction O 0 7.219042430506306e-08
of O 0 1.3060781611784478e-07
0 O 0 3.4343756283305993e-07
. O 0 4.1937263972613437e-07

04 O 0 0.011172425001859665
. O 0 0.00015820750559214503

A O 0 2.7092417440144345e-05
crossover O 0 5.708223397959955e-06
was O 0 9.251943993149325e-07
shown O 0 3.626724165428641e-08
to O 0 8.236071380451904e-09
have O 0 4.2568575331358716e-09
occurred O 0 1.4412174209610384e-07
between O 0 1.2345263478152901e-08
genes O 0 6.593225965190186e-09
for O 0 3.751773114402113e-09
Factor O 0 3.7367496474871587e-07
B O 0 7.003517339398968e-07
and O 0 1.7489389492197915e-08
HLA O 0 1.185486871690955e-05
- O 0 1.2247098766238196e-06
D O 0 1.41269913456199e-06
, O 0 8.271998197528774e-09
in O 0 6.38111696815713e-09
which O 0 2.5350892940423364e-08
HLA O 0 4.688302396971267e-06
- O 0 1.1512623814269318e-06
D O 0 5.78475373913534e-06
segregared O 0 1.652286300668493e-05
with O 0 1.5646655526779796e-07
HLA O 0 9.966233483282849e-05
- O 0 9.673325394032872e-07
A O 0 1.1704254347932874e-06
and O 0 5.67095206349677e-08
B O 0 8.904417882149573e-06
. O 0 7.625932880728215e-07

These O 0 3.7339711411732424e-07
studies O 0 5.455687528410635e-07
suggest O 0 7.506301358262135e-08
that O 0 1.1896050811088799e-09
the O 0 5.7916844653504995e-09
genes O 0 7.274077340468921e-09
for O 0 7.890607278682182e-09
Factor O 0 2.4003769794944674e-05
B O 0 0.09899807721376419
and O 0 1.9451876141829416e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.801803837357511e-08
located O 0 1.0164881558694105e-07
outside O 0 1.9406162010682237e-08
those O 0 2.5848416740359426e-09
for O 0 3.534989190256965e-08
HLA O 0 0.0005061943084001541
, O 0 1.1368413765922014e-08
that O 0 3.2241911362973497e-09
the O 0 1.2342414201782503e-08
order O 0 2.4176710411438762e-08
of O 0 2.424769434128393e-07
genese O 0 1.9304443412693217e-05
is O 0 1.71482113842103e-07
HLA O 0 5.7816873777483124e-06
- O 0 2.0251671628557233e-07
A O 0 3.2228160762315383e-07
, O 0 4.868128122836879e-09
- O 0 2.2193667348346935e-08
B O 0 8.612749979874934e-08
, O 0 4.0305736526136116e-09
- O 0 5.724528762129921e-08
D O 0 4.4741207716469944e-07
, O 0 2.948393351687173e-08
Factor O 0 1.1487048823255464e-06
B O 0 1.3737155313719995e-05
allotype O 0 0.015288311056792736
, O 0 2.7926873372052796e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 3.0303453968372196e-08
that O 0 2.9601856521566106e-09
the O 0 3.8402404811677116e-08
genes O 0 1.347105893501066e-07
coding O 0 1.7626446151552955e-06
for O 0 9.718070259623346e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.6038233070503338e-06
Factor O 0 0.00023180815333034843
B O 0 7.017001735221129e-06
allotypes O 0 1.9527858512446983e-06
are O 0 2.239546992299779e-09
approximately O 0 2.743428417772975e-08
3 O 0 1.7102244953548507e-08
- O 0 7.218601894010135e-08
- O 0 1.2443196339972928e-07
5 O 0 6.891520598628631e-08
centimorgans O 0 4.810181053471752e-07
from O 0 1.6603497243750098e-08
the O 0 8.15578715673837e-08
HLA O 0 2.85406417788181e-06
- O 0 1.0884234313834895e-07
A O 0 3.915041872915026e-07
and O 0 1.8220111641653602e-08
HLA O 0 1.4514989743474871e-05
- O 0 9.579813422533334e-07
B O 0 1.9017425074707717e-06
loci O 0 3.5235053985616105e-08
, O 0 1.2375503954942246e-09
and O 0 4.448961476999358e-10
that O 0 9.43690015020593e-10
the O 0 1.810433936100253e-08
apparent O 0 5.361940225157014e-07
lack O 0 1.4409508253265813e-07
of O 0 7.089913367508416e-08
recombinants O 0 7.5609855230140965e-06
between O 0 5.364430322174485e-08
the O 0 1.0401866745723964e-07
Factor O 0 1.5267287380993366e-06
B O 0 7.689505764574278e-06
gene O 0 1.1731700624295627e-06
and O 0 5.0830194595619105e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.320034693388152e-06
suggests O 0 6.397694107818097e-08
that O 0 4.4756098827036794e-10
these O 0 3.8408226599173645e-10
two O 0 5.3306874470138155e-09
genes O 0 5.998499119641565e-08
lie O 0 1.8596757627165061e-06
in O 0 1.3445645663523464e-07
close O 0 4.6052928155404516e-06
proximity O 0 1.1387161293896497e-06
to O 0 2.9254710653958682e-08
one O 0 1.5111479001461703e-07
another O 0 1.4747297427675221e-06
. O 0 1.116499674935767e-06

Distribution O 0 1.8527827705838718e-05
of O 0 1.046549095917726e-05
emerin O 1 0.5698754787445068
and O 0 1.4415983287108247e-06
lamins O 1 0.9817667603492737
in O 0 4.931530952489993e-07
the O 0 5.113223551234114e-07
heart O 0 1.0937131264654454e-05
and O 0 3.193730790940208e-08
implications O 0 1.1318682027194882e-06
for O 0 3.2161690910470497e-07
Emery B-Disease 1 0.9955666661262512
- I-Disease 1 0.9999998807907104
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999058246612549
. O 0 2.3649603463127278e-05

Emerin O 0 0.3905541002750397
is O 0 1.5503867416555295e-06
a O 0 9.444333386454673e-07
nuclear O 0 3.4190929000033066e-05
membrane O 0 2.2354259272105992e-05
protein O 0 3.541870796652802e-07
which O 0 1.178130393242327e-08
is O 0 1.9676081208785945e-08
missing O 0 6.126021503405354e-07
or O 0 1.4221802757674595e-07
defective O 0 6.322353783616563e-06
in O 0 4.2181619619441335e-07
Emery B-Disease 1 0.9864174127578735
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.04523562639951706
EDMD B-Disease 1 1.0
) O 0 1.6076692190836184e-05
. O 0 3.4617517030710587e-06

It O 0 1.0930665439445875e-06
is O 0 1.2906170354654023e-07
one O 0 3.682326266130076e-08
member O 0 5.319771290146491e-08
of O 0 1.8523535061376606e-07
a O 0 1.0603804412312456e-06
family O 0 1.0361753766119364e-06
of O 0 4.006908511655638e-06
lamina O 1 0.9999996423721313
- O 1 0.922936737537384
associated O 0 2.160740677936701e-06
proteins O 0 5.220391230409405e-08
which O 0 7.445370098224657e-09
includes O 0 7.903775411932656e-08
LAP1 O 0 0.15331250429153442
, O 0 3.467794442713057e-07
LAP2 O 0 0.003257154021412134
and O 0 3.468439331300033e-07
lamin O 0 7.860142068238929e-05
B O 0 0.0001513793395133689
receptor O 0 1.5106498722161632e-05
( O 0 2.2490742139780195e-06
LBR O 0 0.019585179165005684
) O 0 3.0385697300516767e-06
. O 0 3.8085975120338844e-06

A O 0 3.6906334571540356e-05
panel O 0 3.971418664150406e-06
of O 0 1.2081062550350907e-06
16 O 0 1.3298523526827921e-06
monoclonal O 0 7.747272547931061e-07
antibodies O 0 1.0206768052967163e-07
( O 0 1.594734726495517e-07
mAbs O 0 2.3322345441556536e-06
) O 0 1.0408272466122526e-08
has O 0 1.8327874773405028e-09
been O 0 3.0406495099555286e-09
mapped O 0 1.835656959769949e-08
to O 0 2.157196643537418e-09
six O 0 4.1876573320109856e-09
specific O 0 1.8071693030918823e-09
sites O 0 7.752229969071323e-09
throughout O 0 5.2593662758226856e-09
the O 0 2.3584334485349245e-08
emerin O 0 2.8295157790125813e-06
molecule O 0 9.608362461221986e-08
using O 0 2.1690386375894377e-08
phage O 0 1.3621119876461307e-07
- O 0 5.4160619100684926e-08
displayed O 0 5.514968037800827e-08
peptide O 0 9.118191002244203e-08
libraries O 0 6.8034520239734775e-09
and O 0 3.777715085195865e-10
has O 0 5.042468664839816e-10
been O 0 1.5662106056524294e-09
used O 0 7.848309557800803e-09
to O 0 3.4722479114179805e-08
localize O 0 0.00018231042486149818
emerin O 0 0.01085010077804327
in O 0 1.6334746533175348e-07
human O 0 3.6773437273041054e-07
and O 0 2.0858453808614286e-07
rabbit O 0 0.00015201925998553634
heart O 0 0.0003596452297642827
. O 0 4.559925855573965e-06

Several O 0 4.827971224585781e-06
mAbs O 0 6.219053466338664e-05
against O 0 4.0750316543380904e-07
different O 0 2.5537696046740166e-07
emerin O 0 0.0002555206883698702
epitopes O 0 2.8015860152663663e-05
did O 0 3.5564758604778035e-07
not O 0 7.283938430191483e-08
recognize O 0 1.8946539626085723e-07
intercalated O 0 4.621060361387208e-05
discs O 0 6.6970583247893956e-06
in O 0 1.4269609494022006e-07
the O 0 2.7976238925475627e-07
heart O 0 2.7042724468628876e-05
, O 0 2.0834669101077452e-08
though O 0 1.1482757855674208e-08
they O 0 6.183964895711824e-09
recognized O 0 8.392368755494317e-08
cardiomyocyte O 0 2.6895177143160254e-05
nuclei O 0 2.7087016860605218e-06
strongly O 0 4.59634144078791e-08
, O 0 1.2677834781982256e-08
both O 0 5.432529537330311e-09
at O 0 1.8854198913231812e-07
the O 0 1.6428326432560425e-07
rim O 0 1.738849277899135e-06
and O 0 1.4360855615791479e-08
in O 0 1.0593479515819126e-07
intranuclear O 0 0.00014335592277348042
spots O 0 1.6956896615738515e-06
or O 0 5.926376047682425e-07
channels O 0 4.010502379969694e-06
. O 0 2.8647100407397375e-06

A O 0 0.0004735901311505586
polyclonal O 0 0.001256675343029201
rabbit O 0 0.0001129955708165653
antiserum O 0 9.80965924100019e-05
against O 0 2.609468538139481e-06
emerin O 0 0.0004527150886133313
did O 0 4.410300391555211e-07
recognize O 0 1.1051293569153131e-07
both O 0 4.9552724590284924e-08
nuclear O 0 2.107848195009865e-05
membrane O 0 1.3944460988568608e-05
and O 0 3.421024885597035e-08
intercalated O 0 8.992025868792553e-06
discs O 0 4.1140839357467485e-07
but O 0 2.4273172360977924e-09
, O 0 5.1069921624957715e-09
after O 0 3.6449907980795615e-08
affinity O 0 5.505383171566791e-08
purification O 0 2.3366195023299952e-07
against O 0 6.853180423149752e-08
a O 0 5.502610633811855e-07
pure O 0 1.3288585250847973e-05
- O 0 3.1433166896022158e-06
emerin O 0 9.986627446778584e-06
band O 0 2.3832735962514562e-07
on O 0 2.484757288812034e-08
a O 0 3.650403357369214e-08
western O 0 4.9705313642789406e-08
blot O 0 1.133063619818131e-06
, O 0 1.943082850175415e-08
it O 0 6.292860454948368e-09
stained O 0 5.392599859987968e-07
only O 0 3.688505145760246e-08
the O 0 2.630862923069799e-07
nuclear O 0 8.580691064707935e-05
membrane O 0 0.00015437162073794752
. O 0 4.0968939174490515e-06

These O 0 3.901411673723487e-07
results O 0 9.78953949015704e-08
would O 0 7.012070035727902e-09
not O 0 4.071074588551937e-09
be O 0 6.441059685613482e-09
expected O 0 1.0518961346406286e-07
if O 0 2.0972865399926377e-07
immunostaining O 0 0.001887575606815517
at O 0 9.22420895221876e-06
intercalated O 0 3.876495247823186e-05
discs O 0 8.398218938054924e-07
were O 0 2.1844916986424323e-08
due O 0 2.1615139900177383e-08
to O 0 3.586439589753354e-09
a O 0 3.502800183241561e-08
product O 0 1.0890792268014593e-08
of O 0 9.405997758449303e-09
the O 0 3.221186872792714e-08
emerin O 0 1.806234104151372e-05
gene O 0 2.2063584736997655e-08
and O 0 1.4477319343342288e-09
, O 0 4.5307619878087735e-09
therefore O 0 2.2842812086310005e-08
, O 0 4.3680419281599825e-09
cast O 0 2.5225968869335702e-08
some O 0 4.033418932181121e-09
doubt O 0 3.2546722650295123e-08
upon O 0 5.592699281464775e-08
the O 0 5.1092847286327014e-08
hypothesis O 0 1.898292936175494e-07
that O 0 4.652508778235642e-08
cardiac B-Disease 1 0.9927436113357544
defects I-Disease 0 0.36766552925109863
in O 0 1.688633710728027e-05
EDMD B-Disease 1 1.0
are O 0 4.3225270474067656e-07
caused O 0 7.805600148458325e-07
by O 0 4.7683300863354816e-08
absence O 0 4.811672624782659e-06
of O 0 1.1170705874974374e-05
emerin O 0 0.32154956459999084
from O 0 8.249286111094989e-06
intercalated O 0 0.0017287962837144732
discs O 0 0.00014833733439445496
. O 0 5.172527835384244e-06

Although O 0 1.0630438737280201e-05
emerin O 0 0.00029810392879880965
was O 0 8.096631972875912e-06
abundant O 0 1.825491835916182e-06
in O 0 2.4811399157442793e-07
the O 0 4.29640522270347e-07
membranes O 0 4.103345872863429e-06
of O 0 3.2870743780222256e-06
cardiomyocyte O 1 0.5527323484420776
nuclei O 0 0.00010492579167475924
, O 0 1.2589453035616316e-07
it O 0 1.1245314901486836e-08
was O 0 2.5994785346483695e-07
absent O 0 9.643466825082214e-08
from O 0 1.1415717260376823e-08
many O 0 4.799195263416323e-09
non O 0 1.0159255907637998e-06
- O 0 1.503828025306575e-05
myocyte O 1 0.5302435159683228
cells O 0 7.138354476410314e-07
in O 0 4.41944898454949e-08
the O 0 7.260523489094339e-07
heart O 0 0.00012298567162360996
. O 0 3.862332960125059e-06

This O 0 1.4022255072632106e-06
distribution O 0 7.582536909467308e-07
of O 0 7.709087412877125e-07
emerin O 0 0.00021801474213134497
was O 0 1.052911443366611e-06
similar O 0 1.1055188764430568e-08
to O 0 8.493072911619493e-09
that O 0 6.173099809103633e-09
of O 0 1.379598728590281e-07
lamin O 0 1.594992500031367e-05
A O 0 2.321791271242546e-06
, O 0 1.1575003178165844e-08
a O 0 3.339852483463801e-08
candidate O 0 3.489869015993463e-08
gene O 0 1.9263371342503888e-08
for O 0 5.172595685110082e-09
an O 0 1.1812787192866381e-07
autosomal O 0 1.4419806575460825e-06
form O 0 4.805673938790278e-07
of O 1 0.5148980617523193
EDMD B-Disease 1 1.0
. O 0 0.0013274324592202902

In O 0 1.0049664524558466e-05
contrast O 0 7.0839842010173015e-06
, O 0 3.2489372188138077e-06
lamin O 0 0.007054547313600779
B1 O 1 0.9993228912353516
was O 0 1.0598764674796257e-05
absent O 0 4.338487087807152e-06
from O 0 5.723862273043778e-07
cardiomyocyte O 0 8.454247290501371e-05
nuclei O 0 9.037691597768571e-06
, O 0 1.3409636778760614e-07
showing O 0 1.404252998327138e-06
that O 0 1.3949534150015097e-07
lamin O 0 0.0011501224944368005
B1 O 1 0.8790709972381592
is O 0 4.8131223451264304e-08
not O 0 7.775063259884973e-09
essential O 0 8.90700277977885e-08
for O 0 4.0134839451866355e-08
localization O 0 3.401297362870537e-05
of O 0 8.395103918701352e-07
emerin O 0 0.00011160349095007405
to O 0 1.9099472581274313e-07
the O 0 1.2256153922862723e-06
nuclear O 0 0.0006388795445673168
lamina O 1 0.9874753355979919
. O 0 2.4753859179327264e-05

Lamin O 1 0.9999955892562866
B1 O 1 0.9999886751174927
is O 0 9.387107411384932e-07
also O 0 2.1036366604221257e-07
almost O 0 4.1831731323327404e-07
completely O 0 3.2343548355129315e-06
absent O 0 6.593369562324369e-06
from O 0 4.8365523070970085e-06
skeletal O 1 0.9994176626205444
muscle O 0 0.0002836861240211874
nuclei O 0 0.10137408971786499
. O 0 5.519828846445307e-05

In O 0 7.614479545736685e-05
EDMD B-Disease 1 1.0
, O 0 2.014399740346562e-07
the O 0 5.424632476547231e-08
additional O 0 4.0758781238992015e-08
absence O 0 5.043628448220261e-07
of O 0 3.4719612358458107e-06
lamin O 1 0.9983281493186951
B1 O 1 1.0
from O 0 8.42966983327642e-06
heart O 1 0.908716082572937
and O 0 5.580227934842696e-06
skeletal O 1 1.0
muscle O 1 0.967777669429779
nuclei O 1 0.8616868853569031
which O 0 1.8016589820035733e-07
already O 0 2.117488691055769e-07
lack O 0 1.8854823338187998e-06
emerin O 0 0.0009198888437822461
may O 0 2.857408354373092e-08
offer O 0 5.0299164833234045e-09
an O 0 4.275556797495028e-09
alternative O 0 4.374286266539684e-09
explanation O 0 1.977996966218143e-08
of O 0 6.8973302624897315e-09
why O 0 8.383725713656531e-09
these O 0 1.470830568450765e-09
tissues O 0 4.375649353960398e-08
are O 0 3.335184572961225e-09
particularly O 0 1.0693499774561133e-07
affected O 0 2.459972847645986e-07
. O 0 4.550428229777026e-07
. O 0 3.0929497825127328e-06

Genetic O 0 0.00023000003420747817
mapping O 0 4.282646477804519e-05
of O 0 7.0938335738901515e-06
the O 0 2.9878467103117146e-05
copper B-Disease 1 0.9999991655349731
toxicosis I-Disease 1 1.0
locus O 0 0.4823904037475586
in O 0 4.16112470702501e-06
Bedlington O 1 0.9992399215698242
terriers O 0 9.766240691533312e-05
to O 0 1.7465528401316988e-07
dog O 0 4.728056410385761e-06
chromosome O 0 4.855819952354068e-06
10 O 0 1.1715963665892559e-07
, O 0 1.4563958927737986e-08
in O 0 2.3945228022625997e-08
a O 0 2.076338887491147e-07
region O 0 5.559705869018217e-07
syntenic O 0 9.699693328002468e-05
to O 0 4.677172782407979e-08
human O 0 4.252904091117671e-07
chromosome O 0 9.983427844417747e-06
region O 0 5.480988420458743e-06
2p13 O 1 0.9816352128982544
- O 0 0.20236097276210785
p16 O 0 0.000803458271548152
. O 0 4.86747103423113e-06

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 0.9999579191207886
is O 0 5.347722549231548e-07
recognized O 0 9.739440542944067e-08
as O 0 1.070149906468032e-07
an O 0 6.925040906935465e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.08450836688280106
man O 1 0.9998570680618286
, O 0 9.594437869964167e-06
mouse O 0 9.659948409534991e-05
, O 0 1.0904843747994164e-06
rat O 0 0.0008765618549659848
and O 0 7.907557915132202e-07
dog O 0 0.0015274056931957603
. O 0 2.2944501324673183e-05

The O 0 6.937508260307368e-06
major O 0 4.813903160538757e-06
cause O 0 7.241311323014088e-06
of O 0 0.00022297797841019928
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 1.0
in O 0 1.0887159987760242e-05
man O 0 0.0004174365312792361
is O 0 4.189173523627687e-07
a O 0 2.21071559280972e-06
dysfunctional O 0 0.00042507643229328096
ATP7B O 1 0.9998102784156799
gene O 0 3.4305726330785546e-06
, O 0 2.1539543126891658e-07
causing O 0 5.444640919449739e-05
Wilson B-Disease 1 0.9862905144691467
disease I-Disease 1 0.9999756813049316
( O 0 0.34973451495170593
WD B-Disease 1 0.9999997615814209
) O 0 2.6036366762127727e-05
. O 0 9.34877880354179e-06

Mutations O 0 2.3057422367855906e-05
in O 0 6.197115567374567e-07
the O 0 1.0012976190409972e-06
ATP7B O 1 0.9650831818580627
genes O 0 1.9068278334088973e-07
have O 0 2.4267801101984787e-09
also O 0 5.538050018571994e-09
been O 0 1.708340136019615e-08
demonstrated O 0 1.3332666526366665e-07
in O 0 1.4358313649154297e-07
mouse O 0 2.405304030617117e-06
and O 0 4.0233791764876514e-07
rat O 0 0.0008183873142115772
. O 0 3.2673037821950857e-06

The O 0 6.57321943435818e-05
ATP7B O 1 0.9730165004730225
gene O 0 3.083471938225557e-06
has O 0 5.554957738240773e-08
been O 0 7.014374148184288e-08
excluded O 0 2.533606107135711e-07
in O 0 2.1216479240138142e-08
the O 0 7.642213262215591e-08
much O 0 2.180414924168872e-07
rarer O 0 7.352356988121755e-06
human O 0 1.0304675924999174e-05
copper B-Disease 1 1.0
overload I-Disease 1 1.0
disease O 1 0.9999984502792358
non B-Disease 1 0.9948816299438477
- I-Disease 0 0.11696862429380417
Indian I-Disease 0 0.0019961046054959297
childhood I-Disease 1 0.9629518985748291
cirrhosis I-Disease 1 0.9999954700469971
, O 0 2.503104781226284e-07
indicating O 0 7.985531738086138e-06
genetic O 0 5.079627499071648e-06
heterogeneity O 0 3.802433639066294e-05
. O 0 2.8718002340610838e-06

By O 0 1.5506469708270743e-06
investigating O 0 6.757781648047967e-06
the O 0 9.43526856644894e-07
common O 0 5.970219717710279e-06
autosomal O 0 0.21543093025684357
recessive O 1 0.9803630709648132
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 1 0.9994307160377502
CT B-Disease 1 1.0
) O 0 4.703268587036291e-06
in O 0 9.109401730711397e-07
Bedlington O 1 0.9798295497894287
terriers O 0 2.8819331419072114e-05
, O 0 2.9064056050742693e-08
we O 0 9.670723777333023e-09
have O 0 2.7436730665186815e-09
identified O 0 2.577527347114028e-08
a O 0 2.355304751233689e-08
new O 0 2.00655723148202e-08
locus O 0 6.320095735645737e-07
involved O 0 2.6069213276969094e-07
in O 0 2.1472405933309346e-06
progressive O 1 0.9999994039535522
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.000642304599750787

We O 0 2.7852074708789587e-06
examined O 0 4.373147930891719e-06
whether O 0 5.690812940883916e-07
the O 0 2.3503896500187693e-06
WD B-Disease 1 0.9194113612174988
gene O 0 3.7850286389584653e-06
ATP7B O 0 0.012893281877040863
was O 0 1.4876518434903119e-06
also O 0 3.193633446585409e-08
causative O 0 9.177512083624606e-07
for O 0 2.7107736499942803e-08
CT B-Disease 0 3.2745112548582256e-05
by O 0 2.7602084173850017e-08
investigating O 0 4.935247943649301e-07
the O 0 3.1962053981260397e-07
chromosomal O 0 4.0885490307118744e-05
co O 0 0.00031041272450238466
- O 0 0.000526280899066478
localization O 0 0.0011942157289013267
of O 0 2.4297980871779146e-06
ATP7B O 1 0.8993197083473206
and O 0 1.0757243984471643e-07
C04107 O 0 1.2202750440337695e-05
, O 0 1.8843712368266097e-08
using O 0 1.7462054913153224e-08
fluorescence O 0 1.457644316360529e-07
in O 0 3.9844994859095095e-08
situ O 0 4.5641463657375425e-06
hybridization O 0 9.512091310170945e-07
( O 0 4.443919863206247e-07
FISH O 0 3.327648983031395e-06
) O 0 7.174457437031379e-07
. O 0 9.60956981543859e-07

C04107 O 0 0.0013023564824834466
is O 0 1.0035959121523774e-06
an O 0 3.288920140676055e-07
anonymous O 0 3.5992843550047837e-06
microsatellite O 0 1.809035529731773e-05
marker O 0 2.7789037631009705e-06
closely O 0 6.860680059617152e-07
linked O 0 1.5762442444611224e-06
to O 0 1.040553343045758e-06
CT B-Disease 1 0.9995712637901306
. O 0 8.657697435410228e-06

However O 0 1.7366155589115806e-05
, O 0 7.103284133336274e-06
BAC O 1 0.9417448043823242
clones O 0 4.585774149745703e-05
containing O 0 5.22735399499652e-06
ATP7B O 1 0.7717375159263611
and O 0 3.4173865515185753e-07
C04107 O 0 5.9656569646904245e-05
mapped O 0 2.565775503171608e-06
to O 0 7.028824455801441e-08
the O 0 7.25551217328757e-07
canine O 0 1.9882905689883046e-05
chromosome O 0 1.7752765415934846e-05
regions O 0 4.2354670881650236e-07
CFA22q11 O 1 0.9952345490455627
and O 0 4.340984958162153e-07
CFA10q26 O 1 0.9980396628379822
, O 0 1.0563535823848724e-07
respectively O 0 2.124916704815405e-07
, O 0 1.6693329385475408e-08
demonstrating O 0 2.633742326452193e-07
that O 0 2.687124478484293e-08
WD B-Disease 0 2.785983815556392e-05
cannot O 0 5.201268749033261e-08
be O 0 4.985523816003479e-08
homologous O 0 1.1310944501019549e-06
to O 0 4.723671054307488e-07
CT B-Disease 1 0.9024441242218018
. O 0 8.106969289656263e-06

The O 0 4.6427354391198605e-05
copper O 0 0.0017441854579374194
transport O 0 6.634923920501024e-05
genes O 0 3.007365739904344e-05
CTR1 O 1 0.9998730421066284
and O 0 7.287515586540394e-07
CTR2 O 1 0.9996387958526611
were O 0 6.478017553490645e-07
also O 0 5.1638743059356784e-08
excluded O 0 9.114539523125131e-08
as O 0 1.07220081702053e-08
candidate O 0 2.996069525806888e-08
genes O 0 1.0358562896328749e-08
for O 0 9.058694239172382e-09
CT B-Disease 0 0.0006276601343415678
since O 0 1.7484451220184383e-08
they O 0 2.508484753249718e-09
both O 0 7.28968840846278e-09
mapped O 0 2.575478674771148e-07
to O 0 9.122609867517895e-08
canine O 0 1.2762608093908057e-05
chromosome O 0 3.701532114064321e-05
region O 0 9.723782568471506e-06
CFA11q22 O 1 0.999494194984436
. O 0 1.2280372175155208e-05

2 O 0 0.00019346832414157689
- O 0 0.0001611454936210066
22 O 0 5.39997527084779e-05
. O 0 7.226616162370192e-06

5 O 0 0.0004477975016925484
. O 0 5.014204725739546e-05

A O 0 2.5510786144877784e-05
transcribed O 0 9.832381692831405e-06
sequence O 0 6.265795491344761e-07
identified O 0 1.988487099424674e-07
from O 0 3.5995029179503035e-08
the O 0 1.2497403645284066e-07
C04107 O 0 2.529735502321273e-05
- O 0 6.781081538065337e-06
containing O 0 1.8968464701174526e-06
BAC O 0 0.0009190330165438354
was O 0 1.6404919733759016e-07
found O 0 6.334515134653884e-09
to O 0 1.2810399407925388e-09
be O 0 3.8146148462203655e-09
homologous O 0 5.254505452967351e-08
to O 0 6.589504497611642e-09
a O 0 7.481773423023697e-08
gene O 0 2.4439589907387926e-08
expressed O 0 5.661351831776074e-09
from O 0 2.0293349223265977e-08
human O 0 7.193477102873658e-08
chromosome O 0 6.057312020857353e-06
2p13 O 0 0.0006593993166461587
- O 0 0.00020772339485120028
p16 O 0 1.7621840015635826e-05
, O 0 1.840014363096998e-08
a O 0 3.2514705594621773e-08
region O 0 7.152119252396005e-08
devoid O 0 1.1196324294360238e-06
of O 0 8.209601531916633e-08
any O 0 5.990644069697737e-08
positional O 0 3.2192451726587024e-06
candidate O 0 1.5722836224085768e-06
genes O 0 3.019625182787422e-06
. O 0 2.245473751827376e-06

Molecular O 0 0.00012302309914957732
analysis O 0 2.1769606064481195e-06
of O 0 5.601083898909565e-07
the O 0 1.1278082183707738e-06
APC B-Disease 0 1.5872947187745012e-05
gene O 0 1.8637045684499753e-07
in O 0 2.2230693730307394e-08
205 O 0 1.8212752195267967e-07
families O 0 1.0536910011182954e-08
: O 0 2.3251665481893724e-08
extended O 0 3.312095770979795e-07
genotype O 0 2.7237049380346434e-06
- O 0 2.943538447652827e-06
phenotype O 0 6.67182519009657e-07
correlations O 0 4.6953266519267345e-07
in O 0 5.4589673226246305e-08
FAP B-Disease 0 1.0187342240897124e-06
and O 0 2.591871828272474e-09
evidence O 0 3.161686734642899e-08
for O 0 3.6273448689172483e-09
the O 0 2.2798067433882352e-08
role O 0 1.5792008412063296e-07
of O 0 2.18847304722658e-07
APC B-Disease 0 3.008725116160349e-06
amino O 0 8.784012095475191e-08
acid O 0 4.4379735442134916e-08
changes O 0 5.4121169767995525e-08
in O 0 1.852621790021658e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 0.0001344257761957124

BACKGROUND O 0 0.06686089187860489
/ O 0 0.0020277886651456356
AIMS O 0 2.308934745087754e-05
The O 0 1.036804064824537e-06
development O 0 7.2870057010732125e-06
of O 0 0.3111424744129181
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.2498321666498668e-07
a O 0 1.387438857136658e-07
variable O 0 8.725550770805057e-08
range O 0 2.5727040053880046e-08
of O 0 8.130191275768084e-08
extracolonic O 0 0.00014294616994448006
manifestations O 0 3.530076355673373e-05
in O 0 2.461637632222846e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999997615814209
FAP B-Disease 1 0.9999809265136719
) O 0 1.204719069392013e-06
is O 0 5.977997119543943e-08
the O 0 5.184134721503142e-08
result O 0 9.17420663881785e-08
of O 0 8.207227324419364e-07
the O 0 4.7983012336771935e-06
dominant O 0 0.00030215218430384994
inheritance O 0 0.001389622688293457
of O 1 0.998784601688385
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9997324347496033
APC B-Disease 1 0.9943978786468506
) O 0 7.523482054239139e-06
gene O 0 5.494795004779007e-06
mutations O 0 3.535607447702205e-06
. O 0 6.729863798682345e-06

In O 0 6.820396265538875e-07
this O 0 2.990063663332876e-08
study O 0 4.525633912066951e-08
, O 0 7.278213143280254e-09
direct O 0 1.9477878865359344e-08
mutation O 0 1.3475319526889962e-08
analysis O 0 1.3797929909742379e-08
of O 0 2.3641623769776743e-08
the O 0 1.3496467943241441e-07
APC B-Disease 0 5.431141289591324e-06
gene O 0 4.0439587678520184e-08
was O 0 3.8560504123097417e-08
performed O 0 3.4119601366455754e-08
to O 0 4.326558222800259e-09
determine O 0 1.5421566956774768e-07
genotype O 0 2.6280144993506838e-06
- O 0 3.0857636375003494e-06
phenotype O 0 3.8215463860069576e-07
correlations O 0 1.6632094457236235e-07
for O 0 1.1053501225433138e-08
nine O 0 2.886314405259327e-07
extracolonic O 0 6.305776332737878e-05
manifestations O 0 8.203346055779548e-07
and O 0 1.042943686968556e-08
to O 0 8.728509470756762e-09
investigate O 0 1.479808418025641e-07
the O 0 1.827026494538586e-07
incidence O 0 2.549105374782812e-06
of O 0 3.6687475812868797e-07
APC B-Disease 0 5.541937753150705e-06
mutations O 0 4.119316798778527e-08
in O 0 7.328084450364258e-08
non O 0 0.0016523388912901282
- O 1 0.9999972581863403
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.912234286777675e-05

METHODS O 0 4.747656566905789e-05
The O 0 6.78760352457175e-06
APC B-Disease 0 1.5038753190310672e-05
gene O 0 1.3047834102053457e-07
was O 0 2.436396471239277e-07
analysed O 0 4.2695290858318913e-07
in O 0 4.765148275964748e-08
190 O 0 4.258005503743334e-07
unrelated O 0 3.91525873055798e-07
FAP B-Disease 0 7.75841385802778e-07
and O 0 8.162506226483401e-09
15 O 0 2.3092738388186262e-07
non O 0 0.17827628552913666
- O 1 0.9999994039535522
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.697318101738347e-07
using O 0 2.0134316969233623e-07
denaturing O 0 0.006281988229602575
gradient O 0 2.3305949071072973e-05
gel O 0 9.456181942368858e-06
electrophoresis O 0 7.885914783400949e-06
, O 0 2.1240612824158234e-08
the O 0 2.5004274206708033e-08
protein O 0 6.728322432536515e-08
truncation O 0 5.543288352782838e-07
test O 0 2.3210946054064152e-08
, O 0 1.0297928731972661e-08
and O 0 7.209489893966747e-09
direct O 0 3.054614126085653e-07
sequencing O 0 5.693527327821357e-06
. O 0 1.7490042409917805e-06

RESULTS O 0 0.000303639069898054
Chain O 0 4.363280822872184e-05
terminating O 0 2.383069613642874e-06
signals O 0 1.7138090413482132e-07
were O 0 1.346211409014586e-08
only O 0 3.911023949143555e-09
identified O 0 3.081320798514753e-08
in O 0 1.7386879491709806e-08
patients O 0 1.3477915672410745e-08
belonging O 0 2.8077568003936904e-07
to O 0 4.191103641915106e-08
the O 0 1.7420394442524412e-06
FAP B-Disease 0 1.8861259377445094e-05
group O 0 1.7021206133449596e-07
( O 0 8.150252028826799e-08
105 O 0 5.289024898047501e-07
patients O 0 1.090898749112057e-07
) O 0 2.1836510200046177e-07
. O 0 7.190719202299078e-07

Amino O 0 2.181062700401526e-05
acid O 0 3.925997020814975e-07
changes O 0 1.7548265063282997e-08
were O 0 2.1493203661293592e-08
identified O 0 4.528431674089006e-08
in O 0 7.93447973990169e-09
four O 0 1.6741223518579318e-08
patients O 0 8.839841747487753e-09
, O 0 2.391459030803844e-09
three O 0 7.782511524112579e-09
of O 0 2.3131620707772527e-07
whom O 0 4.020383528313687e-07
belonged O 0 4.930542490910739e-05
to O 0 6.084785297844064e-08
the O 0 5.493068329087691e-07
non O 0 4.99035777465906e-05
- O 0 3.2221025321632624e-05
FAP O 0 1.1626108971540816e-05
group O 0 2.2003787591984292e-07
of O 0 4.3422853195806965e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.04370153695344925
. O 0 8.142161277646665e-06

Genotype O 0 0.045283738523721695
- O 0 0.0003633688320405781
phenotype O 0 6.960165137570584e-06
correlations O 0 1.9567416984500596e-06
identified O 0 2.1330870936253632e-07
significant O 0 6.685187514676727e-08
differences O 0 4.7808796921344765e-08
in O 0 1.6282232451203527e-08
the O 0 4.9156223980162395e-08
nature O 0 1.3272256182972342e-07
of O 0 9.184308424892151e-08
certain O 0 1.0370784764290875e-07
extracolonic O 0 0.002450220985338092
manifestations O 0 3.203535015927628e-05
in O 0 8.274051879197941e-07
FAP B-Disease 0 4.8219480959232897e-05
patients O 0 4.746298642999136e-08
belonging O 0 2.1532744653995906e-07
to O 0 2.0462188388137292e-08
three O 0 2.3623125855465332e-07
mutation O 0 1.2376121958368458e-06
subgroups O 0 1.971193341887556e-05
. O 0 3.1177962682704674e-06

CONCLUSIONS O 0 0.00015340317622758448
Extended O 0 6.052463504602201e-05
genotype O 0 8.29627679195255e-05
- O 0 2.998885429406073e-05
phenotype O 0 3.2818622912600404e-06
correlations O 0 6.600727715522225e-07
made O 0 1.818469996806016e-08
in O 0 5.481020526332259e-09
this O 0 4.523077468121528e-09
study O 0 1.9446030563585737e-08
may O 0 5.451639140119369e-09
have O 0 8.227746262079449e-10
the O 0 8.363952197498747e-09
potential O 0 1.4501868150773589e-08
to O 0 1.4584410346074606e-09
determine O 0 1.2017793871166305e-08
the O 0 6.54209175721121e-09
most O 0 1.0442708919811139e-09
appropriate O 0 8.670268947241766e-09
surveillance O 0 7.283382075229383e-08
and O 0 4.001496467509469e-09
prophylactic O 0 2.7191372282686643e-06
treatment O 0 1.1619846418398083e-07
regimens O 0 2.617953214212321e-07
for O 0 2.595908821234616e-09
those O 0 4.0971470660622344e-09
patients O 0 3.1389060239916944e-09
with O 0 1.2805856375308622e-09
mutations O 0 2.357111306139359e-08
associated O 0 7.461224527105514e-08
with O 0 2.0391006216868846e-08
life O 0 4.366600933281006e-06
threatening O 0 8.946663911046926e-06
conditions O 0 1.6586978745181113e-05
. O 0 6.9080429057066794e-06

This O 0 8.429843205703946e-07
study O 0 2.904450298046868e-07
also O 0 2.3200190213401584e-08
provided O 0 6.62807906337548e-08
evidence O 0 7.156062764579474e-08
for O 0 1.2082471023688868e-08
the O 0 1.5142943254886632e-07
pathological O 0 2.5982095394283533e-05
nature O 0 1.6646376366225013e-07
of O 0 1.1379611919437593e-07
amino O 0 1.103631674936878e-07
acid O 0 2.4674907450616956e-08
changes O 0 4.509914219852362e-09
in O 0 1.6479347664244415e-08
APC O 0 7.618148174515227e-07
associated O 0 3.9646526062142584e-08
with O 0 8.066672663176178e-09
both O 0 2.157637801758483e-08
FAP B-Disease 0 1.4815326494499459e-06
and O 0 3.0479270662908675e-08
non O 0 0.2854272127151489
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.2270049713552e-05
. O 0 8.144033358803426e-07
. O 0 3.904596724169096e-06

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.5787357687950134
cancer B-Disease 1 1.0
risk O 0 0.43715405464172363
of O 0 0.05434656888246536
the O 0 0.0022842632606625557
APC O 1 0.530446469783783
I1307K O 0 0.005130114033818245
polymorphism O 0 7.662628195248544e-05
. O 0 8.686892215337139e-06

Germ O 1 0.999998927116394
- O 0 0.0017938148230314255
line O 0 7.416023436235264e-06
and O 0 1.1068485150644847e-07
somatic O 0 1.4482485539701884e-06
truncating O 0 4.742814780911431e-06
mutations O 0 3.7248302220405094e-08
of O 0 4.9653010592010105e-08
the O 0 1.8889636521635111e-07
APC B-Disease 0 5.473340934258886e-06
gene O 0 2.5996266472816387e-08
are O 0 9.865219752214216e-10
thought O 0 4.74237147329859e-08
to O 0 5.5425857681257185e-08
initiate O 0 0.00015008320042397827
colorectal B-Disease 1 1.0
tumor I-Disease 1 1.0
formation O 1 0.9999978542327881
in O 1 0.9993641972541809
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.8746094107627869
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.00012525460624601692
respectively O 0 0.000550120894331485
. O 0 2.186965684813913e-05

Recently O 0 1.495644301030552e-05
, O 0 2.5363138433931454e-07
an O 0 4.3916526237808284e-07
isoleucine O 0 0.00011002544488292187
- O 0 0.00012775319919455796
- O 0 0.0001000844276859425
> O 0 3.632135849329643e-05
lysine O 0 6.736721388733713e-06
polymorphism O 0 1.7974388129005092e-06
at O 0 1.6365104329452151e-06
codon O 0 8.568755220039748e-06
1307 O 0 3.4621803933987394e-05
( O 0 4.333663525812881e-07
I1307K O 0 4.080369308212539e-06
) O 0 3.6338629882948226e-08
of O 0 5.0602302792412956e-08
the O 0 1.727314753452447e-07
APC B-Disease 0 4.83658914163243e-06
gene O 0 2.6168391897840593e-08
has O 0 2.6963851151862173e-09
been O 0 3.908145806974517e-09
identified O 0 1.9982577370569743e-08
in O 0 1.5662264374327606e-08
6 O 0 3.883782255797996e-07
% O 0 2.4068728521342564e-07
- O 0 4.75525638421459e-07
7 O 0 3.138491990739567e-07
% O 0 2.6418693011009964e-08
of O 0 2.0879026507714116e-08
the O 0 4.956936194844275e-08
Ashkenazi O 0 7.5110156103619374e-06
Jewish O 0 2.3129821329348488e-06
population O 0 1.2009779482013982e-07
. O 0 3.257125911204639e-07

To O 0 1.1790709777415032e-06
assess O 0 3.4421707368892385e-06
the O 0 3.737383735824551e-07
risk O 0 3.3380857189513335e-07
of O 0 1.6905487143503706e-07
this O 0 6.661169749122564e-08
common O 0 2.97698193207907e-07
APC B-Disease 0 2.3448987121810205e-05
allelic O 0 6.464572379627498e-06
variant O 0 4.339389306551311e-06
in O 0 1.351329160570458e-06
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.2041948593832785e-07
we O 0 1.3607662552317379e-08
have O 0 2.4819899469008533e-09
analyzed O 0 8.217465818916025e-08
a O 0 2.525100128991653e-08
large O 0 3.864665032438097e-08
cohort O 0 4.692122274718713e-06
of O 0 3.597149316192372e-07
unselected O 0 0.18839192390441895
Ashkenazi O 0 0.00018620675837155432
Jewish O 0 1.6685266928107012e-06
subjects O 0 8.568000566810952e-07
with O 0 1.4163966000069195e-07
adenomatous B-Disease 1 0.8527277708053589
polyps I-Disease 0 5.0022266805171967e-05
and O 0 1.2500943569193623e-07
. O 0 1.8689762555368361e-06
or O 1 0.999996542930603
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.0669574951170944e-05
for O 0 7.552248462161515e-07
the O 0 4.352791074779816e-05
APC O 0 0.0011240976164117455
I1307K O 0 0.0004998156218789518
polymorphism O 0 3.182822183589451e-05
. O 0 1.067894663719926e-05

The O 0 0.00010396419384051114
APC O 0 0.00036689109401777387
I1307K O 0 5.863654223503545e-05
allele O 0 3.9055998968251515e-07
was O 0 4.3358133439141966e-07
identified O 0 1.1543216515974564e-07
in O 0 2.2886466055638266e-08
48 O 0 6.00832379404892e-08
( O 0 4.36206626375224e-08
10 O 0 1.1767199659118432e-08
. O 0 2.2681339029162473e-09
1 O 0 6.375924499479879e-08
% O 0 3.699440398463594e-08
) O 0 2.4882860216735025e-08
of O 0 9.834061387437032e-08
476 O 0 5.193945526116295e-06
patients O 0 4.335172434366541e-07
. O 0 1.2292266546864994e-06

Compared O 0 4.028772309538908e-06
with O 0 1.7148366282526695e-08
the O 0 2.684967626009893e-08
frequency O 0 4.5357793965195015e-08
in O 0 2.01134975341688e-09
two O 0 5.121211787972868e-10
separate O 0 3.397937486937508e-09
population O 0 1.8298359494295369e-09
control O 0 5.1025521585756906e-09
groups O 0 6.205501668077318e-10
, O 0 3.744374144076801e-09
the O 0 2.1724324028582487e-07
APC O 0 3.2577390811638907e-05
I1307K O 0 1.0245431440125685e-05
allele O 0 3.184059949035145e-08
is O 0 2.7801634328028513e-09
associated O 0 4.415815268998813e-09
with O 0 5.785310563943824e-10
an O 0 1.0690478724484365e-08
estimated O 0 5.4022159190481034e-08
relative O 0 7.456044954778918e-07
risk O 0 2.2334231175591412e-07
of O 0 5.381800747272791e-07
1 O 0 4.985018676961772e-06
. O 0 1.1123740932816872e-06

5 O 0 6.059521183487959e-05
- O 0 7.567139255115762e-05
1 O 0 1.2464919564081356e-05
. O 0 4.769267434312496e-06

7 O 0 6.717239011777565e-05
for O 0 6.588774340343662e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999351501464844
( O 0 1.052279731084127e-05
both O 0 9.65456138146692e-07
P O 0 0.0023672860115766525
= O 0 1.359569523629034e-05
. O 0 1.4516292878852255e-07
01 O 0 2.201075949415099e-05
) O 0 7.461080713255797e-07
. O 0 5.782789571640023e-07

Furthermore O 0 5.335525202099234e-05
, O 0 8.626393537269905e-07
compared O 0 6.722569310113613e-07
with O 0 8.959686681464518e-08
noncarriers O 0 0.0015861570136621594
, O 0 1.8080792187902262e-06
APC O 0 0.00038512187893502414
I1307K O 0 0.00012406519090291113
carriers O 0 1.4439619633321854e-07
had O 0 5.861187446498661e-08
increased O 0 5.0500869264169523e-08
numbers O 0 5.557035365200136e-08
of O 0 4.911920541417203e-07
adenomas B-Disease 1 0.9989834427833557
and O 0 3.8084704101493116e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999762773513794
per O 0 1.2622754184121732e-05
patient O 0 1.6425630064986763e-06
( O 0 1.2966535223313258e-07
P O 0 1.0023332833952736e-05
= O 0 3.9645925653530867e-07
. O 0 8.737704781935918e-09
03 O 0 5.61208764793264e-07
) O 0 3.5656224639524225e-09
, O 0 6.815683017968865e-10
as O 0 6.837662658298882e-10
well O 0 1.3326554304526894e-09
as O 0 4.62460203465298e-09
a O 0 1.2496580836796056e-07
younger O 0 2.761120185823529e-07
age O 0 3.3737264857336413e-06
at O 0 8.326576789841056e-05
diagnosis O 0 0.0043723490089178085
. O 0 5.65821437703562e-06

We O 0 3.7168892959016375e-06
conclude O 0 1.0885810297622811e-05
that O 0 2.0822002966269793e-07
the O 0 2.18124182538304e-06
APC O 0 0.00013167182623874396
I1307K O 0 0.00010133980686077848
variant O 0 5.083770702185575e-06
leads O 0 1.010556957226072e-06
to O 0 2.036464081811573e-07
increased O 0 1.5423436707351357e-05
adenoma B-Disease 1 1.0
formation O 0 2.770696119114291e-05
and O 0 4.1753210666684026e-08
directly O 0 6.626967063994016e-08
contributes O 0 3.8487026898792465e-08
to O 0 3.895048727997619e-09
3 O 0 3.440833395984555e-08
% O 0 1.7211281289064573e-08
- O 0 2.7245306455370155e-08
4 O 0 1.6498280075438743e-08
% O 0 2.3986721497948338e-09
of O 0 2.8790378969745234e-09
all O 0 7.238618593419233e-09
Ashkenazi O 0 8.41059154481627e-05
Jewish O 1 0.937637209892273
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.661388786393218e-05

The O 0 2.4070111521723447e-06
estimated O 0 1.0828620133906952e-06
relative O 0 1.2500221373556997e-06
risk O 0 4.704533012045431e-07
for O 0 3.346860566466603e-08
carriers O 0 9.310506499105031e-08
may O 0 3.815606319790277e-08
justify O 0 3.149333736018889e-07
specific O 0 1.7449405476099855e-08
clinical O 0 1.643885809698986e-07
screening O 0 2.7148301384727347e-08
for O 0 8.240094828693145e-09
the O 0 2.7141261682572804e-08
360 O 0 9.43161850841534e-08
, O 0 2.8044815358896358e-09
000 O 0 3.842071905069133e-08
Americans O 0 5.767135213829988e-09
expected O 0 4.7148338566671555e-09
to O 0 2.8016959863208513e-09
harbor O 0 6.814980224589817e-07
this O 0 4.049923951754408e-09
allele O 0 1.2060021425952527e-08
, O 0 1.197650756346036e-09
and O 0 1.1132373911593163e-09
genetic O 0 1.6048554485337263e-08
testing O 0 8.135245366247545e-09
in O 0 3.197898390538967e-09
the O 0 1.0353505608406977e-08
setting O 0 1.6456866092084965e-07
of O 0 2.803349374858044e-08
long O 0 1.1368395291810884e-07
- O 0 1.564408762533276e-07
term O 0 1.747232545312727e-07
- O 0 8.003625850960816e-08
outcome O 0 3.536459303177253e-08
studies O 0 1.2451085495968073e-08
may O 0 3.1591231852701185e-09
impact O 0 2.203238125275675e-08
significantly O 0 6.824821241480095e-08
on O 0 6.661698535026517e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 1 0.8266445398330688
in O 0 3.386816160855233e-08
this O 0 2.2190873139038558e-08
population O 0 4.544317633303763e-08
. O 0 2.4735561510169646e-07

Localization O 0 0.007204865105450153
of O 0 5.420637080533197e-06
human O 0 4.4023718146490864e-06
BRCA1 O 0 7.44422550269519e-06
and O 0 2.1725540477746108e-08
its O 0 2.850919322838763e-08
loss O 0 1.2296861768845702e-06
in O 0 2.241736893893176e-07
high O 0 9.316160685557406e-06
- O 0 1.3920172932557762e-05
grade O 0 0.0005009605665691197
, O 0 3.037370674974227e-07
non B-Disease 0 0.0003468734212219715
- I-Disease 1 0.7461568713188171
inherited I-Disease 1 0.9999997615814209
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 4.612417978933081e-05

Although O 0 1.8150207097278326e-06
the O 0 4.590200148868462e-07
link O 0 1.8082516817230498e-06
between O 0 3.178344627485785e-07
the O 0 2.1933592506684363e-06
BRCA1 O 1 0.9749622941017151
tumour B-Disease 1 1.0
- O 1 0.9999425411224365
suppressor O 1 0.9772627949714661
gene O 0 7.068187528602721e-07
and O 0 6.913190730983843e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 0.00012858941045124084
established O 0 9.402499472344061e-07
, O 0 8.46861514247621e-09
the O 0 1.7665064078187243e-08
role O 0 6.955633580219e-08
, O 0 5.777936795681171e-09
if O 0 2.1065058586344776e-09
any O 0 1.2788045289369165e-08
, O 0 1.2772590096687964e-08
of O 0 1.8159299486342206e-07
BRCA1 O 0 2.150031377823325e-06
in O 0 1.8120063316473534e-07
non B-Disease 1 0.9977854490280151
- I-Disease 1 0.9999964237213135
familial I-Disease 1 0.9999988079071045
cancers I-Disease 1 0.9999301433563232
is O 0 1.1739377896446967e-06
unclear O 0 1.0071232281916309e-05
. O 0 2.496773277016473e-06

BRCA1 O 0 0.0005117259570397437
mutations O 0 6.525843332383374e-07
are O 0 9.015224122776999e-09
rare O 0 8.694203046388793e-08
in O 0 7.315389893847168e-08
sporadic B-Disease 0 0.014882518909871578
cancers I-Disease 1 0.937021791934967
, O 0 9.116364907413299e-08
but O 0 5.318726437053556e-08
loss O 0 1.9635197531897575e-05
of O 0 1.0215780093858484e-05
BRCA1 O 0 2.5282304704887792e-05
resulting O 0 1.2993619691314962e-07
from O 0 3.176477747501849e-08
reduced O 0 6.137763364222337e-08
expression O 0 3.0341279710910385e-08
or O 0 3.306833917804397e-08
incorrect O 0 1.1202113228137023e-06
subcellular O 0 1.52911579789361e-05
localization O 0 1.2035293366352562e-06
is O 0 5.018694348990493e-09
postulated O 0 5.5991776548580674e-08
to O 0 9.159267233549429e-10
be O 0 1.6667297542127812e-09
important O 0 9.119561994452852e-09
in O 0 2.0056733163187346e-08
non B-Disease 0 0.00017725380894262344
- I-Disease 1 0.9731999635696411
familial I-Disease 1 0.9999897480010986
breast I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.013525200076401234

Epigenetic O 0 0.025178370997309685
loss O 0 3.0152456020005047e-05
, O 0 1.6835758742672624e-07
however O 0 7.072166141597336e-08
, O 0 1.6755599574480584e-08
has O 0 2.6362556582171237e-09
not O 0 1.4636187817274049e-09
received O 0 1.30629205230548e-08
general O 0 7.761790499216659e-08
acceptance O 0 3.702115805026551e-07
due O 0 1.6235473765391362e-07
to O 0 2.6561529864466138e-08
controversy O 0 2.1179774023494247e-07
regarding O 0 1.0493992874671676e-07
the O 0 1.1320683768190065e-07
subcellular O 0 2.2308984625851735e-05
localization O 0 4.979877758160001e-06
of O 0 1.9369835513316502e-07
BRCA1 O 0 6.327043138298905e-07
proteins O 0 2.027334744525433e-08
, O 0 4.685777987845086e-09
reports O 0 1.389978443455675e-08
of O 0 9.574880444063183e-09
which O 0 1.2870893240091164e-09
have O 0 1.003602867477582e-09
ranged O 0 5.6695565575637374e-08
from O 0 8.082813529597388e-09
exclusively O 0 3.828779782111269e-08
nuclear O 0 2.737214686021616e-07
, O 0 1.982048525306368e-09
to O 0 1.4896535116548648e-09
conditionally O 0 5.128283930844191e-08
nuclear O 0 3.8407171132348594e-07
, O 0 1.5457782609473725e-08
to O 0 1.2429042683947955e-08
the O 0 4.042155126171565e-07
ER O 1 0.9974986910820007
/ O 0 2.7070049327448942e-05
golgi O 0 7.787474896758795e-05
, O 0 2.424759593111503e-08
to O 0 2.3939701776498623e-08
cytoplasmic O 0 2.7357320959708886e-06
invaginations O 0 1.464066644984996e-05
into O 0 2.0089895258479373e-07
the O 0 4.486759621613601e-07
nucleus O 0 1.2185469131509308e-05
. O 0 2.2842020825919462e-06

In O 0 4.826443273486802e-06
an O 0 3.2757884582679253e-07
attempt O 0 3.121784288850904e-07
to O 0 1.5685643006690952e-08
resolve O 0 1.2684468231327628e-07
this O 0 1.4854777852235657e-08
issue O 0 4.122688324059709e-08
, O 0 4.262780795016852e-09
we O 0 9.219021102069291e-09
have O 0 5.455123464059852e-09
comprehensively O 0 9.821620778893703e-07
characterized O 0 4.885585553893179e-07
19 O 0 1.30266403175483e-06
anti O 0 2.3110987967811525e-06
- O 0 1.7397420378983952e-05
BRCA1 O 0 6.869708613521652e-06
antibodies O 0 5.11152620674693e-07
. O 0 7.57388647798507e-07

These O 0 7.898302669673285e-07
reagents O 0 1.9497376797517063e-06
detect O 0 2.044578195636859e-06
a O 0 1.739174308568181e-06
220 O 0 6.916401162015973e-06
- O 0 1.1701213225023821e-05
kD O 0 0.0013558075297623873
protein O 0 5.801880433864426e-07
localized O 0 1.1547180633897369e-07
in O 0 4.257702190813006e-09
discrete O 0 8.279388907794782e-08
nuclear O 0 9.567095275997417e-07
foci O 0 3.400471996428678e-06
in O 0 2.2451166259429556e-08
all O 0 3.276522164696871e-08
epithelial O 0 2.670166577445343e-05
cell O 0 4.48146647613612e-06
lines O 0 1.304303225424519e-07
, O 0 2.9503945953024413e-09
including O 0 5.066949526622011e-09
those O 0 8.076956881097885e-09
derived O 0 6.77935986459488e-07
from O 0 3.584284741009469e-06
breast B-Disease 1 0.8981056809425354
malignancies I-Disease 0 0.3494243621826172
. O 0 8.99137285159668e-06

Immunohistochemical O 1 0.9895771741867065
staining O 0 0.0002942883293144405
of O 0 7.760606422380079e-06
human O 0 1.0059262422146276e-05
breast O 0 0.0028239714447408915
specimens O 0 3.997572548541939e-06
also O 0 2.2405912147860363e-07
revealed O 0 2.863960253307596e-05
BRCA1 O 0 1.2524202247732319e-05
nuclear O 0 0.00014269530947785825
foci O 0 0.0016470003174617887
in O 0 2.847050950549601e-07
benign O 1 0.7371801137924194
breast O 0 0.029942791908979416
, O 0 2.654831632753485e-06
invasive B-Disease 1 0.99964439868927
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9984923601150513
and O 0 2.303173459949903e-06
low B-Disease 1 0.9999228715896606
- I-Disease 1 0.9999978542327881
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 6.394806405296549e-05

Conversely O 0 0.0007362920441664755
, O 0 3.796923238041927e-06
BRCA1 O 0 2.388644134043716e-05
expression O 0 3.1889652518657385e-07
was O 0 4.159282127602637e-07
reduced O 0 5.3235169161780505e-08
or O 0 2.8434683940758987e-08
undetectable O 0 1.5099205938895466e-06
in O 0 8.33509528064269e-09
the O 0 1.219708511968065e-08
majority O 0 2.4711725998827205e-09
of O 0 5.8851714612728756e-08
high O 0 6.1526880017481744e-06
- O 0 0.0001368583762086928
grade O 1 0.9998296499252319
, O 0 5.276003139442764e-05
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 6.01762479846002e-08
suggesting O 0 1.931720419179328e-07
that O 0 2.8425559683853407e-09
absence O 0 8.990037514422511e-08
of O 0 3.6020034599459905e-07
BRCA1 O 0 5.290253284329083e-06
may O 0 6.20013622665283e-08
contribute O 0 1.0744756906433395e-07
to O 0 2.870343429606237e-08
the O 0 1.0249252682115184e-06
pathogenesis O 1 0.8303914666175842
of O 0 1.725753833170529e-07
a O 0 8.976244458835936e-08
significant O 0 5.849438977634236e-08
percentage O 0 1.5514383733261639e-07
of O 0 1.9013077690033242e-07
sporadic B-Disease 0 0.0002907942107412964
breast I-Disease 1 0.9988638162612915
cancers I-Disease 1 0.7826896905899048
. O 0 1.3118058177497005e-06
. O 0 4.822164555662312e-06

